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   vCHROMIUM
FOREWORD
This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the toxic substances each profile describes.  Each peer-reviewed profile identifies and
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is
also presented but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with 
a public health statement that describes, in nontechnical language, a substance's relevant toxicological
properties.  Following the public health statement is information concerning levels of significant human 
exposure and, where known, significant health effects. A health effects summary describes the adequacy
of information to determine a substance's health effects. ATSDR identifies data needs that are significant
to protection of public health. 
Each profile:
(A) Examines, summarizes, and interprets available toxicologic information and
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) Determines whether adequate information on the health effects of each substance is
available or being developed to determine levels of exposure that present a significant risk to
human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of
exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are federal, state, and local health professionals;
interested private sector organizations and groups; and members of the public.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been
peer-reviewed.  Staff of the Centers for Disease Control and Prevention and other federal scientists also 
have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel
and was made available for public review.  Final responsibility for the contents and views expressed in
this toxicological profile resides with ATSDR. 
Christopher J. Portier, Ph.D. 
Assistant Administrator















    






   
 
  
     
       
 
   vi CHROMIUM
*Legislative Background
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise













   
   
  






     
   
    
  
 
    
  
 
   
  
   
   
     




   
    
   
   
 
 
   




          




    
  
   




QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets,
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?  
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?  
Section 3.7 Children’s Susceptibility  
Section 6.6 Exposures of Children  
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center 
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178 
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure
history is provided.  Other case studies of interest include Reproductive and Developmental
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide













    
     
   
  
 





   
 
 
   
   
  
















    




Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials. Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. 	 Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2. 	 Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each
profile, and makes recommendations for derivation of MRLs.
3. 	 Data Needs Review. The Environmental Toxicology Branch (proposed) reviews data needs 
sections to assure consistency across profiles and adherence to instructions in the Guidance.









































   
    
     
   
 
  
    
 
xiCHROMIUM
PEER REVIEW  
A peer review panel was assembled for chromium.  The panel consisted of the following members:
1. 	 Dr. Detmar Beyersmann, Professor Emeritus of Biochemistry, University of Bremen, Germany,
2. 	 John Pierce Wise, Sr., Ph.D., Director, Maine Center for Toxicology and Environmental Health, 
Professor of Toxicology and Molecular Epidemiology, Department of Applied Medical Sciences,
University of Southern Maine, 96 Falmouth St., Portland, ME 04104-9300, and 
3. 	 Richard Sedman, Ph.D., Toxicologist, Office of Environmental Health Hazard Assessment, 
California Environmental Protection Agency, Oakland, CA. 
These experts collectively have knowledge of chromium’s physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final
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1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about chromium and the effects of exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term
federal clean-up activities. Chromium has been found in at least 1,127 of the 1,699 current or former 
NPL sites. Although the total number of NPL sites evaluated for this substance is not known, the 
possibility exists that the number of sites at which chromium is found may increase in the future as more 
sites are evaluated.  This information is important because these sites may be sources of exposure and 
exposure to this substance may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  Such a release does not always lead to exposure.  You 
can be exposed to a substance only when you come in contact with it.  You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact. 
If you are exposed to chromium, many factors will determine whether you will be harmed.  These factors 
include the dose (how much), the duration (how long), the form (chromium VI as opposed to chromium III), 
and how you come in contact with it.  You must also consider any other chemicals you are exposed to and
your age, sex, diet, family traits, lifestyle, and state of health. 
   
 










   




   
  

















    
 
    
 
      
     
 














1.  PUBLIC HEALTH STATEMENT
1.1  WHAT IS CHROMIUM?
Description Chromium is a naturally-occurring element found in rocks, animals, plants,
and soil, where it exists in combination with other elements to form various
compounds.  




Small amounts of chromium(III) are needed for human health.
Uses
• manufacturing Chromium is widely used in manufacturing processes to make various
metal alloys such as stainless steel.  
Consumer
products
Chromium can be found in many consumer products such as:
• wood treated with copper dichromate,
• leather tanned with chromic sulfate, and
• stainless steel cookware.
• metal-on-metal hip replacements
1.2  WHAT HAPPENS TO CHROMIUM WHEN IT ENTERS THE ENVIRONMENT?  
Sources Chromium can be found in air, soil, and water after release from industries
that use chromium, such as industries involved in electroplating, leather
tanning, textile production, and the manufacture of chromium-based 
products.  Chromium can also be released into the environment from the 
burning of natural gas, oil, or coal.
Break down
• air
• water and soil
Chromium does not usually remain in the atmosphere, but is deposited 
into the soil and water.
Chromium can change from one form to another in water and soil,
















































1. PUBLIC HEALTH STATEMENT 
1.3 HOW MIGHT I BE EXPOSED TO CHROMIUM?
Air exposure You can be exposed to trace levels of chromium by breathing air 
containing it.  Releases of chromium into the air can occur from:  
• industries using or manufacturing chromium
 • living near a hazardous waste facility that contains chromium
 • cigarette smoke
Rural or suburban air generally contains lower concentrations of chromium 
than urban air.   
• <10 ng/m3 in rural areas 
• 0–30 ng/m3 in urban areas  
• as a result of smoking, indoor air contaminated with chromium can be 
10–400 times greater than outdoor air concentrations
Workplace air A large number of workers are potentially exposed to chromium.  The 
highest potential exposure occurs in the metallurgy and tanning industries, 
where workers may be exposed to high air concentrations.   
Water and soil Chromium is occasionally detected in groundwater, drinking water, or soil 
samples.  Some ways to be exposed to chromium include:   
• drinking water containing chromium
 • bathing in water containing chromium
Food The general population is most likely to be exposed to trace levels of 
chromium in the food that is eaten. Low levels of chromium(III) occur 
naturally in a variety of foods, such as fruits, vegetables, nuts, beverages, 
and meats.   
1.4 HOW CAN CHROMIUM ENTER AND LEAVE MY BODY?  
Enter your body
 • inhalation 
 • ingestion
 • dermal 
contact
When you breathe air containing chromium, some of the chromium will enter 
your body through your lungs.  Some forms of chromium can remain in the 
lungs for several years or longer. 
A small percentage of ingested chromium will enter the body through the 
digestive tract.  
When your skin comes in contact with chromium, small amounts of 
chromium will enter your body. 
Leave your body Chromium(VI) is changed to chromium(III) in the body.  Most of the 
chromium leaves the body in the urine within a week, although some may 
remain in cells for several years or longer.
   
 





































   











1.  PUBLIC HEALTH STATEMENT
1.5  HOW CAN CHROMIUM AFFECT MY HEALTH?
This section looks at studies concerning potential health effects in animal and human studies.
Respiratory tract The most common health problem in workers exposed to chromium
involves the respiratory tract.  These health effects include irritation of the 
lining of the nose, runny nose, and breathing problems (asthma, cough,
shortness of breath, wheezing). Workers have also developed allergies to 
chromium compounds, which can cause breathing difficulties and skin 
rashes.
The concentrations of chromium in air that can cause these effects may be 
different for different types of chromium compounds, with effects occurring 
at much lower concentrations for chromium(VI) compared to chromium(III).
However, the concentrations causing respiratory problems in workers are at
least 60 times higher than levels normally found in the environment.
Respiratory tract problems similar to those observed in workers have been 
seen in animals exposed to chromium in air.
Stomach and The main health problems seen in animals following ingestion of
small Intestine chromium(VI) compounds are to the stomach and small intestine (irritation 
and ulcer) and the blood (anemia).  Chromium(III) compounds are much 
less toxic and do not appear to cause these problems.  
Male reproductive
system
Sperm damage and damage to the male reproductive system have also 
been seen in laboratory animals exposed to chromium(VI).
Cancer The International Agency for Research on Cancer (IARC) has determined 
that chromium(VI) compounds are carcinogenic to humans. The National
Toxicology Program 11th Report on Carcinogens classifies chromium(VI)
compounds as known to be human carcinogens.
In workers, inhalation of chromium(VI) has been shown to cause lung 
cancer.  Mixed results have been found in studies of populations living in 
areas with high levels of chromium(VI) in the drinking water.  
In laboratory animals, chromium(VI) compounds have been shown to cause 
tumors to the stomach, intestinal tract, and lung.
   
 








   
 
   
  
 
    
   
































   











1.  PUBLIC HEALTH STATEMENT
1.6  HOW CAN CHROMIUM AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from
conception to maturity at 18 years of age.
Effects in children There are no studies that have looked at the effects of chromium exposure 
on children.  It is likely that children would have the same health effects as
adults. We do not know whether children would be more sensitive than
adults to the effects of chromium.
Developmental
effects
There are no studies showing that chromium causes birth defects in 
humans.
In animals, some studies show that exposure to high doses during 
pregnancy may cause miscarriage, low birth weight, and some changes in 
development of the skeleton and reproductive system.  Developmental
effects in animals may be related, in part, to chromium toxicity in the 
mothers.








Chromium is a component of tobacco smoke.  Avoid smoking in enclosed
spaces like inside the home or car in order to limit exposure to children and 
other family members.
In the past, pressure treated wood used chromated copper arsenate;
however, the use of this product in residential settings was discontinued
effective December 31, 2003.  Avoiding older pressure treated lumber can 
reduce your risk of exposure to chromium.  You may also have your water
tested to ensure that you are not exposed to high levels of chromium.
Clothing or items removed from the workplace may contain chromium if you 
are employed in a setting where occupational exposure is significant.
Therefore, common sense hygiene and laundry practices may help avoid 
unnecessary exposures.
If your doctor finds that you have been exposed to significant amounts of chromium, ask whether your
children might also be exposed.  Your doctor might need to ask you state health department to investigate.
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1.  PUBLIC HEALTH STATEMENT




Since chromium is a required nutrient in the body and is normally present in
food, chromium is normally present in blood, urine, and body tissues.
Measuring
exposure
Higher than normal levels of chromium in blood or urine may indicate that a 
person has been exposed to chromium.  However, increases in blood and 
urine chromium levels cannot be used to predict the kind of health effects
that might develop from that exposure.
1.9  	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  Regulations
can be enforced by law.  The EPA, the Occupational Safety and Health Administration (OSHA), and the
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic
substances.  Recommendations provide valuable guidelines to protect public health, but cannot be
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels. These are levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value. This critical value is usually based
on levels that affect animals; they are then adjusted to levels that will help protect humans.  Sometimes
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that provides it.
Some regulations and recommendations for chromium include the following:
   
 











   
       
         
          










   























     
   
 
 
   
     
   
  
   
   
 
7CHROMIUM
1.  PUBLIC HEALTH STATEMENT
Levels in drinking The EPA has established a maximum contaminant level of 0.1 mg/L for total
water set by EPA chromium in drinking water. EPA currently seeks voluntary monitoring of
hexavalent chromium in drinking water by municipalities. However, it is
reviewing health effects data of hexavalent chromium and may set limits on its
levels in drinking water in the future.
Levels in bottled
water set by FDA
The FDA has determined that the chromium concentration in bottled 
drinking water should not exceed 0.1 mg/L.
Levels in OSHA set a legal limit for chromium(VI) of 0.005 mg/m3 chromium in air
workplace air set averaged over an 8-hour work day, for chromium(III) of 0.5 mg/m3 chromium
by OSHA in air averaged over an 8-hour work day, and for chromium(0) of 1.0 mg/m3 
chromium in air averaged over an 8-hour work day.
Levels in NIOSH recommends an exposure limit of 0.5 mg/m3 chromium as chromium
workplace air set metal and chromium(II) and chromium(III) compounds in air averaged over
by NIOSH an 8-hour work day.  NIOSH also recommends an exposure limit of
0.001 mg/m3 for chromium(VI) compounds in air averaged over 10-hour
work day.
1.10  WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location of occupational and environmental health clinics. These clinics
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You may
request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing
to: 
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences (proposed)




   
 








   
 
    
   
   
   
   
 
8CHROMIUM
1.  PUBLIC HEALTH STATEMENT
Organizations for-profit may request copies of final Toxicological Profiles from the following:
National Technical Information Service (NTIS)
5285 Port Royal Road
Springfield, VA 22161
Phone: 1-800-553-6847 or 1-703-605-6000
Web site:  http://www.ntis.gov/

















     
     
 
 
   
  
  
    
   
  
 








      
    
    
   
 
   
9CHROMIUM
2. RELEVANCE TO PUBLIC HEALTH  
2.1  	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO CHROMIUM IN THE
UNITED STATES
Chromium is a naturally occurring element present in the earth’s crust.  Chromium is released to the 
environment from natural and anthropogenic sources, with the largest release occurring from industrial
releases. The industries with the largest contribution to chromium release include metal processing,
tannery facilities, chromate production, stainless steel welding, and ferrochrome and chrome pigment
production.  The estimated atmospheric concentrations of chromium in U.S. urban and nonurban areas
typically contains mean total chromium concentrations ranging from 5 to 525 ng/m3. The levels of
chromium in U.S. fresh waters typically range from <1 to 30 μg/L, with a median value of 10 μg/L. 
Typical U.S. drinking water supplies contain total chromium levels within a range of 0.2–35 μg/L
however, most supplies in the United States contain <5 µg/L of chromium.  Recent monitoring data of
drinking water supplies in California indicated that 86% of the sources tested had levels of chromium
(reported for chromium(VI)) below 10 μg/L. U.S. soil levels of total chromium range from 1 to 
2,000 mg/kg, with a mean level of 37 mg/kg.  In ocean water, the mean chromium concentration is
0.3 μg/L. 
The general population is exposed to chromium by inhaling ambient air, ingesting food, and drinking 
water containing chromium.  Dermal exposure of the general public to chromium can occur from skin 
contact with certain consumer products or soils that contain chromium.  The primary route of
nonoccupational workers, however, is food ingestion.  Chromium content in foods varies greatly and 
depends on the processing and preparation.  In general, most fresh foods typically contain chromium
levels ranging from <10 to 1,300 μg/kg.  Present-day workers in chromium-related industries can be 
exposed to chromium concentrations 2 orders of magnitude higher than the general population.  
2.2  	 SUMMARY OF HEALTH EFFECTS 
Chromium as an Essential Nutrient. Chromium(III) is an essential nutrient required for normal energy
metabolism.  The Institute of Medicine (IOM) of the National Research Council (NRC) determined an
adequate intake (e.g., a level typically consumed by healthy individuals) of 20–45 μg chromium(III)/day
for adolescents and adults. IOM reported average plasma chromium concentrations of 2–3 nmol/L
(equivalent to 0.10–0.16 μg/L) and an average urinary chromium excretion of 0.22 μg/L or 0.2 μg/day. 
Currently, the biological target for the essential effects of chromium(III) is unknown.  Chromodulin, also 
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referred to as glucose tolerance factor (GTF), has been proposed as one possible candidate.  The function
of chromodulin, an oligopeptide complex containing four chromic ions, has not been established;
however, a possible mechanism is that chromodulin facilitates the interaction of insulin with its cellular
receptor sites, although this has not been proven. 
Although the Institute of Medicine considers chromium(III) an essential element, some critics question its
essentiality.  Reports of chromium(III) deficiency are rare and there is no recognized disease that is 
attributed to chromium deficiency as there is with most other essential minerals (e.g., Wilson’s disease for
people with copper deficiency).  Evidence of overt signs of apparent chromium deficiency in humans is
limited to a few case reports.  In one such case report, a woman receiving total parenteral nutrition for
3 years exhibited peripheral neuropathy, weight loss, and impaired glucose metabolism.  Administration 
of insulin did not improve glucose tolerance.  Administration of 250 μg/day chromium without exogenous
insulin resulted in normal glucose tolerance of an oral load of glucose and the absence of peripheral
neuropathy.  Thus, direct evidence of chromium(III) deficiency in humans is lacking. In animals, severe 
chromium deficiency is also difficult to induce, but when it was induced hyperglycemia, decreased weight
gain, elevated serum cholesterol levels, aortic plaques, corneal opacities, impaired fertility, and lethality
were observed.  Administration of inorganic trivalent chromium compounds or extracts of brewers' yeast
resulted in decreased blood glucose levels and cholesterol levels and regression of atherosclerotic plaques.  
Improved insulin sensitivity also resulted in an increased incorporation of amino acids into proteins and 
cell transport of amino acid in rats receiving supplemental chromium.  Thus, whether chromium is a true
essential element or a pharmacological agent is still under debate.
Studies have shown that chromium supplementation (Brewer's yeast, extracts of brewer's yeast, synthetic 
chromium compounds with biological activity, chromium(III) picolinate, and inorganic trivalent
chromium) in deficient and marginally deficient subjects can result in improved glucose, protein, and 
lipid metabolism. In general, these studies have demonstrated improved glucose tolerance to an oral
glucose load in Type II diabetics (adult onset) and nondiabetic elderly subjects receiving a 4–200 μg/day 
chromium supplement  and improved plasma lipid profiles (e.g., decreased total cholesterol, LDL-
cholesterol, and serum lipids and increased in HDL-cholesterol); improvements in serum lipids and 
cholesterol levels may be secondary to the decreased serum glucose levels.
Chromium picolinate has been used as a dietary supplement to aid in weight loss and increase lean body
mass; however, the role of chromium in the regulation of lean body mass, percentage body fat, and weight
reduction is highly controversial with negative and positive results being reported in the literature.  
   
 








   




    
   
    
  
   
   
   
    
    
   
  

















2. RELEVANCE TO PUBLIC HEALTH
Numerous studies have evaluated the relationship between weight loss or increases in lean body mass in
active and sedentary adults and chromium picolinate supplementation, with mixed results reported.  
Information on adverse health effects of chromium(III) compounds, including dietary supplements, in 
humans and animals is reviewed below.  However, based on a limited number case studies reporting
adverse effects in humans ingesting high-dose chromium(III) supplements, individuals using chromium
supplements are cautioned to avoid taking more than recommended doses.
Chromium Toxicokinetics. The toxicokinetics of a given chromium compound depend on the valence
state of the chromium atom and the nature of its ligands.  For inhaled chromium compounds of any
valence state, the amount and location of deposition of inhaled chromium will be determined by factors
that influence convection, diffusion, sedimentation, and interception of particles in the airways.  In
general, less water-soluble chromium compounds that deposit in the pulmonary region can be expected to 
have a longer retention time in the lung than more soluble forms.  Most quantitative studies of the 
gastrointestinal absorption of chromium in humans have estimated the absorption fraction to be <10% of
the ingested dose.  In general, these studies suggest that the absorption fraction of soluble chromium
compounds is higher than insoluble forms (e.g., CrCO3), and is higher for soluble chromium(VI)
compounds (e.g., K2Cr2O7) than soluble chromium(III) (e.g., CrCl3).  Chromium(VI) is reduced in the
stomach to chromium(III), which lowers the absorbed dose from ingested chromium(VI).  Absorption is
also affected by nutritional status.  The absorption fraction is higher when dietary intakes are lower. 
Chromium(III) and chromium(VI) can penetrate human skin to some extent, especially if the skin is
damaged.
Absorbed chromium distributes to nearly all tissues, with the highest concentrations found in kidney and 
liver.  Bone is also a major depot and may contribute to long-term retention kinetics of chromium.  
Chromium(VI) is reduced to chromium(III) via the intermediate forms of chromium(V) and 
chromium(IV).  Reduction of chromium(VI) to chromium(III) can give rise to reactive intermediates,
chromium adducts with proteins and deoxyribonucleic acid (DNA), and secondary free radicals.  
Chromium(VI) in blood is taken up into red blood cells, where it undergoes reduction and forms stable 
complexes with hemoglobin and other intracellular proteins, which are retained for a substantial fraction 
of the red blood cell lifetime.  Absorbed chromium can be transferred to fetuses through the placenta and 
to infants via breast milk.  Absorbed chromium is excreted predominantly in urine.  Chromium has been 
shown to be secreted in bile of animals following parenteral (e.g., intravenous) injection of chromium(VI)
or chromium(III) compounds.  Chromium can also be eliminated by transfer to hair and nails.
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2. RELEVANCE TO PUBLIC HEALTH
Health Effects of Chromium. The health effects associated with exposures to chromium(VI), 
chromium(III) and chromium (IV) are reviewed in detail in Chapter 3.  In general, chromium(VI)
compounds are more toxic than chromium(III) compounds.  The higher toxic potency of chromium(VI)
compared to chromium(III) is complex.  Chromium(VI) enters cells by facilitated uptake, whereas
chromium(III) crosses cell membranes by simple diffusion; thus, cellular uptake of chromium(VI) is more 
effective than the uptake of chromium(III).  Furthermore, in biological systems, reduction of
chromium(VI) to chromium(III) results in the generation of free radicals, which can form complexes with
intracellular targets.  Health effects of chromium compounds can vary with route of exposure, with 
certain effects specific for the portal of entry.  For example, respiratory effects are associated with
inhalation of chromium compounds, but not with oral and dermal exposures, and gastrointestinal effects
are primarily associated with oral exposure.  However, as described below, effects of chromium are not
limited to the portal of entry, with hematological, immunological, and reproductive systems also
identified as targets for chromium.  In addition to noncancer health effects, results of occupational
exposure studies and chronic-duration animal studies indicate that inhalation and oral exposures to 
chromium(VI) compounds are associated with respiratory and gastrointestinal system cancers,
respectively (see discussion under chromium(VI) below for additional information).
Chromium(VI)
The primary effects associated with exposure to chromium(VI) compounds are respiratory, 
gastrointestinal, immunological, hematological, reproductive, and developmental.  In addition, dermal and
ocular irritation may occur from direct contact.  Based on available dose-response data in humans and 
animals, the most sensitive noncancer effects of chromium(VI) compounds are respiratory (nasal and lung
irritation, altered pulmonary function), gastrointestinal (irritation, ulceration and nonneoplastic lesions of
the stomach and small intestine), hematological (microcytic, hypochromic anemia), and reproductive 
(effects on male reproductive organs, including decreased sperm count and histopathological change to
the epididymis).  As reviewed below, respiratory and gastrointestinal effects appear to be portal-of-entry 
effects for inhalation and oral exposure, respectively.  Similarly, chromium sensitization, the major
immunological effect of chromium(VI), typically presents as allergic contact dermatitis resulting from
dermal exposures in sensitized individuals, although respiratory effects of sensitization (asthma) may also
occur.  Accidental or intentional ingestion of extremely high doses of chromium(VI) compounds by
humans has resulted in severe respiratory, cardiovascular, gastrointestinal, hematological, hepatic, renal,
and neurological effects as part of the sequelae leading to death or in patients who survived because of
medical treatment.
   
 









         
 
 
    
    




    
  
 
   
  
 
    
     
   
    
    
      
        
    
   
   






2. RELEVANCE TO PUBLIC HEALTH
Respiratory Effects. The respiratory tract is the major target of inhalation exposure to chromium(VI)
compounds in humans and animals.  Respiratory effects have been observed in workers in the following
chromium-related industries:  chrome plating, chromate and dichromate production, stainless steel 
welding, and possibly ferrochromium production and chromite mining.  Respiratory effects due to
inhalation exposure are probably due to direct action of chromium at the site of contact.  Intermediate-
and chronic-duration exposure of workers to chromium(VI) compounds has resulted in epistaxis, chronic
rhinorrhea, nasal itching and soreness, nasal mucosal atrophy, perforations and ulceration of the nasal
septum, bronchitis, pneumonoconiosis, decreased pulmonary function, and pneumonia.  In some
chromium-sensitive patients, inhalation of airborne chromium(VI) compounds in the workplace has
resulted in asthma.  Nasal irritation and mucosal atrophy and decreases in pulmonary function have
occurred at occupational exposure levels ≥0.002 mg chromium(VI)/m3 as chromium trioxide mist.  
Autopsies of humans who died from cardiopulmonary arrest after ingesting chromium(VI) compounds
have revealed pleural effusion, pulmonary edema, bronchitis, and acute bronchopneumonia.  Respiratory 
effects due to ingestion of nonlethal doses are not likely to occur.  It is not certain whether skin contact
with chromium compounds could result in respiratory effects.
Adverse effects on the respiratory system following inhalation exposure to chromium(VI) have also been 
observed in animals.  Acute- and intermediate-duration exposure to moderate levels of chromium(VI)
compounds generally caused mild lung irritation, accumulation of macrophages, hyperplasia, 
inflammation, and impaired lung function.  A lowest-observed-adverse-effect level (LOAEL) of 0.025 mg
chromium(VI)/m3 as potassium dichromate particles for increased percentage of lymphocytes in
bronchoalveolar lavage (BAL) fluid in rats exposed for 28 or 90 days was identified.  Obstructive
respiratory dyspnea at ≥0.2 mg chromium(VI)/m3, fibrosis at ≥0.1 mg chromium(VI)/m3, and hyperplasia
at ≥0.05 mg chromium(VI)/m3 were found in the lungs of rats exposed to sodium dichromate for 30 or
90 days.  The fibrosis and hyperplasia were reversible. Increases in the levels of total protein, albumin,
and activity of lactate dehydrogenase and β-glucuronidase were observed in the bronchoalveolar lavage 
fluid.  Nasal septum perforation, hyperplasia and metaplasia of the larynx, trachea, and bronchus, and 
emphysema developed in mice exposed to chromium trioxide mists for 1 year.  Mice exposed chronically
to 4.3 mg chromium(VI)/m3 as calcium chromate also had epithelial necrosis and hyperplasia of the 
bronchiolar walls.
Gastrointestinal Effects.    Acute oral exposure of humans to lethal or near-lethal doses of
chromium(VI) has produced adverse gastrointestinal effects, including abdominal pain, vomiting, 
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gastrointestinal ulceration, hemorrhage and necrosis, and bloody diarrhea.  Gastrointestinal effects have 
also been reported in association with chronic oral exposure of humans to chromium(VI).  In a cross-
sectional study conducted in 1965 of 155 people whose well water contained 20 mg chromium(VI)/L as a 
result of pollution from an alloy plant in the People's Republic of China, associations were found between 
drinking the contaminated water and oral ulcer, diarrhea, abdominal pain, indigestion, and vomiting.  
Epigastric pain, irritation, and ulceration have been reported in occupational studies of chrome plating and
chromate production workers.  Exposures in these studies included inhalation and ingestion of chromium
(e.g., mucocilliary clearance of inhaled chromium particles to the gastrointestinal tract and/or ingestion 
secondary to hand-to-mouth activity) and outcomes may have been influenced by other factors, such as 
stress and diet.  Gastrointestinal effects from dermal exposures or absorption of inhaled chromium(VI) are 
not anticipated.
Studies in animals show that the gastrointestinal system is a primary target of intermediate- and chronic-
duration oral exposure to chromium(VI).  Adverse effects were observed in the gastrointestinal tract of
F344/N rats and B6C3F1 mice exposed to sodium dichromate dihydrate in drinking water for 14 weeks, 
with LOAEL values of 3.5 mg chromium(VI)/kg/day for duodenal histiocytic infiltration of the
duodenum in male and female rats and of 3.1 mg chromium(VI)/kg/day for epithelial hyperplasia in mice.  
At a higher dose (20.9 mg chromium(VI)/kg/day), more severe effects (ulcer and epithelial hyperplasia
and metaplasia of the glandular stomach) were observed in rats.  Histopathological changes of the 
duodenum (epithelial hyperplasia and histiocytic cellular infiltrate) were also reported in a 3-month 
comparative study in male B6C3F1, BALB/c, and C57BL/6 mice exposed to sodium dichromate
dihydrate in drinking water for 14 weeks, a LOAEL values of 2.8 mg chromium(VI)/kg/day.  After 
exposure for 2 years, histopathological changes were observed in the gastrointestinal tract of rats and
mice.  In male and female rats exposed to 0.77 and 2.4 chromium(VI)/kg/day, respectively, histiocytic
infiltration of the duodenum was observed.  In mice, duodenal epithelial hyperplasia was observed in 
males and females at 0.38 mg chromium(VI)/kg/day and histiocytic cellular infiltration of the duodenum
was observed in males at 2.4 mg chromium(VI)/kg/day and in females at 3.1 mg chromium(VI)/kg/day.  
Results of intermediate-duration inhalation studies in animals yield mixed results regarding the potential
for gastrointestinal effects.  Although rats exposed by inhalation to ≤0.2 mg chromium(VI)/m3 as sodium
dichromate for ≤90 days did not have histopathological changes in the gastrointestinal tract, mice exposed
chronically to 4.3 mg chromium(VI)/m3 were reported to have occasional small ulcerations in the
stomach and intestinal mucosa; however, the potential of oral exposure via grooming behavior cannot be
excluded.
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Immunological Effects. Exposure to chromium(VI) compounds may lead to allergic sensitization in 
some individuals.  Sensitization to chromium is produced through two types of hypersensitivity reactions:
type I, an immediate onset, IgE-mediated immune mechanism, and type IV, a delayed, cell-mediated
immune mechanism.  Following an induction phase during which the individual becomes sensitized,
subsequent exposures result in an allergic response, with symptoms typically presenting as dermatitis or
asthma.  Sensitization may occur from inhalation, oral, and/or dermal exposure.  Estimates of the
prevalence of chromium sensitivity in the general U.S. population range from 0.08 to 7%, depending
upon the population evaluated.  For dermal responses, the allergic response following direct skin contact
with chromium compounds is characterized by eczema or dermatitis; typically, chromium-induced 
allergic contact dermatitis is isolated to areas at the site of contact, rarely occurring in areas remote from
the point of contact.  However, oral exposure to chromium(VI) has been shown to exacerbate dermatitis
of sensitive individuals. The acute response phase lasts for a few days to a few weeks and is
characterized by erythema, edema, and small and large blisters; the chronic phase exhibits similar clinical
features, but may also include thickened, scaly, and fissured skin.  Exposure to chromium compounds in 
chromium-related occupations appears to be the major cause of chromium contact dermatitis.  Patch
testing has identified chromium-sensitized workers in the printing and lithography industry, in automobile
factories where assemblers handled nuts, bolts, and screws, in wet sandpapering of primer paint where
workers were exposed to zinc chromate, in the cement industry, in railroad systems and diesel locomotive
repair shops where antirust diesel-engine coolants and radiator fluids contained sodium chromate, in 
tanneries, and in the welding, plating, wood, and paper industries.  Other sources of chromium that have
resulted in chromium sensitivity include dichromate-containing detergents and bleach, glues, machine
oils, foundry sand, match heads, boiler linings, and magnetic tapes.  Exposure to low levels of chromium
as found in consumer products could result in sensitization or a reaction in sensitized individuals;
therefore, in hypersensitive individuals may develop rashes and erythema from contact with consumer
products containing chromium.  Oral doses of potassium dichromate exacerbated the dermatitis of
sensitive individuals.
Several studies have estimated the exposure level required to elicit a dermal response in chromium-
sensitized individuals; exposure levels of 4–25 ppm produced sensitization and elicitation of chromium-
induced allergic dermatitis.  However, confounding factors, such as variability in testing methods
(including different chromium compounds used in challenge testing) and individual sensitivity, 
complicate interpretation of results.  Furthermore, the response of an individual to dermal challenge may
vary over time due to changes in exposure to the sensitizing agents; if an individual is removed from
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exposure, circulating IgE levels may decrease, resulting in decreased sensitivity to dermal challenge.  
Therefore, it is anticipated that the exposure level required to elicit a dermal response in sensitized
individuals will be highly variable.
Asthmatic attacks have occurred in chromium-sensitive individuals exposed by inhalation in occupational
settings to chromium trioxide vapors and chromium fumes from stainless steel welding.  When 
challenged with sodium chromate or potassium dichromate via nebulizer, chromium-sensitive patients
displayed anaphylactoid reactions, characterized by dermatitis, facial angioedema and erythema,
nasopharyngeal pruritus, cough, wheezing, bronchospasms, increased plasma histamine levels, urticaria, 
and decreased forced expiratory volume.  While chromium-induced asthma might occur in some
sensitized individuals exposed to elevated concentrations of chromium in air, the number of sensitized 
individuals is low, and the number of potentially confounding variables in the chromium industry is high.
Studies in animals also indicate that the immune system is a target for inhaled and ingested chromium(VI)
compounds.  Effects reported include stimulation of the humoral immune system and increased 
phagocytic activity of macrophages, increased proliferative responses of splenocytes to T- and B-cell
mitogens and to the antigen mitomycin C and histopathological alteration (histiocytic cellular infiltration)
of pancreatic lymph nodes; contact dermatitis has been elicited in guinea pigs and mice. 
Hematological Effects. As discussed above (Chromium Toxicokinetics), chromium(VI) is
distributed to and accumulated by the erythrocyte; once inside the cell, it is rapidly reduced to 
chromium(III) via the reactive intermediates chromium(V) and chromium(IV), and binds to hemoglobin 
and other ligands.  The chromium-hemoglobin complex is relatively stable and remains sequestered
within the cell over the life-span of the erythrocyte, with approximately 1% of chromium eluting from the
erythrocyte daily.  Occupational studies and other studies in humans have not consistently reported 
hematological effects, although microcytic, hypochromic anemia has been reported in several recent
animals studies on chromium(VI) compounds (detailed discussion follows).  However, it is possible that
small, exposure-related changes in hematological parameters may not have been detected in occupational
exposure studies, if values were within normal clinical ranges.  Hematological findings in humans 
exposed to lethal doses of chromium(VI) compounds are difficult to interpret in the context of multiple
systemic effects observed leading up to death, including hemorrhage.
Results of acute-, intermediate-, and chronic-duration studies in animals identify the hematological 
system as one of the most sensitive effects of oral exposure to chromium(VI).  Microcytic, hypochromic
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anemia, characterized by decreased mean cell volume (MCV), mean corpuscular hemoglobin (MCH),
hematocrit (Hct), and hemoglobin (Hgb), was observed in rats and mice orally exposed to chromium(VI)
compounds for exposure durations ranging from 4 days to 1 year. The severity of anemia exhibited dose-
and duration-dependence, with maximum effects observed after approximately 3 weeks of exposure; with
increasing exposures durations (e.g., 14 weeks–1 year), anemia is less severe, presumably due to
compensatory hematopoietic responses.  In general, effects observed in rats were more severe than those
in mice. 
Acute exposure of male rats to sodium dichromate dihydrate in drinking water for 4 days, produced a
slight, but statistically significant decrease (2.1%) in MCH in rats exposed to 2.7 mg chromium(VI)/ 
kg/day, but not at 0.7 mg chromium(VI)/kg/day.  With increasing doses (≥7.4 mg chromium(VI)/kg/day), 
additional decreases in MCH and decreased MCV were observed.  Similar effects were observed in male 
and female rats exposed for 5 days, with effects observed at 4.0 and 4.1 chromium(VI)/kg/day, 
respectively; a no-observed-adverse-effect level (NOAEL) was not established.  Although the magnitude
of changes to hematological parameters after acute exposure was minimal, since severe effects on
hematological parameters were observed following intermediate exposure durations, with severity
peaking at exposure durations of 22 days to 3 months, the minimal hematological alterations observed 
following acute exposure are considered to be indicative of adverse hematological effects.
More severe microcytic, hypochromic anemia occurred in rats and mice following exposure to sodium
dichromate dihydrate in drinking water for 22 or 23 days.  Decreased Hct, Hgb, MCV, and MCH
occurred at ≥0.77 mg chromium(VI)/kg/day, with decreases exhibiting dose-dependence; effects were not
observed at 0.21 mg chromium(VI)/kg/day.  After exposure for 3 months to 1 year, microcytic, 
hypochromic anemia in rats and mice was less severe than that observed after 22 or 23 days.  
Hematological effects, including decreased hematocrit, hemoglobin, and erythrocyte count, have also 
been reported in rats exposed to chromium trivalent oxide mist for 90 days, with a LOAEL value of
0.23 mg chromium(VI)/m3.
Reproductive Effects. Results of studies in humans and animals suggest that chromium(VI) causes 
adverse reproductive effects, although evidence from studies in animals is much stronger than from
studies in humans.  Although information regarding reproductive effects in humans is limited, the
following effects have been reported: a significant increase in the number of morphologically abnormal
sperm; significant decreases on sperm count and motility; and greater incidences of complications during
   
 













   
  
  
   
  
  
   
 
   
 
 
   
  
 
   
  
 










2. RELEVANCE TO PUBLIC HEALTH
pregnancy and childbirth (toxicosis and postnatal hemorrhage).  There no evidence of reproductive effects
in humans environmentally exposed to chromium(VI). 
Studies in laboratory animals show that acute- and intermediate-duration exposure to chromium(VI)
produces adverse reproductive effects, with the male reproductive system exhibiting the highest
sensitivity.  Following a 6-day gavage administration of ≥5.2 mg chromium(VI)/kg/day as chromic acid
to Wister rats, decreased sperm count, increased percentage of abnormal sperm, and morphological
changes to seminiferous tubules (decreased diameter of seminiferous tubules and germ cell
rearrangement) were observed (observations were made 6 weeks after completion of treatment); a
NOAEL was not defined in this study.  The male reproductive system was identified as a target for oral
chromium(VI) exposure in intermediate-duration studies in monkeys, rats, and rabbits.  Decreased sperm
count and motility and histopathological changes to the epididymis (ductal obstruction, development of
microcanals, depletion of germ cells, hyperplasia of Leydig cells, and Sertoli cell fibrosis) have been
reported in monkeys exposed to 2.1 mg chromium(VI)/kg/day as potassium dichromate in drinking water
for 180 days.  Effects on male reproductive organs and sexual behavior in rats and mice have been
reported at doses of ≥2.6 mg chromium(VI)/kg/day. 
In NTP studies designed to confirm or refute these findings of one study, the reproductive effects of
different concentrations of chromium(VI) as potassium dichromate in the diet on BALB/c mice and 
Sprague-Dawley rats were investigated.  Microscopic examinations of the testes and epididymis for
Sertoli nuclei and preleptotene spermatocyte counts in stage X or XI tubules did not reveal any treatment-
related effects at daily doses up to 32.2 mg chromium(VI)/kg/day.  Similarly, exposure to sodium
dichromate dihydrate in drinking water did not produce morphological changes to male reproductive
organs of B6C3F1 mice exposed to 27.9 or 5.9 mg chromium(VI)/kg/day for 3 months or 2 years,
respectively, or affect sperm count or motility in male B6C3F1, BALB/c, and C57BL/6N mice exposed to 
8.7 mg chromium(VI)/kg/day for 3 months.
Other reproductive effects reported in rats and mice include altered weights of female reproductive 
organs, decreased number of follicles and ova, increased pre- and/or postimplantation losses, and 
increased resorptions at doses of ≥5 mg chromium(VI)/kg/day. Mixed results have been found in studies
designed to assess the effects of chromium(VI) exposure on fertility.  No effects on fertility were 
observed in mice exposed to ≤37 mg chromium(VI)/kg/day as potassium dichromate in the diet.  
Decreased mating and fertility, increased preimplantation losses, and increased resorptions have been 
observed in rats and mice exposed to ≥37 mg chromium(VI)/kg/day or 52 mg chromium(VI)/kg/day as
   
 








      
    
   
  
   
   
   
  
 
    
      
 
 
       
   
    
 
  
   












2. RELEVANCE TO PUBLIC HEALTH
potassium dichromate in drinking water for 20 or 90 days prior to mating.  Pre- and postimplantation loss
and decreased litter size was also observed in mice exposed to ≥46 mg chromium(VI)/kg/day as
potassium dichromate in drinking water throughout gestation.  Significant decreases in the number of
implantations and viable fetuses were observed when male mice exposed to 6 mg chromium(VI)/kg/day
as potassium dichromate in drinking water for 12 weeks were mated with unexposed female mice;
however, sperm count was not measured and the classification of non-viable fetuses was not presented in
this report.  However, a similarly designed study did not find any alterations in the number of
implantations or viable fetuses in unexposed female rats mated with males exposed to 42 mg
chromium(VI)/kg/day as potassium dichromate in drinking water for 12 weeks.  It is not known if the
species difference contributed to these conflicting results.  Decreases in the number of implantations and
viable fetuses and an increase in the number of animals with resorptions were also seen in females 
exposed for 12 weeks to 6 mg chromium(VI)/kg/day as potassium dichromate mated with unexposed 
males. 
Developmental Effects. No studies were located regarding developmental effects in humans after
exposure to chromium compounds.  A number of oral exposure animal studies have shown that
chromium(VI) is a developmental toxicant following premating and/or in utero exposure, or lactational
exposure.  In developmental studies in rats and mice, gestational exposure produced increased 
postimplantation loss, decreased number of live fetuses/litter, decreased fetal weight, internal and skeletal 
malformations, and delayed sexual maturation in offspring; however, these effects were observed at
relatively high doses (e.g., ≥35 mg chromium(VI)/kg/day).  In mated female rats administered 35.7 mg
chromium(VI)/mg/day as potassium dichromate by gavage on gestational days 1–3, a decreased number
of pregnancies were observed; exposure on gestational days 4–6 resulted in decreased number of viable 
fetuses and increased number of resorptions, but did not alter the number of pregnancies.  Exposure of
female rats to ≥37 mg chromium(VI)/kg/day and mice to ≥52 mg chromium(VI)/kg/day to potassium
dichromate(VI) in drinking water for 20 or 90 days followed by mating to unexposed males resulted in 
fetal mortality (postimplantation losses, resorptions, and decreased number of live fetuses), decreased
growth (decreased fetal body weights and crown-rump length), reduced ossification, subdermal
hemorrhagic patches, and kinky tails.  Similar effects (increased resorptions, increased postimplantation 
losses, subdermal hemorrhages, decreased cranial ossification, tail kinking, and decreased fetal body
weight and decreased crown-rump length) were observed in the offspring of mice exposed to 46 mg
chromium(VI)/kg/day as potassium dichromate in drinking water during gestation.  In mice exposed to 
53 mg chromium(VI)/kg/day as potassium dichromate in drinking water during gestational days 6–14, 
fetal mortality, subdermal hemorrhagic patches, and reduced ossification were observed in the offspring.  
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Impaired development of the reproductive system (delayed vaginal opening) was observed in the 
offspring of mice exposed to 66 mg chromium(VI)/kg/day as potassium dichromate in the drinking water
on gestation day 12 through lactation day 20.  Delayed vaginal opening was also reported in offspring of
rats exposed to ≥2.9 mg chromium(VI)/kg/day as potassium dichromate in the drinking water on postnatal
days 1–21. Perinatal exposure to doses ≥2.9 chromium(VI)/kg/day as potassium dichromate in the
drinking water caused oxidative stress in the uterus, liver, kidney, and bone from the offspring.  
Microscopic examination of the kidney, liver, and bone showed morphological alterations in the three
tissues.  A single study reported that gavage administration of 4.4 mg chromium(VI)/kg/day as potassium
dichromate to neonatal rats reduced mandibular growth and delayed tooth eruption.   
Dermal Effects.    Chromium(VI) compounds can produce effects on the skin and mucous membranes.  
These include irritation, burns, ulcers, and an allergic type of dermatitis.  Irritation of respiratory mucosal
tissues, nasal septum ulcers, and perforation are reviewed above under Respiratory Effects and allergic
dermatitis is reviewed above under Respiratory Effects and Immunological Effects.  Most dermal effects 
reported were either due to occupational intermediate-chronic exposure or acute exposure to high levels
of chromium compounds.  Environmental exposure to chromium compounds is not likely to result in 
dermal effects.  Acute dermal exposure to chromium(VI) compounds can cause skin burns.  Application 
of a salve containing potassium chromate to the skin of some individuals to treat scabies resulted in 
necrosis and sloughing of the skin, and some individuals even died as a result of infections of these areas.  
A worker whose skin came into direct contact with the chromic acid as a result of an industrial accident
developed extensive skin burns.
Although skin contact with chromate salts may cause rashes, untreated ulcers or sores (also called chrome 
holes) on the skin can be a major problem because they can deeply penetrate the skin with prolonged 
exposure.  For example, in an early case of a tannery worker, the penetration extended into the joint, 
necessitating amputation of the finger.  However, chrome sores heal if exposure is discontinued, leaving a
scar.  Chrome sores are more often associated with occupational exposure to chromium(VI) compounds.  
Although chrome sores are more likely associated with direct dermal contact with solutions of chromates,
exposure of the skin to airborne fumes and mists of chromium(VI) compounds may contribute to the
development.  Industries that have been associated with the development of chrome sores in workers 
include chromate and dichromate production, chrome plating, leather tanning, planographic printing, and 
chromite ore processing.  Among the chromium(VI) compounds that workers in these industries are
exposed to are chromium trioxide, potassium dichromate, sodium dichromate, potassium chromate, 
sodium chromate, and ammonium dichromate.
   
 
















     
 
 
         
   




   
  
   
    
      










2. RELEVANCE TO PUBLIC HEALTH
In addition, tonsillitis, pharyngitis, atrophy of the larynx, and irritation and ulceration of mouth structures
and buccal mucosa can occur from exposure to high levels of chromium(VI) compounds. These effects 
were seen in workers in chrome plating plants, where excessively high concentrations of chromium
trioxide fumes were present.  High incidences of inflammation of oral structures, keratosis of the lips,
gingiva, and palate, gingivitis, and periodontis were also observed in chromate production workers.  Oral
doses of potassium dichromate exacerbated the dermatitis of chromium sensitized individuals.
Dermal effects observed in animals after direct application of potassium dichromate to their skin include
inflammation, necrosis, corrosion, eschar formation, and edema in rabbits and skin ulcers in guinea pigs. 
Ocular Effects. Ocular effects can occur as a result of direct contact of eyes with chromium(VI)
compounds.  Effects reported include corneal vesication in a man with ocular exposure to a drop or
crystal of potassium dichromate and congestion of the conjunctiva, discharge, corneal scar, and burns in 
chromate production workers as a result of accidental splashes.
Genotoxicity.    Numerous studies have evaluated the genotoxicity of chromium(VI) compounds.  
Results of occupational exposure studies in humans, although somewhat compromised by concomitant
exposures to other potential genotoxic compounds, provide evidence of chromium(VI)-induced DNA
strand breaks, chromosome aberrations, increased sister chromatid exchange, unscheduled DNA
synthesis, and DNA-protein crosslinks.  Although most of the older occupational exposure studies gave
negative or equivocal results, more recent studies have identified chromosomal effects in exposed
workers.  Findings from occupational exposure studies are supported by results of in vivo studies in
animals, in vitro studies in human cell lines, mammalian cells, yeast and bacteria, and studies in cell-free 
systems.
Cancer.    Occupational exposure to chromium(VI) compounds in various industries has been associated 
with increased risk of respiratory system cancers, primarily bronchogenic and nasal.  Among the 
industries investigated in retrospective mortality studies are chromate production, chromate pigment
production and use, chrome plating, stainless steel welding, and ferrochromium alloy production.  
Numerous studies of cancer mortality among chromate production workers have been reported.  
Collectively, these studies provide evidence for associations between lung cancer mortality and
employment in chromate production, with risks declining with improved industrial hygiene.  Less
consistently, nasal cancers have been observed.  In chromate pigment and chrome plating workers, 
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elevated lung cancer rates in comparison to reference populations (e.g., standard mortality ratios [SMRs])
and increased lung cancer rates in association with increased potential for chromium exposure (e.g., job
type, employment duration) have been reported.  Workers in the stainless steel welding and
ferrochromium alloy industries are exposed to chromium(VI) compounds, as well as other chemical
hazards that could contribute to cancer (e.g., nickel); however, results of studies of cancer mortality in
these populations have been mixed.  Environmental exposure of humans to chromium(VI) in drinking
water resulted in statistically significant increases in stomach cancer.  However, a re-analysis of these 
data using a more relevant control group did not find a significant increase in stomach cancer.  Another
study reported an increased incidence of liver, lung, and kidney and urogenital organ cancers in residents 
living in an area of Greece with elevated chromium(VI) levels in the drinking water.  Two other
ecological studies have not found elevated cancer risks in populations with contaminated drinking water.
Chronic inhalation studies provide evidence that chromium(VI) is carcinogenic in animals. Mice exposed
to 4.3 mg chromium(VI)/m3 as calcium chromate had a 2.8-fold greater incidence of lung tumors, 
compared to controls.  In addition, numerous animal studies using the intratracheal, intrapleural, and 
intrabronchial routes of exposure show that chromium(VI) produces respiratory tract tumors.  However, 
no carcinogenic effects were observed in rats, rabbits, or guinea pigs exposed to 1.6 mg chromium(VI)/m3 
as potassium dichromate or chromium dust 4 hours/day, 5 days/week. 
Exposure of rats and mice to sodium dichromate dihydrate in drinking water for 2 years resulted in
cancers of the gastrointestinal tract.  In male and female rats, the incidences of neoplasms of the 
squamous epithelium of the oral mucosa and tongue were significantly increased in males (7.0 mg
chromium(VI)/kg/day) and females (5.9 mg chromium(VI)/kg/day); in mice, the incidence of neoplastic 
lesions of the small intestine (duodenum, jejunum, and ileum) was increased in males at 2.4 mg
chromium(VI)/kg/day and females at 3.1 mg chromium(VI)/kg/day.  The National Toxicology Program
concluded that results demonstrate clear evidence of carcinogenic activity in male and female F344/N rats 
(increased incidences of squamous cell neoplasms of the oral cavity) and in male and female B6C3F1
mice (increased incidences of neoplasms of the duodenum, jejunum, or ileum).  Mice exposed to 
chromium(VI) as potassium chromate (9 mg chromium(VI)/kg/day) in drinking water for three
generations (880 days) showed statistically significant increases in the incidence of forestomach adenoma
or carcinomas of the forestomach and in the incidence of forestomach adenomas alone, compared to 
control; however, study authors concluded that evidence of carcinogenicity was equivocal.
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NTP lists certain chromium compounds as substances that are known to be human carcinogens.  This
classification is based on sufficient evidence for a number of chromium(VI) compounds (calcium
chromate, chromium trioxide, lead chromate, strontium chromate, and zinc chromate).  The International
Agency for Research on Cancer (IARC) classified chromium(VI) as carcinogenic to humans (Group 1)
and metallic chromium and chromium(III) compounds as not classifiable as to their carcinogenicity to
humans (Group 3).  EPA has classified chromium(VI) as a known human carcinogen by the inhalation 
route of exposure.
Chromium(III)
Although much less information is available on the health effects of chromium(III) compounds compared 
to that for chromium(VI) compounds, chromium(III) compounds appear to be less toxic than 
chromium(VI) compounds.  Health effects associated with exposure to chromium(III) compounds have
been reported in studies of occupationally exposed populations and individuals; however, interpretation of
study results is complicated by concomitant exposures to chromium(VI) or other compounds that can
induce adverse health effects.  Similarly, interpretation of findings in case reports of exposures to dietary
supplements containing high-dose chromium(III) are also complicated, since most supplements contain 
numerous chemicals; thus, the most reliable information on adverse health effects of chromium(III) is
obtained from studies in animals.  Chromium(III) picolinate, a dietary supplement, has been shown to be
mutagenic in bacterial and mammalian cells in vitro.
The primary effects of chromium(III) compounds are on the respiratory and immunological systems.  As 
described below, respiratory effects appear to be portal-of-entry effects for inhalation exposure.  
Similarly, chromium allergic dermatitis, the major immunological effect of chromium(III), is typically
elicited by dermal contact in sensitized individuals; however, initial sensitization may result from
inhalation, oral, or dermal exposure or from a combination of these exposure routes.  Conflicting results
of studies in animals have been reported in developmental and reproductive studies of chromium(III)
compounds; however, results provide evidence of adverse effects on the developing and adult
reproductive system.  Evidence of developmental or reproductive effects of chromium(III) in humans has
not been identified.  Based on results of chronic-duration oral studies in animals, chromium(III)
compounds (chromium acetate, chromium chloride, chromium nicotinate, chromium oxide, chromium
picolinate) do not appear to produce gastrointestinal, hematological, hepatic, renal, cardiovascular,
endocrine, or musculoskeletal effects.  This is in contrast to chromium(VI) compounds which produce
effects in the gastrointestinal, hematological, hepatic and renal systems.
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Respiratory Effects. Occupational exposure studies and case reports indicate that respiratory effects 
occur from exposure of humans to chromium(III) compounds; however, results of these studies are
difficult to interpret since most study populations were also exposed to chromium(VI) compounds or
other compounds associated with respiratory effects, and/or the studies were not adequately controlled for
other confounding factors (e.g., respiratory diseases).  Acute- and chronic-duration studies in animals
indicate that the respiratory tract is the primary target of inhaled chromium(III).  Analysis of BAL fluid
from rats exposed for 5 days to 3–30 mg chromium(III)/m3 as basic chromium sulfate (soluble) showed
alterations, including increased amounts of cell debris and lysed cells and significant decreases in
nucleated cells and in the percentage of segmented neutrophils and mononuclear cells; cytoplasmic 
accumulation of a yellow crystalline material in mononuclear cells was observed in BAL fluid of rats 
exposed to 3–30 mg chromium(III)/m3 as chromic oxide (insoluble).  With longer exposure (13 weeks), 
histopathological changes to respiratory tissues and increased lung weights were observed in rats exposed
to ≥3 mg chromium(III)/m3 chromic oxide or basic chromium sulfate.  However, differences were 
observed in severity and location of respiratory effects produced by insoluble chromic oxide and soluble
basic chromium sulfate; effects of chromic oxide were less severe and isolated to the lung and respiratory
lymph tissues, whereas the effects of basic chromium sulfate were more severe and observed throughout
the respiratory tract (e.g., nose, larynx, lung, and respiratory lymph tissues).  Differences in the 
respiratory toxicity of these compounds may be due to differences in chemical-physical properties (e.g., 
solubility, acidity).  Studies examining respiratory effects from chronic-duration inhalation exposure were
not identified.  Respiratory effects from oral or dermal exposure to chromium(III) compounds have not
been reported.  
Immunological Effects. As discussed above for chromium(VI) compounds, exposure to chromium
compounds may induce allergic sensitization in some individuals.  In patients with known chromium-
induced allergic dermatitis, positive results have been reported using patch tests with chromium(III)
compounds as the challenge agent, suggesting that allergic sensitization to chromium(III) can occur.  In 
sensitized patients, dermal responses were elicited using a concentration of 1 mg chromium(III)/L as
chromium trichloride.  However, since positive responses were also observed on challenge with
chromium(VI) compounds, it is unclear if individuals were sensitized to both chromium(VI) and 
chromium(III) or if cross-sensitivity occurs between chromium(VI) and chromium(III).  Studies in 
animals show that chromium(III) can induce sensitization and that cross-reactivity occurs between
chromium(VI) and chromium(III).  Sensitization to chromium(III) was observed in guinea pigs treated 
with a series of intradermal injections of 0.004 mg chromium(III)/kg as chromium trichloride.  In guinea
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pigs sensitized with chromium(III), cross-sensitivity with chromium(VI) was observed on patch test
challenge.
Reproductive Effects. Adverse reproductive effects have been observed in rats and mice exposed
orally to chromium(III) compounds, although conflicting results have been reported.  Adverse
reproductive effects have been reported following acute- and intermediate-duration exposure of animals
to chromium(III) by gavage or in drinking water; effects include decreased number of pregnancies in 
female rats administered 33.6 mg chromium(III)/kg/day, alterations in sexual behavior, aggressive 
behavior toward other males, and significantly lower absolute weight of testes, seminal vesicles, and
preputial glands in male Sprague-Dawley rats (40 mg chromium(III)/kg/day), decreased number of
pregnant female Swiss mice following the mating of unexposed females to exposed males (13 mg
chromium(III)/kg/day), impaired fertility in exposed female mice (5 mg chromium(III)/kg/day) mated to 
unexposed males, and increased testes and ovarian weights and decreased preputial gland and uterine 
weights in mice (5 mg chromium(III)/kg/day).  Decreased spermatogenesis was observed in BALB/c 
mice treated with 9.1 mg chromium(III)/kg/day as chromium sulfate in drinking water for 7 weeks. 
In contrast to the reproductive effects of chromium(III) chloride in drinking water, dietary exposure to 
chromium picolinate or chromium nicotinate has not been associated with reproductive effects.  Exposure
to chromium picolinate in the diet for 3 months did not produce adverse effects on reproductive tissues, as
assessed by organ weights, gross and histopathological examinations, sperm count, sperm motility, 
duration of estrous cycle stages, and estrous cycle length at doses up to 505 and 506 mg chromium(III)/ 
kg/day in male and female rats, respectively, or at doses up to 1,415 and 1,088 mg chromium(III)/kg/day
in male and female mice.  No morphological changes to reproductive organs, as assessed by
histopathological examination, were observed in male and female Sprague-Dawley rats exposed to
chromium nicotinate in the diet at 1.2 and 1.5 mg chromium(III)/kg/day, respectively for 2 months or
0.22 and 0.25 mg chromium(III)/kg/day, respectively, for 1 year.
In summary, conflicting results on reproductive effects of chromium(III) compounds have been reported.  
It is unclear if differences in results are related to experimental methods, including exposure media 
(drinking water versus feed), or to differences in toxicity of the specific chromium(III) compounds
evaluated.
Developmental Effects. Little information is available on the potential developmental effects of
chromium(III) compounds, although results of available studies are conflicting.  Chromium(III) did not
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produce developmental effects in offspring of rats fed 1,806 mg chromium(III)/kg/day as chromium oxide
for 60 days before mating and throughout the gestational period.  Significant decreases were observed in
the relative weights of reproductive tissues (testes, seminal vesicles, and preputial glands in males and
ovaries and uterus in females) of offspring of BALB/c mice exposed to 74 mg chromium(III)/kg/day as 
chromium(III) chloride in the drinking water on gestation day 12 through lactation day 20; however, 
fertility was not affected when these exposed offspring were mated with unexposed animals. The number
of pregnancies was decreased in rats administered 33.6 mg chromium(III)/kg/day (only dose tested) by
gavage as chromium chloride on gestational days 1–3, although when exposed on gestational days 4–6,
no effects on pregnancy rates, implantations, viable fetuses, or resorptions were observed.  In a different
type of study, neurological testing of offspring of mice exposed during gestation and lactation to 25 mg
chromium(III)/kg/day as chromium picolinate in the diet did not reveal significant differences, as
compared to controls. Thus, the available evidence does not indicate that exposure to chromium(III)
consistently produces adverse developmental effects.
Cancer.    No studies evaluating the carcinogenic activity of chromium(III) compounds in humans were
identified.  In male rats exposed to dietary chromium picolinate for 2 years, the incidence of preputial
gland adenoma was significantly increased in males at 61 mg chromium(III)/kg/day, with the incidence
also exceeding the historical control ranges; however, the incidence was not increased at a higher dose 
(313 mg chromium(III)/kg/day) and similar lesions were not observed in corresponding tissues in female
rats or in male and female mice.  Therefore, one study considered the evidence of carcinogenic activity to
be equivocal.  The relationship of preputial gland adenoma to male reproductive function in this study
was not defined.
2.3  MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for chromium.  An 
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
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Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990a), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic
bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
Inhalation MRLs—Chromium(VI)
Acute. The inhalation database for acute-duration exposure of humans to inhaled chromium(VI)
compounds is limited to a few studies reporting signs of respiratory irritation (dyspnea, cough, wheezing, 
sneezing, rhinorrhea, choking sensation), dizziness, and headaches in individuals or small numbers of
workers (n≤5) exposed to high concentrations of chromium(VI) (Lieberman 1941; Meyers 1950; Novey
et al. 1983).  In addition, acute inhalation exposure of individuals previously sensitized to chromium
compounds has produced symptoms of asthma and signs of respiratory distress consistent with a type I
allergic response (decreased forced expiratory volume, facial erythema, nasopharyngeal pruritus, blocked 
nasal passages, cough, and wheeze) (Leroyer et al. 1998; Olaguibel and Basomba 1989); however, the
available data are not adequate to characterize the exposure-response relationship for effects of acute 
inhalation challenge in sensitized individuals.  No other effects of acute inhalation exposure of humans to 
chromium(VI) have been reported.
The acute toxicity of inhaled chromium(VI) in animals has not been well investigated, and most studies
are 4-hour lethality studies (American Chrome and Chemicals 1989; Gad et al. 1986).  Nasal hemorrhage
was observed in two of five rats after inhalation for 10 days to 1.15 mg chromium(VI)/m3 during a
13-week exposure study (Kim et al. 2004), with no nasal effects observed at 0.49 mg chromium(VI)/m3. 
However, only a small number of animals were evaluated and histopathological evaluations of the 
respiratory tract (or other tissues) were not conducted following the acute-duration period; thus, data are
not suitable for defining NOAEL or LOAEL values for respiratory effects.  Although longer duration 
inhalation studies show that the respiratory tract is a sensitive target of inhaled chromium(VI), the data
are insufficient to determine acute-duration exposure levels that would produce respiratory tract, or other
effects.  In the absence of studies that could be used to identify the targets of low level exposure, an acute-
duration inhalation MRL for hexavalent chromium was not derived.
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Intermediate
•	 An inhalation MRL of 5x10-6 mg chromium(VI)/m3 has been derived for intermediate (15– 
364 days) exposure for dissolved hexavalent chromium aerosols and mists.
The available data on inhalation exposure of humans and animals to chromium(VI) compounds indicate
that dissolved chromium(VI) compounds (aerosols and mists) and particulate chromium(VI) compounds
have different toxic potencies for producing adverse respiratory effects.  Although the respiratory system
is the most sensitive target for inhalation exposure to both types of chromium(VI) compounds, the
primary respiratory effects of inhaled chromic acid mists are observed in the nose (see the following
discussion), while the effects of inhaled particulate chromium(VI) compounds occur throughout the
respiratory tract.  Since toxic potencies of these compounds appear to be different and the likelihood for
environmental exposure to chromium trioxide (e.g., chromic acid mist) and other soluble chromium(VI) 
compound mists is less than the likelihood for environmental exposure to particulate chromium(VI)
compounds, distinct intermediate-duration inhalation MRLs have been derived for dissolved 
chromium(VI) compounds (aerosols and mists) and particulate chromium(VI) compounds. 
The intermediate-duration inhalation database for humans exposed to dissolved chromium(VI) aerosols
and mists consists of occupational exposure studies on chromium trioxide mists (Gibb et al. 2000a, 
2000b; Gomes 1972; Kleinfeld and Rosso 1965; Lindberg and Hedenstierna 1983); these studies identify
the upper respiratory tract as the primary target of exposure.  Upper respiratory effects include nasal
irritation, ulceration, and mucosal atrophy and rhinorrhea, with LOAEL values ranging from 0.002 to 
0.1 mg chromium(VI)/m3. Other effects (e.g., non-respiratory) specific for dissolved chromium(VI)
aerosols and mists in humans have not been reported.  Exposure to chromium(VI) compounds (not
compound-specific) can produce allergic sensitization, which may manifest as symptoms of asthma upon 
subsequent inhalation exposures (Keskinen et al. 1980; Leroyer et al. 1998; Moller et al. 1986; Olaguibel
and Basomba 1989).  The exposure route for the initial sensitization in an occupational setting is most
likely a combination of inhalation, oral, and dermal exposures; however, the available data do not define
the exposure-response relationship for chromium sensitization by inhalation.
Available animal studies on the effects of intermediate-duration exposure to dissolved chromium(VI)
aerosols and mists identify the respiratory tract as the primary target, with LOAEL values ranging from
0.49 to 3.63 mg chromium(VI)/m3 (Adachi 1987; Adachi et al. 1986; Kim et al. 2004).  Respiratory
effects reported in animals exposed to chromium(VI) trioxide include alveolar inflammation in rats (Kim
et al. 2004) and nasal septal perforation and symptoms of emphysema in mice (Adachi 1987; Adachi et al. 
   
 









    
  
    








   
  
  
    
   
   
   
  
 
    
 









2. RELEVANCE TO PUBLIC HEALTH
1986).  The only other effect (e.g., non-respiratory) observed in animal studies on dissolved 
chromium(VI) aerosols and mists were hematological effects and decreased body weight in rats exposed
to chromium trioxide mist for 13 weeks.  Hematological effects include decreased in hematocrit at
≥0.23 and 1.15 mg chromium(VI)/m3 (but not 0.49 mg chromium(VI)/m3) decreased hemoglobin at
≥0.49 mg chromium(VI)/m3 and decreased erythrocyte count at 1.15 mg chromium(VI)/m3 (Kim et al.
2004).  In this study, body weight gain was also decreased by ~9%, with NOAEL and LOAEL values of
0.49 and 1.15 mg chromium(VI)/m3, respectively.
Based on a comparison of LOAEL values for respiratory effects, hematological effects, and decreased
body weight gain, the respiratory tract was identified as the most sensitive effect of intermediate-duration 
inhalation exposure to dissolved chromium(VI) aerosols and mists.  The lowest LOAEL value of
0.002 mg chromium(VI)/m3 was reported for nasal irritation, mucosal atrophy, and ulceration and
decreases in spirometric parameters observed in workers exposed to chromic acid mist (Lindberg and 
Hedenstierna 1983); therefore, this value was selected as the basis for derivation of the intermediate-
duration inhalation MRL for dissolved chromium(VI) aerosols and mists.  The population evaluated by
Lindberg and Hedenstierna (1983) included 85 male and 19 female chrome plating workers exposed to 
chromic acid and a reference group of 119 auto mechanics not exposed to chromium.  Workers were
assessed for nose, throat, and chest symptoms, were inspected for effects in nasal passages, and were 
given pulmonary function tests.  The length of worker exposures to chromic acid ranged from 0.1 to 
36 years, with a mean of 2.5 years, spanning both intermediate and chronic durations.  Since the study
population included workers exposed for an intermediate duration, data are considered appropriate for
derivation of the intermediate-duration inhalation MRL.  Nasal irritation (p<0.05), mucosal atrophy
(p<0.05), and ulceration (p<0.01), and decreases in spirometric parameters (forced vital capacity, forced
expired volume in 1 second, and forced mid-expiratory flow) were observed in workers occupationally
exposed to ≥0.002 mg chromium(VI)/m3 as chromic acid.  Approximately 60% of the exposed subjects 
were smokers, but no consistent association between exposure and cigarette smoking was observed.  
Additional details on study methods and results are provided in Appendix A.
The LOAEL of 0.002 mg chromium(VI)/m3 was multiplied by 8 hour/24 hour and by 5 days/7 days to 
yield a duration-adjusted LOAEL (LOAELADJ) of 0.0005 mg chromium(VI)/m3. The intermediate-
duration MRL of 5x10-6 was obtained by dividing the LOAELADJ (0.0005 mg chromium(VI)/m3) by an
uncertainty factor of 100 (10 for human variability and 10 for extrapolating from a LOAEL). 
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•	 An inhalation MRL of 0.0003 mg chromium(VI)/m3 was derived for intermediate exposures 
to particulate chromium(VI) compounds.
As discussed above, available data on inhalation exposure of humans and animals to chromium(VI)
compounds indicate that dissolved chromium(VI) compounds (aerosols and mists) and particulate
chromium(VI) compounds have different toxic potencies for producing adverse respiratory effects (the
primary target organ).  Furthermore, since the likelihood for environmental exposure to chromium 
trioxide and other soluble chromium(VI) compound mists is less than the likelihood for environmental
exposure to particulate chromium(VI) compounds, distinct intermediate-duration inhalation MRLs have
been derived for dissolved chromium(VI) compounds (aerosols and mists) and particulate chromium(VI)
compounds. 
Although few animal studies have reported adverse effects of intermediate-duration inhalation exposure
to particulate chromium(VI) compounds (Cohen et al. 1998; Glaser et al. 1985, 1990), results of available 
studies conducted in rats indicate that the respiratory tract is the primary target organ.  In rats exposed to
inhaled sodium dichromate for 30–90 days, adverse respiratory effects included obstructive respiratory
dyspnea, increased lung weights, hyperplasia of the lung, focal inflammation of the upper airway, and 
alterations to BAL fluid concentrations of lactate dehydrogenase, protein, and albumin, with a LOAEL
value of 0.2 mg chromium(VI)/m3 (Glaser et al. 1990).  Other effects reported in the Glaser et al. (1985, 
1990) studies were an increased percentage of lymphocytes in BAL fluid (LOAEL of 0.025 mg
chromium(VI)/m3), increased serum phospholipids and triglycerides (NOAEL and LOAEL values of
0.1 and 0.2 mg chromium(VI)/m3, respectively), increased white blood cell count (LOAEL value of
0.05 mg chromium(VI)/m3), decreased body weight gain (NOAEL and LOAEL values of 0.1 and 0.2 mg
chromium(VI)/m3), and an enhanced immune response to sheep erythrocytes (LOAEL 0.025 mg
chromium(VI)/m3); however, the toxicological significance of these finding is uncertain.  Effects that may
be indicative of altered immune function (altered white blood cell counts and cytokine levels in BAL
fluid) were observed in rats exposed to 0.36 mg chromium(VI)/m3 as potassium chromate or barium
chromate for 2–4 weeks (Cohen et al. 1998); however, results of this study are difficult to interpret, since
effects were not clearly adverse, only one exposure level was evaluated, and histopathological assessment
of respiratory tissues (or other tissues) was not conducted.
Based on the available data, respiratory effects were identified as the most sensitive target of
intermediate-duration exposure to particulate chromium(VI) compounds, with the study by Glaser et al. 
(1990) selected as the critical study.  In this study, 8-week-old male Wistar rats (30 animals/group) were
exposed 22 hours/day, 7 days/week to 0, 0.05, 0.1, 0.2, or 0.4 mg chromium(VI)/m3 as sodium
   
 









   




    
   
  
     
     
  




     
 
 
   
    
 
     
       
  
   
   
 





2. RELEVANCE TO PUBLIC HEALTH
dichromate aerosol particulates.  Detailed discussion of study methods is presented in Appendix A.  No 
deaths or abnormal clinical signs occurred at any of the exposures.  Obstructive respiratory dyspnea
occurred at ≥0.2 mg chromium(VI)/m3 after 30 and 90 days.  Mean lung weight was increased in all
exposure groups and was statistically increased at 0.05 mg chromium(VI)/m3 for 30 days, and at 0.1 mg
chromium(VI)/m3 for 90 days and in the 90-day plus recovery period group.  Histological examination
revealed slight hyperplasia in high incidence at 0.05 mg chromium(VI)/m3 at 30 days.  Lung fibrosis
occurred at 0.1 mg chromium(VI)/m3 for 30 days, but was not seen in rats exposed for 90 days.  
Accumulation of macrophages was observed in all exposed rats, regardless of exposure concentration or
duration.  Histology of upper airways revealed focal inflammation.  Results of bronchoalveolar lavage 
(BAL) analysis provided further information of the irritation effect.  Total protein in BAL fluid was
significantly increased in all exposed groups, but declined in the recovery period.  Albumin in BAL fluid 
increased in a dose-related manner at all concentrations in the 30-day group, but recovery started during
90-day exposure and continued during the 30-day observation period.  The activities of lactate
dehydrogenase and β-glucuronidase, measures of cytotoxicity, were elevated at 0.2 and 0.4 mg
chromium(VI)/m3 for 30 and 90 days, but returned to control values during the recovery period.  The
number of macrophages in the BAL fluid had significantly increased after 30 and 90 days, but normalized 
during the recovery period.  The macrophages were undergoing cell division or were multinucleate and 
larger. This activation of macrophages was not observed in the recovered rats.  Additional details on
study results are presented in Appendix A.
Results of the benchmark concentration (BMC) analysis of the Glaser et al. (1990) data conducted by
Malsch et al. (1994) were identified as the basis for derivation of an intermediate-duration inhalation 
MRL for hexavalent chromium particulate compounds.  Using the 90-day exposure data (as described
above), Malsch et al. (1994) developed BMCLs (defined as the 95% lower limit on the concentration
corresponding to a 10% relative change in the end point compared to the control) for lung weight and 
BAL fluid levels of lactate dehydrogenase, protein, and albumin.  Prior to conducting the benchmark
analysis, Malsch et al. (1994) adjusted the dose-response data for intermittent exposure (22 hours/day).  
Duration-adjusted data were then fitted to a polynomial mean response regression model by the maximum
likelihood method to derive BMCLs.  The lowest BMCL, 0.016 mg chromium(VI)/m3 for alterations in 
lactate dehydrogenase levels in BAL fluid, was selected to derive the intermediate-duration inhalation 
MRL.  The BMCL of 0.016 mg chromium(VI)/m3 was converted to a human equivalent concentration
(BMCLHEC) of 0.010 mg chromium(VI)/m3 using the regional deposited dose ratio (RDDR) program
(EPA 1994c) (see Appendix A for details).
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The intermediate-duration inhalation MRL of 0.0003 mg chromium(VI)/m3 for hexavalent chromium
particulate compounds was derived by dividing the BMCLHEC of 0.010 mg chromium(VI)/m3 by a
composite uncertainty factor of 30 (3 for extrapolation from animals to humans and 10 for human 
variability).
Chronic
•	 An inhalation MRL of 5x10-6 mg chromium(VI)/m3 has been derived for chronic (≥365 days)
exposure for dissolved hexavalent chromium aerosols and mists.
The chronic-duration inhalation database for humans exposed to dissolved chromium(VI) aerosols and
mists consists of occupational exposure studies on chromium trioxide mists, reporting effects to the 
respiratory, renal, and gastrointestinal systems (Franchini and Mutti 1988; Gibb et al. 2000a, 2000b;
Hanslian et al. 1967; Lindberg and Hedenstierna 1983; Lucas and Kramkowski 1975).  Respiratory
effects included bleeding nasal septum, nasal mucosal atrophy, nasal septal ulceration and perforation,
epitaxis, rhinorrhea, and decreased lung function, with LOAEL values ranging from 0.002 to 0.414 mg
chromium(VI)/m3. Effects indicative of renal toxicity include increased retinol binding protein and 
tubular antigen and increased urinary β-2-microglobulin (Franchini and Mutti 1988; Lindberg and 
Hedenstierna 1983); LOAEL values for these effects range from 0.004 to 0.05 mg chromium(VI)/m3. 
Gastrointestinal effects reported in workers include stomach pains, cramps, and ulcers, with a LOAEL
value of 0.004 mg chromium(VI)/m3 (Lucas and Kramkowski 1975).  Other effects specific for dissolved
chromium(VI) aerosols and mists in humans exposed for chronic exposure durations have not been
reported.  Exposure to chromium(VI) compounds (not compound-specific) can produce allergic 
sensitization, which may manifest as symptoms of asthma upon subsequent inhalation exposures 
(Keskinen et al. 1980; Leroyer et al. 1998; Moller et al. 1986; Olaguibel and Basomba 1989).  The
exposure route for the initial sensitization in an occupational setting is most likely a combination of
inhalation, oral, and dermal exposures; however, the available data do not define the exposure-response 
relationship for chromium sensitization by inhalation. Studies in animals evaluating the effects of
chronic-duration exposure to dissolved chromium(VI) aerosols and mists were not identified.
Based on a comparison of LOAEL values for respiratory, renal and gastrointestinal effects in workers, the 
respiratory tract was identified as the most sensitive effect of chronic-duration inhalation exposure to 
dissolved chromium(VI) aerosols and mists.  The lowest LOAEL value of 0.002 mg chromium(VI)/m3 
was reported for nasal irritation, mucosal atrophy, and ulceration and decreases in spirometric parameters
in workers occupationally exposed to chromic acid mist (Lindberg and Hedenstierna 1983); therefore, this
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value was selected as the basis for derivation of the chronic-duration inhalation MRL for dissolved 
chromium(VI) aerosols and mists.  The population evaluated in this study had a mean exposure duration 
of 2.5 years, with a range of 0.1–23.6 years, spanning both intermediate and chronic durations.  A
description of study methods and results is provided above under the discussion of Intermediate-Duration 
Inhalation MRL for Chromium(VI) aerosols/mists and in Appendix A.
The LOAEL of 0.002 mg chromium(VI)/m3 was multiplied by 8 hour/24 hour and by 5 days/7 days to 
yield a duration-adjusted LOAEL (LOAELADJ) of 0.0005 mg chromium(VI)/m3. The chronic-duration 
MRL of 5x10-6 was obtained by dividing the LOAELADJ (0.0005 mg chromium(VI)/m3) by an uncertainty
factor of 100 (10 for human variability and 10 for extrapolating from a LOAEL). 
Few studies have evaluated the effects of chronic inhalation exposure to particulate hexavalent chromium
compounds.  In workers chronically exposed to inhaled chromium(VI) compounds at 0.0042 mg
chromium(VI)/m3, the prevalence of high urinary N-acetyl-β-glucosamidase was increased, indicating
possible renal damage (Liu et al. 1998); however, since the chemical form of chromium(VI) was not
reported, data from this study are not suitable as the basis for the chronic-duration inhalation MRL
specific for particulate hexavalent chromium compounds.  The chronic-duration database in animals 
consists of studies that either did not identify adverse effects of chronic inhalation exposure to particulate 
hexavalent chromium compounds (Glaser et al. 1986, 1988; Lee et al. 1989) or older studies that did not
report sufficient experimental details (Nettesheim and Szakal 1972; Steffee and Baetjer 1965).  Thus, due
to inadequate data, a chronic-duration inhalation MRL for particulate hexavalent chromium compounds
was not derived.
Oral MRLs—Chromium(VI)
Acute. Studies on the acute toxicity of orally-administered chromium(VI) in humans are mostly limited 
to case reports on ingestion of fatal doses (Clochesy 1984; Iserson et al. 1983; Kaufman et al. 1970;
Loubieres et al. 1999; Saryan and Reedy 1988).  At lower doses (≥0.036 mg chromium (IV)/kg as
potassium dichromate), oral exposure to chromium(VI) has been shown to enhance dermatitis in 
individuals with known chromium sensitivity (Goitre et al. 1982; Kaaber and Veien 1977).
In animals, acute-duration studies on oral exposure to chromium(VI) compounds have shown effects on 
hematology and clinical chemistry (NTP 2007, 2008a), male reproductive organs (Li et al. 2001) and 
development (Elsaieed and Nada 2002; Junaid et al. 1996b); however, the available studies did not
   
 





















    
   
 
     
  
    





   
  
 
   
    
  
    
 
34CHROMIUM
2. RELEVANCE TO PUBLIC HEALTH
evaluate comprehensive toxicological end points.  Decreased MCV, MCH, and reticulocyte count were 
observed in rats exposed to ≥0.70 mg chromium(VI)/kg/day after 4–5 days of exposure (NTP 2007, 
2008a); however, the magnitude of changes was small and may not yet represent an adverse effect of
chromium(VI).  Significant alterations in the serum activities of liver enzymes (alanine aminotransferase 
[ALT] and aspartate aminotransferase [AST]) and creatine kinase were observed at ≥4.0–4.1 mg
chromium(VI)/kg/day in rats exposed for 4–5 days (NTP 2007, 2008a).  Effects on male reproductive
organs, including decreased sperm count, increased percentage of abnormal sperm, and morphological
change to seminiferous tubules (decreased diameter of seminiferous tubules and germ cell rearrangement)
were observed in Wister rats following a 6-day gavage administration of ≥5.2 mg chromium(VI)/kg/day
as chromic acid; observations were made 6 weeks after the dosing period (Li et al. 2001).  A NOAEL was
not defined in this study.  
Developmental effects, including increased pre- and postimplantation loss, resorptions, dead fetuses/litter, 
and skeletal (incomplete ossification of skull bone) and visceral (renal pelvis dilatation) malformations
were observed in Wister rats exposed to 8 mg chromium(VI)/kg/day (the only dose tested) as potassium
chromate in drinking water (Elsaieed and Nada 2002).  Other studies reported total litter loss, decreased 
viable fetuses and increased resorptions in rats (Bataineh et al. 2007) and increased resorptions in mice
(Junaid et al. 1996b) exposed at higher doses.
Results of acute-duration studies in animals show that exposure to oral chromium(VI) compounds may
cause hematological (NTP 2007, 2008a), reproductive (Li et al. 2001), and developmental effects
(Elsaieed and Nada 2002; Junaid et al. 1996b).  However, since the available studies did not evaluate
comprehensive toxicological end points, data are inadequate for derivation of an acute-duration oral MRL
for chromium(VI).  Therefore, an acute-duration oral MRL for hexavalent chromium was not derived.
Intermediate
•	 An oral MRL of 0.005 mg chromium(VI)/kg/day has been derived for intermediate (15– 
364 days) exposure to hexavalent chromium compounds.
Hematological effects (microcytic, hypochromic anemia) in male rats and female mice observed after
exposure for 22 days in the NTP (2008a) 2-year study were identified as the most sensitive effect of
intermediate-duration oral exposure to chromium(VI) for the purpose of derivation of an intermediate-
duration oral MRL for chromium(VI) compounds of 0.005 mg chromium(VI)/kg/day. The basis for this
determination is as follows.
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No human intermediate-duration studies on chromium(VI) were identified.  Numerous animal studies 
examining systemic, neurological, reproductive, and developmental toxicity have reported effects
following oral exposure to chromium(VI) compounds, with hematological effects (microcytic, 
hypochromic anemia) identified as the most sensitive. Microcytic, hypochromic anemia, characterized by
decreased MCV, MCH, Hct, and Hgb, was observed in rats and mice exposed to chromium(VI)
compounds in drinking water or feed for intermediate-duration exposures ranging from 22 days to 
6 months (NTP 1996a, 1996b, 1997, 2007, 2008a).  The lowest reported LOAEL values for
hematological effects were 0.77 mg chromium(VI)/kg/day (with a NOAEL value of 0.21 mg
chromium(VI)/kg/day) for decreased Hct, Hgb, MCV, and MCH in male rats; and 0.38 mg
chromium(VI)/kg/day (a NOAEL was not established) for decreased MCV and MCH in female mice 
exposed to sodium dichromate dihydrate in drinking water for 22 days (NTP 2008a).  Slightly higher
LOAEL values were observed for hematological effects in rats and mice exposed to dietary potassium
dichromate for 9 weeks (NTP 1996a, 1996b, 1997).
The duration-dependence of hematological effects was evaluated in rats and mice exposed to sodium
dichromate dihydrate in drinking water from 23 days up to 6 months (NTP 2007, 2008a).  Results of both 
studies show that the severity of microcytic, hypochromic anemia was dose-dependent, with maximum
effects observed after 22–23 days of exposure.  For all intermediate-duration exposures (22 days to 
6 months), NOAEL and LOAEL values in male rats for hematological effects were 0.21 and 0.77 mg
chromium(VI)/kg/day, respectively.  In female mice, microcytic, hypochromic anemia was also observed,
with LOAEL values of 0.38, 1.4, and 3.1 mg chromium(VI)/kg/day at the 22-day, 3-month, and 6-month 
assessments, respectively, with effects less severe than those observed in rats.
Studies examining systemic toxicity in animals have reported numerous effects, including hepatotoxicity
(Achaya et al. 2001; Kumar and Rana 1982, Kumar et al. 1985; NTP 1996a, 2007), gastrointestinal 
effects (NTP 2007), renal toxicity (Acharya et al. 2001; Diaz-Mayans et al. 1986; Kumar and Rana 1982, 
1984), lymphatic and immunological effects (NTP 2007; Snyder and Valle 1991), and decreased body
weight (Bataineh et al. 1997; Chowdhury and Mitra 1995; Elbetieha and Al-Hamood 1997; Kanojia et al. 
1996, 1998; NTP 2007; Quinteros et al. 2007; Trivedi et al. 1989).  However, LOAEL values for these
effects were higher than those producing hematopoietic effects.  Studies on reproductive toxicity in 
animals identify the male reproductive system as a target for intermediate-duration exposure to oral
chromium(VI) (Aruldhas et al. 2004, 2005, 2006; Bataineh et al. 1997; Chowdhury and Mitra 1995;
Subramanian et al. 2006; Yousef et al. 2006; Zahid et al. 1990), although these effects are less sensitive
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than hematological effects.  In developmental studies in rats and mice, gestational exposure produced
increased postimplantation loss, decreased number of live fetuses/litter, decreased fetal weight, internal
and skeletal malformations, and delayed sexual maturation in offspring; however, these effects were 
observed high doses (e.g., ≥35 mg chromium(VI)/kg/day) (Al-Hamood et al. 1998; Bataineh et al. 2007;
Junaid et al. 1996a; Kanojia et al. 1998; Trivedi et al. 1989).
Hematological effects (microcytic, hypochromic anemia) in male rats observed after exposure for 22 days 
in the NTP (2008a) 2-year study were identified as the most sensitive effect of intermediate-duration oral
exposure to chromium(VI).  In this study, male F344/N rats (6–7 weeks old) were exposed to sodium
dichromate dihydrate in drinking water in a 2-year toxicology and carcinogenicity study, with 
hematological assessments conducted at 22 days, 3 months, 6 months, and 1 year (see Appendix A for a
detailed description of study methods and results).  To determine the point of departure for derivation of
the intermediate-duration oral MRL, available continuous-variable models in the EPA Benchmark Dose 
(version 1.4.1) were fit to the data for Hct, Hgb, MCV, and MCH in male rats (NTP 2008a) (detailed 
results of the benchmark dose analysis are provided in Appendix A).  Because several hematological
parameters are used to define the clinical picture of anemia, the BMDL2sd values for hemoglobin, MCV, 
and MCH (none of the models provided an adequate fit for hematocrit) were averaged resulting in a 
BMDL2sd of 0.52 mg chromium(VI)/kg/day.  The intermediate-duration MRL of 0.005 mg
chromium(VI)/kg/day was derived by dividing the average BMDL2sd by a composite uncertainty factor of
100 (10 for extrapolation from animals to humans and 10 for human variability).
Chronic
•	 An oral MRL of 0.0009 mg chromium(VI)/kg/day has been derived for chronic (≥1 year)
exposure to hexavalent chromium compounds.
Nonneoplastic lesions of the duodenum in mice reported in a chronic drinking water study (NTP 2008a)
was selected as the critical effect for derivation of a chronic-duration MRL for chromium(VI) compounds
of 0.0009 mg chromium(VI)/kg/day.  There are limited data on the chronic oral toxicity of chromium in
humans.  Gastrointestinal effects, including oral ulcer, diarrhea, abdominal pain, and vomiting, were
observed in residents living in an area of the People’s Republic of China with high chromium(VI) levels 
in the drinking water.  However, the exposure levels associated with these effects is not well
characterized.  Other ecological studies have examined cancer mortality (Beaumont et al. 2008; Bednar
and Kies 1991; Fryzek et al. 2001; Kerger et al. 2009; Linos et al. 2011), but did not report noncarcino-
genic effects.
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The chronic-duration oral toxicity database in drinking water in humans consists of ecological studies of
an area near a ferrochromium production plant in the Liaoning Province, China comparing cancer
mortality in locations that had relatively high or low chromium concentrations in well water (Beaumont et
al. 2008; Zhang and Li 1987).  Evaluations of cancer mortality rates (cancers deaths per person-year in an
8-year observation period) show that the adjusted stomach cancer mortality rate was higher for the 
exposed population compared to the control population (Beaumont et al. 2008).  However, it was not
possible to estimate exposure levels based on the description of the pollution process.  Thus, available 
human data are not adequate as the basis for the chronic-duration oral MRL.
Chronic-duration oral toxicity studies have been conducted in rats and mice (Mackenzie et al. 1958; NTP
2008a).  No hematological, hepatic, or renal effects or changes in body weight were observed in study in
Sprague-Dawley rats exposed to 3.6 chromium(VI)/kg/day as potassium chromate in drinking water for
1 year (Mackenzie et al. 1958).  NTP (2008a) exposed groups of F344/N rats (50/sex/group) and B6C3F1 
mice (50/sex/group) to sodium dichromate dihydrate in drinking water in a 2-year toxicology and 
carcinogenicity study (see Appendix A for a detailed description of all study methods and results).
Results of this study identify several chromium(VI)-induced effects, including microcytic, hypochromic
anemia, and nonneoplastic lesions of the liver, duodenum, mesenteric and pancreatic lymph nodes,
pancreas, and salivary gland.  Based on comparison of LOAEL values, the lowest LOAELs were 
observed for histopathological changes of the liver (chronic inflammation in female rats and histiocytic 
cellular infiltration in female mice), duodenum (diffuse epithelial hyperplasia in male and female mice), 
mesenteric lymph node (histiocytic cellular infiltration in male and female mice), and pancreas 
(cytoplasm cellular alteration of acinar epithelial cells in female mice), with effects occurring in all
treatment groups (see Appendix A for incidence data for all nonneoplastic lesions).  Therefore, all effects
with LOAEL values of the lowest dose tested were considered as the possible the critical effect for
derivation of the chronic-duration oral MRL.  
To determine the specific end point for derivation of the chronic-duration oral MRL, all available 
dichotomous models in the EPA Benchmark Dose Software (BMDS version 1.4.1) were fit to the
incidence data for selected end points in female rats and male and female mice exposed to sodium
dichromate dihydrate in drinking water for 2 years (NTP 2008a) (details of benchmark dose analysis are 
presented in Appendix A). Based on the lowest BMDL10 value of 0.09 mg chromium(VI)/kg/day, diffuse
epithelial hyperplasia of the duodenum in female mice was selected as the point of departure for
derivation of the chronic-duration oral MRL.  The chronic-duration MRL of 0.0009 mg chromium(VI)/ 
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kg/day was derived by dividing the BMDL10 by a composite uncertainty factor of 100 (10 for 
extrapolation from animals to humans and 10 for human variability).  The chronic-duration oral MRL
based on nonneoplastic lesions of the duodenum in female mice is expected to be protective for all other
adverse effects observed in the 2-year drinking water study (e.g., hematological effects and lesions of the
liver, lymph nodes, pancreas and salivary gland).
Inhalation MRLs—Chromium(III)
Acute. Studies evaluating the effects of acute exposure of humans to chromium(III) compounds were not
identified.  Acute-duration exposure studies in rats and hamsters indicate that the respiratory tract is a 
target of inhaled chromium(III) compounds (Derelanko et al. 1999; Henderson et al. 1979).  Derelanko et
al. (1999) evaluated effects of acute exposure to chromium(III) as chromic oxide (insoluble) or basic
chromium sulfate (soluble) in rats (5 rats/sex/group) on composition of bronchoalveolar lavage (BAL)
fluid.  After exposure of rats for 5 days (6 hours/day) to 3, 10, or 30 mg chromium(III)/m3 as chromic 
oxide (insoluble), analysis of BAL fluid revealed cytoplasmic accumulation of a yellow crystalline 
material in mononuclear cells of all exposure groups; however, it is not clear if this observation represents 
an adverse effect.  No other BAL parameters were affected (nucleated cell count and differential, protein, 
and BAL fluid activities of β-glucuronidase, lactic dehydrogenase, and glutathione reductase).  In rats 
treated for 5 days (6 hours/day) with 3, 10, or 30 mg chromium(III)/m3 as basic chromium sulfate 
(soluble), BAL fluid analysis showed significant decreases in nucleated cells at all doses in males and
females and decreases in the percentage of segmented neutrophils and mononuclear cells at 30 mg
chromium(III)/m3 in males.  Increased amounts of cellular debris and lysed cells were present in BAL
fluid of rats treated with ≥3 mg chromium(III)/m3 as basic chromium sulfate (incidence data were not
reported).  In Syrian hamsters, changes in BAL fluid and lung tissue enzyme activities were observed
following exposure to inhaled chromium trichloride for 30 minutes (Henderson et al. 1979); effects
included “sporadic changes” in activities of acid phosphatase and alkaline phosphatase in the BAL fluid
at 25 mg chromium(III)/m3 and increased acid phosphatase activity in lung tissue at 0.9 mg
chromium(III)/m3. In addition, histological examination of the lung revealed focal accumulations of
macrophages and polymorphonuclear cells.  However, it is not clear that the effects observed in this study
are toxicologically significant.  Thus, results of acute-duration studies in rats and hamsters show that
inhaled chromium(III) compounds produce alterations in BAL fluid composition and lung tissue enzyme
activities; however, data are not adequate to characterize the exposure-response relationship for
respiratory effects. Therefore, an acute-duration inhalation MRL for trivalent chromium was not derived.
   
 








    
 
 
   
 
  





     
     
    
   
    
    
 
  
     
 
   
  





    




2. RELEVANCE TO PUBLIC HEALTH
Intermediate. Studies evaluating the effects of intermediate-duration exposure of humans to 
chromium(III) compounds were not identified.  In animals exposed to inhaled chromium(III) compounds
for intermediate durations, the respiratory tract has been identified as the primary target organ, based on 
results of a 13-week study in rats exposed to chromic oxide (insoluble) or basic chromium sulfate
(soluble) (Derelanko et al. 1999).  In this study, which examined comprehensive toxicological end points, 
male and female CDF rats (15/sex/group) were exposed by nose-only inhalation to 0, 3, 10, or 30 mg
chromium(III)/m3 as chromic oxide or as basic chromium sulfate for 6 hours/day, 5 days/week for 
13 weeks.  Of the 15 rats/sex/group, 10 rats/sex/group were sacrificed after 13 weeks of exposure and 
5 rats/sex/group were sacrificed after an additional 13-week recovery period (e.g., no exposure).  
Assessments made in this study included mortality; clinical signs of toxicity; body weight; hematology; 
clinical chemistry; urinalysis; sperm morphology, count and motility; gross necropsy; microscopic
examination of comprehensive tissues for all animals in the control and 30 mg chromium(III)/m3 groups;
and microscopic examination of respiratory tissues (nasal tissues, trachea, lungs, larynx, and mediastinal
and mandibular lymph nodes) in all animals.  Both chromic oxide and basic chromium sulfate produced 
adverse respiratory effects (histopathological changes to respiratory tissues and increased lung weights) in
male and female rats, with no adverse effects in other tissues.  However, differences between the two
compounds were observed with respect to severity and location of respiratory effects; effects of chromic
oxide were less severe and isolated to the lung and respiratory lymph tissues, whereas the effects of basic 
chromium sulfate were more severe and observed throughout the respiratory tract (e.g., nose, larynx, lung, 
and respiratory lymph tissues). The study authors suggested that differences in the respiratory toxicity of
these compounds may be related to differences in chemical-physical properties (e.g., solubility, acidity).  
The only other intermediate-duration inhalation study in animals was conducted in rabbits exposed to 
0.6 mg chromium(III)/m3 as chromium nitrate for 4–6 weeks (6 hours/day, 5 days/week) (Johansson et al. 
1986b).  Results of this study showed effects on pulmonary macrophages (altered functional and 
metabolic activities); however, the toxicological significance of this finding is uncertain and animals were
not examined for other effects.  Thus, the 13-week inhalation study by Derelanko et al. (1999) was
selected as the critical study for derivation of intermediate-duration inhalation MRLs for chromium(III)
compounds.  Based on the differences in respiratory toxicity between insoluble chromic oxide and soluble
basic chromium sulfate, distinct intermediate-duration inhalation MRLs were derived for insoluble and 
soluble trivalent chromium particulate compounds.  Additional details of respiratory effects produced by
chromic oxide and basic chromium sulfate are described below under derivation of intermediate-duration 
inhalation MRLs for insoluble trivalent chromium compounds and for soluble trivalent chromium
compounds, respectively.  
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•	 An inhalation MRL of 0.005 mg chromium(III)/m3 has been derived for intermediate (15– 
364 days) exposure to insoluble trivalent chromium particulate compounds.
The lung and respiratory lymphatic tissues were identified as the target tissues for inhaled insoluble 
trivalent chromium particulate compounds, based on observations reported in the study by Derelanko et
al. (1999) (as discussed above).  Similar effects were observed in male and female rats exposed to 
chromic oxide for 13 weeks, with histopathological changes to the respiratory lymphatic tissue occurring
at ≥3 mg chromium(III)/m3 and to the lung at ≥10 mg chromium(III)/m3. Lymphoid hyperplasia of the
mediastinal node was observed in rats of all treatment groups (severity not reported).  In rats exposed to 
10 and 30 mg chromium(III)/m3, trace-to-mild chronic interstitial inflammation of the lung, characterized
by inflammatory cell infiltration, was observed in alveolar septa, and hyperplasia of Type II pneumocytes
(severity not reported) were observed.  Histopathological changes were isolated to the lungs and 
respiratory lymphatic tissues and were not observed in other tissues, including nasal tissues and the 
larynx.  
For evaluations conducted at the end of the 13-week treatment period, a LOAEL of 3 mg
chromium(III)/m3 for hyperplasia of the mediastinal node was identified for both males and females; the 
severity of this effect was not reported.  Following a 13-week posttreatment recovery period, trace-to-
mild septal cell hyperplasia and trace-to-mild chronic interstitial inflammation of the lung were observed 
at ≥3 mg chromium(III)/m3 in males and at ≥10 mg chromium(III)/m3 in females.  In addition, pigmented 
macrophages and black pigment in peribronchial lymphatic tissues and the mediastinal lymph node in 
animals from all treatment groups were also observed; this finding, although not considered adverse, 
indicates that the test material had not been completely cleared from the lung during the treatment-free 
recovery period.  Thus, for evaluations conducted at the 13-week posttreatment recovery period, a 
minimal LOAEL (based on severity) of 3 mg chromium(III)/m3 for trace-to-mild septal cell hyperplasia
and chronic interstitial inflammation of the lung in male rats was identified.
The LOAEL of 3 mg chromium(III)/m3 for hyperplasia of the mediastinal node in males and females 
(observed at the end of the 13-week treatment period) and the minimal LOAEL of 3 mg chromium(III)/m3 
for trace-to-mild septal cell hyperplasia and chronic interstitial inflammation of the lung in males
(observed at the end of the 13-week recovery period) were considered as potential critical effects for
derivation of the intermediate-duration inhalation MRL for insoluble trivalent chromium particulate
compounds.  A benchmark concentration for these effects could not be determined since incidence data
for lesions of the lung and respiratory lymphatic tissue were not reported; thus, a NOAEL/LOAEL
approach was used.  To determine the point of departure, the LOAEL value of 3 mg chromium(III)/m3 
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was first adjusted for intermittent and converted to human equivalent concentrations (LOAELHEC) (see 
Appendix A for details).
Based on the lowest LOAELHEC of 0.43 mg chromium(III)/m3, trace-to-mild septal cell hyperplasia and
chronic interstitial inflammation of the lung in male rats were selected as the critical effect. The 
intermediate-duration inhalation MRL for insoluble trivalent chromium particulate compounds of
0.005 mg chromium(III)/m3 was derived by dividing the minimal LOAELHEC of 0.43 mg
chromium(III)/m3 by a composite uncertainty factor of 90 (3 for use of a minimal LOAEL, 3 for
extrapolation from animals to humans, and 10 for human variability). 
•	 An inhalation MRL of 0.0001 mg chromium(III)/m3 has been derived for intermediate (15– 
364 days) exposure to soluble trivalent chromium particulate compounds.
The lung and respiratory lymphatic tissues were identified as the target tissues for inhaled soluble
trivalent chromium particulate compounds, based on observations reported in the study by Derelanko et
al. (1999) (as discussed above).  Similar effects were observed in male and female rats exposed to inhaled
basic chromium sulfate for 13 weeks, with histopathological changes to the nose, larynx, lung, and 
respiratory lymphatic tissues and increased relative lung weight occurring at ≥3 mg chromium(III)/m3. 
Microscopic examination of the lung revealed the following changes in all treatment groups:  chronic 
inflammation of the alveoli; alveolar spaces filled with macrophages, neutrophils, lymphocytes, and
cellular debris; foci of “intense” inflammation and thickened alveolar walls; chronic interstitial
inflammation with cell infiltration; hyperplasia of Type II pneumocytes; and granulomatous 
inflammation, characterized by infiltration of macrophages and multinucleated giant cells.  Macrophage
infiltration and granulomatous inflammation of the larynx, acute inflammation, and suppurative and
mucoid exudates of nasal tissues and histiocytosis and hyperplasia of peribronchial lymphoid tissues and
the mediastinal lymph node were also observed in all treatment groups. Thus, data for histopathological
changes in various regions of the respiratory tract and increased relative lung weights were evaluated to
determine the specific end point for derivation of the intermediate-duration MRL for soluble trivalent
chromium particulate compounds.
Benchmark dose analysis could not be conducted for respiratory tract lesions, since incidence data were 
not reported by Derelanko et al. (1999); therefore, a NOAEL/LOAEL approach was used, with 
adjustment of the LOAEL for intermittent exposure and human equivalent concentrations (see
Appendix A for details).  Data for relative lung weights in males and females (presented in Appendix A)
were modeled using all available continuous-variable models in the EPA Benchmark Dose program
   
 








    
 
   
    
 
    
    







    
  
  
     
   
   
  
      
 
 









2. RELEVANCE TO PUBLIC HEALTH
(version 1.4.1).  The BMC and the 95% lower confidence limit (BMCL) calculated were estimated for
doses associated with a change of 1 standard deviation from the control mean (BMDL1sd).  The BMCL1sd 
values for the best fitting models in male and female rats were adjusted for intermittent exposure and
human equivalent concentrations, yielding BMCL1sd, HEC values of 0.17 and 0.34 mg chromium(III)/m3 in 
males and females, respectively (see Appendix A for detail of benchmark dose analysis).
Based on comparison of LOAELHEC values for respiratory tract lesions and BMCL1sd, HEC values for
increased lung weight, the lowest value of 0.04 mg chromium(III)/m3 (the LOAELHEC for lesions of the
larynx and nose in female rats) was selected as the point of departure. The intermediate-duration 
inhalation MRL for soluble trivalent chromium particulate compounds of 0.0001 mg chromium(III)/m3 
was derived by dividing the LOAELHEC of 0.04 mg chromium(III)/m3 by a composite uncertainty factor
of 300 (10 for use of a LOAEL, 3 for pharmacodynamic variability between animals to humans, and 
10 for human variability).  It should not be concluded from comparison of the intermediate-duration 
MRLs for soluble particulate chromium(VI) and soluble particulate chromium(III) compounds that
chromium(III) is more toxic than chromium(VI).
The respiratory tract is the major target of inhalation exposure to chromium compounds in humans and 
animals.  Respiratory effects due to inhalation exposure are probably due to direct action of chromium at
the site of contact.  For chronic exposure of humans, the available occupational studies for exposure to 
chromium(III) compounds include or likely include concomitant exposure to chromium(VI) compounds
and other compounds that may produce respiratory effects (Langård 1980; Mancuso 1951; Osim et al. 
1999).  Thus, while the available data in humans suggest that respiratory effects occur following
inhalation exposure to chromium(III) compounds, the respiratory effects of inhaled chromium(VI) and 
other compounds are confounding factors in estimating exposure levels for these effects for the purpose
of deriving MRLs.
Chronic. No studies evaluating the effects of chronic-duration inhalation exposure of animals to 
chromium(III) compounds alone were identified.  Exposure to mixtures of chromium(VI) and 
chromium(III) compounds (3:2 mixture of chromium(VI) trioxide and chromium(III) oxide) have resulted 
in adverse respiratory effects in Wistar rats, including increased lung weight and histopathological
changes to lung tissues (interstitial fibrosis and thickening of the septa of the alveolar lumens; Glaser et
al. 1986, 1988).  However, these data not appropriate as the basis for a chronic-duration inhalation MRL
for chromium(III) compounds due to concomitant exposure to chromium(VI). 
   
 











   






    
   

















2. RELEVANCE TO PUBLIC HEALTH
Oral MRLs—Chromium(III)
No acute-, intermediate-, or chronic-duration oral MRLs were derived for chromium(III) because studies 
evaluating the effects of chromium(III) in humans and animals following acute, intermediate, and chronic 
oral exposure were inadequate for establishing the exposure concentrations associated with adverse health
effects (as discussed below). The IOM has recommended an adequate intake level of 20–45 μg 
chromium(III) for adolescents and adults, equivalent to 0.28–0.64 μg chromium(III)/kg/day (0.0003– 
0.0006 mg chromium(III)/kg/day), assuming a 70-kg body weight (IOM 2001).
Little information is available on the effects of acute-duration oral exposure to chromium(III) compounds.  
Information on the effects of intermediate-duration oral exposure of humans is limited to case reports of
renal failure (Wani et al. 2006; Wasser et al. 1997) and rhabdomyolysis (Martin and Fuller 1998)
following ingestion of dietary supplements containing chromium(III).  In animals, acute exposure of rats
to dietary chromium(III) picolinate did not produce alterations in hematology or clinical chemistry.  
Following acute exposure of mated rats, an increase in total litter loss was observed in female rats (at
33.6 mg chromium(III)/kg/day) (Bataineh et al. 2007).  In a study evaluating effects of chromium(III) on 
maturation of the reproductive system in mice (74 mg chromium(III)/kg/day), significant decreases in the 
relative weights of reproductive tissues (testes, seminal vesicles, and preputial glands in males; ovaries 
and uterus in females) and a significant delay in timing of vaginal opening in the female offspring were 
observed (Al-Hamood et al. 1998).  However, gestational exposure studies on chromium(III) compounds
were conducted at high daily doses and do not provide sufficient information to characterize the dose-
response relationship for adverse developmental effects.  Thus, the data are inadequate for derivation of
an acute-duration oral MRL.   
Information on adverse effects of intermediate-duration oral exposure of humans to chromium(III)
compounds was not identified.  Results of most animal studies show no adverse effects associated with 
intermediate-duration oral exposure to chromium(III) compounds (chromium chloride, chromium
nicotinate, chromium oxide, chromium picolinate, and chromium potassium sulfate) (Anderson et al. 
1997b; De Flora et al. 2006; Ivankovic and Preussmann 1975; NTP 2008b; Rhodes et al. 2005; Shara et
al. 2005, 2007), even at very high daily doses.  In the study conducted by NTP (2008b; Rhodes et al. 
2005), daily doses of up to 506 and 1,415 mg chromium(III)/mg/day as chromium picolinate were
evaluated in rats and mice, respectively, and in the Ivankovic and Preussmann (1975) study, daily doses
up to 1,806 mg chromium(III)/kg/day as chromium oxide were evaluated in rats.
   
 








   
  
  
   
  





   
 
  
   
 
  
    
 
 
    
   
     
  
   
   
   
 
      
    
  





2. RELEVANCE TO PUBLIC HEALTH
Adverse reproductive effects have been reported following intermediate-duration exposure of animals to
chromium(III) as chromium chloride administered by gavage or in drinking water.  A series of studies by
the same research group evaluated reproductive effects of exposure to chromium(III) as chromium
chloride in drinking water for 12 weeks (Al-Hamood et al. 1998; Bataineh et al. 1997, 2007; Elbetieha
and Al-Hamood 1997).  Reproductive effects observed included alterations in sexual behavior (reductions
in the number of mounts, increased postejaculatory interval, and decreased rates of ejaculation), 
aggressive behavior toward other males, and significantly lower absolute weight of testes, seminal
vesicles, and preputial glands in male Sprague-Dawley rats (40 mg chromium(III)/kg/day; only dose
tested) (Bataineh et al. (1997); decreased number of pregnant female Swiss mice following the mating of
unexposed females to exposed males (13 mg chromium(III)/kg/day) (Elbetieha and Al-Hamood 1997);
impaired fertility in exposed female mice (5 mg chromium(III)/kg/day) mated to unexposed males
(Elbetieha and Al-Hamood 1997); and increased testes and ovarian weights and decreased preputial gland 
and uterine weights in mice (5 mg chromium(III)/kg/day) (Elbetieha and Al-Hamood 1997).  Results of
the study by Elbetieha and Al-Hamood (1997) should be interpreted with caution due to concerns
regarding experimental methods, including decreased water consumption in the higher concentration 
group (resulting in a potential overestimate of exposure and uncertainty regarding daily dose
calculations); the study was not conducted using a standard mating protocol; sperm counts were not
conducted; and the definition and classification of non-viable fetuses was not described.  Decreased
spermatogenesis was observed in BABL/c mice treated with 9.1 mg chromium(III)/kg/day as chromium 
sulfate in drinking water for 7 weeks (Zahid et al. 1990); however, sensitivity of methods used to evaluate
spermatogonia in this study have been questioned by NTP (1996a).  NOAEL values for reproductive
effects were not identified in these studies. In studies designed to confirm or refute the findings of the
Zahid et al. (1990) study, the reproductive effects of different concentrations of chromium(VI) as
potassium dichromate in the diet on BALB/c mice and Sprague-Dawley rats were investigated (NTP
1996a, 1996b).  Groups of 24 of each species were fed potassium dichromate(VI) in their feed
continuously for 9 weeks followed by an 8-week recovery period. The average daily ingestions of
chromium(VI) were 1.05, 3.5, 7.5, and 32.2 mg/kg/day for male mice and were 0.35, 1.05, 2.1, and
8.4 mg/kg/day for rats (NTP 1996b).  Microscopic examinations of the testes and epididymis for Sertoli
nuclei and preleptotene spermatocyte counts in stage X or XI tubules did not reveal any treatment-related
effects.  Similarly, exposure to sodium dichromate dihydrate in drinking water did not produce
morphological changes to male reproductive organs of B6C3F1 mice exposed to 27.9 or 5.9 mg
chromium(VI)/kg/day for 3 months or 2 years, respectively, or affect sperm count or motility in male
B6C3F1, BALB/c, and C57BL/6N mice exposed to 8.7 mg chromium(VI)/kg/day for 3 months (NTP
2007, 2008a).
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In contrast to the reproductive effects of chromium chloride in drinking water, dietary exposure to 
chromium(III) picolinate has not been associated with reproductive effects.  Exposure to chromium
picolinate in the diet for 3 months did not produce adverse effects on reproductive tissues, as assessed by
organ weights, gross and histopathological examinations, sperm count, sperm motility, duration of estrous
cycle stages and estrous cycle length at doses up to 505 and 506 mg chromium(III)/kg/day in male and 
female rats, respectively, or at doses up to 1,415 and 1,088 mg chromium(III)/kg/day in male and female
mice (NTP 2008b).  No morphological changes to reproductive organs, as assessed by histopathological
examination, were observed in male and female Sprague-Dawley rats exposed to chromium nicotinate in 
the diet at 1.2 and 1.5 mg chromium(III)/kg/day, respectively for 2 months or at 0.22 and 0.25 mg
chromium(III)/kg/day, respectively for 1 year (Shara et al. 2005, 2007).  In summary, conflicting results
on reproductive effects of chromium(III) compounds have been reported.  It is unclear if differences in 
results are related to experimental methods, including exposure media (drinking water versus feed) or to 
differences in toxic potency of the specific chromium(III) compounds evaluated. Thus, available data are 
not sufficient to define the dose-response relationship for adverse reproductive effects of chromium(III)
compounds. 
Little information is available on the potential developmental effects of chromium(III) compounds.  No 
developmental effects were observed in the offspring of rats fed 1,806 mg chromium(III)/kg/day as
chromium oxide for 60 days before mating and throughout the gestational period (Ivankovic and 
Preussmann 1975).
Results of studies in animals exposed to oral chromium(III) compounds indicate that adverse reproductive
effects may occur.  However, the available data are do not identify NOAEL values for effects and,
therefore, are not sufficient to characterize the dose-response relationship.  Thus, data are inadequate for
derivation of an intermediate-duration oral MRL.
Chronic-duration studies on oral exposure of humans to chromium(III) compounds were not identified.  
Several animals studies show no adverse effects associated with chronic-duration oral exposure to 
chromium(III) compounds (chromium acetate, chromium chloride, chromium nicotinate, chromium
oxide, chromium picolinate) (Ivankovic and Preussmann 1975; Mackenzie et al. 1958; Schroeder et al.
1965; Shara et al. 2007), even at very high daily doses.  Thus, in the absence of data showing adverse
effects of chronic oral exposure, a chronic-duration oral MRL for chromium(III) compounds was not
derived.
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A summary of the inhalation and oral MRLs for chromium(VI) and chromium(III) is presented in 
Table 2-1.
   
 











       
     
     
    
      











      





     
    
    
      













      
 
    
    








     
      
      





2. RELEVANCE TO PUBLIC HEALTH
Table 2-1.  Summary of MRL Values for Chromium(VI) and Chromium(III)
Point of departure	 UF MRL
Inhalation MRLs
Chromium(VI)
Acute Insufficient data to derive MRL
Intermediate
Aerosols and mists LOAEL of 0.002 mg Cr/m3 for nasal irritation, 100
mucosal atrophy, impaired lung function in workers
(Lindberg and Hedenstierna 1983)
Particulates BMCL10 of 0.016 mg Cr/m3 (converted to a BMCLHEC 30
of 0.010 mg Cr/m3) based on alterations in lactate 
dehydrogenase levels in BAL in rats (Glaser et al.
1990)
Chronic
Aerosols and mists LOAEL of 0.002 mg Cr/m3 for nasal irritation, 100
mucosal atrophy, impaired lung function in workers
(Lindberg and Hedenstierna 1983)
Particulates Insufficient data to derive MRL
Chromium(III)
Acute Insufficient data to derive MRL
Intermediate
Insoluble particulates	 LOAEL of 3 mg Cr/m3 (adjusted to 0.54 mg Cr/m3 for 90
intermittent exposure and converted to a LOAELHEC 
of 0.43 mg Cr/m3) for septal cell hyperplasia and 
chronic interstitial inflammation of the lungs in rats
(Derelanko et al. 1999)
Soluble particulates	 LOAEL of 3 mg Cr/m3 (adjusted to 0.54 mg Cr/m3 for 300
intermittent exposure and converted to a LOAELHEC 
of 0.04 mg Cr/m3) for nasal and larynx lesions in rats
(Derelanko et al. 1999)
Chronic Insufficient data to derive MRL
Oral MRLs
Chromium(VI)
Acute Insufficient data to derive MRL
Intermediate BMDL2SD of 0.52 mg Cr/kg/day for microcytic, 100
hypochromic anemia in rats (NTP 2008a)
Chronic BMDL10 of 0.09 mg Cr/kg/day for diffuse epithelial 100
hyperplasia of the duodenum in mice (NTP 2008a)
Chromium(III)
Acute Insufficient data to derive MRL
Intermediate Insufficient data to derive MRL















BAL = bronchoalveolar lavage; LOAEL = lowest-observed-adverse-effect level; MRL = minimal risk level;
UF = uncertainty factor
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3. HEALTH EFFECTS 
3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of chromium.  It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
Chromium is a naturally occurring element found in animals, plants, rocks, and soil and in volcanic dust
and gases.  Chromium has oxidation states (or "valence states") ranging from chromium(-II) to
chromium(VI).  Elemental chromium (chromium(0)) does not occur naturally.  Chromium compounds are
stable in the trivalent (III) state and occur in nature in this state in ores, such as ferrochromite.  The 
hexavalent (VI) form is the second-most stable state. However, chromium(VI) rarely occurs naturally,
but is usually produced from anthropogenic sources (EPA 1984a).
Trivalent chromium compounds, except for acetate, nitrate, and chromium(III) chloride-hexahydrate salts,
are generally insoluble in water.  Some hexavalent compounds, such as chromium trioxide (or chromic
acid) and the ammonium and alkali metal (e.g., sodium, potassium) salts of chromic acid are readily
soluble in water. The alkaline metal (e.g., calcium, strontium) salts of chromic acid are less soluble in
water. The zinc and lead salts of chromic acid are practically insoluble in cold water.  Chromium(VI)
compounds are reduced to chromium(III) in the presence of oxidizable organic matter.  However, in 
natural waters where there is a low concentration of reducing materials, chromium(VI) compounds are
more stable (EPA 1984a).  For more information on the physical and chemical properties of chromium, 
see Chapter 4.
In humans and animals, chromium(III) is an essential nutrient that plays a role in glucose, fat, and protein
metabolism by potentiating the action of insulin (Anderson 1981). The biologically active form of
chromium, called chromodulin, is an oligopeptide complex containing with four chromic ions (Jacquamet
et al. 2003).  Both humans and animals are capable of converting inactive inorganic chromium(III)
compounds to physiologically active forms.  The nutritional role of chromium is further discussed in 
Section 3.4.3.  Although chromium(III) has been reported to be an essential nutrient, exposure to high 
levels via inhalation, ingestion, or dermal contact may cause some adverse health effects.  Most of the 
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studies on health effects discussed below involve exposure to chromium(III) and chromium(VI)
compounds.  In addition, chromium(IV) was used in an inhalation study to determine permissible 
exposure levels for workers involved in producing magnetic tape (Lee et al. 1989).
Several factors should be considered when evaluating the toxicity of chromium compounds.  The purity
and grade of the reagent used in the testing is an important factor.  Both industrial- and reagent-grade 
chromium(III) compounds can be contaminated with small amounts of chromium(VI) (Levis and Majone
1979).  Thus, interpretation of occupational and animal studies that involve exposure to chromium(III)
compounds is difficult when the purity of the compounds is not known.  In addition, it is difficult to 
distinguish between the effects caused by chromium(VI) and those caused by chromium(III) since
chromium(VI) is rapidly reduced to chromium(III) after penetration of biological membranes and in the
gastric environment (Petrilli et al. 1986b; Samitz 1970).  However, whereas chromium(VI) can readily be
transported into cells, chromium(III) is much less able to cross cell membranes.  The reduction of
chromium(VI) to chromium(III) inside of cells may be an important mechanism for the toxicity of
chromium compounds, whereas the reduction of chromium(VI) to chromium(III) outside of cells is a
major mechanism of protection.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
   
 








     
   
     
    
    








   
 
   
 
 
    
      
 




   
 









insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) are indicated in
Tables 3-1 and 3-4 and Figures 3-1 and 3-3 for chromium(VI).  
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure 
Due to the extremely high boiling point of chromium, gaseous chromium is rarely encountered.  Rather, 
chromium in the environment occurs as particle-bound chromium or chromium dissolved in droplets.  As
discussed in this section, chromium(VI) trioxide (chromic acid) and soluble chromium(VI) salt aerosols 
may produce different health effects than insoluble particulate compounds.  For example, exposure to 
chromium(VI) trioxide results in marked damage to the nasal mucosa and perforation of the nasal septum, 
whereas exposure to insoluble(VI) compounds results in damage to the lower respiratory tract. 
3.2.1.1  Death 
No studies were located regarding death in humans after acute inhalation of chromium or chromium
compounds.  An increased risk of death from noncancer respiratory disease was reported in retrospective 
   
 








   


































mortality studies of workers in a chrome plating plant (Sorahan et al. 1987) and chromate production 
(Davies et al. 1991; Taylor 1966) (see Section 3.2.1.2, Respiratory Effects).  However, a number of
methodological deficiencies in these studies prevent the establishment of a definitive cause-effect
relationship.  Retrospective mortality studies associating chromium exposure with cancer are discussed in
Section 3.2.1.7.
Acute inhalation LC50 values in rats for several chromium(VI) compounds (sodium chromate, sodium
dichromate, potassium dichromate, and ammonium dichromate) ranged from 29 to 45 mg 
chromium(VI)/m3 for females and from 33 to 82 mg chromium(VI)/m3 for males (Gad et al. 1986).  Acute
inhalation LC50 values for chromium trioxide were 87 and 137 mg chromium(VI)/m3 for female and male 
rats, respectively (American Chrome and Chemicals 1989).  Female rats were more sensitive than males 
to the lethal effects of most chromium(VI) compounds except sodium chromate, which was equally toxic
in both sexes.  Signs of toxicity included respiratory distress, irritation, and body weight depression (Gad
et al. 1986).  The LC50 values for chromium(VI) are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.1.2  Systemic Effects
No studies were located regarding musculoskeletal effects in humans or animals after inhalation exposure 
to chromium or its compounds.  Respiratory, cardiovascular, gastrointestinal, hematological, hepatic, 
renal, endocrine, dermal, ocular, body weight, and metabolic effects are discussed below. The highest
NOAEL values and all reliable LOAEL values for each systemic effect in each species and duration
category are recorded in Table 3-1 and plotted in Figure 3-1 for chromium(VI) and recorded in Table 3-2 
and plotted in Figure 3-2 for chromium(III).
Respiratory Effects. The respiratory tract in humans is a major target of inhalation exposure to 
chromium compounds.  Chromate sensitive workers acutely exposed to chromium(VI) compounds may
develop asthma and other signs of respiratory distress.  Five individuals who had a history of contact
dermatitis to chromium were exposed via a nebulizer to an aerosol containing 0.035 mg 
chromium(VI)/mL as potassium dichromate.  A 20% decrease in the forced expiratory volume of the
lungs was observed and was accompanied by erythema of the face, nasopharyngeal pruritus, nasal
blocking, coughing, and wheezing (Olaguibel and Basomba 1989). 
Dyspnea, cough, and wheezing were reported in two cases in which the subjects inhaled "massive 
















































137 M (LC50) 
87 F (LC50) 
2 Rat 
(Fischer- 344) 
4 hr 82 M (LC50) 
45 F (LC50) 
3 Rat 
(Fischer- 344) 
4 hr 35 M (LC50) 
29 F (LC50) 
4 Rat 
(Fischer- 344) 
4 hr 70 M (LC50) 

















0.49 M 1.15 M (nasal hemorrhage) 
0.025 M (irritated nasal septum) 
33 (LC50) 
Reference 
Chemical Form Comments 
American Chrome and 
Chemicals 1989 
CrO3 (VI) 
Gad et al. 1986 
(NH4)2Cr2O7 (VI) 
Gad et al. 1986 
K2Cr2O7 (VI) 
Gad et al. 1986 
Na2Cr2O7.2H2O (VI) 
Gad et al. 1986 
Na2CrO4 (VI) 
Kim et al. 2004 
CrO3 (VI) 














































Chemical Form Comments 




0.033 M perforated nasal septum 
0.036 M perforated eardrum 
Gibb et al. 2000a 
CrO3 (VI) 




Resp 0.1 (epitaxis rhinorrhea, 




10 Human 0.5-12 mo 




Resp 0.09 M (epitaxis, rhinorrhea 
ulceration of nasal 
septum) 
Kleinfield and Rosso 1965 
CrO3 (VI) 
11 Human 0.2-23.6 yr 






0.002 (nasal mucosa atrophy 
and ulceration, mild 
decreased lung function) 






































Key to Species Frequency 
































Chemical Form Comments 











0.025 M (increased percentage of 
lymphocytes in bronchial 
alveolar lavage fluid) 




0.1 M 0.2 M (increased levels of 









































Key to Species Frequency 
Figure (Strain) (Route) 
14 Rat 
(Wistar) 































Chemical Form Comments 
c 
0.05 M (increased lung weight, 
hyperplasia, macrophage 
infiltration, increased 
protein, albumin, lactate 
dehydrogenase in BAL 
fluid) 
Glaser et al. 1990 
Na2Cr2O7.2H2O (VI) 
0.4 M 




0.1 M 0.2 M (28% decreased body 
weight gain) 
0.23 M 0.49 M (inflammation and 
macrophage aggregation 
in alveolar regions of the 
lung) 




































































Resp 3.63 F (emphysema, nasal 
septum perforation) 













Resp 0.9 M 
0.36 (increased neutrophils, 
monocytes, and 
decreased macrophages 
in BAL fluid; decreased 
cytokine levels) 
Johansson et al. 1986b 
Na2CrO4 (VI) 







0.36 (decreased tumor 
necrosis factor-alpha 
levels and production of 
superoxide anion and 
hydrogen peroxide and 
increased nitric oxide 
production) 























































0.025 M (increased response to 
sheep red blood cells, 











0.025 M (increased response to 
sheep RBC, increased % 
of lymphocytes in 
bronchoalveolar lavage 
fluid, increased % of 
macrophages in 
telophase, increased 
activity of macrophages) 

































0.05 M (increase in retinol 
binding protein and 
tubular antigen) 
Kim et al. 2004 
CrO3 (VI) 

















































Chemical Form Comments 




0.025 M (bleeding nasal septum) 
0.049 M 
Gibb et al. 2000a 
CrO3 (VI) 
28 Human (occup) Resp 0.414 (nasal septum 
perforation, chronic 
pharyngitis, atrophy of 
larynx) 
Hanslian et al. 1967 
CrO3 (VI) 
Gastro 0.414 (chronic tonsilitis) 
29 Human 0.2-23.6 yr 






0.002 (nasal mucosa atrophy 
and ulceration, mild 
decreased lung function) 
Lindberg and Hedenstierna 
1983 
CrO3 (VI) 
30 Human 0.1-26 yr 




Renal 0.004 M (increased urinary 
beta-2-microglobulin) 
Lindberg and Vesterberg 
1983b 
CrO3 (VI) 























































Chemical Form Comments 
32 Human 7.5 yr avg 
(range 3-16 yr) 
(occup) 
Resp 0.004 M (epitaxis, rhinorrhea, 
nasal septum ulceration 
and perforation) 
Lucas and Kramkowski 1975 
CrO3 (VI) 


























Resp 1.6 (granulomata, giant cells, 
bronchopneumonia, 
abscesses) 
Steffee and Baetjer 1965 







Resp 4.3 (epithelial necrosis, 
hyperplasia) 

























































37 Human 5.8 yr 
(Occup) 









0.5 M (CEL: lung cancer) 




0.5 (CEL: lung cancer) 




0.25 (CEL: lung cancer) 




0.1 M (CEL: lung cancer) 
Reference 
Chemical Form Comments 
Steffee and Baetjer 1965 
Mixed chromium roast 
K2Cr2O7, Na2CrO4 (VI) 
Mignini et al. 2004 
Cr (VI) 
Hayes et al. 1989 
PbCrO4 and ZnCrO4 (VI) 
Langård and Norseth 1975 
PbCrO4 and ZnCrO4 (VI) 
Mancuso 1975 
Soluble Cr(VI) 
Sheffet et al. 1982 





















































4.3 (CEL: alveologenic 
adenomas and 
adenocarcinomas) 
Nettesheim et al. 1971 
CaCrO4 (VI) 
a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate and chronic inhalation minimal risk level (MRL) of 0.000005 mg chromium(Vl)/m3 for dissolved chromium (VI) aerosols and mists..  Exposure 
concentration adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for human variability and 10 for extrapolating from a LOAEL). 
c Used to derive an intermediate inhalation minimal risk level (MRL) of 0.0003 mg chromium(Vl)/m3 for particulate hexavalent chromium.  Benchmark concentration of 0.016 mg 
chromium (Vl)/m3 was divided by an uncertainty factor of 30 (3 extrapolation from animals to humans using dosimetric adjustments and 10 for human variability). 
avg = average; BAL = bronchoalveolar lavage; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; F = female; Gastro = 
gastrointestinal; Gn Pig = guinea pig; Hemato = hematological; hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LC50 = lethal concentration, 50% kill; LOAEL = 
lowest-observed-adverse-effect level; M = male; min = minute(s); mo = rnonth(s); NS = not specified; NOAEL = no-observed-adverse-effect level; occup = occupational; RBC = red 













































o-Other  Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans
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o-Other  Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans








































































o-Other  Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans
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o-Other  Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans





*Doses represent the lowest dose tested per study that produced a tumorigenic
















































Key to Species Frequency 
Figure (Strain) (Route) 
ACUTE EXPOSURE 
Systemic 


























Chemical Form Comments 
0.9 (increased acid 
phosphatase activity in 
lung tissue) 




3 M (septal cell hyperplasia 
and interstitial 
inflammation of the lung; 
increased absolute and 
relative lung weight at 30 
mg/m3) 
Derelanko et al. 1999 
Cr2O3 (III) 
10 F (interstitial inflammation 


















































































5 Rat 13 wk 
6 hr/d(CDF) 
5 d/wk 




Resp 3	 (inflammation of lung; 
nasal tissues and larynx 








Bd Wt 3 M 10 M (~10% decreased in body 
weight) 
Resp 0.6 M (decreased macrophage 
activity) 
3	 (hyperplasia of 
mediastinal lymph node) 




mediastinal lymph nodes) 
Reference 
Chemical Form Comments 
Derelanko et al. 1999 
Cr2(OH)x(SO4)yNaSO4.2H2O 
(III) 
Johansson et al. 1986b 
Cr(NO3)39H2O(III) 
Derelanko et al. 1999 
Cr2O3 (III) 
























































30 Derelanko et al. 1999 
Cr2O3 (III) 
Increased absolute and 
relative lung weight in 























Derelanko et al. 1999 
Cr2(OH)x(SO4)yNaSO4.2H2O 
(III) 
Foa et al. 1988 
Cr2O3 (III) 
12 Human (occup) Resp 1.99 Korallus et al. 1974a 






















Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/m³) (mg/m³) (mg/m³) Chemical Form Comments 
Hemato 1.99 
a The number corresponds to entries in Figure 3-2. 
b Used to derive an intermediate-duration inhalation MRL of 0.005 mg chromium(III)/m3 as insoluble trivalent chromium particulates.  The minimal LOAEL of 3 mg chromium(III)/m3 
was adjusted for intermittent exposure, converted to a human equivalent concentration (0.43 mg chromium(III)/m3), and divided by a composite uncertainty factor of 90 (3 for use of a 
minimal LOAEL, 3 for extrapolation from animals to humans using dosimetric adjustments and 10 for human variability). 
c Used to derive an intermediate-duration inhalation MRL of 0.0001 mg chromium(III)/m3 as soluble trivalent chromium particulates.  The LOAEL of 3 mg chromium(III)/m3 was 
duration-adjusted for intermittent exposure, converted to a human equivalent concentration (0.04 mg chromium(III)/m3) and divided by a composite uncertainty factor of 300 (10 for 
use of a LOAEL, 3 for extrapolation from animals to humans using dosimetric adjustments and 10 for human variability). 
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = female; Gastro = gastrointestinal; Hemato = hematological; hr = hour(s); Immuno/Lymphoret = 
immunological/lymphoreticular; LOAEL = lowest-observed-adverse-effect level; M = male; min = minute(s); NOAEL = no-observed-adverse-effect level; NS = not specified; occup = 






















Figure 3-2 Levels of Significant Exposure to Chromium Ill - Inhalation 
































o-Other  Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans
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o-Other  Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans


























































c-Cat         -Human f-Ferret n-Mink Cancer Effect Level-Humans  Minimal Risk LevelLD50/LC50
d-Dog k-Monkey j-Pigeon o-Other  Cancer Effect Level-Animals  LOAEL, More Serious-Humans  for effects
r-Rat m-Mouse e-Gerbil LOAEL, More Serious-Animals  LOAEL, Less Serious-Humans  other than
p-Pig h-Rabbit s-Hamster LOAEL, Less Serious-Animals  NOAEL - Humans  Cancer






























































o-Other  Cancer Effect Level-Animals
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NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
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NOAEL - Humans

























   
 






















   
  
   
  
      
    
  
     
  
 











perforation was found in both subjects upon physical examination (Meyers 1950).  In a chrome plating
plant where poor exhaust resulted in excessively high concentrations of chromium trioxide fumes, 
workers experienced symptoms of sneezing, rhinorrhea, labored breathing, and a choking sensation when 
they were working over the chromate tanks.  All five of the subjects had thick nasal and postnasal
discharge and nasal septum ulceration or perforation after 2–3 months of exposure (Lieberman 1941).  
Asthma developed in a man who had been well until 1 week after beginning employment as an
electroplater.  When challenged with an inhalation exposure to a sample of chromium(III) sulfate, he
developed coughing, wheezing, and decreased forced expiratory volume.  He also had a strong asthmatic
reaction to nickel sulfate (Novey et al. 1983).  Thus, chromium-induced asthma may occur in some 
sensitized individuals exposed to elevated concentrations of chromium in air, but the number of sensitized
individuals is low and the number of potentially confounding variables in the chromium industry is high.
Intermediate- to chronic-duration occupational exposure to chromium(VI) may cause an increased risk of
death due to noncancer respiratory disease.  In a retrospective mortality study of 1,288 male and
1,401 female workers employed for at least 6 months in a chrome plating and metal engineering plant in 
the United Kingdom between 1946 and 1975, a statistically significant excess of death from diseases of
the respiratory system (noncancer) were obtained for men (observed/expected [O/E]=72/54.8, standard 
mortality ratio [SMR]=131, p<0.05) and men and women combined (O/E=97/76.4, SMR=127, p<0.05), 
but not for women alone.  Exposure was mainly to chromium trioxide, but exposure concentrations were
not precisely known.  The contribution of nickel exposure to the effects was found to be unimportant, 
while data on smoking habits were not available (Sorahan et al. 1987).  Similarly, a high SMR was found 
for noncancer respiratory disease among 1,212 male chromate workers who were employed for at least
3 months in three chromate plants in the United States during the years 1937–1960 and followed for
24 years (O/E=19/7.843, SMR=242) (Taylor 1966).  The increased risk of death from respiratory effects 
correlated with duration of employment in chromate production, but no information on exposure levels, 
smoking habits, or exposure to other chemicals was provided. The nature of the respiratory diseases was 
not further described in either of these reports.  Chromate production workers in the United Kingdom who 
were first employed before 1945 had a high risk of death from chronic obstructive airways disease 
(O/E=41/28.66, SMR=143, p<0.05) (Davies et al. 1991).  Exposure concentrations were not known, and 
reliable smoking data were not available.
Occupational exposure to chromium(VI) as chromium trioxide in the electroplating industry caused upper
respiratory problems.  A case history of nine men in a chrome plating facility reported seven cases of
nasal septum ulceration.  Signs and symptoms included rhinorrhea, nasal itching and soreness, and 
   
 








    
 
   
  
 





    
  
     
 
  
   
   
  
   
   
  
  
   
   
 
   
    
 
    
 




epistaxis.  The men were exposed from 0.5 to 12 months to chromium trioxide at concentrations ranging
from 0.09 to 0.73 mg chromium(VI)/m3 (Kleinfeld and Rosso 1965).  Electroplating workers in Sao 
Paulo, Brazil, exposed to chromium trioxide vapors while working with hot chromium trioxide solutions
had frequent incidences of coughing, expectoration, nasal irritation, sneezing, rhinorrhea, and nose-bleed 
and developed nasal septum ulceration and perforation.  The workers had been employed for <1 year, and 
most of the workers had been exposed to concentrations >0.1 mg chromium(VI)/m3 (Gomes 1972).  Nose
and throat irritation, rhinorrhea, and nose-bleed also occurred at higher incidence in chrome platers in
Singapore than in controls (Lee and Goh 1988).
Numerous studies of workers chronically exposed to chromium(VI) compounds have reported nasal
septum perforation and other respiratory effects.  Workers at an electroplating facility exposed to 0.0001– 
0.0071 mg chromium(VI)/m3 as chromium trioxide for an average of 26.9 months complained of
excessive sneezing, rhinorrhea, and epistaxis. Many of the workers had ulcerations and/or perforations of
the nasal mucosa (Cohen et al. 1974).  A study using only questionnaires, which were completed by
997 chrome platers and 1,117 controls, found a statistically significant increase in the incidence of
chronic rhinitis, rhinitis with bronchitis, and nasal ulcers and perforations in workers exposed to 
chromium(VI) in the chrome plating industry in 54 plants compared to the control population (Royle
1975b). The workers had been exposed to chromium(VI) in air and in dust.  The air levels were generally 
<0.03 mg chromium(VI)/m3, and dust levels were generally between 0.3 and 97 mg chromium(VI)/g.
The exposure levels at which effects first occurred could not be determined.  A NIOSH Health Hazard
Evaluation of an electroplating facility in the United States reported nasal septum perforation in 4 of
11 workers employed for an average of 7.5 years and exposed to mean concentrations of 0.004 mg
chromium(VI)/m3.  Many of the workers had epistaxis, rhinitis, and nasal ulceration (Lucas and
Kramkowski 1975).  Nasal mucosal changes ranging from irritation to perforation of the septum were
found among 77 employees of eight chromium electroplating facilities in Czechoslovakia where the mean
level in the breathing zone above the plating baths was 0.414 mg chromium(VI)/m3 (Hanslian et al.
1967).  The incidence of olfactory cleft obstruction, dry nose, feelings of nasal obstruction, and nasal
crusting was significantly increased in workers employed at chromium plating factories (mean
employment duration of 7.9 years) in An-San, Korea compared to an unexposed control group (Kitamura
et al. 2003).  Air concentrations of chromium(VI) ranged from 0.005 to 0.03 mg chromium(VI)/m3 and of
chromium(III) ranged from 0.005 to 0.06 mg chromium(III)/m3. Increased incidences of nasal septum
perforation, nasal septum ulcer, and nasal obstruction were observed in workers at chromium
electroplating facilities exposed for a mean duration of 6.1 years, as compared to workers at zinc 
electroplating facilities (Kuo et al. 1997a).  The chromium electroplating workers had 31.7 and 43.9 times 
   
 








   
   
    
  
  
     










    
     
  
  














greater risks of developing nasal septum ulcers or nasal perforations, respectively, than the zinc workers.
A significant relationship between duration of exposure and the risk of nasal septum ulcers was also
found; the chromium electroplating workers with a work duration of >9 years had a risk 30.8 times higher
than those with a work duration of <2 years.  Duration did not significantly affect the risk of nasal
perforation.  Statistically significant decreases in vital capacity, forced vital capacity (FVC), and forced
expiratory volume in 1 second (FEV1) were also observed in the chromium workers. Alterations in lung
function were also reported in a study of 44 workers at 17 chromium electroplating facilities (Bovet et al.
1977).  Statistically significant decreases in forced expiratory volume in 1 second and forced expiratory
flow were observed; vital capacity was not altered.  Lower lung function values were found among
workers with high urinary chromium levels (exposure levels were not reported), and it was determined
that cigarette smoking was not a confounding variable.
A study of respiratory effects, lung function, and changes in the nasal mucosa in 43 chrome plating
workers in Sweden exposed to chromium(VI) as chromium trioxide for 0.2–23.6 years 
(median=2.5 years) reported respiratory effects at occupational exposure levels of 0.002 mg
chromium(VI)/m3.  Signs and symptoms of adverse nasal effects were observed and reported at mean
exposure levels of 0.002–0.2 mg chromium(VI)/m3 . Effects noted at ≤0.002 mg chromium(VI)/m3 
included a smeary and crusty septal mucosa and atrophied mucosa.  Nasal mucosal ulceration and septal
perforation occurred in individuals exposed at peak levels of 0.02–0.046 mg chromium(VI)/m3; nasal
mucosal atrophy and irritation occurred in individuals exposed at peak levels of 0.0025–0.011 mg
chromium(VI)/m3; and no significant nasal effects were observed in individuals exposed at peak levels of
0.0002–0.001 mg chromium(VI)/m3.  Workers exposed to mean concentrations of 0.002–0.02 mg 
chromium(VI)/m3 had slight, transient decreases in FVC, forced expired volume in 1 second (FEV1), and 
forced mid-expiratory flow during the workday.  Workers exposed to <0.002 mg chromium(VI)/m3 
showed no effects on lung function (Lindberg and Hedenstierna 1983). The concentrations at which 
minor lung function changes were observed (0.002–0.02 mg chromium(VI)/m3) and those at which no 
changes were observed (<0.002 mg chromium(VI)/m3) are similar to those for nasal effects (0.0025– 
0.011 mg chromium(VI)/m3).  The effects observed in this study may not have resulted from exposure
levels actually measured, but may have resulted from earlier exposure under unknown conditions.
Furthermore, poor personal hygiene practices resulting in transfer of chromium(VI) in chrome plating
solutions from the hands to the nose could contribute to the development of nasal ulceration and 
perforation (Cohen et al. 1974; Lucas and Kramkowski 1975), perhaps leading to an underestimation of
airborne levels of chromium(VI) necessary to cause these effects.  Despite these considerations, the study
by Lindberg and Hedenstierna (1983) is useful because it indicates concentration-responses of
   
 









   
   
   
 
  
     
  
 




    
  
    
   
  
  
   




   
    
 
   
  
   
 
   
   
78CHROMIUM
3. HEALTH EFFECTS
chromium(VI) compounds that cause significant nasal and respiratory effects.  The LOAEL of 0.002 mg 
chromium(VI)/m3 for respiratory effects in humans was used to calculate an inhalation MRL of 5x10-6 mg 
chromium(VI)/m3 for intermediate-duration exposure to chromium(VI) as chromium trioxide mists and 
other dissolved hexavalent chromium aerosols or mists as described in the footnotes in Table 3-1. 
Occupational exposure to chromium(VI) and/or chromium(III) in other chromium-related industries has 
also been associated with respiratory effects. These industries include chromate and dichromate
production, stainless steel welding, and possibly ferrochromium production and chromite mining. 
In a survey of a facility engaged in chromate production in Italy, where exposure concentrations were
≥0.01 mg chromium(VI)/m3, high incidences of nasal septum perforation, septal atrophy and ulcerations, 
sinusitis, pharyngitis, and bronchitis were found among 65 men who worked in the production of
dichromate and chromium trioxide for at least 1 year (Sassi 1956).  Medical records of 2,307 male 
workers employed at a chromate production plant in Baltimore, Maryland between 1950 
and 1974 were evaluated to determine the percentage of workers reporting clinical symptoms, mean time 
of employment to first diagnosis of symptoms, and mean exposure to chromium(VI) at the time of first
diagnosis (exposure for each worker was the annual mean in the area of employment during the year of
first diagnosis) (Gibb et al. 2000a).  The most frequently reported clinical symptoms were irritation and 
ulcerated nasal septum, occurring in 68.1 and 62.9% of the cohort, respectively.  For irritation of the nasal
septum, the mean time of employment to first diagnosis was 89 days and the mean annual exposure level
during the year of first diagnosis was 0.025 mg chromium(VI)/m3; for nasal septal ulceration, the mean
time of employment to first diagnosis was 86 days and the mean annual exposure level during the year of
first diagnosis was 0.028 mg chromium(VI)/m3.  Other nasal effects had a longer time to first diagnosis.  
The time to first diagnosis for perforated nasal septum was 313 days, occurring in 17.3% of the cohort at
a mean exposure level of 0.033 mg chromium(VI)/m3, and for bleeding nasal septum, the time to first
diagnosis was 418 days, occurring in 12.1% of the cohort at a mean exposure level of 0.025 mg
chromium(VI)/m3. In a study of 97 workers from a chromate plant exposed to a mixture of insoluble
chromite ore containing chromium(III) and soluble chromium(VI) as sodium chromate and dichromate, 
evaluation for respiratory effects revealed that 63% had perforations of the nasal septum, 86.6% had 
chemical rhinitis, 42.3% had chronic chemical pharyngitis, 10.35% had laryngitis, and 12.1% had sinus, 
nasal, or laryngeal polyps.  The number of complaints and clinical signs increased as the exposure to
respirable chromium(VI) and chromium(III) compounds increased, but exposure levels at which effects
first occurred were not clearly defined (Mancuso 1951).  An extensive survey to determine the health
status of chromate workers in seven U.S. chromate production plants found that effects on the lungs
   
 


















    




   
   
     
    
    
   
 
   
   
   
   
   
   







consisted of bilateral hilar enlargement. Various manufacturing processes in the plants resulted in
exposure of workers to chromite ore (mean time-weighted concentration of 0–0.89 mg 
chromium(III)/m3); water-soluble hexavalent chromium compounds (0.005–0.17 mg chromium(VI)/m3);
and acid-soluble/water-insoluble chromium compounds (including basic chromium sulfate), which may
or may not entirely represent trivalent chromium (0–0.47 mg chromium/m3) (PHS 1953).  Challenge tests
with fumes from various stainless steel welding processes indicated that the asthma observed in two
stainless steel welders was probably caused by chromium or nickel, rather than by irritant gases 
(Keskinen et al. 1980).  In a study of 54 male miners in Zimbabwe exposed to chrome ore dust, decreases 
in pulmonary function, as indicated by measures of FVC, FEV1, peak expiratory flow rate (PEFR), and 
FEV1%, was observed compared to an unexposed control (e.g., non-mining) population (Osim et al.
1999).  Exposure levels were reported only as respirable dust, not as chromium specifically, and the
mining company did not employ industrial hygiene practices to reduce exposure.  In this same study, no 
changes in lung function were observed in a group of 46 male miners working for a company following
industrial hygiene procedures (again, specific chromium exposure levels were not reported). The analysis 
controlled for smoking and infectious respiratory diseases.  In a report of 10 cases of pneumoconiosis in 
underground workers in chromite mines in South Africa, radiographic analysis revealed fine nodulation 
and hilar shadows.  Chromium in the chromite ore in South Africa was in the form of chromium(III)
oxide.  The cause of the pneumoconiosis was considered to be deposition of insoluble radio-opaque
chromite dust in the tissues, rather than fibrosis (Sluis-Cremer and du Toit 1968).  In a case report of a
death of a sandblaster in a ferrochromium department of an iron works, the cause of death was silicosis,
but autopsy also revealed diffuse enlargement of alveolar septae and chemical interstitial and alveolar
chronic pneumonia, which were attributed to inhalation of chromium(III) oxide (Letterer 1939).  In an 
industrial hygiene survey of 60 ferrochromium workers exposed to chromium(III) and chromium(VI)
(0.02–0.19 mg total chromium/m3) conducted in 1975, appreciably higher incidences of subjective
symptoms of coughing, wheezing, and dyspnea were reported compared with controls. These workers 
had been employed at the plant for at least 15 years.  The control group consisted of workers employed at
the same plant for <5 years.  Statistically significant decreased mean FVC (p<0.01) and FEV1 (p<0.05)
were found in the ferrochromium workers compared with controls.  Two of the ferrochromium workers
had nasal septum perforations, which were attributed to previous exposure to hexavalent chromium.  A
major limitation of this study is that the control group was significantly younger than the study cohort.  In 
addition, the weekly amount of tobacco smoked by the control group was slightly greater than that
smoked by the study groups, and the controls began smoking 5 years earlier than the study groups.  
Therefore, the increase in subjective respiratory symptoms and decreased pulmonary function parameters 
cannot unequivocally be attributed to chromium exposure (Langård 1980).  However, no increase in the
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prevalence of respiratory illness was found in a study of 128 workers from two factories that produced 
chromium(III) oxide or chromium(III) sulfate (Korallus et al. 1974b) or in 106 workers at a factory that 
produced these chromium(III) compounds where workroom levels were ≤1.99 mg chromium(III)/m3 
(Korallus et al. 1974a).  Similar results were reported in a cross-sectional study that was conducted to
determine whether occupational exposure to trivalent chromium or hexavalent chromium caused
respiratory diseases, decreases in pulmonary function, or signs of pneumoconiosis in stainless steel 
production workers (Huvinen et al. 1996).  The median personal exposure levels were 0.0005 μg/m3 for 
chromium(VI) and 0.022 μg/m3 for chromium(III); the 221 workers were employed for >8 years with an
average potential exposure of 18 years.  Spirometry measurements were taken and chest radiographic
examinations were conducted.  There were no significant differences in the odds ratios between the
exposed workers and the 95 workers in the control group.  The deficits in lung function shown in both 
populations could be explained by age and smoking habits.  In a follow-up study of these workers 
(Huvinen et al. 2002a), no adverse respiratory effects were observed (as assessed by spirometry, chest
x-ray, and self-reported symptoms) in workers in the chromium(VI) group (n=104) compared to controls
(n=81).  Workers exposed to chromium(III) in the sintering and crushing departments (n=68) reported an 
increase in respiratory symptoms (phlegm production, shortness of breath on exertion) compared to 
control, but no differences in spirometry or chest x-ray.  Workers exposed to chromium(III) as chromite 
ore (n=31) had lower lung function tests, although smoking was a confounding factor.  In addition to
chromium, workers were also exposed to nickel and molybdenum.  In a study of stainless steel workers
(all nonsmokers) exposed for a minimum of 14 years to chromium(VI) (n=29), chromium(III) (n=14), or
chromite(III) ore (n=5), no increase was observed in the incidence of nasal diseases or nasal symptoms in
chromium-exposed workers compared to a control population of 39 workers (Huvinen et al. 2002b).  
However, although an exposure-related increase in the incidence of clinical signs of nasal irritation was
not observed, anterior rhinoscopy revealed a slight increase in the incidence of inflammatory changes in
the nasal mucosa of workers exposed to chromium(VI) (risk ratio=2.4) or chromium(III) (risk ratio=2.3), 
compared to control.  The mean exposure level for the chromium(VI) group was 0.5 μg Cr(VI)/m3, for the
chromium(III) group was 248 μg total Cr/m3 (concentration of chromium(III) not reported) and for the
chromite ore group was 22 μg Cr(III)/m3.
The respiratory system in animals is also a primary target for acute- and intermediate-duration inhalation 
exposure to chromium(VI) and chromium(III).  Rats exposed to sodium dichromate for 28 or 90 days had 
increased lung weight but no histopathological abnormalities at concentrations ≤0.2 mg 
chromium(VI)/m3.  The percentage of lymphocytes was increased in the bronchoalveolar lavage fluid at
≥0.025 mg/m3.  A decrease in macrophage activity was observed in the 0.2 mg chromium(VI)/m3 group 
   
 









   
   
   
  
    
     
  
    
     
   
   
   
   
  
   
 
  
    
    
 
     
  
   
    
    
 
 







exposed for 90 days.  Clearance of iron oxide from the lungs decreased in rats exposed to 0.2 mg
chromium(VI)/m3 for 42 days prior to and 49 days after challenge with iron oxide particles when 
compared to controls.  The decreased clearance of iron oxide correlated with the decrease in macrophage 
activity (Glaser et al. 1985).  In a similar but more extensive study, obstructive respiratory dyspnea was 
observed in rats exposed to sodium dichromate at ≥0.2 mg chromium(VI)/m3 for 30 or 90 days, and mean 
lung weight was increased at ≥0.05 mg chromium(VI)/m3. Slight hyperplasia was observed at high 
incidence in rats at ≥0.05 mg chromium(VI)/m3. Lung fibrosis occurred at low incidence in the rats 
exposed to ≥0.1 mg chromium(VI)/m3 for 30 days, but not in the 0.05 mg/m3 or the control groups.  The
incidence of both these lesions declined after longer exposure, indicating repair.  Accumulation of
macrophages and inflammation occurred at ≥0.05 mg chromium(VI)/m3 regardless of duration.  Results 
of bronchoalveolar lavage (BAL) analysis provided further evidence of an irritation effect that was 
reversible (Glaser et al. 1990).  The data from the Glaser et al. (1990) study was used to develop
benchmark concentrations (BMCs) (Malsch et al. 1994).  The BMC of 0.016 mg chromium(VI)/m3 for 
alterations in lactate dehydrogenase levels in BAL fluid was used to calculate an inhalation MRL of
0.0003 mg chromium(VI)/m3 for intermediate-duration exposure to chromium(VI) as particulate
hexavalent compounds as described in the footnote of Table 3-1.
Male Sprague-Dawley rats exposed to 1.15 mg chromium(VI)/m3 as chromium trioxide mist developed 
nasal hemorrhage after 10 days (lasting for 4 weeks) during a 90-day inhalation study (Kim et al. 2004).  
"Peculiar sounds" during respiration were noted starting after 1 week of exposure and resolving by
week 8 in rats exposed to ≥0.23 mg chromium(VI)/m3; however, no additional information on this
observation was reported.  After 90 days, histopathological changes to respiratory tissue included 
macrophage aggregation and foamy cells, and inflammation of alveolar regions; however, no
abnormalities were observed in nasal tissue at 0.49 mg chromium(VI)/m3 (incidence data were not
reported).  Mice exposed to chromium trioxide mist at concentrations of 1.81 and 3.63 mg
chromium(VI)/m3 intermittently for ≤12 months developed perforations in the nasal septum, hyperplastic
and metaplastic changes in the larynx, trachea, and bronchus, and emphysema (Adachi 1987; Adachi et
al. 1986).
The respiratory effects of chromium(III) compounds were investigated in male and female CDF rats 
exposed to insoluble chromic oxide or soluble basic chromium sulfate by nose-only inhalation at 3, 10, or
30 mg chromium(III)/m3 for 6 hours/day, 5 days/week for 13 weeks (Derelanko et al. 1999).  After 5 days
of exposure, BAL was conducted on a subgroup of animals.  In rats treated with chromic oxide, a yellow
crystalline material was observed in the cytoplasm of mononuclear cells of all exposure groups; however, 
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it is not clear if this observation represents an adverse effect.  No other BAL parameters were affected
(nucleated cell count and differential, protein and BAL fluid activities of β-glucuronidase, lactic
dehydrogenase, and glutathione reductase).  In rats treated with basic chromium sulfate, BAL fluid 
analysis showed significant decreases in nucleated cells at all doses in males and females and decreases in
the percentage of segmented neutrophils and mononuclear cells at 30 mg chromium(III)/m3 in males.
Increased amounts of cell debris and lysed cells were present in all basic chromium sulfate groups
(incidence data were not reported).  In rats exposed to chromic oxide for 13 weeks, absolute and relative 
lung weights were increased by 12 and 13%, respectively, in males exposed to 30 mg chromium(III)/m3 
as chromic oxide; no change was observed in females. Histopathological examination of respiratory
tissues showed pigmented macrophages containing a dense black substance, presumably the test
substance, throughout the terminal bronchioles and alveolar spaces in rats from all treatment groups; this
finding is consistent with normal physiological clearance mechanisms for particulates deposited in the 
lung and is not considered to be adverse.  At concentrations of 10 and 30 mg chromium(III)/m3, trace to 
mild chronic interstitial inflammation, characterized by inflammatory cell infiltrates, and septal cell
hyperplasia was observed.  No lesions were observed in the nasal cavity.  Following a 13-week recovery
period, microscopic examination of respiratory tissues of rats treated with chromic oxide showed 
pigmented macrophages and black pigment in peribronchial tissues and the mediastinal lymph node in all
treatment groups and septal cell hyperplasia and chronic interstitial inflammation of the lung, both trace-
to-mild in severity, in males of all treatment groups and in females exposed to 10 and 30 mg
chromium(III)/m3. In rats treated with basic chromium sulfate, a dose-related increase in absolute and
relative lungs weights was observed in all treatment groups.  Histopathological examination of respiratory
tract tissues revealed chronic inflammation of the lung (characterized by cell infiltration and debris in 
alveolar spaces and intense inflammation) and alveolar wall hyperplasia in all treatment groups.  In
addition, inflammation and suppurative and mucoid exudates of nasal tissues and granulomatous
inflammation of the larynx were observed in all treatment groups.  Incidence data for histopathological
findings were not reported.  Following the 13-week recovery period for rats treated with basic chromium
sulfate, enlargement of the mediastinal lymph node was observed on gross necropsy in all treatment
groups.  Microscopic examination of respiratory tissues showed changes to the lung (chronic alveolar
inflammation, interstitial inflammation, septal cell hyperplasia, and granulomatous inflammation) in all 
treatment groups, larynx (granulomatous inflammation) in the 10 and 30 mg chromium(III)/m3 groups, 
nasal tissues (trace suppurative exudates) in one to two animals in each group, and mediastinal lymph 
node (histiocytosis and hyperplasia) in all chromium(III) exposed groups.  Results of this study
demonstrate differences in the respiratory effects of inhaled chromium oxide and inhaled basic chromium
sulfate. Effects of soluble basic chromium sulfate were more severe and were observed throughout the
   
 








    
    
   
   
  
   
      
       
  
    





    
   
   
  
   
  
  
   





    
   
  





respiratory tract, while effects of chromic oxide were more mild and limited to the lung; these
observations may be related to differences in chemical-physical properties of the test compounds.  Data
from the Derelanko et al. (1999) study was used as the basis for intermediate-duration inhalation MRLs
for chromium(III) compounds.  Since soluble and insoluble chromium(III) compounds exhibited different
effects in the respiratory tract, distinct intermediate-duration MRLs were derived for insoluble and soluble
trivalent chromium particulates.  For insoluble chromium(III) compounds (chromic oxide), the minimal
LOAEL of 3 mg chromium(III)/m3 was used to calculate an intermediate-duration inhalation MRL of
0.005 mg chromium(III)/m3 for exposure to trivalent chromium particulates as described in the footnote
of Table 3-2.  For soluble chromium(III) (basic chromium sulfate) compounds, the LOAEL of 3 mg
chromium(III)/m3 was used to calculate an intermediate-duration inhalation MRL of 0.0001 mg
chromium(III)/m3 for exposure to trivalent chromium particulates as described in the footnote of
Table 3-2.
Pulmonary fluid from hamsters exposed to 0.9 or 25 mg chromium(III)/m3 as chromium trichloride for 
30 minutes revealed sporadic changes in activities of acid phosphatase and alkaline phosphatase in the 
lavage fluid at 25 mg chromium(III)/m3. In the lung tissue, a 75% increase in the acid phosphatase
activity was found at 0.9 mg chromium(III)/m3 and in the β-glucuronidase activity at an unspecified
concentration.  Histological examination revealed alterations representing mild nonspecific irritation but
no morphological damage (Henderson et al. 1979).  In rabbits exposed to 0.6 mg chromium(III)/m3 as 
chromium nitrate intermittently for 4–6 weeks, changes in the lungs were confined to nodular
accumulations of macrophages in the lungs.  Macrophage morphology demonstrated black inclusions and 
large lysosomes.  These changes represent normal physiological responses of the macrophages to the 
chromium particle.  Phagocytosis and the reduction of nitroblue tetrazolium to formazan was impaired by
chromium(III), indicating a decrease in the functional and metabolic activity of the macrophage
(Johansson et al. 1986a, 1986b).  
Chronic exposure to chromium(VI) compounds and mixtures of chromium(VI) and chromium(III)
compounds have also resulted in adverse respiratory effects in animals.  Experiments in which rats were 
exposed to either chromium(VI) alone as sodium dichromate or a 3:2 mixture of chromium(VI) trioxide
and chromium(III) oxide for 18 months showed similar loading of macrophages and increases in lung
weight.  However, histopathology of rats exposed to 0.1 mg/m3 of chromium(III) and chromium(VI)
together revealed interstitial fibrosis and thickening of the septa of the alveolar lumens due to the large 
accumulation of chromium in the lungs, whereas histopathology of the lungs was normal in rats exposed 
only to chromium(VI) (Glaser et al. 1986, 1988).  Mice exposed to 4.3 mg chromium(VI)/m3 as calcium
   
 










   
   










   
 
   
    
 
  
   
 
  
   
   
     
  
  








chromate dust intermittently for 18 months had epithelialization of alveoli.  Histopathology revealed
epithelial necrosis and marked hyperplasia of the large and medium bronchi, with numerous openings in 
the bronchiolar walls (Nettesheim and Szakal 1972).  Significantly increased incidences of pulmonary
lesions (lung abscesses, bronchopneumonia, giant cells, and granulomata) were found in rats exposed 
chronically to a finely ground, mixed chromium roast material that resulted in airborne concentrations of
1.6–2.1 mg chromium(VI)/m3 compared with controls.  In the same study, guinea pigs exposed 
chronically to the chromium roast material along with mists of potassium dichromate or sodium chromate
solutions that also resulted in 1.6–2.1 mg chromium(VI)/m3 had significantly increased incidences of
alveolar and interstitial inflammation, alveolar hyperplasia, and interstitial fibrosis, compared with 
controls.  Similarly, rabbits were also exposed and also had pulmonary lesions similar to those seen in the 
rats and guinea pigs, but the number of rabbits was too small for meaningful statistical analysis (Steffee 
and Baetjer 1965).  
In the only study of chromium(IV) exposure, all rats treated with 0.31 or 15.5 mg chromium(IV)/m3 as 
chromium dioxide dust for 2 years had discolored mediastinal lymph nodes and lungs, and dust laden 
macrophages.  Lung weight was increased at 12 and 24 months in the 15.5 mg chromium(IV)/m3 group 
(Lee et al. 1989).  The increased lung weight and macrophage effects probably represent the increased
lung burden of chromium dioxide dust and normal physiological responses of macrophages to dust.
Cardiovascular Effects.    Information regarding cardiovascular effects in humans after inhalation
exposure to chromium and its compounds is limited.  In a survey of a facility engaged in chromate
production in Italy, where exposure concentrations were ≥0.01 mg chromium(VI)/m3, electrocardiograms 
were recorded for 22 of the 65 workers who worked in the production of dichromate and chromium
trioxide for at least 1 year.  No abnormalities were found (Sassi 1956).  An extensive survey to determine
the health status of chromate workers in seven U.S. chromate production plants found no association 
between heart disease or effects on blood pressure and exposure to chromates. Various manufacturing
processes in the plants resulted in exposure of workers to chromite ore (mean time-weighted 
concentration of 0–0.89 mg chromium(III)/m3); water-soluble chromium(VI) compounds (0.005–0.17 mg
chromium(VI)/m3); and acid-soluble/water-insoluble chromium compounds (including basic chromium
sulfate), which may or may not entirely represent trivalent chromium (0–0.47 mg chromium/m3) (PHS 
1953).  No excess deaths were observed from cardiovascular diseases and ischemic heart disease in a 
cohort of 4,227 stainless steel production workers from 1968 to 1984 when compared to expected deaths
based on national rates and matched for age, sex, and calendar time (Moulin et al. 1993).  No measure-
ments of exposure were provided.  In a cohort of 3,408 individuals who had worked in four facilities that 
   
 









     
   
   
    
 
   
  
 
    
 
   




   
     
   
   
   
  
 
      
     
    
 
 
    
 





produced chromium compounds from chromite ore in northern New Jersey sometime between 1937 and 
1971, where the exposure durations of workers ranged from <1 to >20 years, and no increases in
atherosclerotic heart disease were evident (Rosenman and Stanbury 1996).  The proportionate mortality
ratios (number of deaths from a specific cause to the total number of deaths) for white and black men
were 97 (95% confidence limits 88–107) and 90 (95% confidence limits 72–111), respectively.
Cardiovascular function was studied in 230 middle-aged workers involved in potassium dichromate
production who had clinical manifestations of chromium poisoning (96 with respiratory effects and
134 with gastrointestinal disorders) and in a control group of 70 healthy workers of similar age.  Both 
groups with clinical manifestations had changes in the bioelectric and mechanical activity of the
myocardium as determined by electrocardiography, kinetocardiography, rheocardiography, and 
ballistocardiography.  These changes were more pronounced in the workers with respiratory disorders due
to chromium exposure than in the workers with chromium-induced gastrointestinal effects. The changes 
in the myocardium could be secondary to pulmonary effects and/or to a direct effect on the blood vessels
and myocardium (Kleiner et al. 1970).
For intermediate-duration exposures, no histopathological changes to the heart were observed in male 
Sprague-Dawley rats exposed to 1.15 mg chromium(VI)/m3 as chromium trioxide (Kim et al. 2004) or in 
male and female CDF rats exposed to 30 mg chromium(III)/m3 as chromic oxide or basic chromium
sulfate for 3 months (Derelanko et al. 1999).  No histopathological lesions were found in the hearts of rats
exposed chronically to chromium dioxide at 15.5 mg chromium(IV)/m3 (Lee et al. 1989).  Additional
information regarding cardiovascular effects in animals after exposure to chromium or chromium
compounds was not located.
Gastrointestinal Effects. Gastrointestinal effects have been associated with occupational exposure 
of humans to chromium compounds.  In a report of two cases of acute exposure to "massive amounts" of
chromium trioxide fumes, the patients complained of abdominal or substernal pain, but further
characterization was not provided (Meyers 1950).
In a NIOSH Health Hazard Evaluation of an electroplating facility in the United States, 5 of 11 workers 
reported symptoms of stomach pain, 2 of duodenal ulcer, 1 of gastritis, 1 of stomach cramps, and 1 of
frequent indigestion. The workers were employed for an average of 7.5 years and were exposed to mean
concentrations of 0.004 mg chromium(VI)/m3 (Lucas and Kramkowski 1975).  These workers were not
compared to a control group.  An otolaryngological examination of 77 employees of eight chromium
   
 









    
  
  
   
  
  
   
  
 
   
     
  
     




      
     
    
   
   




   
 
     




electroplating facilities in Czechoslovakia, where the mean level in the breathing zone above the plating
baths was 0.414 mg chromium(VI)/m3, revealed 12 cases of chronic tonsillitis, 5 cases of chronic 
pharyngitis, and 32 cases of atrophy of the left larynx (Hanslian et al. 1967).  In a study of 97 workers 
from a chromate plant exposed to a mixture of insoluble chromite ore containing chromium(III) and 
soluble chromium(VI) as sodium chromate and dichromate, gastrointestinal radiography revealed that
10 of the workers had ulcer formation, and of these, 6 had hypertrophic gastritis.  Nearly all of the
workers breathed through the mouth while at work and swallowed the chromate dust, thereby directly
exposing the gastrointestinal mucosa.  Only two cases of gastrointestinal ulcer were found in 41 control
individuals, who had the same racial, social, and economic characteristics as the chromium-exposed 
group (Mancuso 1951).  In a survey of a facility engaged in chromate production in Italy where exposure
concentrations were ≥0.01 mg chromium(VI)/m3, 15.4% of the 65 workers who worked in the production 
of dichromate and chromium trioxide for at least 1 year had duodenal ulcers and 9.2% had colitis.  The
ulcers were considered to be due to exposure to chromium (Sassi 1956).  Gastric mucosa irritation leading
to duodenal ulcer was found in 21 of 90 workers engaged in the production of chromium salts.
Symptoms of gastrointestinal pathology appeared about 3–5 years after the workers' initial contact
(Sterekhova et al. 1978).  Most of these studies reporting gastrointestinal effects did not compare the
workers with appropriate controls.  Although the gastrointestinal irritation and ulceration due to exposure
to chromium(VI) in air could be due to a direct action of chromium(VI) on the gastrointestinal mucosa 
from swallowing chromium as a result of mouth breathing (or transfer via hand-to-mouth activity), other
factors, such as stress and diet, can also cause gastrointestinal effects.  While occupational exposure to
chromium(VI) may result in gastrointestinal effects, a lower than expected incidence of death from
diseases of the digestive tract was found among a cohort of 2,101 employees who had worked for at least
90 days during the years 1945–1959 in a chromium production plant in Baltimore, Maryland, and were
followed until 1977.  The rate (O/E=23/36.16, SMR=64) is based on comparison with mortality rates for
Baltimore (Hayes et al. 1979).  In contrast to findings with chromium(VI) compounds, no indication was
found that exposure to chromium(III) resulted in stomach disorders in workers employed in two factories 
that produced chromium(III) oxide or chromium(III) sulfate (Korallus et al. 1974b). 
Information regarding gastrointestinal effects in animals after inhalation exposure to chromium or its
compounds is limited.  For intermediate-duration exposures, no histopathological changes to 
gastrointestinal tissues in male and female CDF rats exposed to 30 mg chromium(III)/m3 as chromic 
oxide or basic chromium sulfate for 3 months, (Derelanko et al. 1999).  Histological examination of the
stomachs of rats exposed to sodium dichromate dihydrate at ≤0.2 mg chromium(VI)/m3 for 28 or 90 days 
revealed no abnormalities (Glaser et al. 1985).  In mice exposed intermittently to 4.3 mg 
   
 








    
  
    
   





     
   
    
   
    
   
  
   
    
    
   













chromium(VI)/m3 as calcium chromate for 18 months, small ulcerations in the stomach and intestinal 
mucosa were reported to occur occasionally, but the incidence in the treated mice or controls and other
details regarding these lesions were not reported (Nettesheim et al. 1971).  No treatment-related
histopathological lesions were found in the stomach, large intestine, duodenum, jejunum, or ileum of rats
chronically exposed to chromium dioxide at 15.5 mg chromium(IV)/m3 (Lee et al. 1989).
Hematological Effects.    Hematological evaluations of workers occupationally exposed to chromium
compounds have yielded equivocal results.  Ninety-seven workers from a chromate plant were exposed to 
a mixture of insoluble chromite ore containing chromium(III) and soluble sodium chromate and 
dichromate.  Hematological evaluations revealed leukocytosis in 14.4% or leukopenia in 19.6% of the
workers.  The leukocytosis appeared to be related primarily to monocytosis and eosinophilia, but controls
had slight increases in monocytes and occasional increases in eosinophils without leukocytosis.  
Decreases in hemoglobin concentrations and slight increases in bleeding time were also observed
(Mancuso 1951).  Whether these hematological findings were significantly different from those seen in
controls was not stated, but the effects were attributed to chromium exposure.  In a survey of a facility
engaged in chromate production in Italy where exposure concentrations were ≥0.01 mg 
chromium(VI)/m3, hematological evaluation of workers who worked in the production of dichromate and 
chromium trioxide for at least 1 year were unremarkable or inconclusive (Sassi 1956).  In an extensive 
survey to determine the health status of chromate workers in seven U.S. chromate production plants, 
hematological evaluations revealed no effects on red blood cell counts, hemoglobin, hematocrit, or white
blood cell counts.  The sedimentation rate of red cells was higher than that of controls, but the difference 
was not statistically significant. Various manufacturing processes in the plants resulted in exposure of
workers to chromite ore (mean time-weighted concentration of 0–0.89 mg chromium(III)/m3); water-
soluble chromium(VI) compounds (0.005–0.17 mg chromium(VI)/m3); and acid-soluble/water-insoluble
chromium compounds (including basic chromium sulfate), which may or may not entirely represent
chromium(III) (0–0.47 mg chromium/m3) (PHS 1953).  Likewise, no effects on red blood cell counts, 
white blood cell counts, hemoglobin levels, or sedimentation rate were found in a case control study of
17 male manual metal arc stainless steel welders from six industries with mean occupational durations of
20 years (Littorin et al. 1984).  The relationship between serum and urine chromium levels and blood 
hemoglobin was examined in workers exposed to chromium(III) at a tannery plant in Leon, Mexico 
(Kornhauser et al. 2002).  Groups of workers were classified as unexposed (control; n=11), moderately
exposed (n=14) or highly exposed (n=11) based on job type; exposure levels were not reported.  Blood 
chromium levels of 0.13, 0.25, and 0.39 μg/L and urine chromium levels of 1.35, 1.43, and 1.71 μg/L
were observed in the control, moderate, and high exposure groups, respectively; statistically significant 
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differences were observed between the control group and both chromium groups for blood chromium and 
between the control and the high exposure groups for urine chromium.  An inverse relationship was
observed between urine chromium and blood hemoglobin (r=-0.530), serum chromium and urine iron 
(r=-0.375) and the chromium/iron ratio in urine and hemoglobin (r=-0.669; <0.05).  Results indicate a
potential effect of chromium(III) exposure on hemoglobin; however, due to small group size, definitive
conclusions cannot be made.  No hematological disorders were found among 106 workers in a 
chromium(III) producing plant where workroom levels were ≤1.99 mg chromium(III)/m3 as 
chromium(III) oxide and chromium(III) sulfate (Korallus et al. 1974a).
Results from hematological evaluations in rats yielded conflicting results.  Hematological effects were 
observed in male Sprague-Dawley rats exposed to chromium trioxide mist for 90 days; changes included 
significant decreases in hematocrit (at 0.23 and 1.15, but not 0.49 mg chromium(VI)/m3), hemoglobin (at
0.49 and 1.15 mg chromium(VI)/m3) and erythrocyte count (at 1.15 mg chromium(VI)/m3) (Kim et al.
2004).  Hematological evaluations of rats exposed to sodium dichromate at 0.025–0.2 mg
chromium(VI)/m3 for 28 or 90 days or 0.1 mg chromium(VI)/m3 for 18 months were unremarkable 
(Glaser et al. 1985, 1986, 1988).  However, increased white blood cell counts were found in rats exposed 
to ≥0.1 mg chromium(VI)/m3 as sodium dichromate for 30 days and at ≥0.05 mg chromium(VI)/m3 for 
90 days.  The white blood cell counts were not increased 30 days postexposure (Glaser et al. 1990).  Rats
exposed to 0.1 mg chromium/m3 as a 3:2 mixture of chromium(VI) trioxide and chromium(III) oxide for
18 months had increased red and white blood cell counts, hemoglobin content, and hematocrit (Glaser et
al. 1986, 1988).
No changes in hematological parameters were observed in rats exposed to 15.5 mg chromium(IV)/m3 as 
chromium dioxide for 2 years (Lee et al. 1989).
In male and female CDF rats exposed to insoluble chromic oxide or soluble basic chromium sulfate by
nose-only inhalation at 3, 10, or 30 mg chromium(III)/m3 for 6 hours/day, 5 days/week for 13 weeks, no 
adverse effects on hematological parameters were observed (Derelanko et al. 1999).
Musculoskeletal Effects. No musculoskeletal effects have been reported in either humans or
animals after inhalation exposure to chromium. 
Hepatic Effects. Chromium(VI) has been reported to cause severe liver effects in four of five workers 
exposed to chromium trioxide in the chrome plating industry.  Derangement of the cells in the liver,
   
 








    
    
 
  
     
  
 
   
   
  
  
   
   
  
   





    
  
   












necrosis, lymphocytic and histiocytic infiltration, and increases in Kupffer cells were reported. 
Abnormalities in tests for hepatic dysfunction included increases in sulfobromophthalein retention, 
gamma globulin, icterus, cephalin cholesterol flocculation, and thymol turbidity (Pascale et al. 1952).  In 
a cohort of 4,227 workers involved in production of stainless steel from 1968 to 1984, excess deaths were
observed from cirrhosis of the liver compared to expected deaths (O/E=55/31.6) based on national rates
and matched for age, sex, and calendar time having an SMR of 174 with confidence limits of 131– 
226 (Moulin et al. 1993).  No measurements of exposure were provided.  Based on limited information, 
however, the production of chromium compounds does not appear to be associated with liver effects.  As 
part of a mortality and morbidity study of workers engaged in the manufacture of chromium(VI)
compounds (84%) and chromium(III) compounds (16%) derived from chromium(VI) in Japan,
94 workers who had been exposed for 1–28 years were given a complete series of liver function tests 
3 years after exposure ended.  All values were within normal limits (Satoh et al. 1981).  In a survey of a
facility engaged in chromate production in Italy, where exposure concentrations were ≥0.01 mg 
chromium(VI)/m3, 15 of 65 men who worked in the production of dichromate and chromium trioxide for
at least 1 year had hepatobiliary disorders.  When the workers were given liver function tests, slight
impairment was found in a few cases. These disorders could have been due to a variety of factors,
especially heavy alcohol use (Sassi 1956).  No indication was found that exposure to chromium(III)
resulted in liver disorders in workers employed in two factories that produced chromium(III) oxide or
chromium(III) sulfate (Korallus et al. 1974b).
The hepatic effects observed in animals after inhalation exposure to chromium or its compounds were
minimal and not considered to be adverse.  Rats exposed to as much as 0.4 mg chromium(VI)/m3 as 
sodium dichromate for ≤90 days did not have increased serum levels of alanine aminotransferase or
alkaline phosphatase, cholesterol, creatinine, urea, or bilirubin (Glaser et al. 1990).  Triglycerides and 
phospholipids were increased only in the 0.2 mg chromium(VI)/m3 group exposed for 90 days (Glaser et
al. 1985).  No histopathological changes to the liver were observed in male Sprague-Dawley rats exposed
to 1.15 mg chromium(VI)/m3 as chromium trioxide (Kim et al. 2004) or in male and female CDF rats
exposed to 30 mg chromium(III)/m3 as chromic oxide or basic chromium sulfate for 3 months, 
(Derelanko et al. 1999).  Chronic exposure of rats to 0.1 mg chromium(VI)/m3 as sodium dichromate, to 
0.1 mg total chromium/m3 as a 3:2 mixture of chromium(VI) trioxide and chromium(III) oxide, or to 
15.5 mg chromium(IV)/m3 as chromium dioxide did not cause adverse hepatic effects as assessed by
histological examination and liver function tests (Glaser et al. 1986, 1988; Lee et al. 1989).
   
 








       
    
   









     
       
     
 
   
   






    
 
  






Renal Effects. No increases in genital/urinary disease were evident in a cohort of 3,408 workers from
four former facilities that produced chromium compounds from chromite ore in northern New Jersey
sometime between 1937 and 1971.  The proportionate mortality ratios for white and black men were
71 (40–117) and 47 (15–111), respectively.  Exposure durations ranged from <1 to >20 years (Rosenman
and Stanbury 1996).
Renal function has been studied in workers engaged in chromate and dichromate production, in chrome
platers, in stainless steel welders, in workers employed in ferrochromium production, in boilermakers, 
and in workers in an alloy steel plant.  Workers exposed to chromium(VI) compounds in a chromate
production plant were found to have higher levels of a brush border protein antigen and retinol binding
protein in the urine compared with controls (Mutti et al. 1985a).  A similar study was conducted in 
43 male workers in the chromate and dichromate production industry, where occupational exposures were
between 0.05 and 1.0 mg chromium(VI)/m3 as chromium trioxide, and mean employment duration was
7 years. Workers with >15 μg chromium/g creatinine in the urine had increased levels of retinol binding
protein and tubular antigens in the urine (Franchini and Mutti 1988). These investigators believe that the 
presence of low molecular weight proteins like retinol binding protein or antigens in the urine are
believed to be early indicators of kidney damage.  In an extensive survey to determine the health status of
chromate workers in seven U.S. chromate production plants, analysis of the urine revealed a higher
frequency of white blood cell and red blood cell casts than is usually found in an industrial population 
(statistical significance not reported).  Various manufacturing processes in the plants resulted in exposure 
of workers to chromite ore (mean time-weighted concentration of 0–0.89 mg chromium(III)/m3); water-
soluble chromium(VI) compounds (0.005–0.17 mg chromium(VI)/m3); and acid-soluble/water-insoluble
chromium compounds (including basic chromium sulfate), which may or may not entirely represent
chromium(III) (0–0.47 mg chromium/m3) (PHS 1953).  Significant increases in urinary N-acetyl-
β-D-glucosaminidase activity and microalbumin and β2-microglobulin levels were observed in chromate 
production workers (Wang et al. 2011a). The mean chromium level in air was 27.13 µg chromium/m3 
and the mean exposure time was 12.86 years; however, no information on the specific chromium
compound was provided.  Although the workers were required to wear masks, significant correlations
between air chromium levels and urinary chromium levels were found; the mean urinary chromium level
was 17.41 µg/g creatinine.  The study also found significant correlations between air, whole blood, and 
urinary chromium levels and biomarkers of renal damage (urinary N-acetyl-β-D-glucosaminidase activity
and microalbumin and β2-microglobulin levels).
   
 








    
   
   
   
 
  
    









   
    
   
    
    
   





    
    
    





Some studies of renal function in chromate production workers found negative or equivocal results.  In a
survey of a facility engaged in chromate production in Italy, where exposure concentrations were
≥0.01 mg chromium(VI)/m3, results of periodic urinalyses of workers who worked in the production of
dichromate and chromium trioxide for at least 1 year were generally unremarkable, with the exception of
one case of occasional albuminuria and a few cases of slight urobilinuria (Sassi 1956).  As part of a 
mortality and morbidity study of workers engaged in the manufacture of chromium(VI) compounds
(84%) and chromium(III) compounds (16%) derived from chromium(VI) in Japan, 94 workers who had 
been exposed for 1–28 years were given a complete series of kidney function tests (not further
characterized) 3 years after exposure ended.  All values were within normal limits (Satoh et al. 1981).
Studies of renal function in chrome platers, whose exposure is mainly to chromium(VI) compounds, have
also yielded equivocal results.  A positive dose-response for elevated urinary levels of β2-microglobulin 
was found in chrome platers who were exposed to 0.004 mg chromium(VI)/m3, measured by personal air
samplers, for a mean of 5.3 years.  However, since no increase in β2-microglobulin levels was found in 
ex-chrome platers who had worked for at least 1 year in an old chrome plating plant from 1940 to 1968, 
this effect may be reversible (Lindberg and Vesterberg 1983b).  Liu et al. (1998) similarly found 
significantly higher urinary β2-microglobulin and N-acetyl-β-glucosaminidase levels in hard-chrome
electroplaters exposed to 0.0042 mg chromium/m3 for a mean of 5.8 years, as compared to aluminum
anode-oxidation workers. The prevalence of elevated levels (higher than reference values) was 
significantly increased for N-acetyl-β-glucosaminidase, but not for β2-microglobulin.  In another study, 
comparison of results of renal function tests between chrome platers and construction workers revealed
that the chrome platers had significantly (p<0.001) increased levels of urinary chromium and increased
clearance of chromium, but decreased (p<0.05) levels of retinol binding protein.  However, no differences
were found for blood urea nitrogen, serum and urinary β2-microglobulin, serum immunoglobulin, total
protein in the urine, urinary albumin, N-acetyl-β-D-glucosamidase, β-galactosidase, or lysozyme 
(Verschoor et al. 1988).
Studies of renal function in stainless steel welders, whose exposure is mainly to chromium(VI) 
compounds, were negative.  Stainless steel welders had significantly increased (p<0.001) levels of urinary
chromium, increased clearance of chromium, and increased serum creatinine compared with controls, but
no differences were found in the levels of retinol binding protein, β2-microglobulin, or other indices of
kidney damage (Verschoor et al. 1988).  Similar negative results were found in another group of stainless
steel welders (Littorin et al. 1984).
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Occupational exposure to chromium(III) or chromium(0) does not appear to be associated with renal
effects.  No renal impairment based on urinary albumin, retinol binding protein, and renal tubular antigens
was found in 236 workers employed in the ferrochromium production industry where ferrochromite is
reduced with coke, bauxite, and quartzite.  The mean airborne concentration of chromium in various
sample locations was 0.075 mg chromium(III)/m3; chromium(VI) was below the detection limit of
0.001 mg chromium(VI)/m3 at all locations (Foa et al. 1988).  Workers employed in an alloy steel plant 
with a mean exposure of 7 years to metallic chromium at 0.61 mg chromium(0)/m3 and to other metals
had normal urinary levels of total protein and β2-microglobulin, enzyme activities of alanine-
aminopeptidase, N-acetyl-β-D-glucosaminidase, gammaglutamyl-transpeptidase, and β-galactosidase 
(Triebig et al. 1987).  In boilermakers exposed to chromium(0), no increase in urinary levels of
chromium, and no differences in the levels of retinol binding protein, β2-microglobulin, or other indices of
renal toxicity were found (Verschoor et al. 1988). 
In a group of 30 men and 25 women who were lifetime residents of an area in northern New Jersey
contaminated with chromium landfill, signs of preclinical renal damage were assessed by examining the 
urinary levels of four proteins, intestinal alkaline phosphatase, tissue nonspecific alkaline phosphatase,
N-acetyl-β-D-glucosaminidase, and microalbumin (Wedeen et al. 1996).  The mean urinary chromium
concentrations were 0.2±0.1 μg/g creatinine for the women and 0.3 μg/g creatinine for the men.  None of
the four proteins exceeded normal urinary levels in either men or women.  The authors concluded that
long-term environmental exposure to chromium dust did not lead to tubular proteinurea or signs of
preclinical renal damage.
Exposure of rats to sodium dichromate at ≤0.4 mg chromium(VI)/m3 for ≤90 days did not cause
abnormalities, as indicated by histopathological examination of the kidneys.  Serum levels of creatinine 
and urea and urine levels of protein were also normal (Glaser et al. 1985, 1990).  No changes in urinalysis
parameters or histopathological changes to the kidneys were observed in male Sprague-Dawley rats 
exposed to 1.15 mg chromium(VI)/m3 as chromium trioxide (Kim et al. 2004) and no histopathological
lesions were observed in the kidneys of male and female CDF rats exposed to 30 mg chromium(III)/m3 as 
chromic oxide or basic chromium sulfate for 3 months (Derelanko et al. 1999).  Furthermore, no renal
effects were observed in rats exposed to 0.1 mg chromium/m3 as sodium dichromate (chromium(VI)) or
as a 3:2 mixture of chromium(VI) trioxide and chromium(III) oxide for 18 months, based on histological
examination of the kidneys, urinalysis, and blood chemistry (Glaser et al. 1986, 1988).  Rats exposed to 
15.5 mg chromium(IV)/m3 as chromium dioxide for 2 years showed no histological evidence of kidney
   
 














   









   
 






     
    
    
  
     




damage or impairment of kidney function, as measured by routine urinalysis.  Serum levels of blood urea 
nitrogen, creatinine, and bilirubin were also normal (Lee et al. 1989).
Endocrine Effects. Increased serum amylase activity (a marker for pancreatic function) was observed
in a group of 50 chrome plating workers in Bangalore, India, compared to 50 workers with no history of
chromium(VI) exposure.  Employment duration of exposed workers ranged from 15 to 20 years; exposure
levels were not reported (Kalahasthi et al. 2007).  Serum amylase activity in exposed workers was
significantly correlated to urine chromium (r=0.289; p<0.05).  No studies were located regarding
endocrine effects in humans following inhalation exposure to chromium(III) compounds.
For intermediate-duration exposures, no histopathological changes to the endocrine tissues were observed
in male Sprague-Dawley rats exposed to 1.15 mg chromium(VI)/m3 as chromium trioxide (Kim et al. 
2004) or in male and female CDF rats exposed to 30 mg chromium(III)/m3 as chromic oxide or basic 
chromium sulfate for 3 months (Derelanko et al. 1999).  Male rats exposed 22 hours/day for 18 months to 
0.1 mg chromium(VI)/m3 as sodium dichromate or exposed to a mixture of chromium(VI) and 
chromium(III) (0.06 mg chromium(VI)/m3 plus 0.04 mg chromium(III)/m3) as chromium(VI) trioxide and 
chromium(III) oxide did not result in any histopathological changes in adrenal glands (Glaser et al. 1986, 
1988).  Rats exposed to 15.5 mg chromium(IV)/m3 as chromium dioxide for 2 years showed no 
histopathological abnormalities in adrenals, pancreas, and thyroid glands (Lee et al. 1989).
Dermal Effects. Acute systemic and dermal allergic reactions have been observed in chromium-
sensitive individuals exposed to chromium via inhalation as described in Sections 3.2.3.2 and 3.2.3.3. 
No studies were located regarding systemic dermal effects in animals after inhalation exposure to
chromium(VI) or chromium(III) compounds.
Ocular Effects. Effects on the eyes due to direct contact of the eyes with airborne mists, dusts, or
aerosols or chromium compounds are described in Section 3.2.3.2.  Medical records of 2,307 male 
workers employed at a chromate production plant in Baltimore, Maryland between 1950 
and 1974 were evaluated to determine the percentage of workers reporting clinical symptoms, mean time 
of employment to first diagnosis of symptoms, and mean exposure to chromium(VI) at the time of first
diagnosis (exposure for each worker was the annual mean in the area of employment during the year of
first diagnosis) (Gibb et al. 2000a).  Conjunctivitis was reported on 20.0% of the study population, at a
mean exposure level of 0.025 mg Cr(VI)/m3 and a mean time-to-onset of 604 days.
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Opthalmoscopic examination did not reveal any changes in male and female CDF rats exposed to 30 mg
chromium(III)/m3 as chromic oxide or basic chromium sulfate for 3 months (Derelanko et al. 1999).
Histopathologic examination of rats exposed to 15.5 mg chromium(IV)/m3 as chromium dioxide for
2 years revealed normal morphology of the ocular tissue (Lee et al. 1989).
Body Weight Effects. In a report of a case of acute exposure to "massive amounts" of chromium
trioxide fumes, the patient became anorexic and lost 20–25 pounds during a 3-month period following 
exposure (Meyers 1950).
In rats exposed to an aerosol of sodium dichromate for 30 or 90 days or for 90 days followed by an 
additional 30 days of nonexposure, body weight gain was significantly decreased at 0.2 and 0.4 mg
chromium(VI)/m3 for 30 days (p<0.001), at 0.4 mg chromium(VI)/m3 for 90 days (p<0.05), and at
0.2 (p<0.01) and 0.4 mg chromium(VI)/m3 (p<0.05) in the recovery group (Glaser et al. 1990).  There
was no effect on body weight gain in rats exposed for 28 days to 0.2 mg/m3 (Glaser et al. 1985) or for 
≤18 months to 0.1 mg chromium(VI)/m3 as sodium dichromate (Glaser et al. 1986, 1988, 1990) or 0.1 mg 
chromium(III and VI)/m3 as a 3:2 mixture of chromium(VI) trioxide and chromium(III) oxide for
18 months (Glaser et al. 1986, 1988).  Body weight was significantly decreased in male Sprague-Dawley
rats exposed to 1.15 mg chromium(VI)/m3 as chromium trioxide mist for 90 days (Kim et al. 2004) and in 
male, but not female, rats exposed to 10 mg chromium(III)/m3 as chromic oxide for 13 weeks (Derelanko 
et al. 1999).  However, exposure of male and female rats to 30 mg chromium(III)/m3 as basic chromium
sulfate for 13 weeks did not produce body weight changes (Derelanko et al. 1999).  Similarly, there was
no effect on body weight gain in rats exposed to 15.5 mg chromium(IV)/m3 as chromium dioxide for
2 years (Lee et al. 1989).
Metabolic Effects. In a study of chromate production workers, a significant increase in plasma total
homocysteine levels and decreases in serum vitamin B12 and folate levels were observed; the mean
urinary chromium level was 17.41 µg/g creatinine (Wang et al. 2011b).  The mean chromium level in air
was 27.13 µg chromium/m3 and the mean exposure time was 12.86 years.  Erythrocyte chromium levels 
were significantly correlated with serum vitamin B12 and folate levels, and urinary chromium levels were
correlated with vitamin B12 levels. The investigators suggested that the increased homocysteine levels 
were due to vitamin B12 and folate deficiency and that vitamin B12 and folate deficiency may be 
secondary to chromium-induced renal damage.
   
 












    
   
   
    
 
 
   
    
 
   
  
 
   
   












    
 
     
   
95CHROMIUM
3. HEALTH EFFECTS
3.2.1.3  Immunological and Lymphoreticular Effects 
Sensitization of workers, resulting in respiratory and dermal effects, has been reported in numerous
occupational exposure studies.  Although the route of exposure for initial sensitization in an occupational
setting is most likely a combination of inhalation, oral, and dermal routes, information on the exposure
levels producing sensitization by the inhaled route was not identified.  Additional information on contact
dermatitis in sensitized workers is provided in Section 3.2.3.3 (Dermal Exposure, Immunological and 
Lymphoreticular Effects).
Acute reactions have been observed in chromium sensitive individuals exposed to chromium via 
inhalation as noted in several individual case reports.  A 29-year-old welder exposed to chromium vapors
from chromium trioxide baths and to chromium and nickel fumes from steel welding for 10 years
complained of frequent skin eruptions, dyspnea, and chest tightness.  Chromium sensitivity in the
individual was measured by a sequence of exposures, via nebulizer, to chromium(VI) as sodium
chromate.  Exposure to 0.029 mg chromium(VI)/mL as sodium chromate caused an anaphylactoid 
reaction, characterized by dermatitis, facial angioedema, bronchospasms accompanied by a tripling of
plasma histamine levels, and urticaria (Moller et al. 1986).  Similar anaphylactoid reactions were 
observed in five individuals who had a history of contact dermatitis to chromium, after exposure, via
nebulizer, to an aerosol containing 0.035 mg chromium(VI)/mL as potassium dichromate.  Exposure
resulted in decreased forced expiratory volume, facial erythema, nasopharyngeal pruritus, nasal blocking, 
cough, and wheezing (Olaguibel and Basomba 1989).  Challenge tests with fumes from various stainless
steel welding processes indicated that the asthma observed in two stainless steel welders was probably
caused by chromium or nickel, rather than by irritant gases produced by the welding process (Keskinen et
al. 1980).  A 28-year-old construction worker developed work-related symptoms of asthma, which
worsened during periods when he was working with (and sawing) corrugated fiber cement containing
chromium.  A skin patch test to chromium was negative.  Asthmatic responses were elicited upon
inhalation challenge with fiber cement dust or nebulized potassium chromate (Leroyer et al. 1998).  A
40-year-old woman exposed to chromium and nickel in a metalworks company developed occupational
asthma and tested positive to skin prick tests and bronchial challenge tests with potassium dichromate
(Cruz et al. 2006).  In four male workers (two electroplating workers, one welder, and one cement
worker) with work-related symptoms of asthma, two tested positive to skin prick tests with potassium
dichromate and nickel sulfate and all tested positive to bronchial challenge tests with potassium
dichromate and nickel sulfate (Fernandez-Nieto et al. 2006).  Chromium-induced asthma may occur in 
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some sensitized individuals exposed to elevated concentrations of chromium in air, but the number of
sensitized individuals is low and the number of potentially confounding variables in the chromium
industry is high.  
Concentrations of some lymphocyte subpopulations (CD4+ helper-inducer, CD5--CD19+ B, 
CD3--CD25+ activated B, and CD3--HLA-DR+ activated B and natural killer lymphocytes) were 
significantly reduced (about 30–50%) in a group of 15 men occupationally exposed to dust containing
several compounds (including hexavalent chromium as lead chromate) in a plastics factory.  Worker
blood lead and urine chromium levels were significantly higher than those of 15 controls not known to be
occupationally exposed to toxic agents.  Serum chromium concentrations and serum immunoglobulins
IgA, IgG, and IgM were not significantly different between the two groups (Boscolo et al. 1997).  
Mignini et al. (2009) did not find significant differences in lymphocyte subpopulations (CD4+, CD8+, 
CD19+, CD16+/CD56+, CD4/CD8) in chromium workers in the shoe, hide, and leather industries, as
compared to unexposed workers.  The immunological effects of chromium were evaluated in a small
group of tannery workers (n=20) in Italy, compared to a matched group of unexposed controls (n=24)
(Mignini et al. 2004).  Exposure of individual workers was not reported, but monitoring of 20 factories
with participating workers reported TWA concentrations of 0.09–0.10 mg total chromium/m3 and 0.001– 
0.002 mg chromium(VI)/m3. The mean time of employment of the exposed group was 5.8 years.  Urine
chromium excretion was significantly increased in workers, although no increase in plasma chromium
was observed, compared to controls.  In workers, proliferative response of peripheral blood 
mononucleocytes (PBMC) in response to concavalin A was increased approximately 24% compared to
controls; no difference between workers and controls were observed for the percent distribution of
lymphocyte subsets (e.g., T lymphocytes, T helper lymphocytes, T cytotoxic lymphocytes,
B lymphocytes, and natural killer cells).  In tannery and chrome-plating workers exposed to high levels of
chromium (mean blood chromium level of 86.71 µg/L), no significant alterations in IL-12, as compared 
to unexposed workers, were found; however, when IL-12 levels were measured in lipopolysaccharide-
stimulated peripheral blood monocyte cells, a significant elevation was found in chromium workers
(Katiyar et al. 2009).  Interferon-γ levels were significantly higher in peripheral blood monocyte cells
(with or without stimulation) in chromium workers; a significant correlation between interferon-γ levels 
(in stimulated cells) and blood chromium levels was also found.  In contrast, a study of shoe, hide, and 
leather industry workers found a significant decrease in IL-12 levels (Mignini et al. 2009).  This study
also found increases in IL-2 and IL-6 levels, but no changes in IL-1β, tumor necrosis factor-α, interferon-
γ, or IL-4 levels.  Immune function, as assessed by the lymphocyte proliferative response to mitogens
(phytohemagglutinin and concanavalin A) was also significantly altered in this group of workers.
   
 













   
   
   
     
 
 





     
  
    
  
   
   
   
 
   
   
 
 
   
   




Immunological effects of exposure to chromic acid were evaluated in 46 electroplating workers in Taiwan
(Kuo and Wu 2002).  The entire group was employed for an average of 6.1 years.  Workers were divided
into low (n=19), moderate (n=17), and high (n=10) subgroups based on mean urine chromium excretion 
of <1.13, 1.14–6.40, and >6.40 μg chromium/g creatinine, respectively.  Airborne chromium was
measured by personal samplers for all study participants for the duration of one 8-hour shift (data not
reported); however, no information was reported on individual or group exposures over the time of
employment.  A negative correlation was observed between urine chromium and B cell percentage and a 
positive correlation was observed between urine chromium and blood IL-8 concentration.  The study
authors report that smoking was an important factor for lymphocyte subsets; thus, interpretation of these
results is limited by confounding factors.
An animal study was designed to examine the immunotoxic effects of soluble and insoluble hexavalent
chromium agents released during welding (Cohen et al. 1998).  Rats exposed to atmospheres containing
soluble potassium chromate at 0.36 mg chromium(VI)/m3 for 5 hours/day, 5 days/week for 2 or 4 weeks 
had significantly increased levels of neutrophils and monocytes and decreased alveolar macrophages in
bronchoalveolar lavage than air-exposed controls.  Significantly increased levels of total recoverable cells
were noted at 2 (but not 4) weeks of exposure.  In contrast, no alterations in the types of cells recovered
from the bronchoalveolar lavage fluid were observed in rats exposed to 0.36 mg chromium(VI)/m3 as 
insoluble barium chromate, as compared to controls.  However, the cell types recovered did differ from
those recovered from rats exposed to soluble chromium.  Changes seen in pulmonary macrophage
functionality varied between the soluble and insoluble chromium(VI) exposure groups.  The production of
interleukin (IL)-1 and tumor necrosis factor (TNF)-α cytokines were reduced in the potassium chromate
exposed rats; only TNF-α was decreased in the barium chromate rats.  IL-6 levels were not significantly
altered in either group.  Barium chromate affected zymosan-inducible reactive oxygen intermediate
formation and nitric oxide production to a greater degree than soluble chromium(VI).  Insoluble
chromium(VI) reduced the production of superoxide anion, hydrogen perodise, and nitric oxide; soluble
chromium(VI) only reduced nitric oxide production.
Rats exposed to 0.025–0.2 mg chromium(VI)/m3 as sodium dichromate for 28 or 90 days had increased
spleen weights at ≥0.05 mg chromium(VI)/m3 and increased response to sheep red blood cells at
≥0.025 mg chromium(VI)/m3. In the 90-day study, serum immunoglobulin content was increased in the
0.05 and 0.1 mg chromium(VI)/m3 groups but not in the 0.2 mg chromium(VI)/m3 group.  There was an 
increase in mitogen-stimulated T-cell response in the group exposed for 90 days to 0.2 mg 
   
 








     
  
  




     
  




     
   
       




   
      
    
   
   
   
  
  








chromium(VI)/m3.  Bronchial alveolar lavage fluid had an increased percentage of lymphocytes in the
groups exposed to 0.025 and 0.05 mg chromium(VI)/m3 and an increased percentage of granulocytes in
the groups exposed to 0.05 mg chromium(VI)/m3 for 28 days.  The phagocytic activity of macrophages 
was increased in the 0.05 mg chromium(VI)/m3 group.  A higher number of macrophages in telophase
was observed in the 0.025 and 0.05 mg chromium(VI)/m3 groups.  Bronchial alveolar lavage fluid from
rats exposed for 90 days had an increased percentage of lymphocytes in the 0.025, 0.05, and 0.2 mg
chromium(VI)/m3 groups and an increased percentage of granulocytes and number of macrophages in the
0.05 mg chromium(VI)/m3 groups. The phagocytic activity of the macrophages was increased in the
0.025 mg and 0.05 mg chromium(VI)/m3 groups and decreased in the 0.2 mg chromium(VI)/m3 group.  A
greater number of macrophages in telophase and an increase in their diameter were observed in the 0.025,
0.05, and 0.2 mg chromium(VI)/m3 groups (Glaser et al. 1985).
Low-level exposure to sodium dichromate seems to stimulate the humoral immune system (as indicated
by the significant increase in total immunoglobin levels); exposure to 0.2 mg chromium(VI)/m3 ceases to
stimulate the humoral immune system (significant decreases in total immunoglobin levels) but still may
have effects on the T lymphocytes. The depression in macrophage cell count and phagocytic activities 
correlated with a 4-fold lower rate of lung clearance for inhaled iron oxide in the 0.2 mg 
chromium(VI)/m3 group (Glaser et al. 1985).
Intermediate-duration exposure of rats to inhaled chromium(III) compounds produces histopathological 
alterations to respiratory lymph nodes and tissues.  In male and female CDF rats, exposure to 3, 10, and 
30 mg chromium(III)/m3 as soluble basic chromium sulfate for 13 weeks resulted in histiocytic cellular
infiltration and hyperplasia of peribronchial lymphoid tissue and mediastinal lymph nodes; lymph node
enlargement was also observed on necropsy (Derelanko et al. 1999). Following a 13-week recovery
period, enlargement, histiocytosis, and hyperplasia of the mediastinal lymph node was observed in rats
exposed to 3, 10, and 30 chromium(III)/m3 as basic chromium sulfate.  Hyperplasia of the mediastinal
lymph node was observed in male and female CDF rats exposed to chromium oxide at concentrations of
3, 10, and 30 mg chromium(III)/m3 for 13 weeks (Derelanko et al. 1999).  Following a 13-week recovery
period, black pigment (trace-to-mild) in peribronchial lymphoid tissue and mediastinal lymph nodes was
found in all treatment groups.  
The LOAELs for immunological effects in rats are recorded in Table 3-1 and plotted in Figure 3-1 for
chromium(VI) and recorded in Table 3-2 and plotted in Figure 3-2 for chromium(III).
   
 










    
 
  
     
 




   
 
  
    
 







    
   
  
   
 
 
   
 
     





3.2.1.4  Neurological Effects 
In a chrome plating plant where poor exhaust resulted in excessively high concentrations of chromium
trioxide fumes, workers experienced symptoms of dizziness, headache, and weakness when they were 
working over the chromate tanks (Lieberman 1941).  Such poor working conditions are unlikely to still
occur in the United States because improvements in industrial hygiene have been made over the years.
Results of olfactory perceptions tests conducted in workers employed at chromium plating factories in
An-San Korea (mean employment duration of 7.9 years) indicate that olfactory recognition thresholds
were significantly higher in exposed workers compared to controls (Kitamura et al. 2003).  Air
concentrations of chromium(VI) ranged from 0.005 to 0.03 mg chromium(VI)/m3 and of chromium(III)
ranged from 0.005 to 0.06 mg chromium(III)/m3.  Although the cause of this change was not determined, 
the study authors suggest that chromium may directly affect the olfactory nerve.
No increases in vascular lesions in the central nervous system were evident in a cohort of 3,408 workers 
from four former facilities that produced chromium compounds from chromite ore in northern New Jersey
(Rosenman and Stanbury 1996).  The proportionate mortality ratios for white and black men were 78 (61– 
98) and 68 (44–101), respectively.  The subjects were known to have worked in the four facilities
sometime between 1937 and 1971 when the last facility closed.  Exposure durations ranged from <1 to 
>20 years.
No information was located regarding neurological effects in humans or animals after inhalation exposure 
to chromium(III) compounds or in animals after inhalation exposure to chromium(VI) compounds.  No 
histopathological lesions were found in the brain of male Sprague-Dawley rats exposed to 1.15 mg
chromium(VI)/m3 as chromium trioxide for 3 months or in male and female CDF rats exposed to 30 mg
chromium(III)/m3 as chromic oxide or basic chromium sulfate for 3 months (Derelanko et al. 1999; Kim
et al. 2004) or in the brain, spinal cord, or nerve tissues of rats exposed to 15.5 mg chromium(IV)/m3 as 
chromium dioxide for 2 years (Lee et al. 1989).  No neurological or behavioral tests were conducted in 
these studies.
3.2.1.5  Reproductive Effects
Information regarding reproductive effects in humans after inhalation of chromium compounds is limited.
Semen quality was evaluated in 61 workers in a chromium sulfate manufacturing plant in India (Kumar et
al. 2005).  Employment duration and chromium exposure levels were not reported.  The study included a
control group of 15 unexposed workers.  Chromium blood levels in the exposed group were significantly
   
 








    
  




    
    
  
 












     
     
    
   









increased compared to the control group.  Although no effect was observed on semen volume, 
liquefaction time, or pH or on sperm viability, count, motility, or concentration, a significant increase was
observed in the number of morphologically abnormal sperm in exposed workers.  In the exposed group, 
53% of subjects had less than 30% normal sperm; in the control group, only 10% of subjects had <30%
normal sperm.  A significant positive correlation (r=0.301; p=0.016) was observed between blood 
chromium and the percentage of abnormal sperm in exposed workers.  Sperm count and motility were
significantly decreased by 47 and 15%, respectively in a group of 21 workers employed at a chrome 
plating plant in Henan, China, compared to age-matched, unexposed controls (Li et al. 2001).  Serum
follicle stimulating hormone (FSH) concentration was significantly increased by 204% and semen lactate
dehydrogenase activity was significantly decreased by 30% in exposed compared to control workers,
although no effect on serum luteinizing hormone (LH) concentration was observed.  Serum chromium
levels were 11% higher in the exposed workers compared to control; however, the increase was not
statistically significant.  Duration of employment for all study participants ranged from 1 to 15 years; no 
information on exposure levels or demographics of the exposed and control groups were reported. 
The effect of chromium(VI) on the course of pregnancy and childbirth was studied in women employees
at a dichromate manufacturing facility in Russia.  Complications during pregnancy and childbirth (not
further described) were reported in 20 of 26 exposed women who had high levels of chromium in blood 
and urine, compared with 6 of 20 women in the control group.  Toxicosis (not further described) was
reported in 12 exposed women and 4 controls.  Postnatal hemorrhage occurred in four exposed and two 
control women (Shmitova 1980).  Similar results were reported in a more extensive study of 407 women 
who worked at a factory producing chromium compounds (not otherwise specified) compared with 
323 controls.  The frequency of birth complications was 71.4% in a subgroup of highly exposed women, 
77.4% in a subgroup of women with a lower level of exposure, and 44.2% in controls.  Toxicosis in the
first half of pregnancy occurred in 35.1% of the high exposure group, 33.3% of the low exposure group, 
and 13.6% of the controls.  The frequency of postnatal hemorrhage was 19.0% for the high exposure
group and 5.2% in controls (Shmitova 1978).  Because these studies were generally of poor quality and 
the results were poorly reported, no conclusions can be made regarding the potential for chromium to 
produce reproductive effects in humans.
The occurrence of spontaneous abortion among 2,520 pregnancies of spouses of 1,715 married Danish 
metal workers exposed to hexavalent chromium from 1977 through 1987 were examined (Hjollund et al. 
1995).  Occupational histories were collected from questionnaires and information on spontaneous
abortion, live births, and induced abortion was obtained from national medical registers.  The number of
   
 














    
    
  




    
  
   
   
 
    
   
   













spontaneous abortions was not increased for pregnant women whose spouses worked in the stainless steel
welding industry when compared to controls (odds ratio 0.78, 95% confidence interval [CI] 0.55–1.1).  
The authors believed that the risk estimate was robust enough that factors such as maternal age and parity
and smoking and alcohol consumptions were not confounders.  There was no association found in 
spontaneous abortions in women whose husbands were in the cohort subpopulations who were mild steel
welders and metal-arc stainless steel welders, which would lead to higher exposures to welding fumes 
(workplace chromium exposures not provided).  This more recent study does not corroborate earlier
findings (Bonde et al. 1992) that showed that wives of stainless steel welders were at higher risk of
spontaneous abortions.  The current study was based on abortions recorded in a hospital register, while
the earlier study was based on self-reporting data.  The latter study probably included more early
abortions and was biased because the job exposure of male metal workers is apparently modified by the 
outcome of their partners’ first pregnancy.   
Histopathological examination of the testes of rats exposed to 0.2 mg chromium(VI)/m3 as sodium
dichromate for 28 or 90 days (Glaser et al. 1985), to 0.1 mg chromium(VI)/m3 as sodium dichromate for
18 months, or to 0.1 mg chromium/m3 as a 3:2 mixture of chromium(VI) trioxide and chromium(III)
oxide for 18 months (Glaser et al. 1986, 1988) revealed no abnormalities.  For intermediate-duration 
exposures to chromium(III) compounds, no histopathological changes to the reproductive tissues in male 
and female CDF rats exposed to 30 mg chromium(III)/m3 as chromic oxide or basic chromium sulfate for
3 months; treatment also had no effect on sperm count, motility, or morphology (Derelanko et al. 1999).
No histopathological lesions were observed in the prostate, seminal vesicle, testes, or epididymis of male 
rats or in the uterus, mammary gland, or ovaries of female rats exposed to 15.5 mg chromium(IV)/m3 as 
chromium dioxide for 2 years (Lee et al. 1989). 
The NOAELs for reproductive effects in rats are recorded in Table 3-1 and plotted in Figure 3-1 for
chromium(VI) and recorded in Table 3-2 and plotted in Figure 3-2 for chromium(III).
3.2.1.6  Developmental Effects 
No studies were located regarding developmental effects in humans or animals after inhalation exposure
to chromium or its compounds.
   
 













   
   
    
    






     
 
    
     
  
  
    
 




   




Occupational exposure to chromium(VI) compounds in various industries has been associated with 
increased risk of respiratory system cancers, primarily bronchogenic and nasal.  Among the industries 
investigated in retrospective mortality studies are chromate production, chromate pigment production and 
use, chrome plating, stainless steel welding, ferrochromium alloy production, and leather tanning.  
Compilations and discussion of many of these studies can be found in reviews of the subject (Goldbohm
et al. 2006; IARC 1990; Steenland et al. 1996).  Studies of chromium workers have varied considerably in
strength of design for determining cancer risks related to chromium exposure.  The strongest designs have 
provided estimates of chromium(VI) (or exposure to other chromium species) for individual members of
the cohorts, enabling application of dose-response analysis to estimate the contribution of chromium
exposure to cancer risk.  Studies that do not provide estimates of chromium exposure have relied on 
surrogate dose metrics (e.g., length of employment at job titles associated with chromium exposure) for
exploring attribution of cancer risk to chromium exposure.  However, these surrogate measures are often
strongly correlated with exposures to other work place hazards, making conclusions regarding possible
associations with chromium exposures more uncertain.  Chromium dose-response relationships have been 
reported for chromate production workers, but not for other categories of chromium workers.  In studies
of chromate production workers, increased risk of respiratory tract cancers have been found in association 
with increased cumulative exposure to chromium(VI) and several estimates of excess lifetime risk
attributed to chromium exposure have been reported.  Studies of chrome platers, who were exposed to 
chromium(VI) and other carcinogenic chemicals, including nickel, have found significant elevations in 
lung cancer risk in association with surrogate indicators of chromium exposure, such as duration of
employment at jobs in which exposure to chromium occurred; however, estimates of risk attributable
specifically to chromium exposure have not been reported.  Results of studies in stainless steel welders
exposed to chromium(VI) and other chemicals, and in ferrochromium alloy workers, who were exposed 
mainly to chromium(0) and chromium(III), but also to some chromium(VI), have been mixed and are
inconclusive with respect to work-associated elevations in cancer rates.  Studies in leather tanners, who 
are exposed to chromium(III), have not found elevated cancer rates.  A summary of select occupational
exposure studies that were considered the best conducted for each type of chromium work is presented in
Table 3-3.
Chromate Production.  Numerous studies of cancer mortality among chromate production workers have
been reported (Alderson et al. 1981; Bidstrup and Case 1956; Buckell and Harvey 1951; Crump et al. 
2003; Davies et al. 1991; Enterline 1974; Gibb et al. 2000b; Korallus et al. 1982; Mancuso 1997a; Ohsaki
   
 




























   
 
  
































   








Table 3-3.  Risk of Cancer Mortality in Chromium Workers
Risk
Cancer type (95% CI) Comments Reference
Chromate production
Lung cancer RR 1.80 2,357 males.  Cancer rate ratio of Gibb et al. 2000b
(1.49–2.14) 2.44 (1.54–3.83) associated with a 
cumulative 45-year exposure to 1 mg/m3-
year (Park et al. 2004)
Lung cancer SMR 268 U.S. reference rate; SMR of 241 (180–317) Luippold et al. 2003
(200–352) using Ohio reference males; lung cancer
mortality risk increased with cumulative 
chromium exposure levels, duration of
exposure, and year of hire; a high 
percentage (73–86%) of workers smoked
Chromate pigment workers
Lung cancer SMR 190 Workers employed >30 years; no significant Hayes et al. 1989
(111–295) alterations in workers with shorter
employment; chromium levels monitored in 
later years were >0.5 and >2 mg/m3 for
highly exposed jobs
Chrome plating
Lung cancer SMR 172 Males and females in chrome bath area for Sorahan et al. 1998
(112–277) >1 year; SMR for workers in chrome bath 
area for >5 years was 320 (128–658);
significant positive trend for lung cancer
mortality and duration of exposure found in 
male chrome bath workers
Lung cancer SMR 1.59 Workers with initial chromium exposure Hara et al. 2010
(1.01–2.38) prior to 1970
Malignant SMR 3.80 Workers with initial chromium exposure Hara et al. 2010
lymphoma (1.39–8.20) prior to 1970
Stainless steel production and welding
Lung cancer SMR 2.49 Not significant when compared to national Sjogren et al. 1987
(0.80–5.81) rates; significant increase when compared 
with an internal reference group and 
stratified for age; average chromium(VI)
concentration in 1975 was 0.11 mg/m3 
Lung cancer SMR 2.29 SMR for stainless steel foundry workers; Moulin et al. 1993
(1.14–4.09) SMR for workers employed >30 years was
3.24 (95% CI=1.19–7.05); no increase in 
lung cancer deaths in workers involved in 
melting and casting stainless steel
CI = confidence interval; RR = relative risk; SMR = standardized mortality ratio
   
 
















     





   
     
 
 
   
   
 
   
  
      










et al. 1978; Park and Stayner 2006; Park et al. 2004; Pastides et al. 1994; PHS 1953; Rosenman and 
Stanbury 1996; Sassi 1956; Satoh et al. 1994; Taylor 1966).  Collectively, these studies provide evidence
for associations between lung cancer mortality and employment in chromate production, with risks
declining with improved industrial hygiene.  Less consistently, nasal cancers have been observed
(Alderson et al. 1981; Rosenman and Stanbury 1996; Sassi 1956; Satoh et al. 1994).  Evidence for
associations between exposure to chromium and cancer is strongest for lung cancer mortality, which has
been corroborated and quantified in numerous studies. A meta-analysis of 49 epidemiology studies based
on 84 papers of cancer outcomes, primarily among chromium workers, found SMRs ranging from 112 to
279 for lung cancer, with and overall SMR of 141 (95% CI 135–147; Cole and Rodu 2005).  When 
limited to high-quality studies controlled for smoking, the overall SMR for lung cancer was 112 (95% CI 
104–119).  SMRs for other forms of cancer from studies that controlled for confounders were not
elevated.  Several studies have attempted to derive dose-response relationships for this association 
(Crump et al. 2003; Gibb et al. 2000b; Mancuso 1997a; Park and Stayner 2006; Park et al. 2004).  These
studies are particularly important because they have included individual exposure estimates to chromium 
for each member of the cohort based on work place monitoring; dose-response modeling to ascertain the 
contribution of changing exposures to chromium to risk (in workers who were also exposed to other
work-place hazards that could have contributed to cancer risk); and evaluation of the impacts of potential
co-variables and confounders (e.g., age, birth cohort, and smoking) on chromium-associated risk.
Gibb et al. (2000b) examined lung cancer mortality in a cohort of chromate production workers (n=2,357, 
males) in Baltimore, Maryland, who were first hired during the period 1950–1974, with mortality
followed through 1992.  This cohort was the subject of numerous earlier studies, which found 
significantly increased lung cancer mortality (i.e., standard mortality ratios) among workers at the plant
(Baetjer 1950; Braver et al. 1985; Hayes et al. 1979; Hill and Ferguson 1979).  In the Gibb et al. (2000b)
study, cumulative exposures to chromium(VI) or chromium(III) (mg/m3-year) were reconstructed for each
member of the cohort from historical workplace air monitoring data and job title records (Gibb et al. 
2000b).  Lung cancer for the entire group had a relative risk of 1.80 (95% CI 1.49–2.14).  Relative risk of
lung cancer mortality (adjusted for smoking) increased by a factor to 1.38 (95% CI 1.20–1.63) in 
association with a 10-fold increase in cumulative exposure to chromium(VI).  The analogous relative risk
for cumulative exposure to chromium(III) was 1.32 (95% CI 1.15–1.51).  Exposures to chromium(III) and 
chromium(VI) were highly correlated; therefore, discrimination of risks associated with either were 
problematic.  However, in a combined model that included cumulative exposure to both chromium
species, relative risk for chromium(VI) exposure remained significant (1.66, p=0.045), whereas relative
risk for chromium(III) was negative (-0.17, p=0.4).  This outcome suggests that exposure to
   
 








   
 
    
   
   
   






   
 
    
   
   
   
  
    
 












chromium(VI), rather than chromium(III), was the dominant (if not sole) contributor to lung cancer risk
(after adjustments for smoking).  Park et al. (2004) reanalyzed the data for the Baltimore, Maryland 
cohort using a variety of dose-response models.  In the preferred model (linear with cumulative chromium
exposure and log-linear for age, smoking, race), cancer rate ratio for a 45-year cumulative exposure to
1 mg/m3-year of chromium(VI) was estimated to be 2.44 (95% CI 1.54–3.83).  This corresponded to an
excess lifetime risk unit risk (i.e., additional lifetime risk from occupational exposure to 1 μg CrO3/m3 or
0.52 μg Cr(VI)/m3) of 0.003 (95% CI 0.001–0.006) or to 100 μg chromium(VI)/m3 of 0.255 (95% CI
0.109–0.416).  Subsequent analyses conducted by Park and Stayner (2006) attempted to estimate possible
thresholds for increasing lung cancer risk.  This analysis was able to exclude possible thresholds in excess 
of 16 μg/m3 chromium(VI) or 0.4 mg/m3-year cumulative exposure to chromium(VI). 
Several studies have examined cancer mortality in a cohort of chromate production workers in 
Painesville, Ohio, and have found increased lung cancer mortality (e.g., SMRs) among workers at the
plant (Crump et al. 2003; Luippold et al. 2003; Mancuso 1997a; Mancuso and Hueper 1951).  Mancuso 
(1997a) reconstructed cumulative exposure histories of individual members of the cohort (n=332), hired 
during the period 1931–1937 and followed through 1993.  The exposure estimations were based on
historical workplace air monitoring data for soluble and insoluble chromium and job title records.  Age-
adjusted death rates from lung cancer were estimated for cumulative exposure strata, and increased with
increasing cumulative exposure to total chromium, insoluble chromium, and soluble chromium (a dose
response model was not reported). The highest rates were observed in soluble chromium strata 
>4 mg/m3-years (2,848 per 100,000).  Death rates were not adjusted for smoking, which would have been 
a major contributor to lung cancer death rates in the cohort. Although the study discriminated exposures
to soluble and insoluble chromium, these classifications are not adequate surrogates for exposures to
trivalent or hexavalent chromium (Kimbrough et al. 1999; Mundt and Dell 1997); therefore, the study 
cannot attribute risk specifically to either species.  More recent studies of this cohort have attempted to
reconstruct individual exposure histories to chromium(VI), based on species-specific air monitoring data,
and have attempted to quantify the potential contribution of smoking to lung cancer risk (Crump et al. 
2003; Luippold et al. 2003).  These studies included workers (n=482) hired after 1940 and followed 
through 1997.  Increasing lung cancer risk was significantly associated with increasing cumulative 
exposure to chromium(VI).  Relative risk for lung cancer mortality was estimated to be 0.794 per mg/m3-
year (90% CI 0.518–1.120).  The analogous additive risk was 0.00161 per mg/m3-year per person year
(90% CI 0.00107–0.00225). These estimates correspond to unit risks (i.e., additional lifetime risk from
occupational exposure to 1 μg/m3) of 0.00205 (90% CI 0.00134–0.00291), based on the relative risk
Poison model, and 0.00216 (90% CI 0.00143–0.00302), based on the additional risk Poison model.  Risk
   
 









    
    




    
     
      
  
 






    
    
    
    
  
 
   
   
  
   
  
 




estimates were not appreciably sensitive to birth cohort or to smoking designation (for the 41% of the 
cohort that could be classified). The latter outcome suggests that smoking did not have a substantial
effect on chromium(VI) associated lung cancer risk (i.e., smoking and chromium appeared to contribute
independently to cancer risk).
A meta-analysis of the Crump et al. (2003); Gibb et al. (2000b), and Mancuso (1997a) studies has also
been reported (Goldbohm et al. 2006).  Excess lifetime risk of lung cancers was estimated from a life 
table analysis (using Dutch population vital statistics) and estimates of relative risk from each study, or in
the case of Mancuso (1997a), estimated in the meta-analysis (approximately 0.0015 per mg/m3-year).
Estimates of excess lifetime risks (deaths attributed to a 40-year occupational exposure to chromium(VI)
at 1 g/m3, for survival up to age 80 years) were 0.0025, 0.0048, and 0.0133, based on Crump et al. 
(2003), Mancuso et al. (1997a), and Gibb et al. (2000b), respectively.
In conclusion, despite limitations of some studies, occupational exposure to chromium(VI) in the
chromate production industry is associated with increased risk of respiratory cancer.  Estimates of excess 
lifetime occupational risks range from 0.002 to 0.005 per g/m3 of chromium(VI).  Changes in production 
process and industrial hygiene appear to have reduced overall risk over the past 30–40 years.
Chromate Pigments Production and Use.  Studies of workers engaged in the production of chromate
pigments provide evidence for increased risk of lung cancer associated with employment in work areas
where exposure to chromium compounds occurred.  However, the contribution of chromium exposure to 
cancer risk in these cohorts remains uncertain for several reasons:  (1) members of the cohorts
experienced exposures to a variety of chemicals that may have contributed to cancer (e.g., nickel);
(2) exposures of the individual cohort members to chromium were not quantified or subjected to 
exposure-response analysis; and (3) dose metrics used in dose-response analysis were measures of
employment duration, which are highly correlated with exposures to chemical hazards other than 
chromium.  Nevertheless, these studies have found elevated lung cancer rates in chromium pigment
workers in comparison to reference populations (e.g., SMRs) and, in some studies, increased lung cancer
rates in association with increased potential (e.g., job type, employment duration) for exposure to 
chromium (Dalager et al. 1980; Davies 1979, 1984; Franchini et al. 1983; Frentzel-Beyme 1983;
Haguenoer et al. 1981; Hayes et al. 1989; Langård and Norseth 1975; Langård and Vigander 1983;
Sheffet et al. 1982).
   
 








     
 
    
      
 
    
   
  
   






     
    
  













    
CHROMIUM 107
3. HEALTH EFFECTS
Chrome Plating.  Studies of chrome platers provide evidence for increased risk of lung cancer associated
with employment in work areas where exposure to chromium compounds occurred.  However, the
contribution of chromium exposure to cancer risk in these cohorts remains uncertain for several reasons:
members of the cohorts experienced exposures to a variety of chemicals that may have contributed to 
(1) cancer (e.g., nickel, sulfuric acid); (2) exposures of the individual cohort members to chromium were
not quantified or subjected to exposure-response analysis; and (3) dose metrics used in dose-response 
analysis were measures of employment duration, which are highly correlated with exposures to chemical
hazards other than chromium.  Nevertheless, these studies have found elevated lung cancer rates in
chrome bath workers in comparison to reference populations (e.g., standard mortality ratios) who were
exposed primarily to soluble chromium(VI) (e.g., chromic acid mists) and, in some studies, increased 
lung cancer rates in association with increased potential (e.g., job type, employment duration) for
exposure to chromium (Dalager et al. 1980; Guillemin and Berode 1978; Hanslian et al. 1967; Okubo and 
Tsuchiya 1977, 1979; Royle 1975a; Silverstein et al. 1981; Sorahan et al. 1987, 1998; Takahashi and 
Okubo 1990).  
Sorahan et al. (1998) examined lung cancer risks in a cohort of nickel/chrome platters (n=1,762, hired 
during the period 1946–1975 with mortality follow-up through 1995).  The same cohort was studied by
Royle (1975a).  Significant excess risks of lung cancer were observed among males and females working 
in the chrome bath area for <1 year (SMR=172; 95% CI 112–277; p<0.05) or >5 years (SMR=320; 95%
CI 128–658; p<0.001), females working in the chrome bath area for <1 year (SMR=245; 95% CI 118– 
451; p<0.5), males starting chrome work in the period of 1951–1955 (SMR=210; 95% CI 132–317;
p<0.01), and in male chrome workers 10–19 years after first chrome work (SMR=203; 95% CI 121–321;
p<0.01).  A significant (p<0.01) positive trend for lung cancer mortality and duration of exposure was
found for the male chrome bath workers, but not for the female workers.  Lung cancer mortality risks 
were also examined using an internal standard approach, in which mortality in chrome workers was
compared to mortality in workers without chromium exposure.  After adjusting for sex, age, calendar
period, year of starting chrome work, period from first chrome work, and employment status, a significant
positive trend (p<0.05) between duration of chrome bath work and lung cancer mortality risk was found.  
Hara et al. (2010) conducted a follow-up of the cohort studied by Takahashi and Okubo (1990). The
study comprised 1,193 male workers of which 626 had ≥6 months of experience in chromium plating and 
567 had no lifetime chromium exposure but ≥6 months plating experience using metals other than 
chromium.  The expected number of deaths was determined by multiplying the number of person-years of
observation by cause-, gender-, and age-specific national death rates for each year from 1976–2003.  The
   
 









    
 
    
    




    
   
    
   
    
   
 
    
  





     
   
   
  
    
    
 
  





analyses found a nonsignificant elevation of lung cancer mortality among a chromium plater subgroup 
(SMR=1.46; 95% CI 0.98–2.04) (Hara et al. 2010).  However, the study found significant elevations for
mortality due to brain tumors (SMR=9.14; 95% CI 1.81–22.09) and malignant lymphoma (SMR=2.84;
95% CI 1.05–5.51).  It should be noted, however, that the risk for brain tumors was based on only three
observed cases versus 0.3 expected.  Analyses according to the follow-up period, exposure duration, and
year of first exposure showed that risks were elevated for lung cancer (SMR=1.59, 95% CI 1.01–2.38)
and malignant lymphoma (SMR=3.80; 95% CI 1.39–8.29) among those with initial chromium exposure
prior to 1970. 
Stainless Steel Production and Welding. Workers in the stainless steel welding industry are exposed to
chromium(VI) compounds, as well as other chemical hazards that could contribute to cancer (e.g., nickel);
however, results of studies of cancer mortality in these populations have been mixed.  Some studies have
found increased cancer mortality rates among workers; however, examinations of possible associations
with exposures to chromium have not been reported. A study of 1,221 stainless steel welders in the
former Federal Republic of Germany found no increased risk of lung cancer or any other specific type of
malignancy compared with 1,694 workers involved with mechanical processing (not exposed to airborne
welding fumes) or with the general population of the former Federal Republic of Germany (Becker et al.
1985).  A follow-up study (Becker 1999) which extended the observation period to 1995, found similar
results for lung (includes bronchus and trachea) cancer (SMR=121.5, 95% CI 80.7–175.6).  An excess
risk of pleura mesothelioma was observed (SMR=1,179.9; 95% CI=473.1–2430.5); however, this was
attributed to asbestos exposure.  A study of 234 workers from eight companies in Sweden, who had 
welded stainless steel for at least 5 years during the period of 1950–1965 and followed until 1984, found 
five deaths from pulmonary tumors, compared with two expected (SMR=2.49; 95% CI=0.80–5.81), based 
on the national rates for Sweden. The excess was not statistically significant.  However, when the
incidence of lung cancer in the stainless steel welders was compared with an internal reference group, a 
significant difference was found after stratification for age.  The average concentration of chromium(VI)
in workroom air from stainless steel welding, determined in 1975, was reported as 0.11 mg/m3 (Sjogren et
al. 1987). The cohort in this study was small, and stainless welders were also exposed to nickel fumes.
Smoking was probably not a confounding factor in the comparisons with the internal reference group. 
In a study of the mortality patterns in a cohort of 4,227 workers involved in the production of stainless
steel from 1968 to 1984, information was collected from individual job histories, and smoking habits
were obtained from interviews with workers still active during the data collection (Moulin et al. 1993).  
The observed number of deaths was compared to expected deaths based on national rates and matched for
   
 








   
   





    
   
 
    
      
    
  
  
   
   
   
  
   
  
 
   
  
   
  
  







age, sex, and calendar time.  No significant excess risk of lung cancer was noted among workers 
employed in melting and casting stainless steel (SMR=1.04; 95% CI=0.42–2.15). However, there was a 
significant excess among stainless steel foundry workers (SMR=2.29; 95% CI=1.14–4.09). The SMR
increased for workers with length of employment over 30 years to 3.24 (95% CI=1.19–7.05).  No 
measurements of exposure were provided.
Ferrochromium Production.  Workers in the ferrochromium alloy industry are exposed to chromium(III)
and chromium(VI) compounds, as well as other chemical hazards that could contribute to cancer;
however, results of studies of cancer mortality in these populations have been mixed.  No significant
increase in the incidence of lung cancer was found among 1,876 employees who worked in a
ferrochromium plant in Sweden for at least 1 year from 1930 to 1975 compared with the expected rates
for the county in which the factory was located. The workers had been exposed mainly to metallic
chromium and chromium(III), but chromium(VI) was also present. The estimated levels ranged from 0 to
2.5 mg chromium(0) and chromium(III)/m3 and from 0 to 0.25 mg chromium(VI)/m3 (Axelsson et al.
1980).  An excess of lung cancer was found in a study of 325 male workers employed for >1 year in a
ferrochromium producing factory in Norway between 1928 and 1977 (Langård et al. 1980), and whose
employment began before 1960 (SMR=850, p=0.026); however, in a follow-up of this cohort (n=379, 
hired before 1965 and followed through 1985), the SMR for lung cancer was not significant (SMR=154;
Langård et al. 1990).  Workroom monitoring in 1975 indicated that the ferrochromium furnace operators 
worked in an atmosphere with 0.04–0.29 mg total chromium/m3, with 11–33% of the total chromium as
chromium(VI) (Langård et al. 1980).
An ecological study examined the distribution of lung cancer cases in Doln Kubin in the Slovak
Republic where ferrochromium production facility was located.  Cases were stratified into three groups 
(males): ferrochromium workers (n=59), workers (n=106) thought not to have been exposed to 
chromium, and residents (n=409) who were not thought to have had appreciable exposure to chromium.  
Lung cancer rates were higher in the chromium workers (320 per 1,000 per year, 95% CI 318–323)
compared to workers (112, 95% CI 109–113) and residents (79, 95% CI 76–80) who were not thought to 
have been exposed to chromium (relative risk=4.04 for chromium workers compared to residents).  Mean 
work shift air concentrations in the smelter were 0.03–0.19 mg/m3 for total chromium and 0.018–0.03 
mg/m3 for chromium(VI).  These estimates were not adjusted for smoking or other potential co-variables 
that might have contributed to cancer rates in the chromium workers.
   
 








    
 
  
   
  
 
   
  
     
 
   
 
  
     




      
    
 
  
    
      
   
  
  
   
  
      
    
CHROMIUM 110
3. HEALTH EFFECTS
Leather Tanning. Studies of workers in tanneries, where exposure is mainly to chromium(III), in the
United States (0.002–0.054 mg total chromium/m3) (Stern et al. 1987), the United Kingdom (no 
concentration specified) (Pippard et al. 1985), and the Federal Republic of Germany (no concentration 
specified) (Korallus et al. 1974a) reported no association between exposure to chromium(III) and excess 
risk of cancer.
Mixed Occupations. Beveridge et al. (2010) examined the link between exposure to chromium(VI)
exposure and lung cancer among workers in occupations that generally entail lower levels of exposure 
than those seen in historical cohorts; the most prevalent occupations were construction painters, sheet
metal workers, and mechanics.  Analysis of the pooled data did not show a significant association
between lung cancer and exposure to chromium(VI) (OR=1.1, 95% CI 0.9–1.5).  Subdividing the exposed
subjects into those with substantial exposure to chromium(VI) and those with nonsubstantial exposure
showed both groups having similar nonsignificantly increased risks.  However, a significantly increased
risk for lung cancer was found among exposed nonsmokers (OR=1.2, 95% CI 1.2–4.8), but not among
smokers (OR=1.0, 95% CI 0.7–1.3). The investigators suggested that the greater ability to detect risk in
nonsmokers could be the result of a cleaner, although imprecise, indication of chromium’s actual effects.
The relationship between occupational exposure to chromium(VI) and cancers other than lung cancer has
also been explored.  Gatto et al. (2010) conducted meta-analyses of 32 studies of gastrointestinal tract 
cancers that met specific inclusion criteria.  Inclusion criteria included: (1) epidemiologic studies
published after 1950 of populations with occupational exposure to chromium(VI) through either
inhalation or ingestion routes; (2) exposure or potential exposure to chromium(VI) was stated explicitly, 
or the cohort was from an industry recognized as having exposure to chromium(VI); (3) morbidity or
mortality from one of the following cancers was studied: oral cavity, esophageal, stomach, small intestine,
colon, or rectum; and (4) measures of effect were estimated in the study, or data were available that
allowed for the calculation of a relative risk estimate and 95% CI.  Meta-analysis summary relative risk
measures were calculated using random effects models and inverse variance weighting methods. The 
following meta-SMRs (95% CI) were obtained: oral cavity 1.02 (0.77–1.34), esophagus 1.17 (0.90–1.51), 
stomach 1.09 (0.93–1.28), colon 0.89 (0.70–1.12), and rectum 1.17 (0.98–1.39).  Analyses of subgroups 
subjected to higher exposure resulted in an elevated meta-SMR of 1.49 (95% CI 1.06–2.09) only for
esophageal cancer among U.S. cohorts.  However, this finding was based on a subgroup of only four
studies, one of which was a proportionate mortality ratio study.  Only three studies reported relative risks
estimated for small intestine cancer and in none of them was there a statistically significant increased risk.
The main limitation of the meta-analyses, acknowledged by the investigators, was the inability to control 
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for potential confounding by smoking and other confounders such as excessive alcohol consumption, 
dietary factors, and socioeconomic status. The overall conclusion was that workers exposed to 
chromium(VI) are not at a greater risk of gastrointestinal cancers than the general population. 
Environmental Exposure. In addition to the occupational studies, a retrospective environmental
epidemiology study was conducted of 810 lung cancer deaths in residents of a county in Sweden where 
two ferrochromium alloy industries are located.  No indication was found that residence near these
industries is associated with an increased risk of lung cancer (Axelsson and Rylander 1980).
A retrospective mortality study conducted on a population that resided in a polluted area near an alloy
plant that smelted chromium in the People's Republic of China found increased incidences of lung and 
stomach cancer.  The alloy plant began smelting chromium in 1961 and began regular production in 1965, 
at which time sewage containing chromium(VI) dramatically increased. The population was followed
from 1970 to 1978.  The size of the population was not reported.  The adjusted mortality rates of the
exposed population ranged from 71.89 to 92.66 per 100,000, compared with 65.4 per 100,000 in the
general population of the district.  The adjusted mortality rates for lung cancer ranged from 13.17 to 
21.39 per 100,000 compared with 11.21 per 100,000 in the general population. The adjusted mortality
rates for stomach cancer ranged from 27.67 to 55.17 per 100,000 and were reported to be higher than the
average rate for the whole district (control rates not reported).  The higher cancer rates were found for
those who lived closer to the dump site (Zhang and Li 1987).  Attempts to abate the pollution from
chromium(VI) introduced in 1967 also resulted in additional pollution from sulfate and chloride
compounds.  It was not possible to estimate exposure levels based on the description of the pollution 
process.  Exposure of this population was mainly due to chromium(VI) in drinking water, although air
exposure cannot be ruled out.
The studies in workers exposed to chromium compounds clearly indicate that occupational exposure to 
chromium(VI) is associated with an increased risk of respiratory cancer.  Using data from the Mancuso
(1975) study and a dose-response model that is linear at low doses, EPA derived a unit risk estimate of
1.2x10-2 for exposure to air containing 1 μg chromium(VI)/m3 (or potency of 1.2x10-2 [μg/m3]-1) (IRIS
2011).  
Chronic inhalation studies provide evidence that chromium(VI) is carcinogenic in animals. Mice exposed
to 4.3 mg chromium(VI)/m3 as calcium chromate had a 2.8-fold greater incidence of lung tumors, 
   
 









    
 
 
    
 
 
   
   
 
 
     
  
 
   
 
    
  
 
   
     




     
   
 
 
   
 
 




compared to controls (Nettesheim et al. 1971).  Lung tumors were observed in 3/19 rats exposed to 
0.1 mg chromium(VI)/m3 as sodium dichromate for 18 months, followed by 12 months of observation.  
The tumors included two adenomas and one adenocarcinoma.  No lung tumors were observed in 
37 controls or the rats exposed to ≤0.05 mg chromium(VI)/m3 (Glaser et al. 1986, 1988).  The increased 
incidence of lung tumors in the treated rats was significant by the Fisher Exact Test (p=0.03) performed 
by Syracuse Research Corporation.
Several chronic animal studies reported no carcinogenic effects in rats, rabbits, or guinea pigs exposed to 
≈1.6 mg chromium(VI)/m3 as potassium dichromate or chromium dust 4 hours/day, 5 days/week (Baetjer
et al. 1959b; Steffee and Baetjer 1965).
Rats exposed to ≤15.5 mg chromium(IV)/m3 as chromium dioxide for 2 years had no statistically
significant increased incidence of tumors (Lee et al. 1989).
The Cancer Effect Levels (CELs) are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.2 Oral Exposure
3.2.2.1  Death 
Cases of accidental or intentional ingestion of chromium that have resulted in death have been reported in 
the past and continue to be reported even in more recent literature.  In many cases, the amount of ingested 
chromium was unknown, but the case reports provide information on the sequelae leading to death.  For
example, a 22-month-old boy died 18.5 hours after ingesting an unknown amount of a sodium dichromate
solution despite gastric lavage, continual attempts to resuscitate him from cardiopulmonary arrest, and
other treatments at a hospital.  Autopsy revealed generalized edema, pulmonary edema, severe bronchitis,
acute bronchopneumonia, early hypoxic changes in the myocardium, liver congestion, and necrosis of the
liver, renal tubules, and gastrointestinal tract (Ellis et al. 1982).  Another case report of a 1-year-old girl 
who died after ingesting an unknown amount of ammonium dichromate reported severe dehydration, 
caustic burns in the mouth and pharynx, blood in the vomitus, diarrhea, irregular respiration, and labored
breathing.  The ultimate cause of death was shock and hemorrhage into the small intestine (Reichelderfer
1968).
Several reports were available in which the amount of ingested chromium(VI) compound could be
estimated.  A 17-year-old male died after ingesting 29 mg chromium(VI)/kg as potassium dichromate in a
   
 
















    
  
  




    
   
 
  
   






   
   
   
  
    
    




suicide.  Despite attempts to save his life, he died 14 hours after ingestion from respiratory distress with
severe hemorrhages.  Caustic burns in the stomach and duodenum and gastrointestinal hemorrhage were 
also found (Clochesy 1984; Iserson et al. 1983).  A 35-year-old female died after ingesting approximately
25 g chromium(VI) (357 mg chromium(VI)/kg assuming 70 kg body weight) as chromic acid in a suicide
(Loubieres et al. 1999).  The patient died of multiple organ failure. Terminal laboratory analysis and 
autopsy revealed metabolic acidosis, gastrointestinal hemorrhage and necrosis, fatty degeneration of the 
liver, and acute renal failure and necrosis.
A few reports have described death of humans after ingesting lower doses of chromium(VI). In one case,
a 14-year-old boy died 8 days after admission to the hospital following ingestion of 7.5 mg
chromium(VI)/kg as potassium dichromate from his chemistry set.  Death was preceded by gastro-
intestinal ulceration and severe liver and kidney damage (Kaufman et al. 1970).  In another case, a 
44-year-old man died of severe gastrointestinal hemorrhage 1 month after ingesting 4.1 mg 
chromium(VI)/kg as chromic acid (Saryan and Reedy 1988).
Acute oral LD50 values in rats exposed to chromium(III) or chromium(VI) compounds varied with the
compound and the sex of the rat.  LD50 values for chromium(VI) compounds (sodium chromate, sodium
dichromate, potassium dichromate, and ammonium dichromate) range from 13 to 19 mg 
chromium(VI)/kg in female rats and from 21 to 28 mg chromium(VI)/kg in male rats (Gad et al. 1986).  
LD50 values of 108 (female rats) and 249 (male rats) mg chromium(VI)/kg for calcium chromate were 
reported by Vernot et al. (1977).  The LD50 values for chromium trioxide were 25 and 29 mg
chromium(VI)/kg for female and male rats, respectively (American Chrome and Chemicals 1989).  An
LD50 of 811 mg chromium(VI)/kg as strontium chromate was reported for male rats (Shubochkin and
Pokhodzie 1980).  Twenty percent mortality was observed when female Swiss Albino mice were exposed
to potassium dichromate(VI) in drinking water at a dose of 169 mg chromium(VI)/kg/day (Junaid et al.
1996a).  Similar exposure to a dose level of 89 mg chromium(VI)/kg/day resulted in 15% mortality
among female rats of the Druckrey strain (Kanojia et al. 1998). The disparity between this dose and the 
LD50 identified in the Gad et al. (1986) study may be due to the route of administration, drinking water
versus gavage.  Chromium(III) compounds are less toxic than chromium(VI) compounds, with LD50 
values in rats of 2,365 mg chromium(III)/kg as chromium acetate (Smyth et al. 1969) and 183 and 200 mg
chromium(III)/kg as chromium nitrate in female and male rats, respectively (Vernot et al. 1977).  The
lower toxicity of chromium(III) acetate compared with chromium(III) nitrate may be related to solubility; 
chromium(III) acetate is less soluble in water than is chromium(III) nitrate.  Signs of toxicity included
hypoactivity, lacrimation, mydriasis, diarrhea, and change in body weight.  Treatment with the
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chromium(III) dietary supplement chromium nicotinate of male and female rats resulted in no mortality at
doses up to >621.6 mg/kg/day (Shara et al. 2005).  The LD50 values for chromium(VI) or chromium(III)
compounds indicate that female rats are slightly more sensitive to the toxic effects of chromium(VI) or
chromium(III) than male rats.  LD50 values in rats are recorded in Table 3-4 and plotted in Figure 3-3 for
chromium(VI) and recorded in Table 3-5 and plotted in Figure 3-4 for chromium(III).
Intermediate and chronic exposure of rats and mice to chromium(III) or chromium(VI) compounds did 
not decrease survival.  Survival was not affected in rats and mice exposed to chromium(VI) as sodium
dichromate dihydrate in drinking water at doses up to 20.9 and 27.9 mg chromium(VI)/kg/day, 
respectively, for 3 months (NTP 2007) or at doses up to 7.0 and 8.7 mg chromium(VI)/kg/day, 
respectively, for 2 years (NTP 2008a).  Mortality was not increased in rats fed 2,040 mg chromium(III)/ 
kg/day as chromium oxide in the diet 5 days/week for 2 years (Ivankovic and Preussmann 1975) or in rats
and mice fed up to 313 and 781 mg chromium(III)/kg/day, respectively, as chromium picolinate in the
diet for 2 years (NTP 2008b). 
3.2.2.2  Systemic Effects
The systemic effects of oral exposure to chromium(III) and chromium(VI) compounds are discussed 
below. The highest NOAEL values and all reliable LOAEL values for each systemic effect in each
species and duration category are recorded in Table 3-4 and plotted in Figure 3-3 for chromium(VI) and 
recorded in Table 3-5 and plotted in Figure 3-4 for chromium(III).
Respiratory Effects.    Case reports of humans who died after ingesting chromium(VI) compounds
have described respiratory effects as part of the sequelae leading to death.  A 22-month-old boy who 
ingested an unknown amount of sodium dichromate died of cardiopulmonary arrest.  Autopsy revealed 
pleural effusion, pulmonary edema, severe bronchitis, and acute bronchopneumonia (Ellis et al. 1982).  
Autopsy of a 17-year-old male who committed suicide by ingesting 29 mg chromium(VI)/kg as
potassium dichromate revealed congested lungs with blood-tinged bilateral pleural effusions (Clochesy
1984; Iserson et al. 1983).  Respiratory effects were not reported at nonlethal doses.  No information was 
identified on respiratory effects in humans after oral exposure to chromium(III) compounds. 
No studies were identified regarding respiratory function in animals after oral exposure to chromium(VI)
or chromium(III) compounds.  The histopathology of lung and nasal tissue has been evaluated in rats and 









































29 M (death) 
Reference 
Chemical Form 
Clochesy 1984; Iserson et al. 
1983 
K2Cr2O7 (VI) 
2 Human once 
(IN) 
7.5 M (death) Kaufman et al. 1970 
K2Cr2O7 (VI) 
3 Human once 
(IN) 
357 F (death) Loubieres et al. 1999 
CrO3 (VI) 
4 Human once 
(IN) 






29 M (LD50) 
25 F (LD50) 




17-year-old, 60 kg boy 
ingested 5 g potassium 
dichromate [1,750 mg 
Cr(VI)]; dose = 29 mg 
Cr(VI)/kg. 
14-year-old boy 
ingested 1.5 g 
potassium dichromate 
[0.53 mg Cr(VI)]. 
Assuming 70 kg body 
weight, dose = 7.5 mg 
Cr(VI)/kg. 
35-year-old woman 
ingested chromic acid 
solution containing 25 
g Cr(VI). Assuming 70 
kg body weight, dose = 
357 mg Cr(VI)/kg. 
44-year-old man 
ingested ~2.8g Cr(VI) 
as chromium trioxide; 









































Key to Species Frequency NOAEL Less Serious Serious Reference 






















































Gad et al. 1986 
Na2Cr2O7.2H2O (VI) 
Gad et al. 1986 
K2Cr2O7 (VI) 
Gad et al. 1986 
(NH4)2Cr2O7 (VI) 
Gad et al. 1986 
Na2CrO4 (VI) 
Kanojia et al. 1998 
K2Cr2O7 (VI) 
Shubochkin and Pokhodzie 
1980 
SrCrO4 (VI) 















































Chemical Form Comments 
Systemic 
13 Human once 
(IN) 
Resp 29 M (congested lungs, pleural 
effusions) 
Clochesy 1984; Iserson et al. 
1983 
K2Cr2O7 (VI) 
17-year-old, 60 kg boy 
ingested 5 g potassium 
dichromate [1,750 mg 
Cr(VI)]; dose = 29 mg 
Cr(VI)/kg. 





29 M (hemorrhage) 
29 M (inhibited coagulation) 
29 M (necrosis swelling of 
renal tubules) 
14 Human once 
(IN) 
Dermal 0.04 M (enhancement of 
dermatitis) 
Goitre et al. 1982 
K2Cr2O7 (VI) 
15 Human once 
(C) 
















































Chemical Form Comments 
16 Human once 
(IN) 
Gastro 7.5 M (abdominal pain and 
vomiting) 
Kaufman et al. 1970 
K2Cr2O7 (VI) 
14-year-old boy 
ingested 1.5 g 
potassium dichromate 
[0.53 mg Cr(VI)]. 
Assuming 70 kg body 
weight, dose = 7.5 mg 
Cr(VI)/kg. 
Hepatic 7.5 M (necrosis) 
17 Human once 
(IN) 
Gastro 357 F (intestinal hemorrhage 
and necrosis) 
Loubieres et al. 1999 
CrO3 (VI) 
35-year-old woman 
ingested chromic acid 
solution containing 25 
g Cr(VI). Assuming 70 
kg body weight, dose = 
357 mg Cr(VI)/kg. 
Hepatic 357 F (fatty degeneration) 
Renal 357 F (acute renal failure and 
renal necrosis) 
Metab 357 F (metabolic acidosis) 
18 Human once 
(IN) 
Gastro 4.1 M (gastrointestinal 
hemorrhage) 
Saryan and Reedy 1988 
CrO3 (VI) 
44-year-old man 
ingested ~2.8g Cr(VI) 
as chromium trioxide; 
~4.1 mg Cr(VI)/kg body 
weight. 

























































Hemato 4 M (decreased mean cell 





Musc/skel 15.9 M 
8.2 F 
31.8 M (serum creatine kinase 
activity increased by 
31%) 
16.4 F (serum creatine kinase 
activity increased by 
45%) 
Hepatic 4 M (serum ALT activity 




















Gastro 4.3 F 10 F (villous atrophy and crypt 
cell hyperplasia in 
duodenum and jejunum) 
























































Bd Wt Junaid et al. 1996b 
K2Cr2O7 (VI) 
53.2 F 101.1 F (8.2% decrease in 
gestational weight gain) 
152.4 F (24.3% decrease in 






25 Human once 
(IN) 
Gastro Thompson et al. 2011 
Na2Cr2O7.2H2O (VI) 
30 F 
Goitre et al. 1982 
K2Cr2O7 (VI) 
0.04 M (enhancement of 
chromium dermatitis) 
26 Human once 
(C) 
Neurological 
27 Human once 
(IN) 
Kaaber and Veien 1977 
K2Cr2O7 (VI) 
0.036 (dermatitis) 
Kaufman et al. 1970 
K2Cr2O7 (VI) 
7.5 M (cerebral edema) 14-year-old boy 
ingested 1.5 g 
potassium dichromate 
[0.53 mg Cr(VI)]. 
Assuming 70 kg body 








Bataineh et al. 2007 
K2Cr2O7 (VI) 



























Table 3-4 Levels of Significant Exposure to Chromium Vl - Oral	 (continued) 
Exposure/ LOAEL 
Duration/ 






























(decreased number of 
viable fetuses; increased 
resorptions) 
(sperm count decreased 
by 76%, percentage of 
abnormal sperm 
increased by 143% and 
histopathological 
changes to seminiferous 
tubules) 
(20% lower final pups' 
body weight) 
(increased pre- and 
post-implantation loss, 
resorptions, dead 
fetuses/litter, skeletal and 
visceral malformations) 
(increase in resorptions) 
Reference 
Chemical Form 
Bataineh et al. 2007 
K2Cr2O7 (VI) 
Li et al. 2001 
CrO3 (VI) 
De Lucca et al. 2009 
K2Cr2O7 (VI) 
Elsaieed and Nada 2002 
K2CrO4 (VI) 



































Table 3-4 Levels of Significant Exposure to Chromium Vl - Oral (continued) 
Exposure/ LOAEL 
Duration/ 













Hepatic 1.3 M (increased serum ALT 





sinusoidal space and 
necrosis) 




of basement membrane 
of Bowman's capsule 





















Renal 10 M 100 M (proteinuria, oliguria) 
Reference 
Chemical Form Comments 
Junaid et al. 1996a 
K2Cr2O7 (VI) 
Acharya et al. 2001 
K2Cr2O2 (VI) 
Bataineh et al. 1997 
K2Cr2O7 (VI) 
Chowdhury and Mitra 1995 
Na2Cr2O7 (VI) 























































Bd Wt Kanojia et al. 1996 
K2Cr2O7 (VI) 
37 70 (14% reduced maternal 
body weight gain) 
87 (21% reduced maternal 





Bd Wt Kanojia et al. 1998 
K2Cr2O7 (VI) 
45 89 (18% reduced maternal 
body weight gain) 
124 (24% reduced maternal 






Hepatic Kumar and Rana 1982 
K2CrO4 (VI) 
13.5 M (lipid accumulation) 






Renal Kumar and Rana 1984 
K2CrO4 (VI) 









Hepatic Kumar et al. 1985 
K2CrO4 (VI) 
13.5 M (changes in liver enzyme 
activities; inhibition of 
acid phosphatase; 


















































Hemato 2.1 M 
2.5 F 
8.4 M 








































Table 3-4 Levels of Significant Exposure to Chromium Vl - Oral	 (continued) 
Exposure/  
Duration/  
a  FrequencyKey to Species (Route)Figure (Strain)	 System 
45 Rat 14 wk Resp


















Chemical Form Comments 
20.9	 NTP 2007 
Na2Cr2O7.2H2O (VI) 
20.9 
1.7	 3.5 (duodenal histiocytic 
cellular infiltration) 
1.7	 (microcytic, hypochromic 
anemia) 
3.5	 5.9 (serum creatine kinase 
activity increased by 31% 
in males and 45% in 
females) 
1.7	 (serum ALT activity 
increased by 14% in 
males 30% in females, 
serum SDH activity 
increased by 77% in 



























































Hemato 1.7 M (decreased hematocrit, 






1.7 F (decreased hemoglibin 













Hemato 0.21 M 
b 








Endocr 73 M (59% decrease in serum 
prolactin) 
Quinteros et al. 2007 
K2Cr2O7 (VI) 

























Table 3-4 Levels of Significant Exposure to Chromium Vl - Oral (continued) 
a 





















Chemical Form Comments 
10 wk 
(W) 
Hepatic 3.7 M (serum ALT activity 
increased by 253%, 
histopathological 





Rafael et al. 2007 
Cr (VI) 




Renal 3.4 F (decreased creatinine 
clearance, increased 
plasma creatinine, urea, 











Renal 9.4 F (kidney hemorrhage and 
necrosis) 
Soudani et al. 2010b 
K2Cr2O7 (VI) 



























































Bd Wt 9.4 F 
9.4 F (liver necrosis) Soudani et al. 2011a 
K2Cr2O7 (VI) 
Antioxidant enzyme 
activities were reduced 






Cardio 26 F (heart hemorrhage and 
necrosis) 
Soudani et al. 2011c 
K2Cr2O7 (VI) 
Chromium caused 






Gastro 0.21 F 2.9 F (histiocytic infiltration in 
the duodenum villi) 
Thompson et al. 2012 
Na2Cr2O7.2H2O (VI) 
Hemato 2.9 F 7.1 F (decreased serum and 





Bd Wt 1.4 F 14 F (13.5% decrease in body 
weight gain) 







































Key to Species Frequency 







85 d + 





























1.1 M 3.5 M 





36.7 F NTP 1997 
K2Cr2O7 (VI) 
7.8 F (decreased mean 








































Key to Species Frequency 

































3.1 (epithelial hyperplasia of 
duodenum) 
3.1 M (decreased mean cell 
volume) 






3.1 F 3.1 M (6% decrease in body 
weight) 
5.2 F (8% decrease in body 
weight) 
0.38 F (microcytic, hypochromic 




































































Gastro 1.1 F 4.6 F (villous cytoplasmic 
vacuolization in 
duodenum and jejunum) 
Thompson et al. 2011 
Na2Cr2O7.2H2O (VI) 





Bd Wt 46 F 98 F (decreased maternal 
weight gain) 













Bd Wt 3.6 M 
11.2 F 1.7 M (histiocytic cellular 
infilratration of pancreatic 
lymph nodes) 




20.9 F (histiocytic cellular 





















































16 (increased proliferation of 
T- and B- lymphocytes in 
response to mitogens 
and antigens) 






3.1 (histiocytic infiltrate of 








10 M 100 M (decreased motor 
activity) 

































































2.1 M (histopathological 







2.1 M (decreased testes 
weight, histopathological 
changes including 
depletion of germ cells, 
hyperplasia of Leydig 
cells, disrupted 
spermatogenesis, Sertoli 




2.1 M (histopathological 
changes to basal cells 




1.1 M 2.1 M (sperm count and motility 
decreased by 25%) 
Reference 
Chemical Form Comments 
Aruldhas et al. 2004 
K2Cr2O7 (VI) 
Aruldhas et al. 2005 
K2Cr2O7 (VI) 
Aruldhas et al. 2006 
K2Cr2O7 (VI) 




















































42 (altered sexual behavior, 
decreased absolute 
testes, seminal vesicles, 








20 M (decreased testicular 
protein, 3 beta-hydroxy 
steroid dehydrogenase 
and serum testosterone) 
40 M (28% decreased 
testicular weight; 
decreased testicular 
protein, DNA, RNA, 
seminiferous tubular 
diameter; decreased 













45 (decreased fertility, 










Chemical Form Comments 
Bataineh et al. 1997 
K2Cr2O7 (VI) 
Chowdhury and Mitra 1995 
Na2Cr2O7 (VI) 
Kanojia et al. 1996 
K2Cr2O7 (VI) 








































































52 F (decreased placental 
weight) 










60 F (decreased number of 
follicles at different 
stages of maturation) 
120 F (decreased number of 
ova/mouse) 












85 d + 
pnd 1-74 (F1) + 
pnd 1-21(F2) 
(F) 
































































46 F (increase in fetal 















2.6 M (plasma testosterone 
decreased by 20.8%, 
sperm count decreased 
by 18%, % dead sperm 
increased by 23.9%, total 
















and decreased number 
of live fetuses) 
Reference 
Chemical Form Comments 
Trivedi et al. 1989 
K2Cr2O7 (VI) 
Zahid et al. 1990 
K2Cr2O7 (VI) 
Yousef et al. 2006 
K2Cr2O7 (VI) 
Banu et al. 2008 
K2Cr2O7 (VI) 
























































Kanojia et al. 1998 
K2Cr2O7 (VI) 
45 (reduced fetal caudal 
ossification, increased 
post-implantation loss, 







Samuel et al. 2011 
K2Cr2O7 (VI) 
2.9 F (13% reduced pup's by 
weight; delayed onset of 
puberty) 
11.4 F (26-33% reduced final 
pup's body weight) 
2.9 mg/kg/day also 
decreased steroid 
hormones in serum and 









Soudani et al. 2010b 
K2Cr2O7 (VI) 










Soudani et al. 2011a 
K2Cr2O7 (VI) 
9.4 (26% reduced pup's 
weight on Pnd 14) 
Antioxidant enzyme 
activities were reduced 








Soudani et al. 2011b 
K2Cr2O7 (VI) 
9.4 (25% reduced final pup's 
body weight) 
Antioxidant enzymes 
were decreased in 

















































Gd 12- Ld 20 
(W) 
66 F (delayed time of vaginal 
opening and impaired 
















52 F (reduced caudal 
ossification in fetuses; 


















Chemical Form Comments 
Al-Hamood et al. 1998 
K2Cr2O7 (VI) 
De Flora et al. 2006 
Na2Cr2O7.2H2O (VI) 
De Flora et al. 2006 
K2Cr2O7 (VI) 
Junaid et al. 1996a 
K2Cr2O7 (VI) 





























































8.7 F NTP 2008a 
Na2Cr2O7.2H2O (VI) 
Systemic 
104 Human NS 
(environ) 
Gastro 0.57 (oral ulcer, diarrhea, 
abdominal pain, 
indigestion, vomiting) 
Zhang and Li 1987 
(VI) 
Exposed to well water 
containing 20 mg 
Cr(VI)/L; assuming 70 
kg body weight and 
drinking water 
consumption of 2 
L/day, dose = 0.57 mg 
Cr(VI)/kg/day. 




















Musc/skel 0.94 M 2.4 M (creatine kinase activity 
increased by 64%) 







































Key to Species Frequency 
Figure (Strain) (Route) 
107	 Rat 2 yr 
(Fischer- 344) (W) 



























0.77 M (histiocytic cellular 
infiltration of duodenum) 
2.4 F (histiocytic cellular 
infiltrate of duodenum) 
0.21 M 
7 F 
0.77 M (basophilic foci of liver) 
0.24 F (chronic inflammation) 
7 F 
7 F 
2.1 M 5.9 M (12% decrease in body 
weight) 
1.4 F 3.1 F (increased RBC count, 
decreased mean cell 



























































Resp 8.7 F NTP 2008a 
Na2Cr2O7.2H2O (VI) 
Cardio 8.7 F 
Gastro 
c 
0.38 (epithelial hyperplasia of 
duodenum in males and 
female and cytoplasmic 
alteration of pancreas in 
females) 
Hepatic 2.4 M 5.9 M (clear cell and 
eosinophilic foci) 
0.38 F (histiocytic cellular 
infiltration) 
Renal 8.7 F 
Endocr 8.7 F 














2.4 F (histiocytic cellular 
infiltration of mesenteric 





















































0.38 (histiocytic cellular 














































































Chemical Form Comments 
Cancer 
116 Human (environ) Zhang and Li 1987 
Cr (VI) 
0.57 (CEL: lung and stomach 
cancer) 
Exposed to well water 
containing 20 mg 
Cr(VI)/L; assuming 70 
kg body weight and 
drinking water 
consumption of 2 








5.9 M (CEL: neoplasm of 
squamous epithelium of 
mouth and tongue) 
7 F (CEL: neoplasm of 
squamous cell epithelium 







3.1 M (CEL: neoplastic lesions 
of small intestine) 
2.4 M (CEL: neoplastic lesions 










a The number corresponds to entries in Figure 3-3. 
b Used to derive an intermediate-duration oral MRL of 0.005 mg chromium(VI)/kg/day for hexavalent chromium compounds. Benchmark dose of 0.52 mg chromium(VI)/kg/day was 
divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability). 
c Used to derive a chronic-duration oral MRL of 0.0009 mg chromium(VI)/kg/day for hexavalent chromium compounds. Benchmark dose of 0.09 mg chromium(VI)/kg/day was 
divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability). 
ad lib = ad libitum; Bd Wt = body weight; (C) = capsule; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; environ = environmental; (F) = feed; F = 
female; F1 = first generation; F2 = second generation; (G) = gavage; Gastro = gastrointestinal; Gd = gestational day; (GW) = gavage in water; Hemato = hematological; 
Immuno/Lymphoret = immunological/lymphoreticular; (IN) = ingestion; Ld = lactational day; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; 
Metab = metabolic; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; pnd = post natal day; RBC = red blood cell; Resp = 
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Figure 3-3 Levels of Significant Exposure to Chromium VI - Oral 
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Figure 3-3 Levels of Significant Exposure to Chromium VI - Oral (Continued) 
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*Doses represent the lowest dose tested per study that produced a tumorigenic
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Figure 3-3 Levels of Significant Exposure to Chromium VI - Oral (Continued) 






































































200 M (LD50) 
183 F (LD50) 













Hemato 506 F 
33.6 F (decreased number of 
pregnancies) 
NTP 2008b 
Cr picolinate (III) 
















25 Bailey et al. 2008a 
Cr picolinate (III) 











Hepatic 9 Anderson et al. 1997b 
CrCl3 (III) 
Renal 9 
























































Hepatic 9 Anderson et al. 1997b 










Bd Wt 40 (24% lower final body 
weight) 

























































Table 3-5 Levels of Significant Exposure to Chromium Ill - Oral	 (continued) 
Exposure/  
Duration/  
a  FrequencyKey to Species (Route)Figure (Strain)	 System 
11 Rat 14 wk Resp



























Chemical Form Comments 
506 F	 NTP 2008b 









1.5 F Shara et al. 2005 




















































































Bd Wt 14 F 5 M (14% decrease in body 
weight gain) 
Reference 
Chemical Form Comments 
Shara et al. 2007 
Cr nicotinate (III) 
De Flora et al. 2006 
CrK(SO4)2 (III) 











































Key to Species Frequency 
Figure (Strain) (Route) 
Mouse 14 wk 
(B6C3F1) (F) 
Immuno/ Lymphoret 
17 Rat 14 wk 
(Fischer- 344) (F) 




19	 Rat 38 wk 
(Sprague- (F) 
Dawley) 
20	 Mouse 14 wk 
(B6C3F1) (F) 
Neurological 
































Cr picolinate (III) 
506 F NTP 2008b 
Cr picolinate (III) 
1.5 F Shara et al. 2005 
Cr nicotinate (III) 
0.25 F Shara et al. 2007 
Cr nicotinate (III) 
1415 M NTP 2008b 
Cr picolinate (III) 



























































506 F NTP 2008b 






506 F NTP 2008b 






1.5 F Shara et al. 2005 






0.25 F Shara et al. 2007 













40 (altered sexual behavior, 
decreased absolute 
testes, seminal vesicles, 
and preputial gland 
weights) 
NTP 2008b 
Cr picolinate (III) 






506 F NTP 2008b 






1.5 F Shara et al. 2005 
































































5 M (increased testes and 
decreased preputial 
gland weights) 
5 F (decreased number of 
implantations and viable 
fetuses; increased 














Gd 12- Ld 20 
(W) 
74 (reduced ovary and testis 
weights in offspring and 
impaired fertility in female 
offspring) 
Reference 
Chemical Form Comments 
Shara et al. 2007 
Cr nicotinate (III) 
Elbetieha and Al-Hamood 1997 
CrCl3 (III) 
NTP 2008b  
Cr picolinate (III)  
Zahid et al. 1990 
Cr2(SO4)3 (III) 
Ivankovic and Preussmann 
1975 
Cr2O3 (III) 


















































Bd Wt 3.6 
Reference 
Chemical Form Comments 
Bailey et al. 2008b	 NOAEL is for standard 
neurodevelopmentalCr picolinate (III) end points. 
Ivankovic and Preussmann 
1975 
Cr2O3 (III) 
MacKenzie et al. 1958 
CrCl3 (III) 
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37 Rat 2 yr 
(BD) 5 d/wk 
(F) 















































































































































































Chemical Form Comments 
0.25 F Shara et al. 2007 







0.22 M (14.9% decrease in body 
weight) 
0.25 F (9.6% decrease in body 
weight) 
781 M	 NTP 2008b 



































































313 F NTP 2008b 






0.25 F Shara et al. 2007 













Cr picolinate (III) 







313 F NTP 2008b 






0.25 F Shara et al. 2007 













Cr picolinate (III) 
NTP 2008b 






0.25 F Shara et al. 2007 





















Table 3-5 Levels of Significant Exposure to Chromium Ill - Oral (continued) 
Exposure/ LOAEL  
Duration/  
a  
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
52 Mouse 2 yr 781 M NTP 2008b  
(B6C3F1) (F)  Cr picolinate (III) 
Cancer 
53 Rat 2 yr 55 M (equivocal evidence for NTP 2008b 
(Fischer- 344) (F) prepubital gland Cr picolinate (III)
adenoma) 
a The number corresponds to entries in Figure 3-4. 
ad lib = ad libitum; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; (F) = feed; F = female; (G) = gavage; Gastro = gastrointestinal; Gd = gestational 
day; (GW) = gavage in water; Hemato = hematological; Immuno/Lymphoret = immunological/lymphoreticular; Ld = lactation day; LD50 = lethal dose, 50% kill; LOAEL = 
lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect level; NS = not specified; Resp = respiratory; x = time(s); (W) = drinking water; wk = week(s); 
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Figure 3-4 Levels of Significant Exposure to Chromium III - Oral 
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*Doses represent the lowest dose tested per study that produced a tumorigenic


















 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans































Figure 3-4 Levels of Significant Exposure to Chromium III - Oral (Continued) 











   
 











   
    
 
   
   
   
 
 
   
   
    
 
   
   
  






     
  
  





nicotinate, chromium oxide and chromium picolinate) for durations of 3 months to 2 years, with no 
abnormalities observed (Ivankovic and Preussmann 1975; NTP 2007, 2008a, 2008b; Shara et al. 2005, 
2007).  For chromium(VI) compounds, the highest doses tested for intermediate and chronic exposure
durations were 27.9 and 8.7 chromium(VI)/kg/day, respectively, as sodium dichromate dihydrate in
drinking water (NTP 2007, 2008a).  For chromium(III) compounds, the highest doses tested for 
intermediate and chronic exposure durations were 1,806 and 2,040 mg chromium(III)/kg/day, 
respectively, as chromium oxide in the diet 5 days/week (Ivankovic and Preussmann 1975).
Cardiovascular Effects.    Case reports of humans who died after ingesting chromium(VI) compounds
have described cardiovascular effects as part of the sequelae leading to death.  A 22-month-old boy who  
ingested an unknown amount of sodium dichromate died of cardiopulmonary arrest.  Autopsy revealed 
early hypoxic changes in the myocardium (Ellis et al. 1982).  In another case, cardiac output, heart rate, 
and blood pressure dropped progressively during treatment in the hospital of a 17-year-old male who had 
ingested 29 mg chromium(VI)/kg as potassium dichromate.  He died of cardiac arrest.  Autopsy revealed
hemorrhages in the anterior papillary muscle of the left ventricle (Clochesy 1984; Iserson et al. 1983).  
Cardiovascular effects have not been reported at nonlethal doses.  No information was identified on 
cardiovascular effects in humans after oral exposure to chromium(III) compounds.
No studies were located regarding effects on cardiovascular function in animals after oral exposure to 
chromium(VI) compounds.  Soudani et al. (2011c) found fibrosis, necrosis, vacuolization, and 
hemorrhage in the heart of rats dosed with 26 mg chromium(VI)/kg/day as potassium dichromate for
3 weeks.  However, in other studies, histopathological examination of the heart of rats and mice exposed
to oral chromium(VI) (as sodium dichromate dehydrate and sodium acetate) and chromium(III) (as 
chromium nicotinate, chromium oxide and chromium picolinate) for durations of 3 months to 2 years, 
revealed no abnormalities (Ivankovic and Preussmann 1975; NTP 2007, 2008a, 2008b; Schroeder et al. 
1965; Shara et al. 2005, 2007).  For chromium(VI) compounds (administered as sodium dichromate
dihydrate in drinking water), the highest doses tested for intermediate-duration exposures were 20.9 mg
chromium(VI)/kg/day in rats and 27.0 mg chromium(VI)/kg/day in mice; for chronic exposure durations 
the highest concentrations were 7.0 mg chromium(VI)/kg/day for rats and 8.7 chromium(VI)/kg/day for 
mice (NTP 2007, 2008a).  For chromium(III) compounds, the highest doses tested for intermediate and
chronic exposure durations were 1,806 and 2,040 mg chromium(III)/kg/day, respectively, as chromium
oxide in the diet 5 days/week (Ivankovic and Preussmann 1975). None of these studies assessed
cardiovascular end points such as blood pressure or electrocardiograms.
   
 


























    
 
 
   
 
 
   
  
    






Gastrointestinal Effects. Cases of gastrointestinal effects in humans after oral exposure to
chromium(VI) compounds have been reported.  In one study, a 14-year-old boy who died after ingesting
7.5 mg chromium(VI)/kg as potassium dichromate experienced abdominal pain and vomiting before
death.  Autopsy revealed gastrointestinal ulceration (Kaufman et al. 1970).  In another study, a 44-year-
old man died of gastrointestinal hemorrhage after ingesting 4.1 mg chromium(VI)/kg as chromic acid 
solution (Saryan and Reedy 1988).  Gastrointestinal hemorrhage and extensive necrosis of all digestive 
mucous membranes were also observed on autopsy of a 35-year-old woman who died following ingestion 
of 357 mg chromium(VI)/kg as chromic acid (Loubieres et al. 1999).  Gastrointestinal burns and 
hemorrhage have also been described as contributing to the cause of death of infants who ingested 
unknown amounts of sodium dichromate (Ellis et al. 1982) or ammonium dichromate (Reichelderfer
1968) and a 17-year-old male who ingested ~29 mg chromium(VI)/kg as potassium dichromate (Clochesy
1984; Iserson et al. 1983).  
Some chromium(VI) compounds, such as potassium dichromate and chromium trioxide, are caustic and 
irritating to mucosal tissue.  A 25-year-old woman who drank a solution containing potassium dichromate 
experienced abdominal pain and vomited (Goldman and Karotkin 1935).  Two people who ate oatmeal
contaminated with potassium dichromate became suddenly ill with severe abdominal pain and vomiting, 
followed by diarrhea (Partington 1950).  Acute gastritis developed in a chrome plating worker who had
accidentally swallowed an unreported volume of a plating fluid containing 300 g chromium trioxide/L.
He was treated by hemodialysis, which saved his life (Fristedt et al. 1965).  Nausea, hemetemesis, and 
bloody diarrhea were reported in a 24-year-old woman who ingested ammonium dichromate in a suicide
attempt (Hasan 2007).
Ingestion of chromium compounds as a result of exposure at the workplace has occasionally produced 
gastrointestinal effects.  In a chrome plating plant where poor exhaust resulted in excessively high 
concentrations of chromium trioxide fumes, in addition to symptoms of labored breathing, dizziness, 
headache, and weakness from breathing the fumes during work, workers experienced nausea and
vomiting upon eating on the premises (Lieberman 1941).  Gastrointestinal effects were also reported in an 
epidemiology study of 97 workers in a chromate plant exposed to dust containing both chromium(III) and 
chromium(VI) compounds.  Blocked nasal passages, as a result of working in the dust laden atmosphere,
forced the individuals to breathe through their mouths, thereby probably ingesting some of the chromium
dust.  A 10.3% incidence of gastric ulcer formation and a 6.1% incidence of hypertrophic gastritis was 
reported.  Epigastric and substernal pain were also reported in the chromate production workers (Mancuso 
1951).  Gastric mucosa irritation resulting in duodenal ulcer, possibly as a result of mouth breathing, has
   
 











   
 
   
  







     
  
  
   
   
 
   
    












also been reported in other studies of chromate production workers (Sassi 1956; Sterekhova et al. 1978).  
Subjective symptoms of stomach pain, duodenal ulcers, gastritis, stomach cramps, and indigestion were
reported by workers exposed to a mean concentration of 0.004 mg chromium(VI)/m3 in an electroplating
facility where zinc, cadmium, nickel, tin, and chromium plating were carried out (Lucas and Kramkowski
1975).  An otolaryngological examination of 77 employees of eight chromium electroplating facilities in 
Czechoslovakia, where the mean level in the breathing zone above the plating baths was 0.414 mg
chromium(VI)/m3, revealed 12 cases of chronic tonsillitis, 5 cases of chronic pharyngitis, and 32 cases of
atrophic changes in the left larynx (Hanslian et al. 1967).  These effects were probably also due to 
exposure via mouth breathing.
In a cross-sectional study conducted in 1965 of 155 villagers whose well water contained 
chromium(VI)/L as a result of pollution from an alloy plant in the People's Republic of China, 
associations were found between drinking the contaminated water and oral ulcer, diarrhea, abdominal
pain, indigestion, and vomiting.  The alloy plant began chromium smelting in 1961 and began regular
production in 1965.  Similar results were found in two similar studies in other villages, but further details
were not provided (Zhang and Li 1987).  The highest concentration of chromium(VI) detected during
sampling was 20 mg chromium(VI)/L, equivalent to a dose of 0.57 mg chromium(VI)/kg/day based on a
default reference water consumption rate and body weight value of 2 L/day and 70 kg, respectively (note
that these values may not be appropriate for the Chinese study population).  However, exposure estimates 
for this population are uncertain and it is likely that exposure levels in many cases were to concentrations 
less than 20 mg chromium(VI)/L. At least some residents obtained drinking water from alternative 
sources (Sedman et al. 2006) and exposure may have been self-limiting due to lack of palatability of
water (Beaumont et al. 2008). Thus, exposure levels associated with adverse effects are not well
characterized.
No information was identified on gastrointestinal effects in humans after oral exposure to chromium(III)
compounds. 
Oral exposure of animals to chromium(VI), but not chromium(III), compounds results in irritation and 
histopathological changes to tissues of the gastrointestinal tract.  Gastrointestinal hemorrhage was 
observed in rats given a lethal gavage dose of potassium dichromate (130 mg chromium(VI)/kg) (Samitz
1970).  Histopathological changes were observed in rats and mice exposed to chromium(VI) as sodium
dichromate dihydrate in drinking water for 8 days (Thompson et al. 2011, 2012), 3 months (NTP 2007; 
Thompson et al. 2011, 2012), or 2 years (NTP 2008a).  After 8 days of exposure, villous atrophy and 
   
 








   
  
 
    
     
  
   
    
   
  
   
  




   
 
 
   







   
 
  
   
   




crypt cell hyperplasia were observed in the duodenum and jejunum of rats exposed to ≥10 mg
chromium(VI)/kg/day (Thompson et al. 2012) and cytoplasmic vacuolization was observed in the
duodenum in mice exposed to 30 mg chromium(VI)/kg/day (Thompson et al. 2011).  Following exposure
for 3 months, duodenal histiocytic infiltration of the duodenum was observed in male and female F344/N
rats exposed at ≥2.9 mg chromium(VI)/kg/day (NTP 2007; Thompson et al. 2012); crypt cell hyperplasia,
apoptosis, and histiocytic infiltration were observed in the duodenum and jejunum at 7.1 mg
chromium(VI)/kg/day (Thompson et al. 2012).  At the highest daily dose (20.9 mg chromium(VI)/ 
kg/day), ulcer and epithelial hyperplasia and metaplasia of the glandular stomach were observed (NTP
2007).  Epithelial hyperplasia and histiocytic cellular infiltration of the duodenum was observed at
≥3.1 and ≥5.2 mg chromium(VI)/kg/day, respectively, in male and female B6C3F1 mice.  Similar
nonneoplastic lesions of the duodenum were also reported in the 3-month comparative study in male
B6C3F1, BALB/c, and C57BL/6 mice, with epithelial hyperplasia at ≥2.8 mg chromium(VI)/kg/day in 
B6C3F1 and BALB/c strains and ≥5.2 in the C57BL/6 strain, and histiocytic cellular infiltration at
≥2.8 mg chromium(VI)/kg/day in B6C3F1 and C57BL/6 strains and ≥5.2 mg chromium(VI)/kg/day in the
BALB/c strain.  After exposure for 2 years, duodenal histiocytic infiltration was observed in male and 
female rats exposed at 0.77 and 2.4 chromium(VI)/kg/day, respectively; in mice, duodenal epithelial
hyperplasia was observed at 0.38 mg chromium(VI)/kg/day for 2 years and histiocytic cellular infiltration
of the duodenum was also observed in males at 2.4 mg chromium(VI)/kg/day and females at 3.1 mg
chromium(VI)/kg/day.  In the 2-year study (NTP 2008a), neoplasms of the squamous epithelium of the
oral mucosa and tongue were observed in rats and of the small intestine (duodenum, jejunum and ileum)
were observed in mice; these findings are discussed in Section 3.2.2.7 (Oral Exposure, Cancer).  In
female mice exposed to 0.38 mg chromium(VI)/kg/day and male mice exposed to 2.4 mg chromium(VI)/ 
kg/day for 2 years, cytoplasmic alteration of the pancreas (depletion of cytoplasm zymogen granules) was
observed; NTP stated that the biological significance of this finding was uncertain (NTP 2008a).  In 
contrast to the findings in the NTP, 3-month and 2-year drinking water studies of sodium dichromate 
dihydrate (NTP 2007, 2008a), no histopathological changes to the gastrointestinal tract were observed in 
BALB/c mice exposed to dietary potassium dichromate at doses up to 36.7 chromium(VI)/kg/day in a
multigeneration continuous breeding study (NTP 1997).  Differences in results of these studies could be
attributed to difference in the exposure media (water versus feed).  Data from the 2-year drinking water
study on sodium dichromate dihydrate in mice (NTP 2008a) were used to used to develop the chronic-
duration oral MRL for chromium(VI) compounds.  The BMDL10 value of 0.09 mg chromium(VI)/kg/day
for diffuse epithelial hyperplasia of the duodenum in female mice was used to calculate an oral MRL of
0.0009 mg chromium(VI)/kg/day for chronic-duration exposure to chromium(VI) a compounds as
described in the footnote of Table 3-4.
   
 











   
  
  
     
 




    
   
  










   
     
  
 




No histopathological changes to the stomach or small intestine were observed in mice and rats exposed to 
oral chromium(III) (as chromium nicotinate, chromium oxide, and chromium picolinate) for 3 months or
2 years (Ivankovic and Preussmann 1975; NTP 2008b; Rhodes et al. 2005; Shara et al. 2005, 2007).  The
highest doses of chromium(III) tested were 1,415 mg chromium(III)/kg/day as chromium picolinate in the
diet for 3 months (NTP 2008b; Rhodes et al. 2005) and 2,040 mg chromium(III)/kg/day as chromium
oxide in the diet 5 days/week for 2 years (Ivankovic and Preussmann 1975).
Hematological Effects. Cases of hematological effects have been reported in humans after the 
ingestion of lethal or sublethal doses of chromium(VI) compounds.  In a case of an 18-year-old woman 
who ingested a few grams of potassium dichromate, decreased hemoglobin content and hematocrit, and 
increased total white blood cell counts, reticulocyte counts, and plasma hemoglobin were found 4 days
after ingestion. These effects were indicative of intravascular hemolysis (Sharma et al. 1978).  A 25-year-
old woman who drank a solution containing potassium dichromate had a clinically significant increase in
leukocytes due to a rise in polymorphonuclear cells (Goldman and Karotkin 1935).  In another study, a
44-year-old man had decreased hemoglobin levels 9 days after ingestion of 4.1 mg chromium(VI)/kg as
chromic acid solution that probably resulted from gastrointestinal hemorrhage (Saryan and Reedy 1988).  
Inhibition of blood coagulation was described in a case of a 17-year-old male who died after ingesting
~29 mg chromium(VI)/kg as potassium dichromate (Clochesy 1984; Iserson et al. 1983).  Anemia
following severe hemorrhaging developed in a chrome plating worker who had accidentally swallowed an 
unreported volume of a plating fluid containing 300 g chromium trioxide/L.  He was treated by
hemodialysis, which saved his life (Fristedt et al. 1965).
In a cross-sectional study conducted in 1965 of 155 villagers whose well water contained 20 mg
chromium(VI)/L as a result of pollution from an alloy plant in the People's Republic of China, 
associations were found between drinking the contaminated water and leukocytosis and immature
neutrophils.  The alloy plant began chromium smelting in 1961 and began regular production in 1965. 
Similar results were found in two similar studies in other villages, but further details were not provided 
(Zhang and Li 1987).  The highest concentration of chromium(VI) detected during sampling was 20 mg 
chromium(VI)/L, equivalent to a dose of 0.57 mg chromium(VI)/kg/day.  However, exposure estimates 
for this population are uncertain and it is likely that exposure levels in many cases were to concentrations 
<20 mg chromium(VI)/L. At least some residents obtained drinking water from alternative sources 
(Sedman et al. 2006) and exposure may have been self-limiting due to lack of palatability of water at
   
 








   
 
 
   
 
 
    
   
    
   
  







   
 
 
     
 
  
   
   
  
   
    
CHROMIUM 170
3. HEALTH EFFECTS
higher concentrations (Beaumont et al. 2008). Thus, exposure levels associated with adverse effects are 
not well characterized.
No reliable information was identified on hematological effects in humans of oral exposure to 
chromium(III) compounds. 
Microcytic, hypochromic anemia, characterized by decreased mean cell volume (MCV), mean
corpuscular hemoglobin (MCH), hematocrit (Hct), and hemoglobin (Hgb), was observed in F344/N rats
and B6C3F1 mice exposed to chromium(III) compounds in drinking water for exposure durations ranging
from 4 days to 1 year (NTP 2007, 2008a).  Severity was dose-dependent. Maximum effects were
observed after approximately 3 weeks of exposure; with increasing exposure durations (e.g., 14 weeks to
1 year), effects were less pronounced, presumably due to compensatory hematopoietic responses.  In 
general, effects were more severe in rats than mice.  Following acute exposure of male rats to sodium
dichromate dihydrate in drinking water for 4 days, a slight, but statistically significant decrease (2.1%) in
MCH was observed at 2.7 mg chromium(VI)/kg/day, but not at 0.7 mg chromium(VI)/kg/day.  With 
increasing doses (7.4 mg chromium(VI)/kg/day and greater), additional decreases in MCH and decreased
MCV were observed (NTP 2008a).  Similar effects were observed in male and female rats exposed for
5 days, with effects observed at 4.0 and 4.1 chromium(VI)/kg/day, respectively (NTP 2007); a NOAEL
was not established. 
More severe microcytic, hypochromic anemia occurred in rats and mice following exposure to sodium
dichromate dihydrate in drinking water for 22 or 23 days (NTP 2007, 2008a).  Decreased Hct (6.1%), 
Hgb (8.4%), MCV (7.7%), and MCH (10.6%) occurred in male rats exposed for 22 days to 0.77 mg
chromium(VI)/kg/day, with decreases exhibiting dose-dependence; effects were not observed at 0.21 mg
chromium(VI)/kg/day (NTP 2008a).  Similar hematological effects were observed in male and female rats 
exposed to 1.7 mg chromium(VI)/kg/day for 23 days (NTP 2007).  In female mice exposed to 22 days, 
slight, but significant decreases in MCV (2.0%) and MCH (1.2%) were observed at 0.38 mg
chromium(VI)/kg/day, with more severe effects at higher doses (NTP 2008a).  After exposure for
3 months to 1 year, microcytic, hypochromic anemia in rats and mice was less severe than that observed
after 22 or 23 days (NTP 2007, 2008a).  For example in male rats exposed for 22 days, decreases in Hct
(6.1%), Hgb (8.4%), MCV (7.7%), and MCH (10.6%) were observed at 0.77 mg chromium(VI)/kg/day, 
whereas after exposure to 0.77 mg chromium(VI)/kg/day for 1 year, decreased MCH (2.4%), but not
MCV, Hct, or Hgb, were observed (NTP 2008a).  Similar decreases in severity was also observed in
female rats and in male and female mice exposed for 1 year compared to 22 days (NTP 2008a).  In 
   
 








   
    
 
  
   
 
   
  
    








     
     
   
   
   
   
 
    
    
   
  
 
   




contrast, routine hematological examination revealed no changes in Sprague-Dawley rats exposed to
3.6 mg chromium(VI)/kg/day as potassium chromate in the drinking water for 1 year (MacKenzie et al.
1958); however, data on hematological parameters or statistical analyses were not presented in the report.  
A 91-day study found decreases in serum iron levels and bone marrow iron content in rats exposed to 
7.1 or 21 mg chromium(VI)/kg/day as sodium dichromate dehydrate in drinking water (Thompson et al. 
2012); however, no alterations in blood ferritin or transferrin levels were found.  No alterations in iron 
status were observed in mice similarly exposed to 31 mg chromium(VI)/kg/day (Thompson et al. 2011).  
Data from the 22-day evaluation in the 2-year NTP (2008a) drinking water study on sodium dichromate 
dihydrate in rats were used to used to develop the intermediate-duration oral MRL for chromium(VI)
compounds.  Because several hematological parameters are used to define the clinical picture of anemia,
the intermediate-duration oral MRL was based on the average BMDL2sd value (e.g., the average of
BMDL2sd values for Hgb, MCV, and MCH; BMD models did not provide adequate fit for hematocrit) of
0.52 mg chromium(VI)/kg/day, as described in the footnote of Table 3-4. 
In feeding studies of potassium dichromate in Sprague-Dawley rats and BALB/c mice, slight microcytic 
hyprochromic anemia, characterized by slightly reduced MCV and MCH values was observed (NTP
1996a, 1996b, 1997).  In rats and mice fed potassium dichromate for 9 weeks, MCV and MCH values,
were decreased at the highest concentration only, which was equivalent to 8.4 and 9.8 mg chromium(VI)/ 
kg/day in male and female rats, respectively (NTP 1996b), and 32.2 and 48 mg chromium(VI)/kg/day in
male and female mice, respectively (NTP 1996a). These effects did not occur at lower dietary
concentrations equivalent to ≤2.1 or ≤2.45 mg chromium(VI)/kg/day for male and female rats,
respectively, or to ≤7.35 or ≤12 mg chromium(VI)/day for male and female mice, respectively.  In a 
multigeneration study of mice given potassium dichromate in the diet, F1 males had decreased MCVs at
dietary concentrations equivalent to 16 and 36.7 mg chromium(VI)/kg/day and decreased MCH values at
36.7 mg chromium(VI)/kg/day (NTP 1997).  F1 females had dose-related decreased MCV at
concentrations equivalent to ≥7.8 mg chromium(VI)/kg/day.  Since 7.8 mg chromium(VI)/kg/day was the
lowest dose in the study, a no effect level was not identified.  Compared to results of the drinking water
studies on sodium dichromate dihydrate (NTP 2007, 2008a), hematological effects observed in the dietary
studies on potassium dichromate (NTP 1996a, 1996b, 1997) occurred at higher daily doses.  Differences
may be related to differences in the exposure media (feed versus drinking water).
No hematological effects were observed in animals after oral exposure to chromium(III) compounds for
exposure durations ranging from acute to chronic.  Exposure of F344/N rats to chromium picolinate in the
diet for 3 days at doses up to 506 mg chromium(III)/kg/day did not produce hematological effects (NTP
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2008b).  For intermediate duration exposure, no hematological effects were observed in rats exposed to 
chromic oxide in the diet at doses up to 1,806 chromium(III)/kg/day for 3 months (Ivankovic and 
Preussmann 1975), in rats and mice exposed to chromium picolinate in the diet at 506 and 1,415 mg
chromium(III)/kg/day, respectively, for 3 months (NTP 2008b), or in rats chromium nicotinate in the diet
at 1.5 or 0.25 mg chromium(III)/kg/day for 3 months or 38 weeks, respectively (Shara et al. 2005). For
chronic exposure durations, no hematological abnormalities were found in rats exposed to 3.6 mg
chromium(III)/kg/day as chromium trichloride in the drinking water for 1 year (MacKenzie et al. 1958), 
or in rats exposed to 0.25 mg chromium(III)/kg/day as chromium nicotinate for 2 years (Shara et al.
2007).
Musculoskeletal Effects.    No information regarding musculoskeletal effects in humans exposed to 
oral chromium(VI) compounds was identified.  The development of rhabdomyolysis was reported in a
24-year-old woman who ingested dietary supplements containing chromium(III) picolinate (Martin and 
Fuller 1998).  Over a 48-hour period, the patient ingested 1,200 μg of chromium(III) picolinate, 
equivalent to148.8 μg of chromium(III) or 2.2 μg of chromium(III)/kg body weight (based on a reported 
body weight of 67 kg) over a 48-hour period.  Upon evaluation 4 days after initially ingesting the dietary
supplement, she reported muscle pain on palpation and had muscular hypertrophy and elevated serum
creatine kinase, although no myoglobin was detected in urine.  In addition to chromium(III) picolinate, 
the dietary supplements contained numerous other substances.
Increases in serum creatine kinase (CK) activity were observed in F344/N rats following acute and 
intermediate exposure to sodium dichromate dihydrate in drinking water (NTP 2007).  After exposure for
5 days, serum CK activity was increased in males by 31% at 31.8 mg chromium(VI)/kg/day and in 
females by 46% at 16.4 chromium(VI)/kg/day; after exposure for 13 weeks, serum CK activity was
increased by 70% and 50% in males and females, respectively, at 5.9 mg chromium(VI)/kg/day.  Since
serum CK activity increased with dose, NTP (2007) suggested that findings were consistent with muscle 
injury.  After exposure of rats for 12 months to 2.4 mg chromium(VI)/kg/day as sodium dichromate
dihydrate in drinking water, serum CK activity was increased by 64% (NTP 2008a).  No information 
regarding muscoskeletal effects in animals exposed to oral chromium(III) compounds was identified.
Hepatic Effects. Effects on the liver have been described in case reports of humans who had ingested
chromium(VI) compounds.  Liver damage, evidenced by the development of jaundice, increased 
bilirubin, and increased serum lactic dehydrogenase, was described in a case of a chrome plating worker
who had accidentally swallowed an unreported volume of a plating fluid containing 300 g chromium 
   
 









     
  
   




    
 
  









   
 
 
    
 
     
 
  





trioxide/L (Fristedt et al. 1965).  In another adult, increased alanine and aspartate aminotransferase, 
γ-glutamyl transferase, and bilirubin levels were observed 4 days after accidental ingestion of 20%
chromic acid (Barešić et al. 2009).  In a 14-year-old boy who died after ingesting 7.5 mg chromium(VI)/ 
kg as potassium dichromate, high levels of the liver enzymes, aspartate aminotransferase and alanine 
aminotransferase, were found in the serum 24 hours after ingestion.  Upon postmortem examination, the
liver had marked necrosis (Kaufman et al. 1970).  Fatty degeneration of the liver was observed on autopsy
of a 35-year-old female who died after ingesting approximately 257 mg chromium(VI)/kg (assuming
a70-kg body weight) as chromic acid in a suicide (Loubieres et al. 1999). 
Effects on the liver of rats and mice exposed to oral chromium(VI) compounds for acute, intermediate
and chronic durations have been detected by biochemical and histochemical techniques.  In male and
female F344/N rats exposed to 4.0 and 4.1 mg chromium(VI)/kg/day, respectively, as disodium
dichromate in drinking water for 5 days, serum alanine aminotransferase (ALT) activity was increased by
15 and 30%, respectively (NTP 2007).  After 14 weeks of exposure, serum ALT activity was increased by 
14% in male rats and by 30% in female rats and serum sorbital dehydrogenase (SDH) activity was 
increased by 77% in male rats and 359% in female rats at 1.7 mg chromium(VI)/kg/day (NTP 2007).  In 
females, morphological changes to the liver included cellular histiocyte infiltration and chronic focal 
inflammation at doses of 3.5 and 20.9 mg chromium(VI)/kg/day, respectively; no morphological changes 
were observed in male rats, indicating that female rats may be more sensitive than males. However,
similar exposure to B6C3F1 mice to 27.9 mg chromium(VI)/kg/day for 14 weeks produced no effects on 
serum liver enzymes or hepatic morphology (NTP 2007).  Increased serum ALT and aspartate 
aminotransferase (AST) activities and hepatic morphological changes (vacuolization, increased sinusoidal
space, and necrosis) were observed in rats exposed to 1.3 mg chromium(VI)/kg/day as potassium
dichromate in drinking water for 22 weeks (Acharya et al. 2001).  Increased serum ALT (253%) and 
histopathological changes (focal necrosis and degeneration with changes in vascularization) were reported
in Wistar rats exposed to chromium(VI) (compound not specified) in drinking water for 10 weeks (Rafael
et al. 2007).  Rats treated by gavage with 13.5 mg chromium(VI)/kg/day as potassium chromate for 
20 days had increased accumulations of lipids (Kumar and Rana 1982) and changes and relocalization of
liver enzymes (alkaline phosphatase, acid phosphatase, glucose-6-phosphatase, cholinesterase, and lipase)
(Kumar et al. 1985), as determined by histochemical means.  In another study, no treatment-related
histological changes in liver cells were observed in groups of Sprague-Dawley rats containing 24 males 
and 48 females that were exposed to chromium(VI) as potassium dichromate in the diet for 9 weeks 
followed by a recovery period of 8 weeks (NTP 1996b).  Average daily ingestion of chromium(VI) for
males was 1, 3, 6, and 24 mg/kg/day and 1, 3, 7, and 28 mg/kg/day for females.  Although no indication 
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of hepatic effects was found in mice exposed to ≤36.7 mg/kg/day in a multigeneration feeding study
(NTP 1997), some indication of liver toxicity was found in a 9-week feeding study in BALB/c mice 
exposed to 1.1, 3.5, 7.4, and 32 mg chromium(VI)/kg/day for males and 1.8, 5.6, 12, and 48 mg 
chromium(VI)/kg/day for females (NTP 1996a).  Hepatocyte cytoplasmic vacuolization occurred in 
1/6 males at 3.5 mg/kg/day, 2/5 males at 7.4 mg/kg/day, and 2/6 males at 32 mg/kg/day, and in 
1/12 control females, 0/12 females at 1.8 mg/kg/day, 3/12 females at 5.6 mg/kg/day, 2/12 females at
12 mg/kg/day, and 4/12 females at 48 mg/kg/day.  The vacuoles were small, clear, and well demarcated,
which is suggestive of lipid accumulation. The small number of animals and lack of a clear dose-
response preclude a definitive conclusion as to whether this effect was toxicologically significant.  For
chronic exposure durations, adverse liver effects have been observed in F344/N rats and B6C3F1 mice
exposed to chromium(VI) as sodium chromate dihydrate in drinking water (NTP 2008a).  In male rats 
exposed for 1 year to 0.77 mg chromium(VI)/kg/day, serum ALT activity was increased by 156%.  After
exposure for 2 years, histopathological examination of the liver showed the following morphological
changes, with females of both species appearing more sensitive than males: chronic inflammation
(2.1 chromium(VI)/kg/day), histiocytic cellular infiltration (5.9 chromium(VI)/kg/day) and basophilic foci
(0.77 chromium(VI)/kg/day) in male rats; chronic inflammation (0.24 mg chromium(VI)/kg/day), 
histiocytic cellular infiltration (0.94 mg chromium(VI)/kg/day) and fatty change (0.94 mg chromium(VI)/ 
kg/day) in female rats; clear cell and eosinophilic foci in male mice (5.9 mg chromium(VI)/kg/day); and 
histiocytic cellular infiltration (0.38 mg chromium(VI)/kg/day) and chronic inflammation (3.1 mg
chromium(VI)/kg/day) in female mice (NTP 2008a).  No morphological changes, however, were detected 
in the livers of rats exposed to 3.6 mg chromium(VI)/kg/day as potassium chromate in the drinking water
for 1 year (MacKenzie et al. 1958).
No evidence of liver damage has been observed in rats and mice treated with oral chromium(III)
compounds for intermediate and chronic exposure durations, based on histopathological examination of
the liver. For intermediate-duration exposures, no morphological changes were observed in rats exposed 
to 1,806 mg chromium(III)/kg/day as chromium oxide in the diet 5 days/week for 90 days (Ivankovic and
Preussmann 1975), rats exposed to 9 mg chromium(III)/kg/day as chromium chloride or chromium
picolinate in the diet for 20 weeks (Anderson et al. 1997b), rats exposed to 506 mg chromium(III)/kg/day
and mice exposed to 1,415 mg chromium(III)/kg/day as chromium picolinate in the diet for 14 weeks
(NTP 2008b; Rhodes et al. 2005), or rats exposed to chromium nicotinate in the diet at 1.5 mg
chromium(III)/kg/day for 14 weeks or 0.25 mg chromium(III)/kg/day as chromium nicotinate for
38 weeks (Shara et al. 2005, 2007).  For chronic-duration exposures, histological examination revealed no 
morphological changes in the livers of rats exposed to chromium oxide in the diet 5 days/week at
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2,040 mg chromium(III)/kg/day for 2 years (Ivankovic and Preussmann 1975), rats exposed to 3.6 mg
chromium(III)/kg/day as chromium trichloride in the drinking water for 1 year (MacKenzie et al. 1958), 
of rats exposed to 513 mg chromium(III)/kg/day and mice exposed to 781 mg chromium(III)/kg/day as
chromium picolinate in the diet for 2 years (NTP 2008b), rats exposed to 0.25 mg chromium(III)/kg/day
as chromium nicotinate in the diet for 2 years (Shara et al. 2005, 2007), or rats exposed to 0.46 mg
chromium(III)/kg/day as chromium acetate in the drinking water for 2–3 years (Schroeder et al. 1965).
Renal Effects. Case studies were located regarding renal effects in humans after oral exposure to 
chromium(VI) compounds.  Acute renal failure, characterized by proteinuria, and hematuria, and 
followed by anuria, developed in a chrome plating worker who had accidentally swallowed an unreported 
volume of a plating fluid containing 300 g chromium trioxide/L.  He was treated by hemodialysis
(Fristedt et al. 1965).  Necrosis of renal tubules was found upon autopsy of a 22-month-old boy who died 
after ingesting an unknown amount of sodium dichromate (Ellis et al. 1982) and of a 17-year-old boy who 
died after ingesting 29 mg chromium(VI)/kg as potassium dichromate (Clochesy 1984; Iserson et al.
1983). A fatal ingestion of 4.1 mg chromium(VI)/kg as a chromic acid solution in a 44-year-old man 
resulted in acute tubular necrosis and renal failure (Saryan and Reedy 1988).  In an adult consuming a
nonlethal dose of 20% chromic acid, a rapid decrease in urine output progressing to anuria was observed
within 4 days of ingestion; abdominal ultrasound revealed enlarged kidneys with edematous cortex and 
pronounced pyramids without other pathology (Barešić et al. 2009).  A 14-year-old boy who ingested 
7.5 mg chromium(VI)/kg as potassium dichromate died from renal failure 8 days after he was admitted to
the hospital.  Upon postmortem examination, the kidneys were pale, enlarged, and necrotic with tubular
necrosis and edema (Kaufman et al. 1970).  Acute renal failure and necrosis also observed on autopsy of a
35-year-old woman who died following ingestion of 357 mg chromium(VI)/kg as chromic acid 
(Loubieres et al. 1999).  Another case study of an 18-year-old woman who ingested a few grams of
potassium dichromate reported proteinuria, oliguria, and destruction of the tubular epithelium of the
kidneys.  She regained renal function following dialysis (Sharma et al. 1978).  Proteinuria and oliguria
were also observed after ingestion of potassium dichromate by a 25-year-old woman (Goldman and 
Karotkin 1935).
Acute renal failure was reported in a 24-year-old man who ingested an unknown quantity of a dietary
supplement (Arsenal X®) containing chromium picolinate daily for 2 weeks (Wani et al. 2006).  Serum
creatinine was elevated approximately 3 times above the normal range, blood urea nitrogen was elevated
slightly above normal range, urinalysis was positive for protein, and renal biopsy showed acute tubular
necrosis.  The patient developed severe impairment of renal function that required hemodialysis.  Renal
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function improved within 4 weeks of discontinuation of treatment with the supplement.  Chemical 
analysis of the dietary supplement was not conducted and the patient’s plasma chromium levels were not
obtained.  Adverse renal effects were reported in a 49-year-old woman who ingested 600 μg of
chromium(III) picolinate (equivalent to 74.4 μg chromium(III)/day or 1.1 μg chromium(III)/kg/day, 
assuming a body weight of 70 kg) daily for 6 weeks (Wasser et al. 1997). The patient was evaluated
approximately 5 months after initiating the 6-week treatment.  Serum creatinine levels were 
approximately 6 times above the normal range, blood urea nitrogen was approximately 4 times above the
normal range, and trace amounts of blood were found in the urine.  Renal biopsy showed severe chronic
active interstitial nephritis.  After 2 months of treatment with prednisone, serum creatinine levels were 
approximately 4 times above the normal range (other values were not reported).  Chemical analysis of the 
dietary supplement was not conducted and the patient’s plasma chromium levels were not obtained.
Renal effects have been observed in animals following oral exposure to chromium(VI), but not
chromium(III), compounds.  Effects on the kidneys of rats exposed to potassium chromate have been 
detected by biochemical and histochemical techniques.  Rats treated by gavage with 13.5 mg
chromium(VI)/kg/day for 20 days had increased accumulation of lipids and accumulated triglycerides and
phospholipids in different regions of the kidney than controls (Kumar and Rana 1982).  Similar treatment
of rats also resulted in inhibition of membrane and lysosomal enzymes (alkaline phosphatase, acid
phosphatase, glucose-6-phosphatase, and lipase) in the kidneys (Kumar and Rana 1984).  
Histopathological changes to the kidneys, including vacuolization in glomeruli, degeneration of basement
membrane of Bowman's capsule, and renal tubular epithelial degeneration, were observed in Wistar rats 
exposed to 1.3 mg chromium(VI)/kg/day as potassium dichromate in drinking water for 22 weeks
(Acharya et al. 2001).  Oliguria and proteinuria were observed in Wistar rats exposed to 100 mg
chromium(VI)/kg/day as sodium chromate in drinking water for 28 days (Diaz-Mayans et al. 1986).  
Significant reductions in creatinine clearance and renal hemorrhage, necrosis, and enlarged glomeruli
space were observed in rats exposed to 9.4 mg chromium(VI)/kg/day as potassium dichromate in drinking
water during pregnancy and lactation (Soudani et al. 2010b) or 3.4 mg chromium(VI)/kg/day as
potassium dichromate in drinking water for 21 days (Soudani et al. 2010a).  However, histological
examination revealed no morphological changes in the kidneys of rats exposed to 3.6 mg 
chromium(VI)/kg/day as potassium chromate in drinking water for 1 year (MacKenzie et al. 1958).  
Results of studies in rats and mice conducted by NTP (1996a, 1996b, 1997, 2007, 2008a) also show no 
histopathological changes in kidneys following intermediate-or chronic-duration exposure to 
chromium(VI) compounds in the diet or drinking water.  The respective highest doses of chromium(VI)
tested for intermediate and chronic exposure durations were 48 mg chromium(VI)/kg/day in mice
   
 











   
  
     
    
   
  
 
     
  
   
    
      
 








     
    
    
     






exposed to dietary potassium dichromate for 9 weeks (NTP 1996a) and 8.7 chromium(VI)/kg/day, as
sodium dichromate dihydrate in drinking water (NTP 2007, 2008a).
Exposure of mice and rats to chromium(III) compounds (chromium acetate, chromium nicotinate, 
chromium oxide, chromium picolinate, and chromium trichloride) in food or drinking water for up to 
2 years did not result in renal damage, based on histopathological examination of kidneys (Anderson et al. 
1997b; Ivankovic and Preussmann 1975; MacKenzie et al. 1958; NTP 2008b; Schroeder et al. 1965;
Shara et al. 2005, 2007). The respective highest doses of chromium(III) tested for intermediate and
chronic exposure durations were 1,806 mg chromium(III)/kg/day as chromium oxide in the diet
5 days/week for 3 months and 2,040 mg chromium(III)/kg/day chromium oxide in the diet 5 days/week
for 2 years (Ivankovic and Preussmann 1975).  Renal function was not assessed in these studies.
Endocrine Effects. No studies were located regarding endocrine effects in humans following oral
exposure to chromium(VI) or (III) compounds.  Serum prolactin levels were decreased by 59% in male
Wistar rats exposed to 74 mg chromium(VI)/kg/day as potassium dichromate in drinking water for
30 days (Quinteros et al. 2007).  Histopathological examination of the endocrine tissues (including
adrenal gland, parathyroid, and thyroid) has been evaluated in rats and mice exposed to oral
chromium(VI) (as sodium dichromate dihydrate) and chromium(III) (as chromium nicotinate and 
chromium picolinate) for durations of 3 months to 2 years, with no abnormalities observed (NTP 2007, 
2008a, 2008b; Shara et al. 2005, 2007).  For chromium(VI) compounds, the highest doses tested for
intermediate and chronic exposure durations were 27.9 and 8.7 chromium(VI)/kg/day, respectively, as
sodium dichromate dihydrate in drinking water (NTP 2007, 2008a).  For chromium(III) compounds, the
highest doses tested for intermediate and chronic exposure durations were 1,415 and 781 mg
chromium(III)/kg/day, respectively, as chromium picolinate in the diet for 3 months and 2 years, 
respectively (NTP 2008b; Rhodes et al. 2005).  Endocrine function was not assessed in these studies.
Dermal Effects. Administration of 0.04 mg chromium(VI)/kg as potassium dichromate in an oral
tolerance test exacerbated the dermatitis of a building worker who had a 20-year history of chromium
contact dermatitis.  A double dose led to dyshidrotic lesions (vesicular eruptions) on the hands (Goitre et
al. 1982).  Dermatitis in 11 of 31 chromium-sensitive individuals worsened after ingestion of 0.036 mg
chromium(VI)/kg as potassium dichromate (Kaaber and Veien 1977).  The sensitizing exposures were not
discussed or quantified.  No information regarding dermal effects of oral exposure of humans to 
chromium(III) compounds was identified.
   
 










     
 
 
        
  
   





      
   
    
  
  
    




    
   
     
     
  
   
 
  




No studies were located regarding noncancer dermal effects in animals after oral exposure to
chromium(VI) or chromium(III) compounds.  The effect of oral exposure to chromium(VI) compounds
on increased susceptibility of hairless mice to ultraviolet light-induced skin cancer is discussed in
Section 3.2.2.7 (Oral Exposure, Cancer).
Ocular Effects. No studies were located regarding ocular effects in humans after oral exposure to
chromium(VI) or chromium(III) compounds.  Histopathologic examination of rats and mice exposed to
sodium dichromate dihydrate in drinking water at 20.9 and 27.9 mg chromium(IV)/kg/day, respectively, 
for 3 months or at 7.0 and 8.7 mg chromium(IV)/kg/day, respectively, for 2 years revealed normal
morphology of the ocular tissue (NTP 2007, 2008a).  Similar negative findings were observed in rats and
mice exposed to chromium(III) as dietary chromium picolinate at 506 and 1415 mg
chromium(III)/kg/day, respectively, for 3 months or at 313 and 781 mg chromium(III)/kg/day, 
respectively, for 2 years (NTP 2008b).
Body Weight Effects. Studies reporting body weight effects in humans exposed to chromium(VI)
were not identified. The potential beneficial effect of dietary supplementation with chromium(III) (as 
chromium picolinate or other chromium(III) compounds) to aid in weight loss and increase lean body
mass has been reported.  Although the role of chromium(III) in the regulation of lean body mass,
percentage body fat, and weight reduction is highly controversial with negative and positive results being
reported in the literature, studies assessing these effects were not designed to evaluate weight loss as a
toxicological end point (Anderson 1998b).  Thus, body weight effects associated with dietary
supplementation with chromium(III) compounds is not considered adverse (see Section 2.2 for additional
information).
Significant decreases in body weight have been reported in several intermediate-duration oral
chromium(VI) studies in animals (Bataineh et al. 1997; Chowdhury and Mitra 1995; De Flora et al. 2006;
Elbetieha and Al-Hamood 1997; NTP 1996a, 1996b, 2007; Quinteros et al. 2007; Yousef et al. 2006).
However, it should be noted that high concentrations of chromium in drinking water decrease palatability
of water, resulting in decreased water consumption; thus, decreased body weight may, in part, be due to 
decreased water consumption, in addition to other causes.  In male rats exposed to 73 mg 
chromium(VI)/kg/day as potassium dichromate in drinking water for 30 days, body weight was decreased
by 11.6% (Quinteros et al. 2007).  A 19% decrease in body weight gain was observed in male rats 
exposed to 42 mg chromium(VI)/kg/day (Bataineh et al. 1997) and a 10% decrease was reported in male 
mice exposed to 6 mg chromium(VI)/kg/day (Elbetieha and Al-Hamood 1997) as potassium dichromate 
   
 








   







    
 
     
   
      
 
  
   
 
   
















in drinking water for 12 weeks.  Note that daily doses in the study by Elbetieha and Al-Hamood (1997)
may be overestimated, due to decreased water consumption in the higher concentration group (decrease
was not quantified by study authors).  Final body weight was decreased in rats and mice exposed to 
sodium dichromate dihydrate in drinking water for 14 weeks (NTP 2007).  In rats, body weight was
decreased in males by 11% at 11.2 mg chromium(VI)/kg/day and in females by 6% at 20.9 mg
chromium(VI)/kg/day; in mice, body weight was decreased by 6% in males at 3.1 mg chromium(VI)/ 
kg/day and by 8% in females at 5.2 mg chromium(VI)/kg/day.  Decreases in body weight were also 
observed in male mice (9.3%) and female (13.5%) mice exposed to 165 and 14 mg chromium(VI)/kg/day
as sodium dichromate dihydrate in drinking water for 210 days (De Flora et al. 2006).  Gavage 
administration of 40 or 60 mg chromium(VI)/kg/day as sodium dichromate for 90 days resulted in 57 and 
59% decreases in body weight gain, respectively (Chowdhury and Mitra 1995).  In contrast, no changes in 
body weight gain were seen in rats or mice exposed to 9.8 or 48 mg chromium(VI)/kg/day, respectively, 
as potassium dichromate in the diet for 9 weeks (NTP 1996a, 1996b) or in rabbits administered 3.6 mg
chromium(VI)/kg/day by gavage as potassium dichromate (Yousef et al. 2006).  No alterations in body
weight gain were observed in rats chronically exposed (1 year) to 3.6 mg chromium(VI)/kg/day as
potassium chromate in drinking water (Mackenzie et al. 1958).  In contrast, final body weight was
decreased by 12% in male rats at 5.9 mg chromium(VI)/kg/day and by 11% in female rats at 7.0 mg
chromium(VI)/kg/day as sodium dichromate dihydrate in drinking water for 2 years (NTP 2008a).
Several studies have examined the effect of exposure to potassium dichromate in drinking water on 
maternal body weight gain.  An acute exposure (9 days) resulted in 8 and 24% decreases in body weight
gain in pregnant mice exposed to 101 or 152 mg chromium(VI)/kg/day, respectively (Junaid et al. 1996b).  
Similarly, a decrease in maternal body weight gain was observed in pregnant mice exposed to 98 mg
chromium(VI)/kg/day as potassium dichromate for 19 days (Trivedi et al. 1989).  Reduced maternal body
weight gains of 8, 14, and 21% were observed in rats exposed to 37, 70, or 87 mg chromium(VI)/kg/day
for 20 days prior to mating (Kanojia et al. 1996).  Similar decreases in body weight gain (18 and 24%)
were observed in rats exposed to 89 or 124 mg chromium(VI)/kg/day, respectively, for 3 months prior to 
mating (Kanojia et al. 1998).  However, no alterations in maternal body weight gain were observed in a
continuous breeding study in which rats were exposed to 36.7 mg chromium(VI)/kg/day as potassium
dichromate in the diet (NTP 1997).
Conflicting results have been reported for alterations in body weight in rats and mice exposed to oral
chromium(III) compounds for intermediate and chronic exposure durations.  Dietary exposure to 9 mg
chromium(III)/kg/day as chromium chloride or chromium picolinate for 20 weeks (Anderson et al. 1997b)
   
 








   
    
 
    
   
     
  









   
 
     
    
 
 
     
 
 
   
    
  
 




or 3.6 mg chromium(III)/kg/day as chromium chloride (Mackenzie et al. 1958) did not result in 
significant alterations in body weight gain.  No alterations on body weight were observed in rats or mice 
exposed to dietary chromium picolinate for 14 weeks at doses up to 506 and 1,415 mg chromium(III)/ 
kg/day, respectively (NTP 2008b; Rhodes et al. 2005) or in male and female mice exposed to chromic
potassium sulfate in drinking water for 210 days at doses of 165 and 140 mg chromium(III)/kg/day, 
respectively (De Flora et al. 2006).  No change in body weight was observed in male and female rats
exposed to dietary chromium nicotinate for 90 days at 1.5 and 1.2 mg chromium(III)/kg/day, respectively 
(Shara et al. 2005); however, body weight was decreased by 8.1% in males at 0.22 mg chromium(III)/
kg/day and by 11.4% in females at 0.25 mg chromium(III)/kg/day following exposure to dietary
chromium nicotinate for 38 weeks (Shara et al. 2007).  Exposure to chromium chloride in drinking water
resulted in 14 and 24% decreases in body weight gain in rats exposed to 40 mg chromium(III)/kg/day for
12 weeks (Bataineh et al. 1997) and male mice exposed to 5 mg chromium(III)/kg/day for 12 weeks 
(Elbetieha and Al-Hamood 1997), respectively.  Note that daily doses in the study by Elbetieha and Al-
Hamood (1997) may be overestimated, due to decreased water consumption in the higher concentration 
group (decrease was not quantified by study authors).  No alterations in body weight gain were observed 
in rats or mice exposed to 0.46 or 0.48 mg chromium(III)/kg/day, respectively, as chromium acetate for a
lifetime (Schroeder et al. 1964, 1965), or in mice and rats exposed to dietary chromium picolinate for
2 years at doses up to 313 and 781 mg chromium(III)/kg/day, respectively (NTP 2008b).  However,
exposure to dietary chromium nicotinate for 2 years resulted in a 14.9% decrease in male rats at 0.22 mg
chromium(III)/kg/day and a 9.6% decrease in female rats at 0.25 mg chromium(III)/kg/day (Shara et al. 
2007).
Metabolic Effects. Metabolic acidosis was observed in a 35-year-old female who died after ingesting
approximately 257 mg chromium(VI)/kg (assuming a 70-kg body weight) as chromic acid in a suicide 
(Loubieres et al. 1999).  No information on adverse metabolic effects of chromium(III) compounds in 
humans was identified.  Serum glucose was elevated by 65% in male Wistar rats exposed to 3.7 mg
chromium(VI)/kg/day (compound not specified) in drinking water for 10 weeks (Rafael et al. 2007).  No 
changes in serum glucose were reported in rats and mice exposed to sodium dichromate dihydrate in 
drinking water for 3 months at doses up to 27.9 mg chromium(VI)/kg/day or for 2 years at doses up to 
8.7 mg chromium(VI)/kg/day (NTP 2007, 2008a); however, data on serum glucose were not presented in
the study reports.  No information on adverse metabolic effects of chromium(III) compounds in animals
was identified.
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3.2.2.3  Immunological and Lymphoreticular Effects 
The only reported effect of orally exposed humans on the immune system was the exacerbation of
chromium dermatitis in chromium-sensitive individuals, as noted for dermal effects in Section 3.2.2.2.  
Sensitization of workers, resulting in respiratory and dermal effects, has been reported in numerous
occupational exposure studies.  Although the route of exposure for initial sensitization in an occupational
setting is most likely a combination of inhalation, oral, and dermal routes, information on the exposure
levels producing sensitization by the oral route was not identified.  Additional information on contact
dermatitis in sensitized workers is provided in Section 3.2.3.3 (Dermal Exposure, Immunological and 
Lymphoreticular Effects).
Oral exposure of animals to chromium(VI), but not chromium(III), compounds resulted in functional and 
histopathological changes to the immune system (NTP 2007, 2008a; Snyder and Valle 1991).  
Splenocytes prepared from rats given potassium chromate in drinking water at 16 mg chromium(VI)/ 
kg/day for 3 weeks showed an elevated proliferative response of T-and B-lymphocytes to the mitogens, 
concanavalin A and liposaccharide, compared with splenocytes from control rats.  A 5-fold enhancement
of the proliferative response to mitomycin C was also seen when splenocytes from rats exposed for
10 weeks were incubated with splenocytes from nonexposed rats and additional chromium (0.1 mg
chromium(VI)/L) was added to the incubation compared to the system without added chromium.  It was
suggested that these increased proliferative responses represent chromium-induced sensitization (Snyder
and Valle 1991).  Microscopic changes to lymphatic tissues, including histiocytic cellular infiltration of
mesenteric and/or pancreatic nodes, were observed in rats and mice exposed to sodium dichromate 
dihydrate in drinking water for 3 months or 2 years (NTP 2007, 2008a).  Following 3 months of exposure,
histiocytic cellular infiltration was observed in male and female rats at 1.7 and 20.9 mg 
chromium(VI)/kg/day, respectively, and in mice at 3.1 mg chromium(VI)/kg/day (NTP 2007).  After
2 years of exposure, histiocytic cellular infiltration and hemorrhage of mesenteric lymph nodes were
observed in male rats at 0.77 mg chromium(VI)/kg/day (NTP 2008a).  Histiocytic cellular infiltration of
lymph nodes, but not hemorrhage, was observed at 2.4 mg chromium(VI)/kg/day in female rats and at
0.38 mg chromium(VI)/kg/day in mice (NTP 2008a).  No abnormal histopathological changes were
observed in lymphatic tissues of rats and mice exposed to oral chromium(III) (as chromium nicotinate and 
chromium picolinate) for 3 months or 2 years (NTP 2008b; Rhodes et al. 2005; Shara et al. 2005, 2007).  
These highest doses of chromium(III) tested for intermediate and chronic exposure durations were 
1,415 mg chromium(III)/kg/day as chromium picolinate in feed for 3 months and 781 mg chromium(III)/ 
kg/day as chromium picolinate in feed for 2 years. The NOAEL and LOAEL values are recorded in
   
 















    
  
 
   
   
  
   
      
   
   
   
 








   
 




Table 3-4 and plotted in Figure 3-3 for chromium(VI) and recorded in Table 3-5 and plotted in Figure 3-4 
for chromium(III).
3.2.2.4  Neurological Effects 
The only information regarding neurological effects in humans after oral exposure to chromium(VI) is the 
report of an enlarged brain and cerebral edema upon autopsy of a 14-year-old boy who died after
ingesting 7.5 mg chromium(VI)/kg as potassium dichromate.  These effects may be the result of
accompanying renal failure (Kaufman et al. 1970).  No information was identified on neurological effects
in humans after oral exposure to chromium(III) compounds. 
A decrease in motor activity and balance was reported in rats given 98 mg chromium(VI)/kg/day as
sodium chromate in drinking water for 28 days (Diaz-Mayans et al. 1986).  No additional studies were
identified evaluating neurological function in laboratory animals following oral exposure to 
chromium(VI) or chromium(III) compounds.  Histopathological examination of the brain and nervous
system tissues has been evaluated in rats and mice exposed to oral chromium(VI) (as sodium dichromate
dihydrate) and chromium(III) (as chromium nicotinate, chromium oxide, and chromium picolinate) for
durations of 3 months to 2 years, with no abnormalities observed (Ivankovic and Preussmann 1975; NTP
2007, 2008a, 2008b; Shara et al. 2005, 2007).  For chromium(VI) compounds, the highest doses tested for
intermediate and chronic exposure durations were 27.9 and 8.7 chromium(VI)/kg/day, respectively, as 
sodium dichromate dihydrate in drinking water (NTP 2007, 2008a).  For chromium(III) compounds, the
highest doses tested for intermediate and chronic exposure durations were 1,806 and 2,040 mg
chromium(III)/kg/day, respectively, as chromium oxide in the diet 5 days/week (Ivankovic and
Preussmann 1975).  None of these studies conducted more sensitive neurological, neurochemical, or
neurobehavioral tests.
The NOAEL and LOAEL values are recorded in Table 3-4 and plotted in Figure 3-3 for chromium(VI) 
and recorded in Table 3-5 and plotted in Figure 3-4 for chromium(III).
3.2.2.5  Reproductive Effects
No studies were located regarding reproductive effects in humans after oral exposure to chromium(VI) or
chromium(III) compounds.   
   
 








   
  
   
   
 
  
    
  
















   
   
 
    




A number of studies have reported reproductive effects in animals orally exposed to chromium(VI).  
Functional and morphological effects on male reproductive organs have been reported in monkeys, rats, 
mice, and rabbits.  In a series of studies in male bonnet monkeys (Macaca radiate) (Aruldhas et al. 2004, 
2005, 2006; Subramanian et al. 2006), decreased testes weight, histopathological changes of the
epididymis, disrupted spermatogenesis, and decreased sperm count and motility were observed following
exposure to 2.1, 4.1, and 8.3 mg chromium(VI)/kg/day as potassium dichromate in drinking water for 180 
days.  Histopathological changes, characterized by ductal obstruction and development of microcanals, 
germ cell depletion, hyperplasia of Leydig cells, and Sertoli cell fibrosis, increased in severity with dose.
Sperm count and motility were significantly decreased, with effects exhibiting duration- and dose-
dependence (Subramanian et al. 2006).  After exposure for 2 months, significant decreases in sperm count
(by 13%) and motility (by 12%) were observed only in monkeys treated with 8.3 mg chromium(VI)/ 
kg/day, whereas after 6 months, dose-dependent decreases in sperm count and motility were observed at
doses of ≥2.1 mg chromium(VI)/kg/day.  No effects on sperm count or motility were observed in 
monkeys treated with 1.1 chromium(VI)/kg/day, although histopathological assessment of male 
reproductive tissues was not conducted in this dose group. 
Exposure of male Wistar rats to 5.2 and 10.4 mg chromium(VI)/kg/day administered as chromic acid by
gavage for 6 days produced decreased sperm count and histopathological changes to the testes (Li et al.
2001).  Similar effects occurred at both doses, with sperm count decreased by 75.5 and 79.6% at 5.2 and 
10.4 mg chromium(VI)/kg/day, respectively, and the “level of abnormal sperm" was increased 2.4-fold 
and 2.8-fold at 5.2 and 10.4 mg chromium(VI)/kg/day, respectively.  Histopathological assessment of
testes showed decreased diameter of seminiferous tubules and germ cell rearrangement within the tubules.  
In contrast, exposure of F344/N male rats to chromium(VI) as sodium dichromate dihydrate in drinking
water at doses up to 20.9 or mg chromium(VI)/kg/day for 3 months or 5.9 mg chromium(VI)/kg/day for
2 years did not produce histopathological changes to male reproductive tissues (NTP 2007, 2008a).
Male reproductive effects were observed in groups of 10 mature male Charles Foster strain rats 
administered 20, 40, and 60 mg chromium(VI)/kg/day as sodium dichromate(VI) by gavage for 90 days 
(Chowdhury and Mitra 1995).  Testis weight, population of Leydig cells, seminiferous tubular diameter, 
testicular protein, DNA, and RNA were all significantly reduced at 40 and 60 mg chromium(VI)/kg/day.  
The number of spermatogonia was not affected by treatment; however, resting spermatocytes (high dose), 
pachytene spermatocytes (high dose, intermediate dose) and stage-7 spermatid (high and intermediate
doses) counts were significantly reduced and were treatment related. Testicular activity of succinic 
dehydrogenase was significantly lowered in the two high-dose groups, testicular cholesterol
   
 










      
  
  
    
    
 
 
   
  
  
     
   




   
  
  
   
 
   
 
  










concentrations were elevated in the highest-dosed group, and both serum testosterone and testicular levels
of 3β-Δ5-hydroxysteroid dehydrogenase were significantly lowered.  The authors also determined that the
total testicular levels of ascorbic acid in the two higher-dosing groups was about twice that of the control
values whereas, in the highest-treated group the total ascorbic acid levels were about half those of
controls.  At the low dose (20 mg/kg/day), testicular protein, 3β-Δ5-hydroxysteroid dehydrogenase, and 
serum testosterone were decreased. The authors indicated that chromium enhanced levels of the vitamin,
but at the highest dose, testicular levels became exhausted, thus decreasing the ability of the cells to
reduce chromium(VI).
Significant alterations in sexual behavior and aggressive behavior were observed in male Sprague-Dawley
rats exposed to 42 mg chromium(VI)/kg/day as potassium dichromate in the drinking water for 12 weeks 
(Bataineh et al. 1997).  The alterations in sexual behavior included decreased number of mounts, lower
percentage of ejaculating males, and increased ejaculatory latency and postejaculatory interval. The 
adverse effects on aggressive behavior included significant decreases in the number of lateralizations,
boxing bouts, and fights with the stud male and ventral presenting.  No significant alterations in fertility
were observed when the exposed males were mated with unexposed females.
Reduced sperm count and degeneration of the outer cellular layer of the seminiferous tubules were 
observed in BALB/c mice exposed for 7 weeks to 15.2 mg chromium(VI)/kg/day as potassium
dichromate in the diet (Zahid et al. 1990).  Morphologically altered sperm occurred in mice given diets
providing 28 mg chromium(VI)/kg/day as potassium dichromate.  No effect was found on testis or
epididymis weight, and reproduction function was not assessed.  In contrast, an increase in testes weight
was observed in Swiss mice exposed in drinking water to 6 mg chromium(VI)/kg/day as potassium
dichromate for 12 weeks.  At the next highest dose (14 mg chromium(VI)/kg/day), decreases in seminal
vesicle and preputial gland weights were observed, although no information of sperm count was reported 
(Elbetieha and Al-Hamood 1997).  At the higher exposure level, mice consumed less water (data on water
consumption were not included in the study report); thus, the daily chromium(VI) dose may be
overestimated for this exposure group.  In studies designed to confirm or refute the findings of the Zahid 
et al. (1990) study, the reproductive effects of different concentrations of chromium(VI) as potassium
dichromate in the diet on BALB/c mice and Sprague-Dawley rats were investigated (NTP 1996a, 1996b). 
Groups of 24 of each species were fed potassium dichromate(VI) in their feed continuously for 9 weeks 
followed by an 8-week recovery period.  For mice, the average daily ingestions of chromium(VI) were 
1.05, 3.5, 7.5, and 32.2 mg/kg/day for males and for rats were 0.35, 1.05, 2.1, and 8.4 mg/kg/day (NTP
1996b).  Microscopic examinations of the testes and epididymis for Sertoli nuclei and preleptotene 
   
 








   
   
   












     
   
   
  
















spermatocyte counts in stage X or XI tubules did not reveal any treatment-related effects.  Similarly,
exposure to sodium dichromate dihydrate in drinking water did not produce morphological changes to
male reproductive organs of B6C3F1 mice exposed to 27.9 or 5.9 mg chromium(VI)/kg/day for 3 months
or 2 years, respectively, or affect sperm count or motility in male B6C3F1, BALB/c and C57BL/6N mice
exposed to 8.7 mg chromium(VI)/kg/day for 3 months (NTP 2007, 2008a).
Reduced sperm count and plasma testosterone were observed in male New Zealand rabbits administered
3.6 mg chromium(VI)/kg/day as potassium dichromate for 10 weeks by gavage (Yousef et al. 2006).  
Sperm count was decreased by 18%, total sperm output was decreased by 25.9%, total number of mobile
sperm was decreased by 34.3%, and number of dead sperm increased by 23.9%. In addition, relative
weight of testes and epididymis were decreased by 22.2% and plasma testosterone was decreased by
20.8%.
Effects of chromium(VI) on the female reproductive system have been reported in rats and mice.  Murthy
et al. (1996) reported a number of reproductive effects in female Swiss albino mice exposed to potassium
dichromate in drinking water for 20 days. The observed effects included a significant reduction in the
number of follicles at different stages of maturation at ≥60 mg chromium(VI)/kg/day, reduction in the
number of ova/mice at ≥120 mg chromium(VI)/kg/day, significant increase in estrus cycle duration at
180 mg chromium(VI)/kg/day, and histological alterations in the ovaries (e.g., proliferated, dilated, and 
congested blood vessels, pyknotic nuclei in follicular cells, and atretic follicles) at ≥120 mg
chromium(VI)/kg/day.  The severity of the reproductive effects appeared to be dose-related.  In an
ancillary study, electron microscopy of selected ovarian tissues revealed ultrastructural changes 
(disintegrated cell membranes of two-layered follicular cells and altered villiform cristae of mitochondria 
and decreased lipid droplets in interstitial cells) in mice exposed to 1.2 mg chromium(VI)/kg/day for
90 days; the toxicological significance of these alterations is not known.  The study authors suggest that
the effects observed in the interstitial cells may be due to a reduction in lipid synthesizing ability, which 
could lead to decreased steroid hormone production.  An increase in relative ovarian weight was observed 
in female Swiss mice exposed for 12 weeks to 14 mg chromium(VI)/kg/day as potassium dichromate
(Elbetieha and Al-Hamood 1997), although the calculated daily dose may be overestimated, due to
decreased water consumption in the higher concentration group (decrease was not quantified by study
authors).  In contrast, microscopic examinations of the ovaries showed no treatment-related effects in
female BALB/c mice and Sprague-Dawley rats fed up to 9.8 and 48 mg chromium(VI)/kg/day, 
respectively, as potassium dichromate(VI) in the diet continuously for 9 weeks followed by an 8-week
recovery period (NTP 1996b).  Similarly, exposure of female F344/N rats and B6C3F1 mice to sodium
   
 








   
 
 







     
  










    






   
CHROMIUM 186
3. HEALTH EFFECTS
dichromate dihydrate in drinking water at doses up to 20.9 and 27.9 mg chromium(VI)/kg/day, 
respectively, for 3 months or at doses up to 7.0 and 8.6 mg chromium(VI)/kg/day, respectively, for
2 years did not produce histopathological changes to the ovaries (NTP 2007, 2008a).
Several studies have reported increases in preimplantation losses and resorptions in rats and mice exposed
to chromium(VI).  However, for studies evaluating high concentration of chromium, it is possible that
effects may, in part, be secondary to maternal toxicity.  In addition, high concentration of chromium in 
food and water decrease palatability and can result in decreased food and drinking water consumption.  
Exposure of pregnant mice to 46 mg chromium(VI)/kg/day as potassium dichromate in drinking water
during gestation resulted in increased preimplantation and postimplantation loss, and decreased litter size.  
Maternal body weight gain decreased at doses ≥98 mg chromium(VI)/kg/day (Trivedi et al. 1989).  In 
female Swiss albino mice exposed for 20 days prior to mating to potassium dichromate in drinking water
at concentrations that resulted in doses of 0, 52, 98, or 169 mg chromium(VI)/kg/day and then mated, the
number of corpora lutea was decreased at 169 mg/kg/day, preimplantation loss and resorptions were
increased at ≥98 mg/kg/day, and placental weights were decreased at ≥57 mg/kg/day (Junaid et al.
1996a).  Increases in the number of resorptions were also found in female Swiss albino rats exposed to 37,
70, or 87 mg chromium(VI)/kg/day (as potassium dichromate in the drinking water) for 20 days prior to 
mating (Kanojia et al. 1996).  Additional reproductive effects observed at 70 or 87 mg chromium(VI)/ 
kg/day include decreased number of corpora lutea, decreased number of implantations, and increased 
number of preimplantation losses. A treatment-related increase in the length of estrus cycle was 
significantly different from controls only in the 87 mg chromium(VI)/kg/day group.  Decreased mating, 
decreased fertility, and increased pre- and postimplantation loss were observed in female Druckrey rats 
receiving doses of 45, 89, and 124 mg chromium(VI)/kg/day (as potassium dichromate in the drinking
water) for 3 months prior to mating; the 89 and 124 mg chromium(VI)/kg/day groups exhibited increased 
resorptions as well (Kanojia et al. 1998).  A decrease in fertility (decreased number of implantations and
viable fetuses) was observed in male and female Swiss mice that were exposed to 6 mg chromium(VI)/
kg/day as potassium dichromate for 12 weeks and then were mated with unexposed males and females;
however, the classification of non-viable fetuses was not presented in this report (Elbetieha and Al-
Hamood 1997).  An increase in the number of mice with resorptions was also observed in the exposed 
females.
No reproductive effects were observed in a multigeneration reproductive assessment by continuous
breeding study of BALB/c mice fed a diet containing potassium dichromate(VI).  Males and females were 
exposed to chromium for 7 days and then 20 pairs (F0) in each dose group were allowed to continuously
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mate for 85 days (NTP 1997).  The mean doses of chromium(VI) in F0 animals were 6.8, 13.5, and 
30.0 mg/kg/day.  Litters produced during the 85-day mating period were examined at postnatal day 1.  
There were no treatment related changes in average litters/pair, number of live and dead pups per litter,
sex ratios, pup weights, or changes in gestational time.  There were no dose related gross pathological
organ differences observed for both F0 males and females, nor any differences in organ to body weight
ratios.  At the highest dose the F0 females had lower mean body weights than control animals by about
7%.  There were no effects on sperm number or motility, nor were there any increases in abnormal sperm
morphology.  Histopathological examination of livers and kidneys from F0 males and females showed no
changes that were treatment related.  F1 litters produced after 85 days were reared by the dam until
weaning on postnatal day 21 then separated and allowed to mature for about 74 days.  At that time, 
20 pairs were allowed to mate and produce F2 progeny.  Mean exposures to chromium(VI) to F1 animals 
were determined to be 7.8, 16.0, and 36.7 mg/kg/day. F2 litters were reared by the dam until weaning on 
postnatal day 21 before being sacrificed. There were no differences in F2 average litters/pair, number of
live and dead pups per litter, sex ratios, pup weights, or changes in gestational time between exposed 
groups and controls.  There were no dose-related gross pathological organ differences observed for both 
F1 males and females, nor any differences in organ to body weight ratios.  No histological lesions were 
observed in liver and kidney cells that were dose related, nor did chromium(VI) have any effects on
estrous cycling.
Studies on the reproductive effects of chromium(III) yield conflicting results.  Exposure to chromium(III)
as chromium oxide did not cause reproductive effects in rats. Male and female rats fed 1,806 mg
chromium(III)/kg/day as chromium oxide 5 days/week for 60 days before gestation and throughout the
gestational period were observed to have normal fertility, gestational length, and litter size (Ivankovic and 
Preussmann 1975).  A study by Bataineh et al. (1997) found significant alterations in sexual behavior
(reductions in the number of mounts, increased postejaculatory interval, and decreased rates of
ejaculation), aggressive behavior toward other males, and significantly lower absolute weight of testes, 
seminal vesicles, and preputial glands in male Sprague-Dawley rats exposed to 40 mg chromium(III)/ 
kg/day as chromium chloride in the drinking water for 12 weeks.  Male fertility indices (assessed by
impregnation, number of implantations, and number of viable fetuses) did not appear to be adversely
affected by exposure to chromium chloride, although the untreated females mated to treated males
exhibited an increase in the total number of resorptions (Bataineh et al. 1997).  In contrast, a decrease in 
the number of pregnant females was observed following the mating of unexposed females to male Swiss
mice exposed to 13 mg chromium(III)/kg/day as chromium chloride (Elbetieha and Al-Hamood 1997).  
Impaired fertility (decreased number of implantations and viable fetuses) was also observed in females 
   
 









     




     
   






      
 
   










    






exposed to 5 mg chromium(III)/kg/day mated to unexposed males; however, no information on sperm
count was reported and the definition and classification of viable fetuses were not provided (Elbetieha and
Al-Hamood 1997).  This study also found increased testes and ovarian weights and decreased preputial
gland and uterine weights at 5 mg chromium(III)/kg/day.  At lower concentrations of chromium chloride
(9 mg chromium(III)/kg/day in the diet for 20 weeks), no alterations in testes or epididymis weights were
observed in rats (Anderson et al. 1997b).  A similar exposure to chromium(III) picolinate also did not
result in testes or epididymis weight alterations (Anderson et al. 1997b).  This study did not assess
reproductive function.  Mice exposed for 7 weeks to 9.1 mg chromium(III)/kg/day as chromium sulfate in
the diet had reduced sperm count and degeneration of the outer cellular layer of the seminiferous tubules.  
Morphologically altered sperm occurred in BALB/c mice given diets providing 42.4 mg chromium(III)/ 
kg/day as chromium sulfate (Zahid et al. 1990).  
Exposure of rats and mice to high doses of chromium(III) compounds (chromium nicotinate and 
chromium picolinate) in the diet for 3 months or 2 years did not produce histopathological changes to 
male or female reproductive organs (NTP 2008b; Rhodes et al. 2005; Shara et al. 2005, 2007).  In the
3-month studies on chromium picolinate, doses up to 505 and 506 mg chromium(III)/kg/day were
evaluated in male and female F344/N rats, respectively, and doses up to 1,415 and 1,088 mg
chromium(III)/kg/day were evaluated in male and female B6C3F1 mice, respectively; in the 2-year
studies, doses up to 286 and 313 mg chromium(III)/kg/day were evaluated in male and female rats, 
respectively and doses up to 781 and 726 mg chromium(III)/kg/day, were evaluated in male and female 
mice, respectively (NTP 2008b; Rhodes et al. 2005).  In addition, the 3-month study in rats and mice did 
not find any treatment-related effects on sperm count and motility or on estrous cycle (percentage of time 
spent in various estrous cycle stages or estrous cycle length, based on evaluation of vaginal cytology
(NTP 2008b; Rhodes et al. 2005).  Although the 3-month and 2-year studies on chromium nicotinate did
not reveal any morphological changes to reproductive tissues of male and female Sprague-Dawley rats,
only low doses were evaluated (up to 1.5 mg chromium(III)/kg/day for 3 months and up to 0.25 mg
chromium(III)/kg/day for 2 years) (Shara et al. 2005, 2007).
As discussed in greater detail in Section 3.2.2.6, the reproductive system is also a target in the developing
organism.  Delayed vaginal opening and decreased relative weights of the uterus, ovaries, testis, seminal
vesicle, and preputial glands were observed in mouse offspring exposed to potassium dichromate or
chromium(III) chloride on gestational day 12 through lactation day 20 (Al-Hamood et al. 1998). 
Impaired fertility was observed in the chromium(III) chloride-exposed female offspring when they were 
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mated with unexposed males (Al-Hamood et al. 1998); no effect on fertility was observed in the male 
offspring. 
The highest NOAEL value and all reliable LOAEL values for reproductive effects in each species and
duration category are recorded in Table 3-4 and plotted in Figure 3-3 for chromium(VI) and recorded in 
Table 3-5 and plotted in Figure 3-4 for chromium(III).
3.2.2.6  Developmental Effects 
No studies were located regarding developmental effects in humans after oral exposure to chromium or its
compounds. 
Several animal studies provide evidence that chromium(VI) is a developmental toxicant in rats and mice.
A series of studies (Junaid et al. 1996a; Kanojia et al. 1996, 1998) were conducted to assess whether pre-
mating exposure to potassium dichromate would result in developmental effects.  In the first study, 
groups of 15 female Swiss albino mice were exposed to 0, 52, 98, or 169 mg chromium(VI)/kg/day as
potassium dichromate in drinking water for 20 days (Junaid et al. 1996a) and then mated with untreated
males.  At 52 mg chromium(VI)/kg/day, there was a 17.5% postimplantation loss over controls and a 30%
decrease in fetal weight.  At 98 mg/kg/day, there were decreases in the number of implantation sites, 
number of live fetuses, and fetal weight.  There were also increases in the number of resorptions and 
number of pre- and postimplantation losses.  At 169 mg chromium(VI)/kg/day, there was 100%
preimplantation loss. The fetuses in the 98 mg/kg/day group had higher numbers of subdermal
hemorrhagic patches and kinky short tails and decreased fetal body weight and crown rump length.  
Although there were no major skeletal abnormalities in any other treated animals, there was a significant
reduction in ossification at 52 mg chromium(VI)/kg/day (53% compared to 12% for controls) and 
significant reduction in ossification in caudal, parietal and interparietal bones of fetuses at 98 mg 
chromium(VI)/kg/day.  There were no significant soft tissue deformities in any of the treated fetuses.  
Although dosing occurred prior to mating, internal chromium levels remaining in females after mating
may have been toxic to the conceptus that caused adverse developmental effects.
In the second study, female Swiss albino rats were exposed to potassium dichromate concentrations in the 
drinking water resulting in doses of 37, 70, or 87 mg chromium(VI)/kg/day for 20 days prior to mating
(Kanojia et al. 1996).  Lower gestational weight gain, increased postimplantation loss, and decreased 
number of live fetuses were observed in all treatment groups, relative to controls. Increased incidences of
   
 








    
 
     
   
    
 
  
   
  
 
     
 
  
   










   
   
  
    
 
 
    
  




reduced fetal ossification in fetal caudal bones were reported at the 70 and 87 mg chromium(VI)/kg/day
dose levels; additionally, the 87 mg chromium(VI)/kg/day dose group of fetuses exhibited increased 
incidences of reduced ossification in parietal and interparietal bones, as well as significant incidences of
subdermal hemorrhagic thoracic and abdominal patches (42%), kinky tails (42%), and short tails (53%), 
relative to 0% in controls. No treatment-related gross visceral abnormalities were seen.
In the third study, groups of 10 female Druckrey rats were exposed to potassium dichromate in the
drinking water for 3 months pre-mating at concentrations yielding dose levels of 45, 89, or 124 mg
chromium(VI)/kg/day (Kanojia et al. 1998).  Reduced maternal gestational weight gain, increased pre-
and postimplantation loss, reduced fetal weight, fetal subdermal hemorrhagic thoracic and abdominal
patches, increased chromium levels in maternal blood, placenta, and fetuses, and increased incidences of
reduced ossification in fetal caudal bones were observed in all treatment groups.  In addition, the 89 and 
124 mg chromium(VI)/kg/day dose groups exhibited increased resorptions, reduced numbers of corpora
lutea and fetuses per litter, reduced implantations, reduced placental weight, increased incidences of
reduced ossification in fetal parietal and interparietal bones, and reduced fetal crown-rump length.  No 
treatment-related gross visceral abnormalities were seen.  A decreased number of pregnancies were 
observed in mated female rats administered 35.7 mg chromium(VI)/mg/day as potassium dichromate by 
gavage on gestational days 1–3; exposure on gestational days 4–6 decreased the number of viable fetuses 
and increased the number of resorptions, but did not alter the number of pregnancies (Bataineh et al. 
2007).
Exposure of pregnant mice to 57 mg chromium(VI)/kg/day as potassium dichromate in drinking water
during gestation resulted in embryo lethal effects (i.e., increased resorptions and increased post-
implantation loss), gross abnormalities (i.e., subdermal hemorrhage, decreased cranial ossification, tail
kinking), decreased crown-rump length, and decreased fetal weight. The incidence and severity of
abnormalities increased at higher doses. Maternal toxicity, evidenced by decreased body weight gain, 
occurred at doses ≥120 mg chromium(VI)/kg/day.  No implantations were observed in the dams given 
234 mg chromium(VI)/kg/day (Trivedi et al. 1989). 
Groups of 10 female Swiss albino mice received chromium(VI) as potassium dichromate in drinking
water during organogenesis on days 6–14 at levels that provided 0, 53.2, 101.1, and 152.4 mg
chromium(VI)/kg/day (Junaid et al. 1996b).  No notable changes in behavior or clinical signs were
observed in control or treated animals.  Reduction of gestational weight gains of 8.2 and 30% were
observed for the animals in the intermediate- and high-dose groups.  The number of dead fetuses was
   
 









     
  
   
     
    
    
     
 
 




   
   
  
  
   
   
     
 
    
 
    
      
 
 







higher in the high-dose group and fetal weight was lower in both intermediate- and high-dose groups
(high dose=1.06 g, intermediate dose=1.14 g) as compared to the control value of 1.3 g.  The number of
resorption sites was 0.31 for controls, 1.00 for the low dose, 1.70 for the intermediate dose, and 2.30 for
the high dose, demonstrating a dose-response relationship.  The studies also showed that there was a
significantly greater incidence of postimplantation loss in the two highest-dose groups of 21 and 34.60%
as compared to control value of 4.32%.  No significant gross structural abnormalities in any of the treated 
dosed groups were observed except for drooping of the wrist (carpal flexure) and subdermal hemorrhagic
patches on the thoracic and abdominal regions in 16% in the offspring of the high-dose group.  Significant
reduced ossification in nasal frontal, parietal, interparietal, caudal, and tarsal bones were observed only in 
the 152.4 mg chromium(VI)/kg/day-treated animals.
Impaired development of the reproductive system was observed in the offspring of female BALB/c mice
exposed to 66 mg chromium(VI)/kg/day as potassium chromate in the drinking water on gestation day 12 
through lactation day 20 (Al-Hamood et al. 1998).  A significant delay in vaginal opening was observed.  
Significant decreases in the numbers of pregnant animals, of implantations, and of viable fetuses were 
also observed when the female offspring were mated at age 60 days with unexposed males.  No 
developmental effects were observed in the male offspring.  Delayed vaginal opening was also reported in
the offspring from rats exposed to ≥2.9 mg chromium(VI)/kg/day as potassium dichromate in the drinking
water on postnatal days 1–21 (Banu et al. 2008; Samuel et al. 2011).  These studies also reported that
exposure to chromium extended the estrous cycle into diestrous; altered ovarian follicle development;
decreased plasma levels of estradiol, testosterone, and progesterone; and increased follicle stimulating
hormone; but did not change plasma luteinizing hormone levels.  In pregnant rats exposed to 8 mg
chromium(VI)/kg/day as potassium chromate in drinking water on gestational days 6 through 15, pre- and 
postimplantation losses and the number of resorbed and dead fetuses per litter were increased compared
to controls (Elsaieed and Nada 2002).  Fetal weight was significantly decreased by 67% and the number
of visceral (renal pelvis dilatation) and skeletal (incomplete ossification of skull bone) anomalies per litter
were significantly increased.  No effects on fetal body weight or the number of fetuses per litter were
observed in mice exposed to 4.8 mg chromium(VI)/kg/day as sodium dichromium dihydrate or 2.4 mg
chromium(VI)/kg/day as potassium dichromate in drinking water on gestational days 0 through 18;
however, no additional assessments on fetal development were conducted in this study (De Flora et al. 
2006).
A series of studies have examined the effects of chromium(VI) on oxidative stress in rat offspring.
Samuel et al. (2011) reported that maternal exposure to ≥2.9 mg chromium(VI)/kg/day as potassium
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dichromate in the drinking water on lactation days 1–21 resulted in dose-related reductions in antioxidant
enzymes activities in uterine tissue from offspring measured on postnatal days 21, 45, and 65.  This
correlated with significant increases in lipid peroxidation and hydrogen peroxide in uterine tissue.  
Similar results were reported by Soudani and coworkers (Soudani et al. 2010b, 2011a, 2011b) in the
kidney, liver, and bone from 14-day-old pups born to dams exposed to 9.4 mg chromium(VI)/kg/day
(only dose level tested) as potassium dichromate in the drinking water on gestation days 14–21 and 
postnatal natal days 1–14. This dose level also caused histological alterations in the tissues studied.  In all
of these studies, final body weight of the pups was significantly reduced, 25% in the Soudani et al. 
(2010b, 2011a, 2011b) studies and 10–13% at 2.9 mg Cr/kg/day and 26–33% at 11.4 mg Cr/kg/day in the
Samuel et al. (2011) study. 
Chromium(VI) was also reported to alter mandibular growth and tooth eruption in rats (De Lucca et al.
2009).  In this study, 4-day-old suckling pups received gavage doses of 2.2 or 4.4 mg chromium(VI)/ 
kg/day as chromium dichromate for 10 consecutive days.  High-dose rats showed significantly reduced
mandibular length, base, height, and area; shorter tails; and delayed eruption of the first molar.  These
effects may have been secondary to a delay in body growth, as terminal body weight was reduced 20 and
40% in the low- and high-dose groups, respectively, relative to controls.
Three studies examined the developmental toxicity of chromium(III) following oral maternal exposure.
In the first study, no developmental effects were observed in offspring of rats fed 1,806 mg
chromium(III)/kg/day as chromium oxide 5 days/week for 60 days before mating and throughout
gestation (Ivankovic and Preussmann 1975).  In contrast, reproductive effects have been observed in the
offspring of mice exposed to chromium(III) chloride.  Significant decreases in the relative weights of
reproductive tissues (testes, seminal vesicles, and preputial glands in males; ovaries and uterus in females)
were observed in the offspring of BALB/c mice exposed to 74 mg chromium(III)/kg/day as
chromium(III) chloride in the drinking water on gestation day 12 through lactation day 20 (Al-Hamood et
al. 1998).  A significant delay in timing of vaginal opening was also noted in the female offspring.  At age
60 days, the male and female offspring were mated with unexposed animals.  No significant alterations in
fertility (number of pregnant animals, number of implantations, number of viable fetuses, and total
number of resorptions) were observed in the exposed males.  A significant decrease in the number of
pregnant females (62.5 versus 100% in controls) was observed among the female offspring mated with 
untreated males.  The conflicting results between the Ivankovic and Preussmann (1975) study and the Al-
Hamood et al. (1998) study may be a reflection on the developmental end points examined or the
differences in the species tested.  In rats administered 33.6 mg chromium(III)/kg/day (only dose tested) by 
   
 










     
  
      











   
 
   
     
    
  











gavage as chromium chloride on gestational days 1–3, a decreased number of pregnancies were observed;
however, when exposed on gestational days 4–6, no effects on pregnancy rates, implantations, viable
fetuses, or resorptions were observed (Bataineh et al. 2007).  Bailey et al. (2008a) reported that exposure
of pregnant CD-1 mice to 25 mg chromium(III)/kg/day (only dose level tested) as chromium picolinate in 
the food on gestation days 6–17 did not significantly affect the number of implantations per litter, the
number of resorbed or dead fetuses per litter, or fetal weight.  In addition, incidences of skeletal
anomalies were comparable between exposed and control groups.  The same group of investigators 
examined neurological development in mice pups from dams exposed during gestation and lactation to 
25 mg chromium(III)/kg/day as chromium picolinate (Bailey et al. 2008b).  Results from a variety of tests
assessing motor and sensory functions, as well as memory performed between the ages of 5 and 60 days 
did not show significant differences between controls, chromium-treated mice, and mice exposed to 
picolinic acid.
The NOAEL and LOAEL values for developmental effects in each species are recorded in Table 3-4 and 
plotted in Figure 3-3 for chromium(VI) and recorded in Table 3-5 and plotted in Figure 3-4 for
chromium(III).
3.2.2.7  Cancer
Studies of associations between environmental exposures to chromium and cancer outcomes in humans
are limited to several ecological studies (Beaumont et al. 2008; Bednar and Kies 1991; Fryzek et al. 2001;
Kerger et al. 2009; Linos et al. 2011; Zhang and Li 1987).  These types of studies investigate possible
associations between rates of selected diseases (e.g., cancer deaths) within a geographic population and 
some measure of average exposure to chromium (e.g., drinking water chromium concentrations or
location with respect to potential sources of exposure).  Actual exposures to individuals are not 
determined and therefore, exposure misclassification bias often contributes to uncertainty regarding
associations between outcomes and exposure.  Findings from ecological studies are mixed and do not
strongly support associations between cancer mortality and exposures to chromium.  One study did find 
significantly higher stomach cancer death rates in areas where well water chromium levels had been
elevated (Beaumont et al. 2008).
An ecological study of an area near a ferrochromium production plant in the Liaoning Province, China
compared cancer mortality in locations that had relatively high or low chromium concentrations in well
water (Zhang and Li 1987).  The briefly reported study (Zhang and Li 1987) found increases in the
   
 








    
  
   
   
   
 
 
   
    
   
      
  
     
  
     
   







     
 
   
 
  
     
 





mortality rates from lung cancer (13.17–21.39/100,000 compared to 11.21/100,000 for the entire Taihe
district) and stomach cancer (27.68–55.17/100,000; comparison value not reported); however, no 
statistical analyses were reported.  Beaumont et al. (2008) re-analyzed the cancer mortality data from this
population and estimated cancer mortality rates (cancers deaths per person-year in an 8-year observation 
period) based on mortality records for the period 1970–1978.  The province was divided into nine areas, 
four of which were designated as no (or low) chromium (groundwater concentration <0.001 mg Cr/L) and 
five which were designated as high chromium.  The main sources of chromium in well water were from
discharges from the plant to surface water and groundwater, which began operating in 1961.  Chromium 
levels in well water from samples collected in the contaminated areas in 1965 (by this time, full-scale 
production was occurring) ranged from 0.6 to 20 mg/L with 15% of wells having concentrations >2 mg/L.  
Total number of cancer deaths were 80 (of 98,458 person-years) in the high chromium areas and 182 (of
252,277 person-years) in the comparison areas. Age-adjusted cancer mortality rate ratios (rate in high
regions/rate in low regions) were 1.82 (95% CI 1.11–2.91) for stomach cancer, 1.15 (95% CI 0.62–2.05)
for lung cancer, 0.86 (95% CI 0.53–1.36) for other cancers, and 1.13 (95% CI 0.86–1.46) for all cancer.  
In a subsequent re-analysis of the cancer mortality data, Kerger et al. (2009) divided the population into 
three groups:  residents of the industrial town of TangHeZi, residents of three agricultural villages without
chromium(VI) groundwater contamination, and residents of five agricultural villages with chromium(VI)
groundwater contamination.  The relative risks of lung and stomach cancers were similar for the
chromium-exposed residents and residents of agricultural villages without chromium contamination, and 
no associations were found between average chromium concentration in the drinking water and stomach 
and lung cancer rates.  However, stomach cancer was higher in the residents of both agricultural groups
when compared to TangHeZi residents.  
An ecological study of areas in Kings County and San Bernardino County, California compared cancer
mortality in locations near natural gas compressor plants with areas not located near the plants (Fryzek et
al. 2001).  Hexavalent chromium compounds had been used as additives in cooling tower water at the gas 
plants during the period 1950 to approximately 1980.  Mortality records for zip codes for the cities of
Kettleman City (in Kings County), and Hinkely and Topock (in San Bernardino County), in which natural
gas compressor plants were located, were compared to records from zip codes in Kings County and San 
Bernardino County, other than those encompassing these three cities. The study included mortality
records for the period 1989–1998, during which time 2,226,214 deaths were recorded.  Age-adjusted 
cancer mortality rate ratios (rate in areas near the plant/rate in comparison areas) were 1.03 (95% CI
0.90–1.17) for lung cancer death, 0.93 (95% CI 0.87–1.00) for all cancer deaths, and 0.98 (95% CI 0.95– 
1.02) for all deaths.
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An ecological study compared levels of chromium (and other chemicals) in drinking water in
453 Nebraska communities with death rates in these areas (Bednar and Kies 1991).  Data on chromium in 
drinking water were obtained for the year period 1986–1987, and mortality data was obtained for the year
1986. Mean chromium concentration in drinking water was 0.002 mg/L (range <0.001–0.01).  Linear
correlation (Pearson) between chromium levels and death from chronic lung disease was -0.101 (p=0.03).
A study of an area of Greece with elevated chromium(VI) levels in the public drinking water supply
found significantly higher SMRs for primary liver cancer (SMR=1104.2; 95% CI=403.2–2403.3), lung 
cancer (SMR 145.1; 95% CI=100.5–202.8), and cancer of the kidney and other genitourinary organs
among women (SMR=367.8; 95% CI=119.4–858.3) (Linos et al. 2011).  Chromium levels in the drinking
water ranged from 8.3 to 51 µg/L.
Chronic exposure to chromium(VI) as sodium dichromate in drinking water resulted in increased 
incidence of neoplasms of the digestive tract in mice and rats (NTP 2008a).  Groups of 50 male and 
50 female F344/N rats were exposed to drinking water containing 0, 14.3, 57.3, 172, or 516 mg/L sodium
dichromate dihydrate for 2 years.  NTP (2008a) calculated 2-year mean daily doses of 0, 0.6, 2.2, 6, or
17 mg sodium dichromate dihydrate/kg/day (equivalent to 0, 0.21, 0.77, 2.1 or 5.9 mg chromium(VI)/ 
kg/day) in male rats and, 0, 0.7, 2.7, 7, or 20 mg sodium dichromate dihydrate/kg/day (equivalent to 0,
0.24, 0.94, 2.4, and 7.0 mg chromium(VI)/kg/day) in female rats.  Incidences of squamous epithelial
neoplasms of the oral mucosa and tongue were elevated in rats exposed to sodium dichromate compared
to controls, with significant increased mortality-adjusted incidence in males at the 5.9 mg chromium(VI)/ 
kg/day dose (15.7 versus 0% in controls, p=0.007), and in females at the 7.0 mg chromium(VI)/kg/day 
(23.9 versus 2.2% in controls, p<0.001).  In both male and female rats, there was a significant dose trend 
for digestive tract neoplasms (p<0.001).  Groups of 50 male B6C3F1 mice were exposed to 0, 14.3, 28.6, 
85.7, or 257.4 mg sodium dichromate dihydrate/L, and 50 female B6C3F1 mice were exposed to drinking
water concentrations of 0, 14.3, 57.3, 172, or 516 mg sodium dichromate dihydrate/L.  NTP (2008a)
calculated 2-year mean daily doses of sodium dichromate dihydrate in male mice of 1.1, 2.6, 7 or 
17 mg/kg/day (equivalent to 0, 0.38, 0.91, 2.4 and 5.9 mg chromium(VI)/kg/day); and in female mice of
0, 1.1, 3.9, 9, or 25 mg/kg/day (equivalent to 0, 0.38, 1.4, 3.1, or 8.7 mg chromium(VI)/kg/day).  
Incidences of neoplasms of the of the small intestine (duodenum, jejunum, or ileum) were elevated in 
mice exposed to sodium dichromate compared to controls, with significant increased mortality-adjusted 
incidence in males at the 2.4 (15.1 versus 2.2% in controls, p=0.032) or 5.9 mg chromium(VI)/kg/day 
dose (43.8 versus 2.2% in controls, p=0.001), and in females at the 3.1 (36.3 versus 2,2% in controls) or
   
 









   








   
   
    
   
   
 
     
     
 
    
  
     





    
   
  
  




8.7 mg chromium(VI)/kg/day (45.9 versus 2.2% in controls, p<0.001).  In both male and female mice, 
there was a significant dose trend for digestive tract neoplasms (p<0.001).  NTP (2008a) concluded that
the results of these studies provided clear evidence of carcinogenic activity of sodium dichromate 
dihydrate in male and female F344/N rats based on increased incidences of squamous cell neoplasms of
the oral cavity; and clear evidence of carcinogenic activity of in male and female B6C3F1 mice based on
increased incidences of neoplasms of the small intestine (duodenum, jejunum, or ileum). 
The carcinogenicity of chromium(VI) was evaluated in mice exposed to potassium chromate in drinking
water at 9 mg chromium(VI)/kg/day for three generations (880 days) (Borneff et al. 1968).  In treated 
mice, 2 of 66 females developed forestomach carcinoma and 9 of 66 females and 1 of 35 males developed 
forestomach papilloma.  The vehicle controls also developed forestomach papilloma (2 of 79 females,
3 of 47 males) but no carcinoma.  The incidence of forestomach tumors in the treated mice was not
significantly higher than controls.  Although study authors concluded that evidence of carcinogenicity
was equivocal, statistical analysis of these data (performed by Syracuse Research Corporation) using
Fischer’s exact test shows statistically significant increases in the incidence of adenoma or carcinomas 
(forestomach) (p=0.0067) and in the incidence of adenomas (forestomach) alone (p=0.027), compared to 
control.  In this same study, coexposure to both potassium chromate and 3,4-benzpyrene in a similar
protocol showed that potassium chromate did not potentiate the carcinogenicity of 3,4-benzpyrene
(Borneff et al. 1968).  Exposure of female hairless mice to ultraviolet light in combination with 
chromium(VI) as potassium chromate in drinking water at concentrations of 2.5 or 5.0 mg potassium
chromate(VI)/L (approximately 0.18, or 0.35 mg chromium(VI)/kg/day) for 182 days, or in the diet at
concentrations of 0, 2.5, or 5.0 mg potassium chromate(VI)/kg food (approximately 0.13, or 0.26 mg
chromium(VI)/kg/day) for 26 weeks, produced an increased incidence of skin tumors compared to
animals exposed to UV light alone or chromium(VI) alone (Davidson et al. 2004; Uddin et al. 2007).  
Exposure to chromium(VI) alone did not result in neoplasms. 
Chronic exposure to chromium(III) as chromium picolinate dihydrate in the diet resulted in increased 
incidence of neoplasms of the preputial gland in male rats; however, no increased neoplasms were 
observed in female rats, or in male or female mice (NTP 2008b).  Groups of 50 male and 50 female
F344/N rats were fed a diet containing 0, 2,000, 10,000, or 50,000 ppm chromium picolinate
monohydrate for 2 years. NTP (2008b) calculated 2-year mean daily doses of chromium picolinate 
monohydrate of 0, 90, 460, and 2,400 mg/kg/day (equivalent to 0, 11, 55, or 286 mg chromium(III)/ 
kg/day) in male rats and 0, 100, 510, and 2,630 mg/kg/day (equivalent to 0, 12, 61, or 313 mg
chromium(III)/kg/day) in female rats.  Mortality-adjusted incidence of adenoma of the preputial gland of 
   
 









   
 
    
   
     
  
 
    
    
   
 
     




    
 
  





     
  
     
 





male rats was significantly elevated in rats that received 55 mg chromium(III)/kg/day (14.9 versus 2.2%
in controls, p=0.031), but not in rats exposed to lower dose or the higher dose (286 mg chromium(III)/ 
kg/day), and there was no significant dose trend for the neoplasm.  Incidences of neoplasms were not
significantly different from controls in females, including neoplasms of the clitoral gland.  Groups of
50 male and 50 female F6C3F1 mice were fed a diet containing 0, 2,000, 10,000, or 50,000 ppm
chromium picolinate monohydrate for 2 years.  NTP (2008b) calculated 2-year mean daily doses of
chromium picolinate monohydrate of 0, 250, 1,200, and 6,565 mg/kg/day (equivalent to 0, 30, 143, 2.1, or
781 mg chromium(III)/kg/day) in male mice and 100, 510, and 2,630 mg/kg/day (equivalent to 0, 29, 143, 
or 726 mg chromium(III)/kg/day) in female mice.  No neoplasms or lesions were attributed to exposure to 
chromium picolinate monohydrate in male or female mice.  NTP (2008b) concluded that evidence for
carcinogenicity of chromium picolinate in male rats was equivocal and that the study provided no 
evidence of carcinogenicity in mice.
No evidence of carcinogenicity was observed in male or female rats fed diets containing chromium oxide 
at 2,040 mg chromium(III)/kg/day 5 days/week for 2 years. Moreover, no evidence of carcinogenicity
was found in the offspring of these rats after 600 days of observation (Ivankovic and Preussmann 1975).
The Cancer Effect Levels (CELs) for chromium(VI) are recorded in Table 3-4 and plotted in Figure 3-3. 
3.2.3 Dermal Exposure 
Some chromium(VI) compounds, such as chromium trioxide (chromic acid), potassium dichromate, 
potassium chromate, sodium dichromate, and sodium chromate, are very caustic and can cause burns 
upon dermal contact.  These burns can facilitate the absorption of the compound and lead to systemic
toxicity.
3.2.3.1  Death 
A 49-year-old man with an inoperable carcinoma of the face was treated with chromic acid crystals.
Severe nephritis occurred following the treatment with the chromium(VI) compounds.  Death occurred
4 weeks after exposure (Major 1922). Twelve individuals died as a result of infection to necrotic areas of
the skin that were caused by application of a salve made up with potassium chromate used to treat
scabies.  Renal failure was observed.  Autopsies revealed fatty degeneration of the heart, hyperemia and 
necrosis of kidney tubules, and hyperemia of the gastric mucosa (Brieger 1920).
   
 








    
  
   




   
 
   
 
     
  
 
     
  
 
      
 




     
  
   








Single-dose dermal LD50 values in New Zealand rabbits exposed to chromium(VI) as sodium chromate,
sodium dichromate, potassium dichromate, and ammonium dichromate were determined by Gad et al. 
(1986).  LD50 values ranged from 361 to 553 mg chromium(VI)/kg for females and from 336 to 763 mg
chromium(VI)/kg for males.  Signs of toxicity included dermal necrosis, eschar formation, dermal edema 
and erythema, diarrhea, and hypoactivity.  The dermal LD50 value for chromium trioxide was 30 mg
chromium(VI)/kg for combined sexes (American Chrome and Chemicals 1989).  In male and female 
Sprague-Dawley rats, no mortalities were observed following a single dermal application of 621.6 mg
chromium(III)/kg as chromium nicotinate (Shara et al. 2005).
The LD50 values are recorded in Table 3-6 for chromium(VI) and Table 3-7 for chromium(III).
3.2.3.2  Systemic Effects
Several reports of health effects in individuals treated with potassium dichromate are discussed below
(Brieger 1920; Major 1922; Smith 1931).  The results of these studies should be interpreted cautiously
because pre-existing conditions may have contributed to the observed effects.  The highest NOAEL value
and all reliable LOAEL values for dermal effects in each species and duration category are recorded in
Table 3-6 for chromium(VI) and Table 3-7 for chromium(III).
Respiratory Effects. Occupational exposure to chromium compounds results in direct contact of
mucocutaneous tissue, such as nasal and pharyngeal epithelium, due to inhalation of airborne dust and 
mists of these compounds.  Such exposures have led to nose and throat irritation and nasal septum
perforation.  Because exposure is to airborne chromium, studies noting these effects are described in 
Section 3.2.1.2.
A case report of a man who was admitted to a hospital with skin ulcers on both hands due to dermal
exposure to ammonium dichromate in a planographic printing establishment where he had worked for a 
few months noted that he also had breathing difficulties.  However, because he also had many previous
attacks of hay fever and asthma, it was not possible to distinguish whether his breathing difficulties were
caused by or exacerbated by dermal exposure to ammonium dichromate (Smith 1931).  In another case
report, dyspnea followed by acute pulmonary edema with subsequent respiratory failure was reported in
an electroplating worker exposed to chromic acid on the legs for approximately 10 minutes while 
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Gad et al. 1986 
(NH4)2Cr2O7 (VI) 








Gad et al. 1986 
K2Cr2O7 (VI) 








Gad et al. 1986 
Na2Cr2O72H2O (VI) 








Gad et al. 1986 
Na2CrO4 (VI) 





































Table 3-6 Levels of Significant Exposure to Chromium Vl - Dermal (continued) 
Exposure/ LOAEL  
Duration/  
Frequency Reference Species 
(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
Systemic 
(NS) 
Rat once Hepatic 0.175 (altered carbohydrate 
Percent (%) metabolism) 
Merkur'eva et al. 1982 
K2Cr2O7 (VI) 
Dermal 0.175 (dermatitis) 
Percent (%) 
(albino) 






Gn Pig 3 d 
1 x/d Dermal 0.35 
mg/kg 
(skin ulcers) 
Samitz and Epstein 1962 
K2Cr2O7 (VI) 
(NS) 
Rabbit 5 min or 24 hr Ocular 0.1 M 
ml 
Fujii et al. 1976 
Na2CrO4 and Na2Cr2O7 (VI) 
(New 
Zealand) 





























































Table 3-6 Levels of Significant Exposure to Chromium Vl - Dermal (continued) 
Exposure/ LOAEL  
Duration/  
Frequency Reference Species 
(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
(New 
Zealand) 







(positive patch test) 
Human 48 hr 
0.001 (increased skin thicknes 






(positive patch test) 
Human 48 hr 
0.18 
Percent (%) 
(positive patch test) 













(positive patch test) 




Eun and Marks 1990 
K2Cr2O7 (VI) 
Hansen et al. 2003 
K2Cr2O7 (VI) 
Hansen et al. 2006b 
K2Cr2O7 (VI) 
Levin et al. 1959 
CrO3 (VI) 
Mali et al. 1966 
K2Cr2O7 (VI) 







































Table 3-6 Levels of Significant Exposure to Chromium Vl - Dermal (continued) 
Exposure/ LOAEL  
Duration/  
Frequency Reference Species 
(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
Human 2 d 
0.175 
Percent (%) 
(positive patch test) 
Newhouse 1963 
K2Cr2O7 (VI) 















(positive patch test) 





(positive patch test) 
Winston and Walsh 1951 
Na2Cr2O7 (VI) 
(albino) 




Gross et al. 1968 
K2Cr2O7 (VI) 
(NS) 














































Mouse 18 d 
NOAEL Less Serious 













>1 yr Dermal 0.03 M 
mg/m³ 
(ulcerated skin) 











Human 7.5 yr avg 
(range 3-16 yr) 
(occup) 
Resp 0.004 M 
mg/m³ 
(nasal septum ulceration 
and perforation) 
Lucas and Kramkowski 1975 
CrO3 (VI) 
Gastro 0.004 M 
mg/m³ 
(possible gastritis, ulcers 












avg = average; d = day(s); F = female; Gastro = gastrointestinal; Gn Pig = guinea pig; hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LD50 = lethal dose, 50% kill; 
LOAEL = lowest-observed-adverse-effect level; M = male; min = minute(s); NOAEL = no-observed-adverse-effect level; NS = not specified; occup = occupational; Resp = respiratory; 










































Gn Pig 3 d 
1 x/d 
Immuno/ Lymphoret 













Samitz and Epstein 1962 
Cr2(SO4)3 (III) 








(positive patch test) 
Hansen et al. 2003 
CrCl3.6H2O (III) 
Human 48 hr 
3.7 
Percent (%) 
(positive patch test) 





(positive patch test) 









































Table 3-7 Levels of Significant Exposure to Chromium Ill - Dermal (continued) 
Exposure/ LOAEL  
Duration/  
Frequency Reference Species 
(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
Gn Pig once Gross et al. 1968
0.004 (erythematic reaction)(albino) CrCl3 (III)mg/kg 
Gn Pig once Jansen and Berrens 1968
0.03 F (erythematic reaction)(NS) Cr2(SO4)3 (III)mg/kg 
B = both sexes; d = day(s); F = female; Gn Pig = guinea pig; hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LOAEL = lowest-observed-adverse-effect level; 









   
 











    
     
     
 
   
 
 
      
     
    
  
     
 
    
 
 
      
 
  
   
   








No studies were located regarding respiratory effects in animals after dermal exposure to chromium or its 
compounds. 
Cardiovascular Effects.    Information regarding cardiovascular effects in humans after dermal
exposure to chromium or its compounds is limited.  Weak, thready, and markedly dicrotic pulse
developed ≈1.5 hours after a salve made up with potassium chromate to treat scabies was applied to skin
of an unspecified number of individuals.  Some of the people died as a result of infection to the exposed 
area, and autopsy revealed degeneration of the heart (Brieger 1920).
No studies were located regarding cardiovascular effects in animals after dermal exposure to chromium or
its compounds.
Gastrointestinal Effects. Vomiting occurred soon after application of a salve made up of potassium
chromate to the skin of an unspecified number of individuals for the treatment of scabies.  Some of these
individuals died as a result of infection of the exposed area, and autopsy revealed hyperemia of the gastric 
mucosa (Brieger 1920).  Nausea, vomiting, and abdominal pain were reported by an electroplating worker
dermally exposed to chromic acid for approximately 10 minutes (Lin et al. 2009).
Diarrhea was reported in New Zealand rabbits exposed to lethal concentrations of chromium(VI)
compounds (Gad et al. 1986).
Hematological Effects. Severe leukocytosis, with notable increases in immature polymorphonuclear
cells, myelocytes, and myeloblasts and nucleated red cells and Howell-Jolly bodies, indicative of
hemolytic anemia were observed in individuals after application of a salve that contained potassium
chromate to treat scabies (Brieger 1920).  Leukocytosis was also described in a case report of a man who
was admitted to a hospital with skin ulcers on both hands due to dermal exposure to ammonium
dichromate in a planographic printing establishment, where he had worked for a few months (Smith 1931)
and in an electroplating worker exposed on the legs to chromic acid for approximately 10 minutes;
anemia and thrombocytopenia developed 5 days postexposure (Lin et al. 2009).
No studies were located regarding hematological effects in animals after dermal exposure to chromium
compounds. 
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Musculoskeletal Effects. Information regarding musculoskeletal effects in humans after dermal
exposure to chromium or its compounds is limited to a case report.  A man was admitted to a hospital
with skin ulcers on both hands due to dermal exposure to ammonium dichromate in a planographic
printing establishment, where he had worked for a few months.  He also had tenderness and edema of the
muscles of the extremities (Smith 1931).
No studies were located regarding musculoskeletal effects in animals after dermal exposure to chromium
or its compounds.
Hepatic Effects. No reliable studies were located regarding hepatic effects in humans after dermal
exposure to chromium compounds.
Information regarding liver effects in animals after dermal exposure to chromium or its compounds is
limited.  A single application of 0.5% potassium dichromate (0.175% chromium(VI)) to the shaved skin 
of rats resulted in increased levels of serotonin in the liver, decreased activities of acetylcholinesterase 
and cholinesterase in the plasma and erythrocytes, increased levels of acetylcholine in the blood, and
increased glycoprotein hexose in the serum.  These effects may indicate alterations in carbohydrate 
metabolism (Merkur'eva et al. 1982).  Application of 50 mg chromium/kg/day (specific chemical or
valence state not reported) for 30 days to clipped skin under occluded conditions to female guinea pigs
produced small increases in enzyme activities in liver tissue, specifically asparatate aminotransferase 
(17%), alanine aminotransferase (2%), acid phosphatase (16%), and gamma glutamyl transpeptidase
(54%), compared to untreated controls (Mathur 2005).  Microscopic evaluation of the liver showed 
“shrunken” hepatocytes and thickening of the walls of hepatic arteries.
Renal Effects.    Acute nephritis with albuminuria and oliguria, polyuria, and nitrogen retention were
observed in individuals after application of a salve that contained potassium chromate.  These effects
disappeared in individuals who survived.  Autopsy of people who died revealed hyperemia and tubular
necrosis (Brieger 1920).  Acute nephritis with polyuria and proteinuria were also described in a man who 
was admitted to a hospital with skin ulcers on both hands due to dermal exposure to ammonium
dichromate in a planographic printing establishment where he had worked for a few months (Smith 1931).
A 49-year-old man with an inoperable carcinoma of the face was treated with chromic acid crystals.
Severe nephritis occurred after treatment with the chromium(VI) compound.  Urinalysis revealed marked
protein in the urine.  Death resulted 4 weeks after exposure.  A postmortem examination of the kidneys 
revealed extensive destruction of the tubular epithelium (Major 1922).  Similarly, oliguria with increasing
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serum creatinine levels were observed within 24 hours in an electroplating worker dermally exposed on 
the legs to chromic acid for approximately 10 minutes; the kidney damage progressed to acute renal
failure (Lin et al. 2009).
Application of 50 mg chromium/kg/day (specific chemical or valence state not reported) for 30 days to
clipped skin under occluded conditions to female guinea pigs produced increases in enzyme activities in 
renal tissue, specifically asparatate aminotransferase (8%), alanine aminotransferase (96%), and acid 
phosphatase (4%), compared to untreated controls (Mathur 2005).  Microscopic evaluation of the kidney
showed lobularization of the glomerular tuft and congestion of capillaries.  No additional information on
renal effects of dermal exposure to chromium(VI) or chromium(III) compounds was identified.
Dermal Effects.    Occupational exposure to airborne chromium compounds has been associated with 
effects on the nasal septum, such as ulceration and perforation. These studies are discussed in
Section 3.2.1.2 on Respiratory Effects.  Dermal exposure to chromium compounds can cause contact
allergic dermatitis in sensitive individuals, which is discussed in Section 3.2.3.3.  Skin burns, blisters, and 
skin ulcers, also known as chrome holes or chrome sores, are more likely associated with direct dermal
contact with solutions of chromium compounds, but exposure of the skin to airborne fumes and mists of
chromium compounds may contribute to these effects.
Acute dermal exposure of humans to chromium(VI) compounds causes skin burns.  Necrosis and 
sloughing of the skin occurred in individuals at the site of application of a salve containing potassium
chromate.  Twelve of 31 people died as a result of infection of these areas (Brieger 1920).  In another
case, a man who slipped at work and plunged his arm into a vat of chromic acid had extensive burns and 
necrosis on his arm (Cason 1959). Multiple skin ulcers were observed in an electroplating worker
exposed on the legs to chromic acid for approximately 10 minutes (Lin et al. 2009).
Longer-term occupational exposure to chromium compounds in most chromium-related industries can 
cause deep penetrating holes or ulcers on the skin.  A man who had worked for a few months in a
planographic printing establishment, where he handled and washed sheets of zinc that had been treated
with a solution of ammonium dichromate, had skin ulceration on both hands (Smith 1931).
In an extensive survey to determine the health status of chromate workers in seven U.S. chromate
production plants, 50% of the chromate workers had skin ulcers or scars.  In addition, inflammation of
oral structures, keratosis of the lips, gingiva, and palate, gingivitis, and periodontis due to exposure of
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these mucocutaneous tissues to airborne chromium were observed in higher incidence in the chromate
workers than in controls. Various manufacturing processes in the plants resulted in exposure of workers 
to chromite ore (mean time-weighted concentration of 0–0.89 mg chromium(III)/m3 air); water-soluble
chromium(VI) compounds (0.005–0.17 mg chromium(VI)/m3); and acid-soluble/water-insoluble
chromium compounds (including basic chromium sulfate), which may or may not entirely represent
chromium(III) (0–0.47 mg chromium/m3 air) (PHS 1953).  Among 258 electroplating workers exposed to 
chromium trioxide fumes at 0.1 mg chromium(VI)/m3 for <1 year, 5% developed dental lesions, 
consisting of yellowing and wearing down of the teeth (Gomes 1972).
Chronic exposure of chrome chemical production workers produced dermal symptoms, including irritated 
and ulcerated skin, dermatitis, and burns (Gibb et al. 2000a).  Medical records of 2,307 male workers 
employed at a chromate production plant in Baltimore, Maryland between 1950 and 1974 
were evaluated to determine the percentage of workers reporting clinical symptoms, mean time of
employment to first diagnosis of symptoms, and mean exposure to chromium(VI) at the time of first
diagnosis (exposure for each worker was the annual mean in the area of employment during the year of
first diagnosis).  Ulcerated skin occurred in 31.6% of workers, at a mean exposure of 0.029 mg Cr(VI)/m3 
and a mean time to first diagnosis of 373 days.  Ulcerated skin was significantly associated with
chromium(VI) exposure (p=0.004), with a relative risk of 1.11.  Burns were observed in 31.4% of
workers, with a mean exposure and time to onset of 0.027 mg/m3 and 409 days, respectively.  Dermatitis 
was observed in 18.5% of workers, with a mean exposure and time to onset of 0.029 mg/m3 and 624 days,
respectively.  Irritated skin was observed in 15.1% of workers, with a mean exposure and time to onset of
0.025 mg/m3 and 719 days, respectively.   
Irritation and ulceration of the buccal cavity, as well as chrome holes on the skin, were also observed in 
workers in a chrome plating plant where poor exhaust resulted in excessively high concentrations of
chromium trioxide fumes (Lieberman 1941).  Electroplaters in Czechoslovakia exposed to an average of
0.414 mg chromium(VI)/m3 above the plating baths also had high incidences of buccal cavity changes, 
including chronic tonsillitis, pharyngitis, and papilloma (Hanslian et al. 1967).  In a study of
303 electroplating workers in Brazil, whose jobs involve working with cold chromium trioxide solutions, 
>50% had ulcerous scars on the hands, arms, and feet.  Air monitoring revealed that most workers were 
exposed to ≥0.1 mg chromium(VI)/m3, but even those exposed to <0.1 mg chromium(VI)/m3 developed 
lesions (Gomes 1972).  Chrome holes were also noted at high incidence in chrome platers in Singapore,
while controls had no skin ulcers (Lee and Goh 1988).  The incidence of skin ulcers was significantly
increased in a group of 997 chrome platers compared with 1,117 controls.  The workers had been exposed 
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to chromium(VI) in air and in dust.  The air levels were generally <0.3 mg chromium(VI)/m3, and dust
levels were generally between 0.3 and 97 mg chromium(VI)/g (Royle 1975b).  In a NIOSH Health 
Hazard Evaluation of an electroplating facility in the United States, seven workers reported past history of
skin sores, and nine had scars characteristic of healed chrome sores. The workers had been employed for
an average of 7.5 years and were exposed to a mean concentration of 0.004 mg chromium(VI)/m3 in air.  
In addition, spot tests showed widespread contamination of almost all workroom surfaces and hands
(Lucas and Kramkowski 1975).
An early report of cases of chrome ulcers in leather tanners noted that the only workmen in tanneries who 
suffered chrome holes were those who handled dichromate salts.  In one of these cases, the penetration
extended into the joint, requiring amputation of the finger (Da Costa et al. 1916).  In a medical survey of a
chemical plant that processed chromite ore, 198 of 285 workers had chrome ulcers or scars on the hands
and arms.  These workers had been exposed to one or more chromium(VI) compounds in the form of
chromium trioxide, potassium dichromate, sodium dichromate, potassium chromate, sodium chromate, 
and ammonium dichromate (Edmundson 1951).
Similar dermal effects have been observed in animals. Dermal application of chromium(VI) compounds 
to the clipped, nonabraded skin of rabbits at 42–55 mg/kg resulted in skin inflammation, edema, and 
necrosis.  Skin corrosion and eschar formation occurred at lethal doses (see Section 3.2.3.1) (Gad et al. 
1986).  Application of 0.01 or 0.05 mL of 0.34 molar solution of potassium dichromate (0.35 mg
chromium(VI) or 1.9 mg chromium(VI)/kg) to the abraded skin of guinea pigs resulted in skin ulcers
(Samitz 1970; Samitz and Epstein 1962).  Similar application of 0.01 mL of a 1 molar solution of
chromium sulfate (1 mg chromium(III)/kg) however, did not cause skin ulcers in guinea pigs (Samitz and 
Epstein 1962).  In a primary dermal irritation test, application of 88 mg chromium(III) as chromium
nicotinate in corn oil to clipped skin of male and female New Zealand albino rabbits produced very slight
erythema after 1 hour after application, with no signs of dermal irritation 48 hours after application (Shara
et al. 2005).
Dermal sensitization due to hypersensitivity to chromium is discussed in Section 3.2.3.3.
Ocular Effects. Medical records of 2,307 male workers employed at a chromate 
production plant in Baltimore, Maryland between 1950 and 1974 were evaluated to determine the
percentage of workers reporting clinical symptoms, mean time of employment to first diagnosis of
symptoms, and mean exposure to chromium(VI) at the time of first diagnosis (exposure for each worker
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was the annual mean in the area of employment during the year of first diagnosis) (Gibb et al. 2000a).  
Conjunctivitis was reported on 20.0% of the study population, at a mean exposure level of 0.025 mg
Cr(VI)/m3 and a mean time-to-onset of 604 days.
Direct contact of the eyes with chromium compounds also causes ocular effects. Corneal vesication was 
described in a worker who accidentally got a crystal of potassium dichromate or a drop of a potassium
dichromate solution in his eye (Thomson 1903).  In an extensive study of chromate workers in seven U.S.
chromate production plants, eyes were examined because accidental splashes of chromium compounds 
into the eye had been observed in these plants.  Congestion of the conjunctiva was found in 38.7% of the
897 workers, discharge in 3.2%, corneal scaring in 2.3%, any abnormal finding in 40.8%, and burning in 
17.0%, compared with respective frequencies of 25.8, 1.3, 2.6, 29.0, and 22.6% in 155 nonchromate
workers.  Only the incidences of congestion of the conjunctiva and any abnormal findings were
significantly higher in the exposed workers than in the controls (PHS 1953).
Instillation of 0.1 mL of a 1,000 mg chromium(VI)/L solution of sodium dichromate and sodium
chromate (pH 7.4) was not irritating or corrosive to the eyes of rabbits (Fujii et al. 1976).  Histological 
examination of the eyes of rats exposed to chromium dioxide (15.5 mg chromium(IV)/m3) in air revealed
no lesions (Lee et al. 1989).  In a primary eye irritation test, direct conjunctival instillation of 5.2 mg
chromium(III) as chromium nicotinate in water to male and female New Zealand albino rabbits produced
conjunctivitis within 1 hour of application, although no corneal opacity or iritis was observed (Shara et al.
2005).
3.2.3.3  Immunological and Lymphoreticular Effects
In addition to the irritating and ulcerating effects, direct skin contact with chromium compounds elicits an 
allergic response, characterized by eczema or dermatitis, in sensitized individuals.  Chromium-induced 
allergic contact dermatitis is typically isolated to areas at the site of contact, rarely occurring in areas 
remote to the point of contact (Winder and Carmody 2002).  Following an induction phase during which 
the patient becomes sensitized, subsequent dermal exposure results in an allergic response.  The acute
response phase lasts for a few days to a few weeks and is characterized by erythema, edema, and small
and large blisters; the chronic phase exhibits similar clinical features, but may also include thickened,
scaly, and fissured skin (Winder and Carmody 2002).  Evaluation by light and electron microscopy of
skin biopsies of individuals with active dermatitis due to chromium shows increased intracellular edema 
   
 








   
    
 
  
   
   









     
 
 





    
 
    
   
  





of lower epidermal keratinocytes, formation of vacuoles in cells of the lower epidermis and dendritic, 
spindle-shaped cells in the upper dermis (Shah and Palmer 2002).  
Studies using dermal patch testing as a technique to diagnose chromium sensitivity show that challenge
with small amounts of chromium(VI) or chromium(III) can induce a response in sensitized individuals.  A
series of studies conducted by Hansen et al. (2003, 2006a, 2006b) show that patients with chromium-
induced dermatitis associated with exposure to leather products responded to both low-dose and high-
dose chromium(VI) and chromium(III) challenge using skin patch tests.  In a group of 18 patients
previously diagnosed with chromium sensitivity, the concentration of chromium(VI) as potassium
dichromate required to elicit a positive response on skin patch challenge was 6 mg chromium(VI)/L and 
1 mg chromium(III)/L as chromium trichloride (Hansen et al. 2003).  Using higher doses in 2,211 patients
with suspected contact dermatitis, 71 (3.2%) tested positive to 0.5% potassium dichromate (0.18%
chromium(VI)) on skin patch challenge; of these 71 chromium(VI)-positive patients, 31 also produce a
positive result when challenged with 13% chromium trichloride (3.7% chromium(III)) (Hansen et al. 
2006b). The positive response to both chromium(VI) and chromium(III) challenge may indicate that 
exposure to both compounds may induce sensitivity or that there is cross-sensitivity between
chromium(VI) and chromium(III) compounds on challenge.  Similar results have been reported with high-
dose chromium(III), showing that patch testing of chromium(VI)-sensitive patients with chromium(III)
compounds can elicit an allergic reaction (Fregert and Rorsman 1964, 1966; Mali et al. 1966). 
A study was performed on 54 volunteers who with chromium-induced allergic contact dermatitis to
determine a dose-response relationship and to determine a minimum-elicitation threshold concentration 
(MET) that produces an allergic response in sensitive individuals (Nethercott et al. 1994).  Patch testing
was performed on the subjects in which the concentration of potassium chromate(VI) was varied up to
4.4 μg chromium/cm2. Two percent (1/54) had a MET of 0.018.  About 10% were sensitized at
0.089 μg/cm2 and all were sensitized at 4.4 μg/cm2.  Comparable studies were performed with
chromium(III) chloride, however, only 1 showed a positive response at 33 μg chromium/cm2, and upon 
retesting was negative.  Based on these findings the authors concluded that soil concentrations of
chromium(VI) and chromium(III) of 450 and 165,000 ppm, respectively, should not pose a hazard of 
allergic contact dermatitis to 99.99% of people who might be exposed to chromium through soil-skin
contact.
Subjects with a sensitivity to chromium and challenged with a 0.001% solution potassium dichromate had 
increased skin thickness and blood flow (Eun and Marks 1990).  Studies conducted on chromium(VI)-
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sensitive printers and lithographers indicate that chromium(VI) compounds elicit reactions more
frequently than do chromium(III) compounds (Levin et al. 1959; Mali et al. 1966; Samitz and Shrager
1966). The authors attributed this to a greater degree of permeation of the hexavalent form than the 
trivalent form through the skin (see Section 3.4.1.3).
In a study of skin disease among workers at an automobile factory, 230 workers with skin disease and
66 controls were patch tested with potassium dichromate (0.175% chromium(VI)).  Sensitivity to 
potassium dichromate was seen in 24% of the patients and 1% of the controls.  Most of the sensitive
patients were assemblers who handled nuts, bolts, screws, and washers, which were found to have
chromate on the surfaces as a result of a chromate dip used in the engine assembly process.
Discontinuation of use of the chromate dip resulted in a significant decrease in the prevalence of
dermatitis 6 months later (Newhouse 1963).  
Numerous studies have investigated the cause of dermatitis in patients and in workers in a variety of
occupations and industries and have found positive results for chromium compounds in patch tests.  In 
these studies, patch tests were conducted with chromium(VI) or chromium(III) compounds using various
concentrations.  In studies of individuals with occupational contact dermatosis, positive patch tests for
chromium (potassium dichromate, sodium chromate, or otherwise not specified) were found in 6–45% of
the subjects (Athavale et al. 2007; Bock et al. 2003; Fregert 1975).  The common occupations of
individuals with the positive reactions to chromium were metal workers, tannery workers, builders,
bricklayers, concrete workers, plasterers, and construction workers.  Other industries and sources of
chromium that have resulted in chromium sensitivity include welding, printing, glues, wood ash, foundry
sand, match heads, machine oils, timber preservative, boiler linings, making of television screens, 
magnetic tapes, tire fitting, chrome plating, wood and paper industry, leather tanning, cement working, 
automobile painting, diesel locomotive repair, and milk testing (Burrows 1983; Cheng et al. 2008;
Engebrigtsen 1952; Engel and Calnan 1963; Gass and Todd 2007; Kaplan and Zeligman 1962; Lockman 
2002; Peltonen and Fraki 1983; Wong et al. 1998).  Chromate sensitivity has also been reported in women 
who frequently used dichromate-containing detergent and bleach (Basketter et al. 2001; Wahba and
Cohen 1979).
A number of large-scale retrospective studies (>3,000 subjects) examined the frequency of positive patch 
tests for potassium dichromate among patients with suspected contact dermatitis. Positive results were 
found in 2.7–6% of the subjects (Carøe et al. 2010; Cheng et al. 2008; Ertam et al. 2008; Hegewald et al. 
2008).  A similar frequency of positive patch test results were found in a study of elderly patients (11%)
   
 

















   




   
  
 
    
  
 




   
  
 






with contact and occupational dermatosis (Balato et al. 2008) and in children (7%) with contact dermatitis
(Milingou et al. 2010).
Animals can also be sensitized to chromium compounds.  Contact sensitivity was induced in mice by
rubbing a solution of 1% potassium dichromate (0.35% chromium(VI)) ≈50 times on the shaved 
abdomens.  Challenge with potassium dichromate on the ear resulted in significant induction of
sensitivity, measured by ear thickness and histologically observed infiltration of nucleophilic leukocytes
(Mor et al. 1988).
Guinea pigs can be sensitized to chromium(VI) and chromium(III) compounds by a series of intradermal
injections of 0.009 mg chromium(VI)/kg as potassium dichromate or of 0.004 mg chromium(III)/kg as
chromium trichloride.  Regardless of the compound used to sensitize the guinea pigs, subsequent patch 
testing with chromium(VI) or chromium(III) yielded the same erythmatic reaction.  The response,
however, was greater when chromium(VI) was used as the sensitizer (Gross et al. 1968).  Similarly, the
same erythmatic response to chromium(VI) and chromium(III) compounds was noted in guinea pigs
sensitized to 0.04 mg chromium(VI)/kg as potassium dichromate or 0.03 mg chromium(III)/kg as
chromium sulfate (Jansen and Berrens 1968).
Results of skin testing to demonstrate or diagnose chromium sensitization are recorded in Table 3-6 for 
chromium(VI) and Table 3-7 for chromium(III).
No studies were located regarding the following health effects in humans or animals after dermal
exposure to chromium compounds:
3.2.3.4  Neurological Effects 
3.2.3.5  Reproductive Effects
3.2.3.6  Developmental Effects 
3.2.3.7  Cancer
No studies were located regarding cancer in humans or animals after dermal exposure to chromium
compounds. 
   
 








   
 
     
  
  
   
 
   
  




   
   
   
 
   




      
 
   
  







In vivo studies of chromium compounds are summarized in Table 3-8.  In vitro studies on the
genotoxicity of chromium(VI) and chromium(III) compounds are summarized in Tables 3-9 and 3-10, 
respectively.  Chromium(VI) compounds rapidly (within seconds to minutes) enter cells by facilitated 
diffusion, while chromium(III) compounds enter much more slowly (within days) by simple diffusion;
therefore, chromium(VI) compounds are of greater concern with regard to health effects.  Available
genotoxicity studies on occupationally exposed humans typically evaluate effects in blood cells since 
blood is easily accessible, whereas evaluation of effects in cells from cancer target tissues (e.g., lung,
gastrointestinal tract) are not easily obtained for analysis.  However, negative genotoxicity results in
tissues that are not cancer targets (e.g., blood) should not be extrapolated to cancer target tissues.
Occupational exposure studies have yielded mixed results on the genotoxic potential of chromium
compounds.  Studies involving workers exposed to chromium(VI) in stainless steel welding and 
electroplating (Halasova et al. 2008; Husgafvel-Pursiainen et al. 1982; Littorin et al. 1983; Nagaya 1986;
Nagaya et al. 1991), and to chromium(III) in tanneries (Hamamy et al. 1987) did not report increases in 
the number of chromosomal aberrations or sister chromatid exchanges in peripheral lymphocytes of these
workers.  No elevations in DNA strand breaks or hydroxylation of deoxyguanosine were detected in
lymphocytes of workers exposed to chromium(VI) involved in the production of bichromate (Gao et al. 
1994), while DNA strand breaks were reported in the peripheral lymphocytes of 19 chromium platers 
(Gambelunghe et al. 2003). DNA damage was also reported in chromium(III) tannery workers (Zhang et
al. 2008).  In contrast, other studies involving electroplaters, stainless steel welders, or workers at
tanneries reported higher levels of chromosomal aberrations, sister chromatid exchanges, or micronuclei
formation in workers exposed to chromium(VI) compared to controls (Balachandar et al. 2010; Deng et
al. 1988; Koshi et al. 1984; Lai et al. 1998; Sarto et al. 1982; Stella et al. 1982; Werfel et al. 1998).
Urine samples from six workers working in chromium plating factories were tested for the induction of
unscheduled DNA synthesis (UDS) in pleural mesothelial cells (Pilliere et al. 1992).  The mean 
chromium concentration in the urine samples was 11.7±8.8 μg/L.  The urine from five of the workers
showed a significant elevated in UDS over control subjects who were nonsmokers, with a trend toward 
increasing amounts of urine being tested.  However, there was no correlation between UDS and 
chromium concentrations in urine.  
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Table 3-8.  Genotoxicity of Chromium In Vivo 
Species
(test system) End point Results Reference Valence Compound














D. melanogaster Gene mutation + Olvera et al. 1993 (VI) Chromium
trioxide
D. melanogaster Gene mutation + Kaya et al. 2002 (VI) Potassium
dichromate








+ Koshi et al. 1984;




















Human lymphocytes Sister chromatid 
exchanges
+ Koshi et al. 1984;
Lai et al. 1998;
Sarto et al. 1982;











– Gao et al. 1994 (VI) Production of
bichromate
Human lymphocytes	 Sister chromatid – Nagaya et al. 1991 (VI) Chromium
exchanges plating
Human lymphocytes	 Sister chromatid + Werfel et al. 1998 (VI) Welding fumes
exchanges, DNA
strand breaks
   
 








   
 
  




















      
 



















































      
 
 
























Table 3-8.  Genotoxicity of Chromium In Vivo 
Species
(test system) End point Results Reference Valence Compound
Human peripheral Chromosomal – Halasova et al. (VI) Welding fumes
lymphocytes aberrations 2008
Human lymphocytes Sister chromatid – Nagaya 1986 (VI) Chromium
exchanges plating
Human peripheral Micronuclei + Vaglenov et al. (VI) Chromium
lymphocytes 1999 electroplating
Human peripheral Micronuclei + Benova et al. 2002 (VI) Chromium
lymphocytes plating
Human buccal mucosa Micronuclei + Benova et al. 2002 (VI) Chromium
plating
Human peripheral Chromosomal – Benova et al. 2002 (VI) Chromium
lymphocytes aberrations, sister plating
chromatid 
exchanges
Human peripheral DNA strand + Gambelunghe et (VI) Chromium
lymphocytes breaks al. 2003 plating




Human whole blood cells Sister chromatid + Wu et al. 2001 (VI) Chromium
exchanges electroplating
Human peripheral Micronuclei, + Medeiros et al. (III) Tanners
lymphocytes DNA-protein 2003a
crosslinks
Human peripheral Chromosomal + Balachandar et al. (VI) Tanners
lymphocytes aberrations, 2010
micronuclei
Human peripheral Micronuclei – Medeiros et al. (VI) Welders
lymphocytes 2003a
Human peripheral DNA-protein + Medeiros et al. (VI) Welders
lymphocytes crosslinks 2003a
Human peripheral DNA damage + Zhang et al. 2008 (III) Tanners
lymphocytes
Human peripheral DNA damage + Zhang et al. 2011 (VI) Chromium
lymphocytes electroplating
New polychromatic Micronuclei + LeCurieux et al. (VI) Potassium
erythrocytes 1992 chromate
Rat lung (intratracheal DNA alterations + Izzotti et al. 1998 (VI) Sodium
exposure) dichromate
Rat liver (intratracheal DNA alterations – Izzotti et al. 1998 (VI) Sodium
exposure) dichromate
Rat liver (oral exposure) DNA-protein + Coogan et al. (VI) Potassium
crosslinks 1991a chromate
   
 








   
 
  
























     
 
 
































































Table 3-8.  Genotoxicity of Chromium In Vivo 
Species
(test system) End point Results Reference Valence Compound

























– Mirsalis et al. 1996 (VI) Potassium
chromate
Rat (F344/N) bone 
marrow cells (oral 
exposure)
















































marrow cells (drinking 
water exposure)













marrow cells (drinking 
water exposure)





   
 








   
 
  






















































































Table 3-8.  Genotoxicity of Chromium In Vivo 
Species





















marrow cells (drinking 
water exposure)







marrow cells (gavage 
exposure)












Mouse (Swiss) bone 
marrow—dams (drinking 
water exposure)





Mouse (Swiss) bone 
marrow—dams (drinking 
water exposure)




Mouse (Swiss) bone 
marrow—dams







Mouse (Swiss) bone 
marrow—dams






Mouse (Swiss) fetal liver
cells (transplacental
exposure from drinking 
water)





Mouse (Swiss) fetal liver
cells (transplacental
exposure from drinking 
water)













   
 








   
 
  
































































































Table 3-8.  Genotoxicity of Chromium In Vivo 
Species



































































































   
 








   
 
  

























     
 
 




Table 3-8.  Genotoxicity of Chromium In Vivo 
Species
(test system) End point Results Reference Valence Compound
Mouse bone marrow Micronuclei + Chorvatoviĉová et (VI) Potassium
(intraperitoneal exposed) al. 1993; Wroska- dichromate
Nofer et al. 1999
Mouse (intraperitoneal Dominant lethality + Paschin et al. 1982 (VI) Potassium
exposure) dichromate
Mouse liver and kidney Single strand + Ueno et al. 2001 (VI) Potassium
cells (intraperitoneal breaks dichromate
exposure)
Mouse spleen, lung, and Single strand – Ueno et al. 2001 (VI) Potassium
brain cells breaks dichromate
(intraperitoneal
exposure)
– = negative results; + = positive results; (0) = 0 valence; (III) = trivalent; (VI) = hexavalent; DNA = deoxyribonucleic
acid
   
 









   
 





   
      
  
 





































   
 



































Table 3-9.  Genotoxicity of Chromium(VI) In Vitro
Results
With Without
Species (test system) End point activation activation Reference Compound
Subcellular targets:
Escherichia coli DNA	 DNA-protein No data – Fornance et al. Potassium
crosslinks 1981 chromate
Nuclei of mouse L1210 DNA fragmentation No data – Fornance et al. Potassium
leukemia cells 1981 chromate
Double-stranded Forward mutations No data + Snow and Xu Potassium
M13mp2 bacteriophage 1989 chromate
DNA transferred to E. 
coli
Puc 19 plasmid DNA Gene mutation No data +	 Kortenkamp et Potassium
al. 1996b chromate
Papilloma virus Gene mutation No data +	 Kowalski et al. Potassium
1996 chromate
PSV2neo-based DNA polymerase + – Bridgewater et Sodium
plasmid DNA arrest al. 1994b, 1998 dichromate
Prokaryotic organisms:




E. coli PQ37, PQ35	 Induction of SOS – + Olivier and Potassium
response	 Marzin 1987 chromate,
potassium
dichromate
E. coli AB1157, Induction of SOS No data + Llagostera et Chromium





E. coli Wp2, Hs30R,	 Reverse mutations No data + Kanematsu et Potassium
B/rWP2	 al. 1980; dichromate,
Nakamuro et potassium
al. 1978; Venitt chromate,
and Levy 1974 sodium
chromate
   
 








   
 





   
 
 












     
 
   
 
    
 
   
 




   
 




   
 




   
 




   
 












   
 




   
 




   
 




   
 




























Table 3-9.  Genotoxicity of Chromium(VI) In Vitro
Results
With Without
Species (test system) End point activation activation Reference Compound
E. coli, WP2/pKM101,
WP2 uvrA/pKM101








Reverse mutations + + NTP 2007 Sodium
dichromate 
dihydrate





S. typhimurium TA100 Base pair
substitutions
No data + DeFlora 1978 Sodium
dichromate
S. typhimurium TA100 Base pair
substitutions




S. typhimurium TA102 Base pair
substitutions




S. typhimurium TA92 Base pair
substitutions




S. typhimurium TA1535 Base pair
substitutions




S. typhimurium TA97 Frame shift
mutations












S. typhimurium TA1978 Frame shift
mutations




S. typhimurium TA1535 Base pair
substitutions




S. typhimurium TA100 Base pair
substitutions




S. typhimurium TA1538 Frame shift
mutations




S. typhimurium TA98 Frame shift
mutations




















   
 








   
 





   
   
 










   
 



























































   




       
 










Table 3-9.  Genotoxicity of Chromium(VI) In Vitro
Results
With Without
Species (test system) End point activation activation Reference Compound
S. typhimurium TA100 Base pair
substitutions










S. typhimurium TA1535 Base pair
substitutions










































S. typhimurium TA 
1535 pSK1002























S. cerrevisiae D7 Reverse mutations No data + Singh 1983 Potassium
dichromate








   
 








   
 





   
 
  

























































































Table 3-9.  Genotoxicity of Chromium(VI) In Vitro
Results
With Without
Species (test system) End point activation activation Reference Compound
Schizosacharomyces Mitotic gene No data + Bonatti et al. Potassium
pombe conversion 1976 dichromate
S. pombe	 Forward mutations No data + Bonatti et al. Potassium
1976 dichromate
Chickens:
Chick embryos	 DNA damage cross No data + Tsapakos et al. Sodium




Human embryonic lung DNA-protein No data + Fornance et al. Potassium
fibroblasts (IMR-90) crosslinks, DNA 1981 chromate
fragmentation
Human bronchial DNA fragmentation No data + Fornance et al. Potassium
epithelial cells 1981 chromate
Human lymphocytes	 Single strand No data + Depault et al. Potassium
breaks 2006 chromate
Human lymphocytes DNA damage No data +	 Blasiak and Potassium
Kowalik 2000 dichromate
Human dermal DNA double-strand No data + Ha et al, 2003, Sodium
fibroblasts (GM03440 breaks 2004 chromate
cells)
Human bronchial chromosome No data + Holmes et al. Sodium
fibroblasts (WTHBF-6 aberrations 2006 chromate
cells)
Human bronchial Disruption of No data + Wise et al. Sodium
fibroblasts (WTHBF-6 mitosis 2006a chromate
cells)
Human bronchial chromosome No data + Wise et al. Sodium
epithelial cells (BEP2D aberrations 2006b chromate
cells)
Human lung fibroblasts	 DNA polymerase No data + Xu et al. 1996 Sodium
arrest, DNA-DNA chromate
crosslinks
Primary human Chromosomal No data + Li Chen et al. Sodium
bronchial fibroblasts aberrations 2009 chromate
Primary human skin Chromosomal No data + Li Chen et al. Sodium
cells aberrations 2012 chromate
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Table 3-9.  Genotoxicity of Chromium(VI) In Vitro
Results
With Without
Species (test system) End point activation activation Reference Compound





























































































B = negative results; + = positive results; ± = weakly positive results; (VI) = hexavalent; DNA = deoxyribonucleic acid
   
 











     
 











































     
 
 
     
 
 




























Table 3-10.  Genotoxicity of Chromium(III) In Vitro
Results
Species










No data + Fornace et al.
1981
Chromium trichloride











































B. subtilis Recombinations No data ± Nakamuro et al. Chromium nitrate
1978
B. subtilis Recombinations No data ± Nakamuro et al. Chromium acetate
1978




























   
 










     
 




   
  
 
    
 
 
   
 












































































Table 3-10.  Genotoxicity of Chromium(III) In Vitro
Results
Species





E. coli PQ37 Induction of SOS
response
– – Venier et al. 1989 Chromium
trichloride, chromium
nitrate
E. coli PQ37 Induction of SOS – ± Venier et al. 1989 Chromium acetate
response



























































































– – Shara et al. 2005 Niacin-bound 
chromium
   
 










     
 




   
 
 























































     
  























Table 3-10.  Genotoxicity of Chromium(III) In Vitro
Results
Species With Without
(test system) End point activation activation Reference Compound





Saccharomyces Reverse No data + Bronzetti et al. Chromium trichloride
cerevisiae mutations, mitotic 1986
gene conversions
S. cerrevisiae DNA deletions No data + Kirpnick-Sobol et Chromium (III)
al. 2006 chloride salt
Chickens:




Human DNA damage No data + Blasiak and Chromium chloride
lymphocytes Kowalik 2000
Human skin Unscheduled No data – Whiting et al. Chromium trichloride
fibroblasts DNA synthesis 1979
Human skin DNA No data – Whiting et al. Chromium trichloride
fibroblasts fragmentation 1979
Human Chromosomal No data ± Nakamuro et al. Chromium
leukocytes aberrations 1978 trichloride, chromium
nitrate, chromium
acetate
Human Chromosomal No data ± Stella et al. 1982 Chromium trichloride 
lymphocytes aberrations hexahydrate
Human Chromosomal No data – Sarto et al. 1980 Chromium trichloride
lymphocytes aberrations
Human Sister chromatid No data – Stella et al. 1982 Chromium trichloride 
lymphocytes exchange hexahydrate
Chinese Chromosomal No data – Newbold et al. Chromium acetate
hamster V79 aberrations 1979
cells
Syrian hamster Chromosomal No data – Tsuda and Kato Chromium trichloride 
embryonal cells aberrations 1977 hexachloride,
chromium sulfate 
tetrahydrate 
Chinese Chromosomal No data – Ohno et al. 1982 Chromium trichloride 
hamster lung aberrations hexahydrate,
DON cells chromium sulfate 
tetrahydrate
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Table 3-10.  Genotoxicity of Chromium(III) In Vitro
Results
Species
















































Mutations + + Whittaker et al.
2005
Chromium picolinate
Mouse L5178Y Mutations – ± Whittaker et al. Chromium chloride
lymphoma 2005
Mouse leukemia Chromosomal No data – Fornace et al. Chromium trichloride
cells aberrations 1981





Mouse fetal cells Chromosomal No data ± Raffetto et al. Chromium trichloride
aberrations 1977
Mouse fetal cells Morphological
transformations
No data + Raffetto et al.
1977
Chromium trichloride
Mouse A18BcR Unscheduled No data – Raffetto et al. Chromium trichloride
cells DNA synthesis 1977
– = negative results; + = positive results; ± = weakly positive results; (III) = trivalent; DNA = deoxyribonucleic acid
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An epidemiology study of stainless steel welders, with mean exposure levels of 0.055 mg 
chromium(VI)/m3 or 0.081 mg chromium (total)/m3, did not report increases in the number of sister
chromatid exchanges in the lymphocytes of exposed workers. The welders were also exposed to nickel
and molybdenum from the welding rods (Littorin et al. 1983).  A similar study was conducted to detect
genotoxic effects of chromium(VI) on workers in electroplating factories.  Of the 24 workers examined, 
none showed significant differences in sister chromatid exchange frequency (Nagaya 1986).  Similarly,
no correlation was found between excretion of chromium in the urine and the frequency of sister
chromatid exchanges in 12 male chromium platers whose mean urinary chromium level was 17.9 μg/g 
creatinine (Nagaya et al. 1991).  In chrome platers (n=15) in low (0.0075 mg Cr(VI)/m3) and high 
(0.0249 mg Cr(VI)/m3) exposure groups, no significant differences in the frequency of sister chromatid 
exchanges and chromosomal aberrations in peripheral lymphocytes and buccal mucosa cells were 
observed compared to controls (0.0004 mg Cr(VI)/m3; n=15) (Benova et al. 2002).  No increase in 
chromosomal aberrations was observed in 17 tannery workers exposed primarily to chromium(III) as
compared with 13 controls (Hamamy et al. 1987).  However, parallel measurements in these tannery
workers showed that the average chromium levels in plasma (0.115 μg/L) and urine (0.14 μg/100 L) did
not differ from the nonexposed workers.  In addition, stainless steel welders occupationally exposed to 
chromium(VI) for a mean of 21 years did not have any increase in chromosomal aberrations or sister
chromatid exchanges compared to a control group; no actual exposure levels were provided (Husgafvel-
Pursiainen et al. 1982).  Similarly, no alterations in chromosomal aberration frequency were observed in
chromium welders exposed to chromium for an average of 10 years (Halasova et al. 2008).  Yet, other
studies involving electroplaters and welders report a higher incidence of chromosomal aberrations or
sister chromatid exchanges in lymphocytes of workers than in controls.  In one study, a causal
relationship between chromium exposure and the observed effects could not be established because the 
exposure was confounded by co-exposure to nickel and manganese (Elias et al. 1989a).  In another study, 
although chromium workers were found to have higher rates of sister chromatid exchanges than workers 
exposed to nickel-chromium or controls (after adjusting for potential confounding factors), the differences 
were not significantly correlated to chromium concentrations in blood or urine (Lai et al. 1998).  The
frequency of sister chromatid exchanges was also higher in the blood of 35 chromium platers in Taiwan 
when compared to controls (Wu et al. 2001).  The frequency of sister chromatid exchanges in the 
lymphocytes of 12 workers exposed to chromium(VI) as chromic acid fumes in a chrome plating industry
was significantly increased (Stella et al. 1982).  Significantly increased incidences of chromosomal
aberrations in peripheral lymphocytes were found in workers exposed to chromium(VI) as chromium
trioxide in two of four electroplating plants.  Of the two plants where the increases were significant, one 
was a "bright" plating plant, where exposure involved nickel as well as chromium, and one was a "hard"
   
 








    
    
   
  
   
  
      
    
  
 












      










plating plant, where exposure involved only chromium.  However, the increase in chromosomal
aberrations correlated poorly with urinary chromium levels, and only the increase in the "bright" platers
showed a significant correlation with duration of exposure.  A significantly increased incidence of sister
chromatid exchanges was found in "hard" platers compared with controls (sister chromatid exchange was 
not evaluated in "bright" platers), and smoking appeared to enhance the increase (7 of 8 smokers and 7 of
11 nonsmokers had incidences significantly higher than controls).  Moreover, the increased incidence of
sister chromatid exchange showed a positive correlation with urinary chromium levels (Sarto et al. 1982).
Repeated cytogenetic analysis of peripheral lymphocytes for 3 years revealed an increased frequency of
chromosomal aberrations and sister chromatid exchanges in a group of stainless steel welders compared
to controls.  The workers were exposed to unreported chromium(VI) concentrations for a mean of
12.1 years, but exposure to ultraviolet rays and small amounts of manganese, nickel, iron, and magnesium
could not be ruled out (Koshi et al. 1984).  Compared to 39 controls, significantly elevated sister
chromatid exchange values in lymphocytes and significantly higher rates of DNA single-strand breakages 
were found in a group of 39 welders exposed to unreported chromium(VI) and nickel concentrations
(Werfel et al. 1998).  Only one study was located regarding the average levels of exposure for
electroplating workers:  workers exposed to an average level of 0.008 mg chromium(VI)/m3 had increases 
in chromosomal aberrations and sister chromatid exchanges.  However, high levels of nickel as well as
chromium were found in hair and stool samples when compared to controls (Deng et al. 1988).  Increased 
levels of chromosomal aberrations and micronuclei formation were observed in tannery workers and 
residents living near the tannery exposed to elevated levels of chromium(VI) (Balachandar et al. 2010);
chromium(VI) levels in air samples were 0.021 and 0.013 mg/m3 in the workers and residents,
respectively, and 0.006 mg/m3 in controls.  Increased frequencies of micronuclei were reported in the
peripheral lymphocytes and buccal mucosa cells in two studies of chromium electroplating workers in 
Bulgaria (Benova et al. 2002; Vaglenov et al. 1999).  In chrome platers (n=15), significant increases in 
micronuclei in peripheral lymphocytes and buccal mucosa cells were observed in low (0.0075 mg
Cr(VI)/m3) and high (0.0249 mg Cr(VI)/m3) exposure groups compared to controls (0.0004 mg
Cr(VI)/m3; n=15) (Benova et al. 2002).  Increased micronuclei frequency and DNA-protein crosslinks
were observed in the peripheral lymphocytes of tanners primarily exposed to chromium(III) compounds, 
while welders, who are primarily exposed to chromium(VI) compounds had evidence of DNA-protein 
crosslinks, but not increased micronuclei frequency in peripheral lymphocytes (Medeiros et al. 2003a).  
No elevated levels of DNA strand breaks or hydroxylation of deoxyguanosine in lymphocytes were found 
in 10 workers occupationally exposed in the production of bichromate when compared with 10 non-
occupationally-exposed workers at the same facility (Gao et al. 1994).  From general background 
monitoring levels of chromium(VI), exposures were estimated to be between 0.001 and 0.055 mg/m3. In 
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contrast, DNA strand breaks were reported in the peripheral lymphocytes of 19 chromium platers with a
mean postshift urinary concentration of 7.31 μg/g creatinine when compared to non-exposed control
subjects (Gambelunghe et al. 2003).  Increases in DNA damage were found in tannery workers exposed to
chromium(III) (Zhang et al. 2008).  Significant associations between DNA damage and blood and urinary
chromium levels were observed; blood chromium levels ranged from 13.10 to 68.30 µg/L (median of
22.95 µg/L) and urinary chromium levels ranged from 1.50 to 42.20 µg/L (median of 10.60 µg/L) in the
high-exposure group and 4.30–64.3 µg/L (median of 22.95 µg/L) and 1.50–18.00 µg/L (median of
2.25 µg/L), respectively, in the low-exposure group.  Increases in DNA damage were also found in
electroplating workers exposed to chromium(VI) for an average of 5.3 years; significant associations 
between erythrocyte chromium levels and DNA damage were also observed (Zhang et al. 2011).  Li et al.
(2008) reported a significant correlation between umbilical cord chromium levels in neonates born to 
mothers living in a chromium-contaminated area of China (median umbilical cord chromium levels were 
5 times higher than controls) and DNA damage. 
Chromium(VI) and chromium(III) have been shown to be genotoxic in human cell lines.  S phase-
dependent DNA double-strand breaks were observed in cultured human dermal fibroblasts exposed to
sodium chromate (chromium(VI)) (Ha et al. 2003, 2004).  Sodium chromate also induced concentration-
dependent chromosome damage in cultured human bronchial fibroblasts and bronchial epithelial cells
(Holmes et al. 2006; Wise et al. 2006b).  Exposure of cultured human bronchial fibroblasts to sodium
chromate produced disruption of mitosis, most likely through spindle assembly checkpoint bypass (Wise
et al. 2006a).  Weakly positive responses were observed for chromium(III) (Nakamuro et al. 1978; Stella
et al. 1982).  However, it should be noted that in positive studies, the genotoxic potency of chromium(III)
compounds was several orders lower than that of chromium(VI) compounds tested in the same systems.
Positive results for increased micronuclei and DNA damage were also observed in lymphocytes exposed
to chromium(III) chloride (Blasiak and Kowalik 2000).  Positive results of chromium(III) in intact cells 
could be due to contamination of the test compounds with traces of chromium(VI) (De Flora et al. 1990;
IARC 1990), nonspecific effects at very high doses, experimental conditions that would increase the
penetration of chromium(III) into cells (e.g., detergents), or a technical artifact formed during the
extraction procedures (De Flora et al. 1990).  In one case, chromium(III) compounds showed genotoxicity
that was linked to redox cycling of a chromium-DNA complex (Sugden et al. 1990).  Although 
chromium(III) compounds are less toxic than chromium(VI) compounds because of its relative inability
to cross cell membranes, chromium(III) causes more DNA damage and mutations when it is formed by
intracellular reduction from chromium(VI) or it is reacted with DNA in subcellular systems (Bridgewater
et al. 1994a, 1994b, 1998; Fornace et al. 1981; Snow 1991; Snow and Xu 1989).
   
 









   
  




    
    
 
  
   






   
  
    
    
  
   
 
 
   
  
  
   





Thus, results of studies in occupationally exposed humans and in human cell lines indicate that
chromium(VI) and chromium(III) are genotoxic; however, studies in humans were limited in several
aspects. Generally, the levels of exposure to chromium(VI) were not known and co-exposure to other
potentially active compounds (namely ultraviolet rays and other potentially genotoxic metals) occurred in 
several studies.  Some negative results (Hamamy et al. 1987) were probably due to low exposure, because
the chromium levels in plasma and urine of exposed and unexposed workers did not differ.  Furthermore, 
some of the studies (Deng et al. 1988; Hamamy et al. 1987; Stella et al. 1982) used groups that were too 
small (<20 individuals) to have the statistical power to reliably assess the cytogenetic changes in workers.
Although most older occupational exposure studies gave negative or equivocal results, most recent studies
have identified chromosomal effects in exposed workers (Benova et al. 2002; Gambelunghe et al. 2003;
Wu et al. 2001).  Furthermore, results of studies in human cell lines provide evidence of the genotoxic
activity of chromium compounds.  Thus, the available studies support that chromium compounds, 
particularly chromium(VI), have carcinogenic potential because interactions with DNA have been linked
with the mechanism of carcinogenicity.  No studies were located regarding genotoxic effects in humans 
after oral exposure to chromium or its compounds.
Numerous studies have evaluated the genotoxicity of chromium compounds in animals by several
exposure routes, including oral, inhalation, and parenteral routes.  No increased incidence of micronuclei
in polychromatic erythrocytes was observed in mice given single gavage doses of potassium chromate at
≤86 mg chromium(VI)/kg (Shindo et al. 1989) or in mice exposed to potassium chromate via drinking
water at 1–20 ppm for 48 hours or to bolus doses up to 4 μg/kg for 2 days (Mirsalis et al. 1996).  
Similarly, no UDS in hepatocytes was found in rats.  However, an increase in DNA-protein crosslinking
was found in the livers of rats exposed to potassium chromate in the drinking water at ≥6 mg
chromium(VI)/kg/day for 3 or 6 weeks (Coogan et al. 1991a).
The clastogenic effects of male Swiss albino mice fed chromium(VI) trioxide (20 mg/kg body weight) by
gavage were studied; after 24 hours, bone marrow cells were isolated and 500 metaphase plates were 
scored for chromosomal aberrations (Sarkar et al. 1993). The treated cells showed a significant increase 
in aberrations per cell over controls by 4.4-fold.  When animals were treated simultaneously with
chlorophyllin (1.5 mg/kg), a sodium-copper derivative of chlorophyll and an antioxidant, numbers of
aberrations were reduced to nearly background levels.
   
 








   





   




    
    
  
  
    
   
   
 
   
      
    
   
 




   
  





An increase in DNA-protein crosslinking was found in the livers of rats that had been exposed to 
potassium chromate in the drinking water at ≥6 mg chromium(VI)/kg/day for 3 or 6 weeks (Coogan et al.
1991a).  Bone marrow cells from male mice fed chromium(VI) trioxide at 20 mg chromium(VI)/kg by
gavage had a 4.4-fold increase in chromosomal aberration over controls (Sarkar et al. 1993).  Significant
DNA alterations were seen in the lung, but not the liver, of rats exposed to chromium(VI) by intratrachael
instillation of sodium dichromate (Izzotti et al. 1998).  DNA damage was also reported in leukocytes and 
peripheral lymphocytes of mice orally exposed to chromium(VI) as potassium chromate (Devi et al. 2001;
Wang et al. 2006), and transplacental exposure of potassium dichromate resulted in DNA deletions of the
retinal pigment epithelium of mice (Kirpnick-Sobol et al. 2006).  Intraperitoneal exposure to 
chromium(VI) as potassium dichromate caused single strand breaks in mouse liver and kidney cells, but
did not in spleen, lung, or brain cells (Ueno et al. 2001).  Micronucleated polychromatic erythrocytes 
were found in mice following intraperitoneal exposure to chromium(VI) as potassium dichromate
(Chorvatovičová et al. 1993; De Flora et al. 2006; Itoh and Shimada 1996, 1997; Wild 1978; Wroñska-
Nofer et al. 1999), though one study reported negative results following intraperitoneal exposure to 
potassium chromate (Shindo et al. 1989).  In contrast, oral exposure of mice to chromium(VI), as
potassium dichromate or sodium dichromate dihydrate, did not induce micronuclei in bone marrow or in 
peripheral blood cells (De Flora et al. 2006; Mirsalis et al. 1996; NTP 2008a).  Similar to chromium(VI)
compounds, oral exposure of chromium(III) compounds also did not induce micronuclei in mouse
erythrocytes (NTP 2008b), bone marrow cells (De Flora et al. 2006; NTP 2008b), or in peripheral blood 
cells (De Flora et al. 2006).  Transplacental exposure to fetuses from dams exposed to chromium(VI) as 
either sodium dichromate dihydrate or potassium dichromate through drinking water did not result in 
micronuclei in fetal liver or peripheral blood cells (De Flora et al. 2006), while transplacental exposure to 
fetuses from dams exposed by intraperitoneal injection to these same chromium(VI) compounds did result
in micronuclei in both fetal liver and peripheral blood cells (De Flora et al. 2006).
No unscheduled DNA synthesis was found in rat hepatocytes after the rats were exposed to potassium
chromate in drinking water (Mirsalis et al. 1996).  The contrasting results may relate to route-specific 
differences in absorption or metabolic fate of chromate in vivo. Furthermore, intraperitoneal exposure to 
chromium(VI) as potassium dichromate induced dominant lethality in mice (Paschin et al. 1982) and a
significant increase in mutant frequency within mouse hepatocytes (Itoh and Shimada 1997, 1998) and 
bone marrow cells (Itoh and Shimada 1998).  Intraperitoneal injection in rats with sodium dichromate
chromium(VI) resulted in DNA crosslinks in liver, kidney, and lung nuclei (Tsapakos et al. 1983b), while
similar injection in rats with chromium(III) trichloride did not cause DNA interstrand crosslinks, DNA-
protein crosslinks, or DNA strand breaks in liver and kidney nuclei (Cupo and Wetterhahn 1985).  Oral
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exposure to niacin-bound chromium(III) did not cause DNA fragmentation in rats after 90 days of dietary
exposure at doses >621.6 mg Cr(III)/kg/day (Shara et al. 2005).  In addition, studies in Drosophila 
melanogaster showed an induction of gene mutations after exposure to chromium(VI) (Amrani et al.
1999; Gava et al. 1989a; Kaya et al. 2002; Rasmuson 1985; Rodriguez-Arnaiz and Martinez 1986; Olvera
et al. 1993; Zimmering et al. 1985), but not after exposure to chromium(III) (Amrani et al. 1999).
The vast majority of studies reported genotoxic effects of chromium(VI) in mammalian cells in vitro
(Blasiak and Kowalik 2000; Briggs and Briggs 1988; Depault et al. 2006; DiPaolo and Casto 1979;
Douglas et al. 1980; Elias et al. 1989b; Fornace et al. 1981; Gomez-Arroyo et al. 1981; Ha et al. 2004;
Koshi 1979; Koshi and Iwasaki 1983; Kowalski et al. 1996; Levis and Majone 1979; Li Cheng et al. 
2008, 2011; MacRae et al. 1979; Majone and Levis 1979; Montaldi et al. 1987; Nakamuro et al. 1978;
Newbold et al. 1979; Ohno et al. 1982; Raffetto et al. 1977; Sarto et al. 1980; Seoane and Dulout 1999;
Stella et al. 1982; Sugiyama et al. 1986a; Trzeciak et al. 2000; Tsuda and Kato 1977; Umeda and 
Nishimura 1979; Venier et al. 1982; Whiting et al. 1979; Wise et al. 2002, 2003; Yang et al. 1992). 
Chromium(VI) also induced DNA damage (DNA interstrand crosslinks, DNA strand breaks, DNA-
protein crosslinks) in cultured chick embryo hepatocytes (Tsapakos et al. 1983a). In contrast, mostly
negative results were reported for chromium(III) in mammalian cells (Fornace et al. 1981; Levis and 
Majone 1979; MacRae et al. 1979; Newbold et al. 1979; Ohno et al. 1982; Raffetto et al. 1977; Sarto et al. 
1980; Shara et al. 2005; Stella et al. 1982; Tsuda and Kato 1977; Umeda and Nishimura 1979; Venier et
al. 1982; Whiting et al. 1979) and chick embryo hepatocytes (Tsapakos et al. 1983a).  Positive results 
were obtained in Chinese hamster ovary cells (Coryell and Stearns 2006; Levis and Majone 1979; Stearns 
et al. 2002), mouse fetal cells (Raffetto et al. 1977), and mouse lymphoma cells (Whittaker et al. 2005).  
Chromium(III) picolinate caused chromosome damage (Stearns et al. 1995b) and mutations in cultured 
mammalian cells (Stearns et al. 2002).
Chromium(VI) was genotoxic in Saccharomyces cerevisiae (Fukunaga et al. 1982; Kirpnick-Sobol et al. 
2006; Singh 1983) and Schizosaccharomyces pombe (Bonatti et al. 1976). Two studies demonstrated the
genotoxicity of chromium(III) in S. cerevisiae (Bronzetti et al. 1986; Kirpnick-Sobol et al. 2006).  
In vitro studies indicated that soluble chromium(VI) compounds are mutagenic in Salmonella 
typhimurium reverse mutation assays (Bennicelli et al. 1983; De Flora 1978, 1981; Haworth et al. 1983;
Nakamura et al. 1987; NTP 2007a; Venier et al. 1982; Watanabe et al. 1998a; Yamamoto et al. 2002), and 
in a Salmonella microsuspension bioassay (Tagliari et al. 2004).  Only one study reported negative results 
with chromium(VI) in all tested strains (Kanematsu et al. 1980).  In contrast, studies with chromium(III)
   
 












   
 
  
    
   
   
     
    
   
  
  
   
 
   
    
  
    
 
  
   
   
  
   
 
    
  
   
  
    
    
CHROMIUM 237
3. HEALTH EFFECTS
did not report the induction of reverse mutations in S. typhimurium (Bennicelli et al. 1983; De Flora 1981;
NTP 2008b; Petrilli and De Flora 1978b; Shara et al. 2005; Venier et al. 1982; Whittaker et al. 2005; 
Yamamoto et al. 2002).  After preincubation with mammalian microsomes, the mutagenicity of
chromium(VI) compounds was reduced or abolished due to concentrations of the reductant glutathione, 
cysteine, or NADPH capable of converting chromium(VI) to chromium(III) compounds (Bennicelli et al.
1983; De Flora 1978,1981).  Chromium(VI) compounds caused gene mutations in Bacillus subtilis
(Kanematsu et al. 1980; Nakamuro et al. 1978; Nishioka 1975) and Escherichia coli (Kanematsu et al.
1980; Kortenkamp et al. 1996b; Llagostera et al. 1986; Nakamuro et al. 1978; NTP 2007; Olivier and
Marzin 1987; Venitt and Levy 1974; Watanabe et al. 1998a).  Negative or weakly positive results were
reported in B. subtilis with chromium(III) (Kanematsu et al. 1980; Matsui 1980; Nakamuro et al. 1978;
Nishioka 1975) and mostly negative results were reported in E. coli (Llagostera et al. 1986; NTP 2008b;
Olivier and Marzin 1987; Venier et al. 1989).  However, hydrophobic ligands such as 2,2´-bipyridine,
1,10-phenanthroline, or picolinic acid form complexes with chromium(III), which are able to penetrate
cell membranes and to cause genotoxicity.  Complexes of chromium(III) with 2,2´-bipyridine or
1,10-phenanthroline were mutagenic in S. typhimurium (Warren et al. 1981).  Chromium(III) picolinate
was not mutagenic in S. typhimurium or E. coli (NTP 2008b).
A chromium(IV) ester was synthesized with 2,4-dimethyl-pentane-2,4-diol to examined its ability to
cause DNA double strand breaks (Luo et al. 1996).  Calf thymus DNA was reacted with the
chromium(IV) complex (1.3 mg/mL) in the presence of 2 mM hydrogen peroxide for 6 days at pH 6.8.  
The results showed that the complex in the presence of hydrogen peroxide significantly damaged DNA by
causing double strand breaks.  Neither chromium(IV) or hydrogen peroxide alone damaged DNA.  The
kinetics of the reaction of chromium(IV) with hydrogen peroxide showed the formation of proportional
amounts of hydroxyl radical with chromium(V).  Use of a free radical scavenger prevented DNA strand
breaks.  Other studies have shown that chromium(IV) is a better Fenton reagent than chromium(V) for
reducing hydrogen peroxide, and thus, chromium(IV)-type damage by generating hydroxyl radicals may
also be a contributor of in vivo genotoxicity. 
In conclusion, chromium(VI) compounds were positive in the majority of tests reported, and their
genotoxicity was related to the solubility and, therefore, to the bioavailability to the targets.  Results of
occupational exposure studies in humans, although somewhat compromised by concomitant exposures to
other potential genotoxic compounds, provide evidence of chromium(VI)-induced DNA strand breaks,
chromosome aberrations, increased sister chromatid exchange, unscheduled DNA synthesis, and DNA-
protein crosslinks.  Findings from occupational exposure studies are supported by results of in vivo
   
 








   
  
      
 




   
 






    
      
    
      
     
     
   
    
    
 
    
  
   
 
 




studies in animals, in vitro studies in mammalian cells, yeast and bacteria, and studies in cell-free 
systems.  Compared to chromium(VI), chromium(III) was more genotoxic in subcellular targets, but lost
this ability in cellular systems.  The reduction of chromium(VI) in the cells to chromium(III) and its
subsequent genotoxicity may be greatly responsible for the final genotoxic effects (Beyersmann and
Koster 1987; Zhitkovich et al. 2005).  Reduction of chromium(VI) can also result in the formation of
chromium(V), which is highly reactive and capable of interaction with DNA (Jennette 1982; Norseth 
1986).
3.4  TOXICOKINETICS
The toxicokinetics of a given chromium compound depend on the valence state of the chromium atom
and the nature of its ligands.  Naturally occurring chromium compounds are generally in the trivalent state 
(chromium(III)), while hexavalent chromium compounds (chromium(VI)) are produced industrially by
the oxidation of chromium(III) compounds.  
The amount and location of deposition of inhaled chromium will be determined by factors that influence
convection, diffusion, sedimentation, and interception of particles in the airways.  These factors include
air flow velocities, which are affected by breathing rate and tidal volume; airway geometry; and aerosol
particle size (ICRP 1994).  In general, deposition in the thoracic and pulmonary regions of the respiratory
tract increase (as a fraction of the total deposited dose) as particle sizes decrease. Larger particles (e.g., 
>10 m in diameter) deposit in the extrathoracic region.  Chromium that deposits in the respiratory tract
are subject to three general clearance processes:  (1) mucociliary transport to the gastrointestinal tract for
the ciliated airways (i.e. trachea, bronchi, and proximal bronchioles); (2) phagocytosis by lung
macrophages and cellular transport to thoracic lymph nodes; or (3) absorption and transfer by blood 
and/or lymph to other tissues.  The above processes apply to all forms of deposited chromium, although 
the relative contributions of each pathway and rates associated with each pathway may vary with the 
physical characteristics (e.g., particle size), chemical form (degree of water solubility), and chemotactic 
properties of the chromium particles.  In general, less water-soluble chromium compounds that deposit in 
the pulmonary region can be expected to have a longer retention time in the lung than more soluble forms.  
In addition, lung concentrations of chromium increase with increasing age.
Most quantitative studies of the gastrointestinal absorption of chromium in humans have estimated the
absorption fraction to be <10% of the ingested dose.  In general, these studies suggest that the absorption 
fraction of soluble chromium compounds is higher than insoluble forms (e.g., CrCO3), and is higher for 
   
 








   
     
  





   








   
  
   
    
  





    
  
 
    




soluble chromium(VI) compounds (e.g., K2Cr2O7) than soluble chromium(III) (e.g., CrCl3).  
Chromium(VI) is reduced in the stomach to chromium(III), which lowers the absorbed dose from
ingested chromium(VI).  Absorption is also affected by the nutritional status of chromium(III); the
absorption fraction is higher when dietary intakes are lower.  Peak plasma concentrations of chromium
occur within 2 hours following an oral dose of soluble chromium, suggesting that absorption occurred.  
Chromium absorption occurs in the upper small intestine.
Chromium(III) and chromium(VI) can penetrate human skin to some extent, especially if the skin is
damaged.  Few quantitative estimates of dermal absorption in humans have been reported.  A 3-hour
immersion in a warm aqueous bath of 22 mg Cr(VI)/L (as K2Cr2O7) resulted in absorption (based on urine
measurements) of approximately 3.3x10-5–4.1x10-4 μg Cr/cm2-hour (Corbett et al. 1997).
Absorbed chromium distributes to nearly all tissues, with the highest concentrations found in kidney and 
liver.  Bone is also a major depot and may contribute to long-term retention kinetics or chromium.  
Chromium(VI) is unstable in the body and is reduced to chromium(V), chromium(IV), and ultimately to
chromium(III) by many substances including ascorbate and glutathione.  Reduction of chromium(VI) to 
chromium(III) can give rise to reactive intermediates, chromium adducts with proteins and DNA, and 
secondary free radicals.  Chromium(VI) in blood is taken up into red blood cells, where it undergoes
reduction and forms complexes with hemoglobin and other intracellular proteins that are sufficiently
stable to retain chromium for a substantial fraction of the red blood cell lifetime.  Absorbed chromium can 
be transferred to fetuses through the placenta and to infants via breast milk. Absorbed chromium is
excreted predominantly in urine.  Studies in animals have shown that chromium can be secreted in bile
following parenteral (e.g., intravenous) injection of chromium(VI) or chromium(III) compounds.  
Chromium can also be eliminated by transfer to hair and nails.  Chromium absorbed following ingestion 
of chromium(VI) (as K2Cr2O7) appears to have a slower elimination rate (t1/2 approximately 40 hours)
than when chromium is absorbed following ingestion of soluble chromium(III) (as CrCl3; t1/2 
approximately 10 hours). 
3.4.1 Absorption 
3.4.1.1  Inhalation Exposure 
The absorption of inhaled chromium compounds depends on a number of factors, including physical and 
chemical properties of the particles (oxidation state, size, solubility) and the activity of alveolar
macrophages.
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The identification of chromium in urine, serum and tissues of humans occupationally exposed to soluble
chromium(III) or chromium(VI) compounds in air indicates that chromium can be absorbed from the
lungs (Cavalleri and Minoia 1985; Gylseth et al. 1977; Kiilunen et al. 1983; Mancuso 1997b; Minoia and 
Cavalleri 1988; Randall and Gibson 1987; Tossavainen et al. 1980).  In most cases, chromium(VI)
compounds are more readily absorbed from the lungs than chromium(III) compounds, due in part to 
differences in the capacity to penetrate biological membranes.  Nevertheless, workers exposed to
chromium(III) lignosulfonate dust at 0.005–0.23 mg chromium(III)/m3 had clearly detectable
concentrations of chromium in the urine at the end of their shifts.  Based on a one-compartment kinetic
model, the biological half-life of chromium(III) from the lignosulfonate dust was 4–10 hours, which is the
same order of magnitude as the half-life for chromium(VI) compounds (Kiilunen et al. 1983).
Rats exposed to 2.1 mg chromium(VI)/m3 as zinc chromate 6 hours/day achieved steady-state 
concentrations in the blood after ~4 days of exposure (Langård et al. 1978).  Rats exposed for a single
inhalation of chromium(VI) trioxide mist from electroplating at a concentration of 3.18 mg
chromium(VI)/m3 for 30 minutes rapidly absorbed chromium from the lungs.  The content of chromium
in the lungs declined from 13.0 mg immediately after exposure to 1.1 mg at 4 weeks in a triphasic pattern
with an overall half-life of 5 days (Adachi et al. 1981).  Based on a study in rats exposed to chromium(VI)
as potassium dichromate or to chromium(III) as chromium trichloride, the pulmonary clearance of both
valence states was dependent on particle size, and chromium(VI) was more rapidly and extensively
transported to the bloodstream than chromium(III).  The rats had been exposed to 7.3–15.9 mg
chromium(VI)/m3 as potassium dichromate for 2–6 hours or to 8 or 10.7 mg chromium(III)/m3 as 
chromium trichloride for 6 or 2 hours, respectively.  Chromium(VI) particles of 1.5 or 1.6 μm had a two-
compartment pulmonary clearance curve with half-lives of 31.5 hours for the first phase and 737 hours
for the second phase.  Chromium(VI) particles of 2 μm had a single component curve with a half-life
between 151 and 175 hours.  Following exposure to chromium(VI), the ratio of blood chromium/lung
chromium was 1.44 at 0.5 hours, 0.81 at 18 hours, 0.85 at 48 hours, and 0.96 at 168 hours after exposure.  
Chromium(III) particles of 1.5–1.8 μm had a single component pulmonary clearance curve with a half-life
of 164 hours.  Following exposure to chromium(III), the ratio of blood chromium/lung chromium was 
0.39 at 0.5 hours, 0.24 at 18 hours, 0.22 at 48 hours, and 0.26 at 168 hours after exposure.  Therefore, the
amount of chromium(VI) transferred to the blood from the lungs was always at least 3 times greater than
the amount of chromium(III) transferred (Suzuki et al. 1984).  Other studies reporting absorption from the
lungs are intratracheal injection studies (Baetjer et al. 1959b; Bragt and van Dura 1983; Visek et al. 1953;
Wiegand et al. 1984, 1987).  These studies indicate that 53–85% of chromium(VI) compounds (particle
   
 








   
     
 
 
    
    
     
    
    
  



















   




size <5 μm) are cleared from the lungs by absorption into the bloodstream or by mucociliary clearance in 
the pharynx; the rest remain in the lungs.  Absorption by the bloodstream and mucociliary clearance was
only 5–30% for chromium(III) compounds. 
The kinetics of three chromium(VI) compounds, sodium chromate, zinc chromate, and lead chromate, 
were compared in rats in relation to their solubility.  The rats received intratracheal injections of the
51chromium-labeled compounds (0.38 mg chromium(VI)/kg as sodium chromate, 0.36 mg chromium(VI)/ 
kg as zinc chromate, or 0.21 mg chromium(VI)/kg as lead chromate).  Peak blood levels of 51chromium 
were reached after 30 minutes for sodium chromate (0.35 μg chromium/mL), and 24 hours for zinc
chromate (0.60 μg chromium/mL) and lead chromate (0.007 μg chromium/mL).  At 30 minutes after
administration, the lungs contained 36, 25, and 81% of the respective dose of the sodium, zinc, and lead 
chromate.  On day 6, >80% of the dose of all three compounds had been cleared from the lungs, during
which time, the disappearance from lungs followed linear first-order kinetics. The residual amounts left
in the lungs on day 50 or 51 were 3.0, 3.9, and 13.9%, respectively.  The results indicate that zinc
chromate, which is ~1,000 times less soluble than sodium chromate, is more slowly absorbed from the
lungs, but peak blood levels are higher than sodium chromate.  Lead chromate was more poorly and 
slowly absorbed, as indicated by very low levels in blood and other tissues, and greater retention in the 
lungs (Bragt and van Dura 1983).
The fate of lead chromate(VI), chromium(VI) trioxide, chromium(III) oxide and chromium(III) sulfate
were examined when solutions or suspensions of these chemicals were slowly infused into the tracheal
lobe bronchus of sheep via bronchoscopic catheterization (Perrault et al. 1995).  At 2, 3, 5, and 30 days, 
the samples of bronchoalveolar lavage were taken, and on day 31, the animals were sacrificed and lung
specimens were examined for chromium particulates.  There was no difference in lung particle
concentrations among the four different compounds.  The values ranged from 0.14x105 to 
1.02x105 particles/g dry tissue compared to control values of 0.03x105.  The alveolar clearance of slightly 
soluble chromium(III) oxide and chromium(III) sulfate was calculated to be 11 and 80 days, respectively.
The insoluble lead chromate particles appeared to break up, forming isometric particles of lead chromate 
as well as lead-containing particulates that may have retarded clearance.  Retention of chromium
particulates from exposure to soluble chromium trioxide may have resulted in the formation of a less-
soluble hydroxyl complex and/or chemical interaction between chromium and protein that prolongs the
retention of the metal.  Analyses of the particulates in lavage samples indicate that these diameters
increase with time for lead chromate, decrease with time for chromium sulfate and chromium trioxide,
and are unchanged for chromium(III) oxide.  The authors state that their findings indicate that slightly
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soluble chromium(III) oxide and chromium sulfate that are chemically stable can be cleared from lungs at
different rates, depending on the nature and morphology of the compound. 
Amounts of total chromium were measured in lymphocytes, blood, and urine after intratracheal
administration of either sodium dichromate(VI) or chromium(III) acetate hydroxide (a water-soluble
chromium(III) compound) to male Wistar rats (Gao et al. 1993).  The total amount of chromium 
administered was 0.44 mg chromium/kg body weight for each compound.  The highest concentrations in 
tissues and urine occurred at 6 hours after treatment, the first time point examined.  Mean chromium
concentrations (n=4 rats per time point) from treatment with chromium(III) were 56.3 μg/L in whole
blood, 96 μg/L in plasma, 0.44 μg/1010 in lymphocytes, and 4,535.6 μg/g creatinine in urine. For
treatment with chromium(VI) the levels were 233.2 μg/L for whole blood, 138 μg/L for plasma, 
2.87 μg/1010 for lymphocytes, and 2,947.9 μg/g creatinine in urine.  The levels in lymphocytes in the
chromium(III) treated animals were no different than in untreated animals.  However, for chromium(VI)
the lymphocyte levels were about 6-fold higher than control values.  After 72 hours, the chromium levels
were significantly reduced.  These results suggest that absorbed chromium(III) compounds may be
excreted more rapidly than absorbed chromium(VI) compounds because of a poorer ability to enter cells.
3.4.1.2  Oral Exposure 
Chromium(III) is an essential nutrient required for normal energy metabolism.  The Institute of Medicine 
(IOM 2001) of the NAS determined an adequate intake (e.g., a level typically consumed by healthy
individuals) of 20–45 μg chromium(III)/day for adolescents and adults (IOM 2001).  Currently, the
biological target for the essential effects of chromium(III) is unknown.  Chromodulin, also referred to as
glucose tolerance factor (GTF), has been proposed as one possible candidate (Jacquamet et al. 2003). The
function of chromodulin, an oligopeptide complex containing with four chromic ions, has not been 
established; however, a possible mechanism is that chromodulin facilitates the interaction of insulin with 
its cellular receptor sites, although this has not been proven (Anderson 1998a, 2003; IOM 2001).  
Chromium(III) picolinate is a common form of chromium(III) nutritional supplementation.
Trivalent chromium is very poorly absorbed from the gastrointestinal tract.  Typically, ≤1% of an orally
administered dose of trivalent chromium has been recovered in the urine of experimental animals of
humans (Aitio et al. 1984; Anderson et al. 1983; Doisy et al. 1971; Donaldson and Barreras 1966; Gargas
et al. 1994; Garcia et al. 2001; Kerger et al. 1996a) or experimental animals (Donaldson and Barreras
1966; Febel et al. 2001).  Oral absorption of trivalent chromium complexed with an organic ligand is
   
 



















    
















   
  




similarly low and not higher than inorganic forms (Anderson et al. 1996; Gonzalez-Vergara et al. 1981).  
Bypassing the stomach by infusing trivalent chromium into the duodenum or jejunum resulted in at most
1–2% of the dose being absorbed in humans (Donaldson and Barreras 1966), or 1% (Febel et al. 2001) to
4% in the rat (Donaldson and Barreras 1966). 
Approximately 0.5–2.0% of dietary chromium(III) is absorbed via the gastrointestinal tract of humans
(Anderson 1986; Anderson et al. 1983) as inferred from urinary excretion measurements.  The absorption 
fraction is dependent on the dietary intake.  At low levels of dietary intake (10 μg), ~2.0% of the
chromium was absorbed.  When intake was increased by supplementation to ≥40 μg, the absorption 
decreased to ~0.5% (Anderson 1986; Anderson et al. 1983).  Net absorption of chromium(III) by a group 
of 23 elderly subjects who received an average of 24.5 μg/day (0.00035 mg chromium(III)/kg/day) from
their normal diets was calculated to be 0.6 μg chromium(III)/day, based on an excretion of 0.4 μg 
chromium/day in the urine and 23.9 μg chromium/day in the feces, with a net retention of 0.2 μg/day.  
Thus, about 2.4% was absorbed.  The retention was considered adequate for their requirements (Bunker et
al. 1984). 
The absorption fraction of soluble chromium(III), as chromium picolinate, is greater than CrCl3 
(DiSilvestro and Dy 2007; Gargas et al. 1994).  Following ingestion of 400 μg chromium(III)/day as
chromium picolinate (in a capsule) for 3 consecutive days, mean absorption fraction in eight healthy
adults was 2.8% (±1.4 % standard deviation [SD]; Gargas et al. 1994).  Based on urinary excretion 
following oral administration of a single dose (200 μg chromium(III)) of four different chromium(III)
supplements to healthy women (n=24; cross-over design), the absorption of chromium picolinate was
higher than that of chromium chloride, chromium polynicotinate, and chromium nicotinate-glucinate; 
estimates of oral absorption were not reported (DiSilvestro and Dy 2007).  Urinary excretion of chromium
following administration of chromium picolinate was approximately 16-fold higher than that following
administration of chromium chloride and approximately 2-fold greater than that following administration 
of the two nicotinate complexes.
Association of chromium with chelating agents, which may be naturally present in feed, can alter the 
bioavailability from food.  In rats that were given 51Cr-chromium(III) trichloride mixed with chelating
agents, either oxalate or phytate, phytate significantly (p<0.05) decreased the levels of radioactivity in
blood, whole body, and urine achieved with chromium(III) trichloride alone (Chen et al. 1973).  Oxalate, 
however, greatly increased the levels in blood, whole body, and urine.  The oxalate served as a strong
ligand to protect against the tendency of chromium(III) to form insoluble macromolecular chromium
   
 









   





   
 
  
   
  
       
   
  
     
  
   
 
   
 
   
     
     
  
 
   
  








oxides at physiological pH.  Fasted rats absorbed significantly more 51chromium than did nonfasted rats, 
indicating that the presence of food in the gastrointestinal tract slows the absorption of chromium.  
Results of an in vitro experiment in this study indicated that the midsection had greater uptake than the
duodenum or ileum and that oxalate significantly (p<0.05) increased, while phytate significantly (p<0.05)
decreased the transport of chromium(III) across all three sections, paralleling the in vivo results.  
Ethylenediamine tetraacetic acid (EDTA) and citrate were also tested in the in vitro system, but were 
found to have no effect on chromium(III) intestinal transport; therefore, these chelating agents were not
tested in vivo (Chen et al. 1973).
The absorption fraction of soluble chromium(VI) is higher than that of soluble chromium(III) (Anderson 
et al. 1983; Donaldson and Barreras 1966; Kerger et al. 1996a).  Average absorption fractions, determined 
from cumulative urinary excretion in 8 healthy adults who ingested 5 mg chromium (in 10 mg Cr/L
drinking water) as CrCl3 or K2Cr2O7 were 0.13% (±0.04, standard error [SE]) and 6.9% (±3.7, SE),
respectively.  Chromium(VI) can be reduced to chromium(III) when placed in an ascorbic acid solution 
(Kerger et al. 1996a).  When K2Cr2O7 was ingested in orange juice (where it was reduced and may have 
formed complexes with constituents of the juice), the mean absorption fraction was 0.60% (±0.11, SE;
Kerger et al. 1996a).  Plasma concentrations generally peaked around 90 minutes following exposure for
all three chromium mixtures tested.  Based on measurements of urinary excretion of chromium in 
15 female and 27 male subjects who ingested 200 μg chromium(III) as CrCl3, the absorption fraction was
estimated to be approximately 0.4% (Anderson et al. 1983).  The absorption fraction of chromium(VI) (as
sodium chromate) was substantially higher when administered directly into the duodenum (approximately
10%) compared to when it is ingested (approximately 1.2%), whereas the absorption fraction for CrCl3 
was similar when administered into the small intestine (0.5%; Donaldson and Barreras 1966).  These
results are consistent with studies that have shown that gastric juice can reduce chromium(VI) to
chromium(III) (De Flora et al. 1987a). 
The absorption of chromium(VI) and chromium(III) was measured in four male and two female 
volunteers (ages ranging from 25 to 39 years) treated orally with potassium chromate (chromium(VI)) or
chromic oxide (chromium(III)) in capsules at doses of 0.005 and 1.0 mg/kg/day, respectively (Finley et al.
1996b).  Subjects were exposed to each compound for 3 days.  Based on urinary excretion data, the mean 
absorption of potassium chromate was 3.4% (range 0.69–11.9%).  No statistically significant increase in
urinary chromium was observed during chromic oxide dosing, indicating that little, if any, was absorbed.  
In a follow-up study by the same group (Finley et al. 1997), five male volunteers ingested a liter, in three
volumes of 333 mL, of deionized water containing chromium(VI) concentrations ranging from 0.1 to 
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10.0 mg/L (approximately 0.001–0.1 mg chromium(VI)/kg/day) for 3 days.  A dose-related increase in
urinary chromium was seen in all subjects and the percent of the dose excreted ranged from <2 to 8%.  
Dose-related increases in plasma and erythrocyte chromium levels were also observed.
In a repeated dose study, three healthy adults ingested chromium(VI) (as K2Cr2O7) in water at 5 mg
chromium/day for 3 consecutive days (Kerger et al. 1997).  Three divided doses were taken at
approximately 6-hour intervals over a 5–15-minute period.  After at least 2 days without dosing, the 3-day 
exposure regimen was repeated at 10 mg chromium/day.  Estimated doses based on body weight were
0.05 and 0.1 mg/kg/day, respectively.  Bioavailability based on 4-day urinary excretion was 1.7% (range
0.5–2.7%) at 0.05 mg chromium(VI)/kg/day and 3.4% (range 0.8–8.0%) at 0.1 mg chromium(VI)/kg/day.
Absorption of 0.05 mg chromium(VI)/kg appeared to be somewhat lower when given as three divided
doses rather than when given as a single bolus dose (1.7 versus 5.7%).
Uptake of potassium dichromate was determined in a man who was given 0.8 mg of chromium(VI) in 
drinking water 5 times each day for 17 days (Paustenbach et al. 1996).  Steady-state concentrations of
chromium in blood were attained after 7 days.  Red blood cell and plasma levels returned to background 
levels within a few days after exposure was stopped. The data are consistent with a bioavailability of 2%
and a plasma elimination half-life of 36 hours.
Studies with 51chromium in animals indicate that chromium and its compounds are also poorly absorbed 
from the gastrointestinal tract after oral exposure.  When radioactive sodium chromate (chromium(VI)) 
was given orally to rats, the amount of chromium in the feces was greater than that found when sodium
chromate was injected directly into the jejunum.  Since chromium(III) is absorbed less readily than 
chromium(VI) by the gastrointestinal tract, these results are consistent with evidence that the gastric 
environment has a capacity to reduce chromium(VI) to chromium(III).  Ex vivo studies in rats and mice 
demonstrate that the reduction of chromium(VI) to chromium(III) in the stomach follows second-order
kinetics and that the reduction rate is concentration-dependent and capacity-limited (Proctor et al. 2012).
The investigators estimated second-rate constants of 0.3 L/mg·hour for rats and 0.2 L/mg·hour for mice
and total reducing capacities of 15.7 and 16.6 mg chromium(VI) equivalents/L of stomach contents, 
respectively.
The administration of radioactive chromium(III) or chromium(VI) compounds directly into the jejunum
decreased the amount of chromium recovery in the feces indicating that the jejunum is the absorption site 
for chromium (Donaldson and Barreras 1966).  Absorption of either valence state was ≤1.4% of the
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administered oral dose in rats (Sayato et al. 1980) and hamsters (Henderson et al. 1979).  Based on 
distribution (see Section 3.3.2.2) and excretion (see Section 3.3.4.2) studies in rats administered 
chromium by gavage for 2–14 days from various sources, that is, from sodium chromate (chromium(VI)), 
from calcium chromate (chromium(VI)), or from soil contaminated with chromium (30% chromium(VI)
and 70% chromium(III)), the low gastrointestinal absorption of chromium from any source was
confirmed.  Chromium appeared to be better absorbed from the soil than from chromate salts, but <50%
of the administered chromium could be accounted for in these studies, partly because not all tissues were 
examined for chromium content and excretion was not followed to completion (Witmer et al. 1989, 
1991).  Adult and immature rats given chromium(III) chloride absorbed 0.1 and 1.2% of the oral dose, 
respectively (Sullivan et al. 1984).  This suggests that immature rats may be more susceptible to potential
toxic effects of chromium(III) compounds. 
Treatment of rats by gavage with a nonencapsulated lead chromate pigment or with a silica-encapsulated
lead chromate pigment resulted in no measurable blood levels of chromium (detection limit=10 μg/L)
after 2 or 4 weeks of treatment or after a 2-week recovery period.  However, kidney levels of chromium
were significantly higher in the rats that received the nonencapsulated pigment than in the rats that
received the encapsulated pigment, indicating that silica encapsulation reduces the gastrointestinal
bioavailability of chromium from lead chromate pigments (Clapp et al. 1991).
The issue of whether or not chromium(VI) absorption occurs only when or principally when the reducing
capacity of the gastrointestinal tract is exhausted is a factor to consider in evaluating and interpreting oral
dosing bioassays in animals and human epidemiology studies of health outcomes related to ingestion 
exposures to chromium.  Potentially, tumor responses could be enhanced if the reducing capacities of
saliva and stomach fluid were exhausted. This is more likely to occur at the relatively high doses of
chromium(VI) administered in animal bioassays than at doses experienced by humans from
environmental exposures.  However, results of experimental studies of chromium absorption in humans
have not found evidence for an effect of limited reducing capacity on absorption of chromium.  The range
of doses of chromium administered to humans in these different studies was considerable and
demonstrated oral bioavailability at all doses.  Donaldson and Barreras (1996) administered 20 ng of
radiolabeled chromium(VI), Kerger et al. (1996a) administered 5 mg of chromium(VI), Finley et al. 
(1996b) administered 0.005 mg/kg/day of chromium(VI) for 3 days, and Finley et al. (1997) administered 
0.1, 0.5, 1.0, 5.0 or 10 mg/day of chromium(VI) for 4 days.  In the Finley et al. (1997) study, the percent
of the administered dose of chromium(VI) recovered in the urine did not increase with dose. The results 
of these studies do not indicate that oral absorption of administered chromium(VI) only begins to occur
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when the reducing capacity of the stomach is exhausted, and are consistent with estimates of
gastrointestinal reducing capacity (De Flora 2000; Proctor et al. 2002).
3.4.1.3  Dermal Exposure 
Both chromium(III) and chromium(VI) can penetrate human skin to some extent, especially if the skin is
damaged.  Systemic toxicity has been observed in humans following dermal exposure to chromium
compounds, indicating significant cutaneous absorption (see Section 3.2.3).  Fourteen days after a salve 
containing potassium chromate was applied to the skin of an individual to treat scabies, appreciable 
amounts of chromium were found in the blood, urine, feces, and stomach contents (Brieger 1920) (see
Section 3.4.2.3).  It should be noted that the preexisting condition of scabies or the necrosis caused by the
potassium chromate (see Section 3.2.3) could have facilitated dermal absorption of potassium chromate.  
Potassium dichromate (chromium(VI)), but not chromium(III) sulfate, penetrated the excised intact
epidermis of humans (Mali et al. 1963).  Dermal absorption by humans of chromium(III) sulfate in 
aqueous solution was negligible, with slightly larger amounts of chromium(III) nitrate in aqueous solution 
absorbed.  The absorption of chromium(III) chloride was similar to potassium dichromate(VI) (Samitz
and Shrager 1966).  Chromium(III) from a concentrated chromium sulfate solution at pH 3 penetrated 
cadaverous human skin at a rate of 5x10-11 cm/sec, compared with a rate for chromium(VI) (source 
unspecified) of 5x10-7 cm/second (Spruit and van Neer 1966).  In contrast, both chromium(VI) from
sodium chromate and chromium(III) from chromium trichloride penetrated excised human mammary skin 
at similar rates, but the rate was generally slightly faster for chromium(VI).  Absolute rates of absorption
in nmol chromium/hour/cm2 increased with increasing concentration of both chromium(VI) and 
chromium(III) (Wahlberg 1970).  The average rate of systemic uptake of chromium in four volunteers
submersed up to the shoulders in a tub of chlorinated water containing a 22 mg chromium(VI)/L solution 
of potassium dichromate for 3 hours was measured to be 1.5x10-4 μg/cm2-hour based on urinary excretion 
of total chromium (Corbett et al. 1997). 
The influence of solvent on the cutaneous penetration of potassium dichromate by humans has been 
studied.  The test solutions of potassium dichromate in petrolatum or in water were applied as occluded
circular patches of filter paper to the skin.  Results with dichromate in water revealed that chromium(VI)
penetrated beyond the dermis and penetration reached steady state with resorption by the lymph and 
blood vessels by 5 hours.  About 10 times more chromium penetrated when potassium dichromate was 
applied in petrolatum than when applied in water.  About 5 times more chromium penetrated when 
potassium dichromate was applied than when a chromium trichloride glycine complex was applied (Liden 
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and Lundberg 1979).  The rates of absorption of solutions of sodium chromate from the occluded forearm
skin of volunteers increased with increasing concentration. The rates were 1.1 μg chromium(VI)/ 
cm2/hour for a 0.01 M solution, 6.4 μg chromium(VI)/cm2/hour for a 0.1 M solution, and 10 μg 
chromium(VI)/cm2/hour for a 0.2 M solution (Baranowska-Dutkiewicz 1981).
Chromium and its compounds are also absorbed dermally by animals.  The dermal absorption of sodium
chromate (chromium(VI)) by guinea pigs was somewhat higher than that of chromium(III) trichloride, but
the difference was not significant.  At higher concentrations (0.261–0.398 M), absorption of sodium
chromate was statistically higher than that of chromium trichloride. The peak rates of absorption were
690–725 and 315–330 nmol/hour/cm2 for sodium chromate at 0.261–0.398 M and chromium trichloride
at 0.239–0.261 M, respectively.  Percutaneous absorption of sodium chromate was higher at pH≥6.5 
compared with pH≤5.6 (Wahlberg and Skog 1965).
3.4.2 Distribution 
3.4.2.1  Inhalation Exposure 
Examination of tissues from Japanese chrome platers and chromate refining workers at autopsy revealed
higher chromium levels in the hilar lymph node, lung, spleen, liver, kidney, and heart, compared to 
normal healthy males (Teraoka 1981).  Analysis of the chromium concentrations in organs and tissues at
autopsy of a man who died of lung cancer 10 years after his retirement from working in a chromate 
producing plant for 30 years revealed measurable levels in the brain, pharyngeal wall, lung, liver, aorta,
kidney, abdominal rectal muscle, suprarenal gland, sternal bone marrow, and abdominal skin.  The levels
were significantly higher than in five controls with no occupational exposure to chromium.  The man had 
been exposed mainly to chromium(VI), with lesser exposure to chromium(III) as the chromite ore (Hyodo 
et al. 1980).  The levels of chromium were higher in the lungs, but not in the liver or kidneys, of autopsy
specimens from 21 smeltery and refinery workers in North Sweden compared with that for a control
group of 8 individuals.  The amount of enrichment in the lungs decreased as the number of elapsed years 
between retirement and death increased (Brune et al. 1980).  Tissues from three individuals having lung
cancer who were industrially exposed to chromium were examined by Mancuso (1997b).  One was
employed for 15 years as a welder, a second worked for 10.2 years, and a third for 31.8 years in ore 
milling and preparations and boiler operations.  The three cumulative chromium exposures for the three
workers were 3.45, 4.59, and 11.38 mg/m3 years, respectively. Tissues from the first worker were 
analyzed 3.5 years after last exposure, the second worker 18 years after, and the third worker 0.6 years 
after last exposure.  All tissues from the three workers had elevated levels of chromium with the possible 
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exception of neural tissues.  Levels were orders of magnitude higher in lungs than other tissues. The 
highest lung level reported was 456 mg/10 g tissue in the first worker, 178 in the second worker, and 
1,920 for the third worker.  There were significant chromium levels in the tissue of the second worker
even though he had not been exposed to chromium for 18 years.  Chromium concentrations in lung
tissues from autopsy samples were 5 times higher in subjects who originated from the Ruhr and
Dortmund regions of Germany, where emissions of chromium are high, than in subjects from Munster
and vicinity. The lung concentrations of chromium increased with increasing age.  Men had twice as high
concentrations of chromium in the lungs than did women, which may reflect the greater potential for
occupational exposure by men, the higher vital capacity of men, and possibly a greater history of smoking
(Kollmeier et al. 1990).
Chromium may be transferred to fetuses through the placenta and to infants via breast milk.  Analysis of
chromium levels in women employees of a dichromate manufacturing facility in Russia during and after
pregnancy revealed that the exposed women had significantly higher levels of chromium in blood and 
urine during pregnancy, in umbilical cord blood, placentae, and breast milk at child birth, and in fetuses
aborted at 12 weeks than did nonexposed controls (Shmitova 1980).  The reliability of this study is
suspect because the levels of chromium reported in the blood and urine of the control women were much 
higher than usual background levels of chromium in these biological fluids (see Section 6.5), perhaps due
to problems with analytical methods.  Measurement of the chromium content in 255 samples from
45 lactating American women revealed that most samples contained <0.4 μg/L, and the mean value was
0.3 μg/L (Casey and Hambidge 1984).  While these probably represent background levels in women 
whose main exposure to chromium is via the diet, the findings indicate that chromium may be transferred
to infants via breast milk.
The distribution of radioactivity in rats given 51chromium as sodium dichromate intratracheally was 
followed for 40 days by autoradiography and scintillation counting.  Three days after the administration
of 0.01 mg chromium(VI)/m3 as radioactive sodium dichromate, the tissue distribution based on the
relative concentrations in the tissue was lung > kidney > gastrointestinal tract > erythrocytes > liver >
serum > testis > skin. Twenty-five days after dosing, the tissue distribution was lung > kidney >
erythrocytes > testis > liver > serum > skin > gastrointestinal tract. Kidney, erythrocytes, and testis 
maintained their chromium levels for a period of 10–15 days before decreasing (Weber 1983). The 
distribution of chromium(VI) compared with chromium(III) was investigated in guinea pigs after
intratracheal instillation of potassium dichromate or chromium trichloride.  At 24 hours after instillation,
11% of the original dose of chromium from potassium dichromate remained in the lungs, 8% in the
   
 








    
   
   
   
      
   
   
     
 
   
 
   
   
     
    
   
 
  
       




     
  
 
    
  
      
  





erythrocytes, 1% in plasma, 3% in the kidney, and 4% in the liver. The muscle, skin, and adrenal glands
contained only a trace.  All tissue concentrations of chromium declined to low or nondetectable levels in 
140 days with the exception of the lungs and spleen.  After chromium trichloride instillation, 69% of the
dose remained in the lungs at 20 minutes, while only 4% was found in the blood and other tissues, with 
the remaining 27% cleared from the lungs and swallowed. The only tissue that contained a significant
amount of chromium 2 days after instillation of chromium trichloride was the spleen.  After 30 and
60 days, 30 and 12%, respectively, of the chromium(III) was retained in the lungs, while only 2.6 and 
1.6%, respectively, of the chromium(VI) dose was retained in the lung (Baetjer et al. 1959a).
3.4.2.2  Oral Exposure
Autopsy studies in the United States indicate that chromium concentrations in the body are highest in 
kidney, liver, lung, aorta, heart, pancreas, and spleen at birth and tend to decrease with age. The levels in
liver and kidney declined after the second decade of life. The aorta, heart, and spleen levels declined
rapidly between the first 45 days of life and 10 years, with low levels persisting throughout life.  The level
in the lung declined early, but increased again from mid life to old age (Schroeder et al. 1962).
The distribution of chromium in human body tissue after acute oral exposure was determined in the case
of a 14-year-old boy who ingested 7.5 mg chromium(VI)/kg as potassium dichromate.  Despite extensive 
treatment by dialysis and the use of the chelating agent British antilewisite, the boy died 8 days after
admission to the hospital.  Upon autopsy, the chromium concentrations were as follows: liver, 
2.94 mg/100 cc (normal, 0.016 mg/100 cc); kidneys, 0.64 and 0.82 mg/100 cc (normal, 0.06 mg/100 cc);
and brain, 0.06 mg/100 cc (normal, 0.002 mg/100 cc) (Kaufman et al. 1970).  Although these data were 
obtained after extensive treatment to rid the body of excess chromium, the levels of chromium remaining
after the treatment clearly demonstrate that these tissues absorbed at least these concentrations after an
acute, lethal ingestion of a chromium(VI) compound.  
Chromium may be transferred to infants via breast milk as indicated by breast milk levels of chromium in
women exposed occupationally (Shmitova 1980) or via normal levels in the diet (Casey and Hambidge
1984).  It has been demonstrated that in healthy women, the levels of chromium measured in breast milk
are independent of serum chromium levels, urinary chromium excretion, or dietary intake of chromium
(Anderson et al. 1993, Mohamedshah et al. 1998), but others (Engelhardt et al. 1990) have disputed this
observation.
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The tissue distribution of chromium was studied in rats administered chromium from a variety of sources.  
In one experiment, sodium chromate in water was administered by gavage for 7 days at 0, 1.2, 2.3, or
5.8 mg chromium(VI)/kg/day.  Very little chromium (generally <0.5 μg/organ) was found in the organs
analyzed (liver, spleen, lung, kidney, and blood) after administration of the two lower doses.  The levels
were generally comparable to those in controls.  After 5.8 mg/kg/day, the largest amount of chromium
(expressed as μg chromium/whole organ) was found in the liver (≈22 μg), followed by the kidney
(≈7.5 μg), lung (≈4.5 μg), blood (≈2 μg), and spleen (≈1 μg).  The total amount of chromium in these
tissues represented only 1.7% of the final dose of 5.8 mg/kg/day, but not all organs were analyzed.  In the
next experiment, rats were exposed by gavage to 7 mg chromium/kg/day for 7 days from various sources:
(1) sodium chromate; (2) calcium chromate; (3) soil containing chromium (30% chromium(VI), 70%
chromium(III)); or (4) a mixture of calcium chromate and the contaminated soil.  The highest levels of
chromium were found in liver, spleen, kidney, lung, blood, brain, and testes after dosing with sodium
chromate, but the relative levels in these tissues after the other treatments followed no consistent pattern.
Rats gavaged for 14 days with 13.9 mg chromium/kg/day from the four different sources had higher
levels of chromium in the tissues after they were dosed with the contaminated soil or the mixture of
calcium chromate and the contaminated soil than with either of the chromate salts alone. Thus, the 
relative organ distribution of chromium depends on the source of chromium (Witmer et al. 1989, 1991).  
Components in soil may affect the oxidation state and the binding of chromium to soil components, and 
pH of the soil may also affect the bioavailability from soil.
The chromium content in major organs (heart, lung, kidney, liver, spleen, testes) of mice receiving
drinking water that provided doses of 4.8, 6.1, or 12.3 mg chromium(III)/kg/day as chromium trichloride
or 4.4, 5.0, or 14.2 mg chromium(VI)/kg/day as potassium dichromate was determined after 1 year of
exposure.  Chromium was detected only in the liver in the chromium(III)-treated mice.  Mice treated with
chromium(VI) compounds had accumulation in all of the above organs, with the highest levels reported in 
the liver and spleen.  Liver accumulation of chromium was 40–90 times higher in the chromium(VI)-
treated group than in the chromium(III)-treated group (Maruyama 1982).  Chromium levels in tissue
(bone, kidney liver, spleen) were 9 times higher in rats given chromium(VI) as potassium chromate in 
drinking water for 1 year than in rats given the same concentration of chromium(III) as chromium
trichloride (MacKenzie et al. 1958).  In rats exposed to potassium chromate in the drinking water for 3 or
6 weeks, a general trend of increasing chromium concentration with time of exposure was apparent in the
liver and kidneys, but only the kidneys showed a difference in the concentration after exposure to 100 and 
200 ppm.  Blood concentrations were almost saturated by 3 weeks with little further accumulation by
6 weeks.  No chromium was detected in the lungs after drinking water exposure (Coogan et al. 1991a).
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After acute oral dosing with radiolabeled chromium trichloride (1 μCi for immature rats, 10 μCi for
adults), adult and neonatal rats accumulated higher levels of chromium in the kidneys than in the liver.  At
7 days after dosing, the liver and kidney contained 0.05 and 0.12% of the dose, respectively, in the
neonates and 0.002 and 0.003% of the dose, respectively, in the adult rats.  The carcass contained 0.95%
of the dose in the neonates and 0.07% of the dose in adult rats.  The lungs contained 0.0088% of the dose
in neonates and 0.0003% of the dose in adult rats.  No chromium(III) was detected in the skeleton or
muscle.  Approximately 35 and 0.2% of the administered dose of chromium(III) at day 7 was retained in 
the gut of neonates and adults, respectively (Sullivan et al. 1984).
The distribution of potassium chromate(VI) was compared in male Fisher rats and C57BL/6J mice 
exposed either by drinking water (8 mg chromium(VI)/kg/day for 4 and 8 weeks) or by intraperitoneal
injection (0.3 and 0.8 mg chromium(VI)/kg/day for 4 or 14 days) (Kargacin et al. 1993).  The
concentrations of chromium (μg/g wet tissue) after drinking water exposures for 8 weeks in mice were:
liver 13.83, kidney 4.72, spleen 10.09, femur 12.55, lung 1.08, heart 1.02, muscle 0.60, and blood 0.42.  
These concentrations were not markedly different than for 4-week exposures.  For rats, the concentrations 
were:  liver 3.59, kidney 9.49, spleen 4.38, femur 1.78, lung 0.67, heart 1.05, muscle 0.17, and blood 
0.58. These results demonstrate that considerable species differences exist between mice and rats and
need to be factored into any toxicological extrapolations across species even if the routes of
administration are the same.  In the drinking water experiments, blood levels in rats and mice were 
comparable, but in intraperitoneal injection experiments, rats’ levels were about 8-fold higher than mice
after 4 days of exposure.  This difference appeared to be due to increased sequestering by rat red blood 
cells, since accumulation in white blood cells was lower in rats than mice.  The higher incidence of red 
cell binding was also associated with greater binding of chromium to rat hemoglobin.
The feeding of five male Wistar rats at 0.49 mg chromium(III)/kg/day as chromium(III) chloride for
10 weeks resulted in increased chromium levels in liver, kidney, spleen, hair, heart, and red blood cells
(Aguilar et al. 1997).  Increases were highest in kidney (0.33 μg/g wet tissue in controls versus 0.83 μg/g 
in treated animals) and erythrocytes (1.44 μg/g wet tissue in controls versus 3.16 μg/g in treated animals).
The higher tissue levels of chromium after administration of chromium(VI) than after administration of
chromium(III) (MacKenzie et al. 1958; Maruyama 1982; Witmer et al. 1989, 1991) reflect the greater
tendency of chromium(VI) to traverse plasma membranes and bind to intracellular proteins in the various 
tissues, which may explain the greater degree of toxicity associated with chromium(VI).  In an 
experiment to determine the distribution of chromium in red and white blood cells, rats were exposed
   
 








    
 
     
   
  
  




      
 
     
 
   
 
  
     
     
     
  
 
    
     
  
   
    
 
   
 
  
   
CHROMIUM 253
3. HEALTH EFFECTS
orally to 0.0031 mg/kg of 51chromium(VI) as sodium chromate.  The 51chromium content of the
fractionated blood cells was determined either 24 hours or 7 days after exposure.  After 24 hours, the
white blood cells contained much more 51chromium (≈250 pg chromium/billion cells) than did the red 
blood cells (≈30 pg chromium/billion cells).  After 7 days, the 51chromium content of the white blood 
cells was reduced only 2.5-fold, while that of the red blood cells was reduced 10-fold.  Thus, white blood 
cells preferentially accumulated chromium(VI) and retained the chromium longer than did the red blood
cells.  As discussed in Section 3.4.2.4, a small amount of chromium(III) entered red blood cells of rats
after intravenous injection of 51chromium trichloride, but no 51chromium was detectable in white blood 
cells (Coogan et al. 1991b).
Twelve pregnant female albino rats (Druckrey strain) and 13 Swiss albino mice were exposed to 500 ppm
potassium dichromate(VI) in their drinking water during pregnancy up to 1 day before delivery (Saxena et
al. 1990a).  The chromium(VI) daily intake was calculated to be 11.9 mg chromium(VI)/day for the rats
and 3.6 mg chromium(VI)/day for mice which were considered to be maximal nontoxic doses for both 
species.  In rats, concentrations of chromium were 0.067, 0.219, and 0.142 μg/g fresh weight in maternal
blood, placenta, and fetuses, respectively, and 0.064, 0.304, and 0.366 μg/g fresh weight in mice, 
respectively.  In treated rats, chromium levels were 3.2-fold higher in maternal blood, 3-fold higher in 
placenta, and 3.1-fold higher in fetal tissue when compared to control values.  In treated mice, chromium
levels were 2.5-fold higher in maternal blood, 3.2-fold higher in placenta, and 9.6-fold higher in fetuses
when compared to control values.  In treated mice, there was a significant elevation in chromium levels in
placental and fetal tissues over maternal blood levels, and a significant increase in chromium levels in
fetal tissue over placental concentrations when compared to controls. These differences were not
observed in rats, indicating that the distribution patterns in mice and rats are different.
A study of transplacental transfer of chromium(III) in different forms indicated that placental transport
varies with the chemical form. Male and female rats were fed either a commercial diet that contained
500 ppb chromium or a 30% Torula yeast diet that contained <100 ppb chromium.  They were also given 
drinking water with or without 2 ppm chromium(III) added as chromium acetate monohydrate.  The rats
were mated and immediately after delivery, the neonates were analyzed for chromium content. The 
neonates whose dams were fed the commercial diet contained almost twice as much chromium as those 
whose dams were fed the chromium-deficient yeast diet.  Addition of chromium(III) acetate to the 
drinking water of the yeast-fed rats (2 ppm) did not increase the levels of chromium in the neonates.  
Administration of chromium(III) trichloride intravenously or by gavage before mating, during mating, or
during gestation resulted in no or only a small amount of chromium in the neonates.  Administration of
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chromium(III) in the form of GTF from Brewer's yeast by gavage during gestation resulted in chromium
levels in the litters that were 20–50% of the dams' levels. The results indicate that fetal chromium is 
derived from specific chromium complexes in the diet (e.g., GTF) (Mertz et al. 1969).
3.4.2.3  Dermal Exposure 
The findings of toxic effects in the heart, stomach, blood, muscles, and kidneys of humans who were
dermally exposed to chromium compounds is suggestive of distribution to these organs (see
Section 3.2.3.2).  Fourteen days after a salve containing potassium chromate(VI) was applied to the skin
of an individual to treat scabies, appreciable amounts of chromium were found in the blood (2– 
5 mg/100 mL), urine (8 mg/L), feces (0.61 mg/100 g), and stomach contents (0.63 mg/100 mL) (Brieger 
1920). The preexisting condition of scabies or the necrosis caused by the potassium chromate could have 
facilitated its absorption.  A transient increase in the levels of total chromium in erythrocytes and plasma 
was observed in subjects immersed in a tank of chlorinated water containing potassium dichromate(VI)
(Corbett et al. 1997).
Chromium compounds are absorbed after dermal administration by guinea pigs.  Measurement of
51chromium in the organs and body fluids revealed distribution, due to dermal absorption of
chromium(III) and chromium(VI) compounds, to the blood, spleen, bone marrow, lymph glands, urine, 
and kidneys.  Absorption was greater for chromium(VI) than for chromium(III) (see Section 3.4.1.3)
(Wahlberg and Skog 1965).
3.4.2.4  Other Routes of Exposure 
The distribution of chromium(III) in humans was analyzed using a whole-body scintillation scanner, 
whole-body counter, and plasma counting.  Six individuals given an intravenous injection of
51chromium(III) as chromium trichloride had >50% of the blood plasma chromium(III) distributed to 
various body organs within hours of administration.  The liver and spleen contained the highest levels.
After 3 months, the liver contained half of the total body burden of chromium.  The study results
indicated a three-compartment model for whole-body accumulation and clearance of chromium(III).  The
half-lives were 0.5–12 hours for the fast component, 1–14 days for the medium component, and 3– 
12 months for the slow component (Lim et al. 1983).
An in vitro study in human blood showed that chromium(VI) was rapidly cleared from the plasma
(Corbett et al. 1998).  The reduction capacity appears to be concentration dependent and is overwhelmed 
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at spike concentrations between 2,000 and 10,000 μg/L.  High chromium(VI) concentrations (10,000 μg/L
spike concentration) resulted in an accumulation of chromium(VI) in the erythrocytes and a lower
plasma:erythrocyte ratio of total chromium.  This study also found that the plasma reduction capacity was
enhanced by a recent meal.
Both human and rat white blood cells accumulated more 51chromium per cell than red blood cells after in 
vitro exposure of whole blood to 51chromium(VI).  The uptake of chromium by rat blood cells was also 
measured after intravenous exposure to 51chromium(VI) as sodium chromate.  After intravenous
exposure, the white blood cells contained significantly more 51chromium (≈30 pg chromium/billion cells)
than the red blood cells (≈4 pg chromium/billion cells), and the amount of 51chromium in the cells was the 
same after 24 hours as it was after 1 hour.  The amount of 51chromium in the white blood cells, but not in 
the red blood cells, decreased by approximately 1.7-fold after 7 days. When rats were injected
intravenously with 20 ng of radiolabeled sodium chromate (chromium(VI)) or radiolabeled chromium
trichloride (chromium(III)), the amount of chromium was ≈2 pg/billion red blood cells but not detectable
in white blood cells after injection of chromium(III) chloride.  The amount of chromium was
≈5 pg/billion red blood cells and ≈60 pg/billion white blood cells after injection of sodium chromate
(Coogan et al. 1991b).
The distribution pattern in rats treated with sodium chromite (chromium(III)) by intravenous injection 
revealed that most of the chromium was concentrated in the reticuloendothelial system, which, together
with the liver, accumulated 90% of the dose.  The accumulation in the reticuloendothelial system was 
thought to result from colloid formation by chromite at physiological pH.  Organs with detectable
chromium levels 42 days postinjection were:  spleen > liver > bone marrow > tibia > epiphysis > lung >
kidney.  Chromium trichloride given to rats by intravenous injection also concentrated in the liver, spleen, 
and bone marrow (Visek et al. 1953).  In rats administered chromium(III) nitrate intraperitoneally for
30 or 60 days, the highest levels of chromium were found in the liver, followed by the kidneys, testes, and
brain. The levels increased with increased doses but not linearly.  The levels in the kidneys, but not the 
other organs, increased significantly with duration (Tandon et al. 1979).
Whole-body analysis of mice given a single intraperitoneal injection of 3.25 mg chromium(III)/kg as
chromium trichloride showed that chromium trichloride was released very slowly over 21 days:  87% was 
retained 3 days after treatment, 73% after 7 days treatment, and 45% after 21 days.  In contrast, mice 
given a single intraperitoneal injection of 3.23 chromium(VI)/kg as potassium dichromate retained only
31% of the chromium(VI) dose at 3 days, 16% at 7 days and 7.5% at 21 days.  Mice injected weekly with
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chromium(III) compounds at 17% of the LD50 retained 6 times the amount of chromium as mice injected
with chromium(VI) compounds at 17% of the LD50. The retention of chromium(III) was attributed to its
ability to form coordination complexes with tissue components such as proteins and amino acids (Bryson 
and Goodall 1983).
In rats injected intraperitoneally with 2 mg chromium(VI)/kg/day as potassium chromate 6 days/week for
45 days, the mean levels of chromium (μg chromium/g wet weight) were 25.68 in the liver, 40.61 in the
kidney, 7.56 in the heart, and 4.18 in the brain (Behari and Tandon 1980).
In rats injected subcutaneously with 5.25 mg chromium(VI)/kg as potassium dichromate, most of the
chromium in the tissues analyzed was found in the red blood cells with a peak level (63 μg chromium/g)
achieved 24 hours after dosing.  White blood cells were not analyzed for chromium content.  Whole
plasma contained 2.7–35 μg/mL and the plasma ultrafiltrate contained 0.15–0.79 μg/mL.  Tissue
distribution 48 hours after dosing was as follows: 221.2 μg/g in renal cortex, 110.0 μg/g in liver,
103.0 μg/g in spleen, 86.8 μg/g in lung, 58.9 μg/g in renal medulla, and 8.8 μg/g in bone, compared with
2.28–5.98 μg/g in any tissues in controls.  When rats were given repeated subcutaneous injections of
1.05 mg chromium(VI)/kg/day, every other day for 2, 4, 8, 10, or 12 weeks, most of the chromium was 
again found in the red blood cells.  However, while red blood cell levels rose progressively during
treatment, levels as high as those seen after a single dose were never achieved, even when the total dose 
exceeded the dose in the single injection experiment 10-fold.  The tissue levels of chromium determined 
48 hours after the last dose in the rats injected for 12 weeks were of the same order of magnitude as those 
seen after a single injection.  These results suggest little tendency of soluble chromium(VI) compounds to 
accumulate in tissues with repeated exposure (Mutti et al. 1979).
In an in vitro study, whole blood samples were spiked with water-soluble chromium(VI) or chromium(III)
compounds.  The results showed a greater level of chromium inside erythrocytes after treatment with
chromium(VI) compounds, compared to chromium(III) compounds.  The investigators reported that only
chromium(VI) compounds are taken up by erythrocytes and, presumably after reduction to chromium(III), 
form complexes with intracellular proteins that could not be eliminated (Lewalter et al. 1985).
The distribution of radioactivity was compared in mouse dams and fetuses following the intravenous
injection of the dams with 51Chromium labelled-sodium dichromate(VI) or 51chromium labelled-
chromium(III) trichloride. In the maternal tissues, the highest levels of radioactivity from both treatments 
were achieved in the renal cortex, but the concentration of radioactivity in the tissues of dams given the 
   
 








    
     
    
   
   
     
    
    
   
   
 




    
 
      
  
 
   
    
 
  
     
    




hexavalent form was much higher than that of the dams given the trivalent form.  The patterns of
distribution of radioactivity in other tissues were identical regardless of administered valence state, with
the skeleton, liver, kidneys, and ovaries accumulating the highest levels and the brain and muscle 
accumulating the lowest levels. The serum concentration of radioactivity after treatment with
chromium(III) was 3 times higher than that after treatment with chromium(VI).  Radioactivity after
treatment with both valence forms crossed the placenta, but the radioactivity from the hexavalent form
crossed more readily.  For chromium(VI), ≈12% of the maternal serum concentration of radioactivity was
found in the fetuses when the dams were administered sodium dichromate in mid-gestation (days 12–15).  
When the dams were injected in late gestation (days 16–18), ≈19% of the radioactivity in maternal serum
was found in the fetuses.  For chromium(III), the fetal concentration of radioactivity was only ≈0.4% of
the maternal serum concentration when the dams were injected with radiolabeled chromium trichloride in
mid-gestation and 0.8% of the maternal serum radioactivity concentration when injected in late gestation. 
Radioactivity from both treatments accumulated in fetal skeletons in calcified areas and in the yolk sac 
placenta (Danielsson et al. 1982).  Danielsson et al. (1982) noted that the radioactivity after administration 
of chromium(VI) may represent chromium(III) after reduction in the tissues.  Chromium(III) also crossed 
the placenta of mice injected intraperitoneally with chromium trichloride (Iijima et al. 1983).  While the
results indicate that both chromium(VI) and chromium(III) may pose developmental hazards, they cannot
be used to indicate that exposure of pregnant animals to chromium(III) by inhalation or oral routes would 
result in significant placental transfer because chromium(III) compounds are not well absorbed by these
routes (see Section 3.4.1).
Tissue distribution in rats and mice after 14 days of intraperitoneal injection of 0.8 mg chromium(VI)/day
as potassium chromate were: liver 6.00 μg/g wet weight in rats and 8.89 in mice, kidney 24.14 and 11.77, 
spleen 15.26 and 6.92, femur 6.53 and 6.30, lung 3.99 and 2.89, heart 3.13 and 1.75, muscle 1.10 and 
0.51, and blood 4.52 and 1.56 (Kargacin et al. 1993).  Kidney and blood chromium concentrations were
2- and 4-fold higher, respectively, in rats compared to mice.  Red blood cell concentrations were 3-fold 
higher in rats than mice and hemoglobin binding of chromium was twice as high in rats.  By contrast, 
chromium levels in the blood were similar in rats and mice following oral exposure.  The authors ascribed 
this to faster entry into the blood after intraperitoneal injection and thus a greater likelihood that 
chromium(VI) could be sequestered in rat erythrocytes by reduction.
   
 








     
 
 
   
    
   
  
 
    
    
  
      
  
 
   
   
      
    
   
    
   
   
   
 
    
 
   
  
  
   
   
    




Chromium(III) compounds are essential to normal glucose, protein, and fat metabolism.  In addition, 
chromium(III) is capable of forming complexes with nucleic acids and proteins. Chromium(III) may also 
participate in intracellular reduction and oxidation reactions. Chromium(VI) is unstable inside the body
and is ultimately reduced to chromium(III) in vivo by a variety of reducing agents.  Chromium(V) and 
chromium(IV) are transient intermediates in this process.
Currently, the biological target for the essential effects of chromium(III) is unknown.  Chromodulin, also 
referred to as GTF, has been proposed as one possible candidate (Jacquamet et al. 2003).  The function of
chromodulin, an oligopeptide complex containing four chromic ions, has not been established; however, a
possible mechanism is that chromodulin facilitates the interaction of insulin with its cellular receptor
sites, although this has not been proven (Anderson 1998a, 2003; IOM 2001).
In vivo and in vitro experiments in rats indicated that, in the lungs, chromium(VI) can be reduced to 
chromium(III) by ascorbate.  The reduction of chromium(VI) by ascorbate results in a shorter residence 
time of chromium in the lungs and constitutes the first defense against oxidizing reagents in the lungs.  
When ascorbate is depleted from the lungs, chromium(VI) can also be reduced by glutathione. The level
of ascorbic acid in the adult human lung has been estimated as approximately 7 mg/100 g wet tissue
(Hornig 1975).  The reduction of chromium(VI) by glutathione is slower and results in greater residence
time of chromium in the lungs, compared to reduction by ascorbate (Suzuki and Fukuda 1990).  Other
studies reported the reduction of chromium(VI) to chromium(III) by epithelial lining fluid (ELF) obtained 
from the lungs of 15 individuals by bronchial lavage.  The average reduction accounted for 0.6 μg 
chromium(VI)/mg of ELF protein.  In addition, cell extracts made from pulmonary alveolar macrophages
derived from five healthy male volunteers were able to reduce an average of 4.8 μg chromium(VI)/106 
cells or 14.4 μg chromium(VI)/mg protein (Petrilli et al. 1986b).  Metabolism of the chromium(VI) to 
chromium(III) by these cell fractions significantly reduced the mutagenic potency of the chromium when 
tested in the Ames reversion assay.  Postmitochondrial (S12) preparations of human lung cells (peripheral
lung parenchyma and bronchial preparations) were also able to reduce chromium(VI) to chromium(III)
(De Flora et al. 1984).  Moreover, large individual differences were observed (De Flora et al. 1984, 
1987b), and extracts from pulmonary alveolar macrophages of smokers reduced significantly more 
chromium(VI) to chromium(III) than extracts from cells of nonsmokers.  Because chromium(III) does not
readily enter cells, these data suggest that reduction of chromium(VI) by the ELF may constitute the first
line of defense against toxicity of inhaled chromium compounds.  Furthermore, uptake and reduction of
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chromium compounds by the pulmonary alveolar macrophages may constitute a second line of defense
against pulmonary toxicity of chromium(VI) compounds.  Microsomal reduction of chromium(VI) occurs
in the lungs mainly as it does in the liver, as discussed below.
The first defense against chromium(VI) after oral exposure is the reduction of chromium(VI) to
chromium(III) in the gastric environment where gastric juice (De Flora et al. 1987a) and ascorbate 
(Samitz 1970) play important roles.  Studies using low-frequency electron paramagnetic resonance (EPR)
spectrometry have shown that chromium(VI) is reduced to chromium(V) in vivo (Liu et al. 1994, 1995, 
1997a, 1997b; Ueno et al. 1995b).  In vitro, low concentrations of ascorbate favor the formation of
chromium(V), whereas higher concentrations of ascorbate favor the formation of the reduced oxidation 
state, chromium(III) (Liu et al. 1995).  EPR spectrometric monitoring also showed that chromium(VI)
was rapidly reduced to chromium(V) on the skin of rats, with a 3-fold greater response when the stratum
corneum was removed (Liu et al. 1997a).  Thus, dermal effects from direct skin contact with 
chromium(VI) compounds may be mediated by rapid reduction to chromium(V).  In whole blood and 
plasma, increasing ascorbate levels led to an increased oxidation of chromium(VI) to chromium(III)
(Capellmann and Bolt 1992).
For humans, the overall chromium(VI)-reducing/sequestering capacities were estimated to be 0.7– 
2.1 mg/day for saliva, 8.3–12.5 mg/day for gastric juice, 11–24 mg for intestinal bacteria eliminated daily
with feces, 3,300 mg/hour for liver, 234 mg/hour for males and 187 mg/hour for females for whole blood, 
128 mg/hour for males and 93 mg/hour for females for red blood cells, 0.1–1.8 mg/hour for ELF, 
136 mg/hour for pulmonary alveolar macrophages, and 260 mg/hour for peripheral lung parenchyma.  
Although these ex vivo data provide important information in the conversion of chromium(VI) to reduced 
states, the values may over- or underestimate the in vivo reducing capabilities (De Flora et al. 1997).
Reduction of chromium(VI) in the red blood cell occurs by the action of glutathione.  Since the red blood
cell membrane is permeable to chromium(VI) but not chromium(III), the chromium(III) formed by
reduction of chromium(VI) by glutathione is essentially trapped within the erythrocyte for the life-span of
the cell (Paustenbach et al. 2003), with approximately 1% of chromium eluting from the erythrocyte daily
(ICSH 1980).  Eventually, the diffusion of chromium(VI), the reduction to chromium(III), and 
complexing to nucleic acids and proteins within the cell will cause the concentration equilibrium to 
change so that more chromium(VI) is diffused through the membrane.  Thus, there is a physiological drag
so that increased diffusion results in greater chromium concentrations in the cell (Aaseth et al. 1982). It
appears that the rate of uptake of chromium(VI) by red blood cells may not exceed the rate at which they
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reduce chromium(VI) to chromium(III) (Corbett et al. 1998).  In vitro incubation of red blood cells with 
an excess of sodium chromate(VI) (10 mM) decreased glutathione levels to 10% of the original amount
(Wiegand et al. 1984).  The above concepts are applicable to the uptake and reduction of chromium(VI)
in other cell types.
The effect of glutathione-depleting agents on the amounts of cellular chromium(III) and chromium(V)
was determined in Chinese hamster V-79 cells treated with sodium chromate (Sugiyama and Tsuzuki
1994).  Buthionine sulfoximine at 25 μM reduced glutatione levels to about 1% of control values, and 
increased chromium(V) levels by about 67%. The total chromium uptake was decreased by about 20%
and chromium(III) levels were decreased by 20%.  Diethylmaleate (1 mM) decreased glutathione levels to
<1%, decreased chromium(V) levels by 27% and chromium(III) levels by 31%. However, the cellular
uptake of total chromium was decreased to nearly 46%.  The authors explained that the reason that the
diethylmaleate inhibited the reduction of chromium(VI) to both chromium(III) and chromium(V) was not
due to the decreased uptake, but involved the inhibition of the chromate-reducing enzymes in the cell.
In addition to the reduction of chromium(VI) by ascorbate or glutathione, in vitro studies have 
demonstrated reduction of chromium(VI) by microsomal enzymes.  Hepatic microsomal proteins from
male Sprague-Dawley rats pretreated with chromium(VI) reduced chromium(VI) to chromium(III).  The
rate of reduction varied both with the concentration of microsomal protein and the concentration of
nicotinamide adenine dinucleotide phosphate (NADPH).  In the absence of NADPH, microsomes did not
reduce significant amounts of chromium(VI) over the 24-hour observation period.  Therefore, the
reduction of chromium(VI) in rat hepatic microsomes is NADPH-dependent (Gruber and Jennette 1978).  
Another study followed the kinetics of chromium(VI) reduction in hepatic microsomes from rats (Garcia 
and Jennette 1981).  Induction of cytochrome P448 enzymes had no effect on the kinetics of the reaction,
while induction of cytochrome P450 and NADPH-cytochrome P450 reductase resulted in a decrease in
the apparent chromate-enzyme dissociation constant, and an increase in the apparent second-order rate
constant, and no change in the apparent turnover number.  Inhibition of NADPH-cytochrome P450 
reductase and NADH-cytochrome b5 reductase inhibited the rate of microsomal reduction of
chromium(VI), as did the addition of specific inhibitors of cytochrome P450.  The results demonstrate the
involvement of cytochrome P450, NADPH-dependent-cytochrome P450 reductase, and to a lesser extent
cytochrome b5 and NADH-dependent-cytochrome b5 reductase, in the reduction of chromate by rat
hepatic microsomes.  The conversion of chromium(VI) to chromium(III) in rats can occur by electron 
transfer through cytochrome P450 and cytochrome b5. Both oxygen and carbon monoxide were found to 
inhibit the in vitro cytochrome P450 and cytochrome b5-dependent reduction of chromium(VI) (Mikalsen 
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et al. 1989).  The assertion that cytochrome P450 is involved in the reduction of chromium(VI) to 
chromium(III) has been further strengthened by Petrilli et al. (1985), who demonstrated that inducers of
cytochrome P450 can increase the conversion of chromium(VI) to chromium(III) in S-9 mixtures
prepared from the liver and lungs of exposed rats.  Furthermore, it was observed that chromium(VI) can 
induce pulmonary cytochrome P450 and thus its own reduction in the lungs (Petrilli et al. 1985).  
Chromium(VI) apparently can alter the P450 activity in isolated rat microsomes. Witmer et al. (1994)
demonstrated that hepatic microsomes from male rats treated with chromium(VI) resulted in a significant 
decrease in hydroxylation of testosterone at the 6β, 16α, and 2α positions, indicating a decrease in the
activity of P4503A1 and 3A2.  In lung microsomes, an increased hydroxylation was observed at the 16α
and 16β positions, indicating an increase in P450IIB1 activity.  However, hepatic microsomes from
treated females showed a 4-to 5-fold increase in hydroxylation activity of testosterone at the 6β position, 
which demonstrated that the metabolic effects of chromium differ between males and females.
Two studies have examined possible species differences in the ability of microsomes to reduce 
chromium(VI) (Myers and Myers 1998; Pratt and Myers 1993).  Chromium(VI) reduction was enzymatic
and NADPH-dependent, and the rates were proportional to the amount of microsome added.  In humans, 
the Km for chromium(VI) was 1–3 orders of magnitude lower than Km values in rats, although the Vmax 
was similar. This suggests that the human liver has a much greater capacity to reduce chromium(VI) than
the rat liver.  Also contrary to the rodent data, oxygen and cytochrome P450 inhibitors (carbon monoxide, 
piperonyl butoxide, metyrapone, and aminopyrine) did not inhibit chromium(VI) reduction. These
differences indicate that, in humans, cytochrome P450 does not play a significant role in the reduction 
process, but that other microsomal flavoproteins are responsible for reducing chromium(VI).  Inhibition 
of flavoproteins by TlCl3 decreased chromium(VI) reduction by 96–100%, while inhibition of
cytochrome c reductase (P450 reductase) by bromo-4'-nitroacetophenone resulted in an 80–85%
inhibition of chromium(VI) reduction.  Combined, these observations implicate P450 reductase, working
independently of cytochrome P450, as a major contributor in the reduction of chromium(VI) in human 
microsomes.  These findings suggest that metabolism of chromium(VI) in rodent systems may not readily
be extrapolated to humans. 
Microsomal reduction of chromium(VI) can also result in the formation of chromium(V), which involves
a one-electron transfer from the microsomal electron-transport cytochrome P450 system in rats. The 
chromium(V) complexes are characterized as labile and reactive.  These chromium(V) intermediates 
persist for 1 hour in vitro, making them likely to interact with deoxyribonucleic acid (DNA), which may
eventually lead to cancer (Jennette 1982).  Because chromium(V) complexes are labile and reactive,
   
 








    
  
     
  
      
   
  
 
    
     
   
 
    
 
    
 
 
    
   
  
  




    
     
   




detection of chromium(V) after in vivo exposure to chromium(VI) was difficult in the past.  More
recently, Liu et al. (1994) have demonstrated that chromium(V) is formed in vivo by using low-frequency
electron paramagnetic resonance (EPR) spectroscopy on whole mice.  In mice injected with sodium
dichromate(VI) intravenously into the tail vein, maximum levels of chromium(V) were detected within 
10 minutes and declined slowly with a life-time of about 37 minutes. The time to reach peak in vivo
levels of chromium(V) decreased, in a linear manner as the administered dose levels of sodium
dichromate decreased. The relative tissue distributions of chromium(V) indicated that most was found in 
the liver and much lesser amounts in blood.  None was detected in kidney, spleen, heart, or lung.  When 
the mice were pretreated with metal ion chelators, the intensity of the EPR signal decreased
demonstrating that the formation of chromium(V) was inhibited.  Reactions of chromium(VI) with 
glutathione produced two chromium(V) complexes and a glutathione thiyl radical.  Reactions of
chromium(VI) with DNA in the presence of glutathione produced chromium-DNA adducts.  The level of
chromium-DNA adduct formation correlated with chromium(V) formation. The reaction of
chromium(VI) with hydrogen peroxide produced hydroxyl radicals.  Reactions of chromium(VI) with 
DNA in the presence of high concentrations of hydrogen peroxide (millimolar compared to 10-7–10-9 M 
inside cells) produced significant DNA strand breakage and the 8-hydroxy guanosine adduct, which 
correlated with hydroxyl radical production (Aiyar et al. 1989, 1991).  Very little chromium(V) was 
generated by this pathway.  It was postulated that the reaction of chromium(VI) with hydrogen peroxide
produces tetraperoxochromium(V) species that act as a catalyst in a Fenton-type reaction producing
hydroxyl radicals in which chromium(V) is continuously being recycled back to chromium(VI).  The
regeneration of chromium(VI) through interactions with chromium(V) and hydrogen peroxide is
consistent with the findings of Molyneux and Davies (1995) (see Section 3.5.2).  As discussed above, 
chromium(VI) is ultimately reduced to chromium(III) within the cell.  Chromium(III) can form stable
complexes with DNA and protein (De Flora and Wetterhahn 1989), which is discussed further in 
Section 3.5.2.
The mechanism for clearance of chromium(VI) once reduced inside the liver cell may involve a
chromium(III)-glutathione complex.  The glutathione complex would be soluble through the cell
membrane and capable of entering the bile (Norseth et al. 1982).  The complexing of chromium(III) to 
other ligands has been shown to make them more permeable to the cell membrane (Warren et al. 1981).
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3.4.4 Elimination and Excretion 
3.4.4.1  Inhalation Exposure 
Normal urinary levels of chromium in humans have been reported to range from 0.22 to 1.8 μg/L
(0.00024–0.0018 mg/L) with a median level of 0.4 μg/L (0.0004 mg/L) (IOM 2001; Iyengar and Woittiez
1988).  Humans exposed to 0.05–1.7 mg chromium(III)/m3 as chromium sulfate and 0.01–0.1 mg 
chromium(VI)/m3 as potassium dichromate (8-hour TWA) had urinary excretion levels of 0.0247– 
0.037 mg chromium(III)/L.  Workers exposed mainly to chromium(VI) compounds had higher urinary
chromium levels than workers exposed primarily to chromium(III) compounds.  An analysis of the urine
did not detect the hexavalent form of chromium, indicating that chromium(VI) was rapidly reduced 
before excretion (Cavalleri and Minoia 1985; Minoia and Cavalleri 1988).  Chromium(III) compounds
were excreted rapidly in the urine of workers, following inhalation exposure to chromium(III) as
chromium lignosulfonate.  Workers exposed to 0.005–0.23 mg chromium(III)/m3 had urine
concentrations of 0.011–0.017 mg chromium(III)/L.  The half-time for urinary excretion of chromium
was short, 4–10 hours, based on an open, one-compartment kinetic model (Kiilunen et al. 1983).  Tannery
workers had higher urinary chromium(III) concentrations in postshift urine samples taken Friday
afternoon and in preshift urine samples taken Monday, compared to controls.  These workers also had hair
concentrations of chromium that correlated with urinary levels.  Analysis of workroom air revealed no 
detectable chromium(VI) and 0.0017 mg chromium(III)/m3 (time-weighted average) (Randall and Gibson 
1987).  Elimination of chromium(III) from hair, serum, and urine has been studied in a group of 5 men 
who had ceased working in a leather tannery 9 months earlier (Simpson and Gibson 1992).  Compared to 
levels recorded during employment, the mean level of chromium in hair was reduced from 28.5 to 
2.9 μmol/g; serum levels were reduced from 9.4 to 3.8 nmol/L.  These levels are comparable to those in 
the general population.  Urine levels were unchanged (13.8 nmol/L while working and 14.4 nmol/L
9 months later); the authors stated that this was probably caused by consumption of beer (a source of
chromium) the night before sampling.  Data from autopsy studies indicate that chromium can be retained 
in the lung for decades following cessation of occupational exposures (Brune et al. 1980; Hyodo et al.
1980; Mancuso 1997b).
Peak urinary chromium concentrations were observed at 6 hours (the first time point examined) in rats 
exposed intratracheally to 0.44 mg/kg chromium(III) as chromium acetate hydroxide or chromium(VI) as
sodium dichromate (Gao et al. 1993).  Chromium urinary concentrations decreased rapidly, falling from
4,535 μg chromium/g creatinine at 6 hours to 148 μg chromium/g at 72 hours for the chromium acetate
   
 












   
     
 
 





   
   
 
    
    
  









   
     





hydroxide and from 2,947 μg chromium/g creatinine at 6 hours to 339 μg chromium/g at 72 hours for
sodium dichromate.
Elimination of chromium was very slow in rats exposed to 2.1 mg chromium(VI)/m3 as zinc chromate 
6 hours/day for 4 days.  Urinary levels of chromium remained almost constant for 4 days after exposure 
and then decreased, indicating that chromium bound inside the erythrocyte is released slowly (Langård et
al. 1978).
3.4.4.2  Oral Exposure
Given the low absorption of chromium compounds by the oral route, the major pathway of excretion after
oral exposure is through the feces.
An acute, oral dose of radioactive chromium(III) as chromium chloride or chromium(VI) as sodium
chromate was administered to humans after which feces and urine were collected for 24 hours and 6 days, 
respectively, and analyzed for chromium.  The amount of chromium in the 6-day fecal collection was 
99.6 and 89.4% of the dose for chromium(III) and chromium(VI) compounds, respectively.  The amount
of chromium in the 24-hour urine collection was 0.5 and 2.1% of the dose for chromium(III) and 
chromium(VI) compounds, respectively (Donaldson and Barreras 1966).  In subjects drinking 0.001– 
0.1 mg chromium(VI)/kg/day as potassium chromate in water for 3 days, <2–8% of the dose was excreted
in the urine (Finley et al. 1997).  The percentage of the dose excreted appeared to increase with increasing
dose.
Urinary excretion rates have been measured in humans after oral exposure to several chromium
compounds (Finley et al. 1996b).  A group of four male and two female volunteers ingested capsules
containing chromium(III) picolinate at a dose of 200 μg/day for 7 days, to ensure that chromium
deficiency was not a confounding factor.  They then ingested 0.005 mg/kg/day chromium(VI) as
potassium chromate (3 days), and 1.0 mg/kg/day chromium(III) as chromic oxide (3 days), with 3 days 
without dosing between the potassium chromate and chromic oxide doses.  Urinary excretion rates of
chromium were significantly elevated compared to postdosing control levels after seven daily doses of
chromium(III) picolinate (2.4±0.8 versus 0.75±0.53 μg/day).  The excretion rate increased sharply on the
first of 3 days of potassium chromate dosing (11±17 μg/day) and remained steady over the next 2 days 
(13–14 μg/day).  Excretion rates fell to 2.5±0.72 during 2 days without dosing and continued to fall 
during the 3 days of chromic oxide dosing, reaching rates similar to those seen postdosing.  Mean pooled 
   
 











    
  
 
   
 
    
   
   
 
       
 
  




   
   
   
   
    
    
  
   








urinary concentrations during the dosing periods were 2.4 μg chromium/g creatinine from exposure to 
chromium(VI) and 0.4 μg chromium/g creatinine from exposure to chromium(III) as compared to 0.23 μg 
chromium/g creatinine during the postdosing time periods.  The lower urinary excretion of chromium(III)
after exposure to chromic oxide reflects the poorer absorption of inorganic chromium(III) compounds
compared to inorganic chromium(VI) compounds.
The half-life for chromium urinary excretion after administration in drinking water as potassium
dichromate has been estimated in humans (Kerger et al. 1997).  Ingestion of 0.05 mg chromium(VI)/kg
resulted in an extended time course of excretion.  Approximately 76–82% of the 14-day total amount of
chromium in the urine was excreted within the first 4 days (mean peak concentration 209 μg chromium/g
creatinine; range 29–585 μg chromium/g creatinine). The average urinary excretion half-life for four of
the volunteers was 39 hours at this dose.  All subjects had returned to background concentrations (0.5– 
2.0 μg chromium/g creatinine) by 14 days postdosing.  About 87% of the total amount of chromium in the 
urine measured over 8 days was excreted during the first 4 days for one volunteer ingesting 0.03 mg
chromium(VI)/kg (peak 97 μg chromium/g creatinine on day of ingestion).  Urinary chromium
concentrations had returned to an average of 2.5 μg chromium/g creatinine within 7 days postdosing, the
last time point measured. Urinary excretion half-life in this volunteer was 37 hours.  Similar time courses 
of excretion were observed when volunteers took the same doses as daily doses over 3-day periods.  An 
earlier study by this group (Kerger et al. 1996a) examined urinary excretion half-lives following a bolus
dose of 10 ppm (approximately 0.06 mg chromium/kg) chromium(III) chloride, potassium dichromate
reduced with orange juice (presumably, the juice reduced the potassium dichromate to chromium(III)-
organic complexes and chromium(III) ions), or potassium dichromate.  The calculated urinary excretion 
half-lives for the three chromium solutions were 10.3, 15, and 39.3 hours, respectively.  The potassium
dichromate half-life is consistent with the results from the Kerger et al. (1997) study.  If, in these studies, 
all of the absorbed chromium(VI) was rapidly and completely converted to chromium(III), there should 
be no difference in urinary half-life. The difference in excretion half-lives following dosing with 
chromium(III) and chromium(VI) appears to reflect incomplete reduction of absorbed chromium(VI) to 
chromium(III) as well as longer retention of chromium(VI) in tissues.  The prolonged half-life following
dosing with chromium(VI) appears to be a composite of the half-lives the chromium(VI) and
chromium(III) derived from the reduction of chromium(VI) in the blood.  Given that most is converted to 
chromium(III), the half-life for the sequestered chromium is quite long (much longer than 40 hours) and 
reflects the half-life of chromium observed in the red blood cells.  Pretreatment of chromium(VI) with 
orange juice apparently did not convert all chromium(VI) to chromium(III), as indicated by a half-life of 
15 hours.
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The urinary excretion kinetics of chromium have also been examined in eight adults that were
administered chromium(III) at 400 μg/day as chromium(III) picolinate for 3 consecutive days (Gargas et
al. 1994).  The mean time to peak urinary concentration was 7.18±2.11 hours (range 2.9–13.0 hours), the
mean peak concentration being 7.92±4.24 μg chromium/g creatinine (range 3.58–19.13 μg/g creatinine).  
Excretion diminished rapidly after the peak, but did not appear to return to background in most of the
volunteers before the next daily dose.
Pharmacokinetic models were used to predict the retention and excretion of ingested chromium(III)
picolinate (Stearns et al. 1995a).  A single dose of 5.01 mg (assuming 2.8% or 140 μg of the
chromium(III) picolinate is absorbed) resulted in 11 μg (7.9%) retained after 1 year.  The model predicted 
that about 1.4 μg would still be present in body tissues 10 years after dosing, and continuous dosing over
a 1-year period would result in 6.2 mg of chromium(III) picolinate being retained, requiring about
20 years to reduce the retained level to 0.046 mg.  These projected retention estimates may be 2–4-fold 
lower than results obtained from actual clinical findings.  The authors caution that accumulative daily
intake of chromium(III) may result in tissue concentrations that could be genotoxic. 
Daily urinary excretion levels of chromium were nearly identical in men and women (averages of
0.17 and 0.20 μg/L, respectively; 0.18 μg/L combined) who ate normal dietary levels of chromium
(≈60 μg chromium(III)/day).  When the subjects' normal diets were supplemented with 200 μg 
chromium(III)/day as chromium trichloride to provide intakes of ≈260 μg chromium(III)/day, urinary
excretion of chromium rose proportionately to an average of 0.98 μg/L combined.  Thus a 5-fold increase
in oral intake resulted in about a five-fold increase in excretion, indicating absorption was proportional to 
the dose regardless of whether the source was food or supplement (Anderson et al. 1983).  A group of
23 elderly subjects who received an average of 24.5 μg/day (0.00035 mg chromium(III)/kg/day) from
their normal diets excreted 0.4 μg chromium/day in the urine (1.6%) and 23.9 μg chromium/day in the
feces (97.6%), with a net retention of 0.2 μg/day (0.8%).  Based on the 1980 daily requirement for
absorbable chromium of 1 μg/day by the National Academy of Science Food and Nutrition Board, the
retention was considered adequate for their requirements (Bunker et al. 1984).
An estimate of the half-life of elimination from plasma has been reported in humans.  Uptake of
potassium dichromate was determined in a man who was given 0.8 mg of chromium(VI) in drinking
water 5 times each day for 17 days (Paustenbach et al. 1996).  Steady-state concentrations of chromium in 
blood were attained after 7 days and a plasma elimination half-life of 36 hours was estimated.
   
 













   
 
      
   




      
 
 















Measurement of the chromium content in 255 milk samples from 45 lactating American women revealed
that most samples contained <0.4 μg/L with a mean value of 0.3 μg/L (Casey and Hambidge 1984).  
Another study (Anderson et al. 1993) measured chromium levels in the breast milk of 17 women 60 days 
postpartum, and reported mean levels of ~0.2 μg/L.  Lactation, therefore, represents a route of excretion 
of chromium and a potential route of exposure to the nursing infant.  However, the precise relationship 
between maternal chromium levels and levels in breast milk is unclear, if such a relationship exists at all 
(Anderson et al. 1993; Engelhardt et al. 1990; Mohamedshah et al. 1998).
Chromium can be excreted in hair and fingernails. Mean trace levels of chromium detected in the hair of
individuals from the general population of several countries were as follows:  United States, 0.23 ppm;
Canada, 0.35 ppm; Poland, 0.27 ppm; Japan, 0.23 ppm; and India, 1.02 ppm (Takagi et al. 1986).  Mean 
levels of chromium in the fingernails of these populations were:  United States, 0.52 ppm; Canada, 
0.82 ppm; Poland, 0.52 ppm; Japan, 1.4 ppm; and India, 1.3 ppm (Takagi et al. 1988).
Rats given 18 mg chromium(VI)/kg as potassium dichromate by gavage excreted about 25 μg chromium
in the first 24 hours after dosing and ≈10 μg chromium in each of the next 24-hour periods (Banner et al. 
1986).
In rats and hamsters fed chromium compounds, fecal excretion of chromium varied slightly from 97 to 
99% of the administered dose.  Urinary excretion of chromium varied from 0.6 to 1.4% of the dose
administered as either chromium(III) or chromium(VI) compounds (Donaldson and Barreras 1966;
Henderson et al. 1979; Sayato et al. 1980).  The urinary and fecal excretion over 2-day periods in rats
treated for 8 days by gavage with 13.92 mg chromium/kg/day in corn oil was higher when soil containing
70% chromium(III) and 30% chromium(VI) was the source of chromium than when chromium(VI) as
calcium chromate was the source (see Section 3.4.2.2).  Total urinary and fecal excretion of chromium on 
days 1 and 2 of dosing were 1.8 and 19%, respectively, of the dose from soil and <0.5 and 1.8%, 
respectively, of the dose from calcium chromate. Total urinary and fecal excretion of chromium on days 
7 and 8 of dosing were higher than on days 1 and 2.  For contaminated soil, urinary excretion was 1.12%
and fecal excretion was 40.6% of the dose.  For calcium chromate, urinary excretion was 0.21% and fecal
excretion was 12.35% of the dose (Witmer et al. 1991).  Whether the higher excretion of chromium after
dosing with soil than with the chromate salt represents greater bioavailability from soil could not be 
determined because about 50% of the administered dose could not be accounted for from the excretion
and distribution data (see Section 3.4.2.2).  Excretion of chromium(III) in dogs was approximately equal
   
 
















   
  









   
   




    
   
  





to the clearance of creatinine, indicating little tubular absorption or reabsorption of chromium in the
kidneys (Donaldson et al. 1984).
3.4.4.3  Dermal Exposure 
Information regarding the excretion of chromium in humans after dermal exposure to chromium or its
compounds is limited.  Fourteen days after application of a salve containing potassium chromate(VI), 
which resulted in skin necrosis and sloughing at the application site, chromium was found at 8 mg/L in
the urine and 0.61 mg/100 g in the feces of one individual (Brieger 1920).  A slight increase (over
background levels) in urinary chromium levels was observed in four subjects submersed in a tub of
chlorinated water containing 22 mg chromium(VI)/L as potassium dichromate(VI) for 3 hours (Corbett et
al. 1997).  For three of the four subjects, the increase in urinary chromium excretion was <1 μg/day over
the 5-day collection period.
51Chromium was detected in the urine of guinea pigs after radiolabeled sodium chromate(VI) or
chromium(III) trichloride solutions were placed over skin depots that were monitored by scintillation 
counting to determine the dermal absorption (Wahlberg and Skog 1965).
3.4.4.4  Other Routes of Exposure
Elevated levels of chromium in blood, serum, urine, and other tissues and organs have been observed in 
patients with cobalt-chromium knee and hip arthroplasts (Michel et al. 1987; Sunderman et al. 1989).  
Whether corrosion or wear of the implant can release chromium (or other metal components) into the
systemic circulation depends on the nature of the device.  In one study, the mean postoperative blood and 
urine levels of chromium of nine patients with total hip replacements made from a cast cobalt-chromium-
molybdenum alloy were 3.9 and 6.2 μg/L, respectively, compared with preoperative blood and urine
levels of 1.4 and 0.4 μg/L, respectively.  High blood and urinary levels of chromium persisted when
measured at intervals over a year or more after surgery.  These data suggest significant wear or corrosion
of the metal components. No significant difference was found for patients with hip replacements made 
from the alloy and articulated with polyethylene (Coleman et al. 1973).  Similarly, serum and urinary
levels of chromium in patients with implants made from a porous coated cobalt chromium alloy with 
polyethylene components (to prevent metal-to-metal contact) were not significantly different from
patients with implants made without chromium (Sunderman et al. 1989).
   
 








   
   






     
   




    
 




   
   
      











A number of factors have been shown to alter the rate of excretion of chromium in humans.  Intravenous
injection of calcium EDTA resulted in a rapid increase in the urinary excretion of chromium in metal
workers (Sata et al. 1998).  Both acute and chronic exercises have been shown to increase chromium
excretion in the urine, though the increased excretion did not appear to be accompanied with decreased
levels of total native chromium (Rubin et al. 1998).  An increased rate of chromium excretion has been 
reported in women in the first 26 weeks of pregnancy (Morris et al. 1995b).  Chromium supplementation 
did not appear to alter the rate of excretion into breast milk in postpartum women (Mohamedshah et al. 
1998).
The urinary excretion of chromium after a single or during repeated subcutaneous injections of potassium
dichromate was followed in rats.  Following a single dose of 5.35 mg chromium(VI)/kg, chromium was
excreted rapidly in two phases and was essentially complete at 48 hours.  The filtered chromium load rose
considerably during the first few hours after dosing and exceeded the tubular reabsorption rate.  This
increase was followed by a decrease that paralleled the urinary excretion of chromium.  During repeated 
injections with 1.05 mg chromium(VI)/kg/day, every other day for 12 weeks, urinary excretion and
diffusible chromium renal clearance rose at relatively high parallel rates, and reached plateaus at
10 ng/min for urinary excretion and 550 μL/minute for renal clearance.  The filtered load increased 
slightly.  Since high levels of chromium were found in the renal cortex (see Section 3.4.2.4), the tubular
reabsorption appeared to be limited by the accumulation of chromium in the tubular epithelium (Mutti et
al. 1979).
Rats given a subcutaneous injection of potassium dichromate (chromium(VI)) and chromium nitrate
(chromium(III)) excreted 36% of the chromium(VI) dose in urine and 13.9% in the feces within 7 days;
8 and 24.2% of the chromium(III) was excreted in the urine and feces within the same time period, 
respectively (Yamaguchi et al. 1983). Within 4 days after an intravenous dose of 51chromium as
chromium(III) chloride at 3 mg/kg chromium, rats excreted 5.23% of the dose in the feces and 16.3% in 
the urine (Gregus and Klaassen 1986).
In rats treated by intravenous injection with 51chromium-labeled sodium chromate (chromium(VI)) or
chromium(III) trichloride at 0.0003 or 0.345 mg chromium/kg, the bile contained 2–2.5% of the dose
following chromium(VI) exposure; however, after chromium(III) exposure the concentration in the bile
was ≈50 times lower (Manzo et al. 1983).  Similarly, 3.5–8.4% of chromium(VI) compounds was
excreted in the bile as chromium(III), compared to 0.1–0.5% of chromium(III) compounds, after
intravenous injection in rats (Cikrt and Bencko 1979; Norseth et al. 1982).  Administration of
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diethylmaleate, which depletes glutathione, resulted in only chromium(VI) in the bile after injection of
sodium chromate.
Two hours after dosing rats intravenously with potassium dichromate at 0.45–4.5 mg chromium(VI)/kg, 
1.4–2.2% of the chromium was recovered in the bile. Less than 1% of the total measurable chromium in
the bile was identified as chromium(VI) compounds (Cavalleri et al. 1985).
Male Swiss mice exposed to 52 mg chromium(III)/kg as chromium chloride by single intraperitoneal 
injection or subcutaneous injection had plasma clearance half-times of 41.2 and 30.6 hours, respectively.
In each case, blood levels reached control levels by 6–10 days (Sipowicz et al. 1997).
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
   
 













      
 
 
    
    
  
    
    
 
 
     
    
    
 
   
 
 




    
 
     
 
  




toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-5 shows a conceptualized representation of a PBPK model.
PBPK models for chromium are discussed in this section in terms of their use in risk assessment, tissue 
dosimetry, and dose, route, and species extrapolations.  Two PBPK models for chromium have been 
reported that simulated developed by O’Flaherty absorption, distribution, metabolism, elimination, and 
excretion of chromium(III) and chromium(VI) compounds in the rat (O’Flaherty 1993c, 1996) and human 
(O’Flaherty et al. 2001).
3.4.5.1  O’Flaherty Model (1993a, 1996, 2001)
The structure of the O’Flaherty model is depicted in Figure 3-6.  Values for chromium parameters in the 
rat and human model are presented in Table 3-11.  The model includes compartments representing bone, 
kidney, liver, gastrointestinal tract, plasma, poorly-perfused tissues (e.g., muscle, skin), red blood cells, 
respiratory tract, and well-perfused tissues (e.g., brain, heart, lung, viscera).  Chromium(VI) is assumed to 
   
 




















Figure 3-5.  Conceptual Representation of a Physiologically Based  
Pharmacokinetic (PBPK) Model for a
Hypothetical Chemical Substance  













































Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  adapted from Krishnan and Andersen 1994
   
 























































Source:  O’Flaherty et al. 1996
   
 














     
       
        
 
       
 
       
  
       
  
 
       
  
       
      
 
      
      
 
         
        
        
        
  
       
  
         
       
        
         
        
      
  
       
  
         
       




Table 3-11.  Chemical-specific Parameters in the Rat and Human Chromium  
Models  
Rat Human
Parametera Cr(IIII) Cr(VI) Cr(IIII) Cr(VI) Definition
Absorption
KGI 0.01 0.04 0.25 2.5 First-order rate constant for absorption from the 
gastrointestinal tract (Da-1) 
KLU 0.2 2.0 NA NA First-order rate constant for absorption from the 
bioavailable lung pool (pool A) (Da-1) 
KMUCOA 0.8 0.8 NA NA First-order rate constant for mucociliary clearance from
pool A to the gastrointestinal tract (Da-1) 
KMUCOB 0.025 0.025 NA NA First-order rate constant for mucociliary clearance from
the nonbioavailable lung pool (pool B) to the
gastrointestinal tract (Da-1)
KLUAB 1.2 1.2 NA NA First-order rate constant for transfer from pool A to 
pool B (Da-1) 
FRLUNG NA NA 0.3 0.3 Fraction of inhaled chromium absorbed to blood
FRTRGI NA NA 0.7 0.7 Fraction of inhaled chromium transferred to 
gastrointestinal tract.
Distribution 
CR 5.0 15.0 NAb NAb Relative clearance of chromium into mineralizing bone 
(liters of blood plasma cleared per liter of new bone 
formed)
KINRBC 0.0003 1.5 12.0 NA Clearance from plasma to red cell (L/Da)
KDIN 0.007 1.5 3.0 30.0 Clearance from plasma to kidney (L/Da)
LDIN 0.0001 1.5 3.0 30.0 Clearance from plasma to liver (L/Da)
WDIN 0.0001 1.5 3.0 30.0 Clearance from plasma to other well-perfused tissues
(L/Da)
PDIN 0.0001 0.01 3.0 30.0 Clearance from plasma to poorly-perfused tissues
(L/Da)
BDIN 0.0001 0.01 NAb NAb Clearance from plasma to bone (L/Da)
CR NA NA 5.0 15.0 Fraction deposition from blood to forming bone
KOUTRBC 0.0003 10.0 12.0 NA Clearance from red cell to plasma (L/Da)
KDOUT 0.001 10.0 3.0 30.0 Clearance from kidney to plasma (L/Da)
LDOUT 0.0003 10.0 3.0 30.0 Clearance from liver to plasma (L/Da)
WDOUT 0.001 10.0 3.0 30.0 Clearance from other well-perfused tissues to plasma 
(L/Da)
PDOUT 0.003 10.0 3.0 30.0 Clearance from poorly perfused tissues to plasma 
(L/Da)
BDOUT 0.003 10.0 NAb NAb Clearance from bone to plasma (L/Da)
Excretion
KFX 1.5 1.5 14.0 14.0 First-order rate constant for loss of chromium from
intestinal tract contents to the feces (Da-1) 
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Table 3-11.  Chemical-specific Parameters in the Rat and Human Chromium  
Models  
Rat Human
Parametera Cr(IIII) Cr(VI) Cr(IIII) Cr(VI) Definition
QEC 0.065 0.065 NAc NAc Excretion clearance from the plasma (urinary
clearance) (L/kg/Da)
CLEARb NA NA 12.0 12.0 Parameter in expression for clearance from blood 
plasma to urine (L/day)
MAXb NA NA 0.008 0.008 Parameter in expression for clearance from blood 
plasma to urine (mg/day)
KMb NA NA 0.0008 0.0008 Parameter in expression for clearance from blood 
plasma to urine (mg/L)
FB 0.0 0.0 NA NA Fraction of body burden secreted in the bile 
FI 0.0 0.0 NA NA Fraction of body burden excreted via the 
gastrointestinal tract
Reduction 
KREDRC NA 0.7 NA 7.0 First-order rate constant for reduction of Cr(VI) to Cr(III)
in the red cell (Da-1) 
KREDBP NA NA NA 0.2 First-order rate constant for reduction of Cr(VI) to Cr(III)
in blood plasma (Da-1)
KREDKL NA NA NA 500.0 First-order rate constant for reduction of Cr(VI) to Cr(III)
in kidney (Da-1) 
KREDGI NA 10.0 NA 100.0 First-order rate constant for reduction of Cr(VI) to Cr(III)
in gastrointestinal tract contents (Da-1) 
KRED NA 0.5 NA 5.0 First-order rate constant for reduction of Cr(VI) to Cr(III)
in all other tissues and in lung contents (Da-1) 
Lag time for excretion of urine
FRHOLD 0.7 0.7 NA NA Fraction of urinary chromium not excreted immediately;
that is, temporarily held in pool
KHOLD 0.05 0.05 NA NA First-order rate constant for excretion from the retained
urine pool (Da-1) 
FR 0.10 0.10 NA NA Fraction of chromium in retained urine that is
associated with the kidney
aParameter names are those for human model in cases where the reported rat and human parameter names were  
not identical.  
bExchanges between blood plasma and cortical and trabecular bone are simulated as functions of bone formation  
and resorption rates.  
MAX c QE = CLEAR − , where QE is clearance from blood plasma to urine (L/day) and CBP is plasma 
KM + CBP 
concentration of chromium (mg/L).
NA =  not applicable
Sources:  O'Flaherty 1996 (rat parameters); O’Flaherty et al. 2001 (human parameters)
   
 









        
     
   
 
     
  




    
     




   
  
   
   
     




   
     
       
  





be reduced to chromium(III) in all tissues, and in the gastrointestinal and respiratory tract.  Reduction is
represented as a first-order rate, with distinct rates for the red cell and gastrointestinal tract, and a single 
value representing all other tissues.
Absorption of chromium from the gastrointestinal tract is simulated as the sum of competing first-order
processes; transfer to the liver (absorption) and transfer of unabsorbed chromium to feces.  Parameter
values for these two processes result in absorption of approximately 1–2% of an oral dose.
The respiratory tract is represented with two subcompartments to distinguish a bioavailable chromium
(pool A) from a nonbioavailable chromium (pool B).  Inhaled chromium first deposits in pool A from
where it can be transferred to blood (i.e., absorption), transferred to the gastrointestinal tract (i.e., 
mucocilliary clearance), or transferred to pool B.  Chromium in pool B is cleared to the gastrointestinal 
tract. Transfers within and out of the respiratory tract are represented with first-order rate constants.
Transfers of chromium between plasma and soft tissues are represented with clearance terms (i.e., L/day), 
where clearance is given by the first-order rate constant (ke) for transfer and tissue volume (V, 
clearance=ke x V).  Distinct plasma-to-tissue and tissue-to-plasma clearance values are assigned to
chromium(III) and chromium(VI), with faster clearances assumed for chromium(VI), by a factor of
3,000–10,000, compared to chromium(III).  In the rat model, transfers of chromium between plasma and
bone are represented with clearance constants; however, this is expanded in the human model to represent
chromium uptake into bone as a function of bone formation rate, and return of chromium to plasma from
bone as a function of bone resorption rate (see also O’Flaherty 1993c, 1995 for further information on the
bone growth and reabsorption model).
Absorbed chromium is excreted in urine.  Although a biliary secretion pathway was included in the
model, flux through the pathway was subsequently set to zero, based on optimizations of the model
against observations.  This parameterization is equivalent to assuming that either chromium is not
secreted in bile, or if it is secreted into bile, it is essentially completely (and rapidly) absorbed.  Urinary
excretion of chromium is represented as clearance from plasma.  In the rat model, plasma-to-urine
clearance was assigned a constant value.  In the human model, urinary clearance is represented as a 
variable fraction of the glomerular filtration rate, with the fraction increasing with increasing plasma
concentration (e.g., 0.7% of GFR at a concentration of 0.0001 mg/L; 40% of GFR at 0.01 mg/L). 
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Validation of the model. Optimization of parameter values and evaluation of the rat model are 
described in O’Flaherty (1996).  Initial values for the rat model were established based on data reported in
various intravenous, oral, or intratracheal rat studies (Bragt and van Dura 1983; Cavalleri et al. 1985;
Cikrt and Bencko 1979; Edel and Sabbioni 1985; MacKenzie et al. 1959; Mertz et al. 1969; Thompson 
and Hollis 1958; Weber 1983).  Parameter values were optimized against data on kinetics of tissue levels 
and chromium excretion measured in rats that received intratracheal doses of 51Cr(VI) or 51Cr(III) (Bragt
and van Dura 1983; Edel and Sabbioni 1985; Weber 1983).  The optimized rat model was evaluated by
comparing predictions of blood 51Cr kinetics to observations made in rats exposed 6 hours/day for 4 days 
to dusts of zinc [51Cr]chromate (76% respirable, Langård et al. 1978).  Predicted blood concentrations
during exposure and postexposure kinetics agreed with observations.  The model was also evaluated
against data from a drinking water study in which rats were exposed to drinking water concentrations of
K2Cr(VI)O4 ranging from 0.45 to 25 mg/L, or to Cr(III)Cl3 at a concentration of 25 mg/L for a period of
1 year (MacKenzie et al. 1958).  This was not a completely independent evaluation of the model since
data from this study were used to set parameters for fractional uptake of chromium into bone.  Ranges for
predicted:observed ratios for terminal tissue levels in rats exposed to 0.45–25 mg chromium(VI)/L were
1.2–5 for liver, 0.3–1.2 for kidney, and 0.2–1.5 for bone (femur).  The ratio for rats exposed to 25 mg
chromium(III)/L were 15 for liver, 0.9 for kidney, and 2 for bone. 
Optimization and evaluation of the human model is described in O’Flaherty et al. (2001).  The model was
optimized with data on plasma and red blood cell chromium concentrations, and urinary chromium
excretion in adult subjects who ingested a single dose of chromium(III) as CrCl3 or chromium(VI) as
K2Cr2O7 (Finley et al. 1997; Kerger et al. 1996a, see Section 3.4.1.2 for description of these studies).  The
model was evaluated against data on plasma chromium concentration kinetics and urinary excretion of
chromium in a single adult subject who ingested 4 mg chromium(VI)/day as K2Cr2O7 for 17 days
(Paustenbach et al. 1996; see Section 3.4.1.2), with the only adjusted parameter being the absorption rate
constant.  Although the model was optimized based on data from single dose studies, it reproduced the
observed steady-state plasma chromium concentration, time to steady state, and elimination kinetics 
following cessation of the 17-day exposure.
Risk assessment. The model accounts for most of the major features of chromium(VI) and
chromium(III) absorption and kinetics, and reduction chromium(VI) to chromium(III), uptake into and 
retention in red blood cells, and uptake and retention in bone.  The human model associated bone
chromium kinetics with bone formation and resorption and provides a structure for simulating age-
dependent kinetics attributable to changes in bone turnover (e.g., growth, pregnancy, senescence).  
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Bioavailability of chromium from environmental sources is mostly unknown, except for a few chemically
defined salts.
Target tissues. The rat and human models include parameters for predicting levels of chromium(III)
and chromium(VI) in plasma, red blood cells, kidney, liver, bone, gastrointestinal tract, and respiratory
tract.  However, the rat model was calibrated against data on the above tissues, only for single dose
intratracheal or intravenous exposures.  Evaluations of predictions for repeated-dose exposures have been
limited to blood concentration kinetics in an acute repeated dose inhalation exposure; and for terminal
bone, kidney, and liver chromium levels in a 1-year drinking water study.  The human model has been 
calibrated against data on plasma and red blood cell chromium concentrations and urinary chromium
excretion following single oral doses administered to humans.  Evaluation of predictions of repeated-dose
outcomes have been limited to plasma and urine chromium kinetics, based on a study of a single subject
exposure to chromium(VI) in drinking water for 17 days.
Species extrapolation. Evaluation of the robustness of extrapolation of the rat or human models to 
other species has not been reported.
Interroute extrapolation. The rat and human models include parameters for simulating inhalation 
and ingestion of chromium.  The rat model was calibrated against data from single-dose intratracheal or
intravenous exposures, and was evaluated against repeated-dose studies of inhaled and ingested 
chromium.  The human model was calibrated and evaluated with data from ingestion studies; evaluation 
of the robustness of the model for predicting chromium kinetics following exposures to other routes has
not been reported.
3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
The absorption of inhaled chromium compounds depends on a number of factors, including physical and 
chemical properties of the particles (oxidation state, size, solubility) and the activity of alveolar
macrophages.  Chromium has been identified in the tissues of occupationally-exposed humans, 
suggesting that chromium can be absorbed from the lungs (Cavalleri and Minoia 1985; Gylseth et al. 
1977; Kiilunen et al. 1983; Mancuso 1997b; Minoia and Cavalleri 1988; Randall and Gibson 1987;
Tossavainen et al. 1980).  Animal studies have also demonstrated increased amounts of chromium in the
blood following inhalation or intratracheal instillation exposures (Baetjer et al. 1959b; Bragt and van
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Dura 1983; Langård et al. 1978; Visek et al. 1953; Wiegand et al. 1984, 1987).  Chromium(VI) is more
rapidly absorbed into the bloodstream than is chromium(III) (Gao et al. 1993; Suzuki et al. 1984).  
Chromium that is not absorbed in the lungs may be cleared via mucociliary clearance and enter the
gastrointestinal tract.
Chromium is poorly absorbed from the gastrointestinal tract; the primary site of chromium absorption 
appears to be the jejunum (Donaldson and Barreras 1966).  The bioavailability of chromium compounds
seems to be most dependent on the oxidation state of the chromium atom.  However, other factors,
including formulation of the chromium, can influence the extent of absorption.  Inorganic chromium(III)
is very poorly absorbed, with only 0.5–2.8% of dietary chromium absorbed via the gastrointestinal tract of
humans (Anderson 1986; Anderson et al. 1983; Donaldson and Barreras 1966; Gargas et al. 1994; Kerger
et al. 1996a; Kuykendall et al. 1996).  Human studies demonstrate that chromium(VI) is effectively
reduced to chromium(III) by gastric juices (De Flora et al. 1987a) and in general, chromium(VI) is better
absorbed than chromium(III) following oral exposure in humans (Donaldson and Barreras 1966; Finley et
al. 1996b; Kerger et al. 1996a; Kuykendall et al. 1996).  Absorption efficiencies ranging from 1.7 to 6.9%
have been estimated in humans (Finley et al. 1996a; Kerger et al. 1996a, 1997; Kuykendall et al. 1996).  
Ingestion of chromium with a meal appears to increase the absorption efficiency (Chen et al. 1973).  
Both chromium(III) and chromium(VI) can penetrate human skin to some extent, especially if the skin is
damaged.  Following dermal exposure, chromium has been detected in the blood, feces, and urine of
exposed humans (Brieger 1920), though in this study, the skin was damaged, which likely facilitated 
absorption.  An average rate of systemic uptake of chromium(VI) in humans submersed in chlorinated
water containing potassium dichromate(VI) for 3 hours was 1.5x10-4 μg/cm2-hour (Corbett et al. 1997).  
Chromium(VI) appears to penetrate the skin faster than chromium(III) (Mali et al. 1963; Spruit and van 
Neer 1966; Wahlberg 1970), though many other factors may be involved, including solvent (Liden and 
Lundberg 1979) and concentration (Baranowska-Dutkiewicz 1981).
Absorbed chromium is carried throughout the body in the blood, eventually being distributed to all
tissues.  Greatest concentrations of chromium are found in the blood, liver, lung, spleen, kidney, and heart
(Kaufman et al. 1970; Schroeder et al. 1962; Teraoka 1981).  Because insoluble chromium is not
completely cleared or absorbed following inhalation exposure, greater levels of chromium are often found 
in lung tissues following inhalation of chromium compounds than following other methods of exposure.  
Tissue levels appeared to be higher after exposure to chromium(VI) than to chromium(III).  This may be 
due to the greater ability of chromium(VI) to cross cell membranes and may also be a function of
   
 













    
 
   
  
    
 
    
 
  
     
 
    
 
  
   
     
   
    
    
    
    
   
    
 





administration of doses high enough to overwhelm the chromium(VI) reduction mechanisms.  De Flora et
al. (1997) have demonstrated that liver, erythrocytes, whole blood, lung epithelial fluid, alveolar
macrophages, and peripheral parenchyma cells all have the ability to reduce chromium(VI) to
chromium(III).  Chromium has been detected in breast milk (Casey and Hambidge 1984; Shmitova 1980), 
but the relationship between chromium exposure, dietary or otherwise, and breast milk chromium levels is
inconclusive (Anderson et al. 1993; Engelhardt et al. 1990; Mohamedshah et al. 1998). 
Systemic chromium(III) does not appear to be stored for extended periods of time within the tissues of the
body.  However, the prolonged half-life of chromium(VI) compared to chromium(III) in humans (Kerger
et al. 1997) and animals indicate that a portion of the absorbed chromium(VI) dose that is not converted
to chromium(III) is being sequestered inside cells.  Single- and multiple-exposure studies in humans have 
shown a one-compartment clearance half-time in humans on the order of 36 hours (Kerger et al. 1997;
Paustenbach et al. 1996) following oral exposure.  This half-time is sufficiently long to allow for
accumulation of chromium following regular repeated exposure.  Following inhalation exposure, 
insoluble chromium that is not cleared from the lungs may remain for a considerable time.  In the blood,
chromium(VI) is taken up by erythrocytes and reduced to chromium(III) which forms complexes with 
hemoglobin and other intracellular macromolecules; these complexes are retained within the erythrocyte
for the life-span of the cell (Paustenbach et al. 2003).
Inhaled chromium can be eliminated from the lungs by absorption into the bloodstream, by mucociliary
clearance, and by lymphatic system clearance (Bragt and van Dura 1983; Perrault et al. 1995; Visek et al.
1953; Wiegand et al. 1984, 1987).  The primary routes of elimination of absorbed chromium is urine and 
feces.  It can also be eliminated in hair and fingernails (Randall and Gibson 1989; Stearns et al. 1995a;
Takagi et al. 1986).  Chromium, once reduced to chromium(III) in the liver, is then conjugated with
glutathione and enters bile where it is excreted in the feces (Norseth et al. 1982). Because chromium is 
poorly absorbed following oral exposure, a large percentage of the amount ingested is excreted in the
feces. The half-time of urinary excretion of chromium is short, 4–10 hours for inhalation exposure
(Kiilunen et al. 1983), 10 hours for oral exposure to chromium(III) (Kerger et al. 1996a), and 40 hours for
oral exposure to chromium(VI) (Kerger et al. 1996a, 1997).  Following dermal exposure, chromium that
is not absorbed into the bloodstream will remain on the skin until it is eliminated, usually by washing or
other physical processes.  Absorbed chromium is primarily eliminated in the urine.
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3.5.2 Mechanisms of Toxicity
The toxic potency of chromium is dependent on the oxidation state of the chromium atom, with 
chromium(VI) more potent than chromium(III).  The mechanisms of chromium toxicity and 
carcinogenicity are very complex.  They are mediated partly through reactive intermediates during
intracellular reduction of chromium(VI) to chromium(III) and oxidative reactions, and partly mediated by
chromium(III) which is the final product of intracellar chromium(VI) reduction and forms deleterious
complexes with critical target macromolecules (Chen and Shi 2002; Costa 2003; Costa and Klein 2006a;
Ding and Shi 2002; Jeejeebhoy 1999; Levina and Lay 2005; Liu and Shi 2001; O’Brien et al. 2003;
Paustenbach et al. 2003; Salnikow and Zhitkovich 2008; Shrivastava et al. 2002; Yao et al. 2008;
Zhitkovich 2005).  Chromium(III) may form complexes with peptides, proteins, and DNA, resulting in 
DNA-protein crosslinks, DNA strand breaks, and alterations in cellular signaling pathways, which may
contribute to toxicity and carcinogenicity of chromium compounds. 
The greater toxic potency of chromium(VI) relative to chromium(III) most likely is related to two factors:
(1) the higher redox potential of chromium(VI) (Levina and Lay 2005; Reddy and Chinthamreddy 1999); 
and (2) the greater ability of chromium(VI) to enter cells (Costa 2003).  Differences in molecular
structure contribute the greater cellular uptake of chromium(VI) compared to chromium(III) (Costa 2003; 
Costa and Klein 2006a).  At physiological pH, chromium(VI) exists as the tetrahedral chromate anion, 
resembling the forms of other natural anions (e.g., sulfate and phosphate) which are permeable across
nonselective membrane channels.  Chromium(III), however, forms octahedral complexes and cannot
easily enter through these channels.  Therefore, the lower toxicity to chromium(III) may be due in part to 
lack of penetration through cell membranes.  It follows that extracellular reduction of chromium(VI) to
chromium(III) may result in a decreased penetration of chromium into cells, and therefore, a decreased 
toxicity.
The higher redox potential of chromium(VI) contributes to the higher toxic potency of chromium(VI)
relative to chromium(III) (Levina and Lay 2005), because once it is taken into cells, chromium(VI) is 
rapidly reduced to chromium(III), with chromium(V) and chromium(IV) as intermediates.  These
reactions commonly involve intracellular species, such as ascorbate, glutathione, or amino acids (Aiyar et
al. 1991; Blankenship et al. 1997; Capellmann et al. 1995; Hojo and Satomi 1991; Kim and Yurkow
1996; Lin et al. 1992; Liu et al. 1997b; Mao et al. 1995; Wiegand et al. 1984; Zhitkovich et al. 1996).  
Chromium(VI), chromium(V), and chromium(IV) have all been shown to be involved in Fenton-like
oxidative cycling, generating oxygen radical species (Aiyar et al. 1991; Chen et al. 1997; Liu et al. 1997b;
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Luo et al. 1996; Mao et al. 1995; Molyneux and Davies 1995; Tsou et al. 1996).  It is believed that the
formation of these radicals, which leads to oxidative stress, may be responsible for many of the
deleterious effects of chromium on cells, including lipid peroxidation (Bagchi et al. 2002a; Hojo et al. 
1999, 2000) and alterations in cellular communication, signaling pathways and cytoskeleton (Chen et al. 
1997; Gao et al. 2002; Gunaratnam and Grant 2002, 2004; Kim and Yurkow 1996; Mikalsen 1990;
O’Hara et al. 2007; Shumilla et al. 1998; Wang et al. 1996a; Xu et al. 1996; Yao et al. 2008; Ye et al.
1995).  The chromium(VI)-induced oxidative stress resulting from the generation of reactive oxygen 
species has been shown in in vitro studies to result in the induction and inhibition of the transcription
factors, NF-κB and AP-1, activation of p53, activation of hypoxia-inducible factor 1 (HIF-1), cell-cycle 
arrest, and p53-dependent apoptosis (Yao et al. 2008).  Cellular damage from exposure to various
chromium compounds can be blocked by radical scavengers, further strengthening the hypothesis that
oxygen radicals play a key role in chromium toxicity (Hojo et al. 2000; Luo et al. 1996; Tsou et al. 1996;
Ueno et al. 1995a).
The products of metabolic reduction of chromium(VI) (free radicals and chromium(IV) and (V)) and the
newly generated chromium(III) are thought to be in part responsible for the carcinogenic effects seen in 
human and animal studies. The interaction of free radicals, chromium(V), chromium(IV), and 
chromium(III) with DNA can result in structural DNA damage, functional damage, and other cellular
effects (Levina and Lay 2005; Singh et al. 1998a). The types of chromium-induced structural damage 
include DNA strand breaks (Aiyar et al. 1991; Bagchi et al. 2002a; Bryant et al. 2006; Casadevall et al. 
1999; Ha et al. 2004; Kuykendall et al. 1996; Manning et al. 1992; Messer et al. 2006; Pattison et al. 
2001; Ueno et al. 1995a), DNA-protein crosslinks (Aiyar et al. 1991; Blankenship et al. 1997;
Capellmann et al. 1995; Costa et al. 1996, 1997; Kuykendall et al. 1996; Lin et al. 1992; Manning et al. 
1992; Mattagajasingh and Misra 1996; Miller et al. 1991; O’Brien et al. 2005; Quievryn et al. 2001;
Zhitkovich et al. 1996), DNA-DNA interstrand crosslinks (Xu et al. 1996), chromium-DNA adducts, and 
chromosomal aberrations (Blankenship et al. 1997; Sugiyama et al. 1986a; Umeda and Nishimura 1979;
Wise et al. 1993).  Functional damage includes DNA polymerase arrest (Bridgewater et al. 1994a, 1994b, 
1998), RNA polymerase arrest, mutagenesis, and altered gene expression.  However, DNA double strand 
breaks may not be due to free radical formation, but due to the formation of chromium-DNA ternary
adducts, which lead to repair errors and collapsed replication forks (Ha et al. 2004).  Double strand breaks
can also lead to alterations in cellular communication and effects on signaling pathways and cytoskeleton.  
In addition, results of recent studies in human lung cells suggest that chromosome instability is an 
important mechanism in the development of lung cancers; specifically, chromium-induced chromosome
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instability appears to be mediated through centrosome and spindle assembly checkpoint bypass (Holmes 
et al. 2006; Wise et al. 2006a).
Location of particle deposition in the lung and extracellular dissolution of chromium(VI) compounds
(e.g., solubility) are also important considerations regarding the mechanism of chromium(VI)-induced 
carcinogenesis.  In chromate workers, analysis of bronchial tissues shows higher chromium
concentrations in areas of bronchial bifurcation compared to other areas in the bronchi (Ishikawa et al.
1994a).  Also, autopsy results show that some precancerous bronchial lesions originated at bronchial
bifurcations (Ishikawa et al. 1994b).  Solubility of chromium(VI) compounds may also play a role in 
carcinogenic potency, with extracellular dissolution of the chromium compound critical to activity (Wise
et al. 2004).  This hypothesis is supported by in vitro data suggesting that extracellular chromium ions are 
the proximate clastogen in Chinese hamster ovary cells (Wise et al. 2004).
Chromium(III) can also interact with DNA to form adducts/complexes and DNA-protein crosslinks that
interfere with DNA replication and transcription, and can promote the expression of regulatory genes
such as nuclear factor-κβ, or may inhibit regulatory genes such as GRP78 (Chen et al. 1997; Kim and 
Yurkow 1996; Manning et al. 1992; Mikalsen 1990; O’Hara et al. 2003; Shumilla et al. 1998; Wang et al. 
1996a; Xu et al. 1996; Ye et al. 1995).  Disruption of these pathways by other compounds has been 
implicated in carcinogenesis.  The structural and functional damage can lead to growth arrest (Xu et al. 
1996) and apoptosis (Carlisle et al. 2000; Singh et al. 1999).  Numerous studies show that chromium can 
induce apoptosis (Asatiani et al. 2004; Bagchi et al. 2001; Carlisle et al. 2000; Flores and Perez 1999;
Gambelunghe et al. 2006; Gunaratnam and Grant 2002, 2004; He et al. 2007; Manygoats et al. 2002; Petit
et al. 2004; Russo et al. 2005; Vasant et al. 2003); although the mechanism by which chromium induces
apoptosis is not fully understood, it is believed to involve oxidative stress and activation of the p-53 
protein (Pulido and Parrish 2003; Singh et al. 1998a).
3.5.3 Animal-to-Human Extrapolations 
Species-related differences in chromium pharmacokinetics have been demonstrated, both between rodent
species and between rodents and humans.  However, studies directly examining species differences have 
been limited.  Human microsomal chromium(VI) reduction is different from the P450-mediated
microsomal reduction in rodents; specifically, the human system is much less oxygen-sensitive, has a 
much greater affinity for chromate, and is apparently mediated by flavoproteins (Myers and Myers 1998;
Pratt and Myers 1993). Tissue distributions of chromium were found to be different between rats and 
   
 













    
 
   
 
   
   
  
  
   
 
  
   
      
  
   
   
    
  
   
   
     
  
   
  
 





mice after administration of bolus amounts of chromium(VI).  Rat erythrocytes had a greater capacity to
sequester chromium(VI) and reduce it to chromium(III) than mouse erythrocytes (Coogan et al. 1991b;
Kargacin et al. 1993), thus demonstrating that both physiologic and metabolic differences can exist
among species.
3.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
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Based on results of in vivo and in vitro studies, chromium(VI) may alter function of the hypothalamic-
pituitary axis function.  Serum prolactin levels were decreased by 59% in male Wistar rats exposed to
74 mg chromium(VI)/kg/day as potassium dichromate in drinking water for 30 days.  Incubation of
cultured rats anterior pituitary cells with 0.1–10 μM chromium(VI) as potassium dichromate decreased 
prolactin secretion and cell viability (Quinteros et al. 2007).  No additional assessments of hypothalamic-
pituitary axis function were conducted in this study.  Exposure of female rats to 11.4 mg chromium(VI)/ 
kg/day as potassium dichromate during lactation days 1–21 resulted in delayed ovarian follicle
development and pubertal onset and impaired ovarian steroidogenesis in female offspring (Banu et al. 
2008).  In in vitro experiments with immortalized granulosa cells, chromium decreased mRNA expression
of a number of steroidogenic enzymes and steroidogenesis regulatory factors (Banu et al. 2008).  Serum
testosterone levels were decreased by 20.8% in male New Zealand rabbits administered 3.6 mg
chromium(VI)/kg/day as potassium dichromate for 10 weeks by gavage (Yousef et al. 2006); however, 
since function of the hypothalamic-pituitary-gonadal axis was not assessed, it is unclear if this effect
reflects endocrine disruption.
3.7  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are
critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
   
 









     
   
   
  
  
    
      
 
  
   
   
    
  
  
   
     




   
 












and metabolism between children and adults.  For example, absorption may be different in neonates
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990b; Leeder
and Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make
the child more or less susceptible also depends on whether the relevant enzymes are involved in activation
of the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
Chromium(III) is an essential nutrient required for maintaining normal glucose metabolism.  The IOM of
the NAS determined an adequate intake of 0.2 μg chromium/day for infants aged 0–6 months; 5.5 μg 
chromium/day for infants aged 7–12 months; 11 μg chromium/day for children aged 1–3 years; 15 μg
chromium/day for children aged 4–8 years; 25 μg chromium/day for boys aged 9–13 years; 21 μg
chromium/day for girls aged 9–13 years; 35 μg chromium/day for boys aged 14–18 years; and 24 μg
chromium/day for girls aged 14–18 years (IOM 2001).
   
 













   
  
   
    
   
      
   
 
  
    
   
     
   





   
   
   
   
     
    
   
  




There is a limited amount of information available on the toxicity of chromium in children.  Most of the
available data come from several case reports of children ingesting lethal concentrations of
chromium(VI).  A variety of systemic effects were observed in a 22-month-old who accidentally ingested 
an unknown amount of sodium dichromate (Ellis et al. 1982), a 1-year-old who ingested an unknown 
amount of ammonium dichromate (Reichelderfer 1968), a 17-year-old who intentionally ingested 29 mg
chromium(VI)/kg as potassium dichromate (Clochesy 1984; Iserson et al. 1983), and a 14-year-old who 
ingested 7.5 mg chromium(VI)/kg as potassium dichromate (Kaufman et al. 1970).  The effects included
pleural effusion, bronchopneumonia, hypoxic changes in the myocardium, decreased blood pressure and 
cardiac output, abdominal pain and vomiting, gastrointestinal burns and hemorrhage, and liver and kidney
necrosis.  An enlarged brain and cerebral edema were also observed in the 14-year-old (Kaufman et al.
1970). These effects are similar to effects observed in adults who have ingested lethal doses and are part
of the sequelae leading to death. 
A number of additional health effects have been observed in adults exposed to chromium (primarily
chromium(VI)) at work. The primary targets appear to be the respiratory tract, gastrointestinal tract,
hematological system, liver, and kidneys; an increased cancer risk has also been observed.  Dermal
contact in chromium sensitized individuals can lead to an allergic type dermatitis. In the absence of data 
to the contrary, it is likely that these organs/systems will also be sensitive targets in children. There is 
insufficient information to determine whether the susceptibility of children would differ from that of
adults.  
Although there are no human studies that examined developmental end points, animal studies have
consistently shown that chromium, particularly chromium(VI), is a developmental toxicant.  A number of
developmental effects have been reported in oral studies involving maternal exposure to ≥2.9 mg
chromium(VI)/kg/day as potassium dichromate (Al-Hamood et al. 1998; Junaid et al. 1996b; Samuel et
al. 2011; Trivedi et al. 1989).  The observed effects included increases in postimplantation losses, gross 
abnormalities (e.g., subdermal hemorrhage, decreased ossification, kinky tail), and impaired development
of the reproductive system (e.g., impaired fertility in female offspring, delayed vaginal opening, altered 
estrous cycling). Similar developmental effects (e.g., post implantation losses, subdermal hemorrhage, 
decreased ossification) have also been observed in the offspring of rats and mice exposed to ≥37 mg
chromium(VI)/kg/day for 20 or 90 days prior to mating (Junaid et al. 1996a; Kanojia et al. 1996, 1998).  
Conflicting results have been found for chromium(III).  No developmental effects were reported in the
offspring of rats fed 1,806 mg chromium(III)/kg/day as chromium oxide for 60 days before mating and 
throughout gestation (Ivankovic and Preussmann 1975).  However, impaired development of the
   
 








    
 








   
   
 
   
    
    
     
 
 
   
  
  
      
    
  
    
    
 
 





reproductive system (decreased reproductive tissue weight and impaired fertility) were observed in the 
offspring of mice exposed to 74 mg chromium(III)/kg/day as chromium chloride (Al-Hamood et al. 
1998).  Exposure to 25 mg chromium(III)/kg/day as chromium picolinate during gestation and lactation 
did not affect the neurological development of the offspring (Bailey et al. 2008a).  Developmental effects
have also been observed following intraperitoneal administration of chromium(III) chloride (Iijima et al. 
1983; Matsumoto et al. 1976).  
Chromium may be transferred to fetuses through the placenta and to infants via breast milk.  Elevated
levels of chromium have been reported in umbilical cord blood, placentae, and breast milk of women 
working in a dichromate(VI) manufacturing facility (Shmitova 1980).  As noted elsewhere in the profile, 
the reliability of this study is suspect because the levels of chromium in the blood and urine of the control
women were much higher than background levels.  Measurement of the chromium content in 255 samples
from 45 lactating American women revealed that most samples contained <0.4 μg/L, and the mean value
was 0.3 μg/L (Casey and Hambidge 1984).  While these probably represent background levels in women 
whose main exposure to chromium is via the diet, the findings indicate that chromium may be transferred
to infants via breast milk.  These findings in humans are supported by animal data.  Studies in rats and
mice have shown that chromium(VI) and chromium(III) crosses the placenta and enters into fetal tissue.
Elevated levels of chromium have been observed in the placenta and fetal tissue of rats and mice exposed
to potassium dichromate(VI) in drinking water during pregnancy (Saxena et al. 1990a).  The levels of
chromium in the placenta were 3-and 3.2-fold higher in the exposed rats and mice, respectively, than in
controls and fetal tissue chromium levels were 3.1-and 9.6-fold higher, respectively; the difference over
control was only statistically significant in the mice.  Another study (Danielsson et al. 1982) also found 
elevated fetal tissue levels of chromium.  The chromium levels in the fetal tissues were 12–19% of
maternal blood levels following maternal intravenous injections of sodium dichromate(VI) on gestational
days 12–15 or 16–18 and 0.4–0.8% following maternal intravenous injections of chromium(III)
trichloride on gestational days 12–15 or 16–18.  A study of transplacental transfer of chromium(III) in 
different forms indicated that placental transport varies with the chemical form (Mertz et al. 1969).
Higher levels of chromium were found in the neonates of rats fed chromium in a commercial diet as 
compared to neonates of rats fed a chromium-deficient diet and given drinking water containing
chromium acetate monohydrate.  Similarly chromium levels were significantly elevated in the offspring 
of rats administered chromium in the form of chromodulin from Brewer’s yeast by gavage than in the 
offspring of rats administered chromium trichloride intravenously or by gavage.   
   
 








   





   
 
    
   
 
 
     




   
    
   
 
   
     
  




   
  
  





There is very little information available in which to assess whether the pharmacokinetic properties of
chromium would be different in children.  Sullivan et al. (1984) found that gastrointestinal absorption of
radiolabeled chromium chloride, administered by gavage, was 10 times higher in 2-day-old rats as 
compared to levels absorbed in adult rats.  A similar pattern of distribution in the body was found in the
immature and mature rats.
3.8  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment
of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  However, several
factors can confound the use and interpretation of biomarkers of exposure.  The body burden of a
substance may be the result of exposures from more than one source. The substance being measured may
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from
exposure to several different aromatic compounds).  Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken.  It may be difficult to
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids
(e.g., essential mineral nutrients such as copper, zinc, and selenium).  Biomarkers of exposure to 
chromium are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by chromium are discussed in Section 3.8.2.
   
 









   
    
  
    
  
 
     
 
  




   
 
   
  
    
    
   
  
 
     
  
   
 
    
   




A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Chromium
As an essential nutrient, chromium is normally present in blood and urine.  Chromium in body fluids
(e.g., blood and urine) is the exposure biomarker of choice.  Mean dietary chromium intake in the general
U.S. population was estimated as 0.505 μg/kg/day (equivalent to 35.35 μg/day, assuming a body weight
of 70 kg), with a range of 0.293–0.867 μg/kg/day (Moschandreas et al. 2002); however, only a small
amount of dietary chromium is absorbed (≤3%). The IOM of the NAS (IOM 2001) determined an 
adequate intake (e.g., a level typically consumed by healthy individuals) of 20–45 μg chromium(III)/day 
for adolescents and adults.  Daily dietary intake levels have been shown to correlate with total excretion 
of chromium in the urine and feces (Bunker et al. 1984).  The IOM (2001) reported average plasma 
chromium concentrations of 2–3 nmol/L (equivalent to 0.10–0.16 μg/L) and an average urinary chromium
excretion of 0.22 μg/L or 0.2 μg/day; endogenous chromium concentrations also have been reported as 
0.01–0.17 μg/L (median 0.06 μg/L) in serum (Sunderman et al. 1989), 0.24–1.8 μg/L (median 0.4 μg/L)
in urine (Iyengar and Woittiez 1988), and 0.234 mg/kg in hair (Takagi et al. 1986).  However, normal
chromium levels in human fluid and tissues should be interpreted with caution.  The low sensitivity of the
most commonly used detection methods and the ubiquitous presence of chromium in laboratories make 
detection of low levels of chromium in blood and urine difficult.
Exposure to chromium may result in increased chromium concentrations in blood (whole blood, serum, 
and erythrocytes), urine, expired air, hair, and nails; of these, elevations of chromium in blood and urine
are considered the most reliable indicators of exposure (Barceloux 1999; Caglieri et al. 2006).  Urinary
elimination half-times for absorbed chromium(III) range from 10–40 hours (Kerger et al. 1996a).  
Assuming an elimination half-time of 40 hours, steady state, plasma concentration, and urinary excretion
rate of chromium would reach 95% of steady state levels in approximately 7 days (Paustenbach et al.
1996).  Once steady state is achieved, the daily amount of chromium excreted in urine will reflect the
daily amount absorbed. With cessation of exposure levels of chromium in plasma and urine will reach
5% of steady state within 7 days.  The relatively rapid elimination kinetics of absorbed chromium(III) has
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implications for the use of plasma and urine as biomarkers of exposure to chromium.  Plasma and urinary
chromium concentrations will largely reflect relatively recent exposure (i.e., exposures that occurred
several weeks prior to the sample may not be detected from plasma or urinary chromium measurements).
During relatively constant or repetitive exposures that achieve a steady state in plasma, daily urinary
chromium excretion measured on a single day can be expected to be highly correlated with chromium
intake.  This correlation will weaken with greater intermittency in the exposure, with greater dependence 
on the time of sampling with respect to the most recent exposure.  The above general principles apply to
exposures to absorbed chromium(III) compounds; however, absorbed chromium(VI) has a longer
retention time in blood.  Chromium(VI) that enters blood is taken up by red blood cells, reduced to 
chromium(III), and, in the process, form adducts with red blood cell hemoglobin and other proteins.  
These complexes are sufficiently stable to remain in the red blood cells for a substantial fraction of the 
lifespan of the red blood cell.  Therefore, following absorption of chromium(VI) in to blood, the
elimination half-time of chromium in blood will be substantially longer than that in plasma.  The
elimination half-time of injected chromium(VI) (e.g., sodium chromate-51, used in the clinical assessment
of red blood cell volume) is approximately 25–35 days (Dever et al. 1989).  Based on a half-time of
30 days in red blood cells, with cessation of exposure to and absorption of chromium(IV), levels of
chromium in red blood cells will reach 5% of a previous steady state level within 130 days.
Although chromium also accumulates in white blood cells, erythrocyte chromium has been shown to be a
more sensitive measure of chromium exposure (Coogan et al. 1991b; Lukanova et al. 1996).  An increase
in plasma levels of chromium may reflect both recent exposure and exposure that occurred during the past
few months (e.g., chromium that is sequestered within erythrocytes for the lifespan of the cell), whereas 
elevated urine chromium primarily reflects exposure over the past 1–2 days (Barceloux 1999).  Distinct
measurements of chromium in plasma and whole blood (reflecting intracellular distribution to
erythrocytes) may also be useful in distinguishing exposures to chromium(VI) compounds versus
chromium(III) compounds; increased plasma levels of chromium may indicate exposure to both
chromium(VI) and chromium(III), whereas increased chromium in erythrocytes indicates exposure to 
chromium(VI), since chromium(III) is not taken up by erythrocytes.  For example, evaluation of postshift 
whole blood, serum, erythrocytes, and urine in groups of dichromate production workers exposed mainly
to chromium(VI) or chromium(III) showed relationships between exposure type (e.g., chromium(VI) or
chromium(III)) and chromium in blood and urine (Minoia and Cavalleri 1988).  In 22 workers exposed 
primarily to chromium(VI) (0.008–0.212 mg chromium(VI)/m3, 0.010–0.10 mg chromium(III)/m3), the
mean postwork-shift urinary chromium level was 31.5 μg total chromium/L; chromium(VI) was not
detected in the urine samples (detection limit=0.05 μg chromium(VI)/L) due to in vivo reduction of
   
 








   






   
    
 
 
   
  
    
   
   
   
 
      
     
   
   
 
   
 
      





chromium(VI) to chromium(III).  Concentrations of total chromium in serum, erythrocytes, and whole
blood were 2.2, 8.9 and 6.9 μg/L, respectively; compared with control levels of 1.1, 1.0, and 1.4 μg/L,
respectively.  In 15 workers exposed primarily to chromium(III) (0.046–1.689 mg chromium(III)/m3, 
0.002–0.023 mg chromium(VI)/m3), the mean postwork-shift urinary chromium level was 24.7 μg total 
chromium/L and concentrations of total chromium in serum, erythrocytes, and whole blood were
3.1 μg/L, 1.4, and 1.8, respectively.  The level of chromium in serum of the workers exposed mainly to 
chromium(III) was significantly (p<0.001) higher than that measured in workers exposed mainly to 
chromium(VI) or in controls.  The level of chromium in erythrocytes of the workers exposed mainly to 
chromium(III) was significantly (p<0.001) less than that in workers exposed mainly to chromium(VI).  
The finding of higher levels of chromium in serum and lower levels of chromium in erythrocytes of
workers exposed mainly to chromium(III) than in workers exposed mainly to chromium(VI) reflects the 
relative inability of chromium(III) to enter erythrocytes.
Although exposure to chromium may produce increases in chromium levels in both blood and urine
chromium levels, the relationship between blood and urinary chromium levels may vary.  Entry of 
chromium(VI) into the red blood cells probably reflects a competition between plasma reduction to 
chromium(III) and red blood cells uptake of chromium(VI) and not the result or consequence of the
exhaustion of plasma reducing ability.  When hexavalent chromium is incubated with washed isolated 
erythrocytes, almost all of the entire dose is taken up by the cells.  Chromium(VI) is then reduced inside 
the cells to trivalent chromium, essentially trapping it inside the erythrocyte.  In contrast, little
chromium(III) appears to be taken up by erythrocytes in vitro incubations (Aaseth et al. 1982; Bentley
1977; Donaldson and Barreras 1966; Gray and Sterling, 1950).  When chromium(VI) is incubated with 
whole blood or erythrocytes plus plasma, only a fraction (depending on conditions) of the chromium(VI)
is taken up by the erythrocytes (Coogan et al. 1991b; Corbett et al. 1998; Lewalter et al. 1985; Wiegand et
al. 1985), most likely due to the reduction of a portion of chromium(VI) to chromium(III) outside of the
erythrocyte (Capellmann and Bolt 1992; Korallus et al. 1984; Richelmi et al. 1984).  Thus, chromium(III)
is then largely excluded from the erythrocyte.  However, Korallus (1986a, 1986b) has proposed that the
relationship between blood and urinary chromium levels may vary, possibly due to variability in plasma 
reduction capacity.  In vitro experiments indicate that when chromium(VI) plasma levels exceed the 
plasma reduction capacity (PRC), chromium(VI) enters erythrocytes, is reduced, and binds to 
hemoglobin.  The bond persists for the lifetime of the erythrocytes (120 days); therefore, a single 
determination of chromium in erythrocytes allows a longitudinal evaluation of exposure for an extended 
period in the past.  Low chromium concentrations in erythrocytes indicate that the amount of
chromium(VI) uptake did not exceed the PRC.  Limited evidence suggests that the capacity of human 
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plasma to reduce chromium(VI) compounds to chromium(III) compounds varies, with slow and fast
reducers recognized (Korallus 1986a, 1986b).  It is not clear what is responsible for individual differences
in the PRC, although difference in magnitude of PRC appears to correlate with the levels of ascorbic acid
in plasma.   
The relationship between serum and urine chromium levels to occupational exposure levels has been
investigated in numerous studies, with results showing correlations between exposure levels and chromium
levels in blood and urine (Gylseth et al. 1977; Iarmarcovai et al. 2005; Kilburn et al. 1990; Lewalter et al. 
1985; Lindberg and Vesterberg 1983a; McAughey et al. 1988; Medeiros et al. 2003a; Minoia and Cavalleri
1988; Muttamara and Leong 2004; Mutti et al. 1985b; Randall and Gibson 1987, 1989; Saner et al. 1984;
Sathwara et al. 2007; Simpson and Gibson 1992; Sjogren et al. 1983; Stridsklev et al. 2004; Takagi et al. 
1986; Tola et al. 1977; Wiegand et al. 1988).  In workers exposed to chromium(VI) as chromium trioxide
in the chrome plating industry, a significant correlation (r=0.71) was observed between exposure levels 
and postshift urinary chromium; for a TWA exposure of 0.002 mg chromium(VI)/m3, the mean urinary
chromium level was 5.2 μg/L (excluding workers with obvious skin contamination) (Lindberg and 
Vesterberg 1983a).  Significant correlations were observed between chromium concentrations in air
(measured by personal sampling devices; 8-hour TWA) and levels of chromium in blood (r=0.99) and 
urine (r=0.89) in workers at a chromium alloy facility (Muttamara and Leong 2004).  In areas of low
exposure, the air concentration of chromium (type not specified) was 5.75 μg/m3; in workers in this area, 
mean chromium concentrations in blood and urine (duration of sample collection was not reported) were
0.925 and 0.095 μg/dL, respectively. In areas of high exposure, the air concentration of chromium was 
7.25 μg/m3, in workers in this area, mean chromium concentrations in blood and urine were 3.64 and 0.34 
μg/dL, respectively.  An increase in urinary chromium of 12.2 μg/g creatinine above preexposure values or
a total concentration of 29.8 μg/g creatinine (end-of-shift values) corresponded to an air concentration of
50 μg chromium(VI)/m3 from welding fumes (Mutti et al. 1985b).  Examination of end-of-shift chromium
levels indicated a correlation between urinary chromium levels and exposure to soluble chromium(VI)
compounds, but not to insoluble chromates or chromium(III) compounds (Minoia and Cavalleri 1988;
Mutti et al. 1985b).  The relationship between workroom air concentrations of water soluble chromium(VI)
compounds and daily increases in urinary chromium (preexposure values subtracted from end-of-shift
values) are shown in Figure 3-7.  Serum and urine concentrations of chromium were significantly elevated 
in a group of 73 tannery workers, with exposure primarily to chromium(III) compounds, compared to a
group of 52 control subjects, at the end of the workweek on Friday and before exposure began on Monday
(Randall and Gibson 1987).  Serum and urine chromium levels correlated with work area of the tannery,  
   
 






















Figure 3-7.  Relationship Between Water Soluble Chromium(VI) CrA and Daily  
Increase in Urinary Chromium Levels (CrU) (Pre-exposure Values were  
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with the highest concentrations in workers handling wet hides in the chrome tanning and wringing
departments. The time-weighted average level of total chromium in tannery air was 1.7 μg/m3 and did not
vary significantly among the various tanneries involved in the study or among the various work areas of
each tannery, with chromium(VI) levels in tannery air below the detection limit of (0.1 μg/m3).
Urinary and blood chromium have also been used as a biomarker for environmental exposure (Bukowski
et al. 1991; Chang et al. 2006; Fagliano et al. 1997). However, interpretation of results may be limited by
several factors, including that exposure must be sufficient such that urinary and blood concentrations are
higher than the range of background concentrations and analytical limit of detection, high inter- and 
intrapersonal variability, and that different chemical forms have different bioavailabilities (Paustenbach et
al. 1997; Finley et al. 1996b; Gargas et al. 1994; Kerger et al. 1997).  Furthermore, the short half-life of 
chromium (e.g., at least 90% of absorbed chromium is eliminated within 24 hours) make it difficult to 
assess exposure incidents.  Low-level, intermittent exposure, such as would occur with environmental
exposures to soil, dust, and residential drinking water, may not be detected with urinary monitoring;
however, it is more likely that urinary monitoring would detect higher-level continuous exposure or daily
inhalation exposure to chromium(VI).  Paustenbach et al. (1997) note that chromium intakes would have
to exceed 2 μg/day in order to distinguish the exposure from background.  Large interpersonal variability
(as high as a factor of 10) and intrapersonal variability (as high as a factor of 3) can result in highly
variable erroneous conclusions regarding significant differences among populations.  
3.8.2 Biomarkers Used to Characterize Effects Caused by Chromium
Chromium has been shown to produce effects to several systems, including the respiratory,
gastrointestinal, hematological, and immunological systems (see Section 3.2); however, many of these
effects are not specific for chromium.  Although effects to these physiological systems can be assessed
with blood and respiratory function tests and by physical examination, these assessments would not serve 
as biomarkers specific for effects of chromium as impairment of these systems can result from a variety
of other causes, including chemical toxicity, nutritional insufficiencies, and disease. 
Occupational exposure to chromium and its compounds has caused respiratory effects, such as
pneumonitis, impaired pulmonary function, nasal septum perforations, irritation of the mucosa, 
inflammation, and cancer.  In addition, chromium can be irritating and corrosive to the skin.  Chromium
exposure may cause asthma attacks and dermatitis in sensitive individuals. Workers with urinary levels 
of chromium >15 μg/g creatinine had increased retinol binding protein and tubular antigens in the urine.  
   
 












    
 
 
   
  
    
     
 
   
   
    
    
 




   
   
 
     
     
   







The workroom levels ranged from 0.05 to 1.0 mg chromium(VI)/m3 as chromium trioxide (Franchini and 
Mutti 1988).  The urine of chromium(VI) exposed workers in a chromate production plant contained 
higher levels of a brush border protein and of retinol-binding protein in the urine than did nonexposed 
controls (Mutti et al. 1985a).  In a study of currently exposed chrome platers, ex-chrome platers, and 
referent groups of nonexposed workers, the urinary levels of β2-microglobulin were significantly higher
(p=0.045), and elevated levels occurred more often in the presently exposed groups compared with its
age-matched control group.  The levels of β2-microglobulin in the urine of the ex-chrome platers, 
however, were not different than those of its age-matched control group (Lindberg and Vesterberg
1983b).  Another study of hard chrome electroplaters found a higher prevalence of workers with elevated 
N-acetyl-β-glucosamindase levels (Liu et al. 1998).  Although this study also found higher levels of
β2-microglobulins in the chrome plater, the prevalence of elevated values was not significantly increased.
The presence of low molecular weight proteins, such as retinol binding protein, antigens, or
ß2-microglobulin in the urine is believed to be an early indication of kidney dysfunction.  The lack of a
significant difference in the ex-chrome platers compared with the control group suggests that the
chromium-induced kidney damage may be reversible.  Cell culture and cell free studies discussed in
Section 3.5.2 demonstrated that chromium forms protein-DNA crosslinks and adducts with DNA, and 
that these end points may be potentially useful biological markers, indicating the possibility of genotoxic
effects or cancer in humans exposed to chromium.  However, no increases in protein-DNA crosslinks 
were observed in white cells from volunteers who were exposed to chromium(VI) in drinking water
(Kuykendall et al. 1996).
The possibility of using an immune-function assay as a potential biomarker for humans exposed to 
chromium has been examined (Snyder et al. 1996).  Isolated mononuclear cells from 46 individuals who 
lived and/or worked in areas in northern New Jersey at sites contaminated by chromium processing were 
stimulated by pokeweed mitogen.  Rates of stimulated cell growth and production of interleukin 6 (IL-6)
were measured and compared to a control population of people who lived/worked in uncontaminated 
areas. There was no significant increase in mitogen stimulation between people from contaminated areas
and controls, but there was a significant (36%) decrease in the levels of IL-6 in monocytes in the
chromium exposed group.  IL-6 is an important cytokine that is involved in the T-cell helper pathway of
antibody production.  The significance of the lower levels may lead to decreased levels of antibody
production.
The effects of chromium(III) chloride, sodium chromate(VI), and potassium chromate(VI) on 
proliferation of mononuclear leukocytes obtained from chromium sensitive individuals (confirmed with 
   
 












   
  
   
 
 
   
 
   
 






   
  
 






   
   





positive patch tests) was compared to nonsensitive controls (confirmed by negative patch tests) (Räsänen
et al. 1991).  Isolated cells were exposed to 25–50 μg/mL culture medium of chromium(III) chloride and 
to 0.025 to 0.1 μg/mL culture medium chromium(VI) salts, which gave optimum responses and cell
growth ratios of treated/nontreated cells from eight sensitive individuals ranging from 1.56 to 13.22, 
average=5.8 (chromium(III)), from 2.24 to 11.43, average 5.4 sodium chromate, and from 1.82 to 9.48, 
average 5.4potassium dichromate.  The nonsensitive individuals’ ratios were consistently lower with
ranges from 0.90 to 2.28 and average ratios of 1.14, 1.30, and 1.56, respectively.  The authors felt that this
in vitro methodology could be used diagnostically to assess chromium-sensitive individuals.
For more information on biomarkers for renal and hepatic effects of chemicals see ATSDR/CDC
Subcommittee Report on Biological Indicators of Organ Damage (Agency for Toxic Substances and 
Disease Registry 1990c) and for information on biomarkers for neurological effects see OTA (1990).
3.9  INTERACTIONS WITH OTHER CHEMICALS
Potassium dichromate (10 mg/kg) administered by subcutaneous injection potentiated the effects of the 
nephrotoxins, mercuric chloride, citrinin, and hexachloro-1,3-butadiene, in rats. Effects on renal function 
included changes in urine volume, osmolality, electrolyte and glucose excretion, and a reduction in renal
cortical slice organic ion transport.  Chromium(VI) compounds potentiated the effect of mercuric chloride
on organic acid uptake but not organic base uptake by renal cortical slices (Baggett 1986; Haberman et al.
1987).  A similar experiment with another nephrotoxin, maleic acid, demonstrated the potentiating effect
of potassium dichromate (10 mg/kg administered subcutaneously) (Christenson et al. 1989).  Christenson
et al. (1989) suggested that the combination of potassium dichromate with maleic acid might enhance
damage to the brush border of the renal proximal tubules or that damage to the luminal cells by potassium 
dichromate might allow maleic acid to more easily enter the cells.
Concomitant exposure of female Sprague-Dawley rats to chromium(VI) potassium dichromate and 
ethanol in drinking water for 22 weeks indicates that ethanol may enhance the hepatic effects of
chromium(VI) (Acharya et al. 2001).  Serum enzyme activity of ALT in rats treated with 10% ethanol and 
25 mg chromium(VI)/L (3.8 mg chromium(VI)/kg/day) was significantly increased compared to 
treatment of rats with ethanol or chromium(VI) alone.  However, the toxicological significance of this
finding is uncertain, since serum ALT activities of rats treated with ethanol and chromium(VI) were
increased by only 18% compared to treatment of rats with chromium(VI) alone.
   
 










    
      
    
 
   
     
  
    
  




    
  
   







    
   
   
     




Interactions between selenium in the diet and ammonium dichromate in the drinking water were
investigated in a study using rats.  During the experiment, one rat died and the other rats had atrophy of
the central liver lobe when given selenium alone.  Dietary selenium and ammonium chromate in 
combination caused hepatic necrosis, resulting in the death of four rats (Moxon and DuBois 1939). 
Although the rats were not fed chromium alone, other studies indicate that the liver is a target for
chromium exposure (see Section 3.2).  The mechanism for the interaction was not discussed.
Exposure of female hairless mice to ultraviolet light in combination with chromium(VI) as potassium
chromate in drinking water at concentrations of 2.5 or 5.0 mg potassium chromate(VI)/L (approximately
0.18 or 0.35 mg chromium(VI)/kg/day) for 182 days, or in the diet at concentrations of 0, 2.5, or 5.0 mg
potassium chromate(VI)/kg food (approximately 0.13 or 0.26 mg chromium(VI)/kg/day) for 26 weeks, 
produced an increased incidence of skin tumors compared to animals exposed to UV light alone or
chromium(VI) alone (Davidson et al. 2004; Uddin et al. 2007).  Exposure to chromium(VI) alone did not
result in neoplasms.  The chromium-induced enhancement of UV light-induced skin tumors did not
appear to be mediated through oxidative damage, since concomitant treatment with vitamin E or
selenomethionine did not decrease the chromium effect.
Concomitant inhalation exposure to ozone and chromium(VI) may alter pulmonary clearance mechanisms
in the deep lung (Cohen et al. 2003).  Compared to rats treated with insoluble chromium(VI) as calcium
chromate (0.34–0.36 mg chromium(VI)/m3) alone for up to 48 weeks, concomitant exposure to ozone
(0.59 mg/m3) resulted in decreased particle uptake and altered postphagocytic/endocytic processing of
chromium particles by alveolar macrophages.  However, since toxicity was not assessed in this study, it is
not known if ozone-induced alteration in alveolar macrophage function would result in increased toxicity
of chromium(VI).
A number of studies indicate an increase in the mutagenic effects of chromium(VI) compounds in
combination with other chemicals.  Synergism has been observed between chromium(VI) and 
9-aminoacridine, nitrilotriacetic acid, and azide (Bronzetti and Galli 1989; Gava et al. 1989a; LaVelle 
1986a, 1986b; Montaldi et al. 1987), but the mechanisms are not clearly understood.  Potassium
dichromate potentiated mutations produced by sodium azide in S. typhimurium or by 9-aminoacridine in
S. typhimurium and E. coli.  Although the data were insufficient for speculation on the specific 
biochemical mechanism, it was suggested that the potentiation involved a specific effect of potassium
dichromate on the interaction of 9-aminoacridine or sodium azide with DNA or on subsequent DNA
replication and/or repair (LaVelle 1986a, 1986b).  Nitrilotriacetic acid, which appears to have no 
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genotoxic potential itself, increased the frequencies of sister chromatid exchanges in Chinese hamster
ovary cells and of micronuclei and chromosomal aberrations in cultured human lymphocytes that were 
seen with lead chromate alone.  However, nitrilotriacetic acid had no effect on the dose-related induction 
of sister chromatid exchanges in Chinese hamster ovary cells that was seen with potassium chromate 
alone.  It was suggested that nitrilotriacetic acid increased the solubility of the originally insoluble lead
chromate, leading to increased uptake of the metal cation by the cells and subsequent increased
genotoxicity (Montaldi et al. 1987).  Nitrilotriacetic acid increased the frequency of point mutations in 
S. cerevisiae observed with a low concentration of sodium chromate, but decreased the frequency with a
5-fold higher concentration of sodium chromate.  It was suggested that at the low concentration of sodium
chromate, nitrilotriacetic acid affected the uptake of chromium(VI), favoring reduction to chromium(III)
ions, which formed a complex with nitrilotriacetic acid that can cross the membrane and interact with
DNA.  At the high dose of sodium chromate, nitrilotriacetic acid may have affected the mechanism of
recombination repair of DNA breaks induced by chromate oxidizing activity (Bronzetti and Galli 1989).  
Nitrilotriacetic acid also increased the mutagenicity of potassium dichromate in S. typhimurium and 
D. melanogaster, presumably by favoring the reduction of chromium(VI) to chromium(III) (Gava et al. 
1989a).  Thus, it is possible that other hazardous substances at hazardous waste sites may be more
dangerous due to the presence of chromium(VI). 
Ascorbic acid has been shown to have a protective effect in rats administered lethal dermal doses of
potassium dichromate (25 mg chromium(VI)/rat), and in preventing ulcerations of the skin (Samitz 1970).  
The nephrotoxicity due to subcutaneous injections of potassium chromate in rats was prevented by
intramuscular administration of ascorbic acid (Powers et al. 1986).  This occurred mainly through the
reduction of chromium(VI) to the less toxic chromium(III) state.  In cultured human bronchial cells, co-
exposure to ascorbic acid and sodium chromate blocked chromate-induced clastogenicity by preventing
uptake of chromium(VI) ions by cells (Wise et al. 2004).  Vitamin E protected against, while vitamin B2 
enhanced, the cytotoxicity and DNA strand breaks induced by sodium chromate in Chinese hamster cells 
in vitro.  Vitamin E may exert its protective effect by scavenging radicals and/or chromium(V) during the
reduction of chromium(VI) (Sugiyama 1991) (see Section 3.11.3).  N-Acetylcysteine, the glutathione
precursor, was reported to be effective in increasing the urinary excretion of chromium in rats (Nadig
1994).
Studies have examined the effects of interactions between chromium and arsenic on blood cholesterol and
glucose levels and changes in organ weight in rats (Aguilar et al. 1997).  Groups of five male Wistar rats
were given food containing 5 μg/g of either arsenic(V) oxide, chromium(III) chloride, or a combination of
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both chemicals for 10 weeks.  Organ weight to body weight ratios of liver, spleen, lung, kidney, and heart 
were similar to control values for the three exposed groups.  Arsenic alone increased the cholesterol blood 
level from 47.27(±6.85 SD) mg/dL in the control group to 96.83(±6.11 SD).  The combination of arsenic
and chromium reduced the blood cholesterol level to 46.69(±6.11 SD) mg/dL.  Neither chemical alone or
in combination affected blood glucose levels.  In most tissues, the combination of chemicals reduced the
chromium level appreciably below control values.  Supplemental chromium increased arsenic levels in
liver, kidney, spleen, heart, and red blood cells, and reduced levels of arsenic in lung and hair tissues.  
Chromium did not appear to alter concentrations of arsenic in the liver.
A study examining the chromium(VI) reduction in microsomes noted that the level of iron in the test 
system markedly influenced the Vmax of chromium(VI) reduction, suggesting that coexposure to 
chromium(VI) and agents that increase intracellular iron might lead to increased risk for chromium(VI)
toxicity (Myers and Myers 1998).  Among chromium cement workers with severe and continuous hand 
dermatitis, the addition of ferrous sulfate to the cement reduced the total chromium body burden (Chou et
al. 2008).
The effects of chromium(III) chloride and sodium chromate(VI) on the hepatotoxicity of carbon 
tetrachloride exposure to mouse hepatocytes were examined by Tezuka et al. (1995).  Primary cultures of
mouse hepatocytes were pretreated with 10 or 100 μM chromium for 24 hours followed by exposure to 1– 
5 mM carbon tetrachloride for up to 1 hour.  Chromium(VI) pretreatment significantly reduced the cell
toxicity as well as lipid peroxidation caused by carbon tetrachloride.  Chromium(III) pretreatment did not
have any effect on cell toxicity.  About 50% of chromium(VI) was taken up and reduced in the cells by
90% to chromium(III) within 10 minutes. The initial uptake rate of chromium(III) into cells was greater
than 500-fold less than chromium(VI), and only about 5% was absorbed.  The protection against carbon 
tetrachloride damage by chromium(VI) was attributed to its rapid uptake and conversion to 
chromium(III), and it was determined that chromium(III) acts as a radical scavenger for the free radicals
generated by carbon tetrachloride within the cell.  Furthermore, chromium(VI) pretreatment reduced the 
activity of NADPH cytochrome c reductase, which metabolizes carbon tetrachloride to reactive species.
In a previous study (Tezuka et al. 1991), the same group found that pretreating mice and rats with 
chromium(III) also protected against hepatic toxicity. 
In order to examine the speciation of chromium in lemonade, Kool Aid, tea, dripped coffee, percolated 
coffee, and orange juice, potassium chromate(VI) was added to each of the beverages at a chromium
concentration of 10 mg/L (Kerger et al. 1996b).  After 15 minutes, the concentrations of chromium(VI)
   
 








      
 
  
   
 
     
  
 





   
   
   
 
    
   
 









   
 
    




were determined to be <0.4 mg/L for orange juice, <0.3 mg/L for coffee and tea, 2 mg/L for Kool Aid, 
and 0.3 mg/L for lemonade.  After 3–5 hours, essentially no residual chromium(VI) remained.  At higher
concentrations (50 mg/L chromium(VI)), >99, 40, and 84% of the chromium(VI) was reduced after 3– 
5 hours in orange juice, lemonade, and coffee, respectively (not tested at the higher concentration in Kool
Aid and tea).  The reducing capacities were not correlated with total organic carbon or pH.  The reducing
capacities of the beverages were attributed in part to ascorbic acid in lemonade and orange juice and to
tannins in tea and coffee.
3.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to chromium than will most
persons exposed to the same level of chromium in the environment.  Reasons may include genetic
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
These parameters result in reduced detoxification or excretion of chromium, or compromised function of
organs affected by chromium.  Populations who are at greater risk due to their unusually high exposure to 
chromium are discussed in Section 6.7, Populations with Potentially High Exposures.
Acute inhalation LC50 and oral and dermal LD50 studies suggest that female animals are more sensitive to
the lethal effects of chromium(VI) compounds (see Sections 3.2.1.1, 3.2.2.1, and 3.2.3.1).  Whether
human females are more sensitive than males to toxic effects of chromium or its compounds is not
known.  Other information identifying possible susceptible populations was not located.  The primary and 
most sensitive effects of exposure to chromium compounds to the respiratory, gastrointestinal,
hematological, and immunological systems; thus, individuals with preexisting conditions of these systems 
may be at increased risk of exposure to chromium compounds.  Due to the sensitizing effects of
chromium, some individuals who are sensitive to chromium may develop asthma as an anaphylactic 
response to inhaled chromium.  Also, there is limited evidence that some individuals have less ability than
others to reduce chromium(VI) in the bloodstream and are more likely to be affected by the adverse
effects of chromium exposure (Korallus 1986a, 1986b).  The ability to reduce chromium(VI) in the
bloodstream may be related to the ascorbic levels in the plasma.  However, the metabolic reduction of
chromium(VI) may result in bioactivation and/or detoxification.
Since chronic inhalation of cigarette smoke may result in squamous metaplasia in the respiratory mucosa,
the risk of lung cancer due to inhalation of carcinogenic chromium compounds may be exacerbated in 
individuals who smoke cigarettes or are excessively exposed to passive smoke (Albert 1991).
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3.11  METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to chromium.  However, because some of the treatments discussed may be experimental and
unproven, this section should not be used as a guide for treatment of exposures to chromium.  When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice.  The following texts provide specific information about treatment following exposures
to chromium:
Haddad LM, Shannon MW, Winchester JF, eds.  1998.  Chromium.  In:  Clinical management of
poisoning and drug overdose.  3rd ed.  Philadelphia, PA:  W.B. Sanders Company, 794-795. 
Leikin JB, Paloucek FP, eds.  2002. In:  Leikin and Paloucek's poisoning and toxicology handbook.  3rd 
ed.  Hudson, OH:  Lexi-Comp, Inc., 372-379. 
Schonwald S.  2004.  Chromium.  In:  Dart RC, ed.  Medical toxicology.  3rd ed.  Philadelphia, PA:
Lippicott Williams & Wilkins, 1415-1417.
3.11.1 Reducing Peak Absorption Following Exposure
General recommendations for reducing absorption of chromium following acute inhalation exposure have
included moving the patient to fresh air, monitoring for respiratory distress, and administering humidified 
supplemental oxygen with assisted ventilation if required (Haddad et al. 1998; Schonwald 2004). If 
pulmonary effects such as bronchoconstriction are present, treatment with oxygen and bronchodilator
drugs may be administered (Haddad et al. 1998).  The absorption of inhaled chromium compounds
depends on such factors as oxidation state, particle size, and solubility.  Chromium(VI) passes through the
alveolar lining of the lungs to the bloodstream more readily than does chromium(III) (see
Section 3.4.1.1), and more soluble compounds are absorbed more readily than those that are less soluble 
(Bragt and van Dura 1983).  Although chromium(VI) is more readily absorbed from the lungs than
chromium(III), various components of the respiratory system can reduce chromium(VI) to chromium(III), 
which is far less capable of crossing cell membranes than chromium(VI), thereby reducing the 
bioavailability of chromium to target cells other than the lung (De Flora and Wetterhahn 1989). 
Epithelial lining fluid (ELF) is capable of reducing chromium(VI) (Petrilli et al. 1986b) and may
represent the first line of defense against inhaled chromium(VI).  Ascorbic acid (vitamin C) and 
glutathione, both of which were found to reduce chromium(VI) to chromium(III) in cell-free 
bronchoalveolar lavage fluid or soluble fractions of rat lungs in vitro, appear to be involved in this activity
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of ELF (Suzuki and Fukuda 1990).  Uptake and reduction of chromium(VI) by pulmonary alveolar
macrophages, catalyzed by NADH- or NADPH-dependent cytosolic enzyme activities, may lead to
virtually irreversible sequestration and efficient removal by mucociliary action (De Flora and Wetterhahn 
1989; De Flora et al. 1984, 1987b).  Reduction of chromium(VI) within pulmonary alveolar macrophage
homogenates was stimulated in rats by the administration of the glutathione precursor, N-acetylcysteine 
(De Flora and Wetterhahn 1989).  As mentioned above, the reduction of chromium(VI) to chromium(III)
by these various processes within the lungs serves as a natural defense mechanism by decreasing the 
amount of chromium absorbed and enhancing mucociliary clearance of chromium(III).  However, 
reduction of chromium(VI) to chromium(III) generates reactive intermediates, which may produce
adverse effects. Theoretically, further clearance from the lungs might be achieved by the administration 
of expectorants, but the efficacy of such a procedure has not been tested.
Chromium(III) is also poorly absorbed by the gastrointestinal tract, and chromium(VI) is reduced to 
chromium(III) in the gastric environment, limiting the bioavailability of chromium(VI) (De Flora et al.
1987a; Donaldson and Barreras 1966).  Thus, the oral toxicity of chromium metal is low.  However, 
chromium(VI) compounds are highly corrosive to the gastrointestinal tract and can lead to hepatic, renal, 
hematological, and neurological effects (Clochesy 1984; Coogan et al. 1991a; Diaz-Mayans et al. 1986;
Iserson et al. 1983; Kaufman et al. 1970; Kumar and Rana 1982, 1984; Samitz 1970; Saryan and Reedy
1988).  The reduction of chromium(VI) to chromium(III) in the stomach is greatly enhanced at low pH
and shortly after meals due to increased gastric juice secretion (De Flora et al. 1987a). The enhanced
reduction of chromium(VI) at low pH suggests that, theoretically, oral administration of bicarbonates and 
antacids should be avoided.  Oral administration of ascorbic acid to further reduce chromium(VI) to 
chromium(III) might further decrease bioavailability (Haddad et al. 1998; Schonwald 2004), although this
has not been proven (Leikin and Paloucek 2002; Schonwald 2004).  Other recommendations for reducing
gastrointestinal absorption of chromium include gastric lavage (Schonwald 2004); however, the approach 
would need to be performed shortly after ingestion and may be associated with risks (e.g., perforation).  
Inducing emesis with syrup of ipecac is not recommended because of the possibility of irritation or burns
to the esophagus (Nadig 1994; Schonwald 2004).
In cases of dermal exposure, the skin should be thoroughly washed to prevent chromium absorption by
the skin (Haddad et al. 1998; Leikin and Paloucek 2002; Schonwald 2004).  As chromium(VI), but not
chromium(III), is readily absorbed by the skin, ascorbic acid in the washing solution could reduce
chromium(VI) to chromium(III), thus decreasing absorption.  Application of the calcium disodium salt of
ethylenediamine tetraacetic acid (EDTA), which acts as a chelating agent, has also been recommended
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after washing with water and application of ascorbic acid (Nadig 1994), especially in cases where the skin
has been cut or abraded (Burrows 1983).  Ascorbic acid was found to protect chromium-sensitive workers 
who handled chromates in the lithographing and printing industries from dermatitis.  The ascorbic acid 
(10% solution) was kept near the work areas, and the workers soaked their hands and forearms as soon as 
possible after handling the chromate mixtures.  In addition, ascorbic acid prevented ulcerations of the skin 
in rats treated with potassium dichromate dermally (Samitz 1970).  An antichrome powder consisting of a
mixture of 40% sodium metabisulfite, 20% ammonium chloride, 20% tartaric acid, and 20% sucrose as a 
10% aqueous solution was effective in reducing the healing time of chrome sores on the skin of guinea
pigs to which potassium dichromate had been applied (Samitz and Epstein 1962).  Thorough irrigation
with water has been recommended if the eyes have been exposed (Haddad et al. 1998; Schonwald 2004).
Both the cytotoxic effects of chromium(III) chloride, chromium(III) nitrate, sodium chromate(VI), 
sodium dichromate(VI), potassium dichromate(VI), and chromium(V) potassium sulfate dodecahydrate
and the ability of ascorbic acid, glutathione 4-acetamido-4'-isothiocyanato-2,2-stibenedisolphonic acid 
(SITS) to prevent chromium toxicity in transformed human keratinocytes were examined (Little et al.
1996).  This cell line was used because histopathological studies have shown that dichromate compounds
have caused keratinocyte necrosis.  Cells were exposed to the chromium salts for 24 hours, and the
viability of the cultures was examined for their ability to take up neutral red dye and release lactate 
dehydrogenase into the media.  None of the chromium(III) or chromium(V) salts seemed toxic to the cells
at concentrations up to about 100 μM.  The chromium(VI) salts showed toxicity at about 8 μM, and there
was little cell survival at 100 μM.  The dose-response curves were similar for all chromium(VI) salts
tested.  Similar experiments were conducted with normal human keratinocytes obtained from
abdominoplasties or breast reductions from six donors and treated with sodium dichromate.  The toxicity
to normal cells overall seemed to be less than in the transformed line.  Ascorbic acid at 500 μM
completely inhibited the cell toxicity caused by chromium(VI), whereas glutathione and SITS were less 
effective.  Ascorbate probably protected cells by reducing chromium(VI) and chelation of the reduced
complex.  Glutathione may have formed complexes with the chromium(VI), which eventually led to 
chromium(III), whereas SITS may have inhibited the cellular uptake of the chromate by altering the
nonspecific membrane anion carrier.  The authors conclude that these available drugs provide protection 
against cytotoxicity to keratinocytes involved in dermatitis and may be useful to prevent toxic reactions to 
metals contacting the skin.
The effect of decreasing the concentration of water-soluble chromium in cement from about 10 to 2 ppm
on the incidences of chromium-induced dermatitis was examined among construction workers in Finland 
   
 
















     
 
  





    
   
   
  
   
  
   
    
  
   
  






(Roto et al. 1996).  After 1987, when the decrease occurred, allergic dermatitis caused by chromium in 
the industry was reduced by 33% from previous levels, whereas irritant contact dermatitis remained
unchanged.
3.11.2 Reducing Body Burden
Once chromium has been absorbed, it can be widely distributed throughout the body (see Section 3.4.2).  
Forced diuresis with careful monitoring of fluid and electrolyte status has been suggested, but not proven, 
to increase the elimination of chromates (Haddad et al. 1998).  In a case report of a fatality after ingestion
of potassium chromate, hemodialysis and charcoal hemoperfusion did not significantly remove chromium
from whole blood and had little effect on the management of chromium toxicity (Iserson et al. 1983).  
However, hemodialysis was effective in saving the life of an electroplater who accidentally swallowed
plating fluid containing chromium trioxide (Fristedt et al. 1965).  Because chromium may be sequestered 
in erythrocytes, exchange transfusion has been used as a way to decrease the body burden in serious acute 
poisoning (Kelly et al. 1982).
Both chromium(VI) and chromium(III) can be transported in the blood.  Chromium(III) tends to bind to 
plasma proteins and is excreted in the urine.  Chromium(VI) may be poorly reduced to chromium(III) in 
plasma, but this reduction can be enhanced by the intravenous administration of ascorbic acid (Korallus et
al. 1984).  However, reactions of chromium(VI) with sulfhydryl compounds or ascorbate may have mixed 
effects on toxicity, since such reactions yield reactive chromium intermediates, reactive oxygen species,
and free cysteinyl and carbon radical species, which may be more damaging than chromium(VI) itself
(Reynolds and Zhitkovich 2007; Shi et al. 1994; Stearns et al. 1994).  Generally, treatments for reducing
body burden of chromium are chelation therapies similar to those used to reduce body burdens of other
metals, although the use of ascorbic acid is specific for chromium.  Use of hemodialysis and
N-acetylcysteine has been suggested to enhance elimination (Haddad et al. 1998; Leikin and Paloucek
2002; Schonwald 2004), however, this has not been proven.  N-acetylcysteine, the glutathione precursor,
was reported to be more effective than EDTA or dimercaptosuccinic acid in increasing the urinary
excretion of chromium in rats (Banner et al. 1986; Nadig 1994); however, chelation with agents available 
in human clinical medicine, such as British Anti Lewisite (dimercaprol) and EDTA, has been shown to be 
generally ineffective in increasing the elimination of chromium (Ellis et al. 1982). However, calcium
EDTA, administered intravenously, resulted in a rapid increase in the urinary excretion of chromium in 
metal workers (Sata et al. 1998).  Other polyaminocarboxylic acid chelating agents may be effective in 
removing chromium from organs.  In rats injected with potassium chromate, subsequent treatment with
   
 













   
  
    
   
    
   
      
    
    
  
    
 
   
 




    
    
 
  
     
  
    
 
    




various polyaminocarboxylic acid chelating agents resulted in significant removal of chromium from the 
liver, kidney, heart, or brain, depending on the agent.  Ethylenediamine N,N'-diacetic acid (EDDA)
removed significant amounts of chromium from the liver and heart.  Ethylenediamine N,N'-di 
(O-hydroxyphenyl acetic acid (EDDHA) removed significant amounts of chromium from the kidney, 
heart, and brain.  N-(2-hydroxyethyl)ethylenediamine triacetic acid (HEDTA) removed significant
amounts of chromium from the liver and kidney.  Hexamethylene 1,6-diamino N,N,N',N'-tetraacetic acid
(HDTA) removed significant amounts of chromium from the liver, kidney, and brain.  Triethylene
tetramine N,N,N',N',N'',N''-hexaacetic acid (TTHA) removed significant amounts of chromium from the
liver.  Ethyleneglycol-bis-(2-aminoethyl) tetraacetic acid (EGATA) did not remove significant amounts of
chromium from any of the organs.  The relative ability of the polyaminocarboxylic acids to remove
chromium from organs may be related to the number of amino or carboxyl groups as complexing centers
or by the presence of hydroxyl groups (Behari and Tandon 1980).  The use of these agents in humans has
not been tested.  Chromium(VI), but not chromium(III), can readily cross cell membranes.
Chromium(VI) readily enters erythrocytes, where it is reduced to chromium(III) by glutathione, and
chromium(III) is essentially trapped within erythrocytes, where it binds to proteins, primarily
hemoglobin.  This may explain the fact that chromium shows little toxicity at sites distant from
administration sites (De Flora and Wetterhahn 1989).  The chromium(III) trapped within the erythrocytes
would be released upon natural destruction of the erythrocyte and excreted in the urine.
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
The reduction of chromium(VI) to chromium(III) inside of cells may be an important mechanism for the
toxicity of chromium, whereas reduction of chromium(VI) outside of cells may be a major mechanism of
protection.  After entering target cells, chromium(VI) itself and/or the metabolically reduced valence 
states exert toxic effects, as discussed in detail below (De Flora and Wetterhahn 1989).  Administration of
a reducing agent (such as ascorbate) early enough after exposure to reduce chromium(VI) to 
chromium(III) in extracellular fluids before chromium(VI) penetrates cells may reduce toxicity; however,
increased intracellular ascorbate may enhance toxicity.  For example, in animal studies, ascorbic acid has
been shown to protect against lethality of dermal potassium dichromate (Samitz 1970) and prevent
nephrotoxicity of subcutaneously administered potassium chromate (Powers et al. 1986). However,
increased intracellular ascorbate concentrations has been shown to enhance chromium(VI) toxicity in 
cultured human fibroblasts (Reynolds and Zhitkovich 2007).  Therefore, agents that enhance reduction of
chromium(VI) to chromium(III) may have mixed effects on toxicity.  The effect of ascorbate or other
reducing agents on chromium toxicity in humans has not been established.
   
 









   
 
  
      
   
 
   
  
  
   
    
    





      
  
 
   
    
 
     
   
    
 
    
   
    




Once chromium enters the cell, ligand displacement and/or redox reactions of chromium(VI) with
enzymes, proteins, and other molecules leads to reduction to chromium(V), chromium(IV), and 
chromium(III), with the generation of active oxygen species and radicals.  The resulting toxicity depends
on the nature of the cellular component that reacts with chromium(VI) and on the nature of the reactive
species formed from the reaction.  Chromium(VI) can be reduced metabolically by a number of cellular
components under physiological conditions.  Reduction by glutathione or cysteine can lead to generation 
of all valence states (particularly chromium(V)) and radicals.  For example, in vitro reaction of
chromium(VI) with glutathione led to the formation of glutathione thiyl radicals and chromium(V)
complexes (Aiyar et al. 1991).  Chromium(V)-glutathione complexes have been shown to form DNA
adducts.  Reduction by ascorbate leads to chromium(III), but chromium(V) has been generated by the
reaction of chromium(VI) with riboflavin (vitamin B2) and ribose derivatives (De Flora and Wetterhahn
1989).  Reaction of chromium(VI) with hydrogen peroxide has led to the formation of chromium(V)
complexes and hydroxyl radicals (Aiyar et al. 1991).  Other important intracellular reduction reactions of
chromium(VI) involve enzyme-catalyzed and NADPH-dependent mechanisms.  Microsomal reduction of
chromium(VI) by cytochrome P450 to chromium(III) may involve the transient formation of
chromium(V) (De Flora and Wetterhahn 1989).  Chromium(III), the final stable product of chromium(VI)
reduction, can form chromium-DNA adducts and mediate crosslinking of DNA strands and DNA protein 
(De Flora and Wetterhahn 1989; Manning et al. 1992; Xu et al. 1996).  Thus, the metabolic reduction of
chromium(VI) may represent bioactivation and/or detoxification.  If a bioactivation process, intracellular
reduction of chromium(VI) would lead to the ultimate toxic species.  Conversely, if chromium(VI) is the 
toxic agent, then effects would be elicited only if the amount of chromium(VI) entering target cells
saturates the reducing mechanisms.
Differences in the intracellular metabolic pathways that result in the reduction of chromium(VI) will 
affect the nature of the reactive intermediates.  For example, chelating ligands, such as glutathione and 
sugars, stabilize chromium(V) as an oxidation state, increasing its lifetime in the cell and ability to reach
DNA in the nucleus.  Cytochrome P450-dependent reduction of chromium(VI) to chromium(V) and 
chromium(IV), with generation of reactive radicals, which takes place in the endoplasmic reticulum, 
could occur in close enough proximity to the nuclear membrane and nonenzymatic reduction within the
nucleus could occur in close enough proximity to chromatin for the transient intermediates to exert their
effects, such as DNA strand breaks and radical-DNA adducts.  As noted above, chromium(III) can form
chromium-DNA adducts and mediate crosslinking of DNA strands and DNA protein (De Flora and 
Wetterhahn 1989).
   
 



















   
  






   
    
   
  
   
 
   
   
    





The role of glutathione in chromium-induced renal toxicity was investigated by Hojo and Satomi (1991).  
Male ddY mice (6 animals per dose group) were administered potassium dichromate(VI) (0.6 mmol
chromium/kg), potassium tetraperoxochromate(V) (1.0 mmol/kg), green chromium(V)-glutathione
complex (1.0 mmol/kg), and chromium nitrate(III) (0.6 mmol/kg); animals were sacrificed 24 hours after
chromium injection and changes in kidney weight and function were assessed.  Chromium(VI) resulted in 
a 10.7%±2.7 decrease in body weight, a 2-fold increase in serum urea nitrogen, a decrease in kidney
nonprotein sulfhydryl contents (3.3±0.1 versus control values of 3.7±0.1) and a decrease of kidney-
glutathione reductase activity from a control value of 17.4±1.5 to 14.1±1.3 U/g.  Potassium
tetraperoxochromate(V) treatment resulted in 50% of the animals dying.  Body weights and kidney-
glutathione reductase activity were much lower than for animals treated with chromium(VI), and serum
urea levels were 102.9±17.7 mg/dL, which is about twice that observed in animals treated with 
chromium(VI).  The chromium(V) glutathione complex was much less toxic and showed values that were
similar or close to control values.  Pretreatment with 10 mmol/kg glutathione methyl ester in the
chromium(VI)-treated animals appeared to reduce the body weight loss and caused the serum urea levels 
to be normal.  Butathione sulfoximine (an inhibitor of glutathione synthesis) greatly enhanced the levels
of serum urea, loss of glutathione reductase activity and decrease in kidney nonprotein sulfhydryl groups.  
Butathione sulfoximine pretreatment resulted in one of the six animals dying.  Animals treated with 
chromium(III) experienced weight loss, but other parameters were not markedly changed from control
values.  Pretreatment with butathione sulfoximine in animals treated with chromium(III) only caused a
decrease in kidney nonprotein sulfhydryl groups.  The authors indicated that with excess levels of
glutathione, chromium(VI) is more readily reduced to chromium(III), whereas at lower levels of
glutathione the reduction process is slower, resulting in slower reduction of the more toxic intermediate
chromium(V).  Also, at higher concentrations of glutathione, chromium(V)-glutathione complexes may
form which may prevent chromium(V) from reacting at target sites that elicit toxic responses.
As discussed above, reactive intermediates formed during intracellular reduction of chromium(VI) to 
chromium(III) may interact with hydrogen peroxide, generating hydroxyl radicals, which can induce cell
damage.  Several animal and in vitro studies have assessed the effects of anti-oxidant agents on 
chromium-induced oxidative cell injury.  Administration of folic acid, a free radical scavenger, to rabbits 
reduced potassium dichromate-induced increases in the concentration of free radical in liver, testes, brain, 
kidney, and lung and in serum liver enzyme activities of AST and ALT (El-Demerdash et al. 2006). 
Vitamin E, an antioxidant, has been shown to reduce potassium dichromate-induced renal toxicity and 
hepatotoxicity in rats (Appenroth et al. 2001; Arreola-Mendoza et al. 2006; Rao et al. 2006).  Vitamin B6, 
   
 








   
       
  
 
   
  
    
    
     
    
   
      
    
 
    





   
      
   
 
   
   
  





which may have anti-oxidant potential due to its role as a co-factor in the synthesis of cysteine, reduced
oxidative stress in the liver of rats exposed to potassium dichromate (Anand 2005). In vitro studies 
indicated that vitamin E protected against, while vitamin B2 enhanced, the cytotoxicity and DNA single-
strand breaks induced by sodium chromate in Chinese hamster cells.  Formation of DNA-protein 
crosslinks by chromium(VI) in cell culture was prevented by addition of ascorbic acid (Capellmann et al.
1995), and ascorbic acid protected cells against chromosomal breakage and apoptosis.  In rats, vitamin C
was reported to prevent the effects of chromium(VI) on ovarian follicular development and the alterations 
in serum levels of estradiol, progesterone, and testosterone (Banu et al. 2008).  Vitamin E also protected 
cells against chromosomal breaks (Blankenship et al. 1997) and decreased chromium(III)-induced 
oxidative damage to calf thymus DNA in vitro, as indicated by decreased formation of
8-hydroxydeoxyguanosine (Qi et al. 2000). Vitamin E may exert its protective effect by scavenging 
radicals and/or chromium(V) during the reduction of chromium(VI) (Sugiyama 1991).  Selenium (as
sodium selenate), an essential trace element, was protective of chromium(VI) toxicity in rat hearts 
(Soudani et al. 2011c).  Selenium (as sodium selenate) also has been shown to reduce the genotoxicity of
chromium dichromate in human lymphocytes in vitro as assessed by the Comet assay, although sodium
selenite and selenous acid enhanced chromium-induced DNA damage; sodium selenate also decreased
chromium-induced genotoxicity in S. typhimurium (strain TA102), as assessed by the Ames assay
(Cemeli et al. 2003).  Other vitamins or essential elements might also be effective in mitigating the effects 
of chromium by modulating the metabolic processes.  The use of vitamins and essential elements for
reducing the toxicity of chromium has not been studied in humans.
Thyroxine was found to ameliorate acute renal failure induced in rats by potassium dichromate, possibly
by stimulating gluconeogenesis and Na-K ATPase activity in the renal cortex, influencing protein 
synthesis, and promoting glucose and amino acid uptake by epithelial cells.  These events would be
expected to aid in the repair and regeneration of the damaged tubular epithelial cells (Siegel et al. 1984).
The use of thyroxine has not been tested in humans.
Todralazine, an antihypertensive drug, was found to markedly reduce the mutagenic activity of potassium
dichromate(VI) in the bacterial tester strain TA100 and in the B. subtilis rec assay (Gasiorowski et al. 
1997).  Spectroanalysis indicated that chromium(VI) was reduced to chromium(III) by todralazine and 
that todralazine formed a complex with the chromium(III) ions.  The reduction and complexing of
chromium may have prevented chromium from crossing the membrane and may have prevented harmful
interactions with DNA.  Another study by this group found that complexing copper(II) chromate(VI) to 
organic ligands (e.g., 2-(2'-pyridyl)imidazole, 2,2'-bipyridyl, 1,10-phenanthroline) resulted in a decrease 
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in the mutagenicity of chromium(VI) as assessed by the Ames and B. subtilis rec assays (Gasiorowski et
al. 1998). 
3.12  ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of chromium is available. Where adequate information is not
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing
methods to determine such health effects) of chromium. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Chromium
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
chromium are summarized in Figures 3-8 and 3-9.  The purpose of these figures is to illustrate the
existing information concerning the health effects of chromium.  Each dot in the figures indicates that one 
or more studies provide information associated with that particular effect. The dot does not necessarily
imply anything about the quality of the study or studies, nor should missing information in this figure be
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature.
A major source of oral exposure of humans to chromium is via the diet including chromium-rich diet 
supplements.  Chromium(III) at low levels is essential to nutrition, and studies of chromium deficiency
have been conducted.  Information regarding health effects of exposure to chromium(VI) or
chromium(III) in humans comes mainly from case reports of acute accidental or intentional ingestion,
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acute accidental dermal exposure, and from occupational case reports and epidemiology studies, which 
primarily involve inhalation and dermal exposure.  In occupational studies, it is often difficult to separate
exposure to chromium(VI) from chromium(III).  Case reports have shown that ingestion and dermal
contact with chromium(VI) can cause death. These reports have also described the serious systemic and
neurological sequelae of exposure leading to death.  Occupational exposures to chromium(VI) and/or
chromium(III) are associated with respiratory and nasal, cardiovascular, gastrointestinal, hematological,
hepatic, renal, and dermal effects.  Immunological effects in humans exposed by inhalation and dermal
contact consist of sensitization resulting in asthma and contact dermatitis, which can be exacerbated by
oral exposure.  Limited information was available regarding reproductive effects of occupational
exposure to chromium(VI).  Limited information was found on neurological behavioral effects.  
Information is also available regarding genotoxic effects in workers exposed to chromium(VI) and cancer
in workers exposed to chromium(VI) and/or chromium(III).
Information regarding the levels of exposure to chromium(VI) compounds that cause death in animals is
available for the inhalation, oral, and dermal routes.  Information regarding respiratory effects of acute
inhalation exposure of animals to chromium(VI) was available.  Acute oral studies have evaluated effects 
of chromium(VI) on hematology and clinical chemistry.  Acute dermal exposure of animals to
chromium(VI) can cause irritation, edema, necrosis, and chrome sores.  Information on systemic effects 
of chromium(VI) in animals is available for intermediate- and chronic-duration exposure by the inhalation 
route.  Information regarding effects of oral exposure is available for intermediate and chronic durations.
The immunological effects of chromium(VI) in animals have been studied after inhalation and dermal
exposure.  An inhalation study reported no developmental or reproductive effects of chromium(VI).  The
reproductive and developmental effects of oral chromium(VI) have been evaluated following oral
exposure, showing adverse effects, particularly to the male reproductive system.  Information regarding
the genotoxicity and carcinogenicity of chromium(VI) is available for both the inhalation and oral routes.  
Information regarding levels of chromium(III) compounds that result in death is available only for the
oral route.  Systemic effects of acute-duration exposure to chromium(III) are limited to the respiratory
system- and intermediate-duration inhalation exposure to chromium(III) are limited to the respiratory
system. Information on systemic effects of chronic inhalation exposure to chromium(III) is limited to a 
study that used a mixture of chromium(VI) and chromium(III).  Studies of intermediate- and chronic
duration oral exposure to chromium(III) failed to find any systemic, neurological, developmental, 
reproductive, or carcinogenic effects.  The immunological and genotoxic effects of chromium(III) in 
   
 








   
    
    
    
 
   
 
  
    









      
    
   
  
   
    
   
   
  








animals have not been tested by the oral route.  Information regarding effects of dermal exposure of
animals to chromium(III) is limited to a study of skin ulceration after acute exposure and dermal
sensitization tests. One report of chronic renal failure after ingestion of over-the-counter chromium
picolinate at 0.6 mg/day was found in literature (Wasser et al. 1997).
In addition to the information on chromium(VI) and chromium(III), limited information is available
regarding health effects of chromium(0) and chromium(IV).  Briefly, the available information on 
chromium(0) consists of studies that examined workers at an alloy steel plant (Triebig et al. 1987) and 
boilermakers (Verschoor et al. 1988) for possible renal effects.  Information on chromium(IV) consists of
a 2-year inhalation study of chromium dioxide in rats that found no effects upon hematological, clinical
chemistry, and urinalysis parameters and no histopathological effects on respiratory, cardiovascular,
gastrointestinal, hepatic, renal, dermal/ocular, neurological, and reproductive organs (Lee et al. 1989).
3.12.2 Identification of Data Needs 
Acute-Duration Exposure.    Acute inhalation exposure of humans to chromium(VI) as occurs in 
occupational settings can result in respiratory irritation (dyspnea, cough, wheezing, sneezing, rhinorrhea, 
choking sensation), dizziness, and headache at high concentrations, and can trigger asthmatic attacks in
sensitized individuals (Lieberman 1941; Meyers 1950; Novey et al. 1983; Olaguibel and Basomba 1989).  
High airborne levels of chromium(VI) can also cause gastrointestinal irritation (Lucas and Kramkowski
1975; Mancuso 1951; Meyers 1950).  Information on toxic effects in humans after oral exposure to
chromium(VI) is limited to case reports of humans who ingested lethal or near lethal doses.  Serious
respiratory, cardiovascular, gastrointestinal, hematological, hepatic, renal, and neurological effects have 
been described as sequelae leading to death (Clochesy 1984; Iserson et al. 1983; Kaufman et al. 1970;
Saryan and Reedy 1988). Acute dermal exposure can cause skin burns and can also have similar sequelae
that lead to death (Brieger 1920; Major 1922).  No information regarding systemic effects of acute
inhalation exposure of animals to chromium(VI) was located.  Information regarding effects of acute oral
exposure of animals to chromium(VI) include a report of gastrointestinal hemorrhage in rats given a lethal
dose of potassium dichromate (Samitz 1970), evaluations of hematology and clinical chemistry
parameters in rats and mice exposed for 4–5 days (NTP 2007, 2008a) and increased resorptions in mice
given potassium dichromate during gestation (Junaid et al. 1996b).  Information regarding effects of acute
dermal exposure of animals to chromium(VI) is limited to studies of dermal irritation and sensitization
(Gad et al. 1986; Merkur'eva et al. 1982; Samitz 1970; Samitz and Epstein 1962).  The information in 
humans indicates that many organs can be targets of acute exposure to chromium(VI) if exposure levels 
   
 









   
   
   
    
  
  




   
  
    
   
  
 
      
 
    
 
   
   
    
  




     
  




are high enough.  Studies in animals show that hematological effects occur following acute oral exposure 
and may be the earliest indication of more severe adverse effects observed following longer duration
exposures. No information was located regarding systemic effects in humans after acute exposure to
chromium(III) compounds by any route.  Acute inhalation studies of chromium trichloride in hamsters
(Henderson et al. 1979) and chromic oxide and basic chromium sulfate in rats (Derelanko et al. 1999)
indicated that the respiratory system is also a target of chromium(III) exposure.  Acute dermal studies 
show that chromium(III) can be a sensitizer, and that dermal challenge of sensitized individuals with 
chromium(III) compounds can elicit a response (Hansen et al. 2003; Samitz and Epstein 1962).  LD50 
values for chromium(VI) and chromium(III) compounds indicate that chromium(III) is less toxic than 
chromium(VI) (Shubochkin and Pokhodzie 1980; Smyth et al. 1969; Vernot et al. 1977).
Additional studies involving acute exposure to both chromium(VI) and chromium(III) compounds by all
routes would be helpful, especially if they evaluated comprehensive toxicological end points and 
exposure-response relationships.  Studies defining the possible synergistic effects of chromium with other
nephrotoxins, such as mercury and cadmium, which may be stored together at toxic waste sites, would 
also be useful.  There are populations surrounding hazardous waste sites that might be exposed to the
substance for short periods; therefore, this information is important.
Intermediate-Duration Exposure. There are no studies regarding systemic effects in humans after
oral exposure of intermediate duration to either chromium(VI) or chromium(III).  Intermediate-duration 
exposure to primarily chromium(VI) in occupational studies caused nasal and respiratory effects (Bovet et
al. 1977; Davies et al. 1991; Gomes 1972; Kleinfeld and Rosso 1965; Lee and Goh 1988; Sorahan et al. 
1987; Taylor 1966).  Intermediate-duration exposure in occupational settings involving dermal exposure
also can cause chrome ulcers or holes in the skin (Gomes 1972; Lee and Goh 1988; Lieberman 1941; PHS
1953; Smith 1931).  An MRL of 5x10-6 mg chromium(VI)/m3 has been determined for upper respiratory
effects in humans after intermediate-duration inhalation exposure to chromium(VI) as chromium(VI)
trioxide mist and other hexavalent chromium mists and dissolved aerosols, based on the study by
Lindberg and Hedenstierna (1983).
The respiratory tract and the immune system are targets in animals exposed to chromium(VI) and
chromium(III) via inhalation for intermediate durations (Adachi 1987; Adachi et al. 1986; Glaser et al. 
1985, 1990; Johansson et al. 1986a, 1986b), with LOAEL values identified for respiratory and immune
effects after inhalation (Glaser et al. 1985, 1990).  An MRL of 0.0003 mg chromium(VI)/m3 has been
determined for lower respiratory effects in humans after intermediate-duration inhalation exposure to
   
 








   
 
  




   




   
  
    
   
  
   
    
   
  
 
   
   
    
   
      
 
 
     
  




chromium(VI) as particulate hexavalent compounds based on the study in rats by Glaser et al. (1990).  An 
intermediate-duration study on chromium(III) compounds in rats identified respiratory system as the 
target for inhaled insoluble chromic oxide and soluble basic chromium sulfate (Derelanko et al. 1999).  
Based on differences in respiratory effects of these two compounds, distinct intermediate-duration MRLs
were derived for insoluble and soluble trivalent chromium compounds.  The minimal LOAEL of 3 mg
chromium(III)/m3 for septal cell hyperplasia and chronic interstitial inflammation of the lung in male rats 
exposed to chromic oxide was used to derive the intermediate-duration inhalation MRL of 0.005 mg
chromium(III)/m3 for insoluble trivalent chromium compounds.  The LOAEL of 3 mg chromium(III)/m3 
for lesions of the larynx (granulomatous inflammation) and nose (inflammation) in female rats exposed to 
basic chromium sulfate was used to derive the intermediate-duration inhalation MRL of 0.0001 mg
chromium(III)/m3 for soluble trivalent chromium compounds.
The gastrointestinal and hematological systems were identified as the primary targets of intermediate-
duration oral exposure of rats and mice exposed to chromium(VI) in drinking water (NTP 2007, 2008a).  
An intermediate-duration oral MRL of 0.005 mg chromium(VI)/kg/day has been determined for
hematological effects (e.g., microcytic, hypochromic anemia) in rats after intermediate-duration oral
exposure to chromium(VI) as sodium dichromate dihydrate in drinking water in a study by NTP (2008a).  
In addition, developmental and reproductive studies identify chromium(VI) as a reproductive and 
developmental toxicant in monkey, rats, and mice after oral exposure (Al-Hamood et al. 1998; Aruldhas
et al. 2004, 2005, 2006; Bataineh et al. 1997; Chowdhury and Mitra 1995; Junaid et al. 1996b; Kanojia et
al. 1996, 1998; Subramanian et al. 2006; Trivedi et al. 1989; Yousef et al. 2006; Zahid et al. 1990).  Oral
studies of intermediate-duration in rats and mice reported no effects of chromium(III) in any system
(Ivankovic and Preussmann 1975; NTP 2008b; Shara et al. 2005).  Adverse reproductive effects were
observed following oral exposure to chromium(III), although NOAEL values were not established.  No
dermal studies of intermediate duration in animals were located. The toxicity of intermediate-duration 
exposure to chromium compounds is relatively well characterized for the oral and inhalation routes. 
Dermal studies would be useful to determine possible target organs other than the skin.  There are
populations surrounding hazardous waste sites that might be exposed to the substance for similar
durations.
Chronic-Duration Exposure and Cancer. The respiratory system (Bovet et al. 1977; Cohen et al.
1974; Davies et al. 1991; Gibb et al. 2000a; Keskinen et al. 1980; Kleinfeld and Rosso 1965; Kuo et al. 
1997a; Letterer 1939; Lindberg and Hedenstierna 1983; Lucas and Kramkowski 1975; Mancuso 1951;
Meyers 1950; Novey et al. 1983; Olaguibel and Basomba 1989; Sassi 1956; Sluis-Cremer and du Toit
   
 













   





   
  
 
    
   
 
    
   
    





     




    




1968; Sorahan et al. 1987; Taylor 1966) and the skin (Gomes 1972; Hanslian et al. 1967; Lee and Goh 
1988; Lieberman 1941; PHS 1953; Royle 1975b) are the primary target organs for occupational exposure
to chromium and its compounds.  An MRL of 5x10-6 mg chromium(VI)/m3 has been determined for upper
respiratory effects in humans after chronic-duration inhalation exposure to chromium(VI) as
chromium(VI) trioxide mist and other hexavalent chromium mists and dissolved aerosols, based on the
study by Lindberg and Hedenstierna (1983). There are more data regarding the effects of chronic 
inhalation exposure in humans and animals than there are regarding the effects of oral exposure.  Studies 
of populations residing in areas contaminated with chromium(VI) in China have found such effects as 
oral ulcer, diarrhea, abdominal pain, indigestion, vomiting, constipation, nose and eye irritation, 
headache, fatigue, dizziness, and leukocytosis (Zhang and Li 1987).  Chronic inhalation studies with rats, 
mice, guinea pigs, and rabbits also identify the respiratory system as the main target of chromium(VI) and
chromium(III) exposure (Glaser et al. 1986, 1988; Nettesheim and Szakal 1972; Steffee and Baetjer
1965).  Chronic oral exposure studies in rats and mice exposed to chromium(VI) in drinking water
identify the hematological and gastrointestinal systems as the primary targets of chronic oral exposure 
(NTP 2008a), with gastrointestinal effects more sensitive than hematological effects.  A chronic-duration 
oral MRL of 0.0009 mg chromium(VI)/kg/day based on gastrointestinal effects (diffuse epithelial
hyperplasia of the duodenum) was derived for hexavalent chromium compounds.  Chronic oral exposure
to chromium(III) compounds did not result in any target organ toxicity in animals (Ivankovic and 
Preussmann 1975; MacKenzie et al. 1958; NTP 2008b; Schroeder et al. 1965; Shara et al. 2007); thus, no 
chronic-duration MRL was derived for chromium(III) compounds since target organs have not been
identified and no NOAEL for reproductive effects of oral exposures has been adequately characterized.
As noted above, the skin is a sensitive target of toxicity in workers exposed to airborne chromium (the
effects resulted from direct dermal contact with chromium).  No chronic dermal studies in animals were
located.  Because water and soil sources can be contaminated near hazardous waste sites, more 
information regarding chronic oral or dermal exposure would be useful.
Cancer. Occupational and environmental epidemiological studies indicate a correlation between long-
term exposure to chromium(VI) compounds and lung cancer (Alderson et al. 1981; Baetjer 1950;
Bidstrup 1951; Bidstrup and Case 1956; Braver et al. 1985; Cole and Rodu 2005; Crump et al. 2003;
Dalager et al. 1980; Davies 1979, 1984; Davies et al. 1991; EEH 1976, 1983; Enterline 1974; Franchini et
al. 1983; Frentzel-Beyme 1983; Gibb et al. 2000b; Goldbohm et al. 2006; Haguenoer et al. 1981; Hayes et
al. 1979, 1989; Korallus et al. 1982; Langård and Norseth 1975; Langård and Vigander 1983; Langård et
al. 1980; Machle and Gregorius 1948; Mancuso 1975, 1997a; Mancuso and Hueper 1951; Ohsaki et al. 
1978; Park and Stayner 2006; Park et al. 2004; Pastides et al. 1994; PHS 1953; Rosenman and Stanbury
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1996; Sassi 1956; Satoh et al. 1981; Sheffet et al. 1982; Silverstein et al. 1981; Sjogren et al. 1987;
Sorahan et al. 1987; Taylor 1966; Zhang and Li 1987).  Occupational studies generally consider
inhalation exposures, while environmental studies involve exposure by inhalation, ingestion, and dermal
contact.  Additional studies on populations exposed to chromium in drinking water would be useful to 
determine if a causal relationship with cancer exists.  A unit risk for cancer from inhalation exposure to
chromium(VI) compounds has been derived (IRIS 2008) from an occupational study (Mancuso 1975).  
Chronic inhalation of chromium(VI) compounds was carcinogenic in rats (Glaser et al. 1986) and mice
(Nettesheim et al. 1971), and the 2-year carcinogenicity study on oral chromium(VI) provided clear
evidence of oral cancers in rats and gastrointestinal cancers in mice (NTP 2008a). Cancer studies by
parenteral route support the conclusions that chromium(VI) is carcinogenic (Furst et al. 1976; Hueper
1955, 1958; Hueper and Payne 1959, 1962; Laskin et al. 1970; Levy et al. 1986; Roe and Carter 1969;
Steinhoff et al. 1986).  For chromium(III) compounds, evidence for carcinogenesis (preputial adenomas in
male rats) in the NTP (2008b) 2-year bioassay was equivocal. The available human and animal data are 
sufficient for determining that chromium(VI) is carcinogenic following inhalation and oral exposure.  
However, additional animal studies are needed to adequately assess the carcinogenic potential of
chromium(III) following inhalation and oral exposure.
Genotoxicity. Several studies evaluating chromosomal aberrations, sister chromatid exchange,
micronuclei, DNA strand breaks and DNA-protein crosslinks in workers exposed to chromium(VI) have
been conducted, some reporting positive results (Benova et al. 2002; Deng et al. 1988; Gambelunghe et
al. 2003; Koshi et al. 1984; Lai et al. 1998; Medeiros et al. 2003a; Sarto et al. 1982; Stella et al. 1982;
Vaglenov et al. 1999; Werfel et al. 1998; Wu et al. 2001) and some reporting negative results (Benova et
al. 2002; Gao et al. 1994; Hamamy et al. 1987; Husgafvel-Pursiainen et al. 1982; Littorin et al. 1983;
Medeiros et al. 2003a; Nagaya 1986; Nagaya et al. 1991).  However, most of these studies are limited by
factors such as lack of exposure data, co-exposure to other potentially genotoxic agents, and too few
workers for meaningful statistical analysis. Mostly positive results have been found in rodents and
D. melanogaster exposed to chromium(VI) compounds in vivo (De Flora et al. 2006; Gava et al. 1989a;
Itoh and Shimada 1993; Kaya et al. 2002; Kirpnick-Sobol et al. 2006; Mirsalis et al. 1996; NTP 2007;
Olvera et al. 1993; Paschin et al. 1982; Rasmuson 1985; Rodriguez-Arnaiz and Martinez 1986; Sarkar
et al. 1993; Shindo et al. 1989; Tsapakos et al. 1983b; Ueno et al. 2001; Wang et al. 2006; Wild 1978;
Zimmering et al. 1985).  Numerous in vitro genotoxicity studies have been conducted in bacteria 
(Bennicelli et al. 1983; De Flora 1978, 1981; Haworth et al. 1983; Kanematsu et al. 1980; Kortenkamp 
et al. 1996b; Llagostera et al. 1986; Nakamuro et al. 1978; Nishioka 1975; NTP 2007; Olivier and Marzin 
1987; Tagliari et al. 2004; Venier et al. 1982; Venitt and Levy 1974; Watanabe et al. 1998a; Yamamoto et
   
 








   
  
    
    
  
  
    






   
  
    
   
     
  
   
   
      
    
  
   
      
    
    






al. 2002), yeast (Bonatti et al. 1976; Fukunaga et al. 1982; Kirpnick-Sobol et al. 2006; Singh 1983),
cultured animal cell systems (Briggs and Briggs 1988; DiPaolo and Casto 1979; Douglas et al. 1980;
Elias et al. 1989b; Fornace et al. 1981; Kowalski et al. 1996; Levis and Majone 1979; MacRae et al. 1979;
Montaldi et al. 1987; Newbold et al. 1979; Ohno et al. 1982; Raffetto et al. 1977; Seoane and Dulout
1999; Sugiyama et al. 1986a; Tsuda and Kato 1977; Ueno et al. 1995a; Umeda and Nishimura 1979;
Venier et al. 1982; Wise et al. 1993; Yang et al. 1992), and human cell systems (Blasiak and Kowalik
2000; Depault et al. 2006; Douglas et al. 1980; Fornace et al. 1981; Gomez-Arroyo et al. 1981; Ha et al.
2004, 2004; Holmes et al. 2006; MacRae et al. 1979; Montaldi et al. 1987; Nakamuro et al. 1978; Sarto et
al. 1980; Stella et al. 1982; Sugiyama et al. 1986a; Trzeciak et al. 2000; Whiting et al. 1979; Wise et al.
2002, 2004, 2006a, 2006b), mostly with positive results.  The vast majority of studies, therefore, clearly
indicated that chromium(VI) compounds are genotoxic.
Genotoxicity data are also available for chromium(III) compounds.  A study in tannery workers, who 
were exposed mainly to chromium(III), reported negative results for chromosomal aberrations and sister
chromatid exchange (Hamamy et al. 1987), while positive results for micronuclei and DNA-protein 
crosslinks were reported in another study on tannery workers (Medeiros et al. 2003a).  Chromium
trichloride, chromium picolinate, and niacin-bound chromium(III) also did not cause DNA damage, or
increased frequencies of micronuclei in rats exposed in vivo (Cupo and Wetterhahn 1985; De Flora et al.
2006; NTP 2008b; Shara et al. 2005).  Transplacental exposure to chromium(III) chloride salt resulted in 
DNA deletions (Kirpnick-Sobol et al. 2006).  Mostly negative results have been found in in vitro
genotoxicity studies of chromium(III) compounds in bacteria (Bennicelli et al. 1983; De Flora 1981;
Kanematsu et al. 1980; Llagostera et al. 1986; Matsui 1980; Nishioka 1975; NTP 2008b; Olivier and
Marzin 1987; Petrilli and De Flora 1978b; Shara et al. 2005; Venier et al. 1982, 1989; Yamamoto et al.
2002), and mammalian cell systems (Fornace et al. 1981; Itoh and Shimada 1996; Le Curieux et al. 1992;
Levis and Majone 1979; MacRae et al. 1979; Newbold et al. 1979; Ohno et al. 1982; Raffetto et al. 1977;
Sarkar et al. 1993; Sarto et al. 1980; Shara et al. 2005; Stella et al. 1982; Tsuda and Kato 1977; Ueno 
et al. 1995a; Umeda and Nishimura 1979; Whiting et al. 1979; Wise et al. 1993; Yang et al. 1992).  
Chromium(III) did not increase the number of micronuclei in polychromatic erythrocytes in mice (Itoh
and Shimada 1996).  Several studies have found weakly positive or positive results in Chinese hamster
ovary cells (Coryell and Stearns 2006; Levis and Majone 1979; Stearns et al. 2002), mouse fetal cells
(Raffetto et al. 1977), mouse lymphoma cells (Whittaker et al. 2005), and human cell lines (Blasiak and
Kowalik 2000; Nakamuro et al. 1978; Stella et al. 1982).
   
 








    






    
  
    
   
  
 
      




     
  




     
   
 
 
   
 




Chromium(III) compounds are less genotoxic than chromium(VI) compounds in intact cell systems
because of the relative inability of chromium(III) to cross cell membranes; however, chromium(III) is 
more genotoxic than chromium(VI) when tested in vitro in subcellular targets (Kowalski et al. 1996;
Snow 1991; Snow and Xu 1989).  The reduction of chromium(VI) to chromium(III) as the ultimate
genotoxicant within cells may account for the genotoxicity of chromium(VI) (Beyersmann and Koster
1987).  However, in intact cells, chromium(III) appears less genotoxic than chromium(VI) due to 
decreased cellular permeability to chromium(III).
Additional studies in workers with known levels of chromium exposure that control for confounding
factors would be useful for defining levels at which chromosomal aberrations occur in humans exposed to 
chromium(VI) in the workplace.  Also, better dose-response relationships would be useful for the various
genotoxic and regulatory effects observed with chromium to better determine which end points are the
most sensitive and dominant at exposures near environmental levels.
Reproductive Toxicity. No reliable information was located regarding reproductive effects in
humans after inhalation, oral, or dermal exposure to chromium or its compounds. Studies in women 
exposed occupationally also show that chromium can be transferred to fetuses through the placenta
(Shmitova 1980).  Inhalation studies would be useful for determining the reproductive toxicity of inhaled 
chromium and compounds and for establishing exposure-response relationships. Adverse effects on the 
male reproductive system (included decreased spermatogenesis and histopathological alterations to the 
epididymis) were observed in monkeys exposed to chromium(VI) in drinking water for 180 days
(Aruldhas et al. 2004, 2005, 2006; Subramanian et al. 2006).  Effects on spermatogenesis were reported in
male rats given chromium(VI) by gavage for 90 days (Chowdhury and Mitra 1995) and in rabbits exposed
to chromium(VI) in drinking water for 10 weeks (Yousef et al. 2006).  In male mice, oral exposure of
intermediate duration to chromium(VI) or chromium(III) was reported to result in decreased 
spermatogenesis and cellular degeneration of the outer layer of seminiferous tubules (Zahid et al. 1990);
alterations in testicular, seminal vesicle, and preputial gland weights and decreased fertility were observed
in mice following intermediate-duration exposure to chromium(VI) or chromium(III) (Elbetieha and Al-
Hamood 1997).  However, results of the study by Elbetieha and Al-Hamood 1997 should be interpreted 
with caution due to concern regarding experimental methods (see discussion in Section 2.3, Minimal Risk
Levels).  But other studies found no reproductive effects in male or female mice (NTP 1996a, 1996b, 
1997, 2007, 2008a) exposed to chromium(VI) or chromium(III) (NTP 2008b; Shara et al. 2005, 2007).  
Alterations in sexual behavior and aggressive behavior toward other males were observed in male rats 
exposed to chromium(VI) or chromium(III) (Bataineh et al. 1997).  Female mice or rats exposed orally to 
   
 





















   
   
     
      
 
   
  
 
      
     
 
    
   
  
     
   






chromium(VI) compounds prior to mating (Junaid et al. 1996a; Kanojia et al. 1996, 1998) or female mice
exposed during gestation (Junaid et al. 1996b; Trivedi et al. 1989) had increased fetal resorptions and 
decreased litter size.  Alterations in ovarian and uterine weights and impaired fertility were observed in
female mice that were exposed to chromium(III) or chromium(VI) and then were mated with unexposed
mice (Elbetieha and Al-Hamood 1997); however, these results should be interpreted with caution due to 
concern regarding experimental methods (see discussion in Section 2.3, Minimal Risk Levels).
Reductions in numbers of follicles and ova/mouse were seen following oral chromium(III) exposure
(Murthy et al. 1996).  Impaired development of the reproductive system was observed in the female 
offspring of mice exposed to potassium dichromate(VI) or chromium(III) chloride (Al-Hamood et al. 
1998).  A decrease in the number of pregnancies was observed in female rats administered 33.6 mg
chromium(III)/kg/day as chromium chloride (by gavage) on gestational days 1–3; the same treatment on 
gestational days 4–6 did not alter the number of pregnancies (Bataineh et al. 2007).  Distribution studies
in pregnant rats given chromium(VI) or chromium(III) orally (Mertz et al. 1969) or intravenously
(Danielsson et al. 1982) and in pregnant mice given chromium(III) intraperitoneally (Iijima et al. 1983)
indicated that chromium can cross the placenta after administration of either valence state. The available 
data on reproductive effects of chromium and its compounds are inadequate for establishing dose
relationships; thus, further studies to establish the LOAEL and NOAEL values would be valuable.  No
dermal toxicity studies examining reproductive end points were identified; dermal studies would be useful
for assessing the reproductive toxicity of chromium and compounds following dermal contact and for
establishing exposure-response relationships.
Developmental Toxicity. No reliable information was located regarding developmental toxicity in
humans after inhalation, oral, or dermal exposure or in animals after dermal exposure to chromium or its
compounds.  A study in women exposed occupationally reported that chromium can be transferred to 
fetuses through the placenta (Shmitova 1980), but the poor quality and reporting of this study preclude its
use for drawing conclusions regarding potential developmental effects of chromium in humans. In female 
rats and mice, oral exposure of acute or intermediate duration to chromium(VI) compounds resulted in
fetal toxicity (Elsaieed and Nada 2002; Junaid et al. 1996a, 1996b; Kanojia et al. 1996, 1998; Trivedi et
al. 1989), but a NOAEL for these effects was not identified.  Chromium(VI) delayed the onset of puberty
in rats (Banu et al. 2008; Samuel et al. 2011).  Chromium(VI) also decreased antioxidant enzyme activity
in the liver, kidney, and bone of neonatal rats born to dams exposed during gestation and lactation 
(Soudani et al. 2010b, 2011a, 2011b).  Impaired development of the reproductive system was observed in
the female offspring of mice exposed to potassium dichromate(VI) or chromium(III) chloride (Al-
Hamood et al. 1998).  Distribution studies in rat dams given chromium(VI) or chromium(III)
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intravenously (Danielsson et al. 1982) or orally (Mertz et al. 1969) and in mouse dams given
chromium(III) intraperitoneally (Iijima et al. 1983) indicated that chromium can cross the placenta after
administration of either valence state.  No developmental effects were observed in the offspring of rats
fed 1,806 mg chromium(III)/kg/day as chromium oxide for 60 days before mating and throughout the
gestational period (Ivankovic and Preussmann 1975).  No pharmacokinetic studies have been conducted 
regarding the distribution of chromium or its compounds to the fetus after inhalation or dermal exposure
of the dams.  Further oral developmental studies of chromium(VI) and chromium(III) in mice and other
species would be useful to determine a NOAEL.  These studies should include examination of
developmental/neural end points.  Developmental studies using inhalation exposure would be useful to 
determine if developmental effects are route specific. Data from oral, inhalation and dermal studies 
would be useful for determining dose-response relationships.
Immunotoxicity. In humans, allergic sensitization, characterized by asthma attacks and dermatitis,
has been reported after occupational inhalation or occupational dermal exposure (Keskinen et al. 1980;
Leroyer et al. 1998; Moller et al. 1986; Olaguibel and Basomba 1989) or dermal exposure (Burrows 1983;
Engel and Calnan 1963; Engebrigtsen 1952; Eun and Marks 1990; Fregert 1975; Hansen et al. 2003;
Kaplan and Zeligman 1962; Levin et al. 1959; Nethercott et al. 1994; Newhouse 1963; Peltonen and Fraki
1983; Samitz and Shrager 1966; Wahba and Cohen 1979; Winder and Carmody 2002; Winston and 
Walsh 1951) to chromium compounds.  Two occupational studies suggest that chromium exposure affects
the leukocyte populations in the blood of workers (Boscolo et al. 1997; Mancuso 1951).  Delayed 
anaphylactoid reaction was observed in one case (Moller et al. 1986).  Dermatitis was exacerbated in
sensitized individuals by oral exposure to chromium(VI) (Goitre et al. 1982; Kaaber and Veien 1977).
In rats, nonspecific disease resistance mechanisms of the lung are inhibited by inhalation exposure to
chromium and its compounds (Glaser et al. 1985).  Inhalation exposure of intermediate duration alters
immunoglobulin levels, lymphocyte responses to antigen and lectin, and spleen weight in rats (Glaser et
al. 1985), as well as altered numbers of total recoverable cells, neutrophils, and monocytes, and 
percentages of pulmonary macrophages in bronchopulmonary lavage (Cohen et al. 1998).  Intermediate-
duration oral exposure of rats to chromium(VI) increased the proliferative response of T- and 
B-lymphocytes to mitogens and antigens (Snyder and Valle 1991).
There are sufficient data to determine that chromium or its compounds affect the immune system.  More
sensitive tests of the immune function after inhalation, oral, or dermal exposure to chromium or its
compounds would be useful to determine the threshold levels for effects in humans.  Studies evaluating
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exposure levels required to produce sensitization and elicitation of allergic responses would also provide
additional information regarding threshold levels.  Additional studies that explore changes in cytokine
levels (Snyder et al. 1996) caused by chromium exposure should prove helpful since they may provide
mechanistic information as to how chromium may affect immune function. 
Neurotoxicity.    Exposure of humans to high levels of airborne chromium(VI) in occupational and 
environmental settings produced symptoms of dizziness, headache, and weakness (Lieberman 1941).  
Cerebral edema was found in a case of fatal poisoning by ingestion (Kaufman et al. 1970).  No studies
were located describing neurotoxic effects in animals after inhalation and dermal exposure to chromium
or its compounds.  A 28-day drinking water study in rats reported decreased motor activity and ponderal
balance, although a complete battery of neurological function tests was not conducted (Diaz-Mayans et al.
1986).  Some distribution studies have detected chromium in the brain (Behari and Tandon 1980;
Danielsson et al. 1982; Kaufman et al. 1970; Tandon et al. 1979).  More recently, patients with 8–25-fold 
higher chromium blood levels that resulted from parenteral feeding did not have increased signs of
somatopsychic responses (Lovrincevic et al. 1996).  However, the number of patients studied was small
and they were suffering from serious clinical diseases.
Since the central nervous system may be a target organ for exposure to chromium or its compounds, 
additional inhalation, oral, and dermal studies would be useful to corroborate the limited data and would 
provide useful information for populations near hazardous waste sites.  More information on people
(adults, children) environmentally exposed to chromium would be useful to assess its potential to effect
neuro/behavioral end points. 
Epidemiological and Human Dosimetry Studies.    Most epidemiology studies use cohorts of
occupationally exposed individuals and provide consistent data indicating that inhaled chromium can be
carcinogenic (Alderson et al. 1981; Baetjer 1950; Bidstrup 1951; Bidstrup and Case 1956; Braver et al.
1985; Cole and Rodu 2005; Crump et al. 2003; Cruz et al. 2006; Dalager et al. 1980; Davies 1979, 1984;
Davies et al. 1991; EEH 1976, 1983; Enterline 1974; Fernandez-Nieto et al. 2006; Franchini et al. 1983;
Frentzel-Beyme 1983; Gibb et al. 2000b; Goldbohm et al. 2006; Haguenoer et al. 1981; Hayes et al. 1979, 
1989; Korallus et al. 1982; Langård and Norseth 1975; Langård and Vigander 1983; Langård et al. 1980;
Machle and Gregorius 1948; Mancuso 1975, 1997a; Mancuso and Hueper 1951; Ohsaki et al. 1978; Park
and Stayner 2006; Park et al. 2004;Pastides et al. 1994; PHS 1953; Rosenman and Stanbury 1996; Sassi
1956; Satoh et al. 1981; Sheffet et al. 1982; Silverstein et al. 1981; Sjogren et al. 1987; Sorahan et al. 
1987; Taylor 1966) and can cause other toxic effects such as respiratory irritation, nasal septum
   
 













   
     
 





     








    
 
  
   
  
   
    
    




perforation, and chrome sores on the skin (due to dermal exposure) (Bovet et al. 1977; Cohen et al. 1974;
Davies et al. 1991; Gibb et al. 2000a; Gomes 1972; Hanslian et al. 1967; Keskinen et al. 1980; Kitamura
et al. 2003; Kleinfeld and Rosso 1965; Lee and Goh 1988; Lieberman 1941; Letterer 1939; Lucas and 
Kramkowski 1975; Mancuso 1951; Meyers 1950; Novey et al. 1983; Olaguibel and Basomba 1989; Osim
et al. 1999; PHS 1953; Royle 1975b; Sassi 1956; Sluis-Cremer and du Toit 1968; Sorahan et al. 1987;
Taylor 1966).  Results of epidemiological data are consistent with results of studies in experimental
animals showing that the lung is the target organ for inhaled chromium(VI).  Epidemiology studies in the
chromate production industry and in chrome pigment manufacture and chrome plating have consistently
shown an association with increased risk of lung cancer, but studies in other industries, such as stainless
steel welding, electroplating, and ferrochromium production, have yielded inconclusive results.  Exposure
to chromium(VI) in these industries is associated with these effects, but the case for chromium(III) is less 
clear.  Further studies in these industries may lead to more conclusive results.  Measurements of
chromium in urine and blood are useful for monitoring occupational exposure to chromium compounds.  
However, chromium(III) is an essential nutrient, and levels in biological fluids might be enough to mask
low level exposures.  One environmental epidemiology study suggested that residence near a
ferrochromium plant did not pose a risk of cancer (Axelsson and Rylander 1980), but an environmental
study (which included oral exposure due to contaminated well water) in China found that residence near
an alloy plant that smelted chromium was associated with increased incidences of lung and stomach 
cancer (Zhang and Li 1987). 
Mechanisms of Action. Numerous studies have investigated the mechanisms of cellular toxicity and 
genotoxicity.  Toxicity appears to be related partly through reactive intermediates during intracellular
reduction of chromium(VI) and oxidative reactions, and partly mediated by chromium(III), which is the
final product of intracellar chromium(VI) reduction and forms deleterious complexes with critical target
macromolecules (Chen and Shi 2002; Costa 2003; Costa and Klein 2006a; Ding and Shi 2002; Jeejeebhoy
1999; Levina and Lay 2005; Liu and Shi 2001; O’Brien et al. 2003; Paustenbach et al. 2003; Shrivastava
et al. 2002; Zhitkovich 2005).  The products of metabolic reduction of chromium(VI) (free radicals and 
chromium(V) and (IV)) and the newly generated chromium(III) are thought to be, in part, primarily
responsible for the genotoxic effects that lead to carcinogenicity seen in human and animal studies.  The
types of chromium-induced structural damage include DNA strand breaks (Aiyar et al. 1991; Bagchi et al.
2002a; Bryant et al. 2006; Casadevall et al. 1999; Ha et al. 2004; Kuykendall et al. 1996; Manning et al. 
1992; Messer et al. 2006; Pattison et al. 2001; Ueno et al. 1995a), DNA-protein crosslinks (Aiyar et al. 
1991; Blankenship et al. 1997; Capellmann et al. 1995; Costa et al. 1996, 1997; Kuykendall et al. 1996;
Lin et al. 1992; Manning et al. 1992; Mattagajasingh and Misra 1996; Miller et al. 1991; O’Brien et al. 
   
 









    
   
   
   
   
   
 
     
 
   
 
    
     
    
   
  
   
   
  
 
     
    
  
   
   








2005; Quievryn et al. 2001; Zhitkovich et al. 1996), DNA-DNA interstrand crosslinks (Xu et al. 1996), 
chromium-DNA adducts, and chromosomal aberrations (Blankenship et al. 1997; Sugiyama et al. 1986a;
Umeda and Nishimura 1979; Wise et al. 1993).  Results of other studies suggest that genotoxicity of
chromium is due to the formation of chromium-DNA ternary adducts, which lead to repair errors,
collapsed replication forks, alterations in cellular communication, and effects on signaling pathways and
cytoskeleton (Ha et al. 2004), and centrosome and spindle assembly checkpoint bypass leading to
chromosome instability (Holmes et al. 2006; Wise et al. 2006a).  Studies on mechanisms of action of
chromium are actively ongoing in the current and future literature (see Section 3.12.3, Ongoing Studies).
Biomarkers of Exposure and Effect.
Exposure. There are studies correlating chromium in urine (Gylseth et al. 1977; Iarmarcovai et al. 2005;
Kilburn et al. 1990; Lindberg and Vesterberg 1983a; Lukanova et al. 1996; Medeiros et al. 2003a;
McAughey et al. 1988; Minoia and Cavalleri 1988; Muttamara and Leong 2004; Mutti et al. 1985b;
Sjogren et al. 1983; Stridsklev et al. 2004; Tola et al. 1977), blood (Iarmarcovai et al. 2005; Kilburn et al.
1990; Medeiros et al. 2003a; McAughey et al. 1988; Minoia and Cavalleri 1988; Muttamara and Leong
2004; Randall and Gibson 1987; Stridsklev et al. 2004; Sathwara et al. 2007), hair (Randall and Gibson 
1989; Saner et al. 1984; Takagi et al. 1986), and erythrocytes (Lukanova et al. 1996; Minoia and Cavalleri
1988) to occupational exposure levels.  All current methods of biological monitoring are useful primarily
for occupational exposure scenarios.  Since chromium is an essential element, levels of chromium
compounds have to be relatively high in humans before they signify an increase due to exposure.  Hair
has been useful in determining chronic occupational exposure to chromium in high concentrations
(Randall and Gibson 1989); the usefulness of this method for detecting prior exposures is limited to a
timespan of months (Simpson and Gibson 1992).  Erythrocytes (with a half-life of 120 days) can be used
to monitor intermediate exposures, and blood or urine can be used to determine acute exposures (Korallus 
1986a, 1986b).  Occupational exposure to chromium can cause chromosomal aberrations (Koshi et al.
1984; Sarto et al. 1982; Stella et al. 1982).  Therefore, chromosomal abnormalities may be useful for
monitoring chromium exposure; however, other chemicals are capable of causing these effects.
Chromium(VI) compounds are able to bind to macromolecules in the body and can form DNA-protein 
crosslinks (Coogan et al. 1991b).  However, no increase in these crosslinks was observed in leukocytes 
from volunteers over a 240-minute time period after ingestion of chromium(VI) as potassium chromate 
(Kuykendall et al. 1996).  The identification of chromium-protein/peptide complexes specific for
chromium(VI) exposure and small enough to be excreted in the urine may be useful for biomonitoring in 
detecting low level exposure to populations near hazardous waste sites.  As discussed in Section 3.8.1,
   
 








    







   
    
    
    
     
      
  
   
    
 
  
     
  
  
    
 
   
 
 






there are a number of limitations to using urinary monitoring to assess environmental exposure to 
chromium (Paustenbach et al. 1997).  However, urinary monitoring has the advantage of easy sample
collection and is noninvasive.  Mathematical models have been used to identify “excess” urinary
chromium in a population exposed to low levels of chromium (Fagliano et al. 1997).  Further refinement
of these models as more data are collected from unexposed and exposed populations will also be useful in
detecting low level exposures.
Effect.  Chromosomal aberrations have been observed in workers exposed by inhalation to chromium
compounds (Koshi et al. 1984; Sarto et al. 1982; Stella et al. 1982).  Moreover, chromium(VI)
compounds can bind to macromolecules that are excreted in the urine (Coogan et al. 1991b). The use of
these techniques to detect chromosomal aberrations and chromium-macromolecular complexes would be 
useful in identifying populations near hazardous waste sites that would be at higher risk.  In addition, the
finding of increased retinol binding protein, ß2-microglobulin, and brush border proteins in the urine of
workers exposed to chromium may serve as an early indication of kidney damage (Franchini and Mutti
1988; Lindberg and Vesterberg 1983b; Liu et al. 1998; Mutti et al. 1985b).  Additional screening for low
molecular weight proteins in occupationally exposed individuals will help to determine if these proteins
can be used as reliable indicators of renal damage due to chromium exposure.  Snyder et al. (1996) found 
no difference in mitogenic stimulation of mononuclear cells isolated from people environmentally/ 
occupationally exposed to chromium as compared to nonexposed individuals.  However, monocytes in 
the exposed population had a 36% lower level of the cytokine IL-6 that is involved in antibody
production.  As discussed in Section 3.3, chromium induces many types of DNA lesions such as 
chromium-DNA complexes, DNA adducts, and DNA-protein crosslinks that are potential markers of
genotoxic or cancer effects due to chromium exposure.  However, only one study has attempted to utilize
such end points and reported that volunteers exposed to chromium in drinking water showed no increase
in protein-DNA crosslinking in blood cells (Kuykendall et al. 1996).  However, further studies may show
that other types of lesions induced by chromium may be more sensitive.  Räsänen et al. (1991) developed 
an in vitro method to assess chromium sensitivity by measuring mononuclear leukocyte proliferation in 
response to chromium(III) chloride, sodium chromate(VI), and potassium chromate(VI).  Additional
studies would be useful to validate this method.
Absorption, Distribution, Metabolism, and Excretion. The pharmacokinetics database is
substantial for human and animal exposure to chromium compounds.  Chromium and its compounds can 
be absorbed after oral (Anderson 1981, 1986; Anderson et al. 1983; Bunker et al. 1984; DiSilvestro and 
Dy 2007; Donaldson and Barreras 1966; Finley et al. 1996b; Gargas et al. 1994; Kerger et al. 1997;
   
 








     
     
    
     
     






   
 
   
     
 
   
    
  
    
    






      
   
 
  
     
    
CHROMIUM 327
3. HEALTH EFFECTS
Kuykendall et al. 1996; Paustenbach et al. 1996), inhalation (Adachi et al. 1981; Cavalleri and Minoia
1985; Gylseth et al. 1977; Langård et al. 1978; Kiilunen et al. 1983; Mancuso 1997b; Minoia and 
Cavalleri 1988; Randall and Gibson 1987; Suzuki et al. 1984; Tossavainen et al. 1980), and dermal
(Baranowska-Dutkiewicz 1981; Brieger 1920; Corbett et al. 1997; Liden and Lundberg 1979; Mali et al. 
1963; Samitz and Shrager 1966; Spruit and van Neer 1966; Wahlberg 1970; Wahlberg and Skog 1965)
exposure.  For the general population, oral exposure via the diet to chromium(III) is the most significant
route.  Occupational exposure usually involves inhalation and dermal routes.  Pharmacokinetic data are
generally consistent with regard to absorption, distribution, and excretion among species.  Chromium(VI)
compounds are absorbed more readily through cell membranes than are chromium(III) compounds
(MacKenzie et al. 1958; Maruyama 1982; Witmer et al. 1989, 1991).  Absorption is greater through the
lungs than through the gastrointestinal tract (Baetjer et al. 1959b; Bragt and van Dura 1983; Kuykendall
et al. 1996; Visek et al. 1953; Wiegand et al. 1984, 1987).
Examination of tissues taken at autopsy from occupationally and environmentally exposed people indicate
widespread distribution of chromium (Brune et al. 1980; Hyodo et al. 1980; Kollmeier et al. 1990;
Mancuso 1997b; Schroeder et al. 1962; Teraoka 1981).  Widespread distribution of chromium has also 
been found in animals after oral exposure (Kargacin et al. 1993; Witmer et al. 1989, 1991).  The
distribution of chromium in animals after intratracheal, parenteral, or dermal exposure is greatest in the
lungs, liver, kidneys, blood, spleen, testes, and brain (Baetjer et al. 1959a; Behari and Tandon 1980;
Bryson and Goodall 1983; Coogan et al. 1991b; Lim et al. 1983; Mutti et al. 1979; Tandon et al. 1979;
Visek et al. 1953; Wahlberg and Skog 1965; Weber 1983).  Oral exposure studies indicate that higher
levels of chromium(VI) compounds are absorbed than are levels of chromium(III) compounds.  Studies in
humans occupationally and environmentally exposed to chromium(VI) (Casey and Hambidge 1984;
Shmitova 1980) and in animals exposed to chromium(VI) or chromium(III) demonstrate the ability for
chromium to cross the placenta (Mertz et al. 1969; Saxena et al. 1990a).  Chromium(VI) crosses more
readily than chromium(III).
There are no data to indicate that the route of exposure influences the metabolism of chromium.  
Regardless of the route of exposure, chromium(VI) inside the body is reduced to chromium(III) by
ascorbic acid, glutathione, or by the NADPH-dependent cytochrome P450 system (Aaseth et al. 1982;
Chen and Shi 2002; Costa 2003; Costa and Klein 2006a; De Flora et al. 1984, 1997; Ding and Shi 2002;
Garcia and Jennette 1981; Gruber and Jennette 1978; Jeejeebhoy 1999; Levina and Lay 2005; Liu and Shi
2001; Liu et al. 1995; Mikalsen et al. 1989; O’Brien et al. 2003; Paustenbach et al. 2003; Petrilli et al. 
   
 












    
    






     
   
  
  
    
 
     
  
  
   
   
     









1985, 1986a; Samitz 1970; Shrivastava et al. 2002; Suzuki and Fukuda 1990; Wiegand et al. 1984;
Zhitkovich 2005).
Analysis of the urine of workers occupationally exposed to chromium(VI) indicates that chromium is
excreted in the trivalent form, which is consistent with in vivo reduction of chromium(VI) to 
chromium(III) (Cavalleri and Minoia 1985; Minoia and Cavalleri 1988).  Oral studies in humans and 
animals indicate that most of the chromium(VI) or chromium(III) ingested is excreted in the feces 
(Bunker et al. 1984; Donaldson and Barreras 1966; Donaldson et al. 1984; Henderson et al. 1979; Sayato 
et al. 1980), consistent with the poor gastrointestinal absorption of chromium.  After dermal exposure of
humans and animals, chromium can be found in the urine and feces (Brieger 1920; Wahlberg and Skog
1965).  Chromium has been detected in hair and fingernails of the general population of several countries
(Takagi et al. 1986, 1988) and in the breast milk of nursing mothers (Casey and Hambidge 1984), 
indicating these media as routes of excretion.  Data regarding excretion after exposure of animals to 
chromium(VI) or chromium(III) by other routes indicated that excretion occurs rapidly, and primarily via
the kidneys, once chromium(VI) is reduced (Gregus and Klaassen 1986; Yamaguchi et al. 1983).  Thus, 
absorption, distribution, and excretion of chromium have been studied extensively.  Additional studies
examining the enzymatic reduction of chromium(VI) compounds in rodents and humans would be of
value in determining the potential biological impact of the reported differences in those pathways.
Comparative Toxicokinetics. Toxicokinetic data in humans, dogs, rats, mice, rabbits, and hamsters
generally correlate well among species (see references above).  However, exposures to chromium(VI)
resulted in different organ distribution patterns between rats and mice (Kargacin et al. 1993), and the
chromium levels in mouse fetal tissues were elevated over maternal blood levels, whereas in rats, these 
differences were not found (Saxena et al. 1990a).  In addition, comparisons of human and rat hepatic
microsomal ability to reduce chromium(VI) indicated differences in microsomal complexes involved 
(Myers and Myers 1998; Pratt and Myers 1993). Therefore, additional comparison studies among species 
would be useful to determine variations in the absorption, distribution, metabolism, and excretion of
chromium.  A PBPK model (O’Flaherty 1996; O’Flaherty et al. 2001) that has been partially validated 
has been developed based on rats.  As described previously, the model is quite sophisticated, but
additional physiological and kinetic parameters from both humans and other animal species are needed in 
order for the model to be employed for extrapolation across species and for use in risk assessment.  
Furthermore, additional metabolic data are needed with regard to insoluble chromium and its elimination 
and solubilization, particularly in lung tissue.
   
 








       
   
  
 
   







    
 
   
   
    
    
     
   
    
   
   
  
  





Methods for Reducing Toxic Effects. Methods for reducing the absorption of chromium from the
lungs consist primarily of administering ascorbic acid or N-acetylcysteine, which enhance the reduction
of chromium(VI) to chromium(III) (De Flora and Wetterhahn 1989; Suzuki and Fukuda 1990).  
Chromium(III) passes the alveolar lining into the bloodstream less readily than chromium(VI) and is 
cleared by mucociliary clearance.  A study might be conducted to determine whether administration of
expectorants would enhance clearance from the lungs.  Oral administration of ascorbic acid to further
reduce chromium(VI) to chromium(III) might further decrease bioavailability (Haddad et al. 1998;
Kuykendall et al. 1996; Schonwald 2004), although this has not been proven (Leikin and Paloucek 2002;
Schonwald 2004).  After dermal exposure, thorough washing and ascorbic acid therapy to enhance the
reduction of chromium(VI) to chromium(III) (Schonwald 2004), followed by chelation with EDTA
(Nadig 1994), would greatly reduce dermal absorption.  Administration of ascorbic acid has also been 
used to enhance the reduction of chromium(VI) to chromium(III) in plasma (Korallus et al. 1984), which 
would reduce the body burden of chromium because chromium(III) would bind to plasma protein and be
excreted in the urine.  Studies could be conducted to determine if other reducing agents would be more
effective than ascorbic acid.  Once inside the cell, chromium(VI) can enter many reactions resulting in
reduction to various oxidation states with the generation of reactive oxygen species and radicals, all of
which may be more or less toxic than chromium(III) (De Flora and Wetterhahn 1989).  Gasiorowski et al. 
(1997, 1998) showed that stabilizing chromium in the hexavalent oxidation state, via complexing to a
ligand, decreased the mutagenicity of chromium(VI).  Methods could be developed to interfere with these
various reactions, but such methods may be counterproductive because they might shift one reaction to 
another with undesirable consequences. In vitro studies have indicated that vitamin E, ascorbic acid, and
glutatione protected against cellular damage, including chromosomal breakage, DNA-protein crosslinks, 
and apoptosis (cell death)  (Blankenship et al. 1997; Little et al. 1996; Sugiyama 1991; Wise et al. 1993,
2004), while vitamin B2 enhanced the cytotoxicity and DNA single-strand breaks induced by
chromium(VI) (Sugiyama 1991).  Vitamin E may have scavenged radicals and/or chromium(V) during
the reduction of chromium(VI) (Sugiyama 1991).  Other vitamins might also be effective in mitigating
chromium's effects; thus, studies on the effect of vitamins on chromium toxicity may provide additional
information on the potential to reduce toxic effects.  Although the administration of thyroxine has been
shown to ameliorate potassium dichromate-induced acute renal failure in rats (Siegel et al. 1984), its use
in humans has not been tested.  Further studies are needed to assess the safety of administering thyroxine
to mitigate chromium toxicity.
   
 








      
    
  
 
    
 
    
  
    
  
 
   
        
    
   
   
   
 
 
   
    




   
    
  
 





Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
A limited amount of information is available on the toxicity of chromium in children; most of the
available data come from children ingesting lethal doses of chromium(VI) (Clochesy 1984; Ellis et al. 
1982; Iserson et al. 1983; Kaufman et al. 1970; Reichelderfer 1968).  Studies that examine sensitive end
points such as respiratory effects following inhalation exposure, or gastrointestinal, hematological, liver
and kidney effects in young animals would be useful for assessing whether children will be unusually
susceptible to chromium toxicity.  The available animal data suggest that chromium is a developmental
toxicant.  As discussed in Section 3.2.2.6, the observed developmental effects include postimplantation 
losses, gross abnormalities, and impaired reproductive development in the offspring (Al-Hamood et al. 
1998; Junaid et al. 1996a, 1996b; Kanojia et al. 1996, 1998; Trivedi et al. 1989). Data needs relating to 
development are discussed in detail in the Developmental Toxicity subsection above.  There are some 
data in humans and animals that provide evidence that chromium can cross the placenta and be transferred
to an infant via breast milk (Casey and Hambidge 1984; Danielsson et al. 1982; Mertz et al. 1969; Saxena
et al. 1990a; Shmitova 1980).  There are no data on whether chromium is stored in maternal tissues and 
whether these stores can be mobilized during pregnancy or lactation.
An age-related difference in the extent of gastrointestinal absorption of chromium(III) was reported in one
study (Sullivan et al. 1984); it is not known if a similar relationship would exist for chromium(VI).  No 
other information is available that evaluated potential differences between adults and children.
Toxicokinetic studies examining how aging can influence the absorption, distribution, and excretion of
chromium, particularly chromium(VI) would be useful in assessing children’s susceptibility to chromium
toxicity.  There are no data to determine whether there are age-specific biomarkers of exposure or effects 
or any interactions with other chemicals that would be specific for children. There is very little available 
information on methods for reducing chromium toxic effects or body burdens; it is likely that research in
adults would also be applicable to children.  
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
   
 












3.12.3 Ongoing Studies 
Ongoing studies pertaining to chromium toxicity have been identified and are shown in Table 3-12. 
   
 











































































Table 3-12.  Ongoing Studies on Chromium
Investigator Study Topic Institution Sponsor
Avery S Role of oxidative mechanisms
in the toxicity of metals
University of
Nottingham
National Institute of General
Medical Sciences
Cohen M Properties of metals may




National Institute of General
Medical Sciences
Myers C Human lung chromium toxicity:


























Zhitkovich A Biological dosimetry of
hexavalent chromium
Brown University National Institute of
Environmental Health Sciences
Zhitkovich A Genotoxicity of chromium
compounds
Brown University National Institute of
Environmental Health Sciences
Zhitkovich A Sensitivity mechanisms in 
chromium toxicity
Brown University National Institute of
Environmental Health Sciences
Source:  FEDRIP 2008












   
 
 
    
 
 
   
 
     
 
  
    
   
   
      
      
   
   
 
   
  
 
   
   
   
     
   
 
      




4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
Information regarding the chemical identity of chromium is located in Table 4-1. 
The synonyms, trade name, chemical formula, and identification numbers of chromium and selected salts 
are reported in Table 4-1. 
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
Information regarding the physical and chemical properties of chromium is located in Table 4-2.
Chromium is a metallic element with oxidation states ranging from chromium(-II) to chromium(+VI)
with the trivalent (III) and hexavalent (VI) sates being the most predominant. The Chemical Abstracts 
Service (CAS) Registry numbers for trivalent and hexavalent chromium are 16065-83-3 and 18540-29-9, 
respectively.  Elemental chromium, chromium(0), does not occur naturally.  Although there is a divalent
state, chromium II (chromous), it is relatively unstable under environmental conditions and is readily
oxidized to the trivalent (III or chromic) state.  Chromium compounds are most stable in the trivalent state
under environmental conditions and occur in nature in ores, such as ferrochromite (FeCr2O4).  The
hexavalent (VI or chromate) is the second most stable state; however, it only occurs naturally in rare
minerals such as crocoite (PbCrO4) (Hurlbut 1971; Papp and Lipin 2001).  Hexavalent chromium
compounds primarily arise from anthropogenic sources (Alimonti et al. 2000; Barceloux 1999; EPA
1984a; Johnson et al. 2006; Shanker et al. 2005).  
The solubility of chromium compounds varies, depending primarily on the oxidation state. Trivalent
chromium compounds, with the exception of acetate, hexahydrate of chloride, and nitrate salts, are
generally insoluble in water (Table 4-2). The zinc and lead salts of chromic acid are practically insoluble 
in cold water (Table 4-2).  The alkaline metal salts (e.g., calcium, strontium) of chromic acid are slightly
soluble in water.  Some hexavalent compounds, such as chromium(VI) oxide (or chromic acid), and the
ammonium and alkali metal salts (e.g., sodium and potassium) of chromic acid are readily soluble in
water. The hexavalent chromium compounds are reduced to the trivalent form in the presence of
oxidizable organic matter. However, in natural waters where there is a low concentration of reducing
materials, hexavalent chromium compounds are more stable (EPA 1984a; Loyaux-Lawniczak et al.
2001).
























    




    
     
     
      
     
     
     
     
 
CHROMIUM 334
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Chromium and Compounds
Characteristic Information
Chemical name Chromium(0) Chromium(III) acetate, Chromium(III) nitrate, 
monohydrate nonahydrate
Synonym(s) Chrome; Chrom Acetic acid, chromium Nitric acid, chromium (III)
(German); Chrome salt, hydrate; chromic salt, nonahydrate; chromium
(French) acetate, hydrate nitrate, nonahydrate
Registered trade name(s) Chrome No data No data
Chemical formula Cr Cr(CH3COO)3•H2O Cr(NO3)3•9H2O
Chemical structure Cr
Identification numbers:
CAS registry 7440-47-3 25013-82-5 7789-02-8
NIOSH RTECS GB420000 AG3053333 GB6300000
EPA hazardous waste D007 No data No data
OHM/TADS 7216647 No data No data
DOT/UN/NA/IMDG shipping Not assigned No data No data
HSDB 910 No data No data
NCI Not assigned No data No data



























    




    
     
     
      
     
     
     
     
 
CHROMIUM 335
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Chromium and Compounds
Characteristic Information
Chemical name Chromium(III) Chromium(III) chloride, Chromite (Cr2FeO4)
chloride hexahydrate (Chromium[III])
Synonym(s) Chromium Hexaaquachromium Chromite; chromite ore;
trichloride (III) chloride chromite homog mineral;
chromite (mineral)
Registered trade name(s) C177295 No data No data
Chemical formula CrCl3 Cr(Cl)3•6H20 FeCr2O4 
Chemical structure Cr[Cl2(H2O)4]Cl•2H2O FeOCr2O3 
Identification numbers:
CAS registry 10025-73-7 10060-12-5 1308-31-2
NIOSH RTECS GB5425000 GB5450000 GB4000000
EPA hazardous waste No data No data D007
OHM/TADS No data No data No data
DOT/UN/NA/IMDG shipping No data No data No data
HSDB No data No data 2963
NCI No data No data No data




























     




    
     
     
      
     
     
     
     
 
CHROMIUM 336
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Chromium and Compounds
Characteristic Information
Chemical name Chromium(III) Chromium(III) Chromium(III) sulfate
oxide phosphate
Synonym(s) Chromium Chromumorthophos- Sulfuric acid, chromium (III)
sesquioxide; phate; phosphoric acid, salt
dichromium chromium (III) salt
trioxide; chromic
oxide
Registered trade name(s) No data Amaudon=s Green Chromitan B
Chemical formula Cr2O3 CrPO4 Cr2(SO4)3 
Chemical structure O=CrCOCCr=O SO4=CrBSO4BCr=SO4 
Identification numbers:
CAS registry 1308-38-9 7789-04-0 10101-53-8
NIOSH RTECS GB6475000 GB6840000 GB7200000
EPA hazardous waste D007 No data D0007
OHM/TADS Not assigned No data 7800052
DOT/UN/NA/IMDG shipping Not assigned No data Not assigned
HSDB 1619 No data 2543
NCI Not assigned No data Not assigned






















    




    
     
     
      
     
     
     
     
 
CHROMIUM	 337
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Chromium and Compounds
Characteristic	 Information
Chemical name	 Sodium chromite Chromium hydroxide Chromium(III) picolinate
(Chromium[III]) sulfate (Chromium III)
Synonym(s) No data	 Chromium hydroxide CrPic; Chromium
sulfate (Cr(OH)(SO4)); 2-pyridinecarboxylate;
basic chromium sulfate Chromium tris(picolinato)-; 
Picolinic acid, chromium salt
Registered trade name(s) No data No data No data
Chemical formula NaCrO2 CrOHSO4 C18H12CrN3O6 
Chemical structure NaOBCr=O
O 
(CrOH)2+ O S O 
O 
Identification numbers:
CAS registry 12314-42-0 12336-95-7 14639-25-9
NIOSH RTECS No data GB6240000 No data
EPA hazardous waste No data No data No data
OHM/TADS No data No data No data
DOT/UN/NA/IMDG shipping No data No data No data
HSDB No data No data No data
NCI No data No data No data






















    





    
     
     
      
     
     
     
     
CHROMIUM 338
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Chromium and Compounds
Characteristic Information
Chemical name Chromic acid Chromium(IV) oxide Ammonium dichromate
(Chromium VI) (Chromium[VI])
Synonym(s) Acide chromique; Chromium dioxide Chromic acid, diamonium
chromic(VI) acid salt
Registered trade name(s) No data No data No data
Chemical formula H2CrO4 CrO2 (NH4)2Cr2O7 
Chemical structure O=Cr=OO 
HO Cr O 
OH 
Identification numbers:
CAS registry 7738-94-5 12018-01-8 7789-09-5
NIOSH RTECS GB6650000 GB6400000 HX7650000
EPA hazardous waste No data D007 Not assigned
OHM/TADS No data No data 7217321
DOT/UN/NA/IMDG shipping 1755 No data UN1439; IM05.1
HSDB 6769 1620 481
NCI No data No data No data





























    
     
     
      
     
    
 
 
     
     
 
CHROMIUM 339
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Chromium and Compounds
Characteristic Information








Chromic acid, lead salt
Registered trade name(s) Calcium Chrome 
Yellow
No data Chrome Yellow G
Chemical formula CaCrO4 CrO3 PbCrO4 
Chemical structure
Identification numbers:
CAS registry 13765-19-0 1333-82-0 7758-97-6
NIOSH RTECS GB2750000 GB6650000 GB2975000
EPA hazardous waste U032; D007 D007 D007; D008
OHM/TADS 7800051 Not assigned Not assigned
DOT/UN/NA/IMDG shipping NA9096 YB1463/UNI5.1; Not assigned
IM05.1
HSDB 248 518; NA1463 1650
NCI Not assigned UN1463 Not assigned




















    
    
 
   
    
     
     
      
     
     
     
     
 
CHROMIUM 340
4.  CHEMICAL AND PHYSICAL INFORMATION












dipotassium salt Chromic acid, disodium salt
Registered trade name(s) No data No data Caswell No. 757
Chemical formula K2CrO4 K2Cr2O7 Na2CrO4 
Chemical structure
Identification numbers:
CAS registry 7789-00-6 7778-50-9 7775-11-3
NIOSH RTECS GB2940000 HX7680000 GB2955000
EPA hazardous waste No data No data D007
OHM/TADS 7217277 7217278 7216891
DOT/UN/NA/IMDG shipping NA9142 NA1479; IM09.0 No data
HSDB 1249 1238 2962
NCI Not assigned Not assigned Not assigned



















   




   
    
    
     
    
    
    
    
 
CHROMIUM 341
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Chromium and Compounds
Characteristic Information
Chemical name Sodium dichromate, dihydrate 
(Chromium[VI]) Strontium chromate (Chromium[VI])
Synonym(s) Chromic acid, disodium salt; Chromic acid, strontium salt
dihydrate
Registered trade name(s) No data No data
Chemical formula NaCr2O7•2H20 SrCrO4 
Chemical structure
Identification numbers:
CAS registry 7789-12-0 7789-06-2
NIOSH RTECS HX7750000 GB3240000
EPA hazardous waste No data D007
OHM/TADS No data 780058
DOT/UN/NA/IMDG shipping No data NA9149
HSDB No data 2546
NCI No data Not assigned














   
 
    
 
    




   
    
    
     
    
    
    










4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Chromium and Compounds
Characteristic Information
Chemical name Zinc chromate (Chromium[VI]) Sodium dichromate
(Chromium VI)
Synonym(s) Chromic acid, zinc salt Chromic acid (H2Cr2O7), sodium
salt (1:2)
Registered trade name(s) CI Pigment Yellow No data
Chemical formula ZnCrO4 Na2Cr2O7 
Chemical structure O O 






CAS registry 13530-65-9 10588-01-9
NIOSH RTECS GB3290000 HX7700000
EPA hazardous waste D007 D007
OHM/TADS 7217401 No data
DOT/UN/NA/IMDG shipping Not assigned 3288
HSDB 6188 737
NCI Not assigned No data
Sources:  HSDB 2012; NIOSH 2005
CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System;
RTECS = Registry of Toxic Effects of Chemical Substances 















   
     
   
 
   
     
     




      
     
     
      
      
     











     
      
      
  
  
   
        
     
     
     
     
     
 
CHROMIUM 343
4.  CHEMICAL AND PHYSICAL INFORMATION










Molecular weight 51.996 229.13 400.15 158.35
Color Steel-gray Gray-green or
bluish-green
Purple or violet Violet or purple
Physical state Solid Solid Solid Solid
Melting point 1,90±10 °C No data 60 °C ≈1,150 °C




Density at 20 °C 7.14 (28 °C)a No data No data 2.87 (25 °C)a 
Odor odorless No data No data No data
Odor threshold:
Water No data No data No data No data
Air No data No data No data No data
Solubility:
Water at 20 °C Insoluble Soluble Soluble Slightly soluble in 
hot water
Organic solvents Insoluble in 
common organic
solvents
45.4 g/L in 
methanol










Log Kow Not applicable Not applicable Not applicable Not applicable 
Log Koc Not applicable Not applicable Not applicable Not applicable
Vapor pressure at 20 °C 1 mmHg 
(1,616 °C)
No data No data No data
Henry's law constant at 25 °C Not applicable Not applicable Not applicable Not applicable
Autoignition temperature No data No data No data No data
Flashpoint No data No data No data No data
Flammability limits No data No data No data No data
Conversion factors No data No data No data No data
Explosive limits No data No data No data No data

















   
     
     
     
     
     
      
     
     
      
      
     
    
 





     
       
      
      
        
     
     
     
     
     
 
CHROMIUM 344
4.  CHEMICAL AND PHYSICAL INFORMATION











Molecular weight 266.45 223.84 151.99 146.97
Color Violet Brown-black Green Gray-brown to blackd 
Physical state Solid Solid Solid Solid
Melting point 83 °C No data 2,435 °C >1,800 °C
Boiling point






5.22 (25 °C)b 
No data
2.94 (32.5 °C)a,c 
Odor No data No data No data No data
Odor threshold:
Water No data No data No data No data
Air No data No data No data No data
Solubility:
Water at 20 °C 58.5 g/100 cc at
25 °C
Insoluble Insoluble Insolublec 
Organic solvents Soluble in 
ethanol





Log Kow No data Not applicable Not applicable Not applicable
Log Koc No data Not applicable Not applicable Not applicable
Vapor pressure at 20 °C No data No data No data No data
Henry's law constant at 25 °C No data Not applicable Not applicable Not applicable
Autoignition temperature No data No data No data No data
Flashpoint No data No data No data No data
Flammability limits No data No data No data No data
Conversion factors No data No data No data No data
Explosive limits No data No data No data No data



















      
       
     
     
     
        
     
      
      
      
     
         
   
 
   
     
        
        
        
            
     
     
      
     
      
CHROMIUM 345
4.  CHEMICAL AND PHYSICAL INFORMATION

























Melting point No data No data >900 °C No data
Boiling point No data No data No data No data
Density at 20 °C 3.012 No data 1.25 No data
Odor No data No data No data No data
Odor threshold:
Water No data No data No data No data
Air No data No data No data No data
Solubility:









1 ppm at 25 °Cd 
>6 g/L (DMSO)d 
Partition coefficients:
Log Kow Not applicable Not applicable Not applicable 1.753f 
Log Koc Not applicable Not applicable Not applicable No data
Vapor pressure at 20 °C No data No data No data No data
Henry's law constant at 25 °C Not applicable Not applicable Not applicable No data
Autoignition temperature No data No data No data No data
Flashpoint No data No data No data No data
Flammability limits No data No data No data No data
Conversion factors No data No data No data No data
Explosive limits No data No data No data No data


















     
     
    




    
       
    
     
     
     
    










    
        
        
       
            
    
    
     
    
     
CHROMIUM 346
4.  CHEMICAL AND PHYSICAL INFORMATION







Molecular weight 118 83.99 252.07
Color Dark purple-red Brown-black Orange
Physical state Solid Solid Solid
Melting point 196 °C Decomposes at 300 °C Decomposes at
180 °C
Boiling point Decompose before 
boiling
Not applicable Not applicable
Density at 20 °C 1.67–2.82 No data 2.15 (25 °C)a 
Odor No data No data odorless
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:






Organic solvents Soluble in alcohol and 
mineral acids
No data Soluble in alcohols,
insoluble in acetone
Partition coefficients:
Log Kow Not applicable Not applicable Not applicable 
Log Koc Not applicable Not applicable Not applicable
Vapor pressure at 20 °C No data No data No data
Henry's law constant at 25 °C Not applicable Not applicable Not applicable
Autoignition temperature No data No data No data
Flashpoint No data No data No data
Flammability limits No data No data No data
Conversion factors No data No data No data
Explosive limits No data No data No data




















     
      
     
      
     
      
     
     
      
      
     





































     
      
      
      
        
     
     
     
     
     
 
CHROMIUM 347
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Chromium and Compounds
Calcium Potassium
chromate Chromium(VI) Lead chromate chromate 
Property (Chromium[VI]) trioxide (Chromium[VI]) (Chromium[VI])
Molecular weight 156.07 99.99 323.19 194.19
Color Yellow Red Yellow Yellow
Physical state Solid Solid Solid Solid
Melting point No data 197 °C 844 °C 975 °C
Boiling point No data Decomposes Decomposes No data
Density at 20 °C 2.89b 2.70 (25 °C) 6.12 (15 °C) 2.732 (18 °C)
Odor No data Odorless No data Odorless
Odor threshold:
Water No data No data No data No data
Air No data No data No data No data
Solubility:
Water at 20 °C 2.23 g/100 mL 61.7 g/100 cc at 5.8 μg/100 mL 62.9 g/100 at 20
0 °C °C















soluble in dilute 
nitric acid and in 













Log Kow Not applicable Not applicable Not applicable Not applicable 
Log Koc Not applicable Not applicable Not applicable Not applicable
Vapor pressure at 20 °C No data No data No data 0
Henry's law constant at 25 °C Not applicable Not applicable Not applicable Not applicable
Autoignition temperature No data No data No data No data
Flashpoint No data No data No data No data
Flammability limits No data No data No data No data
Conversion factors No data No data No data No data
Explosive limits No data No data No data No data


















    
    
    




     
    
    
     
     
    




    
     
     
     
       
    
    
    
    
    
 
CHROMIUM 348
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Chromium and Compounds
Potassium Sodium dichromate,
dichromate Sodium chromate dihydrate 
Property (Chromium[VI]) (Chromium[VI]) (Chromium[VI])
Molecular weight 294.18 161.97 298.00
Color Red Yellow Red
Physical state Solid Solid Solid
Melting point 398 °C 792 °C 356.7 °C
Boiling point Decomposes at 500 No data Decomposes at 400 °C
°C
Density at 20 °C 2.676 (25 °C) 2.710B2.736b 2.52 (13 °C)
Odor No data No data No data
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water at 20 °C 4.9 g/100 cc at 0 °C 87.3 g/100 cc at 30 °C 230 g/100 cc at 0 °C
Organic solvents Insoluble in ethanol Soluble in methanol Insoluble in ethanol
and acetone
Partition coefficients:
Log Kow Not applicable Not applicable Not applicable 
Log Koc Not applicable Not applicable Not applicable
Vapor pressure at 20 °C No data No data No data
Henry's law constant at 25 °C Not applicable Not applicable Not applicable
Autoignition temperature No data No data No data
Flashpoint No data No data No data
Flammability limits No data No data No data
Conversion factors No data No data No data
Explosive limits No data No data No data


















    
    
    
    
     
     
    
    
     
     
    
        
   
 
  
    
     
     
     
       
    
    
    
    












4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Chromium and Compounds
Strontium chromate Zinc chromate Sodium dichromate
Property (Chromium[VI]) (Chromium[VI]) (Chromium[VI])
Molecular weight 203.61 181.97 262
Color Yellow Lemon-yellow Bright orange-red
Physical state Solid Solid Solid
Melting point No data No data 356.7 °C
Boiling point No data No data Decomposes at 400 °C
Density at 20 °C 3.895 (15 °C) 3.40b 2.52 at 13 °C
Odor No data Odorless Odorless
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water at 20 °C 0.12 g/100 cc at 15 °C Insoluble 2,380 g/L at 0 °C
Organic solvents Soluble in acetyl Insoluble in acetone 513.4 g/L (methanol)
acetone
Partition coefficients:
Log Kow Not applicable Not applicable Not applicable
Log Koc Not applicable Not applicable Not applicable
Vapor pressure at 20 °C No data No data No data
Henry's law constant at 25 °C Not applicable Not applicable Not applicable
Autoignition temperature No data No data No data
Flashpoint No data No data No data
Flammability limits No data No data No data
Conversion factors No data No data No data
Explosive limits No data No data No data
aTemperature at which the densities were measured has been given only when such data are available
bTemperature at which density was measured was not specified.
cO’Neil et al. 2006 
dBroadhurst et al. 1997
eIPCS 2004
fChakov et al. 1999
DMSO=dimethylsulfoxide










    
    
   
   
  
  
   





4.  CHEMICAL AND PHYSICAL INFORMATION
In humans, chromium(III) is an essential nutrient that may play a role in glucose, fat, and protein 
metabolism possibly by potentiating the action of insulin.  However, there is some emerging controversy
whether chromium(III) is essential and more work has been suggested to elucidate its mechanism of
action.  Chromium picolinate, a trivalent form of chromium complexed with picolinic acid, is used as a
dietary supplement, because it is claimed to speed metabolism and may have anti-diabetic effects 
(Broadhurst et al. 1997).  However, there still remains controversy over the use of chromium(III) in
diabetes, and several researchers claim no demonstrated effects of chromium(III) on diabetes or insulin
resistance (Althuis et al. 2002).  Currently, the mechanism of transport and absorption of chromium
picolinate has not been determined, although spectroscopic analysis has shown that chromium picolinate
is a very stable complex in the body and its absorption properties may be due to its ability to cross
membranes (Chakov et al. 1999).















   
   
      
     
 











      
  
 
   
 
     
 




5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
Tables 5-1 and 5-2 list the facilities in each state that manufacture or process chromium, the intended use, 
and the range of maximum amounts of chromium that are stored on site. The data listed in Tables 5-1 and 
5-2 are derived from the Toxics Release Inventory (TRI) (TRI09 2011).  The data presented in Table 5-1 
are for chromium metal and the data from Table 5-2 are for all chromium compounds.  Only certain types
of facilities were required to report. Therefore, this is not an exhaustive list.
Chromium metal is commercially produced in the United States by the reduction of chromite ore with 
carbon, aluminum, or silicon, and subsequent purification.  Sodium chromate and dichromate are
produced by roasting chromite ore with soda ash.  Most other chromium compounds are produced from
sodium chromate and dichromate (Hartford 1979; Papp and Lipin 2001; Westbrook 1979).  For example, 
basic chromic sulfate (Cr(OH)SO4), commonly used in tanning, is commercially produced by the
reduction of sodium dichromate with organic compounds (e.g., molasses) in the presence of sulfuric acid 
or by the reduction of dichromate with sulfur dioxide.  Lead chromate, commonly used as a pigment, is
produced by the reaction of sodium chromate with lead nitrate or by reaction of lead monoxide with 
chromic acid solution (IARC 1990).
The major manufacturers of chromium compounds in 2007 are summarized in Table 5-3 (SRI 2007). 
Tables 5-1 and 5-2 report the number of facilities in each state that manufacture and process chromium, 
the intended use of the products, and the range of maximum amounts of chromium products that are
stored on site.  The data reported in Tables 5-1 and 5-2 are derived from TRI of EPA (TRI09 2011).  The
TRI data should be used with caution since only certain types of facilities were required to report.  Hence, 
this is not an exhaustive list. 
5.2  IMPORT/EXPORT
Chromite ore and foundry sand; chromium chemicals, ferroalloys, and metal; and stainless steel represent
the bulk of the market for chromium.  In 2006, the United States produced chromium ferroalloys, metal,
chemicals, and stainless steel. The United States is a major producer of the end products of chromium, 
which include chromium chemicals, metal, and stainless steel, but until recently, the United States had not
mined chromium (Stokinger 1981; USGS 2008b).  Oregon Resources Corporation (ORC), a subsidiary of
   
 















     
     
         
        
        
        
        
        
        
          
         
      
        
        
        
        
          
        
        
        
        
       
        
        
        
       
          
         
       
        
       
        
          
        
        
         
        
CHROMIUM 352
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1.  Facilities that Produce, Process, or Use Metallic Chromium
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AK 2 10,000 999,999 12
AL 106 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AR 63 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AZ 68 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CA 190 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CO 60 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14
CT 83 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
DE 12 100 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12
FL 55 0 499,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14
GA 103 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
HI 2 0 99,999 1, 5, 8, 9
IA 96 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14
ID 16 0 999,999 1, 3, 5, 8, 9, 10, 12, 13
IL 148 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
IN 176 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
KS 60 0 9,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
KY 118 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
LA 77 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MA 75 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MD 54 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ME 23 0 9,999,999 1, 2, 3, 5, 8, 9, 11, 12
MI 177 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MN 83 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MO 77 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MS 40 0 499,999,999 1, 2, 3, 5, 7, 8, 10, 11, 12, 14
MT 14 100 999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 14
NC 94 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ND 14 1,000 999,999 1, 2, 3, 5, 7, 8, 9, 12, 13
NE 41 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
NH 28 0 49,999,999 2, 3, 4, 6, 7, 8, 9, 11, 12
NJ 101 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
NM 22 0 999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 14
NV 48 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
NY 130 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OH 251 0 10,000,000,000 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OK 91 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
   
 














     
        
        
        
       
        
        
        
        
        
        
       
         
        
        






















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1.  Facilities that Produce, Process, or Use Metallic Chromium
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
OR 74 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
PA 264 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
PR 15 0 99,999,999 1, 2, 3, 5, 7, 8, 9, 11, 12
RI 22 0 999,999 1, 2, 3, 6, 7, 8, 9, 11, 12
SC 108 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
SD 18 100 999,999 1, 5, 7, 8, 9, 11, 12, 13, 14
TN 109 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
TX 214 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT 60 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
VA 66 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
VT 16 100 999,999 2, 3, 4, 6, 8, 9, 11
WA 75 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WI 134 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WV 51 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14
WY 10 0 999,999 1, 8, 9, 11, 12, 13
aPost office state abbreviations used.  
bAmounts on site reported by facilities in each state.  
cActivities/Uses:  
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI09 2011 (Data are from 2009)
   
 















     
        
        
        
        
        
        
        
        
        
        
        
        
        
        
         
        
        
        
         
        
        
        
        
        
        
          
         
        
        
          
        
        
        
        
        
        
CHROMIUM 354
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-2.  Facilities that Produce, Process, or Use Chromium Compounds
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AK 22 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
AL 140 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AR 87 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AZ 102 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CA 198 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CO 38 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CT 62 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
DE 32 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
FL 91 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
GA 128 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
HI 10 1,000 999,999 1, 5, 6, 7, 8, 9, 12, 13, 14
IA 70 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ID 25 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
IL 241 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
IN 212 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
KS 70 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
KY 121 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
LA 88 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MA 71 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MD 83 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ME 34 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
MI 216 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MN 80 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MO 98 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MS 80 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MT 21 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14
NC 134 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ND 17 1,000 999,999 1, 2, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14
NE 44 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
NH 17 0 99,999 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13
NJ 129 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
NM 38 0 10,000,000,000 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
NV 47 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
NY 154 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OH 330 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OK 75 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
   
 














     
        
        
        
        
        
        
        
        
        
        
         
        
        
        
        
 
  



















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-2.  Facilities that Produce, Process, or Use Chromium Compounds
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
OR 63 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
PA 293 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
PR 27 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
RI 23 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
SC 115 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
SD 17 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13
TN 142 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
TX 319 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT 76 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
VA 78 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
VT 9 100 999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 11
WA 86 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WI 141 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WV 85 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WY 25 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
aPost office state abbreviations used.  
bAmounts on site reported by facilities in each state.  
cActivities/Uses:  
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7. Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI09 2011 (Data are from 2009)
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-3.  Major Manufacturers of Chromium Compounds in 2007
Chemical Manufacturer Location
Chromium oxide Elementis Chromium LP Corpus Christi, Texas
Chromium potassium sulfate McGean-Rohco, Inc.; McGean Cleveland, Ohio
Specialty Chemicals Division
Chromium-silicon monoxide CERAC, Inc. Milwaukee, Wisconsin
Chromium(III) sulfate Blue Grass Chemical Specialties, LLC New Albany, Indiana
Elementis LTP L.P. Amarillo, Texas
Dakota City, Nebraska
Milwaukee, Wisconsin
Johnson Mathey, Inc.; Alfa Aesar Ward Hill, Massachusetts
Chromotropic acid, disodium salt Johnson-Mathhey, Inc.; Alfa Aesar Ward Hill, Massachusetts
Source:  SRI 2007  
   
 








   
 
  
   
  







   
    
  
      
   
 
    
  
  
     
  
   
        
    
   
 
   
   
     
 
     
   
CHROMIUM 358
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Industrial Minerals Corporation (Australia), extracted bulk samples of chromite ore at its surface mine in 
Coos County, Oregon.  ORC developed its material beneficiation process to recover chromite, garnet, and 
zircon minerals with production expected to start in 2008 (IMC 2007).  Although chromium is currently
mined in Oregon, the United States receives the majority of chromium ores from other countries.  From
2003 to 2006, chromium contained in chromite ore and chromium ferroalloys and metal were imported
from South Africa (34%), Kazakhstan (18%), Russia (7%), Zimbabwe (6%), and other (35%) (USGS
2008b).
U.S. imports and exports are summarized in Table 5-4 (USGS 2008a).
5.3  USE 
The metallurgical, refractory, and chemical industries are the fundamental users of chromium.  In the
metallurgical industry, chromium is used to produce stainless steels, alloy cast irons, nonferrous alloys,
and other miscellaneous materials.  In 1988, the U.S. chemical and metallurgical industries accounted for
83.9% and the refractory industry for 16.1% of the total domestic consumption of chromite (USDI
1988a).  The stainless steel industry is the leading consumer of chromium materials.  A significant 
amount of chromium is imported and exported in stainless steel mill products and scrap, with 
ferrochromiums as the main components used by the metallurgical industry.  Typical weight percent of
chromium in stainless steel and chromium alloys ranges from 11.5 to 30%.  In the refractory industry, 
chromium is a component in chrome and chrome-magnesite, magnesite-chrome bricks, and granular
chrome-bearing and granular chromite, which are used as linings for high temperature industrial furnaces.
In the chemical industry, both chromium(III) and chromium(VI) are used primarily in pigments.  Other
uses include chromium(VI) in metal finishing, chromium(III) in leather tanning, and chromium(VI) in 
wood preservatives. Table 5-5 lists the approximate distribution of use for chromium chemicals in the
major applications in the United States and Western world in 1996 with a comparison to use in the United 
States for 1951 (Barnhart 1997).  Smaller amounts of chromium are used as catalysts and in 
miscellaneous applications, such as drilling muds, chemical manufacturing, textiles, toners for copying
machines, magnetic tapes, and dietary supplements (Carlton 2003; CMR 1988a, 1988b; Davis and 
Vincent 1997; EPA 1984a; IARC 1990; Papp and Lipin 2001; Radivojevic and Cooper 2008; USDI
1988a).  Chromium alloys are also used in metal joint prostheses (Sunderman et al. 1989).  Chromium
picolinate, a trivalent form of chromium complexed with picolinic acid, is used as a dietary supplement,
with the claim that it reduces symptoms of type II diabetes and hypoglycemia (Broadhurst et al. 1997), 
although a recent meta-review concludes that the results are still inconclusive (Althuis et al. 2002).
   
 














   
 
   
   
   
   





5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-4.  U.S. Chromium Imports and Exports







Source:  USGS 2008a
   
 











    
    
    
    
    
    





5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-5.  Historical Use of Chromium in the United States and Western World
Use 1996 Western world 1996 United States 1951 United States
Wood preservation 15% 52% 2%
Leather tanning 40% 13% 20%
Metals finishing 17% 13% 25%
Pigments 15% 12% 35%
Refractory 3% 3% 1%
Other 10% 7% 17%
Source:  Barnhart 1997
   
 









   
 
    
  
   
 
   
     
    
 
 
   
 
   
  
     
   
   
  
 
   




     
  




5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.4  DISPOSAL
Information regarding the disposal of finished products and wastes produced during the manufacturing of
consumable items that contain chromium is limited.  In 1987, 25% of the chromium demand in the United 
States was supplied by recycled stainless steel scrap.  Although a large portion of the chromium wastes
from plating operations is also recovered, large amounts of chromium-containing waste waters from
plating, finishing, and textile industries are discharged into surface waters.  A substantial amount of
chromium enters sewage treatment plants from industrial and residential sources (Klein et al. 1974; TRI06
2008).  Presently, slag from roasting/leaching of chromite ore is one of the materials excluded from
regulation under the Resource Conservation and Recovery Act by the 1980 Bevill Amendment.  However, 
emission control dust or sludge from ferrochromium and ferrochromium-silicon production is listed as
hazardous waste by EPA (1988b).  Land filling appears to be the most important method for the disposal
of chromium wastes generated by chemical industries.  Of the total chromium released in the environment
by chemical industries, approximately 82.3% is released on land.  An equally large amount of chromium
waste is transferred off-site (see Section 5.2).  It is anticipated that most of this off-site waste will be 
disposed of in landfills after proper treatment.  It is important to convert chromium wastes into forms of
chromium that have low mobilities in soils and low availabilities to plants and animals before land
disposal.  Chromium(III) oxide is one such form.  Chromium in chemical industry wastes occurs
predominantly in the hexavalent form.  The treatment of chromium(VI) waste often involves reduction to 
chromium(III) and precipitation as the hydrous oxide with lime or caustic soda.  Chromium(III) waste can 
also be converted into hydrous oxide or may be incinerated to form the oxide before land disposal.  There
is not much known about the disposal method of waste refractory materials used as lining for metallurgical 
furnaces or the disposal practices for the finished products containing chromium, such as chromium-
containing pigments (Fishbein 1981; Komori et al. 1990a; NRCC 1976; Polprasert and Charnpratheep 
1989; Westbrook 1979).
Chromium is listed as a toxic substance under Section 313 of the Emergency Planning and Community
Right to Know Act (EPCRA) under Title III of the Superfund Amendments and Reauthorization Act
(SARA) (EPA 1995).  Disposal of wastes containing chromium is controlled by a number of federal
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CHROMIUM 363
6. POTENTIAL FOR HUMAN EXPOSURE 
6.1  OVERVIEW
Chromium has been identified in at least 1,127 of the 1,699 hazardous waste sites that have been
proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2007).  However, the number
of sites evaluated for chromium is not known.  The frequency of these sites can be seen in Figure 6-1.  Of
these sites, 1,117 are located within the United States and 10 are located in the Commonwealth of Puerto 
Rico (not shown).
Human exposure to chromium occurs from both natural and anthropogenic sources.  Chromium is present
in the Earth's crust, with the main natural source of exposure being continental dust present in the
environment (Barnhart 1997; Fishbein 1981; Pellerin and Booker 2000).  Chromium is released into the
environment in larger amounts as a result of human activities, which account for 60–70% of the total
emissions of atmospheric chromium (Alimonti et al. 2000; Barceloux 1999; Seigneur and Constantinous
1995).  This is indicated by the value of the enrichment factor (the enrichment factor relates the amount of
chromium relative to an aluminum standard) of 3.5–8.1 (Dasch and Wolff 1989; Milford and Davidson 
1985).  Elements with enrichment factors >1 are assumed to have originated from anthropogenic sources 
(Schroeder et al. 1987).  Of the estimated 2,700–2,900 tons of chromium emitted to the atmosphere
annually from anthropogenic sources in the United States, approximately one-third is in the hexavalent 
form (EPA 1990b; Johnson et al. 2006).  Industrial releases to the air, water, and soil are also potential
sources of chromium exposure, and account for the majority of the anthropogenic releases (Johnson et al. 
2006).  The electroplating, leather tanning, and textile industries release large amounts of chromium to 
surface waters (Avudainayagam et al. 2003; Fishbein 1981; Johnson et al. 2006).  Disposal of chromium-
containing commercial products and coal ash from electric utilities and other industries are major sources 
of chromium releases into the soil (Barceloux 1999; Nriagu and Pacyna 1988).  Solid waste and slag
produced during chromate manufacturing processes when disposed of improperly in landfills can be 
potential sources of chromium exposure as well (Barceloux 1999; Kimbrough et al. 1999). 
Chromium is primarily removed from the atmosphere by fallout and precipitation.  The residence time of
chromium in the atmosphere has not been directly measured, but by using copper as a model, it is
expected to be <10 days (Nriagu 1979).  The arithmetic mean concentrations of total chromium in the
ambient air in United States, urban, suburban, and rural areas monitored during 1977–1984 ranged from
5 to 525 ng/m3, with the vast majority of samples <100 ng/m3 (EPA 1984a, 1990b).  Ambient air in the
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6. POTENTIAL FOR HUMAN EXPOSURE
<300 ng/m3 and median levels were <20 ng/m3. As a result of smoking, indoor air contaminated with 
chromium can be 10–400 times greater than outdoor air concentrations (WHO 2003). 
Chromium in the aquatic phase occurs in the soluble state or as suspended solids adsorbed onto clayish 
materials, organics, or iron oxides.  Most of the soluble chromium is present as chromium(VI) or as 
soluble chromium(III) complexes and generally accounts for a small percentage of the total.  Soluble 
chromium(VI) may persist in some bodies of water, but will eventually be reduced to chromium(III) by
organic matter or other reducing agents in water (Cary 1982; EPA 1984a; Lide 1998).  The residence 
times of chromium (total) in lake water range from 4.6 to 18 years, with the majority of the chromium in 
lakes and rivers ultimately deposited in the sediments (Schmidt and Andren 1984).  In the United States, 
chromium concentrations are up to 84 µg/L in surface water and 0.2–1 µg/L in rainwater (WHO 2003).  
Most drinking water supplies in the United States contain <5 µg/L of chromium (WHO 2003).  In ocean 
water, the mean chromium concentration is 0.3 μg/L (Cary 1982). In the United States, the groundwater 
concentration of chromium is generally low, with measurements in the range of 2–10 µg/L in shallow 
groundwater; levels as high as 50 µg/L have been reported in some supplies (WHO 2003). 
Total chromium concentrations in U.S. soils range from 1 to 2,000 mg/kg, with a mean of 37.0 mg/kg 
(USGS 1984).  Chromium(III) in soil is mostly present as insoluble carbonate and oxide of
chromium(III); therefore, it will not be mobile in soil.  The solubility of chromium(III) in soil and its 
mobility may increase due to the formation of soluble complexes with organic matter in soil, with a lower 
soil pH potentially facilitating complexation (Avudainayagam et al. 2003).  Chromium has a low mobility
for translocation from roots to the aboveground parts of plants (Calder 1988; Cary 1982; EPA 1984a, 
1985a; King 1988; Stackhouse and Benson 1989).
A common source of chromium exposure is from food.  Total chromium levels in most foods typically
range from <10 to 1,300 µg/kg, with the highest concentrations being found in meat, fish, fruits, and 
vegetables (WHO 2003).  The general population is exposed to chromium by inhaling air, drinking water, 
or eating food or food supplements that contain chromium.  However, the primary source of exposure for 
the general population and non-occupationally exposed workers to chromium comes from food sources, 
although drinking water can contribute significantly when the levels are >25 µg/L (WHO 2003). 
Dermal exposure to chromium may also occur during the use of consumer products that contain 
chromium, such as fertilizer, wood treated with copper dichromate or chromated copper arsenate, and 
































6. POTENTIAL FOR HUMAN EXPOSURE
disposal sites and chromium manufacturing and processing plants have a greater probability of elevated 
chromium exposure (Pellerin and Booker 2000).  
Exposure to chromium for occupational groups can be two orders of magnitude higher than the exposure 
to the general population (Hemminki and Vainio 1984).  Occupational exposure to chromium occurs 
mainly from chromate production, stainless steel production and welding, chrome plating, production of 
ferrochrome alloys, chrome pigment production and user industries, and from working in tanning 
industries (Pellerin and Booker 2000; Stern 1982)
6.2 RELEASES TO THE ENVIRONMENT 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing 
facilities are required to report information to the TRI only if they employ 10 or more full-time 
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005).
6.2.1 Air 
Estimated releases of 512,134 pounds of chromium to the atmosphere from 2,011 domestic 
manufacturing and processing facilities in 2009, accounted for about 6.6% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI09 2011).  Estimated releases of 
269,599 pounds of chromium compounds to the atmosphere from 1,334 domestic manufacturing and 
processing facilities in 2009, accounted for about 1% of the estimated total environmental releases from
facilities required to report to the TRI (TRI09 2011).  These releases are summarized in Tables 6-1 and 
6-2.













   





          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
CHROMIUM 367
6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or  
Use Metallic Chromiuma  
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
AL 45 3,708 565 0 32,551 37,542 7,720 66,646 74,366
AK 1 0 0 25,000 27,000 0 52,000 0 52,000
AZ 20 1,055 91 0 345,591 17,749 334,967 29,520 364,487
AR 25 5,067 280 0 4,070 250 5,078 4,589 9,667
CA 85 1,653 1,287 382 11,059 11,749 1,674 24,457 26,131
CO 21 290 29 0 28,935 27,412 27,627 29,039 56,666
CT 45 542 2,060 0 15,242 36,845 10,913 43,777 54,689
DE 2 5 0 0 334 0 5 334 339
FL 29 90 31 0 255,926 1,889 188,645 69,290 257,935
GA 44 1,003 396 0 47,228 1,886 1,320 49,193 50,513
ID 5 105 0 0 130,286 487 107,517 23,361 130,879
IL 109 4,982 26,157 0 24,175 17,870 5,012 68,172 73,184
IN 119 15,813 3,811 0 1,490,024 85,846 29,247 1,566,247 1,595,493
IA 43 2,183 65 0 61,992 109,972 2,245 171,968 174,213
KS 40 8,066 217 0 3,330 270 8,088 3,795 11,883
KY 49 7,123 623 0 22,447 9,475 7,222 32,446 39,668
LA 35 1,367 232 0 49,357 164 17,636 33,484 51,121
ME 8 88 122 0 43 2,970 88 3,134 3,222
MD 7 1 14 0 9 11 1 34 35
MA 34 1,026 350 0 12,580 10,706 1,281 23,380 24,662
MI 78 7,673 2,382 0 25,049 4,951 8,729 31,326 40,055
MN 38 2,163 39 0 7,146 69 2,163 7,255 9,418
MS 22 2,806 12 0 454 72 2,808 536 3,344
MO 37 298,980 513 0 4,206 76 298,995 4,781 303,775
MT 1 0 0 0 520,172 0 520,172 0 520,172
NE 11 809 257 0 82,754 75 46,541 37,354 83,895
NV 14 238 6,631 0 1,080,422 407 1,076,822 10,876 1,087,699
NH 15 126 45 0 26 1,125 126 1,195 1,321
NJ 21 440 17 0 26,248 141 448 26,398 26,846
NM 3 52 0 0 54 0 106 0 106
NY 49 4,612 6,544 0 48,786 880 19,512 41,309 60,821
NC 52 928 312 0 4,008 6,969 976 11,241 12,217
ND 5 21 9 0 10,453 0 10,236 247 10,483
OH 164 9,119 5,675 0 204,658 73,201 43,141 249,513 292,654
OK 66 2,389 59 0 6,561 1,551 2,394 8,167 10,560













   





          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
 










   










6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or  
Use Metallic Chromiuma  
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
OR 14 2,726 43 0 73,071 24 70,154 5,710 75,864
PA 180 12,514 1,378 0 658,699 217,491 47,732 842,350 890,082
PR 5 29 0 0 20 0 29 20 49
RI 5 0 0 0 0 1 0 1 1
SC 51 6,009 2,892 0 99,752 868 6,103 103,417 109,520
SD 8 45 1 0 42,240 1 42,162 125 42,287
TN 49 1,629 837 0 57,445 13,005 1,900 71,017 72,917
TX 140 6,499 8,912 213,649 20,672 5,244 221,563 33,414 254,976
UT 18 624 10 0 27,087 3,726 19,141 12,308 31,448
VT 4 22 13 0 32 215 27 255 282
VA 22 172 20,799 0 49,635 396 19,270 51,733 71,002
WA 21 1,608 142 0 48,867 4,633 2,864 52,386 55,249
WV 7 2,984 706 0 14,833 501 2,991 16,034 19,024
WI 142 92,652 4,452 0 476,398 27,955 93,201 508,256 601,456
WY 3 95 2 0 41,823 176 41,892 204 42,096
Total 2,011 512,134 99,011 239,031 6,193,750 736,849 3,410,482 4,370,293 7,780,775
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an  
exhaustive list.  Data are rounded to nearest whole number.  
bData in TRI are maximum amounts released by each facility.  
cPost office state abbreviations are used.  
dNumber of reporting facilities.  
eThe sum of fugitive and point source releases are included in releases to air by a given facility.  
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal  
and metal compounds).  
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface  
impoundments, other land disposal, other landfills.
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for  
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
kTotal amount of chemical transferred off-site, including to POTWs.  
RF = reporting facilities; UI = underground injection
Source:  TRI09 2011 (Data are from 2009)














   





          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
CHROMIUM 369
6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-2.  Releases to the Environment from Facilities that Produce, Process, or  
Use Chromium Compoundsa  
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
AK 4 192 10 0 1,051,055 0 1,051,257 0 1,051,257
AL 41 12,995 3,368 0 855,643 33,148 756,162 148,992 905,154
AR 25 1,830 209 0 89,381 51,460 61,330 81,549 142,880
AZ 19 1,876 42 0 1,462,139 1,739 1,460,380 5,416 1,465,796
CA 42 699 17,437 0 252,991 58,991 190,150 139,969 330,119
CO 11 510 15 0 394,416 250 346,695 48,496 395,191
CT 13 1,305 820 0 16,344 20,567 1,328 37,707 39,035
DE 4 208 297 0 508,021 0 27,157 481,369 508,526
FL 25 4,306 357 0 385,025 22,394 346,871 65,211 412,082
GA 41 6,050 3,428 0 560,164 4,984 549,328 25,298 574,625
HI 1 0 0 0 0 0 . . .
IA 15 7,476 50 0 146,295 110 74,254 79,676 153,930
ID 1 5,922 4 0 464,262 5 470,188 5 470,194
IL 72 5,913 19,980 636 949,161 164,644 219,738 920,596 1,140,334
IN 76 17,409 196,624 900 2,128,495 693,344 1,490,246 1,546,525 3,036,771
KS 23 6,121 2,902 250 368,352 213,474 106,741 484,358 591,099
KY 45 21,332 9,012 0 2,670,506 44,468 972,602 1,772,715 2,745,318
LA 21 1,229 440 1 260,204 16,688 214,862 63,700 278,562
MA 11 538 6 0 28,267 15,101 617 43,295 43,911
MD 21 2,401 532 0 110,310 144,631 74,943 182,931 257,873
ME 6 133 450 0 31,822 71,378 543 103,240 103,783
MI 73 10,157 9,079 4,400 557,893 16,191 340,219 257,502 597,720
MN 25 1,573 14,278 0 127,028 15,383 75,650 82,612 158,261
MO 26 4,537 618 0 336,752 37,987 104,979 274,916 379,894
MS 33 3,277 1,026 2,297,309 1,008,735 32,026 3,168,752 173,623 3,342,374
MT 8 1,805 0 0 250,394 645 102,190 150,653 252,843
NC 42 7,004 39,737 0 1,299,616 16,645 1,183,540 179,461 1,363,001
ND 7 4,869 242 0 289,934 1,533 134,352 162,226 296,578
NE 11 3,629 2,770 0 84,154 5,697 75,712 20,538 96,251
NH 3 69 10 0 10,650 250 2,079 8,900 10,979
NJ 17 1,590 39,946 0 3,865 52,021 3,765 93,658 97,423
NM 4 659 0 0 180,656 0 181,315 0 181,315
NV 7 255 0 0 1,531,094 0 1,531,349 0 1,531,349
NY 21 898 1,103 0 64,214 1,238 32,491 34,962 67,453
OH 101 28,059 17,971 444,822 2,125,297 247,620 1,578,830 1,284,938 2,863,768













   





          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
 





















6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-2.  Releases to the Environment from Facilities that Produce, Process, or  
Use Chromium Compoundsa  
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
OK 19 3,389 306 0 465,657 3,844 444,881 28,315 473,196
OR 11 235 106 0 58,134 653 7,961 51,167 59,128
PA 113 50,601 15,177 0 2,004,874 235,591 818,001 1,488,242 2,306,243
PR 7 5,285 51 0 3,193 198 5,285 3,443 8,728
RI 5 0 0 0 300 0 0 300 300
SC 2 3,260 2,945 0 389,283 130,685 278,206 247,966 526,172
SD 27 13 8 0 0 0 13 8 20
TN 3 4,604 30,074 0 2,109,366 5,918 1,570,982 578,980 2,149,962
TX 43 16,668 3,020 31,886 1,316,207 110,630 1,283,443 194,969 1,478,412
UT 92 2,088 1,262 0 1,632,406 14,465 1,538,140 112,081 1,650,221
VA 15 1,002 6,116 0 171,669 359 163,200 15,947 179,146
WA 16 568 36,434 0 75,005 106,290 43,057 175,240 218,298
WI 23 6,195 4,745 0 204,646 68,916 11,886 272,616 284,502
WV 16 4,465 2,878 0 911,062 29,786 603,016 345,175 948,191
WY 47 4,399 180 0 211,926 636 190,665 26,476 217,141
Total 1,334 269,599 486,063 2,780,204 30,156,862 2,692,585 23,889,351 12,495,962 36,385,312
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an  
exhaustive list.  Data are rounded to nearest whole number.  
bData in TRI are maximum amounts released by each facility.  
cPost office state abbreviations are used.  
dNumber of reporting facilities.  
eThe sum of fugitive and point source releases are included in releases to air by a given facility.  
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal  
and metal compounds).  
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface  
impoundments, other land disposal, other landfills.
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for  
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
kTotal amount of chemical transferred off-site, including to POTWs.  
RF = reporting facilities; UI = underground injection
Source:  TRI09 2011 (Data are from 2009)
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Total chromium has been identified in air samples at 48 of 1,699 current or former NPL hazardous waste
sites where it was detected in some environmental media (HazDat 2007).
Continental dust flux is the main natural source of chromium in the atmosphere; volcanic dust and gas
flux are minor natural sources of chromium in the atmosphere (Fishbein 1981).  Chromium is released
into the atmosphere mainly by anthropogenic stationary point sources, including industrial, commercial, 
and residential fuel combustion, via the combustion of natural gas, oil, and coal (Kimbrough et al. 1999;
Pacyn and Pacyn 2001; Seigneur and Constantinous 1995).  Other important anthropogenic stationary
point sources of chromium emission to the atmosphere are metal industries, such as chrome plating and 
steel production (EPA 1990b; Johnson et al. 2006; Pacyn and Pacyn 2001).  Approximately one-third of
the atmospheric releases of chromium are believed to be in the hexavalent form, chromium(VI) (Johnson 
et al. 2006).  Other potentially small sources of atmospheric chromium emission are cement-producing
plants (cement contains chromium), the wearing down of asbestos brake linings that contain chromium, 
incineration of municipal refuse and sewage sludge, and emission from chromium-based automotive
catalytic converters.  Emissions from cooling towers that previously used chromate chemicals as rust
inhibitors are also atmospheric sources of chromium (EPA 1984b, 1990b; Fishbein 1981).
6.2.2 Water
Estimated releases of 99,011 pounds of chromium to surface water from 2,011 domestic manufacturing
and processing facilities in 2009, accounted for about 1% of the estimated total environmental releases 
from facilities required to report to the TRI (TRI09 2011).  Estimated releases of 486,063 pounds of
chromium compounds to surface water from 1,334 domestic manufacturing and processing facilities in
2009, accounted for about 1% of the estimated total environmental releases from facilities required to
report to the TRI (TRI09 2011).  
Total chromium has been identified in surface water and groundwater samples at 427 of 1,699 and 813 of
1,699 current or former NPL hazardous waste sites where it was detected in some environmental media 
(HazDat 2007).  
On a worldwide basis, the major chromium source in aquatic ecosystems is domestic waste water
effluents (32.2% of the total) (Barceloux 1999).  The other major sources are metal manufacturing
(25.6%), ocean dumping of sewage (13.2%), chemical manufacturing (9.3%), smelting and refining of
nonferrous metals (8.1%), and atmospheric fallout (6.4%) (Nriagu and Pacyna 1988).  Annual
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anthropogenic input of chromium into water has been estimated to exceed anthropogenic input into the
atmosphere (Nriagu and Pacyna 1988).  However, land erosion, a natural source of chromium in water, 
was not included in the Nriagu and Pacyna (1988) estimation of chromium contributions to the aquatic
environment. 
6.2.3 Soil 
Estimated releases of 6,193,750 pounds of chromium to soils from 2,011 domestic manufacturing and 
processing facilities in 2009, accounted for about 80% of the estimated total environmental releases from
facilities required to report to the TRI (TRI09 2011).  An additional 239,031 pounds of chromium were
released via underground injection.  Estimated releases of 30,156,862 pounds of chromium compounds to 
soils from 1,334 domestic manufacturing and processing facilities in 2009, accounted for about 83% of
the estimated total environmental releases from facilities required to report to the TRI (TRI09 2011).  An 
additional 2,780,204 pounds were released via underground injection. These releases are summarized in
Tables 6-1 and 6-2.  
Total chromium has been identified in soil and sediment samples at 696 of 1,699 and 471 of 1,699 current
or former NPL hazardous waste sites where it was detected in some environmental media (HazDat 2007).  
On a worldwide basis, the disposal of commercial products that contain chromium may be the largest
contributor, accounting for 51% of the total chromium released to soil (Nriagu and Pacyna 1988).  Other
significant sources of chromium release into soil include the disposal of coal fly ash and bottom fly ash
from electric utilities and other industries (33.1%), agricultural and food wastes (5.3%), animal wastes
(3.9%), and atmospheric fallout (2.4%) (Nriagu and Pacyna 1988).  Solid wastes from metal
manufacturing constituted <0.2% to the overall chromium release in soil.  However, the amount of
chromium in sludge or residue that is disposed of in landfills by manufacturing and user industries that
treat chromate wastes in ponds and lagoons is not included in the estimation by Nriagu and Pacyna
(1988).
6.3  ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
Chromium is present in the atmosphere primarily in particulate form; naturally occurring gaseous forms
of chromium are rare (Cary 1982; Kimbrough et al. 1999; Seigneur and Constantinous 1995).  The
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transport and partitioning of particulate matter in the atmosphere depends largely on particle size and
density.  Atmospheric particulate matter is deposited on land and water via wet and dry deposition.  Wet, 
dry, and total deposition rates of chromium and several other trace metals in remote, rural and urban areas 
were summarized by Schroeder et al. (1987).  Deposition rates tended to be highest in urban areas that
had greater atmospheric levels of chromium as compared to rural and remote locations. The rates of wet
and dry deposition are dependent upon several factors, including particle and aerosol size distribution 
(Kimbrough et al. 1999). The mass mean aerodynamic diameter (MMAD) of chromium aerosols or
particulates emitted from several industrial sources are ≤10 μm and it has been estimated that chromium-
containing particulates emitted from these industrial sources can remain airborne for 7–10 days and are
subject to long-range transport (Kimbrough et al. 1999).  Based on a troposphere to stratosphere turnover
time of 30 years (EPA 1979), atmospheric particles with a residence time of <10 days are not expected to 
transport from the troposphere to the stratosphere and there are no data in the reviewed literature
indicating that chromium particles are transported from the troposphere to the stratosphere (Pacyna and 
Ottar 1985).  
Since chromium compounds cannot volatilize from water, transport of chromium from water to the
atmosphere is not likely, except by transport in windblown sea sprays.  Most of the chromium released
into water will ultimately be deposited in the sediment.  A very small percentage of chromium in the
water column is present in both soluble and insoluble forms.  In the aquatic phase, chromium(III) occurs
mostly as suspended solids adsorbed onto clayish materials, organics, or iron oxide (Fe2O3) present in 
water.  Approximately 10.5–12.6% of chromium in the aquatic phase of the Amazon and Yukon Rivers
was in solution, the rest being present in the suspended solid phase (Cary 1982; King 1988).  The ratio of
chromium in suspended solids to dissolved form in an organic-rich river in Brazil was 2.1 (Malm et al.
1988).  
The bioconcentration factor (BCF) for chromium(VI) in rainbow trout (Salmo gairdneri) is 1.  In bottom-
feeder bivalves, such as the oyster (Crassostrea virginica), blue mussel (Mytilus edulis), and soft shell
clam (Mya arenaria), the BCF values for chromium(III) and chromium(VI) range from 86 to 192 (EPA
1980, 1984a; Fishbein 1981; Schmidt and Andren 1984).  The bioavailability of chromium(III) to
freshwater invertebrates (Daphnia pulex) decreased with the addition of humic acid (Ramelow et al.
1989). This decrease in bioavailability was attributed to lower availability of the free form of the metal
due to its complexation with humic acid.  Based on this information, chromium is not expected to 
biomagnify in the aquatic food chain.  Although higher concentrations of chromium have been reported in 
plants growing in high chromium-containing soils (e.g., soil near ore deposits or chromium-emitting
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industries and soil fertilized by sewage sludge) compared with plants growing in normal soils, most of the
increased uptake in plants is retained in roots, and only a small fraction is translocated in the aboveground 
part of edible plants (Cary 1982; WHO 1988).  Therefore, bioaccumulation of chromium from soil to 
aboveground parts of plants is unlikely (Petruzzelli et al. 1987).  There is no indication of
biomagnification of chromium along the terrestrial food chain (soil-plant-animal) (Cary 1982).
The mobility of chromium in soil is dependent upon the speciation of chromium, which is a function of
redox potential and the pH of the soil.  In most soils, chromium will be present predominantly in the
chromium(III) oxidation state.  This form has very low solubility and low reactivity, resulting in low
mobility in the environment (Barnhart 1997; Jardine et al. 1999; Robson 2003).  Under oxidizing
-conditions, chromium(VI) may be present in soil as CrO4–2 and HCrO4  (James et al. 1997).  In this form, 
chromium is relatively soluble and mobile.  A leachability study comparing the mobility of several 
metals, including chromium, in soil demonstrated that chromium had the least mobility of all of the
metals studied (Sahuquillo et al. 2003).  These results support previous data finding that chromium is not
very mobile in soil, especially in the trivalent oxidation state (Balasoiu et al. 2001; Jardine et al. 1999; Lin
et al. 1996; Robson 2003).  These results are further supported by a leachability investigation in which 
chromium mobility was studied for a period of 4 years in a sandy loam (Sheppard and Thibault 1991). 
The vertical migration pattern of chromium in this soil indicated that after an initial period of mobility, 
chromium forms insoluble complexes and little leaching is observed.  Chromium present as insoluble 
oxide, Cr2O3·nH2O, exhibited limited mobility in soil (Rifkin et al. 2004).  Flooding of soils and the
subsequent anaerobic decomposition of plant detritus matters may increase the mobilization of
chromium(III) in soils due to formation of soluble complexes (Stackhouse and Benson 1989).  This
complexation may be facilitated by a lower soil pH.  
A smaller percentage of total chromium in soil exists as soluble chromium(VI) and chromium(III)
complexes, which are more mobile in soil.  Chromium that is irreversibly sorbed onto soil (e.g., in the
interstitial lattice of geothite, FeOOH) will not be bioavailable to plants and animals under any condition.  
Organic matter in soil is expected to convert soluble chromate, chromium(VI), to insoluble chromium(III)
oxide, Cr2O3 (Calder 1988).  Surface runoff from soil can transport both soluble and bulk precipitate of
chromium to surface water.  Soluble and unadsorbed chromium(VI) and chromium(III) complexes in soil
may leach into groundwater.  The leachability of chromium(VI) in the soil increases as the pH of the soil
increases.  On the other hand, lower pH present in acid rain may facilitate leaching of acid-soluble
chromium(III) complexes and chromium(VI) compounds in soil.  Chromium has a low mobility for
translocation from roots to aboveground parts of plants (Cary 1982).  However, depending on the
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geographical areas where the plants are grown, the concentration of chromium in aerial parts of certain
plants may differ by a factor of 2–3 (Cary 1982).
6.3.2 Transformation and Degradation
6.3.2.1  Air
In the atmosphere, chromium(VI) may be reduced to chromium(III) at a significant rate by vanadium
(V2+, V3+, and VO2+), Fe2+, HSO3-, and As3+ (EPA 1987b; Kimbrough et al. 1999).  Conversely, 
chromium(III), if present as a salt other than Cr2O3, may be oxidized to chromium(VI) in the atmosphere
if 1% of the manganese in atmospheric aerosols is present as MnO2 (EPA 1990b).  The estimated 
atmospheric half-life for chromium(VI) reduction to chromium(III) was reported in the range of 16 hours
to about 5 days (Kimbrough et al. 1999).
6.3.2.2  Water
The reduction of chromium(VI) to chromium(III) and the oxidation of chromium(III) to chromium(VI) in 
water has been investigated extensively.  Reduction of chromium(VI) to chromium(III) can occur under
suitable conditions in the aqueous environment, if an appropriate reducing agent is available.  The most
common reducing agents present in aqueous systems include:  organic matter; hydrogen sulfide; sulfur, 
iron sulfide; ammonium; and nitrate (Kimbrough et al. 1999).  The reduction of chromium(VI) by S-2 or
Fe+2 ions under anaerobic conditions occurs rapidly, with the reduction half-life ranging from
instantaneous to a few days (Seigneur and Constantinous 1995).  However, the reduction of
chromium(VI) by organic sediments and soils was much slower and depended on the type and amount of
organic material and on the redox condition of the water.  The reduction half-life of chromium(VI) in
water with soil and sediment ranged from 4 to 140 days, with the reaction typically occurring faster under
anaerobic rather than aerobic conditions (Saleh et al. 1989).  Generally, the reduction of chromium(VI) to 
chromium(III) is also favored under acidic conditions (Kimbrough et al. 1999). 
Oxidation of chromium(III) to chromium(VI) can also occur in the aqueous environment, depending on 
several factors.  Although oxygen is known to oxidize chromium(III) to chromium(VI), dissolved oxygen 
by itself in natural waters did not cause any measurable oxidation of chromium(III) to chromium(VI) over
a period of 128 days (Saleh et al. 1989).  When chromium(III) was added to lake water, a slow oxidation 
of chromium(III) to chromium(VI) occurred, corresponding to an oxidation half-life of nine years.
Addition of 50 mg/L manganese oxide accelerated the process, decreasing the oxidation half-life to
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approximately 2 years (Saleh et al. 1989).  The oxidation of chromium(III) to chromium(VI) during
chlorination of water was highest in the pH range of 5.5–6.0 (Saleh et al. 1989).  However, the process 
would rarely occur during chlorination of drinking water because of the low concentrations of
chromium(III) in these waters, and the presence of naturally occurring organics that may protect
chromium(III) from oxidation, either by forming strong complexes with chromium(III) or by acting as a
reducing agent to free available chlorine (EPA 1988c).  In chromium(III)-contaminated waste waters 
having pH ranges of 5–7, chlorination may convert chromium(III) to chromium(VI) in the absence of
chromium(III)-complexing and free chlorine reducing agents (EPA 1988c).
Chromium speciation in groundwater also depends on the redox potential and pH conditions in the
aquifer.  Chromium(VI) predominates under highly oxidizing conditions; whereas chromium(III)
predominates under reducing conditions.  Oxidizing conditions are generally found in shallow, 
oxygenated aquifers, and reducing conditions generally exist in deeper, anaerobic groundwaters.  In 
natural groundwater, the pH is typically 6–8, and CrO4-2 is the predominant species of chromium in the
hexavalent oxidation state, while Cr(OH)2+1 will be the dominant species in the trivalent oxidation state.  
This species and other chromium(III) species will predominate in more acidic pH; Cr(OH)3 and 
Cr(OH)4-1 predominate in more alkaline waters (Calder 1988).
6.3.2.3  Sediment and Soil
The fate of chromium in soil is greatly dependent upon the speciation of chromium, which is a function of
redox potential and the pH of the soil.  In most soils, chromium will be present predominantly in the
chromium(III) state. This form has very low solubility and low reactivity resulting in low mobility in the
environment and low toxicity in living organisms (Ashley et al. 2003; Barnhart 1997; EPA 1994b).  
-Under oxidizing conditions, chromium(VI) may be present in soil as CrO4–2 and HCrO4 (James et al.
1997).  In this form, chromium is relatively soluble, mobile, and toxic to living organisms.  In deeper soil
where anaerobic conditions exist, chromium(VI) will be reduced to chromium(III) by S-2 and Fe+2 present
in soil. The reduction of chromium(VI) to chromium(III) is possible in aerobic soils that contain 
appropriate organic energy sources to carry out the redox reaction, with the reduction of chromium(VI) to 
chromium(III) facilitated by low pH (Cary 1982; EPA 1990b; Saleh et al. 1989). 
The oxidation of chromium(III) to chromium(VI) in soil is facilitated by the presence of organic
substances, oxygen, manganese dioxide, moisture, and the elevated temperatures in surface soil that result 
from brush fires (Calder 1988; Cary 1982).  Organic forms of chromium(III) (e.g., humic acid complexes)
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are more easily oxidized than insoluble oxides.  However, oxidation of chromium(III) to chromium(VI)
was not observed in soil under conditions of maximum aeration and a maximum pH of 7.3 (Bartlett and 
Kimble 1976).  It was later reported that soluble chromium(III) in soil can be partly oxidized to 
chromium(VI) by manganese dioxide in soil, and the process is enhanced at pH values >6 (Bartlett 1991).  
Because most chromium(III) in soil is immobilized due to adsorption and complexation with soil
materials, the barrier to this oxidation process is the lack of availability of mobile chromium(III) to 
immobile manganese dioxide in soil surfaces.  Due to this lack of availability of mobile chromium(III) to 
manganese dioxide surfaces, a large portion of chromium in soil will not be oxidized to chromium(VI), 
even in the presence of manganese dioxide and favorable pH conditions (Bartlett 1991; James et al.
1997).  
The microbial reduction of chromium(VI) to chromium(III) has been discussed as a possible remediation 
technique in heavily contaminated environmental media or wastes (Chen and Hao 1998; EPA 1994b).  
Factors affecting the microbial reduction of chromium(VI) to chromium(III) include biomass
concentration, initial chromium(VI) concentration, temperature, pH, carbon source, oxidation-reduction 
potential, and the presence of both oxyanions and metal cations.  Although high levels of chromium(VI) 
are toxic to most microbes, several resistant bacterial species have been identified that could ultimately be 
employed in remediation strategies (Chen and Hao 1998; EPA 1994b).  Elemental iron, sodium sulfite, 
sodium hydrosulfite, sodium bisulfite, sodium metabisulfite sulfur dioxide, and certain organic
compounds such as hydroquinone have also been shown to reduce chromium(VI) to chromium(III) and 
have been discussed as possible remediation techniques in heavily contaminated soils (Higgins et al.
1997; James et al. 1997). The limitations and efficacy of these and all remediation techniques are 
dependent upon the ease in which the reducing agents are incorporated into the contaminated soils.
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to chromium depends in part on the reliability of
supporting analytical data from environmental samples and biological specimens.  Concentrations of
chromium in unpolluted atmospheres and in pristine surface waters are often so low as to be near the
limits of current analytical methods.  In reviewing data on chromium levels monitored or estimated in the
environment, it should also be noted that the amount of chemical identified analytically is not necessarily
equivalent to the amount that is bioavailable. The analytical methods available for monitoring chromium
in a variety of environmental media are detailed in Chapter 7.
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6.4.1 Air
Levels of total chromium in the ambient air in U.S. urban and nonurban areas during 1977–1984 are
reported in EPA's National Aerometric Data Bank (EPA 1984a, 1990b).  According to this databank, the
arithmetic mean total chromium concentrations from a total of 2,106 monitoring stations ranged from 5 to 
525 ng/m3. The two locations that showed the highest total arithmetic mean chromium concentrations 
were in Steubenville, Ohio, in 1977 (525 ng/m3) and in Baltimore, Maryland, in 1980 (226 ng/m3) (EPA
1990b).  Arithmetic mean total chromium concentrations in only 8 of 173 sites monitored in 1984 were
>100 ng/m3 (EPA 1990b).  
An indoor/outdoor air study was conducted in southwestern Ontario to measure levels of chromium(VI)
and the size fraction of chromium(VI).  Indoor and outdoor samples were taken from 57 homes during the
summer months of 1993.  The concentrations were 0.1–0.6 ng/m3 indoors (geometric mean 0.2 ng/m3) 
and were 0.10–1.6 ng/m3 outdoors (geometric mean 0.55 ng/m3).  The indoor concentrations were less 
than half of the outdoor concentrations.  Analysis of airborne chromium(VI) particles showed that they
were inhalable in size (Bell and Hipfner 1997).  A study measured the levels of chromium(VI) and total
chromium in the ambient air in Hudson County, New Jersey.  The concentrations of chromium(VI) in the
indoor air of residences in Hudson County in 1990 ranged from 0.38 to 3,000 ng/m3, with a mean of
1.2 ng/m3 (Falerios et al. 1992). 
Another study analyzed the relationship between soil levels of chromium and chromium content of the
atmosphere.  An indoor/outdoor study was conducted at 25 industrial sites in Hudson County, New Jersey
to analyze soils containing chromite ore processing residues. The industrial sites include industrial,
manufacturing, trucking, and warehouse facilities.  The study found industrial indoor chromium(VI) and 
total chromium concentrations to be 0.23–11 and 4.1–130 ng/m3 and industrial outdoor chromium(VI)
and total chromium concentrations to be 0.013–15.3 and 1.9–84.5 ng/m3. The results of this study found 
that higher levels of chromium(VI) in soil do not necessarily result in higher levels of chromium(VI) in 
air (Finley et al. 1993). The mean concentration of total chromium at the same sites was 7.1 ng/m3, with a
concentration range of 3.7–12 ng/m3. Monitoring data in Hudson County, New Jersey has shown a 
background chromium(VI) concentration of 0.2–3.8 ng/m3 with a mean concentration of 1.2 ng/m3 (Scott
et al. 1997a). The airborne total chromium concentration range was 1.5–10 ng/m3 with a mean
concentration of 4.5 ng/m3 (Scott et al. 1997a).  The mean airborne chromium(VI) and total chromium
concentrations in the indoor air of industrial sites in Hudson County, New Jersey, contaminated by
chromite ore-processing residue were 3 ng/m3 (range, 0.23–11 ng/m3) and 23 ng/m3 (range, 4.11– 
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130 ng/m3), respectively.  The mean airborne chromium(VI) and total chromium concentrations in 
outdoor air for the same sites were 9.9 ng/m3 (range, 0.13–110 ng/m3) and 37 ng/m3 (range, 1.9– 
250 ng/m3), respectively (Falerios et al. 1992).  
An air dispersion model was developed which accurately estimated chromium(VI) concentrations at two
of these industrial sites in Hudson County, New Jersey (Scott et al. 1997b).  The background corrected 
airborne concentrations in ng/m3 for seven sampling dates are reported as measured (modeled values in
parentheses): 0.0 (0.41); 6.2 (7.7); 0.9 (1.7); 2.8 (2.7); 0.0 (0.08); 0.3 (0.1); and 1.2 (0.12).  The estimated 
percent levels of chromium(III) and chromium(VI) in the U.S. atmosphere from anthropogenic sources
are given in Table 6-3 (EPA 1990b).  Fly ash from a coal-fired power plant contained 1.4–6.1 mg/kg 
chromium(VI) (Stern et al. 1984).  In a field study to assess inhalation exposure to chromium during
showering and bathing activities, the average chromium(VI) concentration in airborne aerosols ranged 
from 87 to 324 ng/m3 when water concentrations of 0.89–11.5 mg/L of chromium(VI) were used in a
standard house shower (Finley et al. 1996a). 
The concentrations of atmospheric chromium in remote areas, such as the Arctic region and the South 
Pole, range from 0.005 to 2.6 ng/m3 (Barrie and Hoff 1985; Cary 1982; Schroeder et al. 1987; Sheridan 
and Zoller 1989).  Saltzman et al. (1985) compared the levels of atmospheric chromium at 59 sites in U.S.
cities during 1968–1971 with data from EPA's National Aerometric Data Bank file for 1975–1983.  They
concluded that atmospheric chromium levels may have declined in the early 1980s from the levels
detected in the 1960s and 1970s.
6.4.2 Water
Chromium concentrations in U.S. river water usually range from <1 to 30 μg/L (EPA 1984a; Malm et al. 
1988; Ramelow et al. 1987), with a median value of 10 μg/L (Eckel and Jacob 1988; Smith et al. 1987).  
Chromium concentrations in lake water generally do not exceed 5 μg/L (Borg 1987; Cary 1982), with 
higher levels of chromium related to anthropogenic pollution sources.  Dissolved chromium
concentrations of 0.57–1.30 μg/L were reported in the Delaware River near Marcus Hook and Fieldsboro, 
Pennsylvania in January 1992, with chromium(III) composing 67% of the total (Riedel and Sanders
1998).  In March 1992, these concentrations decreased to 0.03–0.23 μg/L.  In general, the concentration 
of chromium in ocean water is much lower than that in lakes and rivers. The mean chromium
concentration in ocean water is 0.3 μg/L, with a range of 0.2–50 μg/L (Cary 1982).  The mean 
concentration of chromium in rainwater is 0.14–0.9 μg/L (Barrie et al. 1987; Dasch and Wolff 1989).
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Table 6-3.  Estimates of U.S. Atmospheric Chromium Emissions from  
Anthropogenic Sources  
Estimated
number of Chromium emissions Estimated hexavalent
Source category sources (metric tons/year) chromium (percent)
Combustion of coal and oil Many 1,723 0.2
Chromium chemical manufacturing 2 18 67
Chemical manufacturing cooling towers 2,039 43 100
Petroleum refining cooling towers 475 32 100
Specialty/steel production 18 103 2.2
Primary metal cooling towers 224 8 100
Chrome plating 4,000 700 ~100
Comfort cooling towers 38,000 7.2–206 100
Textile manufacturing cooling towers 51 0.1 100
Refractory production 10 24 1.3
Ferrochromium production 2 16 5.4
Sewage sludge incineration 133 13 <0.1
Tobacco cooling towers 16 0.2 100
Utility industry cooling towers 6 1.0 100
Chrome ore refining 6 4.8 <0.1
Tire and rubber cooling towers 40 0.2 100
Glass manufacturing cooling towers 3 0.01 100
Cement production 145 3 0.2
Municipal refuse incineration 95 2.5 0.3
National total 2,700–2,900
Source:  EPA 1990b
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The concentrations of total chromium in groundwater at the Idaho National Engineering Laboratory, 
where chromate is used as a corrosion inhibitor, ranged from <1 to 280 μg/L (USGS 1989).  The water
from a village well situated near a waste pond receiving chromate waste in Douglas, Michigan, contained 
10,800 μg/L chromium(VI).  Similarly, water from a private well adjacent to an aircraft plant in Nassau 
County, New York, contained 25,000 μg/L chromium(VI), while water from a public well adjacent to 
another aircraft plant in Bethpage, New York, contained 1,400 μg/L chromium(VI) (Davids and Lieber
1951).  In a later study, water from an uncontaminated well in Nassau County, New York, contained an 
undetectable level of chromium(VI), whereas a contaminated well in the vicinity of a plating plant
contained 6,000 μg/L chromium(VI) (Lieber et al. 1964).  A chromium concentration of 120 μg/L was 
detected in private drinking water wells adjacent to an NPL site in Galena, Kansas (Agency for Toxic 
Substances and Disease Registry 1990a).  
The chromium levels detected in drinking water in an earlier study (1962–1967 survey) may be erroneous
due to questionable sampling and analytical methods (see Section 7.1) (EPA 1984a).  Total chromium
levels in drinking water were reported to range from 0.2 to 35 μg/L (EPA 1984a).  Most drinking water
supplies in the United States contain <5 µg/L of total chromium (WHO 2003).  The concentration of
chromium in household tap water may be higher than supply water due to corrosion of chromium-
containing pipes.  At a point of maximum contribution from corrosion of the plumbing system, the peak
chromium in tap water in Boston, Massachusetts was 15 μg/L (Ohanian 1986).  A survey that targeted 
drinking waters from 115 Canadian municipalities during 1976–1977 reported the median chromium
concentration to be <2.0 μg/L (detection limit) and the maximum chromium concentration to be 8.0 μg/L
(Meranger et al. 1979).  A recent monitoring survey of drinking water by the California Department of
Public Health found that levels of chromium(VI) were <10 μg/L in 86% (2,003 out of 2,317 sources) of
the drinking water sources sampled; however, levels above 50 μg/L were noted in six sources (CDPH
2007).  In this survey, a source was defined as those reporting more than a single detection of
chromium(VI) and may include both raw and treated sources, distribution systems, blending reservoirs, 
and other sampled entities.  These data did not include agricultural wells, monitoring wells, or more than
one representation of the same source (e.g., a source with both raw and treated entries is counted a single
source).
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6.4.3 Sediment and Soil
The chromium level in soils varies greatly and depends on the composition of the parent rock from which 
the soils were formed.  Basalt and serpentine soils, ultramafic rocks, and phosphorites may contain
chromium as high as a few thousand mg/kg (Merian 1984) whereas soils derived from granite or
sandstone will have lower concentrations of chromium (Swaine and Mitchell 1960).  The concentration 
range of chromium in 1,319 samples of soils and other surficial materials collected in the conterminous
United States was 1–2,000 mg/kg, with a geometric mean of 37 mg/kg (USGS 1984).  Chromium
concentrations in Canadian soils ranged from 5 to 1,500 mg/kg, with a mean of 43 mg/kg (Cary 1982).  In 
a study with different kinds of soils from 20 diverse sites including old chromite mining sites in
Maryland, Pennsylvania, and Virginia, the chromium concentration ranged from 4.9 to 71 mg/kg (Beyer
and Cromartie 1987).  A polynuclear aromatic hydrocarbon (PAH) soil study was conducted to determine
the metal levels in soil at the edge of a busy road that runs through the Aplerbecker Forest in West
Germany.  Chromium(VI) concentrations of 64 mg/kg were measured, and these concentrations were 
2- to 4-fold higher along the road than in the natural forest (Munch 1993).  The soil beneath decks treated 
with chrominated copper arsenate (CCA), a wood preservative, had an average chromium content of
43 mg/kg (Stilwell and Gorny 1997).
Chromium has been detected at a high concentration (43,000 mg/kg) in soil at the Butterworth Landfill 
site in Grand Rapid City, Michigan, which was a site listed on the NPL (Agency for Toxic Substances 
and Disease Registry 1990b).
Chromium was detected in sediment obtained from the coastal waters of the eastern U.S. seashore at
concentrations of 3.8–130.9 μg/g in 1994 and 0.8–98.1 μg/g in 1995 (Hyland et al. 1998).
6.4.4 Other Environmental Media 
The concentration of chromium in the particulate portion of melted snow collected from two urban areas
(Toronto and Montreal) of Canada ranged from 100 to 3,500 mg/kg (Landsberger et al. 1983).  In the
suspended materials and sediment of water bodies, chromium levels ranged from 1 to 500 mg/kg (Byrne
and DeLeon 1986; EPA 1984a; Mudroch et al. 1988; Ramelow et al. 1987).  The chromium concentration 
in incinerated sewage sludge ash may be as high as 5,280 mg/kg (EPA 1984a).
Total chromium levels in most fresh foods are extremely low (vegetables [20–50 μg/kg], fruits
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reported in Table 6-4.  In a study to find the concentrations of chromium in edible vegetables in Tarragon 
Province, Spain, the highest levels of chromium were found in radish root and spinach, with a 
nonsignificant difference between the samples collected in two areas (northern industrial and southern 
agricultural). The samples ranged in concentration from 0.01 to 0.21 μg/g (industrial) and from 0.01 to 
0.22 μg/g (agricultural) (Schuhmacker et al. 1993).  Acidic foods that come into contact with stainless 
steel surfaces during harvesting, processing, or preparation for market are sometimes higher in chromium
content because of leaching conditions. Processing, however, removes a large percentage of chromium
from foods (e.g., whole-grain bread contains 1,750 μg/kg chromium, but processed white bread contains 
only 140 μg/kg; and molasses contains 260 μg/kg chromium, but refined sugar contains only 20 μg/kg
chromium) (Anderson 1981; EPA 1984a). 
Chromium levels in oysters, mussels, clams, and mollusks vary from <0.1 to 6.8 mg/kg (dry weight) 
(Byrne and DeLeon 1986; Ramelow et al. 1989).  Fish and shellfish collected from ocean dump sites off 
New York City, Delaware Bay, and New Haven, Connecticut, contained <0.3–2.7 mg/kg chromium (wet 
weight) (Greig and Jones 1976).  The chromium concentration in fish sampled from 167 lakes in the 
northeastern United States was 0.03–1.46 μg/g with a mean concentration of 0.19 μg/g (Yeardley et al. 
1998).  Higher levels of chromium in forage of meat animals have been reported for plants grown in soils 
with a high concentration of chromium (see Section 6.3.1).  Cigarette tobacco reportedly contains 0.24– 
14.6 mg/kg chromium, but no estimates were available regarding the chromium levels in inhaled cigarette 
smoke (Langård and Norseth 1986).  Cigarette tobacco grown in the United States contains ≤6.3 mg/kg 
chromium (IARC 1980).
Cement-producing plants are a potential source of atmospheric chromium.  Portland cement contains 
41.2 mg/kg chromium (range 27.5–60 mg/kg).  Soluble chromium accounts for 4.1 mg/kg (range 1.6– 
8.8 mg/kg) of which 2.9 mg/kg (range 0.03–7.8 mg/kg) is chromium(VI) (Fishbein 1981).  The wearing 
down of vehicular brake linings that contain asbestos represents another source of atmospheric chromium.  
Asbestos may contain ≈1,500 mg/kg of chromium.  The introduction of catalytic converters on U.S. 
automobiles in 1975 in the United States represented an additional source of atmospheric chromium.  
Catalysts, such as copper chromite, emit <106 metal-containing condensation nuclei per cubic centimeter 
in vehicular exhaust, under various operating conditions (Fishbein 1981).
Fertilizers also contain chromium and other metals.  Commercially available bulk fertilizers had total 
chromium levels of 50–114 μg/g (Gorman et al. 2011).
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Table 6-4.  Chromium Content in Various U.S. Foods
Mean concentration 
Sample (μg/kg) Reference
Fresh vegetables 30–140 EPA 1984a
Frozen vegetables 230 EPA 1984a
Canned vegetables 230 EPA 1984a
Fresh fruits 90–190 EPA 1984a
Fruits 20 EPA 1984a
Canned fruits 510 EPA 1984a
Dairy products 100 EPA 1984a
Chicken eggs 60 Kirpatrick and Coffin 1975
Chicken eggs 160 Schroeder et al. 1962
Chicken eggs 520 Gormican 1970
Whole fish 50–80 EPA 1984a
Edible portion of fresh fin fish <100–160 Eisenberg and Topping 1986
Meat and fish 110–230 EPA 1984a
Seafoods 120–470 EPA 1984a
Grains and cereals 40–220 EPA 1984a
Sugar, refineda <20 WHO 1988
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6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
The general population is exposed to chromium by inhaling ambient air, ingesting food, and drinking
water containing chromium.  Home-based exposures can occur to the families of occupational workers in 
what is known as worker-to-family exposures.  Home exposures can also occur through proximity to
hazardous waste sites (Pellerin and Booker 2000).  A study measured the relationships between chromium
in household dust and chromium in the urine of Hudson County, New Jersey residents (Pellerin and 
Booker 2000).  Three major producers of chromium(VI) in the form of chromate were active in the area 
for over 70 years, and produced over 2 million tons of chromium containing slag waste (Pellerin and 
Booker 2000).  Chromium(VI) levels as high as several hundred parts per million were measured in some
of the soil samples extracted from the area (Pellerin and Booker 2000).  Similarly, residents living in an 
area of Taiwan with a large number of electroplating industries had elevated blood chromium levels, and 
a significant correlation between blood chromium levels and soil chromium levels were found (Chiang et 
al. 2011).
Dermal exposure of the general public to chromium can occur from skin contact with consumer products 
that contain chromium.  Some of the consumer products known to contain chromium are certain wood 
preservatives, cement, cleaning materials, textiles, and leather tanned with chromium (WHO 1988).  Both 
chromium(III) and chromium(VI) are known to penetrate the skin, although chromium(VI) penetrates to a 
higher degree (Robson 2003).  Elevated levels of chromium were observed in urine and blood of people 
who have had knee or hip replacements made with chromium containing metal alloys (Price 2011; 
Sunderman et al. 1989).  Levels of chromium in ambient air (<0.01–0.03 μg/m3) (Fishbein 1984; Pellerin 
and Booker 2000) and tap water (<1 μg/L) (Pellerin and Booker 2000) have been used to estimate the 
daily intake of chromium via inhalation (<0.2–0.6 μg) and tap water (<4 μg). These estimates are based 
on an air inhalation rate of 20 m3/day and a drinking water consumption rate of 2 L/day.  The daily
chromium intake for the U.S. population from consumption of selected diets (diets with 25 and 43% fat) 
has been estimated to range from 25 to 224 μg with an average of 76 μg (Kumpulainen et al. 1979).  The 
chromium concentrations in tissues and body fluids of the general population are given in Table 6-5.
Workers in industries that use chromium can be exposed to concentrations of chromium two orders of 
magnitude higher than exposure to the general population, and workers in some 80 different professions 
may be exposed to chromium(VI) (Hemminki and Vainio 1984; Pellerin and Booker 2000).  Occupational 
exposure to chromium occurs mainly from chromate production, stainless steel production and welding, 
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Table 6-5.  Chromium Content in Tissues and Body Fluids of the General  
Population  
Sample Median or mean Range Reference
Serum 0.006 μg/L 0.01–0.17 μg/L Sunderman et al. 1989
Urine 0.4 μg/L 0.24–1.8 μg/L Iyengar and Woittiez 1988
Lung 201 μg/kg (wet weight) 28–898 μg/kg (wet weight) Raithel et al. 1987
Breast milk 0.30 μg/L 0.06–1.56 μg/L Casey and Hambidge 1984
Hair 0.234 mg/kg Not available Takagi et al. 1986
Nail 0.52 mg/kg No applicable Takagi et al. 1988
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chromium plating, ferrochrome alloys and chrome pigment production, and working in tanning industries
(Ashley et al. 2003).  A list of industries that may be sources of chromium exposure is given in Table 6-6.  
For most occupations, exposure is due to both chromium(III) and chromium(VI) present as soluble and 
insoluble fractions.  However, exceptions include the tanning industry, where exposure is mostly from
soluble chromium(III), and the plating industry, where exposure is due to soluble chromium(VI).  The
typical concentration ranges of airborne chromium(VI) to which workers in these industries were exposed 
during an average of 5–20 years of employment were:  chromate production, 100–500 μg/m3; stainless 
steel welding, 50–400 μg/m3; chromium plating, 5–25 μg/m3; ferrochrome alloys, 10–140 μg/m3; and 
chrome pigment, 60–600 μg/m3 (Stern 1982).  In the tanning industry, except for two bath processes, the
typical exposure range due to chromium(III) was 10–50 μg/m3. A study of chromium(VI) levels of in the
air of a chrome plating shop measured concentrations of chromium(VI) in the range of 10–30 µg/m3 for 
chrome plating shops with local exhaust (Pellerin and Booker 2000).  In plating shops without local
exhaust, the levels were much higher, up to 120 µg/m3 (Pellerin and Booker 2000).  In an occupational
exposure study of chromium in an aircraft construction factory, airborne samples were collected over a 
4-hour period; urinary samples were collected at the beginning (Monday), end (Friday), and after the 
work shift in order to analyze the absorption of chromium during working hours (Gianello et al. 1998). 
The air sampling results were 0.02–1.5 mg/m3, and the urine sampling results were 0.16–7.74 μg/g 
creatinine.  Compared to the ACGIH and BEI-ACGIH Hygiene Standard of 50 μg/m3, both sets of results 
indicated a very low risk of exposure.  The National Occupational Exposure Survey (NOES) conducted
by NIOSH from 1981 to 1983 estimated that 304,829 workers in the United States were potentially
exposed to chromium(VI) (NIOSH 1989).  The NOES database does not contain information on the
frequency, concentration, or duration of exposure; the survey only estimates the number of workers 
potentially exposed to chemicals in the workplace.
In a survey of workers in pigment factories in England that produced strontium and lead chromate, the
concentrations of chromium in the whole blood in exposed workers ranged from 3 to 216 μg/L, compared 
to a level of <1 μg/L for the nonoccupationally exposed population (McAughey et al. 1988).  The
corresponding concentrations in the urine of exposed workers and the unexposed population were 1.8– 
575 μg chromium/g creatinine and <0.5 μg chromium/g creatinine, respectively (McAughey et al. 1988).  
Other investigators have found a higher lung burden for chromium in occupational groups than in 
unexposed groups.  The median concentration of chromium in the lungs of deceased smelter workers in
Sweden was 450 μg/kg (wet weight), compared to a value of 110 μg/kg (wet weight) for rural controls
and 199 μg/kg (wet weight) for urban controls (Gerhardsson et al. 1988).
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A study of seasonal workers who manually replant trees in harvested forests in British Columbia, Canada, 
examined whether there were potentially higher exposures to arsenic, lead, cadmium, chromium, and 
nickel for workers who used fertilizer relative to tree planters who did not use fertilizer (Gorman et al. 
2011).  The study concluded that there was no evidence to suggest that tree planters who worked with 
fertilizer were at an elevated risk of exposure to these metals as compared to those who did not use 
fertilizer. 
6.6 EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes ingest inappropriate materials (such as dirt or paint chips), and spend more time outdoors.  
Children also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 
1993).
Children living in vicinities where there are chromium waste sites nearby may be exposed to chromium to 
a greater extent than adults through inhalation of chromium particulates and through contact with 
contaminated soils.  One study has shown that the average concentration of chromium in the urine of 
children at ages five and younger was significantly higher than in adults residing near sites where 
chromium waste slag was used as fill material (Fagliano et al. 1997), and the soil levels of a hazardous 
waste disposal site in New Jersey were measured at levels up to 120 µg/m3 (Pellerin and Booker 2000).  
The tendency of young children to ingest soil, either intentionally through pica or unintentionally through 
hand-to-mouth activity, is well documented and can result in ingestion of chromium present in soil and 
dust. Soil may affect the bioavailability of contaminants in several ways, most likely by acting as a 
competitive sink for the contaminants.  In the presence of soil, the contaminants will partition between 
absorption by the gut and sorption onto the soil particles (Sheppard et al. 1995). If the contaminant is 
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irreversibly bound to soil particles, then the contaminant is unlikely to be absorbed in the gastrointestinal
tract.  Hexavalent chromium exists in soils as a relatively soluble anion and may be present in
bioavailable form, possibly with enhanced absorption due to the presence of the soil itself.  In contrast, 
chromium(III) present in soil is generally not very soluble or mobile under most environmental conditions
and is not readily bioavailable (James et al. 1997).  Studies discussing the oral absorption of chromium in 
rats from a soil surface in which 30% of the chromium was in hexavalent form and 70% was in trivalent 
form suggested that while absorption in animals is quite low, chromium appeared to be better absorbed 
from soil than from soluble chromate salts (Witmer et al. 1989, 1991).  However, less than half of the
administered dose of chromium could be accounted for in this study, and in separate experiments with 
low dosages administered to the rats, the control animals actually had higher concentrations of chromium
than the animals that were administered the oral dose.  Children may accidently ingest chromium
picolinate in households whose members use this product as a dietary supplement unless it is well stored
and kept away from children.  Small amounts of chromium are used in certain consumer products such as
toners in copying machines and printers, but childhood exposure from these sources is expected to be low.
Children may also be exposed to chromium from parents’ clothing or items removed from the workplace
if the parents are employed in a setting where occupational exposure is significant (see Section 6.5).  
Chromium has been detected in breast milk at concentrations of 0.06–1.56 μg/L (Casey and Hambidge
1984), suggesting that children could be exposed to chromium from breast-feeding mothers.  Studies on
mice have shown that chromium crosses the placenta and can concentrate in fetal tissue (Danielsson et al.
1982; Saxena et al. 1990a). 
A study done on the potential exposure of teenagers to airborne chromium from steel dust in the New
York City subway system found significantly higher concentrations of chromium than in home and 
ambient samples.  The conclusion from the study was that the increased concentration was most likely
due to steel dust present in the subway system as the source of chromium (Chillrud et al. 2004).  
Chromium levels in the New York City subway system are greater than ambient levels by approximately
two orders of magnitude. Chromium levels observed in the study (≈84 ng/m3) are similar to chronic 
reference guidelines in both Canada and the United States and were 40–100 times the adult range in the
estimated 10-5 lifetime cancer risk (Chillrud et al. 2004).  The reference values for exposure to chromium
range from 2 to 100 ng/m3 (Wu et al. 2001).  The study measured total chromium levels, without
separating the species of chromium into chromium(III) and chromium(VI).  Previous studies have
suggested that airborne chromium generated from steel welding have a significant amount of
chromium(VI) present, extending the possibility that there is a possibility for chromium(VI) to be present 
in the steel dust in the New York City subway system as well (Chillrud et al. 2004; Edme et al. 1997).
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Another study done on the bones of deceased neonatal humans in Poland found that statistically
significant differences in chromium concentrations were observed.  In addition, a positive correlation 
between pairs of metals was observed, specifically between the pairing of chromium and lead.  
(Baranowski et al. 2002). Bones were chosen to examine, since they are a useful reference in regards to
heavy metal exposure and accumulation, and are therefore an accurate measure of chronic exposure.
6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
In addition to individuals who are occupationally exposed to chromium (see Section 6.5), there are
several groups within the general population that have potentially high exposures (higher-than-
background levels) to chromium.  Persons using chromium picolinate as a dietary supplement will also be 
exposed to higher levels of chromium than those not ingesting this product (Anderson 1998b).  Like many
other products used to promote weight loss or speed metabolism, there is also the potential for overuse of
this product by some members of the population in order to achieve more dramatic results (Wasser et al.
1997).  People may also be exposed to higher levels of chromium if they use tobacco products, since
tobacco contains chromium (IARC 1980). 
Workers in industries that use chromium are one segment of the population that is especially at high risk
to chromium exposure.  Many industrial workers are exposed to chromium(VI) levels in air that exceed
the accepted occupational exposure limits (Blade et al. 2007).  Occupational exposure from chromate
production, stainless steel welding, chromium plating, and ferrochrome and chrome pigment production is
especially significant since the exposure from these industries is to chromium(VI).  Occupational
exposure to chromium(III) compounds may not be as great a concern as exposure to chromium(VI)
compounds.  Among the general population, residents living near chromate production sites may be 
exposed to higher levels of chromium(VI) in air.  Ambient concentrations as high as 2.5 μg/m3 chromium
in air were detected in a 1977 sample from Baltimore, Maryland (EPA 1984a).  People who live near
chromium waste disposal sites and chromium manufacturing and processing plants may be exposed to 
elevated levels of chromium.  The airborne concentrations of chromium(VI) and total chromium in a
contaminated site in Hudson County, New Jersey were studied (Falerios et al. 1992).  The mean 
concentrations of both chromium(VI) and total chromium in indoor air of the contaminated site were
about three times higher than the mean indoor air concentrations of uncontaminated residential sites in 
Hudson County.  Although the mean concentration of chromium(VI) in outdoor air was much lower than 
the current occupational exposure limit of 50 μg/m3, levels in 10 of 21 samples at the contaminated site 
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exceeded the background urban outdoor chromium(VI) concentration of 4 ng/m3. Similarly, the total 
chromium concentration in 11 of 21 outdoor air samples from the contaminated site exceeded the outdoor
mean concentration of 15 ng/m3 for urban New Jersey.  However, recent sampling data from Hudson 
County, New Jersey have shown that more than two-thirds of previously sampled sites contaminated with
chromite ore processing residue did not have statistically significant mean concentrations greater than the
background levels (Scott et al. 1997a). These data, as well as the results of a soil dispersion model (Scott
et al. 1997b), suggest that heavy vehicular traffic over unpaved soil surfaces containing chromium(VI) are
required for high levels of atmospheric chromium(VI) at these sites.  Persons using contaminated water
for showering and bathing activities may also be exposed via inhalation to potentially high levels of
chromium(VI) in airborne aerosols (Finley et al. 1996a).  In a field study to simulate daily bathing
activity, airborne chromium(VI) concentrations were about 2 orders of magnitude greater than ambient
outdoor air concentrations when water concentrations of 5.4 and 11.5 mg/L were used in the shower.
A study was conducted from September to November 1989 to determine the levels of chromium in urine
and red blood cells of state employees who worked at a park (with only indirect exposure potential)
adjacent to chromium-contaminated sites in Hudson County, New Jersey (Bukowski et al. 1991).  The
chromium levels in red blood cells and urine of 17 of these employees showed no differences compared
to 36 employees who worked at state parks outside Hudson County.  The authors concluded that urinary
and blood levels of chromium are poor biological markers in gauging low-level environmental exposure
to chromium.  This study also concluded that chromium levels in blood and urine depended on other
confounding variables, such as exercise, past employment in a chromium-exposed occupation, beer
drinking, and diabetic status.  Other lifestyle (e.g., smoking), dietary, or demographic factors had no 
measurable effect on blood and urinary chromium.  These conclusions are consistent with the results of a
study that measured the urinary excretion of chromium following oral ingestion of chromite ore
processing residue material for three days (Finley and Paustenbach 1997). These results indicate no
statistical difference in mean urinary chromium concentrations in groups of individuals exposed to 
chromite ore processing residue material versus the control group.  High levels of chromium were 
detected in the urine and hair of individuals living near a chromite ore-processing plant in Mexico (Rosas
et al. 1989), which suggests the possibility of using these media as biological markers in gauging long
term, high-level environmental exposure to chromium.
Elevated levels of chromium in blood, serum, urine, and other tissues and organs have been observed in 
patients with cobalt-chromium knee and hip arthroplasts (Coleman et al. 1973; Michel et al. 1987;
Sunderman et al. 1989).
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The chromium content in cigarette tobacco from the United States has been reported to be 0.24–6.3 mg/kg 
(IARC 1980), but neither the chemical form nor the amount of chromium in tobacco smoke is known.  
People who use tobacco products may be exposed to higher-than-normal levels of chromium.
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of chromium is available. Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of chromium.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. As seen in Section 4.2, the relevant physical and chemical
properties of chromium and its compounds are known (Hartford 1979; NIOSH 2008; Weast 1985) and 
prediction of environmental fate and transport of chromium in environmental media is possible.  
However, the physical or chemical forms and the mode by which chromium(III) compounds are
incorporated into biological systems are not well characterized. The determination of the solubilities of
hexavalent chromium compounds in relevant body fluids (e.g., the solubility of chromates in lung fluid)
may also be helpful.
Production, Import/Export, Use, Release, and Disposal. Knowledge of a chemical's 
production volume is important because it may indicate environmental contamination and human 
exposure.  If a chemical's production volume is high, there is an increased probability of general
population exposure via consumer products and environmental sources, such as air, drinking water, and 
food.  Data concerning the production (Hartford 1979; Papp and Lipin 2001; SRI 1997; USGS 2008b), 
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import (USGS 2008b), and use (CMR 1988a, 1988b; EPA 1984a; IARC 1990; Papp and Lipin 2001;  
USDI 1988a; USGS 2008b) of commercially significant chromium compounds are available.  Chromium  
is not generally used to process foods for human consumption or added to foods other than diet  
supplements.  Thus, consumer exposure to chromium occurs mostly from natural food sources (Bennett  
1986; EPA 1984a; Kumpulainen et al. 1979), but this exposure will increase particularly for people who  
consume acidic food cooked in stainless steel utensils (Anderson 1981; EPA 1984a).  Exposure to  
chromium occurs to a much lesser extent from products such as toners of photocopying machines, some  
wood treatment chemicals, and through other chromium-containing consumer products (CMR 1988a,  
1988b; EPA 1984a; IARC 1990; USDI 1988a).  
As seen in Tables 6-1 and 6-2, the largest amount of chromium from production and user facilities is  
disposed of on land or transferred to an off-site location.  More detailed site-and medium-specific (e.g.,  
air, water, or soil) release data for chromium that is disposed of off-site are necessary to assess the  
exposure potential to these compounds from different environmental media and sources.  There are EPA  
guidelines regarding the disposal of chromium wastes and OSHA regulations regarding the levels of  
chromium in workplaces (EPA 1988a; OSHA 1998a).  
According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C.  
Section 11023, industries are required to submit substance release and off-site transfer information to the  
EPA. The TRI, which contains this information for 2009, became available in May of 2011. This  
database is updated yearly and should provide a list of industrial production facilities and emissions.  
Environmental Fate. Information is available to permit assessment of the environmental fate and  
transport of chromium in air (Pacyna and Pacyna 2001; Schroeder et al. 1987; Scott et al. 1997a, 1997b),  
water (Cary 1982; Comber and Gardner 2003; EPA 1980, 1984a; Fishbein 1981; Schmidt and Andren  
1984; WHO 2003) and soil (Ashley et al. 2003; Avudainayagam et al. 2003; Balasoiu et al. 2001; Bartlett  
1991; Calder 1988; Cary 1982; Jardine et al. 1999; Rifkin et al. 2004).  Chromium is primarily removed  
from the atmosphere by fallout and precipitation. The residence time of chromium in the atmosphere is  
expected to be <10 days (Nriagu 1979).  Most of the chromium in lakes and rivers will ultimately be  
deposited in the sediments.  Chromium in the aquatic phase occurs in the soluble state or as suspended  
solids adsorbed onto clayish materials, organics, or iron oxides (Cary 1982).  Most of the soluble  
chromium is present as chromium(VI) or as soluble chromium(III) complexes and generally accounts for  
a small percentage of the total (Cary 1982).  Additional data, particularly regarding chromium's nature of  
speciation, would be useful to fully assess chromium's fate in air.  For example, if chromium(III) oxide  










   
   
  
    
   
 
 





   
    
     





    
   
 
 





    




6.  POTENTIAL FOR HUMAN EXPOSURE
forms some soluble salt in the air due to speciation, its removal by wet deposition will be faster.  No data
regarding the half-life of chromium in the atmosphere or a measure of its persistence are available.  In
aquatic media, sediment will be the ultimate sink for chromium, although soluble chromates may persist
in water for years (Cary 1982; EPA 1984a).  Additional data elucidating the nature of speciation of
chromium in water and soil would also be desirable and a direct measurement of the chromium residence 
time in the atmosphere would be useful.
Bioavailability from Environmental Media. The bioavailability of chromium compounds from
contaminated air, water, soil, or plant material in the environment has not been adequately studied.  
Absorption studies of chromium in humans and animals provide information regarding the extent and rate
of inhalation (Cavalleri and Minoia 1985; Kiilunen et al. 1983; Langård et al. 1978) and oral exposure
(Anderson 1981, 1986; Anderson et al. 1983; Donaldson and Barreras 1966; Randall and Gibson 1987;
Suzuki et al. 1984).  A sorption study has measured the amount of chromium(VI) when iron particles are
present in the water samples; the conclusion was that soluble chromium(VI) present in the water could
sorb on to iron particles present in the acidic environment of the stomach, and thus, be less bioavailable
(Parks et al. 2004).  These available absorption studies indicate that chromium(VI) compounds are
generally more readily absorbed from all routes of exposure than are chromium(III) compounds.  This is
consistent, in part, with the water solubilities of these compounds (Bragt and van Dura 1983).  The
bioavailability of both forms is greater from inhalation exposure than from ingestion or dermal exposure.  
The bioavailability of chromium from soil depends upon several factors (Witmer et al. 1989).  Factors
that may increase the mobility of chromium in soils include the speculated conversion of chromium(III)
to chromium(VI), increases in pH, and the complexation of chromium(III) with organic matter from
water-soluble complexes.  Data on the bioavailability of chromium compounds from actual environmental
media and the difference in bioavailability for different media need further development. 
Food Chain Bioaccumulation. It is generally believed that chromium does not bioconcentrate in
fish (EPA 1980, 1984a; Fishbein 1981; Schmidt and Andren 1984) and there is no indication of
biomagnification of chromium along the aquatic food chain (Cary 1982).  However, recent skin biopsy
data indicate that North Atlantic right whales are exposed to hexavalent chromium and accumulate a 
range of 4.9–10 μg chromium/g tissue with a mean of 7.1 μg chromium/g tissue (Wise et al. 2008).  Some
data indicate that chromium has a low mobility for translocation from roots to aboveground parts of plants
(Cary 1982; WHO 1988).  However, more data regarding the transfer ratio of chromium from soil to 
plants and biomagnification in terrestrial food chains would be desirable.
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Exposure Levels in Environmental Media. The atmospheric total chromium concentration in the
United States is typically <10 ng/m3 in rural areas and 10–30 ng/m3 in urban areas (Fishbein 1984; WHO
2003).  Most drinking water supplies in the United States contain <5 µg/L of chromium (WHO 2003).  
The chromium level in soils varies greatly and depends on the composition of the parent rock from which 
the soils were formed.  Basalt and serpentine soils, ultramafic rocks, and phosphorites may contain
chromium as high as a few thousand mg/kg (Merian 1984), whereas soils derived from granite or
sandstone will have lower concentrations of chromium (Swaine and Mitchell 1960).  The concentration 
range of chromium in 1,319 samples of soils and other surficial materials collected in the conterminous 
United States was 1–2,000 mg/kg, with a geometric mean of 37 mg/kg (USGS 1984). There is a large 
variation in the available data regarding the levels of chromium in foods (EPA 1984a).  Concentrations 
ranges are 30–230 μg/kg in vegetables, 20–510 μg/kg in fruits, 40–220 μg/kg in grains and cereals, and
110–230 μg/kg in meats and fish (EPA 1984a).  It would be useful to develop nationwide monitoring data
on the levels of chromium in U.S. ambient air and drinking water, and these data should quantitate levels
of both chromium(III) and chromium(VI) and not just total chromium.  EPA is working with state and
local officials to determine the prevalence of chromium (VI) in drinking water (Erickson 2011; Kemsley
2011).  
Exposure Levels in Humans. The general population is exposed to chromium by inhaling ambient
air and ingesting food and drinking water containing chromium.  Dermal exposure of the general public to 
chromium can occur from skin contact with certain consumer products that contain chromium or from
contact with chromium contaminated soils.  Some of the consumer products known to contain chromium
are certain wood preservatives, cement, cleaning materials, textiles, and leather tanned with chromium
(WHO 1988).  However, no quantitative data for dermal exposure to chromium-containing consumer
products were located.  Levels of chromium in ambient air (<0.01–0.03 μg/m3) (Fishbein 1984; WHO
2003) and tap water (<2 μg/L) (WHO 2003) have been used to estimate the daily intake of chromium via
inhalation (<0.2–0.6 μg) and tap water (<4 μg). These estimates are based on an air inhalation rate of
20 m3/day and a drinking water consumption rate of 2 L/day.  The daily chromium intake for the U.S. 
population from consumption of selected diets (diets with 25 and 43% fat) has been estimated to range 
from 25 to 224 μg, with an average of 76 μg (Kumpulainen et al. 1979). This value is within the range
established by the World Health Organization (WHO) as a mean chromium intake from food and water of
52–943 µg/day (WHO 2003).  However, few data on the levels of chromium in body tissues or fluids for
populations living near hazardous waste sites are available.  Such data could be a useful tool as an early
warning system against harmful exposures.  In addition, there is a need for data on the background levels 










    
 
 




   
 
   
   
     
 
 








        
  
    





6.  POTENTIAL FOR HUMAN EXPOSURE
of chromium in body fluids of children.  Such data would be important in assessing the exposure levels of
this group of people.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children.    Limited data exist regarding exposure and body burdens of chromium in 
children.  Chromium has been detected in breast milk at concentrations of 0.06–1.56 μg/L (Casey and 
Hambidge 1984), suggesting that children could be exposed to chromium from breast-feeding mothers.  
Studies in mice have shown that chromium crosses the placenta and can concentrate in fetal tissue
(Danielsson et al. 1982; Saxena et al. 1990a).  Because children living near areas contaminated with 
chromium have been shown to have elevated chromium levels in urine as compared to adults (Fagliano et
al. 1997), additional body burden studies are required to evaluate the exposures and the potential
consequences that this might have upon children.  This is particularly important around heavily
contaminated soils where children may be exposed dermally or through inhalation of soil particulates
during play activities. These studies may determine if children may be more susceptible than adults to the
toxic effects of chromium including immunosensitivity.  Studies are necessary that examine children’s 
weight-adjusted intake of chromium and determine how it compares to that of adults.  Since chromium is 
often detected in soil surfaces and children ingest soil either intentionally through pica or unintentionally
through hand-to-mouth activity, pica is a unique exposure pathway for children.  Studies have shown that
although absorption of chromium is low, it may be enhanced slightly from contaminated soil surfaces
(Witmer et al. 1989, 1991).
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs:  Children’s Susceptibility.
Exposure Registries. No exposure registries for chromium were located.  This substance is not
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry. The substance will be considered in the future when chemical selection is made for sub-
registries to be established. The information that is amassed in the National Exposure Registry facilitates 
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to
this substance.
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6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2008) database provides additional information obtainable
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1 (see
Table 6-7). 













   


























    















    
 
   
 
  
   





6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-7.  Ongoing Studies on Chromium
Principal investigator Affiliation	 Research description
David Brautigan University of Virginia Define the biochemical basis of chromium
enhancement of insulin action
William Cefalu Pennington Biomedical Study the changes in insulin uptake on chromium
Research Center supplementation
Mitchell Cohen New York University School Study biological interactions of metals and 
of Medicine improve deign of metallopharmaceuticals
Jeffrey Elmendorf Indiana University: Purdue Chromium action and role in the glucose transport
University at Indianapolis system
Emily Horvath Indiana University: Purdue Cellular insulin resistance mechanisms
University at Indianapolis
Joshua Jacobs Rush University Medical Metal release and effects in people with metal-on-
Center hip replacements
Sushil Jain Louisiana State University Cytokine production; role of chromium in 
preventing oxidative stress
Umesh Masharani University of California, San The effects of chromium on insulin action
Francisco
Mahmood Mozaffari Medical College of Georgia Effect of chromium on glucose metabolism
Charles Myers Medical College of Wisconsin Study the mechanisms of chromium(VI) in the
human lung system
Patricia Opresko University of Pittsburgh at Understand the mechanisms of genomic
Pittsburgh instability associated with aging
Viresh Rawal University of Chicago	 Investigation of metal-salen complexes for use in 
C-C bond forming reactions; Diels-Alder catalyst
development
James Rigby Wayne State University	 Study metal mediated cyclo-addition reactions to 
synthesize natural products
Diane Stearns Northern Arizona University	 Study the difference in mutations caused by
soluble chromium vs. insoluble chromium;
discover mechanism of cellular entry by soluble 
chromium compounds
Kent Sugden University of Montana Study the role of chromium in DNA mutations and 
cancer
Bo Xu Southern Research Institute The effect of chromium exposure on DNA
damage
Ziling Xue University of Tennessee, Development of an analytical method to 
Knoxville determine chromium levels in biological fluids
Anatoly Zhitkovich Brown University Study the role of chromium in genetic alteration of
cells after exposure
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring chromium compounds, their metabolites, and other biomarkers of exposure
to chromium compounds.  The intent is not to provide an exhaustive list of analytical methods, but to 
identify well-established methods that are used as the standard methods of analysis.  Many of the
analytical methods used for environmental samples are approved by federal agencies and organizations 
such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other methods
presented in this chapter are those that are approved by groups such as the Association of Official
Analytical Chemists (AOAC) and the American Public Health Association (APHA).  Additionally,
analytical methods are included that modify previously used methods to lower detection limits and/or to 
improve accuracy and precision in detection.
7.1  BIOLOGICAL MATERIALS
Several methods are available for the analysis of chromium in different biological media, with some 
methods of chromium determination summarized in Table 7-1.  Multiple reviews on the subject provide
more detailed descriptions of the available analytical methods (EPA 1984a; Fishbein 1984; IARC 1986a, 
1990; Torgrimsen 1982; WHO 1988).  Frequently used techniques for determining low levels of
chromium in biological samples include neutron activation analysis (NAA) (Cornelis 1985; Greenberg
and Zeisler 1988); inductively-coupled plasma-mass spectrometry (ICP-MS) (Bonnefoy et al. 2005; 
D’illio et al. 2011; McShane et al. 2007); graphite furnace atomic absorption spectrometry (GFAAS)
(Dube 1988; Randall and Gibson 1987)); and electrothermal atomization-atomic absorption spectrometry
(ET-AAS) (Olmedo et al. 2010).
There are numerous issues and considerations in collecting and analyzing the chromium content in 
presented samples.  Some of these issues include problems with collection, contamination, and 
determining accurate concentration levels of the chromium content in the samples.  The determination of
trace quantities of chromium in biological materials requires special precautionary measures, from the 
initial sample collection process to the final analytical manipulations of the samples. The sample 
collection and handling of human blood and urine samples as it pertains to the analysis of trace metals 
including chromium has been discussed elsewhere (Cornelis et al. 1996). For chromium, a stainless steel
needle should not be used for blood collection due to possible contamination of the sample, and it is
advised that any anti-coagulants used be analyzed for the presence of chromium.  In addition, acid-
   
 









   
 




















   





   
 
  
    
 
   
 











       
 
 







Table 7-1. Analytical Methods for Determining Chromium in Biological Materials
Sample 
Sample 	 Analytical detection Percent
matrix	 Preparation method method limit recovery Reference
Plasma	 Wet ashing with 
HNO3/HCIO4/H2SO4; 
residue complexed with 
APDC and extracted with 
MIBK; evaporated 
residue dissolved 
deposited in HNO3/HCE, 
and solution on a 
polycarbonate foil
Blood, serum	 Sample after wet




Serum	 Mg(NO3)3 added to 
serum, dried by
Lyophilization, ashed,
and dissolved in 0.1 N
HCI
Blood	 Diluted with 0.1% EDTA
and 5% isopropanol
Blood	 Collect blood samples in 
glass tubes containing 
sodium heparinate to 
prevent coagulation and 
store at 4 °C
Blood	 Collection and storage at
4 °C
Blood or Wet ashing with 
tissue HNO3/HCIO4/H2SO4 
Erythrocytes	 Dilution with Triton X100






















1 μg/100 g 







87% at	 Simonoff et al.
4.5 μg/g		 1984
No data	 Fishbein 1984
103% at	 Randall and 
0.30 μg/L		 Gibson 1987
No data	 Dube 1988
No data	 Bonnefoy et al. 
2005
99.15%	 Olmedo et al.
2010
114% NIOSH 1994a 
recovery at (Method No.
10 μg/sample 8005)
No data	 Lewalter et al.
1985
No data	 Sunderman et al.
1989
   
 








   
 


















     
   




























   
  
 







    
 
    
   
  
    
 



















Dried sample ashed by
oxygen plasma, H2O2 


























No data Harnly et al. 1983
Urine No sample preparation 
other than addition of
yttrium internal standard




Urine Sorption onto 
polydithiocarbonate 
resin, ash sorbate in low
temperature oxygen 
plasma and dissolve in 
HNO3/HCIO4 






Urine None GFAAS 0.0052 μg/L No data Kiilunen et al.
1987





No data Veillon et al. 1982
Urine Diluted with water GFAAS-
Zeeman-




Urine Samples collected and
diluted for analysis with 
2% (v/v) double-distilled
grade ultrapure nitric
acid (and 0.002% Triton 
X-100
ICP-MS 0.26 μg/L No data McShane et al.
2007
(diluent)
Urine Collection and storage at
4 °C with or without
ET-AAS 0.19 μg/L 101.74% Olmedo et al.
2010
dilute nitric acid solution. 
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EPR 0.1 mmol/kg No data Liu et al. 1994
Hair Wash with double-
distilled water and 
ETAAS 0.19 μg/L 103.00% Olmedo et al.
2010
neutral soap followed by
acid digestion
AAS = atomic absorption spectrometry; APDC = ammonium pyrrolidine dithiocarbonate; CEWM = continuum source 
echelle monochromator wavelength-modulated; ECD = electron capture detector; EDTA = ethylenediaminetetra-
acetic acid; EPR = electron paramagnetic resonance spectroscopy; ET-AAS = electrothermal-atomic absorption 
spectrometry GC = gas chromatography; GFAS = graphite furnace AAS; H2O2 = hydrogen peroxide; H2SO4 = sulfuric
acid; HCI = hydrochloric acid; HCIO4 = perchloric acid; HNO3 = nitric acid; ICP-AES = inductively coupled plasma-
atomic emission spectrometry; ICP-MS = inductively coupled plasma-mass spectrometry; Mg(NO3)3 = magnesium
nitrate; MIBK = methylisobutyl ketone; MS = mass spectrometry; PIXE = proton-induced X-ray emission 
spectrometry; XRF = X-ray fluorescence analysis; WM-AES = wavelength-modulated atomic emission spectrometry
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washed plastic tubes are required for blood collection. Unwashed commercially available tubes were 
found to contain trace amounts of chromium in blank samples (Cornelis et al. 1996).
Contaminates including dust contamination or losses of the samples during collection, transportation, and 
storage should be avoided (EPA 1984a).  Chromium-containing grinding and homogenizing equipment
should not be used for preparation of biological samples.  Reagents of the highest purity should be used to 
avoid contamination, and the potential loss of chromium due to volatilization during wet and dry ashing
should be minimized (EPA 1984a).
The determination of chromium in most biological samples is difficult because of the matrix interference
and the very low concentrations present in these samples.  Prior to 1978, numerous erroneous results were 
reported for the chromium level in urine using electrothermal atomic absorption spectrometry (EAAS)
because of the inability of conventional atomic absorption spectrometry systems to correct for the high
nonspecific background absorption.  Similarly, the reported serum and plasma chromium concentrations
of normal subjects have varied more than 5,000-fold since the early 1950s.  A limitation of ICP-MS is the 
presence of other elements that may combine with plasma argon ions to form polyatomic ions.  The main 
polyatomic ions that interfere with the analysis of chromium are 40Ar12C+, 36Ar16O+, 38Ar14N+, 35Cl16O1H+, 
and 37Cl15O+ because they have similar mass-to-charge ratios as the most abundant isotope of chromium, 
52Cr+ (D’illio et al. 2011). Matrix interference problems have been improved by using ICP-MS equipped 
with a dynamic reaction cell (DRC) (Bonnefoy et al. 2005; D’illio et al. 2011; McShane et al. 2007).  The
DRC contains a gas such as ammonia, which can react with polyatomic ions such as 40Ar12C+ resulting in 
a new species with a different mass-to-charge ratio.  
The chromium levels in human serum or plasma as reported in the mid-1980s ranged from 0.01 to 
0.3 μg/L (Anderson 1987) and the daily urinary excretion rate of chromium in healthy and 
nonoccupationally exposed humans range from approximately 0.24 to 1.8 μg/L; however, these levels are
greatly influenced by food and beverage intake, smoking, and exercise (Paustenbach et al. 1997).
The problem with generating accurate data for chromium in biological materials in the past was 
associated with the lack of Standard Reference Materials (SRM). Recently, the National Institute of
Standards and Technology (NIST) with collaboration of Centers for Disease Control and Prevention
(CDC) released a new reference material (SRM 2668), toxic elements in frozen human urine, which 
contains chromium among other elements (DOC 2012). This will significantly improve the precision and
accuracy of the analytical measurements of chromium in clinical samples.  However, due to the previous
   
 











   
  








     
  
    
     
  
   
   
   
  
   
 
   
  
    
 
   
  





lack of SRMs, older data should be interpreted with caution (EPA 1984a), unless the data are verified by
interlaboratory studies (WHO 1988).
In addition to the consideration of contamination and potential loss of sample, it should be noted that
chromium may exist as several different oxidation states in biological media.  Two of the most common 
oxidation states are chromium(III) and chromium(VI).  Each of these oxidation states displays very
different physical and biological properties.  In biological samples where chromium is generally present
as chromium(III), the choice of a particular method is dictated by several factors, including the type of
sample, its chromium level, and the scope of the analysis (Kumpulainen 1984).
7.2  ENVIRONMENTAL SAMPLES 
Analytical methods for determining chromium in environmental samples are reported in Table 7-2.  Many
of the issues that affect the measurement of chromium in biological samples are also present in
environmental analysis, including issues of collection, contamination, and detection.  Chromium may be
present in both the trivalent and hexavalent oxidation states in most ambient environmental and 
occupational samples, as well as existing in soluble and insoluble forms.  Soluble chromium(VI) may be
reduced to chromium(III) on some filtering media, particularly at low concentrations, and under acidic
conditions.  Teflon® filter and alkaline solution are most suitable to prevent this reduction (Sawatari
1986).  As in the case of biological samples, contamination and chromium loss in environmental samples
during sample collection, storage, and pretreatment should be avoided.  Chromium loss from aqueous
samples due to adsorption on storage containers should be avoided by using polyethylene or similar
containers and adjusting the solution to the proper pH.
Methods are available for the detection of hexavalent chromium in airborne particulate matter based on
ion chromatography followed by UV-VIS spectroscopy (Ashley et al. 2003; ASTM 2008 [Method 
D6832]; CARB 1990; ISO 2005 [Method 16740]; NIOSH 2003a [Method 7605]; Sheehan et al. 1992).  
In general, a known volume of air is drawn through a filter to collect particulate chromium in workplace
air and these samples are dissolved to extract hexavalent chromium.  Following dissolution and treatment
with ion chromatography in order to separate the extracted hexavalent chromium from trivalent chromium
and other metal cations, the solutions are derivitized with 1,5-diphenylcarbazide to form a chromium
diphenylcarbazone complex, which has a characteristic absorption band at approximately 540 nm.  Field-
portable instruments that can be employed to rapidly measure chromium(VI) levels in workplace air have 
been developed based upon these methods (NIOSH 2003b [Method 7703]; Wang et al. 1999).  Different
   
 









   
 
 

































   





































Table 7-2. Analytical Methods for Determining Chromium in Environmental  
Samples  
Sample Analytical Sample Percent


















collected on filter is cut




dissolved in HNO3, dried 
and redissolved in 
acidified water
Particulate matter
collected on cellulose 
ester filter, digested with 
aqua regia
Air particulate collected 
on cellulose ester filter,
wet wash with HCI/HNO3 





Collect 80 m3 air using
polystyrene filters
Sample collected on 
sodium carbonate-
impregnated cellulose 






Sample collected on 
sodium carbonate-
impregnated cellulose 
filter and extracted with 
sodium bicarbonate




























0.017 μg/m3	 No data
0.05–0.2 ng/m3 No data
1 μg/m3	 87–102% at
0.5–100 μg
0.06 μg/sample 98% at 45– 
90 μg/sample
1 μg/sample		 98% at
2.5 μg/filter
0.25 ng/m3	 No data
0.1 ng/m3 for 89–99% at
20 m3 sample 100 ng
0.1 ng/m3 for 87–101 %















   
 








   
 
 






































































Table 7-2. Analytical Methods for Determining Chromium in Environmental  
Samples  
Sample Analytical Sample Percent















Sample collected on 





A known volume of air is








A known volume of air is









captured on the filter
was dissolved with hot
H2SO4 and chromium(III)
was oxidized to 
chromium(VI) by
addition of Na2O2; iron






acidified with HCl and
reduced to chromium(III)
by SO2; the solution was
complexed with
β-isoproyl tropolone in 
CHCl3 
Extract with 0.05 M 
(NH4)2SO4–0.5 M 
(NH4)2SO4.1 M NH3. 
Ion 0.25 μg/m3 for 94.8% NIOSH 2003a 







Ion 0.1–100 μg/m3 96% ASTM 2008 







Ion 0.01–10 μg/m3 96% ISO 2005 







HPLC-UV 10 pg No data	 Maiti and Desai
1986
FIA-UV/VIS 0.11 ng >90% Wang et al.
1997a
   
 








   
 
 













































   
 
 



































Table 7-2. Analytical Methods for Determining Chromium in Environmental  
Samples  
Sample Analytical Sample Percent
























Sample solution at pH 5 
reacted with disodium
ethylenediamine 
tetraacetic acid at 50 °C 
for 1 hour
The melted snow filtered 
through Nucleopore 
filter; the filtrate acidified 
with HNO3; and dried by
freeze-drier; residue 
dissolved in HNO3; this
preconcentrated solution 
placed in plastic tubes;
both plastic tube and 
Nucleopore filter
irradiated with protons
Either the above 
Nucleopore filter or the 
preconcentrated liquid 




introduced directly into 
the ion chromatograph 
and Cr(VI) is separated 
from the other matrix






in water with APDC at



























2.0 ng by UV
5.0 ng by AAS
for chromium














95–105% at Suzuki and 
0.002–2.0 μg Serita 1985








87.1–103% EPA 2011 
(results for (Method 218.7)
different types
of water and 
preservatives
used)
No data	 EPA 1983b 
(Method 218.4)
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Table 7-2. Analytical Methods for Determining Chromium in Environmental  
Samples  
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Drinking water, Buffer solution Ion 0.3 μg/L 100% at EPA 1996a 
groundwater introduced into ion chromato- 100 μg/L (Method 7199)
and water chromatograph. graphy with 





Waste water Buffered sample mixed DPPA at 30 μg/L 90% at Harzdorf and 
and industrial with AlCl3 and the pH 10–12 0.2 mg/L Janser 1984
effluent for precipitate separated by
chromium(VI) centrifugation or filtration
only
Waste water Derivatization with UV-VIS Lower than No data Qi and Zhu 1986
1986 o-nitrophenylfluorone spectro- diphenyl-
(chromium(VI)) metry at carbazone 
582 nm method
Water (total	 Calcium nitrate added to GFAAS or 1.0 μg/L 97–101% at EPA 1983a,
chromium)	 water and chromium is ICP/AES (GFAAS) 19–77 μg/L 1986a (Method 
converted to 7.0 μg/L 218.2 and 7191)
chromium(III) by
acidified H2O2 
Water Solid-phase extraction ICP-MS 0.009 μg/L 86–113% Guerrero et al.  
(chromium(III) using anion exchange (chromium VI); 2012  
and chromium resins for Cr(VI) 0.03 μg/L  
(VI)) adsorption and chelating (chromium III)  
resins for Cr(III)  
adsorption  




Industrial Digest with nitric ICP-AES 4.7 μg/L 101% at EPA 1996b 






Oil wastes, Dissolve in xylene or AAS or 0.05 mg/L 107% at EPA 1986b 




   
 








   
 
 


















































    
 
  
       
 
       





Table 7-2. Analytical Methods for Determining Chromium in Environmental  
Samples  
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Groundwater, Chromium(VI) is AAS or 0.05 mg/L 93–96% at EPA 1986c
domestic and coprecipitated with lead GFAAS (AAS) 2.3 μg/L 40 μg/L (Method 7195)
industrial waste sulfate, reduced, and (GFAAS)
(chromium[VI]) resolubilized in nitric
acid
Groundwater- Chelation with AAS No data 96% at EPA 1983b,
EP extract, ammonium pyrrolidine 50 μg/L 1986d (Method 
domestic, and dithiocarbamate and 218.4 and 7197)
industrial waste extraction with methyl
(chromium[VI]) isobutyl ketone
Water, waste Direct DPPA 10 μg/L 93% at 5 mg/L EPA 1986e 
water, and EP (Method 7198)
extracts 
(chromium(VI))
Soil, sediment Acid digestion extraction GFAAS No data No data Oygard et al.
and sludges using hot HNO3 2004
(chromium(VI))
Sediment (total Samples digested with XRF No data No data Adekola and
chromium) HNO3 and HF and dried Eletta (2007)
Sediment Acid digestion using AAS No data 94.88% Ayyamperumal
0.5N HCl followed by 2006
filtration
AAS = atomic absorption spectrophotometry; AlCl3 = aluminum chloride; APDC = ammonium pyrrolidine 
dithiocarbamate; CHCl3 = chloroform; DPPA = differential pulse polarographic analysis; EAAS = electrothermal
atomic absorption spectrometry; EP = extraction procedure (for toxicity testing); FIA/uv/vis = flow injection analysis-
ultraviolet/visible spectroscopy; GFAAS = graphite furnace atomic absorption spectrometry; H2SO4 = sulfuric acid;
HCI = hydrochloric acid; HF = hydrofluoric acid; HNO3 = nitric acid; HPLC = high pressure liquid chromatography;
ICP-AES = inductively coupled plasma-atomic emission spectrometry; NAA = neutron activation analysis;
MIBK = methylisobutyl ketone; Na2O2 = sodium peroxide; NaOH = sodium hydroxide; Na2CO3 = sodium carbonate;
(NH4)2SO4 = ammonium sulfate; NH3 = ammonia; PIXE = proton-induced X-ray emission spectrometry; SO2 = sulfur
dioxide; UV = ultraviolet; XRF = X-ray fluorescence analysis
   
 









    
    
  
    
   
    
  
















   
  
 





procedures may be employed for the extraction of soluble versus insoluble hexavalent chromium
compounds and the various sequential extraction procedures described in standardized methods ASTM
D6832 and ISO 16740 have been compared for their effectiveness for recovering hexavalent chromium
from workplace air (Ashley et al. 2009).  A three-step sequential extraction procedure was outlined that
employed deionized water to dissolve soluble chromium compounds such as potassium chromate, an 
ammonium sulfate buffer for sparingly soluble species, and a sodium carbonate buffer to dissolve
insoluble chromium complexes such as lead chromate.  Recovery data for chromium compounds spiked
onto PVC filters suggested that the three-step procedure may result in excessively high recoveries of
soluble chromium species.  A two-step extraction process using either water or sulfate buffer to dissolve 
soluble hexavalent chromium compounds followed by sonication in a carbonate buffer to obtain insoluble
species yielded acceptable results when applied to the analysis of hexavalent chromium in paint pigments 
and stainless steel welding fumes (Ashley et al. 2009). 
Measurements of low levels of chromium concentrations in water have been made by methods, such as
ICP-MS (Guerrero et al. 2012; Henshaw et al. 1989; Parks et al. 2004; Yang et al. 2004), GFAAS
(Gonzalez et al. 2005), ICP-AES (Malinski et al. 1988), and high resolution capillary column gas
chromatography (HRGC) with ECD (Schaller and Neeb 1987).  EPA Method 218.7 uses ion 
chromatography followed by derivatization with 1,5-diphenylcarbazide and UV-VIS analysis for the
detection of hexavalent chromium in drinking water (EPA 2011).  Proper storage and maintenance of
water samples is critical since chromium(III) can be oxidized to chromium(VI) especially in the presence 
of free chlorine.  Samples are typically stored at pH 8 or above and with buffers containing ammonium
ions to complex free chlorine.  Methods using high performance liquid chromatography (HPLC)
interfaced with a direct current plasma emission spectrometer have also been used for the determination
of chromium(III) and chromium(VI) in water samples (Krull et al. 1983).  Abranko et al. (2004)
employed GC-ECD, electron impact-mass spectrometry (EI-MS) and ICP-MS to the quantification of
chromium in seawater following derivatization with trifluoroacetylacetone and solid phase
microextraction (SPME).  Detection limits ranging from 0.011 to 0.015 ng/mL were reported for all three
techniques.  Acid leachable and digestion procedures followed by AAS have been developed that can 
quantify chromium(VI) and total chromium in soil, sediment, and sludge (Ayyamperumal 2006; Oygard 
et al. 2004).  The preferred methods for digestion of environmental samples have been discussed by
Griepink and Tolg (1989) and Parks et al. (2004).
   
 











   











    
 
      
   
       
 
    
    
   
  
    
    








7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of chromium compounds is available. Where adequate
information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a
program of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of chromium compounds. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect. There are studies correlating
chromium in urine (Cocker et al. 2007; Gylseth et al. 1977; Kilburn et al. 1990; Lindberg and Vesterberg
1983a; McAughey et al. 1988; Minoia and Cavalleri 1988; Mutti et al. 1985b; Sjogren et al. 1983; Tola et
al. 1977), blood (Kilburn et al. 1990; Lewalter et al. 1985; McAughey et al. 1988; Wiegand et al. 1988), 
hair (Randall and Gibson 1987, 1989; Takagi et al. 1986), hair in children (Chiba et al. 2004), nails
(Takagi et al. 1988), and erythrocytes (Lukanova et al. 1996) to occupational exposure levels.  Since
chromium is an essential element, levels of chromium compounds have to be relatively high in humans
before they signify an increase due to exposure.  Hair has been useful in determining chronic occupational
exposure to chromium in high concentrations (Randall and Gibson 1989), although the utility of this
method for detecting prior exposures has a limited timespan of months (Simpson and Gibson 1992).  
Analytical methods to detect chromium concentrations in urine (Randall and Gibson 1987), whole blood 
(Case et al. 2001; Dube 1988; Fahrni 2007), serum/plasma (Simonoff et al. 1984), and tissue (Fahrni
2007; Liu et al. 1994) have been reported.  Generally, the detection limits are in the sub ppb to ppb range, 
and recoveries are good (>70%).  
Chromium induced DNA-protein complexes were prepared as a biomarker of exposure, as discussed in
Section 3.12.2.  These complexes can be detected by potassium chloride-sodium dodecyl sulfate mediated
precipitation.  These methods have a number of inherent limitations including tedious methodology and 
   
 








   
  
     
     










        
  
     
     
   
  
   
   
     
   
    
   
  
  




being subject to considerable interindividual and interlaboratory variations (Singh et al. 1998b).  Only one
study has attempted to utilize this biomarker, and it was found that volunteers exposed to chromium in 
drinking water showed no increase in protein-DNA crosslinking in blood cells (Kuykendall et al. 1996). 
This suggests that this procedure may not be sensitive enough for use in environmental monitoring unless
an individual has received a potentially toxic level of exposure.  In addition, chromium forms chromium-
DNA complexes inside of cells, and these complexes constitute a potential biomarker for the assessment
of environmental or occupational exposure.  A novel method has been described for the sensitive
detection of chromium-DNA adducts using inductively coupled plasma mass spectrometry (Singh et al.
1998b).  The detection limits of this method are in the parts per trillion range and allow for the detection 
of as few as 2 chromium adducts per 10,000 bases, which coupled with the low DNA sample
requirements, make this method sensitive enough to measure background levels in the population.  There
are no data to determine whether there are age-specific biomarkers of exposure or effects or any
interactions with other chemicals that would be specific for children.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. Methods are available and in use for detecting chromium in air, water, and soil environments.  
Methods have been developed that can determine low levels of total chromium and chromium(VI) in the 
air, with detection limits in the ng/m3 range and excellent recoveries (90% or better) (Ashley et al. 2003;
Barrie and Hoff 1985; CARB 1990; NIOSH 2003a; Sheehan et al. 1992). These methods are sufficient to 
determine background chromium levels in the environment and levels at which health effects may occur.
There are also field-portable instruments that can be employed to rapidly measure chromium(VI) levels in
workplace air (NIOSH 2003b; Wang et al. 1999).  Chromium can be detected in water at concentrations
in the ppb range (Abu-Saba and Flegal 1997; EPA 1983a, 1996a; Harzdorf and Janser 1984 Parks et al. 
2004) and household and bottled drinking water (Al-Saleh and Al-Doush 1998), with recoveries of ≥90%
being reported in some studies.  In addition, there are also methods that can differentiate chromium(VI)
from chromium(III) in water samples (EPA 1986c, 2011).  A reliable analytical method for extracting and
quantifying chromium from soil surfaces has also been reported (Ayyamperumal et al. 2006; Oygard et al. 
2004).  Analytical methods exist that are sufficient for measuring background levels of chromium in soil
(Ayyamperumal et al. 2006; EPA 1996b; Finley and Paustenbach 1997; Oygard et al. 2004) and water
(EPA 1983a, 1983b, 1983c, 1986a, 1996a; Finley and Paustenbach 1997) and also water samples 
collected from various geological sites of interest (Gonzalez et al. 2005; Parks et al. 2004).
   
 








    
 
     
    
   
    
CHROMIUM 415
7. ANALYTICAL METHODS
7.3.2 Ongoing Studies 
Analytical methods for the detection of chromium compounds at increasingly lower concentrations are
currently under development.  Targeted areas of interest include air, water, and soil monitoring, with 
special emphasis being placed on populations considered vulnerable or potentially at risk, such as
children and occupational workers.  Additionally, more reliable methods to separate chromium(III)
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8. REGULATIONS, ADVISORIES, AND GUIDELINES  
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
An MRL of 5x10-6 mg chromium(VI)/m3 has been derived for intermediate- and chronic-duration 
inhalation exposure to chromium(VI) as chromium trioxide mist and other dissolved hexavalent
chromium aerosols and mists.  The MRL is based on a LOAEL of 0.002 mg chromium(VI)/m3 for upper
respiratory effects in humans in the occupational exposure study by Lindberg and Hedenstierna (1983), 
which spanned both intermediate and chronic durations. 
An MRL of 0.0003 mg chromium(VI)/m3 has been derived for intermediate-duration inhalation exposure
to chromium(VI) as particulate hexavalent chromium compounds.  The MRL is based on a benchmark
concentration of 0.016 mg chromium(VI)/m3 for increases in lactate dehydrogenase activity in
broncholavage fluid from rats in the study by Glaser et al. (1990).
An MRL of 0.005 mg chromium(VI)/kg/day has been derived for intermediate-duration oral exposure to 
hexavalent chromium compounds for hematological effects (e.g., microcytic, hypochromic anemia) in
rats using data from a study by NTP (2008a).  Because several hematological parameters are used to
define the clinical picture of anemia, the MRL is based on the average BMDL2sd values for hemoglobin, 
MCV, and MCH of 0.52 mg chromium(VI)/kg/day.  
An MRL of 0.0009 mg chromium(VI)/kg/day has been derived for chronic-duration oral exposure to 
hexavalent chromium compounds.  The MRL is based on a benchmark dose of 0.09 mg
chromium(VI)/kg/day for diffuse epithelial hyperplasia of the duodenum in mice in a study by NTP
(2008a).
An MRL of 0.005 mg chromium(III)/m3 has been derived for intermediate-duration inhalation exposure
to insoluble trivalent chromium particulate compounds.  The MRL is based on a minimal LOAEL of
3 mg chromium(III)/m3 for trace-to-mild septal cell hyperplasia and chronic interstitial inflammation of
the lung in rats in the study by Derelanko et al. (1999).
   
 









    
     
 
 
   
















   
  
     








8. REGULATIONS, ADVISORIES, AND GUIDELINES
An MRL of 0.0001 mg chromium(III)/m3 has been derived for intermediate-duration inhalation exposure
to soluble trivalent chromium particulate compounds. The MRL is based on a LOAEL of 3 mg
chromium(III)/m3 for nasal and larynx lesions in rats in the study by Derelanko et al. (1999).
A chronic oral reference dose (RfD) of 0.003 mg chromium(VI)/kg/day has been derived and verified by
EPA for soluble salts of chromium(VI) (e.g., potassium chromate, sodium chromate, potassium
dichromate, and sodium dichromate) (IRIS 2008).  The RfD is based on a NOAEL for systemic effects in 
rats exposed to 2.5 mg chromium(VI)/kg/day as potassium chromate in the drinking water for 1 year in
the study by MacKenzie et al. (1958).
A chronic inhalation RfC of 0.008 μg chromium(VI)/m3 has been derived and verified by EPA for
chromic acid mists and dissolved chromium(VI) aerosols (IRIS 2008).  The RfC is based on a LOAEL for
nasal septum atrophy in workers exposed to 0.002 mg chromium(VI)/m3 (Lindberg and Hedenstierna
1983).
A chronic inhalation RfC of 0.0001 mg chromium(VI)/m3 has been derived and verified by EPA for
chromium(VI) particulates (IRIS 2008).  The RfC is based on a benchmark concentration of 0.016 mg
chromium(VI)/m3 derived from data for lactate dehydrogenase activity in bronchoalveolar lavage fluid in 
rats exposed to sodium dichromate (Glaser et al. 1990).
A chronic oral RfD of 1.5 mg chromium(III)/kg/day has been derived and verified by EPA for insoluble
salts of chromium(III) (e.g., chromium oxide and chromium sulfate) (IRIS 2008).  The RfD is based on a
NOAEL for systemic effects in rats fed 1,800 mg chromium(III)/kg/day for 5 days/week for 600 feedings
(840 total days) in the study by Ivankovic and Preussmann (1975).  EPA has determined that the data are 
inadequate for the development of an RfC for chromium(III) due to the lack of relevant toxicity study
addressing the respiratory effects of chromium(III) (IRIS 2008). 
The Institute of Medicine (IOM) of the National Academy of Sciences (NAS) determined an adequate
intake (e.g., a level typically consumed by healthy individuals) of 20–45 µg chromium(III)/day for
adolescents and adults (IOM 2001)
The international and national regulations, advisories, and guidelines regarding chromium in air, water, 
and other media are summarized in Table 8-1.   
   
 









    
 
    
    
    
     
    
     
     
     
    
 
    
    
    
 
   
    
     
     
   
 
 
    
 
 
    
 
 
    
 
 
    
     
     
     
    
   
    
    












8. REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Chromium
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification IARC 2008





WHO Air quality guidelines
Chromium (VI) 1 µg/m3 for a lifetime 
risk of 4x10-2 
WHO 2000
Drinking water quality guidelines WHO 2004





ACGIH TLV (8-hour TWA)
















Strontium chromate (as Cr)





TLV basis (critical effects)
Calcium chromate (as Cr) Lung cancer
Chromium











   
 








    
 
    
     
     




    
    
    
    




    
     
     
     
    
 
 
   
      
   
      
   
  
  
   
   
 
    
 
 
     
    
    
    





      
      
    
  
   
      
  
CHROMIUM 420
8. REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Chromium
Agency Description Information Reference
NATIONAL (cont.)
ACGIH TLV basis (critical effects) ACGIH 2007






Strontium chromate (as Cr) Cancer
Zinc chromates (as Cr) Nasal cancer
EPA AEGL-1, -2, and -3 No data EPA 2007a
Second list of AEGL priority EPA 2008a
chemicals for guideline development
Chromium (III) chloride Yes
Hazardous air pollutant EPA 2007b
Chromium compounds Yes 42 USC 7412
NIOSH REL (8-hour TWA) NIOSH 2005
Chromium, metal, chromium (II), 0.5 mg/m3 
and chromium (III) compounds
REL (10-hour TWA)
Chromium (VI) trioxide (as Cr)d,e 0.001 mg/m3 
IDLH
Chromium, metal (as Cr) 250 mg/m3 




Chromium, metal Eyes, skin, and 
respiratory system
Chromium (VI) trioxide Blood, respiratory
system, liver, kidneys,
eyes, and skin
Category of pesticides NIOSH 1992
Potassium chromate Group 1 pesticide
Potassium dichromate Group 1 pesticide
Sodium chromate Group 1 pesticide
OSHA PEL (8-hour TWA) for general OSHA 2007a
industry (ceiling limit) 29 CFR 1910.1000,
Table Z-2
Chromium (II) compounds (as Cr) 0.5 mg/m3 
Chromium (III) compounds (as Cr) 0.5 mg/m3 
Chromium metal and insoluble salt 1.0 mg/m3 ,
(as Cr)
Chromium (VI) compounds 5 μg/m3 OSHA 2007d
29 CFR 1910.1026
   
 








    
 
    





      
      
   
  
   







      
      
    
  
   
     
  
     




   
    
    
    
    




    
    
 
 
   
 
 
     
     
   
 
  
    
      
      
CHROMIUM 421
8. REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Chromium
Agency Description Information Reference
NATIONAL (cont.)
OSHA PEL (8-hour TWA) for shipyard OSHA 2007c
industry (ceiling limit) 29 CFR 1915.1000
Chromium (II) compounds (as Cr) 0.5 mg/m3 
Chromium (III) compounds (as Cr) 0.5 mg/m3 
Chromium metal and insoluble salt 1.0 mg/m3 
(as Cr)
Chromium (VI) compounds 0.5 μg/m3 OSHA 2007e
29 CFR 1915.1026
PEL (8-hour TWA) for construction OSHA 2007b
industry (ceiling limit) 29 CFR 1926.55,
Appendix A
Chromium (II) compounds (as Cr) 0.5 mg/m3 
Chromium (III) compounds (as Cr) 0.5 mg/m3
Chromium metal and insoluble salt 1.0 mg/m3 
(as Cr)
Chromium (VI) compounds 0.5 μg/m3 OSHA 2007f
29 CFR 1926.1126
b.  Water
EPA Designated as hazardous substances
in accordance with Section





Chromium (III) sulfate Yes
Potassium chromate Yes
Strontium chromate Yes




1-day health advisory for a 
10-kg child
1 mg/L










Public health goal 0.1 mg/L
   
 








    
 
    
     
  
 
   
    
     
     
    
     
     
     
      








   
    
    
    




    
     
     
      
    




    
    
       
CHROMIUM 422
8. REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Chromium
Agency Description Information Reference
NATIONAL (cont.)
EPA National recommended water quality
criteriag 
No data EPA 2006b
Chromium (III)
Freshwater CMC 570 μg/L
Freshwater CCC 74 μg/L
Chromium (VI)
Freshwater CMC 16 μg/L
Freshwater CCC 11 μg/L
Saltwater CMC 1,100 μg/L
Saltwater CCC 50 μg/L
Toxic pollutants designated pursuant




Chromium and compounds Yes
Reportable quantities of hazardous
substances designated pursuant to 
Section 311 of the Clean Water Act
EPA 2008c
40 CFR 117.3
Chromium (III) sulfate 100 pounds
Potassium chromate 10 pounds
Strontium chromate 10 pounds
c.  Food
EPA Inert ingredients permitted for use in 
nonfood use pesticide products
EPA 2008e
Chromium (III) oxide Yes
Sodium chromate Yes








Indirect food additives: adhesives








   
 








    
 
    
     
    
     
    
    
    
 
 
    
 
 
    
 
 
    
     
     
    
    
     
    
    
 
 




    
 
  
     
    
    
     
     
   
    
    
   
 
  
      
   
     
     
CHROMIUM 423
8. REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Chromium




Calcium chromate (as Cr) A2i 
ACGIH 2007
Chromium










As Pb A2i 
As Cr A2i 
Strontium chromate (as Cr)







Total chromium in urine at
end of shift at end of
workweek
25 μg/L




Chromium(III), insoluble salts Group Dl 
IRIS 2008
Chromium (VI)
Inhalation route of exposure




Chromium(III), insoluble salts Not available
Chromium (VI)
Chromic acid mists and 









   
 








    
 
    
     





    
      













     
     
     
     
     
     
     
   
 
  
      
      
     
     
     
     
     
     
   
 
  
   
     
     
  
 
     
       
       
CHROMIUM 424
8. REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Chromium
Agency Description Information Reference
NATIONAL (cont.)
EPA Master Testing List
RCRA waste minimization PBT
priority chemical list
Chromium
Standards for owners and operators
of hazardous waste TSD facilities;
groundwater monitoring list
Chromium (total)































































   
 








    
 
    
     
     
   
     
    
    
    
    
    
 
  
   
   
 
     
     
 
  




     
 
   
 
   






    
   
 
   




      
     
       
    
       
    
       
     
        
      
        
      
 
CHROMIUM 425
8. REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Chromium
Agency Description Information Reference
NATIONAL (cont.)
NTP Carcinogenicity classification NTP 2005







aGroup 3:  The agent is not classifiable as to its carcinogenicity to humans.
bGroup 1:  The agent is carcinogenic to humans.  
cProvisional guideline value, as there is evidence of a hazard, but the available information on health effects is  
limited.  
dThe NIOSH REL (10-hour TWA) is 0.001 mg Cr(VI)/m3 for all hexavalent chromium (Cr[(VI]) compounds.  NIOSH  
considers all chromium (VI) compounds (including chromic acid, tert-butyl chromate, zinc chromate, and chromyl  
chloride) to be potential occupational carcinogens.  
eNIOSH potential occupational carcinogen.  
fGroup 1 pesticides:  contains the pesticides that pose a significant risk of adverse acute health effects at low  
concentrations.  
gThe CMC is an estimate of the highest concentration of a material in surface water to which an aquatic  
community can be exposed briefly without resulting in an unacceptable effect.  The CCC is an estimate of the  
highest concentration of a material in surface water to which an aquatic community can be exposed indefinitely  
without resulting in an unacceptable effect.
hThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food  
additives or listed or affirmed as GRAS.  
iA2: Suspected human carcinogen.  
jA4: Not classifiable as a human carcinogen.
kA1:  Confirmed human carcinogen.  
lGroup D:  not classified as to its human carcinogenicity.  
mGroup A:  known human carcinogen by the inhalation route of exposure.  
nChromium was recommended to the MTL by ATSDR in 1994 and the testing needs development is currently  
underway.  The testing needs include acute toxicity, neurotoxicity, reproductive, and immunotoxicity health effects.  
oDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) of the Clean Water Act.  
pDesignated CERCLA hazardous substance pursuant to Section 3001 of the Resource Conservation and  
Recovery Act.  
qDesignated CERCLA hazardous substance pursuant to Section 307(a) of the Clean Water.  
rDesignated CERCLA hazardous substance pursuant to Section 307(a) of the Clean Water Act and Section 112 of  
the Clean Air Act.  
sIndicates that no reportable quantity is being assigned to the generic or broad class.  
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;  
CCC = Criterion Continuous Concentration; CERCLA = Comprehensive Environmental Response, Compensation,  
and Liability Act; CFR = Code of Federal Regulations; CMC = Criteria Maximum Concentration; DWEL = drinking  
water equivalent level; EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection  
Agency; FDA = Food and Drug Administration; FR = Federal Register; GRAS = Generally Recognized As Safe;  
IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health;  
IRIS = Integrated Risk Information System; MTL = Master Testing List; NIOSH = National Institute for  
Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health  
Administration; PBT = persistant, bioacumulative, and toxic; PEL = permissible exposure limit; RCRA = Resource  
Concervation and Recovery Act; REL = recommended exposure limit; RfC = inhalation reference concentration;  
RfD = oral reference dose; TLV = threshold limit values; TSD = transport, storage, and disposal; TWA = time- 
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CHROMIUM 497
10.  GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.













   
 
 
      
     
 
 
   
   
 
   
 
 
   









    
 
 
   
    
      
 
   
 
 
    
   
   
 












Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.












   
 
 
   
 
 




      
 
 
    
    
 
    
  
 
     
 
 















   









Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study,
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.












   
 
   
  
 
   
 
 
   
   








   







   
  
 
     







   
 
  
     
   





Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
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10.  GLOSSARY
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.











   
 
  








   









    
 











   
    
  
   
  
   
   
     
 
 




Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or
inherited characteristic that is associated with an increased occurrence of disease or other health-related
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism. 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system














   
  
 
    
   
 
  
   
    
   
    
     
    
   




    
     
   
  
 





     
     
CHROMIUM A-1
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach. They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that










    
  
   
   
  
   
   
    
  
 
   
   
  
     
     





are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences (proposed), expert panel peer reviews, and agency-
wide MRL Workgroup reviews, with participation from other federal agencies and comments from the
public. They are subject to change as new information becomes available concomitant with updating the 
toxicological profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously
published levels.  For additional information regarding MRLs, please contact the Division of Toxicology
and Human Health Sciences (proposed), Agency for Toxic Substances and Disease Registry, 1600 Clifton 
Road NE, Mailstop F-62, Atlanta, Georgia 30333.














   
   
   











    
 
    
  
    
 
 
   
  





   
    
  
   
 
 
    
 
 
    
 
    
 
 
    
CHROMIUM A-3
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical name: Chromium(VI) aerosols and mists
CAS number: 18540-29-9
Date: June 2012
Profile status: Third Draft Post-Public Comment
Route: [X] Inhalation [ ] Oral
Duration: [ ] Acute [X] Intermediate [X] Chronic
Key to figure: 11, 29
Species: Human
Minimal Risk Level:  5x10-6 mg chromium(VI)/m3 for dissolved hexavalent chromium aerosols and 
mists.
Reference:  Lindberg E, Hedenstierna G.  1983. Chrome plating:  Symptoms, findings in the upper
airways, and effects on lung function.  Arch Environ Health 38:367-374. 
Experimental design: Eighty-five male and 19 female chrome-plating workers exposed to chromic acid 
were assessed for nose, throat, and chest symptoms, were inspected for effects in nasal passages, and were 
given pulmonary function tests.  Study participants were compared to a reference group of 119 auto 
mechanics who were not exposed to chromium.  The length of worker exposures to chromic acid ranged 
from 0.1 to 36 years, spanning intermediate- and chronic-exposure durations.  Since the study population 
included workers exposed for both intermediate and chronic durations, data are considered appropriate for
derivation of the intermediate- and chronic-duration inhalation MRLs.  Chromium exposures were
measured using personal air samplers and stationary equipment positioned close to the baths containing
chromic acid. The exposure categories were defined as high average daily concentrations >0.002 mg
chromium(VI)/m3], low (average daily concentrations <0.002 mg chromium(VI)/m3), and mixed category
(chromium(VI) was <0.002 mg chromium(VI)/m3, with exposure to other acids and metallic salts).
Correlations with nasal irritation and respiratory functions were also determined for peak exposures.  
Statistical analyses were performed using the chi-square test with Yate’s correction when comparing
nasal findings, and the Student’s two tail t-test was used when comparing lung function findings.  
Effects noted in study and corresponding doses:  Nasal irritation (p<0.05), mucosal atrophy (p<0.05), and 
ulceration (p<0.01), and decreases in spirometric parameters (forced vital capacity, forced expired volume
in 1 second, and forced mid-expiratory flow) were observed in workers occupationally exposed to 
≥0.002 mg chromium(VI)/m3 as chromic acid with a median exposure period of 2.5 years.  About 60% of
the exposed subjects were smokers, but no consistent association between exposure and cigarette smoking
was observed.  Short-term peak exposures to chromic acid correlated better with nasal septum damage 
than with 8-hour mean concentrations.
Dose end point used for MRL derivation:  0.002 mg chromium(VI)/m3 (nasal irritation, mucosal atrophy, 
decreased FVC, FEP1, and FEV)
[ ] NOAEL [X] LOAEL [ ] benchmark concentration (BMC)
The LOAEL of 0.002 mg chromium(VI)/m3 for upper respiratory effects was selected as the point of
departure for derivation of the intermediate- and chronic-duration inhalation MRLs for dissolved 
hexavalent chromium aerosols and mists.  The LOAEL was duration-adjusted to a LOAELADJ of
0.0005 mg chromium(VI)/m3 for continuous exposure.  The intermediate- and chronic-duration inhalation 
MRLs of 0.000005 mg chromium(VI)/m3 for dissolved hexavalent chromium aerosols and mists were 























    
 
 
      
   




    
   
 
 
   
  
  
   
  
 






derived by dividing the LOAELADJ of 0.0005 mg chromium(VI)/m3 by a composite uncertainty factor of
100 (10 for use of a LOAEL and 10 for human variability).
Uncertainty factors used in MRL derivation:
[X] 10 for use of a LOAEL
[  ]  10 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  No.  
Not applicable.
Was a conversion used from intermittent to continuous exposure?  Yes, the LOAEL of 0.002 mg
chromium(VI)/m3 was multiplied by 8 hour/24 hour and by 5 days/7 days to yield a duration-adjusted 
LOAEL (LOAELADJ) of 0.0005 mg chromium(VI)/m3. 
Other additional studies or pertinent information that lend support to this MRL: The respiratory tract is
the major target of inhalation exposure to chromium(VI) compounds in humans and animals.  Respiratory
effects due to inhalation exposure are probably due to direct action of chromium at the site of contact.  In 
workers exposed to dissolved hexavalent chromium aerosols and mists (as chromium trioxide mist) for
intermediate durations, nasal irritation, ulceration, and mucosal atrophy and rhinorrhea have been 
reported, with LOAEL values ranging from 0.09 to 0.1 mg chromium(VI)/m3 (Gibb et al. 2000a; Gomes
1972; Kleinfeld and Rosso 1965).  Similarly, studies in rats and mice have shown that the upper
respiratory tract is a primary target of exposure to inhaled chromium trioxide mist, with LOAEL values
ranging from 0.49 to 3.63 mg chromium(VI)/m3 (Adachi 1987; Adachi et al. 1986; Kim et al. 2004).  In 
addition, numerous intermediate- and chronic-duration exposure studies of workers to chromium(VI)
compounds in general identify the respiratory tract as the primary target of exposure, with reports of
epistaxis, chronic rhinorrhea, nasal itching and soreness, nasal mucosal atrophy, perforations and 
ulceration of the nasal septum, bronchitis, pneumonoconiosis, decreased pulmonary function, and 
pneumonia (Bovet et al. 1977; Cohen et al. 1974; Davies et al. 1991; Gomes 1972; Greater Tokyo Bureau 
of Hygiene 1989; Hanslian et al. 1967; Keskinen et al. 1980; Kleinfeld and Rosso 1965; Lee and Goh 
1988; Letterer 1939; Lieberman 1941; Lindberg and Hedenstierna 1983; Lucas and Kramkowski 1975;
Mancuso 1951; Meyers 1950; Novey et al. 1983; Pastides et al. 1991; PHS 1953; Royle 1975b; Sassi
1956; Sluis-Cremer and du Toit 1968; Sorahan et al. 1987; Taylor 1966).  
Agency Contact (Chemical Manager):  Sharon Wilbur














   
   
   
















   
 
 
   
  
  
   
 
  
    
   
 
 
   
  
   
   
  
 
   
    
  
  
   
   
    
CHROMIUM A-5
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical name: Chromium(VI) particulates
CAS number: 18540-29-9
Date: June 2012
Profile status: Third Draft Post-Public Comment
Route: [X] Inhalation [ ] Oral
Duration: [ ] Acute [X] Intermediate [ ] Chronic
Key to figure: 14 
Species: Rat
Minimal Risk Level:  0.0003 mg chromium(VI)/m3 for hexavalent chromium particulate compounds
Reference:  Glaser U, Hochrainer D, Steinholf D.  1990.  Investigation of irritating properties of inhaled 
CrVI with possible influence on its carcinogenic action.  Environ Hyg 2:235-245. 
Experimental design: Eight-week-old male Wistar rats (30 animals in each group) were exposed 
22 hours/day, 7 days/week to 0, 0.05, 0.1, 0.2, or 0.4 mg chromium(VI)/m3 as sodium dichromate aerosol
particulates.  Groups of 10 animals were sacrificed after 30 or 90 days of exposure or after 90 days of
exposure and a 30-day recovery period. The respective mass median mean diameters (MMAD) and 
geometric standard deviation were 0.28 μm and 1.63 for the 0.5 and 0.1 mg chromium(VI)/m3 
concentrations and 0.39 μm and 1.72 for the 0.2 and 0.4 mg chromium(VI)/m3 concentrations.  
Hematological, clinical chemistry, and urinalysis tests were performed.  Gross and histological
examinations were limited to the upper airway epithelia, left lung lobes, and the kidneys.  In addition, 
lung lavage fluid was analyzed for total protein, albumin, lactate dehydrogenase, and β-glucuronidase
activities.
Effects noted in study and corresponding doses:  No deaths or abnormal clinical signs occurred at any of
the exposures.  Body weight was significantly (p<0.001) decreased at 0.2 and 0.4 mg chromium(VI)/m3 
for 30 days, at 0.4 mg chromium(VI)/m3 for 90 days (p<0.05), and at 0.2 (p<0.01) and 0.4 mg
chromium(VI)/m3 (p<0.05) in the recovery group.  No differences in urinary protein and no exposure-
related histopathological lesions were noted.  No differences were seen in analysis of serum levels or
activities of alanine aminotransferese, alkaline phosphatase, glucose, urea, total bilirubin, total
cholesterol, or phospholipids.  There were no hematological effects on red blood cells, but the white
blood cell counts increased significantly in a dose-related manner at ≥0.1 mg chromium(VI)/m3 after 
30 days and at ≥0.05 mg chromium(VI)/m3 after 90 days.  White blood cells counts were not increased in 
90 day exposure plus 30-day observation group. 
Obstructive respiratory dyspnea occurred at ≥0.2 mg chromium(VI) chromium(VI)/m3 after 30 and 
90 days.  Mean lung weight was increased in all exposure groups and was statistically increased at
≥0.05 mg chromium(VI)/m3 for 30 days, and at ≥0.1 mg chromium(VI)/m3 for 90 days and in the 90-day 
plus recovery period group.  Histological examination revealed slight hyperplasia in high incidence at
≥0.05 mg chromium(VI)/m3 at 30 days.  With longer exposure, the incidence declined, indicating repair.  
Lung fibrosis occurred at ≥0.1 mg chromium(VI)/m3 for 30 days, but was not seen in rats exposed for 
90 days.  Accumulation of macrophages was observed in all exposed rats, regardless of exposure 
concentration or duration. This histiocytosis probably accounts for the increased lung weight.  Histology
of upper airways revealed focal inflammation.  Results of bronchoalveolar lavage (BAL) analysis 
provided further information of the irritation effect.  Total protein in BAL fluid was significantly
increased in all exposed groups, but declined in the recovery period.  Albumin in BAL fluid increased in a
dose-related manner at all concentrations in the 30-day group, but recovery started during 90-day 
exposure and continued during the 30-day observation period. The activities of lactate dehydrogenase 











   
  
   
   
 
     
   
 
     
 
   
 






     
    




   
 
 


















and β-glucuronidase, measures of cytotoxicity, were elevated at 0.2 and 0.4 mg chromium(VI)/m3 for 
30 and 90 days, but returned to control values during the recovery period.  The number of macrophages in 
the BAL fluid had significantly increased after 30 and 90 days, but normalized during the recovery
period.  The macrophages were undergoing cell division or were multinucleate and larger.  This activation 
of macrophages was not observed in the recovered rats.  The study authors concluded that inflammation is
essential for the induction of most chromium inhalation effects and may influence the carcinogenicity of
chromium(VI) compounds. 
Dose end point used for MRL derivation:  0.016 mg/m3 (alterations in lactate dehydrogenase levels in
bronchoalveolar lavage), converted to a BMCLHEC of 0.010 mg chromium(VI)/m3 
[ ] NOAEL [ ] LOAEL [X] benchmark concentration (BMC)
The Agency adopted the benchmark concentration (BMC) analysis of the Glaser et al. (1990) data
conducted by Malsch et al. (1994) for deriving an intermediate-duration inhalation MRL for hexavalent
chromium particulate compounds.  Using the 90-day exposure data (as described above), Malsch et al. 
(1994) developed BMCLs for lung weight and BAL fluid levels of lactate dehydrogenase, protein, and 
albumin.  Prior to conducting the benchmark analysis, Malsch et al. (1994) adjusted the dose-response 
data for intermittent exposure.  Duration-adjusted data were then fitted to a polynomial mean response 
regression model by the maximum likelihood method to derive BMCLs (defined as the 95% lower
confidence limit on the concentration corresponding to a 10% relative change in the end point compared 
to the control).  The BMCL values for lung weight, lactate dehydrogenase in the BAL fluid, protein in 
BAL fluid, and albumin in BAL fluid were 0.067, 0.016, 0.035, and 0.031 mg chromium(VI)/m3, 
respectively.  The lowest BMCL, 0.016 mg chromium(VI)/m3 for alterations in lactate dehydrogenase 
levels in BAL fluid, was selected to derive the intermediate-duration inhalation MRL.  The BMCL of
0.016 mg chromium(VI)/m3 was converted to a human equivalent concentration (BMCLHEC) of 0.010 mg
chromium(VI)/m3, as described below. The intermediate-duration inhalation MRL of 0.0003 mg
chromium(VI)/m3 for hexavalent chromium particulate compounds was derived by dividing the
BMCLHEC of 0.010 mg chromium(VI)/m3 by a composite uncertainty factor of 30 (3 for extrapolation 
from animals to humans and 10 for human variability).
Uncertainty factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X] 3 for extrapolation from animals to humans, with dosimetric adjustments
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
The BMCL of 0.016 mg chromium(VI)/m3 was converted to a human equivalent concentration 
(BMCLHEC) of 0.010 mg chromium(VI)/m3 using the RDDR (regional deposited dose ratio) program
(EPA 1994c) as follows:
BMCLHEC = BMCL x RDDR  
BMCLHEC = 0.016 mg chromium(VI)/m3 x 0.630 = 0.010 mg chromium(VI)/m3  
where
RDDR is a multiplicative factor used to adjust an observed inhalation particulate exposure concentration 
of an animal to the predicted inhalation particulate exposure concentration for a human.  The RDDR










    
 
    
   
     
 
 
    
   
     
 
 
      
 
   




   
 








   
 





multiplier of 0.630 for the thoracic region tract was determined using the default subchronic body weight
of 217 g for male Wistar rats (EPA 1988d) and a particle size MMAD±GSD of 0.5±1.63 μm reported in 
the Glaser et al. (1984) study.  Although the actual mean particle size reported in the critical study was
0.28 μm, the RDDR program (EPA 1994c) can only run be run for particle sizes ranging from 0.5 to 
30 μm; therefore, 0.5 μm was used as the default particle size to calculated the RDDR.  Since the critical
study did not report body weight, the default subchronic body weight of 217 g for male Wistar rats was
used.
Was a conversion used from intermittent to continuous exposure? Yes.  Animals were exposed for
22 hours/day, 7 days/week.  Prior to conducting the benchmark analysis, Malsch et al. (1994) adjusted the
dose-response data for intermittent exposure (22 hours/day) by multiplying data points for all outcome
measures by 22 hours/24 hours.
Other additional studies or pertinent information that lend support to this MRL: The findings in this study
are supported by another 90-day study conducted by the same group (Glaser et al. 1985).  In this study, 
groups of 20 male Wistar rats were exposed to 0, 0.025, 0.05, 0.1, or 0.2 mg chromium(VI)/m3 as sodium
dichromate for 22 hours/day, 7 days/week for 90 days.  No deaths occurred at any of the exposures.  All
exposed animals showed normal histologic findings in lung, kidney, liver, stomach, and gonads.  Lung
and spleen weights were increased significantly at doses above 0.025 mg chromium(VI)/m3. Serum
levels of triglycerides and phospholipid were increased in rats exposed to 0.2 mg chromium(VI)/m3. 
Serum contents of total immunoglobulins were significantly increased in the 0.05 and 0.1 mg
chromium(VI)/m3 groups.  At 0.025 and 0.2 mg chromium(VI)/m3, serum immunoglobulin contents were
no different than controls.  The SRBC antibody response was increased in all dosed groups over control
values.  Chromium treatment at 0.2 mg chromium(VI)/m3 also enhanced the mitogenic-stimulation of
splenic Concanavalin T-lymphocytes.  At 0.025 mg chromium(VI)/m3, there were significant increases in
polynuclear macrophages and the number of macrophages in telophase, and increases in lymphocytes in 
bronchoalveolar lavage samples.  At 0.05 and 0.2 mg chromium(VI)/m3, there were significant decreases 
in total numbers of macrophages.  The percentages of polynuclear macrophages, lymphocytes, and 
granulocytes were increased at chromium exposures of 0.05 mg chromium(VI)/m3, but at 0.2 mg
chromium(VI)/m3, the percentage of granulocytes cells was lower than control values.  At 0.025 and 
0.05 mg chromium(VI)/m3 exposures, phagocytosis of latex particles by alveolar macrophages was 
increased over controls.  However, at 0.2 mg chromium(VI)/m3, the phagocytic activity was less than
controls and there was a decrease in lung clearance of iron oxide particulates.
Agency Contact (Chemical Manager):  Sharon Wilbur














   
   
  












   
 
  
   
  








   
    
  
  
    
   




   
   
   
  
 
    
   
CHROMIUM A-8
APPENDIX A




Profile status: Third Draft Post-Public Comment
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute [X] Intermediate   [ ] Chronic
Graph Key: 48 
Species: Rat
Minimal Risk Level:  0.005   [X] mg chromium(VI)/kg/day   [ ] ppm
Reference:  NTP.  2008a.  NTP technical report on the toxicology and carcinogenesis studies of sodium
dichromate dihydrate (CAS No. 7789-12-0) in F344/N rats and B6C3F1 mice (drinking water studies).  
Washington, DC:  National Toxicology Program.  NTP TR 546.  
http://ntp.niehs.nih.gov/files/546_web_FINAL.pdf. August 13, 2008.
Experimental design:  Male F344/N rats (6–7 weeks old) were exposed to sodium dichromate dihydrate in 
drinking water in a 2-year toxicology and carcinogenicity study.  Male rats (50/group) were exposed to 
drinking water concentrations of 0, 14.3, 57.3, 172, or 516 mg sodium dichromate dihydrate/L.  In a
subgroup of 10 male rats, blood was collected from the retroorbital sinus after exposure durations of
4 days, 22 days, 3 months, 6 months, and 1 year and evaluated for hematology (Hct; hemoglobin 
concentration; erythrocyte, reticulocyte, and platelet counts; erythrocyte and platelet morphology; MCV;
MCH; MCHC; and leukocyte count and differentials) and clinical chemistry (urea nitrogen, creatinine, 
total protein, albumin, ALT, AP, creatine kinase, SDH, and bile acids).  Clinical signs of toxicity were
assessed over the course of exposure.  NTP calculated mean daily doses of sodium dichromate dihydrate
in male rats of 0, 0.6, 2.2, 6, or 17 mg/kg (equivalent to 0, 0.21, 0.77, 2.1, or 5.9 mg chromium(VI)/ 
kg/day, respectively) over the course of the 2-year study.  Since observations were made at various time 
points during the chronic study (e.g., 22 days to 1 year), rather than using different dosage scales for each 
observation and outcome in the dose-response modeling, time-averaged dosages for the chronic duration
(i.e., 101 weeks) were used to represent the dosage received during the intermediate- (i.e., >2–<52 weeks)
and chronic- (>2–101 weeks) duration periods.  This is an approximation of the actual dosages received, 
which varied as a function of body weight, and therefore, time of observation, with the differences most
pronounced at the earliest periods of the intermediate-duration exposure (e.g., 3–12 weeks).  The rationale 
for this simplification of the dose-response analysis is as follows: (1) outcomes observed at specific time 
points in the study (e.g., blood effects) after the acute period (>2 weeks) were considered to be relevant to
the entire intermediate-duration period (>2–<52 weeks), if observed at multiple observation times during
the intermediate-duration period; (2) chronic duration dosages were nearly identical to the time-averaged
dosages for intermediate-duration exposure (e.g., <12% difference in the rat study); and (3) the possible
bias introduced into estimates of BMDLs as a result of using chronic-duration dosages to represent
intermediate-duration dosages is small (<12%) and conservative (i.e., BMDLs based on the chronic-
duration dosages may be slightly lower than BMDLs based on actual intermediate-duration dosages).
Effect noted in study and corresponding doses: No treatment-related clinical signs of toxicity were 
observed in rats over the course of this study.  Hematological effects consistent with microcytic,
hypochromic anemia were observed at all intermediate-duration time points (22 days to 6 months) in male
rats exposed to sodium dichromate dihydrate in drinking water; severity exhibited dose-dependence.  At
the 22-day assessment in rats, decreases were observed in Hct, Hgb, MCV, and MCH at ≥0.77 mg
chromium(VI)/kg/day; effects at higher doses included decreased MCHC and platelet count at ≥2.1 mg
chromium(VI)/kg/day, and decreased erythrocyte and reticulocyte counts, and increased nucleated


















   
  
   
 
  
   
 
   












    
 








   
   
     
   





erythrocytes at 5.9 mg chromium(VI)/kg/day).  At the 3-month assessment in rats, decreases were 
observed for MCV and MCH at ≥0.77 mg chromium(VI)/kg/day; effects at higher doses included 
decreased Hgb at ≥2.1 mg chromium(VI)/kg/day and decreased Hct and increased erythrocyte, 
reticulocyte, platelet, leukocyte, and segmented neutrophil counts at ≥5.9 mg chromium(VI)/kg/day.  
Increases in cell counts indicate a compensatory hematopoietic response to anemia.  At 6 months in rats, 
decreased MCV, MCH, and MCHC were observed at ≥0.77 mg chromium(VI)/kg/day; at 5.9 mg
chromium(VI)/kg/day, decreased Hgb was observed.  For all intermediate-duration exposures (22 days to 
6 months), NOAEL and LOAEL values in male rats for hematological effects were 0.21 and 0.77 mg
chromium(VI)/kg/day, respectively.  Although effects in rats were similar at the 22-day and 3-month 
assessments, NTP (2008a) concluded that effects were more severe at 22 days than at 3 months based on 
the magnitude of changes and the number of parameters affected in rats exposed to 0.77 mg
chromium(VI)/kg/day.  Effects at 6 months were less severe than those observed at the 22-day and 
3-month assessments.  Although the magnitude of the decreases in hematological parameters was small at
0.77 mg chromium(VI)/kg/day compared to the control group (6.1–10.6%), there is clear indication of
damage to the hematological system and this dose level was considered a minimal LOAEL.  At the next
highest dose (2.1 mg chromium(VI)/kg/day), these parameters were 16–25% lower than controls.  As
defined by ATSDR, an effect that enhances the susceptibility of an organism to the deleterious effects of
other chemical, physical, microbiological, or environmental influences should be considered adverse.  
Thus, the slight, but statistically significant, decrease in hematological parameters at 0.77 mg
chromium(VI)/kg/day was considered minimally adverse.
Evaluation of clinical chemistry parameters in male rats showed significant alterations in serum liver
enzyme activities, although changes were not consistent over all intermediate-duration exposures.  At the
22-day assessment, increases were observed for ALT (≥0.77 mg chromium(VI)/kg/day) and AP (5.9 mg
chromium(VI)/kg/day), but no change was observed for SDH.  At 3 months, ALT was increased 
(≥0.77 mg chromium(VI)/kg/day), but AP was decreased (≥0.21 mg chromium(VI)/kg/day) and no 
change was observed for SDH.  At 6 months, increases were observed for ALT and SDH (≥2.1 mg
chromium(VI)/kg/day), but AP was decreased (0.77 mg chromium(VI)/kg/day).  Due to the inconsistent
changes in serum liver enzyme activities, NTP (2008a) concluded that alterations in liver enzymes 
(specifically ALT) were suggestive of enzyme induction, rather than hepatocellular damage.  Thus, 
altered serum liver enzyme activities were not considered indicative of an adverse effect on the liver.
Dose and end point used for MRL derivation:  0.52 mg chromium(VI)/kg/day (microcytic, hypochromic
anemia)
[ ] NOAEL   [ ] LOAEL   [X] benchmark dose (BMD)
Exposure to sodium dichromate dihydrate in drinking water resulted in microcytic, hypochromic anemia
in male rats at all intermediate-duration exposures (22 days to 6 months).  The severity was greatest at the 
22-day assessment compared to the 3- and 6-month assessments; therefore, microcytic, hypochromic
anemia observed at the 22-day assessment was identified as the critical effect for derivation of the 
intermediate-duration oral MRL.  In male rats, decreases in Hct, Hgb, MCV, and MCH were the most
sensitive measures of hematological effects, with NOAEL and LOAEL values of 0.21 and 0.77 mg
chromium(VI)/kg/day, respectively; data sets for these end points are summarized in Table A-1. 














     
 
       
       
       
       
 
  
           







   
      
   
   
   
   
  
 
    
   
     
    
    
     
   
 
   
   
    
  
    
   
  





Table A-1.  Hematological Effects in Male F/344 Rats Exposed to Sodium  
Dichromate Dihydrate in Drinking Water for 22 Days  
Dose (mg chromium(VI)/kg/day)
0 0.21 0.77 2.1 5.9
Male rats
Hematocrit (percent) 46.0±1.1a 44.4±0.4 43.2±0.6b 38.7±0.6c 33.5±0.8c 
Hemoglobin (g/dL) 15.5±0.3 15.1±0.2 14.2±0.2c 12.0±0.3c 10.1±0.2c 
MCV (fL) 59.5±0.4 58.6±0.5 54.9±0.5c 47.4±0.4c 45.0±0.7c 
MCH (pg) 19.8±0.1 19.5±0.2 17.7±0.2c 14.8±0.2c 16.3±0.5c 
aMean±standard error: number of rats/group=10; number of mice/group=10
bSignificantly different (p≤0.05) from the control group by Dunn’s or Shirley’s test
cSignificantly different (p≤0.01) from the control group by Dunn’s or Shirley’s test
MCH = mean corpuscular hemoglobin; MCV = mean corpuscular volume
Source:  NTP 2008a
To determine the point of departure for derivation of the intermediate-duration oral MRL, available
continuous-variable models in the EPA BMDs (version 1.4.1) were fit to the data for Hct, Hgb, MCV, 
and MCH in male rats (NTP 2008a; Table A-1).  The BMD and the 95% lower confidence limit (BMDL)
calculated is an estimate of the doses associated with a change of 2 standard deviations from the control
(BMDL2sd); the use of 2 standard deviations takes into consideration of the normal variability in the 
population and decreases the possibility of misclassifying a small change as anemia. The model-fitting
procedure for continuous data is as follows.  The simplest model (linear) is applied to the data while
assuming constant variance.  If the data are consistent with the assumption of constant variance (p≥0.1), 
then the other continuous models (polynomial, power, and Hill models) are applied to the data.  Among
the models providing adequate fits to the means (p≥0.1), the one with the lowest AIC for the fitted model
is selected for BMD derivation.  If the test for constant variance is negative, the linear model is run again
while applying the power model integrated into the BMDS to account for nonhomogenous variance.  If
the nonhomogenous variance model provides an adequate fit (p≥0.1) to the variance data, then the other
continuous models are applied to the data.  Among the models providing adequate fits to the means
(p≥0.1), the one with the lowest AIC for the fitted model is selected for BMD derivation.  If the tests for
both constant and nonconstant variance are negative, then the data set is considered not to be suitable for
BMD modeling. 
A summary of the BMDs and BMDLs for the best fitting models for each hematological end point are 
shown in Table A-2.  For male rats, BMDL2sd values ranged from 0.37 mg chromium(VI)/kg/day for
MCH to 0.71 mg chromium(VI)/kg/day for hemoglobin.  None of the models provided adequate fit to the
data, even with the two highest doses dropped from the analysis, for Hct.  Additional details of the
benchmark dose analysis for each data set modeled are presented in the last section of this worksheet.
Because several hematological parameters are used to define the clinical picture of anemia, the BMDL2sd 
values for hemoglobin, MCV, and MCH were averaged resulting in a BMDL2sd of 0.52 mg
chromium(VI)/kg/day.  The intermediate-duration MRL of 0.005 mg chromium(VI)/kg/day was derived 
by dividing the average BMDL2sd by a composite uncertainty factor of 100 (10 for extrapolation from
animals to humans and 10 for human variability).



















     
  
    
     
      
 
 
   
 





    
    
   
  
  
   




    
 
   
   
  
  
   
 




   






Table A-2.  Summary of BMDs and BMDLs From the Best Fitting Models for  
Hematological End Points in Male Rats Exposed to Sodium Dichromate  
Dihydrate in Drinking Water for 22 Days  
BMD2sd BMDL2sd 
End point Model Number of doses (mg/kg/day)b (mg/kg/day)b 
Hematocrit (percent)a –— –— –— –—
Hemoglobin (g/dL) Polynomial
(2-degree) 5 0.88 0.71
MCV (fL) Hill 4 0.63 0.49
MCH (pg) Linear 4 0.44 0.37
aNone of the models provided an adequate fit to the data.
bUnits of BMD1sd and BMDL1sd are mg chromium(VI)/kg/day.
BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark dose; MCH = mean corpuscular
hemoglobin; MCV = mean corpuscular volume; 2sd = a 2 standard deviation change from the control
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.  Daily doses for
each exposure group based on measured body weight and drinking water intake were reported by study
authors (NTP 2008a).  Additional information on daily doses used for intermediate-duration exposure is
discussed in the experimental design section above. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL:  Identification of anemia, 
as defined by significant alterations in hematocrit, hemoglobin, MCH, and MCV, as the critical end point
for deriving an intermediate-duration oral MRL is supported by results of a 22-day study in female mice 
(NTP 2008a), 3-month drinking water study on sodium dichromate dihydrate in rats and mice (NTP
2007), and dietary studies on potassium dichromate in rats and mice (NTP 1996a, 1996b, 1997).  In the
3-month sodium dichromate dihydrate drinking water study in male and female F344/N rats (NTP 2007), 
blood was collected for hematology assessments after 23 days and after 3 months of exposure; for
B6C3F1 mice, hematological assessments were conducted only after 3 months.  Dose-dependent
hematological effects consistent with microcytic, hypochromic anemia, including decreased Hct, Hgb, 
MCV, and MCH, were observed in rats at the 23-day and 14-week hematological assessments; the 
LOAEL value at both time points in males and females was 1.7 mg chromium(VI)/kg/day (a NOAEL was 
not established).  Hematological effects were more severe at the 23-day assessment compared to the 
14 week assessment.  Similar hematological effects were observed in male and female B6C3F1 mice and
male BALB/c and C57BL/6 mice exposed to sodium dichromate dihydrate in drinking water for
14 weeks, with a LOAEL value of 3.1 mg chromium(VI)/kg/day (a NOAEL was not established).  
Results of the 3-month study in rats and mice (NTP 2007) were not selected as the basis for the 










   
 
 
   
  
   
  
  
    
  
  
   
    
  




   
   
   







      
     
   
    
    
  
  






intermediate-duration MRL because a lower LOAEL value (0.77 mg chromium(VI)/kg/day) was
observed for intermediate-duration exposures in the 2-year study (NTP 2008a).  In a dietary studies on 
potassium dichromate, microcytic, hypochromic anemia was observed in male and female Sprague-
Dawley rats exposed for 9 weeks, with NOAEL and LOAEL values in males of 2.1 and 8.4 mg
chromium(VI)/kg/day, respectively, and of 2.5 and 9.8 mg chromium(VI)/kg/day, respectively, in females
(NTP 1996b).  Similar hematological effects were observed in male and female BALB/c mice exposed to
potassium dichromate in the diet for 9 weeks with NOAEL and LOAEL values in males of 7.3 and 
32.2 mg chromium(VI)/kg/day, respectively, and in females of 12 and 48 mg chromium(VI)/kg/day, 
respectively (NTP 1996a).  In a multigeneration study on dietary potassium dichromate in BALB/c mice,
a LOAEL value of 7.8 for hematological effects was reported (a NOAEL was not established) (NTP
1997).  Compared to the LOAEL values for hematological effects at 22 days and 3 months in male rats
(0.77 mg chromium(VI)/kg/day) and female mice (0.38 mg chromium(VI)/kg/day) observed in the critical
study on sodium dichromate dihydrate in drinking water, higher LOAEL values were reported in the
9-week dietary study on potassium dichromate in rats (8.4 and 9.8 mg chromium(VI)/kg/day in males and
females, respectively) (EPA 1996b) and mice (32.2 and 48 mg chromium(VI)/kg/day in males and 
females, respectively) (NTP 1996a). The reason for the differences in LOAEL values has not been
established, but could be due to different exposure media (drinking water versus feed) or differences in
strain sensitivity (rats).
The erythrocyte has a high capacity for chromium(VI) uptake and binding.  Chromium(VI) enters the
erythrocyte though a sulfate ion channel; once inside the cell, it is rapidly reduced to reactive 
intermediates (chromium(V) and chromium(IV)) and binds to hemoglobin and other ligands.  The
chromium-hemoglobin complex is stable and remains sequestered within the cell over the life-span of the
erythrocyte (Paustenbach et al. 2003).  Thus, chromium(VI) uptake and subsequent sequestration as a
chromium-Hgb complex by erythrocytes provides supporting information regarding the plausibility of
adverse hematological effects following intermediate-duration oral exposure to chromium(VI).
Details of Benchmark Dose Analysis for the Intermediate-duration Oral MRL
Hematocrit in Male Rats. The simplest model (linear) was applied to the data first to test for a fit for
constant variance. The constant variance model did not provide an adequate fit (as assessed by the 
p-value for variance) to the data (Table A-3).  The linear model was applied to the data again while 
applying the power model integrated into the BMDS to account for nonhomogenous variance.  The
nonconstant variance model also did not provide an adequate fit (as assessed by the p-value for variance).
In an attempt to achieve an adequate fitting model, the highest doses were dropped from the data set.  As 
with the full data set, statistical tests indicated that the variances were not constant across exposure groups 
without the highest doses.  Similar to the full data set, applying the nonhomogenous variance model also
did not provide an adequate fit (as assessed by the p-value for variance); therefore, the data set is 
considered not suitable for benchmark dose modeling.











   
 








       
       
       
       
       
       
       
       
 
       
       
       
       
       
       
       
 
       
       
       
       
       









   




       
   
  
 




Table A-3.  Model Predictions for Changes in Hematocrit (Percent) in Male Rats  
Exposed to Sodium Dichromate Dihydrate in Drinking Water for 22 Days
Variance p-Value for BMD2sd BMDL2sd 
Model p-valuea the meansa AIC (mg/kg/day) (mg/kg/day)
All doses
Linearb,c 0.03 0.02 145.49 — —
Linearc,d 0.01 0.02 147.49 — —
Polynomial (1-degree)c,d 0.01 0.02 147.49 — —
Polynomial (2-degree)c,d 0.01 0.02 147.49 — —
Polynomial (3-degree)c,d 0.01 0.02 147.49 — —
Polynomial (4-degree)c,d 0.01 0.02 147.49 — —
Powerd 0.01 0.02 147.49 — —
Hilld 0.01 0.28 142.76 — —
Highest dose dropped
Linearb,c 0.01 0.64 109.33 — —
Linearc,d 0.02 0.43 109.21 — —
Polynomial (1-degree)c,d 0.02 0.43 109.21 — —
Polynomial (2-degree)c,d 0.02 0.43 109.21 — —
Polynomial (3-degree)c,d 0.02 0.43 109.21 — —
Powerd 0.02 0.43 109.21 — —
Hilld 0.02 0.21 111.09 — Fe 
Two highest doses dropped
Linearb,c 0.01 0.37 86.65 — —
Linearc,d 0.02 0.15 85.61 — —
Polynomial (1-degree)c,d 0.02 0.15 85.61 — —
Polynomial (2-degree)c,d 0.02 0.15 85.61 — —
Powerd 0.02 0.15 85.61 — —
Hilld NAf 




eF = BMDL computation failed
fNA = model failed to generate output
AIC = Akaike’s Information Criteria; p = p value from the Chi-squared test; BMD = benchmark dose; BMDL = lower
confidence limit (95%) on the benchmark dose; 2sd = a 2 standard deviation change from the control
Source:  NTP 2008a
Hemoglobin in Male Rats.  The simplest model (linear) was applied to the data first to test for a fit for
constant variance. The constant variance model did provide an adequate fit (as assessed by the p-value 
for variance) to the data.  The polynomial, power, and Hill models were then fit to the data with constant
variance assumed.  Only the Hill model provided an adequate fit to the data (as assessed by the p-value 
for the means) (Table A-4); however, the model failed to generate a figure. Without a visual
representation of the model, an assessment of model fit is not complete.  In order to obtain an appropriate











   
 
  
    












      
      
      
      
      
      
      
 
      
      
      
      
      






   






assessment for model fit adequacy, the highest dose was dropped from the dataset.  After dropping the 
highest dose from the dataset, all models provided an adequate fit to the constant variance model and to 
the means (as assessed by the p-values for variance and means).  Most models, with the exception of the 
Hill model, took the form of a linear model.  Comparing across models, the best fitting model is generally
determined by the lowest AIC.  As assessed by the AIC, the linear model provides the best fit to the data.  
The predicted BMD2sd and BMDL2sd for the data are 0.88 and 0.71 mg chromium(VI)/kg/day
(Figure A-1). 
Table A-4.  Model Predictions for Changes in Hemoglobin (g/dL) in Male Rats  
Exposed to Sodium Dichromate Dihydrate in Drinking Water for 22 Days  
p-Value 
Variance for the BMD2sd BMDL2sd 
Modela p-valueb meansb AIC (mg/kg/day) (mg/kg/day)
Linearc 0.40 <0.0001 46.98 — —
Polynomial (1-degree)c 0.40 <0.0001 46.98 — —
Polynomial (2-degree)c 0.40 <0.0001 46.98 — —
Polynomial (3-degree)c 0.40 <0.0001 46.98 — —
Polynomial (4-degree)c 0.40 <0.0001 46.98 — —
Power 0.40 <0.0001 46.98 — —
Hill 0.40 0.51 24.37 0.83 0.55
Highest dose dropped
Linear 0.36 0.99 20.37 0.88 0.71
Polynomial (1-degree)c 0.36 0.99 20.37 0.88 0.71
Polynomial (2-degree)c 0.36 0.99 20.37 0.88 0.71
Polynomial (3-degree)c 0.36 0.99 20.37 0.88 0.71
Power 0.36 0.99 20.37 0.88 0.71
Hill 0.36 0.99 22.36 0.87 0.57
aConstant variance assumed for all models
bValues <0.1 fail to meet conventional goodness-of-fit criteria.
cRestriction = non-positive
AIC = Akaike’s Information Criteria; p = p value from the Chi-squared test; BMD = benchmark dose; BMDL = lower
confidence limit (95%) on the benchmark dose; 2sd = a 2 standard deviation change from the control
Source:  NTP 2008a




















   
  
     
    




Figure A-1.  Predicted and Observed Changes in Hemoglobin in Male Rats  
Exposed to Sodium Dichromate Dihydrate in Drinking Water for 22 Days*  














11 BMD BMDL 
Linear 
0 0.5 1 1.5 2 
dose 
13:32 09/26 2008 
*BMDs and BMDLs indicated are associated with a 2 standard deviation change from the control, and are in units of
mg chromium(VI)/kg/day.
Source:  NTP 2008a
Mean Cell Volume in Male Rats.  The simplest model (linear) was applied to the data first to test for a fit
for constant variance. The constant variance model did provide an adequate fit (as assessed by the 
p-value for variance) to the data. The polynomial, power, and Hill models were then fit to the data with
constant variance assumed.  The Hill model was the only model which provided an adequate fit to the 
data (as assessed by the p-value for the means) (Table A-5).  Using the constant-variance Hill model, the
BMD2sd and BMDL2sd are 0.63 mg chromium(VI)/kg and 0.49 mg chromium(VI)/kg, respectively
(Figure A-2).  





















      
      
      
      
      
      













Table A-5.  Model Predictions for Changes in MCV (fL) in Male Rats Exposed to  
Sodium Dichromate Dihydrate in Drinking Water for 22 Days  
p-Value 
Variance for the BMD2sd BMDL2sd 
Modela p-valueb meansb AIC (mg/kg/day) (mg/kg/day)
Linearc 0.41 <0.0001 168.50 — —
Polynomial (1-degree)c 0.41 <0.0001 168.50 — —
Polynomial (2-degree)c 0.41 <0.0001 168.50 — —
Polynomial (3-degree)c 0.41 <0.0001 168.50 — —
Polynomial (4-degree)c 0.41 <0.0001 168.50 — —
Power 0.41 <0.0001 168.50 — —
Hill 0.41 0.41 104.52 0.63 0.49
aConstant variance assumed for all models
bValues <0.1 fail to meet conventional goodness-of-fit criteria.
cRestriction = non-positive
AIC = Akaike’s Information Criteria; p = p value from the Chi-squared test; BMD = benchmark dose; BMDL = lower
confidence limit (95%) on the benchmark dose; 2sd = a 2 standard deviation change from the control
Source:  NTP 2008a





















       
     
      
      
    
   
     






Figure A-2.  Predicted and Observed Changes in MCV in Male Rats Exposed to  
Sodium Dichromate Dihydrate in Drinking Water for 22 Days*  















0 1 2 3 4 5 6 
dose 
13:49 09/26 2008 
*BMDs and BMDLs indicated are associated with a 2 standard deviation change from the control, and are
in units of mg chromium(VI)/kg/day
Source:  NTP 2008a
Mean Cell Hemoglobin in Male Rats. The simplest model (linear) was applied to the data first to test for
a fit for constant variance. The constant variance model did not provide an adequate fit (as assessed by
the p-value for variance) to the data. The linear model was run again while applying the power model
integrated into the BMDS to account for nonhomogenous variance.  The nonconstant variance model also 
did not provide an adequate fit (as assessed by the p-value for variance).  In an attempt to achieve an
adequate fitting model, the highest dose was dropped from the data-set.  Unlike the full data-set, statistical
tests indicated that the variances were constant across exposure groups without the highest dose.  All of
the models reverted to the linear model and provided an adequate fit to the means (Table A-6).  Using the
constant-variance Linear model (without the highest dose), the BMD2sd and BMDL2sd are 044 and 
0.37 mg chromium(VI)/kg, respectively (Figure A-3). 





















       
        
        
       
       
       
       
       
 
        
       
       
       
       






        
 
   






Table A-6.  Model Predictions for Changes in MCH (pg) in Male Rats Exposed to  











Linearb,c <0.0001 <0.0001 107.27 — —
Linear c,d 0.00 <0.0001 57.60 — —
Polynomial (1-degree)c,d 0.00 <0.0001 57.60 — —
Polynomial (2-degree)c,d 0.00 <0.0001 57.60 — —
Polynomial (3-degree)c,d 0.00 <0.0001 57.60 — —
Polynomial (4-degree)c,d 0.00 <0.0001 57.60 — —
Powerd 0.00 <0.0001 57.60 — —
Hilld 0.00 0.02 34.64 — —
Highest dose dropped (four doses)
Linear b,c 0.14 0.15 -3.57 0.44 0.37
Polynomial (1-degree)b,c 0.14 0.15 -3.57 0.44 0.37
Polynomial (2-degree)b,c 0.14 0.15 -3.57 0.44 0.37
Polynomial (3-degree)b,c 0.14 0.15 -3.57 0.44 0.37
Powerb 0.14 0.15 -3.57 0.44 0.37
Hillb 0.14 NAe -3.39 0.46 0.32




eNA = degrees of freedom are ≤0; the Chi-Square test for fit is not valid.
AIC = Akaike’s Information Criteria; p = p value from the Chi-squared test; BMD = benchmark dose; BMDL = lower
confidence limit (95%) on the benchmark dose; 2sd = a 2 standard deviation change from the control
Source:  NTP 2008a

























Figure A-3.  Predicted and Observed Changes in MCH in Male Rats Exposed to 
Sodium Dichromate Dihydrate in Drinking Water for 22 Days*









14:14 09/26 2008 
*BMDs and BMDLs indicated are associated with a 2 standard deviation change from the control, and are 
in units of mg chromium(VI)/kg/day.
Source:  NTP 2008a
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Profile status: Third Draft Post-Public Comment
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute   [ ] Intermediate  [X] Chronic
Graph Key: 109 
Species: Mouse
Minimal Risk Level:  0.0009 [X] mg chromium(VI)/kg/day   [ ] ppm
Reference:  NTP.  2008a.  NTP technical report on the toxicology and carcinogenesis studies of sodium
dichromate dihydrate (CAS No. 7789-12-0) in F344/N rats and B6C3F1 mice (drinking water studies).  
Washington, DC:  National Toxicology Program.  NTP TR 546.  
http://ntp.niehs.nih.gov/files/546_web_FINAL.pdf. August 13, 2008.
Experimental design:  Groups of F344/N rats (50/sex/group) and B6C3F1 mice (50/sex/group) were
exposed to sodium dichromate dihydrate in drinking water in a 2-year toxicology and carcinogenicity
study.  Rats and female mice were exposed to drinking water concentrations of 0, 14.3, 57.3, 172, or
516 mg sodium dichromate dihydrate/L.  NTP (2008a) calculated mean daily doses of sodium dichromate
dihydrate in male rats of 0, 0.6, 2.2, 6, or 17 mg/kg (equivalent to 0, 0.21, 0.77, 2.1, or 5.9 mg
chromium(VI)/kg/day, respectively), in female rats of 0, 0.7, 2.7, 7, or 20 mg/kg (equivalent to 0, 0.24, 
0.94, 2.4, and 7.0 mg chromium(VI)/kg/day, respectively), and in female mice of 0, 1.1, 3.9, 9, or
25 mg/kg (equivalent to 0, 0.38, 1.4, 3.1, or 8.7 mg chromium(VI)/kg/day, respectively) over the course
of the 2-year study.  Male mice were exposed to 0, 14.3, 28.6, 85.7, or 257.4 mg sodium dichromate
dihydrate/L.  NTP (2008a) calculated mean daily doses of sodium dichromate dihydrate in male mice of
1.1, 2.6, 7, or 17 mg/kg (equivalent to 0, 0.38, 0.91, 2.4, and 5.9 mg chromium(VI)/kg/day, respectively).  
Mortality, clinical signs of toxicity, body weight, and water intake were assessed over the course of
exposure.  In a subgroup of 10 male rats and 10 female mice, blood was collected from the retroorbital
sinus after exposure durations of 4 days (rats only), 22 days, 3 months, 6 months, and 1 year and 
evaluated for hematology (Hct; hemoglobin concentration; erythrocyte, reticulocyte, and platelet counts; 
erythrocyte and platelet morphology; MCV; MCH; MCHC; and leukocyte count and differentials) in rats
and mice and clinical chemistry (urea nitrogen, creatinine, total protein, albumin, ALT, AP, creatine
kinase, SDH, and bile acids) in rats only.  Blood for hematology and clinical chemistry was not obtained 
at the end of the 2-year treatment period.  At the end of the 2-year treatment period, necropsies and
histopathological assessment of comprehensive tissues, gross lesions and tissue masses were performed
on all animals.  No data on organ weights were presented in the study report (NTP 2008a).
Effect noted in study and corresponding doses:  Study results presented in the following discussion are 
noncancer findings associated with chronic-duration exposures only; results of hematological and clinical
chemistry assessments conducted at 4 days and from 22 days to 6 months are described in the acute- and 
intermediate-duration MRL worksheets, respectively; carcinogenic effects are reviewed in Section 3.2.2.7
(Oral Exposure, Cancer).  In rats, no treatment-related effects were observed on survival and no clinical
signs of toxicity were observed.  Final body weight was significantly decreased by 12% in male and 11%
in females exposed to the highest drinking water concentration.  Study authors attributed alterations in 
body weight to decreased water intake (due to decreased palatability) rather than to a toxicological effect.
Hematological assessments conducted in male rats at 1-year showed dose-dependent effects indicative of
microcytic, hypochromic anemia:  decreased MCH (≥0.77 mg chromium(VI)/kg/day), decreased MCV
and MCHC (≥2.1 mg chromium(VI)/kg/day), and decreased Hgb (5.9 mg chromium(VI)/kg/day).  No 















   
   
   
   
  




   
 
  
    
 
    
    
  
   
    
  
    




   
 
   
   
   
 
  
     
 
   
  
   
   
   
   
    
 
    
      
CHROMIUM A-21
APPENDIX A
hematological effects were observed at 2.1 mg chromium(VI)/kg/day.  Other hematological effects
observed were decreased leukocyte (5.9 mg chromium(VI)/kg/day) and segmented neutrophil counts
(≥0.77 mg chromium(VI)/kg/day).  Alterations in clinical chemistry parameters observed after 1 year of 
exposure were increased ALT and decreased AP (≥0.77 mg chromium(VI)/kg/day), increased BUN and 
creatine kinase (≥2.1 mg chromium(VI)/kg/day), and decreased total protein (5.9 mg
chromium(VI)/kg/day).  Regarding the toxicological significance of elevated ALT, as discussed below,
histopathological assessment of the liver showed minimal-to-mild chronic inflammation in males
(≥2.1 mg chromium(VI)/kg/day) and females (≥0.24 mg chromium(VI)/kg/day).  However, since serum
activities of AP, SDH, or bile acids were not increased, elevated serum ALT activity may have resulted
from enzyme induction rather than hepatocellular injury.  Histopathological evaluations revealed an 
increased incidence of nonneoplastic lesions in the liver (males and females), small intestine (males and
females), mesenteric lymph nodes (males and females), pancreatic lymph nodes (females only) and
salivary gland (females only).  Hepatic lesions observed in male rats included minimal-to-mild chronic
inflammation (≥0.77 mg chromium(VI)/kg/day) and histiocytic cellular infiltration (5.9 mg
chromium(VI)/kg/day); hepatic lesions in females included chronic inflammation (≥0.24 mg
chromium(VI)/kg/day), histiocytic cellular infiltration (≥0.94 mg chromium(VI)/kg/day) and fatty change
(≥0.94 mg chromium(VI)/kg/day).  Although chronic hepatic inflammation is commonly observed in 
aging rats, the incidence was significantly enhanced by exposure.  Histiocytic cellular infiltration
(minimal-to-mild) of the duodenum, was observed in males (≥0.77 mg chromium(VI)/kg/day) and
females (≥2.4 mg chromium(VI)/kg/day).  Nonneoplastic lesions of lymph nodes included the following:
histocytic cellular infiltration of mesenteric lymph nodes in males and females at ≥0.77 and ≥2.4 mg
chromium(VI)/kg/day, respectively; hemorrhage of mesenteric lymph nodes in males and females at
≥0.77 and ≥7.0 mg chromium(VI)/kg/day, respectively; and histocytic cellular infiltration of pancreatic
lymph nodes in females at ≥2.4 mg chromium(VI)/kg/day only.  The incidence of salivary gland atrophy
was significantly in female rats at 2.4 mg chromium(VI)/kg/day; although the incidence was also
increased at 7.0 mg chromium(VI)/kg/day, the change was not significantly different from control. 
Salivary atrophy was not observed in male rats.  No data on organ weights were presented in the study
report (NTP 2008a).
In mice, no treatment-related effects on survival or signs of toxicity were observed.  Final body weight
was significantly decreased by 15% in male and 8% in females exposed to the highest drinking water
concentration.  The study authors attributed the alterations in body weight to decreased water intake (due
to decreased palatability) rather than to a toxicological effect.  Hematological assessments conducted in
female mice at 1 year showed dose-dependent effects indicative of microcytic, hypochromic anemia and 
compensatory erythropoiesis:  decreased MCV and MCH (≥3.1 mg chromium(VI)/kg/day) and increased 
erythrocyte count at ≥3.1 mg chromium(VI)/kg/day.  Platelet count and segmented neutrophil count were
decreased at 8.7 mg chromium(VI)/kg/day.  Severity of hematological effects on mice was less than in
rats.  Clinical chemistry was not evaluated in male or female mice.  Histopathological evaluations 
revealed an increased incidence of nonneoplastic lesions in the liver (females), small intestine (male and
females), and mesenteric and pancreatic lymph nodes (males and females).  Histiocytic cellular
infiltration of the liver was observed in all treatment groups, with incidence and severity exhibiting dose-
dependence.  Chronic inflammation of the liver was also observed in females at ≥3.1 mg chromium(VI)/ 
kg/day.  In males, only pre-neoplastic (clear cell and eosinophilic foci) lesions were observed at the
highest dose tested.  Diffuse epithelial hyperplasia of the duodenum was observed in all treatment groups
in males and females (≥0.38 mg chromium(VI)/kg/day), with histiocytic cellular infiltration of the
duodenum in males and females at ≥2.4 and 3.1 mg chromium(VI)/kg/day, respectively. Histiocytic
cellular infiltration was observed in mesenteric lymph nodes in all treatment groups in males and females 
(≥0.38 mg chromium(VI)/kg/day) and in pancreatic lymph nodes at ≥2.4 and ≥3.1 mg chromium(VI)/ 
kg/day in males and females, respectively. Increased incidence of cytoplasm alteration of the pancreas 
(depletion of zymogen granules from acinar epithelial cells) was observed in males at ≥2.4 mg










   







   
  
 
     
  
  
     
     








    
     
     
     
     
     
      
     
 











chromium(VI)/kg/day and in females in all treatment groups (≥0.38 mg chromium(VI)/kg/day); the
toxicological significance of this finding is not clear.
Dose and end point used for MRL derivation:  0.09 mg chromium(VI)/kg/day (diffuse epithelial
hyperplasia of the duodenum)
[ ] NOAEL   [ ] LOAEL   [X] benchmark dose (BMD)
Chronic-duration exposure of rats and mice to sodium dichromate dihydrate in drinking water resulted in 
microcytic, hypochromic anemia and nonneoplastic lesions of the liver, duodenum, mesenteric and 
pancreatic lymph nodes, pancreas and salivary gland.  Based on comparison of LOAEL values 
(Table A-7), the lowest LOAELs were observed for histopathological changes of the liver (chronic
inflammation in female rats and histiocytic cellular infiltration in female mice), duodenum (diffuse
epithelial hyperplasia in male and female mice), mesenteric lymph node (histiocytic cellular infiltration in
male and female mice) and pancreas (cytoplasm cellular alteration of acinar epithelial cells in female 
mice), with effects occurring in all treatment groups. Therefore, all effects with LOAEL values of the
lowest dose tested were considered as the possible the critical effect for derivation of the chronic-duration 
oral MRL.  Incidence data for these lesions are summarized in Table A-8.
Table A-7.  NOAEL and LOAEL Values for Effects in Rats and Mice Exposed to  
Sodium Dichromate Dihydrate in Drinking Water for 1–2 Years  
NOAEL/LOAEL value (mg chromium(VI)/kg/day)
Effect or tissue with lesion Male rats Female rats Male mice Female mice
Hematological effects 0.21/0.77 N/A N/A 1.4/3.1
Liver 0.21/0.77 0.24a 2.4/5.9c 0.38a 
Duodenum 0.21/0.77 0.94/2.4 0.38a 0.38a 
Mesenteric lymph node 0.21/0.77 0.94/2.4 0.38a 0.38a 
Pancreatic lymph node N/O 0.94/2.4 0.91/2.4 1.4/3.1
Pancreas N/O N/O 0.91/2.4 0.38a 
Salivary gland N/O 2.4b N/O N/O
aNo NOAEL value was identified; effects occurred in all treatment groups
bNot observed at other doses
cPre-neoplastic lesions
LOAEL = lowest-observed-adverse-effect level; N/A = not assessed; N/O = effect not observed; NOAEL = no-
observed-adverse-effect level
Source:  NTP 2008a













   





     
 








           
   
 
         
  
     
 
  
          
   
          
  
          
   




           




   
    
   
 
    
   
    
   
    
       
 




Table A-8.  Incidence Data for Nonneoplastic Lesionsa Occurring in All Treatment  
Groups of Female F/344 Rats and Male and Female B6C3F1 Mice Exposed to  
Sodium Dichromate Dihydrate
in Drinking Water for 2 Years  
Dose (mg chromium(VI)/kg/day)
0 0.24 0.94 2.4 7.0
Female rats
Liver, chronic inflammation 12/50b (1.3) 21/50c (1.2) 28/50d (1.3) 35/50d (1.6) 39/50d (2.1)
Dose (mg chromium(VI)/kg/day)
0 0.38 0.91 2.4 5.9
Male mice
Duodenum:  diffuse epithelial 0/50 11/50d (2.0) 18/50d (1.6) 42/50d (2.1) 32/50c (2.1)
hyperplasia
Mesenteric lymph node: 14/47 (1.2) 38/47d (1.1) 31/49d (1.2) 32/49d (1.5) 42/46c (2.5)
histiocytic cellular infiltration
Dose (mg chromium(VI)/kg/day)
0 0.38 1.4 3.1 8.7
Female mice
Duodenum:  diffuse epithelial
hyperplasia 0/50 16/50d (1.6) 35/50d (1.7) 31/50d (1.6) 42/50d (2.2)
Mesenteric lymph node:
histiocytic cellular infiltration 3/46 (1.0) 29/48d (1.3) 26/46d (1.1) 40/50d (1.9) 42/50d (2.7)
Liver:  histiocytic cellular
infiltration 2/49 (1.0) 15/50d (1.1) 23/50d (1.0) 32/50d (1.0) 45/50d (1.9)
Pancreas:  acinus, cytoplasmic
alteration 0/48 6/50c (2.5) 6/49c (2.0) 14/50d (2.4) 32/50d (2.6)
aLesion severity (1=minimal, 2=mild, 3=moderate, 4=marked)
bNumber of animals with lesions/number of animals examined
cSignificantly different (p≤0.05) from the control group by Dunn’s or Shirley’s test
dSignificantly different (p≤0.01) from the control group by Dunn’s or Shirley’s test
Source:  NTP 2008a
To determine the specific end point for derivation of the chronic-duration oral MRL, all available 
dichotomous models in the EPA (version 1.4.1) were fit to the incidence data for selected end points in 
female rats and male and female mice exposed to sodium dichromate dihydrate in drinking water for
2 years (NTP 2008a) (Table A-8).  To provide potential points of departure for MRL derivation, 10%
extra risk was selected as the benchmark response in accordance with U.S. EPA (2000) technical
guidance for benchmark dose analysis to select a response level near the lower range of detectable 
observations. The BMD10s and BMDL10s from the best fitting models for nonneoplastic lesions of the
liver (female rats and mice), duodenum (male and female mice), mesenteric lymph nodes (male and
female mice), and pancreas (female mice) are shown in Table A-9.  For chronic inflammation of the liver
in female rats, the log-logistic model provided the best fit, with BMD10 and BMDL10 values of 0.22 and
0.14 mg chromium(VI)/kg/day, respectively.  For diffuse epithelial hyperplasia in male mice, the 
multistage and quantal linear models provided the best fit, with BMD10 and BMDL10 values of 0.16 and 
0.13 mg chromium(VI)/kg/day, respectively.  For diffuse epithelial hyperplasia in female mice, the best










    
   
     
   
    
   
   
    
   
   
  
  
   
   
 
 



















   
 
 










   
 
 























fit was provided by several models (gamma, multistage, quantal linear, and weibull) with BMD10 and 
BMDL10 values of 0.12 and 0.09 mg chromium(VI)/kg/day, respectively.  For histiocytic alteration of the
liver and cytoplasm alteration of the pancreas in female mice, the log-logistic model provided the best fit,
with BMD10 and BMDL10 values of 0.17 and 0.12 mg chromium(VI)/kg/day, respectively, for liver
lesions and of 0.68 and 0.52 mg chromium(VI)/kg/day, respectively, for pancreas lesions.  For lesions of
the mesenteric lymph nodes in male and female mice, none of the models provided adequate fit to the
data, even with the two highest doses dropped from the analysis; thus, data sets for these lesions were 
considered not suitable for BMD analysis.  Additional details of the benchmark dose analysis for each
data set modeled are presented in the last section of this worksheet.  Based on the lowest BMDL10 value 
of 0.09 mg chromium(VI)/kg/day, diffuse epithelial hyperplasia of the duodenum in female mice was
selected as the point of departure for derivation of the chronic-duration oral MRL.  The chronic-duration 
oral MRL based on nonneoplastic lesions of the duodenum in female mice is expected to be protective for
all other adverse effects observed in the 2-year drinking water study (e.g., hematological effects and
lesions of the liver, lymph nodes, pancreas, and salivary gland).  The chronic-duration MRL of 0.0009 mg
chromium(VI)/kg/day was derived by dividing the BMDL10 by a composite uncertainty factor of 100 
(10 for extrapolation from animals to humans and 10 for human variability).
Table A-9.  Summary of BMD10 and BMDL10 from the Best Fitting Models for  
Nonneoplastic Lesions of the Liver, Duodenum, Mesenteric Lymph Nodes,
and Pancreas in Female Rats and Male and Female Mice After Exposure 
to Sodium Dichromate Dihydrate in Drinking Water for 2 Years  
Number BMDa BMDLa 
End point Species/sex Model of doses (mg/kg/day) (mg/kg/day)
Liver, chronic
inflammation




















Mouse/female –— –— –— –—
Liver:  histiocytic
cellular infiltration




Mouse/female Log-logistic 5 0.68 0.52
aBMDs and BMDLs from dichotomous data are associated with a 10% extra risk; doses are in terms of mg  
chromium(VI)/kg/day.
bNone of the models provided an adequate fit to the data.  
BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark dose
Source:  NTP 2008a













   
    
   
  
  





    
 
    
    
 
 
   
  
   
  
   








   
 
   
 
    
  
   
   
CHROMIUM A-25
APPENDIX A
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.  Daily doses for
each treatment group were reported by study authors (NTP 2008a) based on body weights and water
intake over the 2-year exposure period.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: Selection of
nonneoplastic lesions of the duodenum in female mice is as the critical effect for the chronic-duration oral
MRL is supported by observations from the same study showing adverse gastrointestinal effects in male 
mice (diffuse epithelial hyperplasia at ≥0.38 mg chromium(VI)/kg/day and histiocytic cellular infiltration 
at 5.9 mg chromium(VI)/kg/day) and in male and female rats (histiocytic cellular infiltration at ≥0.77 and 
≥0.94 mg chromium(VI)/kg/day, respectively) exposed to sodium dichromate dihydrate in drinking water
for 2 years (NTP 2008a).  Although no other chronic-duration studies on oral chromium(VI) in animals
were identified, a 3-month study on sodium dichromate dihydrate in drinking water revealed adverse
gastrointestinal effects in rats and mice (including a comparative study in 3 mouse strains) (NTP 2007).
Epithelial hyperplasia and histiocytic cellular infiltration of the duodenum was observed at ≥3.1 and 
≥5.9 mg chromium(VI)/kg/day, respectively, in male and female B6C3F1 mice.  Similar nonneoplastic
lesions of the duodenum were also reported in the 3-month comparative study in male B6C3F1, BALB/c, 
and C57BL/6 mice, with epithelial hyperplasia at ≥2.8 mg chromium(VI)/kg/day in B6C3F1 and BALB/c
strains and ≥5.2 in the C57BL/6 strain, and histiocytic cellular infiltration at ≥2.8 mg chromium(VI)/kg/ 
day in B6C3F1 and C57BL/6 strains and ≥5.2 mg chromium(VI)/kg/day in the BALB/c strain.  In male
and female F344/N rats, histiocytic cellular infiltration was observed at ≥3.5 mg chromium(VI)/kg/day.  
At a higher daily dose (20.9 mg chromium(VI)/kg/day), ulcer, epithelial regenerative focal hyperplasia,
and epithelial focal squamous metaplasia of the glandular stomach were observed.
Details of Benchmark Dose Analysis for the Chronic-duration Oral MRL
Chronic Inflammation of the Liver in Female Rats. As assessed by the chi-square goodness-of-fit 
statistic, only the log-logistic model provided an adequate fit (X2 p-value ≥0.1) to the data (Table A-10).  
Based on the log-logistic model, the BMD associated with a 10% extra risk was 0.22 mg
chromium(VI)/kg/day and its lower 95% confidence limit (BMDL) was 0.14 mg chromium(VI)/kg/day 
(Figure A-4). 











   
 
 






    
     
     
     
     
      
     
     




    
    
 







Table A-10.  BMD10 and BMDL10 Values and Goodness-of-Fit Statistics from  
Models Fit to Incidence Data for Chronic Inflammation of the Liver in 
Female Rats Exposed to Sodium Dichromium Dihydrate in Drinking 
Water for 2 Years
BMD10 BMDL10 
Model (mg/kg/day) (mg/kg/day) x2 p-value AIC
Gammaa 0.51 0.37 0.04 317.97
Logistic 0.84 0.65 0.01 321.45
Log-logisticb 0.22 0.14 0.37 312.57
Multi-stagec 0.51 0.37 0.04 317.97
Probit 0.88 0.70 0.01 321.80
Log-probitb 0.89 0.61 0.01 320.86
Quantal linear 0.51 0.37 0.04 317.97
Weibulla 0.51 0.37 0.04 317.97
aRestrict power ≥1
bSlope restricted to >1
cRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 3-degree polynomial is reported.
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark
dose
Source:  NTP 2008a














   
 
 




    
    
  
     
  
   
 
    




Figure A-4.  Predicted and Observed Incidence of Chronic Inflammation of the  
Liver in Female Rats Exposed to Sodium Dichromium Dihydrate in Drinking  
Water for 2 Years*  





















0 1 2 3 4 5 6 7 
dose 
13:34 04/08 2008 
*BMDs and BMDLs indicated are associated with a 10% extra risk, and are in units of mg chromium(VI)/kg/day.
Source:  NTP 2008a
Diffuse Epithelial Hyperplasia of the Duodenum in Male Mice. As assessed by the chi-square 
goodness-of-fit statistic, none of the models provided an adequate fit (X2 p-value ≥0.1) to the full dataset
(Table A-11).  In order to achieve a statistically fit model, the highest dose was dropped.  This is 
determined to be appropriate, as the area of concern is with the low-dose region of the response curve.
After dropping the highest dose, the gamma, log-logistic, multistage, log-probit, quantal linear, and 
weibull models provided adequate fits to the data (X2 p-value >0.1).  Comparing across models, a better
fit is generally indicated by a lower AIC (EPA 2000).  As assessed by AIC, the 1-degree polynomial
multistage model provided the best fit to the data (Figure A-5).  Based on the multistage model, the BMD
associated with a 10% extra risk was 0.16 mg chromium(VI)/kg/day and its lower 95% confidence limit
(BMDL) was 0.13 mg chromium(VI)/kg/day.




















    
 
      
      
      
      
       
      
      
      
 
      
      
      
      
       
      
      




    
   
   
 







Table A-11.  BMD10 and BMDL10 Values and Goodness-of-Fit Statistics from  
Models Fit to Incidence Data for Diffuse Epithelial Hyperplasia in the 
Duodenum in Male Mice Exposed to Sodium Dichromium Dihydrate
in Drinking Water for 2 Years  
BMD10 BMDL10 
Model (mg/kg/day) (mg/kg/day) x2 p-value AIC
All doses
Gammaa 0.31 0.25 0.00 270.99
Logistic 0.90 0.74 0.00 296.25
Log-logisticb 0.15 0.12 0.00 247.93
Multi-stagec 0.31 0.25 0.00 270.99
Probit 0.90 0.76 0.00 296.18
Log-probitb 0.48 0.36 0.00 274.38
Quantal linear 0.31 0.25 0.00 270.99
Weibulla 0.31 0.25 0.00 270.99
Highest dose dropped (four doses modeled)
Gammaa 0.22 0.14 0.43 167.67
Logistic 0.47 0.39 0.03 177.09
Log-logisticb 0.26 0.15 0.20 169.23
Multi-staged 0.16 0.13 0.52 166.34
Probit 0.45 0.37 0.04 176.19
Log-probitb 0.28 0.23 0.33 167.41
Quantal linear 0.16 0.13 0.52 166.34
Weibulla 0.22 0.14 0.47 167.50
aRestrict power ≥1
bSlope restricted to >1
cRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 3-degree polynomial is reported.
dRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; degree polynomial =1.
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark
dose
Source:  NTP 2008a














   
 
 




       
     
     
     
    
      
CHROMIUM A-29
APPENDIX A
Figure A-5.  Predicted and Observed Incidence of Diffuse Epithelial Hyperplasia in
the Duodenum of Male Mice Exposed to Sodium Dichromium Dihydrate in 
Drinking Water for 2 Years*


















0 0.5 1 1.5 2 2.5 
dose 
15:45 04/08 2008 
*BMDs and BMDLs indicated are associated with a 10% extra risk, and are in units of mg chromium(VI)/kg/day.
Source:  NTP 2008a
Histiocytic Cellular Infiltration of the Mesenteric Lymph Nodes in Male Mice. As assessed by the chi-
square goodness-of-fit statistic, none of the models provided an adequate fit (X2 p-value ≥0.1) to the full
dataset (Table A-12).  In order to achieve a statistically fit model, the highest dose was dropped.  This is
determined to be appropriate, as the area of concern is with the low-dose region of the response curve.
Dropping the highest dose did not result in adequately fitting models, nor did dropping the two highest
doses. This dataset is considered not suitable for benchmark dose modeling.  











   
 







    
 
      
      
      
      
       
      
      
      
 
      
      
      
      
       
      
      
      
 
      
      
      
      
       
      
      




    
   
      
   
     
   
 







Table A-12.  BMD10 and BMDL10 Values and Goodness-of-Fit Statistics from  
Models Fit to Incidence Data for Histiocytic Cellular Infiltration in 
Mesenteric Lymph Nodes of Male Mice Exposed to Sodium
Dichromium Dihydrate in Drinking Water for 2 Years  
BMD10 BMDL10 
Model (mg/kg/day) (mg/kg/day) x2 p-value AIC
All doses
Gammaa 0.38 0.26 0.00 285.94
Logistic 0.53 0.39 0.00 286.38
Log-logisticb 0.16 0.08 0.00 284.48
Multi-stagec 0.43 0.26 0.00 287.88
Probit 0.56 0.43 0.00 286.35
Log-probitb 0.83 0.52 0.00 289.36
Quantal linear 0.38 0.26 0.00 285.94
Weibulla 0.38 0.26 0.00 285.94
Highest dose dropped (four doses modeled)
Gammaa 0.47 0.24 0.00 258.50
Logistic 0.61 0.35 0.00 259.04
Log-logisticb 0.21 0.08 0.00 256.81
Multi-staged 0.47 0.24 0.00 258.50
Probit 0.63 0.37 0.00 259.08
Log-probitb 1.24 0.56 0.00 261.28
Quantal linear 0.47 0.24 0.00 258.50
Weibulla 0.47 0.24 0.00 258.50
Two highest doses dropped (three doses modeled)
Gammaa 0.11 0.07 0.00 187.77
Logistic 0.17 0.12 0.00 189.97
Log-logisticb 0.05 0.03 0.00 183.77
Multi-stagee 0.11 0.07 0.00 187.77
Probit 0.17 0.12 0.00 190.12
Log-probitb 0.17 0.11 0.00 190.37
Quantal linear 0.11 0.07 0.00 187.77
Weibulla 0.11 0.07 0.00 187.77
aRestrict power ≥1
bSlope restricted to >1
cRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 3-degree polynomial is reported.
dRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 2-degree polynomial is reported.
eRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 1-degree polynomial is reported.
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark
dose
Source:  NTP 2008a










    
    
   
     
   
     
   
 
    





Diffuse Epithelial Hyperplasia of the Duodenum in Female Mice. As assessed by the chi-square 
goodness-of-fit statistic, none of the models provided an adequate fit (X2 p-value ≥0.1) to the data
(Table A-13).  In order to achieve a statistically fit model, the highest dose was dropped.  This is
determined to be appropriate, as the area of concern is with the low-dose region of the response curve.
After dropping the highest dose, an adequate fit was still not achieved.  After dropping the two highest
doses, all of the models except for the logistic and probit models provided an adequate fit (X2 p-value 
≥0.1) to the data.  Comparing across models, a better fit is generally indicated by a lower AIC (EPA
2000).  As assessed by AIC, the gamma, multistage, quantal linear, and weibull models generated 
identical goodness of fit statistics and benchmark doses, as these models all took the form of a 1-degree 
polynomial multistage model which provides the best fit (Figure A-6).  Based on these models, the BMD
associated with a 10% extra risk was 0.12 mg chromium(VI)/kg/day and its lower 95% confidence limit
(BMDL) was 0.09 mg chromium(VI)/kg/day.




















    
 
      
      
      
      
       
      
      
      
 
      
      
      
      
       
      
      
      
 
      
      
      
      
       
      
      




   
   
    
   
    
   
 







Table A-13.  BMD10 and BMDL10 Values and Goodness-of-Fit Statistics from  
Models Fit to Incidence Data for Diffuse Epithelial Hyperplasia in the 
Duodenum of Female Mice Exposed to Sodium Dichromium
Dihydrate in Drinking Water for 2 Years  
BMD10 BMDL10 
Model (mg/kg/day) (mg/kg/day) x2 p-value AIC
All doses
Gammaa 0.34 0.27 0.00 275.34
Logistic 0.88 0.72 0.00 293.17
Log-logisticb 0.12 0.09 0.04 245.54
Multi-stagec 0.34 0.27 0.00 275.34
Probit 0.93 0.78 0.00 294.03
Log-probitb 0.52 0.38 0.00 279.54
Quantal linear 0.34 0.27 0.00 275.34
Weibulla 0.34 0.27 0.00 275.34
Highest dose dropped (four doses modeled)
Gammaa 0.20 0.16 0.00 213.41
Logistic 0.55 0.46 0.00 236.10
Log-logisticb 0.11 0.08 0.04 200.07
Multi-staged 0.20 0.16 0.00 213.41
Probit 0.54 0.45 0.00 235.61
Log-probitb 0.29 0.24 0.00 220.04
Quantal linear 0.20 0.16 0.00 213.41
Weibulla 0.20 0.16 0.00 213.41
Two highest doses dropped (three doses modeled)
Gammaa 0.12 0.09 0.87 126.06
Logistic 0.34 0.27 0.00 141.77
Log-logisticb 0.12 0.06 1.00 127.77
Multi-stagee 0.12 0.09 0.87 126.06
Probit 0.32 0.26 0.00 140.65
Log-probitb 0.20 0.16 0.48 127.17
Quantal linear 0.12 0.09 0.87 126.06
Weibulla 0.12 0.09 0.87 126.06
aRestrict power >=1
bSlope restricted to >1
cRestrict betas >=0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 3-degree polynomial is reported.
dRestrict betas >=0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 2-degree polynomial is reported.
eRestrict betas >=0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 1-degree polynomial is reported.
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark
dose
Source:  NTP 2008a













   
 
 




   
    
    
   
    
   
CHROMIUM A-33
APPENDIX A
Figure A-6.  Predicted and Observed Incidence of Diffuse Epithelial Hyperplasia in
the Duodenum of Female Mice Exposed to Sodium Dichromium Dihydrate in 
Drinking Water for 2 Years*





















0 0.2 0.4 0.6 0.8 1 1.2 1.4 
dose 
09:36 04/09 2008 
*BMDs and BMDLs indicated are associated with a 10% extra risk, and are in units of mg chromium(VI)/kg/day.
Source:  NTP 2008a
Histiocytic Cellular Infiltration of the Mesenteric Lymph Nodes in Female Mice.  As assessed by the 
chi-square goodness-of-fit statistic, none of the models provided an adequate fit (X2 p-value ≥0.1) to the
full dataset (Table A-14).  In order to achieve a statistically fit model, the highest dose was dropped.  This
is determined to be appropriate, as the area of concern is with the low-dose region of the response curve.  
Dropping the highest dose did not result in adequately fitting models, nor did dropping the two highest
doses. This dataset is not suitable for benchmark dose modeling.   











   
    







    
 
      
      
      
      
      
      
      
      
 
      
      
      
      
       
      
      
      
 
      
      
      
      
       
      
      




    
   
      
   
     
   
 







Table A-14.  BMD10 and BMDL10 Values and Goodness-of-Fit Statistics from  
Models Fit to Incidence Data for Histiocytic Cellular Infiltration in
Mesenteric Lymph Nodes of Female Mice Exposed to Sodium
Dichromium Dihydrate in Drinking Water for 2 Years  
BMD10 BMDL10 
Model (mg/kg/day) (mg/kg/day) x2 p-value AIC
All doses
Gammaa 0.41 0.30 0.00 282.46
Logistic 0.77 0.61 0.00 290.18
Log-logisticb 0.09 0.06 0.00 263.55
Multi-stagec 0.41 0.30 0.00 282.46
Probit 0.85 0.69 0.00 291.41
Log-probitb 0.68 0.47 0.00 285.85
Quantal linear 0.41 0.30 0.00 282.46
Weibulla 0.41 0.30 0.00 282.46
Highest dose dropped (four doses modeled)
Gammaa 0.20 0.15 0.00 224.84
Logistic 0.40 0.33 0.00 230.81
Log-logisticb 0.07 0.05 0.00 215.19
Multi-staged 0.20 0.15 0.00 224.84
Probit 0.40 0.34 0.00 230.85
Log-probitb 0.37 0.24 0.00 231.76
Quantal linear 0.20 0.15 0.00 224.84
Weibulla 0.20 0.15 0.00 224.84
Two highest doses dropped (three doses modeled)
Gammaa 0.14 0.10 0.00 172.32
Logistic 0.31 0.24 0.00 178.99
Log-logisticb 0.07 0.04 0.00 164.47
Multi-stagee 0.14 0.10 0.00 172.32
Probit 0.30 0.23 0.00 178.74
Log-probitb 0.21 0.15 0.00 178.11
Quantal linear 0.14 0.10 0.00 172.32
Weibulla 0.14 0.10 0.00 172.32
aRestrict power ≥1
bSlope restricted to >1
cRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 3-degree polynomial is reported.
dRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 2-degree polynomial is reported.
eRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 1-degree polynomial is reported.
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark
dose
Source:  NTP 2008a










     
     
  
   
 









    
     
     
     
     
     
     
     




    
   
 







Histiocytic Cellular Infiltration of the Liver in Female Mice. As assessed by the chi-square goodness-
of-fit statistic, only the log-logistic model provided an adequate fit (X2 p-value ≥0.1) to the data
(Table A-15).  Based on the log-logistic model, the BMD associated with a 10% extra risk was 0.17 mg
chromium(VI)/kg/day and its lower 95% confidence limit (BMDL) was 0.12 mg chromium(VI)/kg/day 
(Figure A-7). 
Table A-15.  BMD10 and BMDL10 Values and Goodness-of-Fit Statistics from  
Models Fit to Incidence Data for Histiocytic Cellular Infiltration in the
Liver of Female Mice Exposed to Sodium Dichromium Dihydrate in 
Drinking Water for 2 Years  
BMD10 BMDL10 
Model (mg/kg/day) (mg/kg/day) x2 p-value AIC
Gammaa 0.35 0.28 0.08 255.40
Logistic 0.85 0.70 0.00 267.56
Log-logisticb 0.17 0.12 0.44 251.36
Multi-stagec 0.35 0.28 0.08 255.40
Probit 0.88 0.75 0.00 268.64
Log-probitb 0.62 0.48 0.01 260.00
Quantal linear 0.35 0.28 0.08 255.40
Weibulla 0.35 0.28 0.08 255.40
aRestrict power ≥1
bSlope restricted to >1
cRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; no degree of polynomial
provided a fit, a 3-degree polynomial is reported.
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark
dose
Source:  NTP 2008a












   
 
 




   
   
  





Figure A-7.  Predicted and Observed Incidence of Histiocytic Cellular Infiltration 
in the Livers of Female Mice Exposed to Sodium Dichromium Dihydrate in 
Drinking Water for 2 Years*
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dose 
11:17 04/09 2008 
*BMDs and BMDLs indicated are associated with a 10% extra risk, and are in units of mg chromium(VI)/kg/day.
Source:  NTP 2008a
Cytoplasmic Alteration of Acinar Epithelial Cells of the Pancreas in Female Mice. As assessed by the 
chi-square goodness-of-fit statistic, all of the models provide adequate fits (X2 p-value ≥0.1) to the data
(Table A-16).  Comparing across models, a better fit is generally indicated by a lower Akaike’s 
Information Criteria (AIC) (EPA 2000).  As assessed by AIC, the log-logistic model provides the best fit 
(Figure A-8).  Based on the log-logistic model, the BMD associated with a 10% extra risk was 0.68 mg
chromium (VI)/kg/day and its lower 95% confidence limit (BMDL) was 0.52 mg chromium (VI)/kg/day. 











   
    







    
     
     
     
     
      
     
     




   
  
 







Table A-16.  BMD10 and BMDL10 Values and Goodness-of-Fit Statistics from  
Models Fit to Incidence Data for Pancreas: Acinus, Cytoplasmic 
Alteration in Female Mice Exposed to Sodium Dichromium
Dihydrate in Drinking Water for 2 Years  
BMD10 BMDL10 
Model (mg/kg/day) (mg/kg/day) x2 p-value AIC
Gammaa 0.92 0.72 0.13 206.82
Logistic 2.43 2.03 0.09 211.78
Log-logisticb 0.68 0.52 0.19 205.22
Multi-stagec 0.92 0.72 0.13 206.82
Probit 2.24 1.89 0.11 210.99
Log-probitb 1.77 1.40 0.11 209.99
Quantal linear 0.92 0.72 0.13 206.82
Weibulla 0.92 0.72 0.13 206.82
aRestrict power ≥1
bSlope restricted to >1
cRestrict betas ≥0; lowest degree polynomial (up to n-2) with an adequate fit is reported; a 1-degree polynomial is
reported.
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark
dose
Source:  NTP 2008a











   
 
  
   
 

















Alteration in Female Mice Exposed to Sodium Dichromium
Dihydrate in Drinking Water for 2 Years*












0 1 2 3 4 5 6 7 8 9 
dose 
11:41 04/09 2008 
*BMDs and BMDLs indicated are associated with a 10% extra risk, and are in units of mg chromium (VI)/kg/day.
Source:  NTP 2008a
Agency Contact (Chemical Manager):  Sharon Wilbur
















   


















     
 
  




     
    
    
    
    
    
 
    
 
    
   
   




MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical name: Chromium(III) insoluble particulates
CAS number: 16065-83-1
Date: February 2012
Profile status: Second Draft Post-Public Comment
Route: [X] Inhalation [ ] Oral
Duration: [ ] Acute [X] Intermediate [ ] Chronic
Key to figure: 2 
Species: Rat
Minimal Risk Level:  0.005 mg chromium(III)/m3 for insoluble trivalent chromium particulate
compounds
Reference:  Derelanko MJ, Rinehart WE, Hilaski RJ, et al.  1999.  Thirteen-week subchronic rat
inhalation toxicity study with a recovery phase of trivalent chromium compounds, chromic acid and basic
chromium sulfate.  Toxicol Sci 52(2):278-288. 
Experimental design:  Groups of 15 male and female CDF (Fisher 344/Crl BR VAF/Plus) rats were 
exposed to chromic oxide or basic chromium sulfate by nose-only inhalation to 0, 3, 10, or 30 mg
chromium(III)/m3 (measured concentrations) 6 hours/day, 5 days/week for 13 weeks.  Mean particle sizes 
(in microns±GSD, based on 21 samples/test group evaluated over the 13-week exposure period) in the 3, 
10, and 30 mg chromium(III)/m3 groups, were 1.8±1.93, 1.9±1.84, and 1.9±1.78, respectively, for
chromic oxide and 4.2±2.48, 4.2±2.37, and 4.5±2.50, respectively, for basic chromium sulfate; no 
chromium(VI) was detected in samples.  Of these 15 rats/sex/group, 10 rats/sex/group were examined and 
sacrificed after 13 weeks of exposure and 5 rats/sex/group were examined and sacrificed after an 
additional 13-week recovery (e.g., no exposure) period.  Throughout the exposure and recovery periods, 
rats were examined daily for mortality and clinical signs of toxicity; body weight was recorded weekly,
but food consumption was not measured.  Ophthamalmoscopic examinations were conducted prior to 
treatment and before terminal sacrifice.  At the end of the treatment and recovery phases, blood was 
analyzed for “standard” hematology and clinical chemistry, and urinalysis was conducted; specific 
outcome measures evaluated for these assessments were not reported.  In five rats/sex/group, urine was
also analyzed for β2-microglobulin.  Gross necropsy was performed on all animals at terminal sacrifice 
and organ weights were recorded for heart, liver, lungs/trachea (combined), spleen, kidneys, brain, 
adrenal, thyroid/parathyroid, testes, and ovaries.  Bone marrow was examined and differential cell counts 
of bone marrow were conducted.  Microscopic examination of comprehensive tissues (described as 
“tissues typically harvested for subchronic studies”) was conducted for all animals and the control and 
30 mg chromium(III)/m3 groups.  For all animals in the 3 and 30 mg chromium(III)/m3 groups, the
following tissues were examined microscopically:  kidneys, liver, nasal tissues, trachea, lungs, larynx,
mediastinal and mandibular lymph nodes, and all tissues with gross lesions.  Histopathological lesions
were described, but no incidence data were reported. Sperm morphology, count, and motility were
assessed in all males at the end of the 13-week treatment period only.
Effects noted in study and corresponding doses: The following study results are for rats exposed to 
chromic oxide only; detailed results of animals exposed to basic chromium sulfate are presented in the 
following intermediate-duration inhalation MRL worksheet for soluble chromium(III) compounds.  No 
mortalities, clinical signs of toxicity, changes in body weight, findings on ophthalmologic examination, or
alterations of sperm count, motility, or morphology were observed.  Evaluations of hematology, clinical
chemistry, and urinalysis did not reveal any treatment-related differences compared to controls;
β2-microglobulin was not detected in urine of rats from any group.  Absolute and relative lung/trachea
weights were significantly increased by 12 and 13%, respectively, in males in the 30 mg










   
   
   
    
    
  
    
    
    
 
    
  
    




    
   
  
  
   
    
 
  
   
    
 







    
    
    
   
   










chromium(III)/m3 group compared to control.  Lung weights were not increased in females.  Other
significant changes in organ weight changes were limited to small increases in absolute 
thyroid/parathyroid weight in females in the 10 mg chromium(III)/m3 group and in relative
thyroid/parathyroid weight (combined) in females in the 10 and 30 mg chromium(III)/m3 groups.  The
study authors stated that the biological significance of changes in thyroid/parathyroid weight could not be
determined; however, no histopathological changes were observed in these tissues in female rats exposed
to 30 mg chromium(III)/m3. On necropsy, most animals (incidence not reported) in the chromic oxide
group had green discoloration of the lungs and mediastinal lymph nodes; the degree of discoloration
increased with exposure level and was presumed to represent deposition of the test material. Mediastinal
lymph node enlargement was noted in the 30 mg chromium(III)/m3 group.  Microscopic examination of
the lung revealed foci or aggregates of dark-pigmented (presumably the test material) macrophages within
alveolar spaces adjacent to junctions of terminal bronchioles and alveolar ducts; black pigment was 
observed at the tracheal bifurcation and in periobronchial lymphoid tissue and the medistinal lymph node
in all chromic oxide treatment groups.  These findings are consistent with normal physiological clearance
mechanisms for particulates deposited in the lung and are not considered adverse.  Lymphoid hyperplasia
of the mediastinal node was observed in rats of all treatment groups (severity not reported).  In rats 
exposed to 10 and 30 mg chromium(III)/m3, trace-to-mild chronic interstitial inflammation of the lung, 
characterized by inflammatory cell infiltration, was observed in alveolar septa, and hyperplasia of Type II
pneumocytes (severity not reported) were observed.  Histopathological changes were isolated to the lungs 
and respiratory lymphatic tissues and were not observed in other tissues, including nasal tissues and the
larynx.  Thus, for evaluations conducted at the end of the 13-week treatment period, a LOAEL of 3 mg
chromium(III)/m3 for hyperplasia of the mediastinal node was identified for both males and females; the 
severity of this effect was not reported.  Following the 13-week recovery period, pigmented macrophages 
and black pigment were observed in peribronchial tissues and the mediastinal lymph node in animals
from all treatment groups.  Septal cell hyperplasia and chronic interstitial inflammation of the lung, both 
trace-to-mild in severity, were observed in males of all treatment groups and in females exposed to 10 and 
30 mg chromium(III)/m3. For evaluations conducted at the 13-week posttreatment recovery period, a
minimal LOAEL (classified as minimal based on severity) of 3 mg chromium(III)/m3 for trace-to-mild
septal cell hyperplasia and chronic interstitial inflammation of the lung in male rats was identified.
Dose end point used for MRL derivation:  3 mg chromium(III)/m3 (trace-to-mild septal cell hyperplasia 
and chronic interstitial inflammation of the lung), adjusted to 0.54 mg chromium(III)/m3 for intermittent 
exposure and converted to a LOAELHEC of 0.43 mg chromium(III)/m3 
[  ] NOAEL [X] LOAEL
The LOAEL of 3 mg chromium(III)/m3 for hyperplasia of the mediastinal node in males and females 
(observed at the end of the 13-week treatment period) and the minimal LOAEL (based on severity) of
3 mg chromium(III)/m3 for trace-to-mild septal cell hyperplasia and chronic interstitial inflammation of
the lung in males (observed at the end of the 13-week recovery period) were further evaluated as potential
critical effects for derivation of the intermediate-duration inhalation MRL for insoluble trivalent
chromium particulate compounds.  A BMCL for these effects could not be determined since incidence
data for lesions of the lung and respiratory lymphatic tissue were not reported; thus, a NOAEL/LOAEL
approach was used.  Following adjustment of LOAELs for intermittent exposure (LOAELADJ) and human 
equivalent concentrations (LOAELHEC), as described below, trace-to-mild septal cell hyperplasia and
chronic interstitial inflammation of the lung in male rats was selected as the critical effect, based on the 
lowest LOAELHEC of 0.43 mg chromium(III)/m3 (Table A-17).  The intermediate-duration inhalation 
MRL for insoluble trivalent chromium particulate compounds of 0.005 mg chromium(III)/m3 was derived
by dividing the minimal LOAELHEC of 0.43 mg chromium(III)/m3 by a composite uncertainty factor of 90 
(3 for use of a minimal LOAEL, 3 for extrapolation from animals to humans, and 10 for human 
variability).
























   
 
 
   
 
 




   
 





   
  
    
   
   
 
   
 
 




     
      
    
 
  
      
    
 
   
   
    
    
CHROMIUM A-41
APPENDIX A
Table A-17.  LOAEL Values (Expressed in Terms Of HEC) for Nonneoplastic  










Rat/male Septal cell hyperplasia 0.789 0.54 0.43
and chronic interstitial
inflammation of the 
lung (thoracic)
Rat/male Hyperplasia of the 1.225 0.54 0.66
mediastinal node 
(tracheobronchial)
Rat/female Hyperplasia of the 1.084 0.54 0.59
mediastinal node 
(tracheobronchial)
aDuration-adjusted for intermittent exposure (LOAELADJ = LOAEL x 6 hours/24 hours x 5 days/7 days = 3 mg 
chromium(III)/m3 x 6 hours/24 hours x 5 days/7 days = 0.54 mg chromium(III)/m3)
bLOAELHEC = LOAELADJ x RDDR
HEC = human equivalent concentration; LOAEL = lowest-observed-adverse-effect level; RDDR = regional deposited 
dose ratio
Source:  Derelanko et al. 1999
Uncertainty factors used in MRL derivation:
[X] 3 for use of a minimal LOAEL
 [X] 3 for extrapolation from animals to humans, with dosimetric adjustment
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  To 
determine the LOAELHEC, the LOAELADJ in rats was multiplied by the RDDR multiplier determined for
lesions in various areas of the respiratory tract in male and female rats (Table A-17).  The RDDR
computer program was used to determine the RDDR multipliers as follows.
For interstitial inflammation of the lung in male rats (specific location of lesion within the lung was not
reported by study authors) observed after the 13-week recovery period, the thoracic region for the RDDR
program was selected since the observed effect could occur in the both the tracheobronchial and
pulmonary regions of the lung.  The RDDR multiplier of 0.789 for the thoracic region of the respiratory 
tract in male rats was determined using the average body weight of 201 g for male rats in the control
group in the basic chromium sulfate portion of the study (data for body weights of male rats in the
chromic oxide portion of the study were not reported) and the average particle size (MMAD±GSD) of
1.9±1.85 reported in the Derelanko et al. (1999) study. 
For hyperplasia of the mediastinal node in male and female rats observed at the end of the 13-week
treatment period, the tracheobronchial region of the respiratory tract was selected for the RDDR program.
Although the mediastinal lymph node is not a respiratory tissue, for the purposes of HEC conversions, it
is considered part of the tracheobronchial region of the respiratory system rather than a systemic tissue;










    
 
  
   
     
     






   





      
   
  
    
  
    
   
   
 
   
  
 
   
   
    
   








classification of the mediastinal lymph node as a systemic tissue is not appropriate, since the test material
reaches the respiratory lymphatic tissues by the pulmonary macrophage clearance system and not by first
entering the systemic circulation.  For male rats, the RDDR multiplier of 1.225 for the tracheobronchial
region of the respiratory tract in male rats was determined using the average body weight of 201 g for
male rats in the control group in the basic chromium sulfate portion of the study (data for body weights of
male rats in the chromic oxide portion of the study were not reported) and the average particle size
MMAD±GSD of 1.9±1.85 reported in Derelanko et al. (1999).  For female rats, the RDDR multiplier of
1.084 for the tracheobronchial region tract was determined using the default subchronic body weight of
124 g for female F344 rats (EPA 1988d) and the average particle size MMAD±GSD of 1.9±1.85 reported 
in the Derelanko et al. (1999) study; the default value for female body weights was used because female 
body weights were not reported in the critical study. 
Was a conversion used from intermittent to continuous exposure?  Rats were exposed for 6 hours/day, 
5 days/week for 13 weeks.
LOAELADJ = 3 mg chromium(III)/m3 x 6 hours/24 hours x 5 days/7 days
LOAELADJ = 0.54 mg chromium(III)/m3 
Other additional studies or pertinent information that lend support to this MRL: The respiratory tract is
the major target of inhalation exposure to chromium(III) and chromium(VI) compounds in humans and 
animals.  Respiratory effects due to inhalation exposure are probably due to direct action of chromium at
the site of contact.  The available occupational studies for exposure to chromium(III) compounds include, 
or likely include, concomitant exposure to chromium(VI) compounds and other compounds that may
produce respiratory effects (Langård 1980; Mancuso 1951; Osim et al. 1999).  Thus, while the available
data in humans suggest that respiratory effects occur following inhalation exposure to chromium(III)
compounds, the respiratory effects of inhaled chromium(VI) and other compounds are confounding
factors.  Studies evaluating respiratory effects of intermediate-duration inhalation exposure of animals are
limited to the critical study evaluating 13-week exposure to chromic oxide or basic chromium sulfate
(Derelanko et al. 1999).  Results of this study show that intermediate-duration inhalation exposure to 
chromic oxide or basic chromium sulfate produced adverse respiratory effects, as indicated by 
histopathological changes and increased lung weight. However, effects of chromic oxide were less severe 
and isolated to the lung and respiratory lymph tissues, whereas the effects of basic chromium sulfate were 
more severe and observed throughout the respiratory tract (e.g., nose, larynx, lung and respiratory lymph 
tissues). The authors suggest that differences in the respiratory toxicity of these compounds may be due 
to differences in chemical-physical properties (e.g., solubility, acidity).  Based on the differences in 
respiratory toxicity between insoluble chromic oxide and soluble basic chromium sulfate, separate 
intermediate-duration inhalation MRLs were derived for insoluble and soluble trivalent chromium
particulate compounds.
Agency Contact (Chemical Manager):  Sharon Wilbur












   
  
   
   
   




     
 











   
  








    
    
    
    
    
    
  
     
   
   
     
      





MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical name: Chromium(III) soluble particulates
CAS number: 16065-83-1
Date: June 2012
Profile status: Third Draft Post-Public Comment
Route: [X] Inhalation [ ] Oral
Duration: [ ] Acute [X] Intermediate [ ] Chronic
Key to figure: 3 
Species: Rat
Minimal Risk Level:  0.0001 mg chromium(III)/m3 for soluble trivalent chromium particulate compounds
Reference:  Derelanko MJ, Rinehart WE, Hilaski RJ, et al.  1999.  Thirteen-week subchronic rat
inhalation toxicity study with a recovery phase of trivalent chromium compounds, chromic acid and basic
chromium sulfate.  Toxicol Sci 52(2):278-288. 
Experimental design:  Groups of 15 male and female CDF (Fisher 344/Crl BR VAF/Plus) rats were 
exposed to chromic oxide or basic chromium sulfate by nose-only inhalation to 0, 3, 10, or 30 mg
chromium(III)/m3 (measured concentrations) 6 hours/day, 5 days/week for 13 weeks.  Mean particle sizes 
(in microns±GSD, based on 21 samples/test group evaluated over the 13-week exposure period) in the 3, 
10, and 30 mg chromium(III)/m3 groups, were 1.8±1.93, 1.9±1.84, and 1.9±1.78, respectively, for
chromic oxide and 4.2±2.48, 4.2±2.37, and 4.5±2.50, respectively, for basic chromium sulfate; no 
chromium(VI) was detected in samples.  Of these 15 rats/sex/group, 10 rats/sex/group were examined and 
sacrificed after 13 weeks of exposure and 5 rats/sex/group were examined and sacrificed after an
additional 13-week recovery (e.g., no exposure) period.  Throughout the exposure and recovery periods, 
rats were examined daily for mortality and clinical signs of toxicity; body weight was recorded weekly
but food consumption was not measured.  Ophthamalmoscopic examinations were conducted prior to 
treatment and before terminal sacrifice.  At the end of the treatment and recovery phases, blood was 
analyzed for “standard” hematology and clinical chemistry, and urinalysis was conducted; specific 
outcome measures evaluated for these assessments were not reported.  In five rats/sex/group, urine was
also analyzed for β2-microglobulin.  Gross necropsy was performed on all animals at terminal sacrifice 
and organ weights were recorded for heart, liver, lungs/trachea (combined), spleen, kidneys, brain, 
adrenal, thyroid/parathyroid, testes, and ovaries.  Bone marrow was examined and differential cell counts 
of bone marrow were conducted.  Microscopic examination of comprehensive tissues (described as 
“tissues typically harvested for subchronic studies”) was conducted for all animals and the control and 
30 mg chromium(III)/m3 groups.  For all animals in the 3 and 30 mg chromium(III)/m3 groups, the
following tissues were examined microscopically:  kidneys, liver, nasal tissues, trachea, lungs, larynx,
mediastinal and mandibular lymph nodes, and all tissues with gross lesions.  Histopathological findings
were described, but no incidence data were reported. Sperm morphology, count, and motility were
assessed in all males at the end of the 13-week treatment period only.
Effects noted in study and corresponding doses: The following study results are for rats exposed to basic
chromium sulfate only; detailed results of animals exposed to chromic oxide are presented in the
preceding intermediate-duration inhalation MRL worksheet for insoluble chromium(III) compounds.  No 
treatment-related mortalities were observed; one male rat in the 30 mg chromium(III)/m3 group died on 
day 4 of exposure; the study authors did not attribute this death to treatment since no significant signs of
toxicity were observed in this animals or in other animals in this treatment group. Females in the 30 mg
chromium(III)/m3 group exhibited sporadic labored breathing; no additional information on this
observation was reported.  No findings on ophthalmologic examination or alterations of sperm count, 
motility, or morphology were observed.  At the end of the 13-week treatment period, body weight was










      
    
     
   
   
 
   
 
  
   
  
   
     
 
  
     
   
   
 
 
   
  
   
    
   
 
    
    
    
  
 
    
    
  
 
   





    
   
    
  






significantly decreased in males in the 10 and 30 mg chromium(III)/m3 groups and females in the 30 mg
chromium(III)/m3 group.  The study authors stated that “most” hematological, clinical chemistry, and
urinalysis values in all exposure groups were similar to controls, although data were not reported.  A
significant, dose-related increase in absolute and relative lung/trachea weights was observed in male rats
in all treatment groups.  Other organ weight changes in males were decreased absolute and increase 
relative brain weights (30 mg chromium(III)/m3), increased relative kidney weight (30 mg
chromium(III)/m3), decreased absolute liver weight (30 mg chromium(III)/m3), increased relative 
thyroid/parathyroid weight (30 mg chromium(III)/m3), decreased relative spleen weight (10 and 30 mg
chromium(III)/m3), and increased relative testes weight (30 mg chromium(III)/m3).  In females, absolute
and relative lungs weights were increased in a dose-dependent fashion in all treatment groups.  Other
organ weight changes in females were increased absolute and relative thyroid/parathyroid weight (30 mg
chromium(III)/m3) and decreased absolute spleen weight (30 mg chromium(III)/m3). With the exception 
of increased absolute and relative lung weights in males and females, small changes in other organs 
weights were not considered adverse in the absence of histopathological changes. On necropsy, grey lung
discoloration was observed in animals exposed to 10 and 30 mg chromium(III)/m3; the degree of
discoloration increased with exposure level.  Microscopic examination of the lung revealed the following
changes in all treatment groups: chronic inflammation of the alveoli; alveolar spaces filled with
macrophages, neutrophils, lymphocytes and cellular debris; foci of “intense” inflammation and thickened 
alveolar walls; chronic interstitial inflammation with cell infiltration; hyperplasia of Type II pneumocytes; 
and granulomatous inflammation, characterized by infiltration of macrophages and multinucleated giant
cells.  Macrophage infiltration and granulomatous inflammation of the larynx, acute inflammation and 
suppurative and mucoid exudates of nasal tissues, and histiocytosis and hyperplasia of peribronchial
lymphoid tissues and the mediastinal lymph node were also observed in all treatment groups.  Following
the 13-week recovery period, enlargement of the mediastinal lymph node was observed on gross necropsy
in all treatment groups.  Microscopic examination of respiratory tissues showed changes to the lung
(chronic alveolar inflammation, interstitial inflammation, septal cell hyperplasia, and granulomatous
inflammation) in all treatment groups, larynx (granulomatous inflammation) in the 10 and 30 mg
chromium(III)/m3 groups, nasal tissues (trace suppurative exudates) in one to two animals in each groups,
and mediastinal lymph node (histiocytosis and hyperplasia) in all treatment groups chromium(III)/m3 
groups.  Following the 13-week recovery period, test material was observed in the respiratory tract on
necropsy; however, incidence was decreased compared to observations made immediately following
treatment (data not presented).  In addition, chronic alveolar and interstitial inflammation and septal cell 
hyperplasia (all trace-to-moderate in severity) were observed in the 10 and 30 mg chromium(III)/m3 
groups, with severity similar to that observed immediately following treatment; in the 3 mg
chromium(III)/m3 group, severity was slightly reduced. 
Dose end point used for MRL derivation:  3 mg chromium(III)/m3 (nasal and larynx lesions), adjusted to 
0.54 mg chromium(III)/m3 for intermittent exposure and converted to a LOAELHEC of 0.04 mg
chromium(III)/m3 
[  ] NOAEL [X] LOAEL
The respiratory tract was identified as the target for inhaled soluble trivalent chromium particulate 
compounds.  Similar effects were observed in male and female rats exposed to inhaled basic chromium
sulfate for 13 weeks, with histopathological changes to the nose, larynx, lung, and respiratory lymphatic
tissues and increased relative lung weight occurring at ≥3 mg chromium(III)/m3. Therefore, data for
histopathological changes in various regions of the respiratory tract and increased relative lung weights
were further evaluated to determine the point of departure for derivation of the intermediate-duration 
MRL for soluble trivalent chromium particulate compounds.












   




































   
 













Benchmark dose analysis could not be conducted for respiratory tract lesions, since incidence data were 
not reported by Derelanko et al. (1999); therefore, a NOAEL/LOAEL approach was used.  The LOAEL
value of 3 mg chromium(III)/m3 for lesions in different regions of the respiratory tract was further 
evaluated as a potential point of departure.  LOAEL values were adjusted for intermittent exposure
(LOAELADJ) and converted to a human equivalent concentration (LOAELHEC), as shown in (Table A-18). 
Table A-18.  LOAEL Values (Expressed in Terms of HEC) for Nonneoplastic  
Lesions in Rats Exposed to Basic Chromium Sulfate 


































aDuration-adjusted for intermittent exposure (LOAELADJ = LOAEL x 6 hours/24 hours x 5 days/7 days = 3 mg 
chromium(III)/m3 x 6 hours/24 hours x 5 days/7 days = 0.54 mg chromium(III)/m3)
bLOAELHEC = LOAELADJ x RDDR
HEC = human equivalent concentration; LOAEL = lowest-observed-adverse-effect level; RDDR = regional deposited 
dose ratio
Source:  Derelanko et al. 1999
To determine the BMC for increased lung weights, available continuous-variable models in the EPA
Benchmark Dose (version 1.4.1) were fit to the data for relative lung weights in male and female rats 
(Derelanko et al. 1999; Table A-19).  The BMC and the 95% lower confidence limit (BMCL) calculated 
is an estimate of the concentrations associated with a change of 1 standard deviation from the control
(BMCL1sd).  The model-fitting procedure for continuous data is as follows.  The simplest model (linear) is
applied to the data while assuming constant variance. If the data are consistent with the assumption of











     
   
     
    
  
   
    
   
      
     
       
   
   
   
    









    
       
     
 
 








constant variance (p≥0.1), then the other continuous models (polynomial, power, and Hill models) are
applied to the data.  Among the models providing adequate fits to the means (p≥0.1), the one with the
lowest Akaike’s Information Criteria (AIC) for the fitted model is selected for BMC derivation.  If the test
for constant variance is negative, then the linear model is run again while applying the power model
integrated into the BMDS to account for nonhomogenous variance.  If the nonhomogenous variance
model provides an adequate fit (p≥0.1) to the variance data, then the other continuous models are applied 
to the data.  Among the models providing adequate fits to the means (p≥0.1), the one with the lowest AIC
for the fitted model is selected for BMC derivation.  If the tests for both constant and nonconstant
variance are negative, then the data set is considered not to be suitable for BMC modeling.  For male rats,
the best model fit (Hill model) did not provide graphic output of the model; since model fit could not be
evaluated by visual inspection, the BMDL1sd from the Hill model was not selected.  All other models took
the form of a linear model (nonconstant variance), yielding predicted BMC1sd and BMCL1sd values of
2.89 and 2.05 mg chromium(III)/m3, respectively.  For female rats, the linear model (nonconstant
variance) provided the best fit, with predicted BMC1sd and BMCL1sd values of 6.33 and 3.96 mg/m3, 
respectively.  Additional details of the benchmark dose analysis for each data set modeled are presented
in the last section of this worksheet. The BMCL1sd values for the best fitting models in male and female 
rats were adjusted for intermittent exposure (BMCL1sd, ADJ) and human equivalent concentrations
(BMCL1sd, HEC), yielding BMCL1sd, HEC values of 0.17 and 0.34 mg chromium(III)/m3 in males and
females, respectively, as shown below (Table A-20). 
Table A-19.  Relative Lung Weightsa of CDF Ratsb Exposed to Basic Chromium  
Sulfate by Nose-Only Inhalation 6 Hours/Day, 5 Days/Week for 13 Weeks 
Concentrations (mg chromium(III)m3)
Relative weight (percent x 10) 0 3 10 30
Basic chromium sulfate, males 4.42±0.187c 5.60±0.271d 7.1 5± 0.252d 10.69±0.688d 
Basic chromium sulfate, females 5.65±0.418 6.99±0.619d 9.24±1.036d 12.89±1.134d 
aCombined lung and trachea
b10 rat in all groups except male rats in the basic chromium sulfate 30 mg/m3 group (n=9)
cmean±Standard deviation
dp<0.01
Source:  Derelanko et al. 1999




















    
    
 
 
     
  
    
 
  




    
   






   
 
     
  
   
 




   
    
    
 
    
     
  
  
      
  
   




Table A-20.  BMCL1sd Values (Expressed in Terms of HEC) for Increased Relative  
Lung Weight in Rats Exposed to Basic Chromium Sulfate by Inhalation for  








Rat/male 0.470 0.37 0.17
Rat/female 0.483 0.71 0.34
aFor thoracic region
bDuration-adjusted for continuous exposure (BMCL1sd, ADJ = BMCL1sd x 6 hours/24 hours x 5 days/7 days); BMCL1sd 
for the best fitting models for male and female rats were 2.05 and 3.96 mg chromium(III)/m3, respectively.
cBMCL1sd, HEC = BMCL1sd, ADJ x RDDR
BMCL = lower confidence limit (95%) on the benchmark concentration; HEC = human equivalent concentration;
RDDR = regional deposited dose ratio
Source:  Derelanko et al. 1999 
Based on comparison of LOAELHEC values for respiratory tract lesions and BMCL1sd, HEC values for
increased lung weight, the lowest value of 0.04 mg chromium(III)/m3 (the LOAELHEC for lesions of the
larynx and nose in female rats) was selected as the point of departure. The intermediate-duration 
inhalation MRL for soluble trivalent chromium particulate compounds of 0.0001 mg chromium(III)/m3 
was derived by dividing the LOAELHEC of 0.04 mg chromium(III)/m3 by a composite uncertainty factor
of 300 (10 for use of a LOAEL, 3 for pharmacodynamic variability between animals to humans, and 
10 for human variability).
Uncertainty factors used in MRL derivation:
[X] 10 for use of a LOAEL
[X] 3 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  To 
determine human equivalent concentrations, LOAELADJ values for lesions in various areas of the 
respiratory tract (Table A-18) and BMCL1sd, ADJ values for changes in changes in lung weights 
(Table A-20) were multiplied by the RDDR multiplier determined for lesions in various areas of the
respiratory tract as follows.
For histopathological changes to the nose and larynx, the extrathoracic region for the RDDR program was
selected.  For male rats, the RDDR multiplier of 0.129 for the extrathoracic region of the respiratory tract 
was determined using the average body weight of 201 g for male rats in the control group in the basic
chromium sulfate portion of the study and the average particle size (MMAD±GSD) of 4.3±2.45 reported 
in Derelanko et al. (1999).  For female rats, the RDDR multiplier of 0.078 for the extrathoracic region of
the respiratory tract was determined using the default subchronic body weight of 124 g for female
F344 rats (EPA 1988d) and the average particle size MMAD±GSD of 4.3±2.45 reported in Derelanko et
al. (1999); the default value for female body weights was used because female body weights were not
reported in Derelanko et al. (1999).











   
   
     
 
  
   
    
     
  
 
   
    
 
  
    
 
      
   
  
    
  
    
    
   
 
   
  
 
   
   
    
   





   
  
 
      
     
     
  
    
     
   
     
    
CHROMIUM A-48
APPENDIX A
For histopathological changes to the lung and increased relative lung weight, the thoracic region (a 
combination of tracheobronchial and pulmonary regions) was selected.  For male rats, the RDDR
multiplier of 0.470 for the thoracic region of the respiratory tract was determined using the average body
weight of 201 g for male rats in the control group in the basic chromium sulfate portion of the study and 
the average particle size (MMAD±GSD) of 4.3±2.45 reported in Derelanko et al. (1999).  For female rats, 
the RDDR multiplier of 0.483 for the thoracic region of the respiratory tract was determined using the
default subchronic body weight of 124 g for female F344 rats (EPA 1988d) and the average particle size
MMAD±GSD of 4.3±2.45 reported in Derelanko et al. (1999); the default value for female body weights
was used because female body weights were not reported in Derelanko et al. (1999).
Was a conversion used from intermittent to continuous exposure?  Rats were exposed for 6 hours/day, 
5 days/week for 13 weeks. The LOAEL and BMCL1sd values were adjusted for continuous exposure as 
follows:
LOAELADJ or BMCL1sd, ADJ = LOAEL or BMCL1sd x 6 hours/24 hours x 5days/7 days
Other additional studies or pertinent information that lend support to this MRL: The respiratory tract is
the major target of inhalation exposure to chromium(III) and chromium(VI) compounds in humans and 
animals.  Respiratory effects due to inhalation exposure are probably due to direct action of chromium at
the site of contact.  The available occupational studies for exposure to chromium(III) compounds include, 
or likely include, concomitant exposure to chromium(VI) compounds and other compounds that may
produce respiratory effects (Langård 1980; Mancuso 1951; Osim et al. 1999).  Thus, while the available
data in humans suggest that respiratory effects occur following inhalation exposure to chromium(III)
compounds, the respiratory effects of inhaled chromium(VI) and other compounds are confounding
factors.  Studies evaluating respiratory effects of intermediate-duration inhalation exposure of animals are
limited to the critical study evaluating 13-week exposure to chromic oxide or basic chromium sulfate
(Derelanko et al. 1999).  Results of this study show that intermediate-duration inhalation exposure to 
chromic oxide or basic chromium sulfate produced adverse respiratory effects, as indicated by 
histopathological changes and increased lung weight. However, effects of chromic oxide were less severe 
and isolated to the lung and respiratory lymph tissues, whereas the effects of basic chromium sulfate were 
more severe and observed throughout the respiratory tract (e.g., nose, larynx, lung and respiratory lymph 
tissues). The authors suggest that differences in the respiratory toxicity of these compounds may be due 
to differences in chemical-physical properties (e.g., solubility, acidity).  Based on the differences in 
respiratory toxicity between insoluble chromic oxide and soluble basic chromium sulfate, separate 
intermediate-duration inhalation MRLs were derived for insoluble and soluble trivalent chromium
particulate compounds.
Details of Benchmark Dose Analysis for the Intermediate-duration Inhalation MRL for Soluble
Trivalent Chromium Particulates
Lung Weights in Male Rats. The simplest model (linear) was applied to the data first to test for a fit for
constant variance. The constant variance model did not provide an adequate fit (as assessed by the 
p-value for variance) to the data. The linear model was applied to the data again while applying the 
power model integrated into the BMCs to account for nonhomogenous variance.  The nonconstant
variance model did provide an adequate fit (as assess by the p-value for variance).  The polynomial, 
power, and Hill models were then fit to the data with nonconstant variance assumed.  All of the models
provided an adequate fit to the data (as assessed by the p-value for the means) (Table A-21).  Comparing
across models, a better fit is generally indicated by a lower AIC.  As assessed by AIC, the Hill model
provides the best fit to the data; however, the BMDS software did not generate the graph output needed to 
assess visual fit of the model to the data.  All other models took the form of a linear model, so the

























      
       
      
      
      
      







     






nonconstant variance-linear model is selected for BMC derivation. The predicted BMC1sd and BMCL 1sd 
for the data are 2.89 and 2.05 mg chromium(III)/m3, respectively (Figure A-9). 
Table A-21.  Model Predictions for Changes in Relative Lung Weights of Male CDF 










Linearb,c 0.00 0.30 56.75 5.79 4.70
Linear c,d 0.40 0.10 44.09 2.89 2.05
Polynomial (1-degree)c,d 0.40 0.10 44.09 2.89 2.05
Polynomial (2-degree)c,d 0.40 0.10 44.09 2.89 2.05
Polynomial (3-degree)c,d 0.40 0.10 44.09 2.89 2.05
Powerd 0.40 0.10 44.09 2.89 2.05
Hilld 0.40 0.26 42.79 1.74 1.07
aValues <0.1 fail to meet conventional goodness-of-fit criteria.
bConstant variance assumed
cRestriction = non-negative
dNonconstant variance model applied
AIC = Akaike’s Information Criteria; p = p value from the Chi-squared test; BMC = benchmark concentration;
BMCL = lower confidence limit (95%) on the benchmark concentration; 1sd = a 1 standard deviation change from the 
control
Source:  Derelanko et al. 1999














   
 
 




       
   
     
   
    
     
   




Figure A-9.  Predicted and Observed Changes in Relative Lung Weights in Male  
Rats Exposed to Basic Chromium Sulfate by Inhalation for 13 Weeks*  























10:44 04/17 2008 
*BMD=BMC; BMDL=BMCL; BMCs and BMCLs indicated are associated with a 1 standard deviation change from the 
control, and are in units of mg chromium(III)/m3.
Source:  Derelanko et al. 1999
Lung Weights in Female Rats. The simplest model (linear) was applied to the data first to test for a fit 
for constant variance.  The constant variance model did not provide an adequate fit (as assessed by the 
p-value for variance) to the data. The linear model was applied to the data again while applying the 
power model integrated into the BMDS to account for nonhomogenous variance.  The nonconstant
variance model did provide an adequate fit (as assess by the p-value for variance).  The polynomial, 
power, and Hill models were then fit to the data with nonconstant variance assumed.  All of the models
provided an adequate fit to the data (as assessed by the p-value for the means) (Table A-22).  Comparing
across models, a better fit is generally indicated by a lower AIC.  As assessed by AIC, the linear model
provides the best fit to the data. The predicted BMC1sd and BMCL1sd for the data are 6.33 and 3.96 mg
chromium(III)/m3, respectively (Figure A-10). 




















      
       
      
      
      
      






   
 
   







Table A-22.  Model Predictions for Changes in Relative Lung Weights of Female  










Linearb,c 0.01 0.51 122.61 11.28 8.59
Linear c,d 0.59 0.14 117.05 6.33 3.96
Polynomial (1-degree)c,d 0.59 0.14 117.05 6.33 3.96
Polynomial (2-degree)c,d 0.59 0.14 117.05 6.33 3.96
Polynomial (3-degree)c,d 0.59 0.14 117.05 6.33 3.96
Powerd 0.59 0.14 117.05 6.33 3.96
Hilld 0.59 NAe 117.13 2.84 1.32
aValues <0.1 fail to meet conventional goodness-of-fit criteria.
bConstant variance assumed 
cRestriction = non-negative
dNonconstant variance model applied
eNA = degrees of freedom are ≤0; the Chi-Square test for fit is not valid.
AIC = Akaike’s Information Criteria; p = p value from the Chi-squared test; BMC = benchmark concentration;
BMCL = lower confidence limit (95%) on the benchmark concentration; 1sd = a 1 standard deviation change from the 
control
Source:  Derelanko et al. 1999















   
 
 








Figure A-10.  Predicted and Observed Changes in Relative 
Lung Weights in Female Rats Exposed to Basic 
Chromium Sulfate by Inhalation for 13 Weeks*  















4  BMD BMDL 
Linear 
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dose 
14:47 04/17 2008  
*BMD=BMC; BMDL=BMCL; BMCs and BMCLs indicated are associated with a 1 standard deviation change from the 
control, and are in units of mg chromium(III)/m3.
Source:  Derelanko et al. 1999  
Agency Contact (Chemical Manager):  Sharon Wilbur
















        
  
   
  
 
    
      






   
 
   
 
   
 
   
 
   
 
 






     
  









     
   
    
 
CHROMIUM	 B-1
APPENDIX B.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions:
1. 	 What effects are known to occur in humans?
2. 	 What effects observed in animals are likely to be of concern to humans?
3. 	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.










   




    
     




    
     
 
  
    
  
  
    
  
    
    
  
 
   
    









    




      




   





MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement,
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study.  Uncertainty factors used




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in
conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.


















   
 
 
     




   
      
   
 
 
   
  
  
   
 




   
    
   
  
    
 
 
     
 




    





See Sample LSE Table 3-1 (page B-6)
(1)	 Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2)	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable
exposure period within the LSE table and figure.
(3)	 Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4)	 Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5)	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL. 
(6)	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen,
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7)	 System.  This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8)	 NOAEL.  A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").












      
  
    
      
   
 
 
    
 
    
    
    
 
 









   
 
 
      
  
 
   
      
 
   






      
    
    
 
    





(9)	 LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile.
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in
experimental or epidemiologic studies.  CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12)	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health
effects observed within the acute and intermediate exposure periods are illustrated.
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15)	 Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.




















(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*).






         
 













    
       

































































































































































Nitschke et al. 1981
CHRONIC EXPOSURE




































a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index 
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX
BMDS Benchmark Dose Software 
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations 
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor










   
   
           





   
  
  















   
  
    
  








   
  
   












DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization




Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie










   













   
    
  







   
  














   





    
  
  
   
   
CHROMIUM C-3
APPENDIX C
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances












   












   
  




















   
  
  











OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio 
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell





RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization











   
  
  

















≥ greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
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APPENDIX D.  INDEX  
absorbed dose.............................................................................................................................. 11, 239, 290  
acetylcholine ............................................................................................................................................. 207  
acetylcholinesterase .................................................................................................................................. 207  
adenocarcinoma ........................................................................................................................................ 112  
adrenal gland............................................................................................................................... 93, 177, 250  
adrenals ....................................................................................................................................................... 93  
adsorbed .................................................................................................................................... 365, 373, 394  
adsorption.................................................................................................................................. 377, 406, 410  
aerobic............................................................................................................................................... 375, 376  
alanine aminotransferase (see ALT) ............................................................................. 34, 89, 173, 207, 208  
ALT (see alanine aminotransferase) ................................................................................... 34, 173, 297, 308  
ambient air .................................................................................................................... 9, 363, 378, 385, 396  
anaerobic ................................................................................................................................... 374, 375, 376  
anemia................................................................... 4, 12, 16, 17, 34, 35, 36, 37, 47, 170, 171, 206, 316, 417  
aspartate aminotransferase (see AST)................................................................................................. 34, 173  
AST (see aspartate aminotransferase)......................................................................................... 34, 173, 308  
bioaccumulation........................................................................................................................................ 374  
bioavailability ........................................... 237, 243, 245, 246, 251, 267, 279, 302, 303, 329, 373, 389, 395  
bioconcentration factor ............................................................................................................................. 373  
biomarker .................................................................... 90, 289, 290, 291, 295, 296, 297, 330, 401, 413, 414  
blood cell count....................................................................................................................... 30, 87, 88, 169  
body weight effects ............................................................................................................................. 94, 178  
breast milk................................................... 11, 239, 249, 250, 267, 269, 280, 288, 328, 330, 389, 390, 397  
cancer ....................4, 21, 36, 37, 52, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 178, 193, 194, 195, 
214, 215, 248, 261, 286, 287, 295, 301, 313, 317, 324, 326, 390, 399, 419, 420  
carcinogen........................................................................................................................................... 23, 425  
carcinogenic .................... 4, 22, 23, 26, 50, 51, 102, 111, 112, 196, 234, 282, 283, 301, 313, 318, 323, 425  
carcinogenicity.......................................................... 22, 23, 36, 37, 196, 197, 234, 281, 313, 318, 324, 425  
carcinoma ............................................................................................................ 22, 196, 197, 207, 226, 230  
cardiovascular ..................................................................................... 12, 23, 52, 84, 85, 165, 206, 313, 314  
cardiovascular effects............................................................................................................ 84, 85, 165, 206  
cholinesterase.................................................................................................................................... 173, 207  
chromosomal aberrations .......................................... 215, 226, 231, 234, 282, 299, 318, 319, 320, 325, 326  
clearance .................................................................... 14, 81, 82, 91, 98, 176, 238, 240, 241, 254, 262, 268, 
269, 270, 274, 275, 276, 279, 280, 298, 303, 329  
death....................................................................... 12, 16, 50, 51, 75, 79, 86, 105, 107, 112, 113, 114, 165,   
166, 193, 194, 195, 248, 287, 298, 313, 314, 329  
deoxyribonucleic acid (see DNA)............................................................................... 11, 221, 226, 230, 261  
dermal effects.................................................................. 20, 93, 95, 177, 178, 181, 198, 208, 210, 259, 313  
developmental effects ......................... 19, 25, 34, 43, 45, 101, 189, 191, 192, 193, 214, 287, 313, 321, 330  
DNA (see deoxyribonucleic acid)........................ 11, 21, 183, 215, 216, 217, 218, 220, 221, 222, 224, 225,   
226, 227, 229, 230, 232, 233, 234, 235, 236, 237, 
239, 261, 281, 282, 283, 289, 296, 298, 299, 307, 
309, 318, 319, 324, 325, 326, 329, 332, 399, 413  
elimination half-time................................................................................................................................. 290  
elimination rate ......................................................................................................................................... 239  
endocrine................................................................................................................. 23, 52, 93, 177, 284, 285  
endocrine effects ................................................................................................................................. 93, 177  





































   















    
  





   
CHROMIUM D-2
APPENDIX D
erythema...................................................................................................... 15, 16, 27, 52, 95, 198, 210, 211  
fetal tissue ................................................................................................................. 253, 288, 328, 390, 397  
fetus................................................................................................................................................... 285, 322  
follicle stimulating hormone (see FSH) ............................................................................................ 100, 191  
FSH (see follicle stimulating hormone) .................................................................................................... 100  
gastrointestinal effects ............................................................ 12, 13, 14, 32, 35, 85, 86, 166, 167, 206, 317  
general population..................................... 3, 9, 108, 111, 263, 267, 327, 328, 365, 366, 385, 391, 393, 396  
genotoxic............................... 21, 50, 215, 231, 233, 234, 236, 237, 266, 296, 299, 313, 318, 320, 324, 326  
genotoxicity......................................... 21, 215, 233, 234, 236, 237, 299, 309, 313, 318, 319, 320, 324, 332  
groundwater .................................................................................. 3, 194, 365, 371, 374, 376, 381, 410, 424  
half-life.............................................................................. 240, 245, 265, 266, 280, 289, 295, 325, 375, 395  
hematological effects .............................. 16, 17, 29, 35, 36, 38, 87, 169, 170, 171, 206, 315, 316, 317, 417  
hematopoietic................................................................................................................................ 17, 35, 170  
hepatic effects ....................................................................................................... 88, 89, 172, 174, 207, 297  
hydroxyl radical ................................................................................................................ 237, 262, 307, 308  
immune system ............................................................................................................. 16, 98, 181, 315, 322  
immunological ...................................................................................... 12, 23, 35, 50, 96, 98, 295, 301, 313  
immunological effects........................................................................................... 15, 20, 24, 35, 96, 98, 313  
Kow ............................................................................................................ 343, 344, 345, 346, 347, 348, 349  
LD50........................................................................................................................... 113, 198, 256, 301, 315  
leukemia............................................................................................................................ 222, 226, 227, 230  
leukopenia................................................................................................................................................... 87  
lymphatic ........................................................................................................................ 35, 40, 41, 181, 280  
metabolic effects ................................................................................................................... 52, 94, 180, 261  
micronuclei ............................................................................... 215, 217, 232, 233, 234, 235, 299, 318, 319  
milk ................................................................................................... 213, 249, 250, 267, 280, 288, 386, 403  
mucociliary ............................................................................................... 238, 241, 274, 279, 280, 303, 329  
musculoskeletal effects ................................................................................................... 23, 52, 88, 172, 207  
neonatal ............................................................................................................................... 20, 252, 321, 391  
neoplasm ................................................................................................................................................... 197  
neoplastic .................................................................................................................................................... 22  
neurobehavioral................................................................................................................................. 182, 284  
neurochemical ........................................................................................................................................... 182  
neurological effects....................................................................................... 12, 99, 182, 214, 297, 303, 314  
nuclear............................................................................................................................................... 283, 307  
ocular effects................................................................................................................. 21, 93, 178, 210, 211  
odds ratio............................................................................................................................................. 80, 101  
pharmacodynamic ............................................................................................................................... 42, 270  
pharmacokinetic................................................................................ 270, 271, 272, 283, 285, 289, 322, 326  
placenta ....................................................... 11, 190, 239, 249, 253, 257, 288, 320, 321, 327, 330, 390, 397  
rate constant ...................................................................................................... 245, 260, 274, 275, 276, 277  
renal effects............................................................................................. 37, 90, 92, 175, 176, 207, 208, 314  
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